

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: July 30, 2004, 12:18:33 ; Search time 54 Seconds
(without alignments)
2579,554 Million cell updates/sec

Title: US-10-018-386-2
Perfect score: 2682
Sequence: 1 MRPLCTGWTGLIAMGAV.....GSYLKRVVMIRNPVTFH 493

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1586107 seqs, 282547505 residues

Total number of hits satisfying chosen parameters: 1586107

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_29Jan04:*
1: geneseqp1980s:*
2: geneseqp1990s:*
3: geneseqp2000s:*
4: geneseqp2001s:*
5: geneseqp2002s:*
6: geneseqp2003as:*
7: geneseqp2003bs:*
8: geneseqp2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	2686	100.0	493	4	AAB66340 Human ang
2	2682	99.9	493	2	AAY05396 Human TIE
3	2682	99.9	493	3	AAY54999 Human sca
4	2682	99.9	493	3	AAY70745 PSEB-3 pr
5	2682	99.9	493	3	AAB47997 Angiopoie
6	2682	99.9	493	4	AAB31179 Amino aci
7	2682	99.9	493	4	AAB12305 Human PRO
8	2682	99.9	493	4	AAB51329 Human 410
9	2682	99.9	493	5	AAO14786 Human mat
10	2682	99.9	493	5	ABG80355 Human TIE
11	2682	99.9	493	5	AAE19825 Human TIE
12	2682	99.9	493	5	ABO17749 Novel hum
13	2682	99.9	493	6	ABO25150 Novel hum
14	2682	99.9	493	6	ADN01417 Human ang
15	2682	99.9	493	6	ABU81003 Human PRO
16	2682	99.9	493	6	AAE32417 Human ang
17	2682	99.9	493	6	ABU66703 Human PRO
18	2682	99.9	493	6	ABU67268 Novel hum
19	2682	99.9	493	6	ABU59784 Novel sec
20	2682	99.9	493	6	ABO24974 Human sec
21	2682	99.9	493	6	ABU72036 Novel hum
22	2682	99.9	493	6	ABU67137 Novel hum
23	2682	99.9	493	6	ABU66979 Human sec
24	2682	99.9	493	6	AAE30335 Human ARP
25	2682	99.9	493	6	ABU79779 Human sec

26	2682	99.9	493	6	ADA45787 Novel hum
27	2682	99.9	493	6	ADA76218 Human PRO
28	2682	99.9	493	6	ADA18868 Human PRO
29	2682	99.9	493	6	ADA61491 Homo sapi
30	2682	99.9	493	6	ADA19276 Novel hum
31	2682	99.9	493	6	ADA827817 Human PRO
32	2682	99.9	493	6	ADA66296 Novel hum
33	2682	99.9	493	6	ADA15860 Human PRO
34	2682	99.9	493	6	ADA47646 Human PRO
35	2682	99.9	493	6	ADA67441 Human PRO
36	2682	99.9	493	6	ADA830448 Human PRO
37	2682	99.9	493	6	ADA85744 Novel hum
38	2682	99.9	493	6	ADA96956 Human PRO
39	2682	99.9	493	6	ADA79260 Human PRO
40	2682	99.9	493	6	ADA87399 Novel hum
41	2682	99.9	493	6	ADA16601 Human PRO
42	2682	99.9	493	6	ADA21693 Novel hum
43	2682	99.9	493	6	ADA14756 Human PRO
44	2682	99.9	493	6	ADA47176 Human sec
45	2682	99.9	493	6	ADA18717 Novel hum

ALIGNMENTS

RESULT 1
ID AAB66340 standard; protein; 493 AA.
XX AAB66340;
AC
DT 05-APR-2001 (first entry)
XX
DE Human angiopoietin-7 (ANG-7).
XX
KM Human angiopoietin-7; ANG-7; angiogenesis; cancer; wound healing;
KM diabetic retinopathy; macular degeneration; cardiovascular disease;
KM reproductive system.
XX
XX Homo sapiens.
OS
XX W0200102434-A1.
XX
PD 11-JAN-2001.
XX
PF 30-JUN-2000; 2000MO-US018170.
XX
PR 02-JUL-1999; 99EP-00113502.
XX
PA (FARB) BAYER AG.
XX
PI Friedrich G, Hagen G, Wick M, Zubov D, Dubois-Stringfellow N;
XX WPI; 2001-123103/13.
XX N-PSDB; AAF29738.
XX
DR Inhibiting angiogenesis for treating cancer, wound healing, diabetic
DR retinopathies, macular degeneration, cardiovascular diseases, by
XX administering angiopoietin-7 polypeptide or its fragments.
XX
PS Claim 2; Fig 2; 86pp; English.
XX
CC The present invention describes a method of preventing angiogenesis by
CC administering angiopoietin-7 (ANG-7) nucleic acid, protein, fragment or
CC derivative. This can be used in the treatment of angiogenesis-related
CC diseases, including cancer, wound healing, macular degeneration,
CC cardiovascular diseases, diabetic retinopathies, infections and
CC conditions of the reproductive system such as regulation of placental
CC vascularization, and also may be used as an abortifacient. Note: In the
CC specification, ANG-7 is also referred to as being angiogenesis-7
XX
SQ Sequence 493 AA:

Query Match 100.0%; Score 2686; DB 4; Length 493;
Best Local Similarity 100.0%; Pred. No. 6.6e-217;
Matches 493; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRPLCTCWMGLGLAAMGAVAGQEDGFEGTEGSRREFIYNRYRAGESQDKCTYTFIV 60
DB 1 MRPLCTCWMGLGLAAMGAVAGQEDGFEGTEGSRREFIYNRYRAGESQDKCTYTFIV 60
QY 61 POORVTGALCVNSKEPEVLENNRVHVKQELINNELKQKQIETLQQLVADGIVSEV 120
DB 61 POORVTGALCVNSKEPEVLENNRVHVKQELINNELKQKQIETLQQLVADGIVSEV 120
QY 121 KILRKESRMNSRVTLQVWQLHEIIRKDNALBESQLENRIINQADMLQASKYKOLE 180
DB 121 KILRKESRMNSRVTLQVWQLHEIIRKDNALBESQLENRIINQADMLQASKYKOLE 180
QY 181 HKYQHLATLANQSEIIAQLEBHCQVPSARVPQPPAAPPVRYQPTVNRINQISTN 240
DB 181 HKYQHLATLANQSEIIAQLEBHCQVPSARVPQPPAAPPVRYQPTVNRINQISTN 240
QY 241 EIQSDQNLKVLPPPLPTMTLTLSPSSTDKPSGPRDCLQALBDHDTSSIYLVKPENTN 300
DB 241 EIQSDQNLKVLPPPLPTMTLTLSPSSTDKPSGPRDCLQALBDHDTSSIYLVKPENTN 300
QY 301 RLMQVWCDOGRHDPGGMVTIQRRLDGSVNFPRWMEYKQGFNIDGEYWLGLENIYWLTNQ 360
DB 301 RLMQVWCDOGRHDPGGMVTIQRRLDGSVNFPRWMEYKQGFNIDGEYWLGLENIYWLTNQ 360
QY 361 GNYKLLVTEWDSGKRVFAEYASFRLPESESEYKRLGRYGNAGDSTFWNGQFTTLD 420
DB 361 GNYKLLVTEWDSGKRVFAEYASFRLPESESEYKRLGRYGNAGDSTFWNGQFTTLD 420
QY 421 RDHDVYTGNCATYQKGGWYNACAHSNLNGVYRGHRSRYQGVYVAEFRGGSYSLSKK 480
DB 421 RDHDVYTGNCATYQKGGWYNACAHSNLNGVYRGHRSRYQGVYVAEFRGGSYSLSKK 480
QY 481 VVMIRPNPNTFH 493
DB 481 VVMIRPNPNTFH 493

RESULT 2
AAV05396
ID AAV05396 standard; protein; 493 AA.

XX AAY05396;
AC AAY05396;
DT 01-JUL-1999 (first entry)
DE Human TIE ligand NL1 protein sequence.
XX Human TIE ligand; NL1; NL4; NL5; NL6; Ig homology domain; angiogenesis;
KW EGF homology domain; receptor tyrosine kinase; vascular endothelial cell;
KW early haemopoietic cell; haemopoiesis; neovascularisation; wound healing;
KW endothelial cell; growth inhibitor; apoptosis inducer; tumour cell;
KW vasculogenesis; detection; diagnosis; therapy.
XX
OS Homo sapiens.
XX
PN W09915653-A2.
PD 01-APR-1999.
XX
PF 14-SEP-1998; 98WO-US019093.
XX
PR 19-SEP-1997; 97US-00933821.
PR 29-OCT-1997; 97US-00960507.
XX
PA (GETH) GENENTECH INC.
XX
PI Godowski PJ, Gurney AL, Hillan K, Botstein D, Goddard A, Roy M;
PI Ferrara N, Tumas D, Schwall R;
XX

DR WP1; 1999-263480/22.
DR N-PSDB; AAX36341.
PT New isolated TIE ligand homologs for, e.g. developing products for
PT treatment of tumors.
XX
XX
PS Claim 8; Fig 3; 132pp; English.
XX
CC This sequence is the human tyrosine kinase containing Ig and EGF homology
CC domains (TIE) ligand of the invention, designated NL1. The TIE receptors
CC are receptor tyrosine kinases which are expressed in vascular endothelial
CC cells and early haemopoietic cells. The TIE receptors are believed to be
CC actively involved in angiogenesis, and may play a role in haemopoiesis as
CC well. The TIE ligand homologs can promote the survival and/or growth
CC and/or differentiation of TIE receptor expressing cells. They can be used
CC for promoting neovascularisation in wound healing and for promoting
CC angiogenic processes, such as for inducing collateral vascularisation in
CC an ischaemic heart or limb, or for promoting bone development and/or
CC maturation and/or growth in a patient or muscle growth and development.
CC The TIE ligand homologs and antibodies can inhibit the growth of
CC endothelial cells and induce apoptosis of cells, particularly tumour
CC cells. They can inhibit vasculogenesis, particularly the vascularisation
CC of tumour cells. The antibodies can also inhibit vascularisation of a
CC cell in which a gene encoding an NL1, NL5, NL8 or NL4 polypeptide is
CC amplified. The products can also be used for detection, diagnosis, drug
CC screening and production of transgenic animals
XX
SQ Sequence 493 AA;

Query Match 99.9%; Score 2682; DB 2; Length 493;
Best Local Similarity 99.8%; Pred. No. 1.4e-216;
Matches 492; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRPLCTCWMGLGLAAMGAVAGQEDGFEGTEGSRREFIYNRYRAGESQDKCTYTFIV 60
DB 1 MRPLCTCWMGLGLAAMGAVAGQEDGFEGTEGSRREFIYNRYRAGESQDKCTYTFIV 60
QY 61 POORVTGALCVNSKEPEVLENNRVHVKQELINNELKQKQIETLQQLVADGIVSEV 120
DB 61 POORVTGALCVNSKEPEVLENNRVHVKQELINNELKQKQIETLQQLVADGIVSEV 120
QY 121 KILRKESRMNSRVTLQVWQLHEIIRKDNALBESQLENRIINQADMLQASKYKOLE 180
DB 121 KILRKESRMNSRVTLQVWQLHEIIRKDNALBESQLENRIINQADMLQASKYKOLE 180
QY 181 HKYQHLATLANQSEIIAQLEBHCQVPSARVPQPPAAPPVRYQPTVNRINQISTN 240
DB 181 HKYQHLATLANQSEIIAQLEBHCQVPSARVPQPPAAPPVRYQPTVNRINQISTN 240
QY 241 EIQSDQNLKVLPPPLPTMTLTLSPSSTDKPSGPRDCLQALBDHDTSSIYLVKPENTN 300
DB 241 EIQSDQNLKVLPPPLPTMTLTLSPSSTDKPSGPRDCLQALBDHDTSSIYLVKPENTN 300
QY 301 RLMQVWCDOGRHDPGGMVTIQRRLDGSVNFPRWMEYKQGFNIDGEYWLGLENIYWLTNQ 360
DB 301 RLMQVWCDOGRHDPGGMVTIQRRLDGSVNFPRWMEYKQGFNIDGEYWLGLENIYWLTNQ 360
QY 361 GNYKLLVTEWDSGKRVFAEYASFRLPESESEYKRLGRYGNAGDSTFWNGQFTTLD 420
DB 361 GNYKLLVTEWDSGKRVFAEYASFRLPESESEYKRLGRYGNAGDSTFWNGQFTTLD 420
QY 421 RDHDVYTGNCATYQKGGWYNACAHSNLNGVYRGHRSRYQGVYVAEFRGGSYSLSKK 480
DB 421 RDHDVYTGNCATYQKGGWYNACAHSNLNGVYRGHRSRYQGVYVAEFRGGSYSLSKK 480
QY 481 VVMIRPNPNTFH 493
DB 481 VVMIRPNPNTFH 493

RESULT 3
AAV54999
ID AAV54999 standard; protein; 493 AA.

XX	AAV54999;
AC	
XX	
DT	18-FEB-2000 (first entry)
XX	
XX	Human scarface 1 protein sequence.
DE	
KM	Scarface 1; human; Sf-1 protein; angiogenesis; wound healing; diagnosis;
KM	tumour growth; cancer; stem cell amplification; endothelial cell;
KM	TIE receptor; neoplastic disease; wound healing; thromboembolic disease;
KM	atherosclerosis; inflammatory disease; neovascularisation; ischaemia;
KM	therapy.
OS	Homo sapiens.
PN	EP962530-A2.
PD	
XX	08-DEC-1999.
XX	
PF	01-JUN-1999; 99EP-00304239.
XX	
PR	02-JUN-1998; 98US-0087710P.
PR	08-JUN-1998; 98US-008503P.
PR	17-SEP-1998; 98US-0100857P.
XX	
PA	(EIL) LILLY & CO EIL.
XX	
P1	Heuer JG, Burgett SG, Leonard RA, Rosteck PR, Santhavaram PR;
DR	WPI; 2000-025636/03.
DR	N-PSDB; AAZ40049.
PT	New substantially pure Scarface 1 (Sf-1) protein, useful for screening
FT	compounds for modulating angiogenesis, to enhance wound healing, inhibit
PT	tumor growth and/or to amplify stem cells.
PS	Claim 2; Page 20-22; 25pp; English.
XX	
CC	This sequence represents the human Scarface 1 (Sf-1) protein of the
CC	invention. The Sf-1 nucleic acids are useful as probes to isolate
CC	paralogous genes from humans and/or orthologous genes from other
CC	organisms. Sf-1 proteins are also useful to screen for compounds that
CC	bind the peptides as potential pharmaceutical compounds for modulating
CC	angiogenesis. The proteins are useful as therapeutics to enhance wound
CC	healing, for developing compounds for inhibiting tumor growth, for
CC	treating cancer and for use in a method to amplify stem cells. Sf-1
CC	proteins may be further used in the diagnosis and treatment of certain
CC	diseases involving endothelial cells and associated TIE receptors e.g.
CC	neoplastic diseases involving tumor angiogenesis, thromboembolic
CC	diseases, atherosclerosis and inflammatory diseases. In addition the
CC	mammalian ligand may be used to promote proliferation and/or
CC	differentiation of haemacopoietic stem cells. Sf-1 may be used to promote
CC	the growth, survival, migration and/or differentiation and/or
CC	stabilization or destabilisation of cells expressing TIE receptor.
CC	Biologically active Sf-1 may be used in the in vitro maintenance of the
CC	TIE receptor expressing cells in culture. Alternatively Sf-1 may be used
CC	to support cells which are engineered to express TIE receptor and its
CC	cognate receptor may be used in assay systems to identify (ant)agonists
CC	of the TIE receptor. Sf-1 may be administered to promote
CC	neovascularisation and especially to treat ischaemia
SQ	
	Sequence 493 AA;
Query March	99.9%; Score 2682; DB 3; Length 493;
Best Local Similarity	99.8%; Pred. No. 1.4e-216;
Matches 492; Conservative	1; Mismatches 0; Indels 0; Gaps 0
Dn	
1 MRPLCVTCWMIGLILAAAGAVAGQEDPEFGTEEGSPREFYILNRYRAGESODKCTYPFIV	60
1 MRPLCVTCWMIGLILAAAGAVAGQEDPEFGTEEGSPREFYILNRYRAGESODKCTYPFIV	60
61 PGGVTATACVNSKEPVLEENVHQQEILENNELTKKRQIETFLQQLVVDGITYSEV	120

D6		61	PQQRVTGALCVNSKSEPVLLNRVHKGSELUNNELLKOKRQJETTQLQVLVEVDGGIVSEY	120
OY		121	KLIRKESRRNNRSRTOLYMQLIHETIKRKDNALBSOLENRIINQTRDMQLASKYKDE	180
D6		121	KLIRKESRRNNRSRVOLMQLIHEIRKRDNALBSOLENRIINQTRADMQLASKYKDE	180
OY		181	HKKQHATLANHQSETIAQLEBHCORVPASAPFVPPPPAAPPVVYPYOPPTYNRLINQISTN	240
D6		181	HKYQLATLANHQSETIAQLEBHCCRPDSAPFVQPPPAAPFRYYQPTTNRILINQISTN	240
OY		241	EIQSDNLKVLPPIPTPMTLTSSSTDKSGPWRCQLALEDHDTSSIYVKPEPNTN	300
D6		241	EIQSDNLKVLPPIPTPMTLTLS.PSSTDKSGPWRCQLALEDHDTSSIYVKPEPNTN	300
OY		301	RLMQWCDGRHPGGWTYIGRLDGSVAFFNMFTTYQGFCNIDGEYWLGLENIYMLTNQ	360
D6		301	RLMQWCDGRHPGGWTYIGRLDGSVAFFNMFTTYQGFENDIGEYWLGLENIYMLTNQ	360
OY		361	GNYKLIVTMEDWSGKRVFAEYASFPLEPSESYYELRLGRVHGNAGDSFTWHNGKOPTILD	420
D6		361	GNYKLIVTMEDWSGKRVFAEVASFPLEPSESYYELRLGRVHGNAAGDSFTWHNGKOPTILD	420
OY		421	RHDVYTTCGAHYQXGGMWRNCAHSNITNGWYRGCHTRSXYQCGYVMAEPFGSGSYLTK	480
D6		421	RHDVYTTCGAHAHQXGGMWYNACAHSNITNGWYRGCHTRSXYQCGYVMAEFPGSGSYLTK	480
OY		481	VVMVIRPNENTFH	493
D6		481	VVMVIRPNENTFH	493
<hr/>				
RESULT_4				
ID	AAY70745		standard; protein; 493 AA.	
XX	AAY70745;			
XX				
DT	24-JUL-2000	(first entry)		
XX				
DE	PSRQ-3	protein encoded by NSEQ gene associated with matrix remodelling.		
XX				
KW	NSEQ gene; matrix-remodeling gene; Incyte clone 2268890; cancer;			
KW	matrix-remodeling disease; cardiomyopathy; arthritis; angiogenesis;			
KW	diabetic necrosis; atherosclerosis; fibrosis; ulceration; cytostatic;			
KW	cardioactive; antiarthritic; angiogenic; antiarteriosclerotic; anticancer.			
XX				
OS	Homo sapiens.			
XX				
Key		Location/Qualifiers		
FH	Peptide	1..22		
FT		/label= Signal_peptide		
FT	Modified-site	12		
FT		/note= "N-myristoylation site"		
FT	Modified-site	18		
FT		/note= "N-myristoylation site"		
FT	Modified-site	22		
FT		/note= "N-myristoylation site"		
FT	Modified-site	29		
FT		/note= "N-myristoylation site"		
FT	Modified-site	34		
FT		/note= "Protein kinase C phosphorylation site"		
FT	Modified-site	34		
FT		/note= "Casein kinase II phosphorylation site"		
FT	Modified-site	127		
FT		/note= "cAMP- and cGMP-dependent protein kinase"		
FT	Modified-site	164		
FT		/note= "N-glycosylation site"		
FT	Modified-site	183		
FT		/note= "Tyrosine kinase phosphorylation site"		
FT	Modified-site	192		
FT		/note= "N-glycosylation site"		
FT	Modified-site	209		
FT		/note= "Protein kinase C phosphorylation site"		

FT Modified-site 209 /note= "Casein kinase II phosphorylation site"
 FT 238 /note= "Casein kinase II phosphorylation site"
 FT 266 /note= "Casein kinase II phosphorylation site"
 FT 268 /note= "Casein kinase II phosphorylation site"
 FT 277 /note= "Protein kinase C phosphorylation site"
 FT 299 /note= "Shows 44% sequence identity with angiotensin-like factor"
 FT 299 /note= "Protein kinase C phosphorylation site"
 FT 305 /note= "Resembles carboxy-terminal domain signatures of fibrinogen beta and gamma chains from BLOCK analysis"
 FT 335 /note= "Protein kinase C phosphorylation site"
 FT 346 /note= "Resembles carboxy-terminal domain signatures of fibrinogen beta and gamma chains from BLOCK analysis"
 FT 365 /note= "Resembles carboxy-terminal domain signatures of fibrinogen beta and gamma chains from BLOCK analysis"
 FT 368 /note= "Resembles carboxy-terminal domain signatures of fibrinogen beta and gamma chains from BLOCK analysis"
 FT 373 /note= "Casein kinase II phosphorylation site"
 FT 383 /note= "Protein kinase C phosphorylation site"
 FT 392 /note= "Protein kinase C phosphorylation site"
 FT 411 /note= "Tyrosine kinase phosphorylation site"
 FT 411 /note= "Resembles carboxy-terminal domain signatures of fibrinogen beta and gamma chains from BLOCK analysis"
 FT 417 /note= "Casein kinase II phosphorylation site"
 FT 428 /note= "Resembles carboxy-terminal domain signatures of fibrinogen beta and gamma chains from BLOCK analysis"
 FT 467 /note= "Tyrosine kinase phosphorylation site"
 FT 477 /note= "Protein kinase C phosphorylation site"
 FT 477 /note= "Protein kinase C phosphorylation site"
 PN WO200021986-A2.
 XX 20-APR-2000.
 PD 06-OCT-1999; 99WO-US023315.
 PF 09-OCT-1998; 98US-00169289.
 XX (INCY-) INCYTE PHARM INC.
 PA Walker MG, Volkmut W, Klingler TM;
 PI MPI: 2000-317934/27.
 DR N-PSDB; AA252359.
 XX
 PT Protein co-expressed with matrix-remodeling proteins, useful in the diagnosis and treatment of cancer, cardiomyopathy, arthritis, angiogenesis, diabetic necrosis, atherosclerosis, fibrosis, and ulceration.
 PT
 PS Claim 1; Page 54-55; 55pp; English.
 CC The present sequence is PSEQ protein encoded by NSEQ gene that is co-expressed with one or more known matrix-remodeling genes in a number of biological samples using an expression vector. The gene, protein, and antibody sequences can be used in the diagnosis, treatment or prevention of a disease associated with its altered expression. The diseases that can be treated are matrix-remodeling diseases, including

CC cancer, cardiomyopathy, arthritis, angiogenesis, diabetic necrosis,
 CC atherosclerosis, fibrosis, and ulceration
 XX Sequence 493 AA;
 SQ
 Query Match 99.3%; Score 2682; DB 3; Length 493;
 Best Local Similarity 99.8%; Pred. No. 1,4e-216;
 Matches 492; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MRPLCTVGMWLGILAMGAVAGQEDGEGTESSSPREFTYLNRYKAGSSQKCTTFTV 60
 DB 1 MRPLCTVGMWLGILAMGAVAGQEDGEGTESSSPREFTYLNRYKAGSSQKCTTFTV 60
 QY 61 PQRVTGATVNSKEPEVLENNVHKELELNNEILXKROLETQOLVKQDGVISVY 120
 DB 61 PQRVTGATVNSKEPEVLENNVHKELELNNEILXKROLETQOLVKQDGVISVY 120
 QY 121 KLIRKESRNNSVSTVQLVQNLHEITRKDNALIELSLENRIINQTDMLQASKYKDL 180
 DB 121 KLIRKESRNNSVSTVQLVQNLHEITRKDNALIELSLENRIINQTDMLQASKYKDL 180
 QY 181 HKYQHLATLTAHNOSEIIIAOLEEHQRPASRPVPOPPAPPRVYOPPTNRIINQISTN 240
 DB 181 HKYQHLATLTAHNOSEIIIAOLEEHQRPASRPVPOPPAPPRVYOPPTNRIINQISTN 240
 QY 241 EIQSDNLTAVLPPLPTMTPTLSLPSSTDXPSGPMWDCIQALEDGHTSSIVLVKRENTN 300
 DB 241 EIQSDNLTAVLPPLPTMTPTLSLPSSTDXPSGPMWDCIQALEDGHTSSIVLVKRENTN 300
 QY 301 RLMOVWCDQHDHGGTIVQRLDGSVNFRRMETTKQFGNIDGMYWGLNIIYWLINQ 360
 DB 301 RLMOVWCDQHDHGGTIVQRLDGSVNFRRMETTKQFGNIDGMYWGLNIIYWLINQ 360
 QY 361 GNYKLVTMEDMSGRKVFAYASFLRPESEYKRLGTHGNAGDSFTWNGKOPTTLD 420
 DB 361 GNYKLVTMEDMSGRKVFAYASFLRPESEYKRLGTHGNAGDSFTWNGKOPTTLD 420
 QY 421 RHDVYTGCAHOKGGMVYNACAHNLNGWYRGHYSRQDGYTAEFEGGSYSLK 480
 DB 421 RHDVYTGCAHOKGGMVYNACAHNLNGWYRGHYSRQDGYTAEFEGGSYSLK 480
 QY 481 VVMVIRPNPTFH 493
 DB 481 VVMVIRPNPTFH 493
 RESULT 5
 AAB47997
 ID AAB47997 standard; protein; 493 AA.
 XX
 AC AAB47997;
 XX
 DT 12-AUG-2002 (first entry)
 XX
 DE Angiotensin-like protein-3, AR3.
 XX
 KW Angiotensin-like protein 2; AR2; angiotensin-like protein 3; AR3;
 KW apple crisp protein; Apple; cocoa crisp protein; COCO;
 KW signal sequence cloning; secretory leader motif; angiogenesis;
 KW wound healing; transplantation.
 XX
 OS Homo sapiens.
 XX
 PN WO200059938-A1.
 XX
 PD 12-OCT-2000.
 XX
 PF 31-MAR-2000; 2000WO-US008832.
 XX
 PR 01-APR-1999; 99US-0126366P.
 XX
 PR 29-MAR-2000; 2000US-00538361.
 XX
 PA (GENY) GENNETICS INST INC.

PI Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WT, Zhang Z;
 DR WPI; 2001-408281/43.
 DR N-PSDB; AAS21377.
 XX
 XX
 PT Isolated, secretory and transmembrane PRO polypeptide used to detect
 PT other PRO polypeptides, link bioactive molecules to cells expressing PRO
 PT polypeptides, and detect the presence of mammalian tumors e.g. lung,
 PT breast, prostate, cervical.
 PS Claim 12; Fig 268; 813p; English.
 XX
 XX
 CC AAU2172-AAU12446 represent novel human secretory and transmembrane PRO
 CC polypeptides. The PRO polypeptides are useful to detect other PRO
 CC polypeptides, to link bioactive molecules to cells expressing PRO
 CC polypeptides, to modulate biological activities of cells expressing PRO
 CC polypeptides, and to detect the presence of mammalian lung, colon,
 CC breast, prostate, rectal, cervical or liver tumors by comparing PRO
 CC polypeptide expression in a cell sample to that in a control sample. Some
 CC of the 275 sequences are also useful to stimulate the release of tumour
 CC necrosis factor-alpha (TNF-alpha) from human blood, the proliferation or
 CC differentiation of chondrocytes, the proliferation or gene expression in
 CC pericyte cells, the release of proteoglycans from cartilage, the
 CC proliferation of inner ear utricular supporting cells or of T-
 CC lymphocytes, the release of a cytokine from peripheral blood monocytes
 CC (PBMCs), or the proliferation of endothelial cells. Some of the PRO
 CC polypeptides may modulate glucose or free fatty acid uptake by skeletal
 CC muscle cells or by adipocytes; or inhibit binding of A-peptide to factor
 CC VIIa. The PRO polypeptides can be used in assays to identify molecules
 CC involved in binding interactions. The polynucleotides encoding PRO
 CC polypeptides can be used to generate probes, antisense RNA/DNA,
 CC transgenic or knock out animals and can be used in gene therapy
 CC
 XX
 SQ Sequence 493 AA:
 Query Match 99.9%; Score 2682; DB 4; Length 493;
 Best Local Similarity 99.8%; Pred. No. 1.4e-216;
 Matches 492; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MRPLCVTCWMLGLLAAGAVAGQEDGEGTEGSPREFIYLNRYKRAGESQDKCTYTFIV 60
 DB 1 MRPLCVTCWMLGLLAAGAVAGQEDGEGTEGSPREFIYLNRYKRAGESQDKCTYTFIV 60
 QY 61 PQRVTGALCVNSKEPEVLLNRYKHQKLELNNELIKOKROIETLQQLVKGIGIVSEV 120
 DB 61 PQRVTGALCVNSKEPEVLLNRYKHQKLELNNELIKOKROIETLQQLVKGIGIVSEV 120
 QY 121 KLLKRESRMNSRVTLQYMLLHEIIRKDNALLESQLENRIINQTDMLQASKYKXDL 180
 DB 121 KLLKRESRMNSRVTLQYMLLHEIIRKDNALLESQLENRIINQTDMLQASKYKXDL 180
 QY 181 HKYQHLATLANQSEIIAQLLEHCQVPSARVPVOPPPAPPRVYQPTVNRRIINOISTN 240
 DB 181 HKYQHLATLANQSEIIAQLLEHCQVPSARVPVOPPPAPPRVYQPTVNRRIINOISTN 240
 QY 241 EIQSDQNLKVLPPPLPTMPTLTLSPSTDKPSGWRDCLQALDGHDTSSITLVKPENTN 300
 DB 241 EIQSDQNLKVLPPPLPTMPTLTLSPSTDKPSGWRDCLQALDGHDTSSITLVKPENTN 300
 QY 301 RLMQVWCDQRHDPGQWTVIQRRLDGSVNFPRNMTYKQGFNIDEGYMLGLENIYWLTLNQ 360
 DB 301 RLMQVWCDQRHDPGQWTVIQRRLDGSVNFPRNMTYKQGFNIDEGYMLGLENIYWLTLNQ 360
 QY 361 GNYKLLVTMEWSGRKVFAYASFRLEPSEYYKLRLGYNAGDSFTWANGKQFTTLD 420
 DB 361 GNYKLLVTMEWSGRKVFAYASFRLEPSEYYKLRLGYNAGDSFTWANGKQFTTLD 420
 QY 421 RHDHVTGNCARHOKGGMWYNACAHSNLNGVWRGGHRSRYODGVYMAEFPGSGYSYLK 480
 DB 421 RHDHVTGNCARHOKGGMWYNACAHSNLNGVWRGGHRSRYODGVYMAEFPGSGYSYLK 480
 QY 481 VVMMIRNPNTFFH 493

DB 481 VVMMIRNPNTFFH 493
 RESULT 8
 ID AAB51329 standard; protein; 493 AA.
 XX
 AC AAB51329;
 XX
 XX 02-APR-2001 (first entry)
 DT
 DT Human 410 angiotensin-like protein SEQ ID NO:4.
 XX
 XX Human; 410; NEW; angiotensin-like protein; angiogenesis.
 KW Homo sapiens.
 OS
 XX JP2000300263-A.
 XX
 XX 31-OCT-2000.
 PD
 XX 14-APR-1999; 99JP-00107234.
 PF
 XX 14-APR-1999; 99JP-00107234.
 PR
 XX 14-APR-1999; 99JP-00107234.
 PA (HERI-) HERIKUSU KENKYUSHO KK.
 XX
 DR WPI; 2001-151128/16.
 DR N-PSDB; AAF26789.
 PT
 PT New genes encoding angiotensin-like proteins 410 and NEW, useful for the
 PT prevention and treatment of diseases relating to angiogenesis.
 PS Claim 1; Page 12-13; 26pp; Japanese.
 XX
 XX
 CC The present invention describes two human angiotensin-like proteins
 CC designated 410 and NEW. The angiotensin-like proteins can be used for
 CC the prevention and treatment of diseases relating to angiogenesis. The
 CC present sequence represents the human 410 angiotensin-like protein
 CC
 XX
 SQ Sequence 493 AA:
 Query Match 99.9%; Score 2682; DB 4; Length 493;
 Best Local Similarity 99.8%; Pred. No. 1.4e-216;
 Matches 492; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MRPLCVTCWMLGLLAAGAVAGQEDGEGTEGSPREFIYLNRYKRAGESQDKCTYTFIV 60
 DB 1 MRPLCVTCWMLGLLAAGAVAGQEDGEGTEGSPREFIYLNRYKRAGESQDKCTYTFIV 60
 QY 61 PQRVTGALCVNSKEPEVLLNRYKHQKLELNNELIKOKROIETLQQLVKGIGIVSEV 120
 DB 61 PQRVTGALCVNSKEPEVLLNRYKHQKLELNNELIKOKROIETLQQLVKGIGIVSEV 120
 QY 121 KLLKRESRMNSRVTLQYMLLHEIIRKDNALLESQLENRIINQTDMLQASKYKXDL 180
 DB 121 KLLKRESRMNSRVTLQYMLLHEIIRKDNALLESQLENRIINQTDMLQASKYKXDL 180
 QY 181 HKYQHLATLANQSEIIAQLLEHCQVPSARVPVOPPPAPPRVYQPTVNRRIINOISTN 240
 DB 181 HKYQHLATLANQSEIIAQLLEHCQVPSARVPVOPPPAPPRVYQPTVNRRIINOISTN 240
 QY 241 EIQSDQNLKVLPPPLPTMPTLTLSPSTDKPSGWRDCLQALDGHDTSSITLVKPENTN 300
 DB 241 EIQSDQNLKVLPPPLPTMPTLTLSPSTDKPSGWRDCLQALDGHDTSSITLVKPENTN 300
 QY 301 RLMQVWCDQRHDPGQWTVIQRRLDGSVNFPRNMTYKQGFNIDEGYMLGLENIYWLTLNQ 360
 DB 301 RLMQVWCDQRHDPGQWTVIQRRLDGSVNFPRNMTYKQGFNIDEGYMLGLENIYWLTLNQ 360
 QY 361 GNYKLLVTMEWSGRKVFAYASFRLEPSEYYKLRLGYNAGDSFTWANGKQFTTLD 420

```
Db 361 GNYKLIVTMDWSGRVPFAEYASFRLEPSEYYKRLGRYHGNAGDSFTWHNGKQFTILD 420
Qy 421 RDHDVYTGCAHYQKGGWYVNAQAHNSLNGVWYRGHYSRYQDGYVMAEPRGGSYSLSK 480
Db 421 RDHDVYTGCAHYQKGGWYVNAQAHNSLNGVWYRGHYSRYQDGYVMAEPRGGSYSLSK 480
Qy 481 VVMMIRPNPTFH 493
Db 481 VVMMIRPNPTFH 493

RESULT 9
AA014786
ID AA014786 standard; protein; 493 AA.
XX
AC AA014786;
XX
DT 11-JUL-2002 (first entry)
XX
DE Human matrix-remodeling-associated protein 3.
XX
KW Human; matrix-remodeling gene; extracellular matrix;
KW matrix-remodeling-associated nucleotide; screening;
KW matrix-remodeling-associated disease; angiogenesis; arthritis;
KW atherosclerosis; cancer; cardiomyopathy; diabetic necrosis; fibrosis;
KW ulceration.
XX
OS Homo sapiens.
XX
PN US2002019000-A1.
XX
PD 14-FEB-2002.
XX
PF 26-MAR-2001; 2001US-00818143.
XX
PR 09-OCT-1998; 98US-00169289.
XX
PA (WALK/) WALKER M G.
PA (VOLK/) VOLKMUETH W.
PA (KLING/) KLINGLER T M.
PI Walker MG, Volkmueth W, Klingler TM;
DR WPI: 2002-338319/37.
DR N-PSDB; AAL42455.
XX
PT New isolated polynucleotide coexpressed with matrix-remodeling genes,
PT useful in diagnosis, prognosis, prevention and treatment of diseases
PT associated with matrix-remodeling such as angiogenesis, arthritis and
PT cancer.
XX
PS Example; Fig 3; 63pp; English.
XX
CC The invention comprises human nucleotide sequences which are co-expressed
CC with matrix-remodeling genes. Matrix-remodeling is associated with the
CC construction, destruction and reorganisation of extracellular matrix
CC components. The matrix-remodeling-associated nucleotides of the invention
CC are useful for screening for and purifying ligands that specifically bind
CC to the nucleotides of the invention. The matrix-remodeling-associated
CC nucleotides of the invention are also useful in the diagnosis, prognosis,
CC prevention, treatment and evaluation of therapies for diseases associated
CC with matrix remodeling (e.g. angiogenesis, arthritis, atherosclerosis,
CC cancer, cardiomyopathy, diabetic necrosis, fibrosis and ulceration). The
CC present amino acid sequence is encoded by a human matrix-remodeling-
CC associated nucleotide of the invention
XX
SQ Sequence 493 AA;

Query Match 99.9%; Score 2682; DB 5; Length 493;
Best Local Similarity 99.8%; Pred. No. 1.4e-216;
Matches 492; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MRPLCVTCMWLGLLAAMGAVAGQEDGFEETGEGSRERFIYLRKRYKAGSDQKCTYTFIV 60
```

```
Db 1 MRPLCVTCMWLGLLAAMGAVAGQEDGFEETGEGSRERFIYLRKRYKAGSDQKCTYTFIV 60
Qy 61 PGGRTGALCVNSKEPEVLLNRYVHKOELFLNNELLKQKQRETIQQYKVDGIVSEY 120
Db 61 PGGRTGALCVNSKEPEVLLNRYVHKOELFLNNELLKQKQRETIQQYKVDGIVSEY 120
Qy 121 KLRKESRNNNSRVTQLYMLLHEIRKRDNALELSQLENRLINQTAQYLQASKYKDE 180
Db 121 KLRKESRNNNSRVTQLYMLLHEIRKRDNALELSQLENRLINQTAQYLQASKYKDE 180
Qy 181 HKYQHLATLANOSETIAQLEEHQVPSARPYQPPPAAPRVYQPPYNNRIINQISN 240
Db 181 HKYQHLATLANOSETIAQLEEHQVPSARPYQPPPAAPRVYQPPYNNRIINQISN 240
Qy 241 EIQSDQYLKVLPPPLPTMPLTSLPSTKPSGPMRDCLQALEGDHDSIYLVKPENTN 300
Db 241 EIQSDQYLKVLPPPLPTMPLTSLPSTKPSGPMRDCLQALEGDHDSIYLVKPENTN 300
Qy 301 RLNQWCDQHRHDPGWTVIQRIDGSVNPFPMETVKQGFQNGIDGYWLGLENIYWLINQ 360
Db 301 RLNQWCDQHRHDPGWTVIQRIDGSVNPFPMETVKQGFQNGIDGYWLGLENIYWLINQ 360
Qy 361 GNYKLIVTMDWSGRVPFAEYASFRLEPSEYYKRLGRYHGNAGDSFTWHNGKQFTILD 420
Db 361 GNYKLIVTMDWSGRVPFAEYASFRLEPSEYYKRLGRYHGNAGDSFTWHNGKQFTILD 420
Qy 421 RDHDVYTGCAHYQKGGWYVNAQAHNSLNGVWYRGHYSRYQDGYVMAEPRGGSYSLSK 480
Db 421 RDHDVYTGCAHYQKGGWYVNAQAHNSLNGVWYRGHYSRYQDGYVMAEPRGGSYSLSK 480
Qy 481 VVMMIRPNPTFH 493
Db 481 VVMMIRPNPTFH 493

RESULT 10
ABG80355
ID ABG80355 standard; protein; 493 AA.
XX
AC ABG80355;
XX
DT 15-NOV-2002 (first entry)
XX
DE Human TIE ligand NL4 protein.
XX
KW Human; TIE ligand NL4; vascularisation; wound healing; heart; limb;
KW ischemic condition; vulnery; vasotropic; gene therapy; NL4; NL5; NL6.
XX
OS Homo sapiens.
XX
PN US6413770-B1.
XX
PD 02-JUL-2002.
XX
PF 19-AUG-1998; 98US-00136801.
XX
PR 19-SEP-1997; 97US-00933821.
PR 29-OCT-1997; 97US-00960507.
XX
PA (GENTH ) GENENTECH INC.
XX
PI Godowski P, Gurney A, Hillan KJ, Botstein D, Goddard A, Roy M;
PI Ferrara N, Tumas D, Schwall R;
XX
DR WPI: 2002-641562/69.
DR N-PSDB; ABS65529.
XX
PT Novel isolated nucleic acid molecules encoding NL4 TIE ligand homologue
PT polypeptides which are useful for inducing vascularization for wound
PT healing and treating ischemic condition of the heart or a limb.
XX
PS Example 1; Fig 3; 85pp; English.
```

XX The present invention relates to a new nucleic acid molecule which
 CC comprises nucleotide 215 to 1252 of fully defined T1E ligand N14
 CC polynucleotide sequence of 2212 base pairs as given in the specification.
 CC The nucleic acid of the invention encodes N14 T1E ligand homologue
 CC polypeptide. The invention is useful for expressing N14 T1E ligand
 CC homologue polypeptide by recombinant techniques. T1E ligand homologue
 CC polypeptide is useful for inducing vascularisation for promoting wound
 CC healing and for treating ischemic condition of heart or limb. The
 CC present amino acid sequence represents a human T1E ligand protein, as
 CC described in the invention

XX Sequence 493 AA;

Query Match 99.9%; Score 2682; DB 5; Length 493;

Best Local Similarity 99.8%; Pred. No. 1,4e-216; Mismatches 0; Indels 0; Gaps 0;

Matches 492; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRPLCTCMTGILAMGAVAGQEDGEGTEGSPREFIYNRYKRGESQDKCTYFIY 60
 Db 1 MRPLCTCMTGILAMGAVAGQEDGEGTEGSPREFIYNRYKRGESQDKCTYFIY 60
 QY 61 PQQRTGALCVNSKPEVLLNRYKQELNELLKOKQIETLQQLVVDGIVSEV 120
 Db 61 PQQRTGALCVNSKPEVLLNRYKQELNELLKOKQIETLQQLVVDGIVSEV 120
 QY 121 KLLKRESRMNSRVTLQYVQLHEIIRKDNALLESOLENRLINOTADMQLASKYKDL 180
 Db 121 KLLKRESRMNSRVTLQYVQLHEIIRKDNALLESOLENRLINOTADMQLASKYKDL 180
 QY 181 HKYQHLATLANQSEIIAOLEHQCQVPSARVPVPPAPPRVYQPTNRIINQISTN 240
 Db 181 HKYQHLATLANQSEIIAOLEHQCQVPSARVPVPPAPPRVYQPTNRIINQISTN 240
 QY 241 EIQSDQNLKVLPPPLPMTPTLSLPSSTDKPSGPRDCIALDEGHDTSSIVLVKPENTN 300
 Db 241 EIQSDQNLKVLPPPLPMTPTLSLPSSTDKPSGPRDCIALDEGHDTSSIVLVKPENTN 300
 QY 301 RLMQVWCDQRHDPGQMTVIOERLDGSVNFERNWETYSKQFGNIDEGYWLGENIYWLTNQ 360
 Db 301 RLMQVWCDQRHDPGQMTVIOERLDGSVNFERNWETYSKQFGNIDEGYWLGENIYWLTNQ 360
 QY 361 GNYKLLVTMEDSGRKVFAYEASFRLEPSEYYTLRLGRYHGNAGDSFTWNGKQFTLLD 420
 Db 361 GNYKLLVTMEDSGRKVFAYEASFRLEPSEYYTLRLGRYHGNAGDSFTWNGKQFTLLD 420
 QY 421 RDHDVYTGNCAYQKQGMWYNACAHSNLNGVWYRGHYRSRYQDGVYAAEFRGGSYSLLK 480
 Db 421 RDHDVYTGNCAYQKQGMWYNACAHSNLNGVWYRGHYRSRYQDGVYAAEFRGGSYSLLK 480
 QY 481 VVMATIRPNNTFH 493
 Db 481 VVMATIRPNNTFH 493

RESULT 11

AAE19825

ID AAE19825 standard; protein; 493 AA.

XX AAE19825;

XX 18-JUN-2002 (first entry)

DE Human T1E ligand N14 protein.

KW Human; T1E ligand; N14; cytosolic; osteopathic; vascularisation; toxin;

KW muscular; immunoassay; therapeutic; anti-tumour agent; muscle growth;

XX bone development; maturation; angiogenesis.

OS Homo sapiens.

XX US6350450-B1.

PD 26-FEB-2002.
 XX 19-AUG-1998; 98US-00136828.
 FR 19-SEP-1997; 97US-0059588P.
 XX (GETH) GENENTECH INC.
 PA Goddard PJ, Gurney AL, Goddard A, Hillan K;
 PI WPI, 2002-215264/27.
 DR N-PSDB; AAD31563.
 DR Novel isolated antibody which specifically binds to a mammalian N14 T1E
 PT ligand useful for immunoassays, delivery of cytotoxic molecules and as
 PT diagnostic agents to detect disease states.
 PS Claim 1; Fig 3; 59pp; English.

XX The invention relates to an isolated antibody which specifically binds to
 CC a mammalian N14 T1E (tyrosine kinase containing Ig and EGF homology
 CC domains) ligand polypeptide which is capable of inducing vascularisation.
 CC The isolated antibody may be used in immunoassays to measure the amount
 CC of a T1E ligand in a biological sample. Additionally, the antibody may be
 CC used for the delivery of cytotoxic molecules, e.g. radioisotopes or
 CC toxins, or therapeutic agents to cells expressing a corresponding T1E
 CC receptor. The therapeutic agents may, for example, be other T1E ligands,
 CC including the T1E-2 ligand, members of the vascular endothelial growth
 CC factor (VEGF) family, or known anti-tumour agents, and agents known to be
 CC associated with muscle growth or development, or bone development.
 CC maturation, or growth. Anti-T1E ligand antibodies are also suitable as
 CC diagnostic agents, to detect disease states associated with the
 CC expression of a T1E (e.g. T1E-2) receptor. These detectably labelled
 CC antibody agonists of a T1E receptor can be used for imaging the presence
 CC of angiogenesis. The present sequence is human T1E ligand N14 protein
 XX Sequence 493 AA;

Query Match 99.9%; Score 2682; DB 5; Length 493;
 Best Local Similarity 99.8%; Pred. No. 1,4e-216;
 Matches 492; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRPLCTCMTGILAMGAVAGQEDGEGTEGSPREFIYNRYKRGESQDKCTYFIY 60
 Db 1 MRPLCTCMTGILAMGAVAGQEDGEGTEGSPREFIYNRYKRGESQDKCTYFIY 60
 QY 61 PQQRTGALCVNSKPEVLLNRYKQELNELLKOKQIETLQQLVVDGIVSEV 120
 Db 61 PQQRTGALCVNSKPEVLLNRYKQELNELLKOKQIETLQQLVVDGIVSEV 120
 QY 121 KLLKRESRMNSRVTLQYVQLHEIIRKDNALLESOLENRLINOTADMQLASKYKDL 180
 Db 121 KLLKRESRMNSRVTLQYVQLHEIIRKDNALLESOLENRLINOTADMQLASKYKDL 180
 QY 181 HKYQHLATLANQSEIIAOLEHQCQVPSARVPVPPAPPRVYQPTNRIINQISTN 240
 Db 181 HKYQHLATLANQSEIIAOLEHQCQVPSARVPVPPAPPRVYQPTNRIINQISTN 240
 QY 241 EIQSDQNLKVLPPPLPMTPTLSLPSSTDKPSGPRDCIALDEGHDTSSIVLVKPENTN 300
 Db 241 EIQSDQNLKVLPPPLPMTPTLSLPSSTDKPSGPRDCIALDEGHDTSSIVLVKPENTN 300
 QY 301 RLMQVWCDQRHDPGQMTVIOERLDGSVNFERNWETYSKQFGNIDEGYWLGENIYWLTNQ 360
 Db 301 RLMQVWCDQRHDPGQMTVIOERLDGSVNFERNWETYSKQFGNIDEGYWLGENIYWLTNQ 360
 QY 361 GNYKLLVTMEDSGRKVFAYEASFRLEPSEYYTLRLGRYHGNAGDSFTWNGKQFTLLD 420
 Db 361 GNYKLLVTMEDSGRKVFAYEASFRLEPSEYYTLRLGRYHGNAGDSFTWNGKQFTLLD 420
 QY 421 RDHDVYTGNCAYQKQGMWYNACAHSNLNGVWYRGHYRSRYQDGVYAAEFRGGSYSLLK 480
 Db 421 RDHDVYTGNCAYQKQGMWYNACAHSNLNGVWYRGHYRSRYQDGVYAAEFRGGSYSLLK 480

Qy 481 VMMIRNPNTFH 493
 Db 481 VMMIRNPNTFH 493

RESULT 12
 ABO17749
 ID ABO17749 standard; protein; 493 AA.
 XX
 AC ABO17749;
 XX
 DT 26-AUG-2003 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO196.
 XX
 KW Human; secreted and transmembrane protein; PRO; antiinflammatory;
 KW antiatherosclerotic; candidant; anti-infectivity; anti-HIV; cytostatic;
 KW antidiabetic; gene therapy; tumour necrosis factor (TNF)-alpha release;
 KW TNF-alpha release; cell proliferation; cell differentiation;
 KW gene expression modulator; proteoglycan release; cytokine release;
 KW tumour; inflammatory disease; organ failure; atherosclerosis;
 KW cardiac injury; infertility; birth defect; premature aging; AIDS;
 KW acquired immunodeficiency syndrome; cancer; diabetic complication;
 KW chromosome mapping; gene mapping; pharmaceutical; diagnostic; biosensor;
 KW bio reactor; tissue typing.
 XX
 OS Homo sapiens.
 XX
 PN US2003032156-A1.
 XX
 PD 13-FEB-2003.
 XX
 XX
 PF 06-MAY-2002; 2002US-00140474.
 XX
 XX
 PR 31-MAR-1997; 97WO-US0005230.
 PR 12-JUN-1998; 98WO-US012456.
 PR 14-JUL-1998; 98WO-US014552.
 PR 28-AUG-1998; 98WO-US017888.
 PR 10-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98WO-US019093.
 PR 14-SEP-1998; 98WO-US019094.
 PR 14-SEP-1998; 98WO-US019177.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019437.
 PR 07-OCT-1998; 98WO-US021141.
 PR 29-OCT-1998; 98WO-US022992.
 PR 29-OCT-1998; 98WO-US024855.
 PR 20-NOV-1998; 98WO-US025108.
 PR 01-DEC-1998; 99WO-US000106.
 PR 05-JAN-1999; 99WO-US005028.
 PR 08-MAR-1999; 99WO-US005190.
 PR 10-MAR-1999; 99WO-US008615.
 PR 20-APR-1999; 99WO-US010733.
 PR 14-MAY-1999; 99WO-US012252.
 PR 02-JUN-1999; 99WO-US020111.
 PR 01-SEP-1999; 99WO-US020594.
 PR 08-SEP-1999; 99WO-US020944.
 PR 13-SEP-1999; 99WO-US021090.
 PR 15-SEP-1999; 99WO-US021547.
 PR 15-SEP-1999; 99WO-US023089.
 PR 05-OCT-1999; 99WO-US028214.
 PR 29-NOV-1999; 99WO-US028213.
 PR 30-NOV-1999; 99WO-US028409.
 PR 30-NOV-1999; 99WO-US028301.
 PR 01-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028564.
 PR 02-DEC-1999; 99WO-US028565.
 PR 16-DEC-1999; 99WO-US030995.
 PR 20-DEC-1999; 99WO-US030911.
 PR 20-DEC-1999; 99WO-US030999.

PR 22-DEC-1999; 99WO-US030720.
 PR 30-DEC-1999; 99WO-US031243.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 15-MAR-2000; 2000WO-US006319.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023322.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000WO-US034259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00806889.
 PR 22-MAR-2001; 2001US-00817744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00906827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerlitsen ME, Goddard A, Godowski FU, Gunney AU, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WT, Zhang Z;
 XX
 DR WPI; 2003-341980/32.
 DR N-PSDB; AC023986.
 PT New secreted and transmembrane PRO nucleic acids, for treating
 inflammation, organ failure, atherosclerosis, cardiac injury.

PT infertility, birth defects, premature aging, acquired immunodeficiency
XX syndrome (AIDS), or cancer.
XX Claim 12; Fig 268; 660pp; English.
XX The invention describes an isolated nucleic acid (1) comprising, or which
CC has 80 % sequence identity to, or the full-length coding sequence of, one
CC of 275 nucleotide sequences, and which encodes a corresponding
CC polypeptide selected from 275 amino acid sequences, where all sequences
CC are given in the specification. The polypeptide encoded by (1) is used to
CC detect PRO polypeptides, link a bioactive molecule to a cell expressing a
CC PRO polypeptide, modulate a biological activity of a cell, stimulate the
CC release of tumour necrosis factor (TNF)-alpha from human blood, modulate
CC the uptake of glucose or free fatty acid by cells, stimulate or inhibit
CC the proliferation or differentiation of cells or gene expression,
CC stimulate the release of proteoglycans, stimulate the release of cytokine
CC from peripheral blood mononuclear cells, inhibit the binding of A-peptide
CC to factor VIIa, or detect the presence of tumour in a mammal. The nucleic
CC acid and polypeptide encoded by it, are useful for treating inflammatory
CC diseases, organ failure, atherosclerosis, cardiac injury, infertility,
CC birth defects, premature aging, acquired immunodeficiency syndrome
CC (AIDS), cancer, or diabetic complications. The nucleic acid is useful as
CC hybridisation probes, in chromosome and gene mapping, and in generating
CC antisense RNA or DNA. The polypeptides are useful as pharmaceuticals,
CC diagnostics, biosensors or bioreactors. Both are useful in tissue typing.
CC This is the amino acid sequence of a novel human secreted and
CC transmembrane PRO polypeptide

Sequence 493 AA;

Query Match 99.9%; Score 2682; DB 6; Length 493;
Best Local Similarity 99.8%; Pred. No. 1.4e-216;
Matches 492; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRPLVTGWMGLLNLAMGVAAGQEDFETEGSGREFEYLNRYRAESQDKCYTIV 60
DB 1 MRPLVTGWMGLLNLAMGVAAGQEDFETEGSGREFEYLNRYRAESQDKCYTIV 60
QY 61 POORVTGACVSKPEVLLNRYVAKOELLELNBLKQKQIETLOOLVYKGGIVSEV 120
DB 61 POORVTGACVSKPEVLLNRYVAKOELLELNBLKQKQIETLOOLVYKGGIVSEV 120
QY 121 KLLRRESRMNSRVTLQVQLHEIIRKDNALIEQLBNRLNQTADMLQLASKYKDL 180
DB 121 KLLRRESRMNSRVTLQVQLHEIIRKDNALIEQLBNRLNQTADMLQLASKYKDL 180
QY 181 HYYOHLATLHNOSEIAGLESHCORVPSARVPQPPAPPRVYQPTVRIINQISTN 240
DB 181 HYYOHLATLHNOSEIAGLESHCORVPSARVPQPPAPPRVYQPTVRIINQISTN 240
QY 241 EIOSDONIKVLPPLPTMPTLTSLPSSTDKPSGPRDCIQALEDGHTTSIYLVKPE 300
DB 241 EIOSDONIKVLPPLPTMPTLTSLPSSTDKPSGPRDCIQALEDGHTTSIYLVKPE 300
QY 301 RLMQWMCORHDPGQMTVIGRLDGSVNFERNWETVYKQFGVIDEYWLGLENITWLTNO 360
DB 301 RLMQWMCORHDPGQMTVIGRLDGSVNFERNWETVYKQFGVIDEYWLGLENITWLTNO 360
QY 361 GNYKLLVTWEDWSGKRVFAEYASFLRPESEYKRLGRYHGNAGDSFTWNGKQFTILD 420
DB 361 GNYKLLVTWEDWSGKRVFAEYASFLRPESEYKRLGRYHGNAGDSFTWNGKQFTILD 420
QY 421 RHHVYTTGCAHYQKGGWYNA CAHSNLNGVYRGGHRSRQDGVYAAEPFGSGYSILK 480
DB 421 RHHVYTTGCAHYQKGGWYNA CAHSNLNGVYRGGHRSRQDGVYAAEPFGSGYSILK 480
QY 481 VMMIRPNPTFH 493
DB 481 VMMIRPNPTFH 493

RESULT 13
ABO25150

ID ABO25150 standard; protein; 493 AA.
XX ABO25150;
AC
XX
XX 05-SEP-2003 (first entry)
DT
XX
XX Novel human secreted and transmembrane protein PRO196.
DE
XX Human, secreted and transmembrane protein; PRO; antidiabetic;
KW opthalmological; cytostatic; immunostimulant; gene therapy;
KW vascular endothelial growth factor inhibitor; hypertrophy of adult heart;
KW protein secretion disorder; pancreas disorder; diabetes;
KW vascular permeability; retinal neuron cell survival; retinal disorder;
KW immune response; inflammation; mononuclear cell infiltration;
KW eosinophil infiltration; apoptosis; neoplastic growth.
XX
XX Homo sapiens.
OS
XX US2003040014-A1.
PN
XX
XX 27-FEB-2003.
PD
XX
XX 01-FEB-2002; 2002US-00066269.
PP
XX
XX 26-AUG-1997; 97US-0056974P.
PR 17-SEP-1997; 97US-0059115P.
PR 18-SEP-1997; 97US-0059263P.
PR 19-SEP-1997; 97US-0059588P.
PR 17-OCT-1997; 97US-0062285P.
PR 24-OCT-1997; 97US-0062816P.
PR 24-OCT-1997; 97US-0063082P.
PR 27-OCT-1997; 97US-0063382P.
PR 29-OCT-1997; 97US-0063733P.
PR 21-NOV-1997; 97US-0066364P.
PR 25-NOV-1997; 97US-0066840P.
PR 16-DEC-1997; 97US-0069684P.
PR 09-FEB-1998; 98US-0074086P.
PR 09-FEB-1998; 98US-0074092P.
PR 25-MAR-1998; 98US-0079294P.
PR 08-APR-1998; 98US-0081049P.
PR 14-JUL-1998; 98MO-US014852.
PR 10-AUG-1998; 98US-0095988P.
PR 18-AUG-1998; 98US-0097000P.
PR 09-SEP-1998; 98US-0099601P.
PR 10-SEP-1998; 98US-0099803P.
PR 10-SEP-1998; 98US-0099811P.
PR 10-SEP-1998; 98US-0099812P.
PR 14-SEP-1998; 98MO-US018824.
PR 14-SEP-1998; 98MO-US019093.
PR 16-SEP-1998; 98MO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98MO-US019437.
PR 24-SEP-1998; 98US-0101922P.
PR 28-OCT-1998; 98US-0106032P.
PR 20-NOV-1998; 98US-01069304P.
PR 20-NOV-1998; 98MO-US024855.
PR 25-NOV-1998; 98MO-US025190.
PR 01-DEC-1998; 98MO-US025108.
PR 08-MAR-1999; 99MO-US005028.
PR 23-MAR-1999; 99US-0125778P.
PR 02-JUN-1999; 99MO-US012252.
PR 15-JUN-1999; 99US-0136965P.
PR 20-JUL-1999; 99US-0145070P.
PR 26-JUL-1999; 99US-0145688P.
PR 17-AUG-1999; 99US-0149396P.
PR 01-SEP-1999; 99MO-US020111.
PR 08-SEP-1999; 99MO-US020594.
PR 15-SEP-1999; 99MO-US021090.
PR 15-SEP-1999; 99MO-US021547.
PR 30-NOV-1999; 99MO-US028313.
PR 01-DEC-1999; 99MO-US028301.
PR 02-DEC-1999; 99MO-US028565.
PR 07-DEC-1999; 99US-0169495P.

PS Claim 25; Page 235-237; 279pp; Japanese.

CC The present invention describes a method for testing drugs that have
CC actively on treating or preventing at least 1 disease selected from
CC hyperlipaemia, arteriosclerosis and hyperglycaemia, which comprises
CC culturing cells originating from a mammal in the presence or absence of a
CC test substance, and detecting expression dose of the mRNA with any of the
CC specified nucleotide sequences. More specifically the method comprises:
CC (a) culturing cells originating from a mammal in the presence or absence
CC of a test substance; (b) detecting expression dose of the mRNA with any
CC of the nucleotide sequences (i)-(v) (where t and u are exchangeable); (i)
CC nucleotides 47-1411 of a 1604 base pair sequence (ADA01398); (ii)
CC nucleotides 78-1457 of a 1716 base pair sequence (ADA01400); (iii) the
CC DNA inserted with a phagemid sustaining in the transformant E. coli
CC PBK/m5-1 SANK 72199 (FERM BP-6940); (iv) the DNA inserted with a
CC phagemid sustaining in the transformant E. coli pTrit/h5-1 SANK 72299
CC (FERM BP-6941); or (v) a nucleotide sequence hybridisable with a
CC polynucleotide containing the antisense sequence of (i)-(iv) under
CC stringent conditions and encoding a polypeptide with the activity of
CC increasing neutral lipid concentration in serum; and (c) comparing the
CC resultant expression doses for selecting a test substance. The nucleotide
CC sequences (i)-(v) have antihyperlipaemic, antihyperglycaemic and
CC antidiabetic activities, and can be used in gene therapy. The method is
CC for testing drugs to treat or prevent diseases e.g. hyperlipaemia,
CC arteriosclerosis and hyperglycaemia. The present sequence is used in the
CC exemplification of the present invention.

CC Sequence 493 AA;

Query Match 99.9%; Score 2682; DB 6; Length 493;
Best Local Similarity 99.8%; Pred.No. 1.4e-216;
Matches 492; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRPLCTVMGLGLLAAAGVAGQEDGEGTEGSEPREFIYINRYKAGESQDKTYTPIV 60
DB 1 MRPLCTVMGLGLLAAAGVAGQEDGEGTEGSEPREFIYINRYKAGESQDKTYTPIV 60
QY 61 POORVTGAI CVNSKEPEVILENVRHKOLELNNELNQLKQKQIEFLQOLVKYDGIASEV 120
DB 61 POORVTGAI CVNSKEPEVILENVRHKOLELNNELNQLKQKQIEFLQOLVKYDGIASEV 120
QY 121 KILKRESNNMSRVTLQVWOLHEIIRKDNALLESQJENILINTADMLQLASKYKOLE 180
DB 121 KILKRESNNMSRVTLQVWOLHEIIRKDNALLESQJENILINTADMLQLASKYKOLE 180
QY 181 HKYQHLATLANQSEIIIAQLBHCQVPSARVPQPPAPAPRYVQPTNRIINQISTN 240
DB 181 HKYQHLATLANQSEIIIAQLBHCQVPSARVPQPPAPAPRYVQPTNRIINQISTN 240
QY 241 ELGSDONLKVLPPLPTMTLTLSLPSSTDKPSGPRDCLQLEDDHTSSIIYVKEPENTN 300
DB 241 ELGSDONLKVLPPLPTMTLTLSLPSSTDKPSGPRDCLQLEDDHTSSIIYVKEPENTN 300
QY 301 RLMQVWCDQRHDPGWTYIQRRLDGSVNFERNMETYKQFGNIDSEYWLGEENIYWLTNQ 360
DB 301 RLMQVWCDQRHDPGWTYIQRRLDGSVNFERNMETYKQFGNIDSEYWLGEENIYWLTNQ 360
QY 361 GNYKLLVMEWDSGRKVPFAEYASFLEPSESEYKRLRGRHNMADSTFWNGKQFTLLD 420
DB 361 GNYKLLVMEWDSGRKVPFAEYASFLEPSESEYKRLRGRHNMADSTFWNGKQFTLLD 420
QY 421 RHHDVYTGCAHYQKGGWVYNACASNTNGVYRGHRSRYQKQDGVYAAEFRGGSYSJLKK 480
DB 421 RHHDVYTGCAHYQKGGWVYNACASNTNGVYRGHRSRYQKQDGVYAAEFRGGSYSJLKK 480
QY 481 VVMATIRPNENTH 493
DB 481 VVMATIRPNENTH 493

RESULT 15
ABU81003
ID ABU81003 standard; protein; 493 AA.

XX AC ABU81003;
XX DT 23-JUN-2003 (first entry)
XX DE Human PRO polypeptide #134.
XX KM Human; PRO polypeptide; secreted and transmembrane protein;
KM anti-PRO antibody; diagnostic assay; gene expression; diabetes;
KM bone disorder; cartilage disorder; rheumatoid arthritis; obesity;
KM sports injury; osteoarthritis; hyper-insulinaemia; hypo-insulinaemia;
KM hearing loss; coagulation disorder; stroke; heart attack; carcinoma;
KM antidiabetic; anorectic; vulnerability; antidiabetic; osteopathic;
KM antineumatic; auditory; cerebroprotective; angiogenic.
XX OS Homo sapiens.
XX PN US2003004311-A1.
XX PD 02-JAN-2003.
XX PF 19-DEC-2001; 2001US-00028072.
XX 18-JUN-1997; 97US-0049911P.
XX 26-AUG-1997; 97US-0056974P.
XX 17-SEP-1997; 97US-0059113P.
XX 17-SEP-1997; 97US-0059115P.
XX 17-SEP-1997; 97US-0059117P.
XX 17-SEP-1997; 97US-0059122P.
XX 17-SEP-1997; 97US-0059184P.
XX 18-SEP-1997; 97US-0059263P.
XX 18-SEP-1997; 97US-0059352P.
XX 19-SEP-1997; 97US-0059588P.
XX 24-SEP-1997; 97US-0059836P.
XX 17-OCT-1997; 97US-0062280P.
XX 17-OCT-1997; 97US-0062285P.
XX 17-OCT-1997; 97US-0063127P.
XX 17-OCT-1997; 97US-0063327P.
XX 17-OCT-1997; 97US-0063755P.
XX 24-OCT-1997; 97US-0062814P.
XX 24-OCT-1997; 97US-0062816P.
XX 24-OCT-1997; 97US-0063045P.
XX 24-OCT-1997; 97US-0063082P.
XX 24-OCT-1997; 97US-0063127P.
XX 27-OCT-1997; 97US-0063327P.
XX 27-OCT-1997; 97US-0063329P.
XX 28-OCT-1997; 97US-0063500P.
XX 28-OCT-1997; 97US-0063561P.
XX 29-OCT-1997; 97US-0063704P.
XX 29-OCT-1997; 97US-0063733P.
XX 29-OCT-1997; 97US-0063735P.
XX 29-OCT-1997; 97US-0063738P.
XX 03-NOV-1997; 97US-0064288P.
XX 07-NOV-1997; 97US-0064809P.
XX 12-NOV-1997; 97US-0065186P.
XX 17-NOV-1997; 97US-0065846P.
XX 21-NOV-1997; 97US-0066364P.
XX 24-NOV-1997; 97US-0066453P.
XX 24-NOV-1997; 97US-0066511P.
XX 24-NOV-1997; 97US-0066702P.
XX 11-DEC-1997; 97US-0069212P.
XX 11-DEC-1997; 97US-0069278P.
XX 11-DEC-1997; 97US-0069344P.
XX 16-DEC-1997; 97US-0069694P.
XX 23-JAN-1998; 98US-0072302P.
XX 04-FEB-1998; 98US-0073612P.
XX 09-FEB-1998; 98US-0074086P.
XX 09-FEB-1998; 98US-0074092P.
XX 12-MAR-1998; 98US-0077791P.
XX 20-MAR-1998; 98US-0078910P.
XX 25-MAR-1998; 98US-0079294P.
XX 27-MAR-1998; 98US-0079663P.
XX 31-MAR-1998; 98US-0079728P.
XX 31-MAR-1998; 98US-0080165P.

12-JUN-1998; 98WO-US012456.
 14-JUL-1998; 98WO-US014552.
 28-AUG-1998; 98WO-US017888.
 10-SEP-1998; 98WO-US018824.
 14-SEP-1998; 98WO-US019093.
 14-SEP-1998; 98WO-US019094.
 14-SEP-1998; 98WO-US019177.
 16-SEP-1998; 98WO-US019330.
 17-SEP-1998; 98WO-US019437.
 07-OCT-1998; 98WO-US021141.
 29-OCT-1998; 98WO-US022991.
 29-OCT-1998; 98WO-US022992.
 20-NOV-1998; 98WO-US024855.
 01-DEC-1998; 98WO-US025108.
 05-JAN-1999; 98WO-US000106.
 08-MAR-1999; 98WO-US005028.
 10-MAR-1999; 98WO-US005150.
 20-APR-1999; 98WO-US008615.
 14-MAY-1999; 98WO-US010733.
 02-JUN-1999; 98WO-US012252.
 01-SEP-1999; 98WO-US020111.
 08-SEP-1999; 98WO-US020594.
 13-SEP-1999; 98WO-US020944.
 15-SEP-1999; 98WO-US021050.
 05-OCT-1999; 98WO-US021547.
 05-OCT-1999; 98WO-US023089.
 29-NOV-1999; 98WO-US028214.
 30-NOV-1999; 98WO-US028313.
 30-NOV-1999; 98WO-US028409.
 01-DEC-1999; 98WO-US028301.
 01-DEC-1999; 98WO-US028634.
 02-DEC-1999; 98WO-US028551.
 02-DEC-1999; 98WO-US028564.
 16-DEC-1999; 98WO-US028565.
 20-DEC-1999; 98WO-US030095.
 20-DEC-1999; 98WO-US030911.
 20-DEC-1999; 98WO-US030999.
 30-DEC-1999; 98WO-US031243.
 30-DEC-1999; 98WO-US031274.
 05-JAN-2000; 2000WO-US000219.
 06-JAN-2000; 2000WO-US000277.
 06-JAN-2000; 2000WO-US000376.
 11-FEB-2000; 2000WO-US003565.
 18-FEB-2000; 2000WO-US004341.
 18-FEB-2000; 2000WO-US004342.
 22-FEB-2000; 2000WO-US004414.
 24-FEB-2000; 2000WO-US004914.
 24-FEB-2000; 2000WO-US005004.
 01-MAR-2000; 2000WO-US005601.
 02-MAR-2000; 2000WO-US005746.

(GETH) GENENTECH INC.

Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W,
 Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S,
 Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z,
 WPI, 2003-352836/33.
 N-PSDB; ACP67127.

New isolated PRO polypeptide useful for treating diabetes, rheumatoid
 arthritis, sports injuries, obesity, hearing loss in mammals, stroke, or
 heart attack.

Claim 12, Fig 268, 643pp; English.

The present invention relates to the isolation of novel human PRO
 polypeptides, and the polynucleotide sequences encoding them. The PRO
 polypeptides are secreted and transmembrane proteins. The PRO
 polypeptides and polynucleotides are useful for preparing a medicament
 useful in the treatment of diabetes, bone and/or cartilage disorders
 (e.g. rheumatoid arthritis, sports injuries, osteoarthritis), obesity,
 hyper- or hypo-insulinaemia, hearing loss, and coagulation disorders

CC (e.g. stroke, heart attack). Anti-PRO antibodies are useful in diagnostic
 CC assays for PRO, by detecting its expression in specific cells, tissues or
 CC serum, and for affinity purification of PRO from recombinant cell culture
 CC or natural sources. AB080870-AB081144 represent the human PRO
 CC polypeptides of the invention. Note: The sequence data for this patent
 CC was obtained in electronic format directly from the USPTO web site at
 CC seqdata.uspto.gov/psipsdidentry.html
 XX

SO Sequence 493 AA.

Query Match 99.9%; Score 2682; DB 6; Length 493;
 Best Local Similarity 99.8%; Pred. No. 1.4e-216;
 Matches 492; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRPLCTCWWLGLLAAAGVAGQDGEFTEGSSPREFFYLRYRAGEGQCKYTFV 60
 DB 1 MRPLCTCWWLGLLAAAGVAGQDGEFTEGSSPREFFYLRYRAGEGQCKYTFV 60
 QY 61 PQORVTGALCVNSKEPEVLENNRVHKOELNNELNKKOQIETLQVLKVDGIVSEV 120
 DB 61 PQORVTGALCVNSKEPEVLENNRVHKOELNNELNKKOQIETLQVLVEVDGIVSEV 120
 QY 121 KILRKESRMNNSKVTLQYMLHEIRKRDNALELSQENRILNQYADMLQASKYKDE 180
 DB 121 KILRKESRMNNSKVTLQYMLHEIRKRDNALELSQENRILNQYADMLQASKYKDE 180
 QY 181 HKYQHLATLAHQSEIIAQLLEHCORVPSARVPQPPAPPRVYQPTYNRIINQISTN 240
 DB 181 HKYQHLATLAHQSEIIAQLLEHCORVPSARVPQPPAPPRVYQPTYNRIINQISTN 240
 QY 241 EIOSDONLKYLPPLPTMPTLTLSPBSTKPSGPMDCQALBDGHDITSITLVKRENTN 300
 DB 241 EIOSDONLKYLPPLPTMPTLTLSPBSTKPSGPMDCQALBDGHDITSITLVKRENTN 300
 QY 301 RLMOVWCDDRDHDPGGTIVTQRIDGSVNFPRMTEYKQSGNIDGFWMLGLENITWLTNQ 360
 DB 301 RLMOVWCDDRDHDPGGTIVTQRIDGSVNFPRMTEYKQSGNIDGFWMLGLENITWLTNQ 360
 QY 361 GNYKLLVTMEDWSGRRVPAEYASFRLEPSEYKRLGRYHGNAGDSFTWNGKQFTTLD 420
 DB 361 GNYKLLVTMEDWSGRRVPAEYASFRLEPSEYKRLGRYHGNAGDSFTWNGKQFTTLD 420
 QY 421 RDHDVYTGCAHYKQKGMWYNAQASHNLGWAYRGSHVRSRYQDPVYAAEPFGSGYSLKK 480
 DB 421 RDHDVYTGCAHYKQKGMWYNAQASHNLGWAYRGSHVRSRYQDPVYAAEPFGSGYSLKK 480
 QY 481 VVMIRPNPNTFH 493
 DB 481 VVMIRPNPNTFH 493

Search completed: July 30, 2004, 12:36:14
 Job time : 57 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: July 30, 2004, 12:35:14 ; Search time 20 Seconds

(without alignments)
1272.580 Million cell updates/sec

Title: US-10-018-386-2

Perfect score: 2686
Sequence: 1 MRPLCTCMTGLIANGAV.....GSISLKRYVMIRNPVTFH 493

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 389414 seqs, 51625971 residues

Total number of hits satisfying chosen parameters: 389414

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database : Issued Patents AA:
1: /cgn2_6/ptodata/2/1aa/5A.COMB.pep:*
2: /cgn2_6/ptodata/2/1aa/5B.COMB.pep:*
3: /cgn2_6/ptodata/2/1aa/6A.COMB.pep:*
4: /cgn2_6/ptodata/2/1aa/6B.COMB.pep:*
5: /cgn2_6/ptodata/2/1aa/CTUS.COMB.pep:*
6: /cgn2_6/ptodata/2/1aa/backfiles1.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	2682	99.9	493	2	US-08-933-821-2
2	2682	99.9	493	3	US-08-960-507-2
3	2682	99.9	493	4	US-09-136-828-2
4	2682	99.9	493	4	US-09-332-928A-2
5	2682	99.9	493	4	US-09-136-801-2
6	2682	99.9	493	4	US-09-332-929-2
7	2682	99.9	493	4	US-09-333-075-2
8	2682	99.9	493	4	US-09-202-088A-2
9	2682	99.9	493	4	US-09-333-077-2
10	1507.5	56.1	491	2	US-08-933-821-4
11	1507.5	56.1	491	3	US-08-960-507-4
12	1507.5	56.1	491	4	US-09-136-828-4
13	1507.5	56.1	491	4	US-09-332-928A-4
14	1507.5	56.1	491	4	US-09-136-801-4
15	1507.5	56.1	491	4	US-09-332-929-4
16	1507.5	56.1	491	4	US-09-333-075-4
17	1507.5	56.1	491	4	US-09-202-088A-4
18	1507.5	56.1	491	4	US-09-333-077-4
19	1500.5	55.9	491	4	US-09-658-644-2
20	1094.5	40.7	470	2	US-08-933-821-6
21	1094.5	40.7	470	3	US-08-960-507-6
22	1094.5	40.7	470	4	US-09-136-828-6
23	1094.5	40.7	470	4	US-09-332-928A-6
24	1094.5	40.7	470	4	US-09-136-801-6
25	1094.5	40.7	470	4	US-09-332-929-6
26	1094.5	40.7	470	4	US-09-333-075-6
27	1094.5	40.7	470	4	US-09-202-088A-6

28	1094.5	40.7	470	4	US-09-333-077-6	Sequence 6, Appli
29	578	21.5	491	3	US-08-740-223A-13	Sequence 13, Appli
30	578	21.5	491	4	US-09-709-188-13	Sequence 13, Appli
31	578	21.5	497	3	US-08-740-223A-4	Sequence 4, Appli
32	578	21.5	497	3	US-09-709-188-4	Sequence 4, Appli
33	577.5	21.5	498	3	US-08-740-223A-20	Sequence 20, Appli
34	577.5	21.5	498	4	US-09-709-188-20	Sequence 20, Appli
35	577	21.5	497	1	US-08-373-579-4	Sequence 4, Appli
36	577	21.5	497	2	US-08-418-595-4	Sequence 4, Appli
37	577	21.5	497	2	US-08-665-926-4	Sequence 4, Appli
38	577	21.5	497	2	US-08-348-492-4	Sequence 4, Appli
39	577	21.5	497	3	US-09-162-437-4	Sequence 4, Appli
40	577	21.5	497	4	US-08-817-318-4	Sequence 4, Appli
41	577	21.5	497	4	US-09-442-717-4	Sequence 4, Appli
42	577	21.5	497	4	US-09-689-020-4	Sequence 4, Appli
43	575.5	21.4	498	4	US-09-202-091-6	Sequence 6, Appli
44	575	21.4	490	3	US-08-740-223A-12	Sequence 12, Appli
45	575	21.4	490	4	US-09-709-188-12	Sequence 12, Appli

ALIGNMENTS

```
RESULT 1
US-08-933-821-2
Sequence 2, Application US-08933821
Patent No. 5972338
GENERAL INFORMATION:
APPLICANT: Godowski, Paul J.
APPLICANT: Gurney, Austin L.
TITLE OF INVENTION: The Ligands
NUMBER OF SEQUENCES: 17
CORRESPONDENCE ADDRESS:
ADDRESS: Genentech, Inc.
STREET: 1 DNA Way
CITY: South San Francisco
STATE: California
COUNTRY: USA
ZIP: 94080
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WinPatIn (Genentech)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US-08/933,821
FILING DATE:
CLASSIFICATION: 536
ATTORNEY/AGENT INFORMATION:
NAME: Dreger, Ganger R.
REGISTRATION NUMBER: 33,055
REFERENCE/DOCKET NUMBER: P1130
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650/225-3216
TELEFAX: 650/952-9881
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 493 amino acids
TYPE: Amino Acid
TOPOLOGY: Linear
US-08-933-821-2
Query Match 99.8% ; Score 2682 ; DB 2 ; Length 493 ;
Best Local Similarity 99.8% ; Pred. No. 4.8e-220 ;
Matches 492 ; Conservative 1 ; Mismatches 0 ; Indels 0 ; Gaps 0 ;
QY 1 MRPLCTCMTGLIANGAVAGDGPETGEGSPREFITLNRYKRGESQDKCTYTFIV 60
DB 1 MRPLCTCMTGLIANGAVAGDGPETGEGSPREFITLNRYKRGESQDKCTYTFIV 60
QY 61 PQGRVTAICVNSKEPEVLLENRVHKOELLNNELLKQKROJETTLOOVYKVDGIVSEV 120
DB 61 PQGRVTAICVNSKEPEVLLENRVHKOELLNNELLKQKROJETTLOOVYKVDGIVSEV 120
```

```

QY      12  KLRKXSRNNNSVLTQWOLHEIIRKXDNALETSOLENNILNOTADMOLASKYDLE  180
      121  KLRKXSRNNNSVLTQWOLHEIIRKXDNALETSOLENNILNOTADMOLASKYDLE  180
Db      121  KLRKXSRNNNSVLTQWOLHEIIRKXDNALETSOLENNILNOTADMOLASKYDLE  180
QY      181  HKYQHLATLAHQSEIIAQLBEEHCQVPSARPVPQPPAAPPRVYQPPYNNRINIQISTN  240
      181  HKYQHLATLAHQSEIIAQLBEEHCQVPSARPVPQPPAAPPRVYQPPYNNRINIQISTN  240
Db      181  HKYQHLATLAHQSEIIAQLBEEHCQVPSARPVPQPPAAPPRVYQPPYNNRINIQISTN  240
QY      241  EIOSDONLKLPLPLPTMTPLTSLBSSSTDKBGPPRDLQALEGHDHSS.YLVKPENTN  300
      241  EIOSDONLKLPLPLPTMTPLTSLBSSSTDKBGPPRDLQALEGHDHSS.YLVKPENTN  300
Db      241  EIOSDONLKLPLPLPTMTPLTSLBSSSTDKBGPPRDLQALEGHDHSS.YLVKPENTN  300
QY      301  RLMQWQCDQHDHGGGTIVIQRLDGSVNFPRMWEYXQGFNIDGEYWLGLENYWTLTNQ  360
      301  RLMQWQCDQHDHGGGTIVIQRLDGSVNFPRMWEYXQGFNIDGEYWLGLENYWTLTNQ  360
Db      301  RLMQWQCDQHDHGGGTIVIQRLDGSVNFPRMWEYXQGFNIDGEYWLGLENYWTLTNQ  360
QY      361  GNYKLLVTMEDMSGRRVPAEYVASFLPEBSEYYKLRIGRYHGNAGDSFTWNGKQFTTLD  420
      361  GNYKLLVTMEDMSGRRVPAEYVASFLPEBSEYYKLRIGRYHGNAGDSFTWNGKQFTTLD  420
Db      361  GNYKLLVTMEDMSGRRVPAEYVASFLPEBSEYYKLRIGRYHGNAGDSFTWNGKQFTTLD  420
QY      421  RQHDVYTGNCANHQKQSGWYNNCAHSNLNGVYRGGHTRSKYQDGYVWAEFRGGSYSLKK  480
      421  RQHDVYTGNCANHQKQSGWYNNCAHSNLNGVYRGGHTRSKYQDGYVWAEFRGGSYSLKK  480
Db      421  RQHDVYTGNCANHQKQSGWYNNCAHSNLNGVYRGGHTRSKYQDGYVWAEFRGGSYSLKK  480
QY      481  VVMMIRPNPNTFH  493
      481  VVMMIRPNPNTFH  493
Db      481  VVMMIRPNPNTFH  493

```

RESULT 2
US-08-960-507-2

PatentNo. 6057435
GENERAL INFORMATION:
APPLICANT: Godowski, Paul J.
APPLICANT: Gurney, Austin L.
TITLE OF INVENTION: The L-gands
NUMBER OF SEQUENCES: 24
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genentech, Inc.
STREET: 1 DNA Way
CITY: South San Francisco
STATE: California
COUNTRY: USA
ZIP: 94080
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM pc compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Wipacfin (Genentech)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/960,507
FILING DATE:
CLASSIFICATION: 536
ATTORNEY/AGENT INFORMATION:
NAME: Dreiser, Ginger R.
REGISTRATION NUMBER: 33,055
REFERENCE/DOCKET NUMBER: P1130p1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650/225-3216
TELEFAX: 650/952-9881
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 493 amino acids
TYPE: Amino Acid
TOPOLOGY: Linear

Query Match	99.9%	Score 2682	DB 3	Length 493
Best Local Similarity	99.8%	Pred. No. 4.8e-220		
Matches 492; Conservative	1	Mismatches 0	Indels 0	Gaps 0

Qy	61	MRBLCTQMWLIGLLAMGVAAGQEDGFETEGTSFREFIYNRKYRAESODKCTYFIV	60
Db	1	MRBLCTQMWLIGLLAMGVAAGQEDGFETEGTSFREFIYNRKYRAESODKCTYFIV	60
Qy	61	POORVTGALCANSKEFEVILNRYKVKOHELINELLQKQOIFTLQOLVYVGGIYSEV	122
Db	61	POORVTGALCANSKEFEVILNRYKVKOHELINELLQKQOIFTLQOLVYVGGIYSEV	122
Qy	121	KILRKESRNNNSKSVTLQYMWOLNHEIRKRDNALIELSQENRILNQTADMLQASKYDLE	180
Db	121	KILRKESRNNNSKSVTLQYMWOLNHEIRKRDNALIELSQENRILNQTADMLQASKYDLE	180
Qy	181	HKQHLATLHNQSEILADLEHCORVNSARVPVPRPALAPRYQOPTYRILINQISTN	240
Db	181	HKQHLATLHNQSEILADLEHCORVNSARVPVPRPALAPRYQOPTYRILINQISTN	240
Qy	241	EIQSDGNLKVLPPELTWPTLTLSLSSSTDCESGPFRCQLADLGDHDSIYLVKPEPNTN	300
Db	241	EIQSDGNLKVLPPELTWPTLTLSLSSSTDCESGPFRCQLADLGDHDSIYLVKPEPNTN	300
Qy	301	RLMQVWCORHDPGCGATVIGRRLDSSVNFPRNWEYTKQFQGNIDGSEYWLGIENIYWLTLNQ	360
Db	301	RLMQVWCORHDPGCGATVIGRRLDSSVNFPRNWEYTKQFQGNIDGSEYWLGIENIYWLTLNQ	360
Qy	361	GNFKLVLTWEDMSGKRVPAEYASFLPESESEYKLLQRYHGNAAGDSFTWNGKQFTLLD	420
Db	361	GNFKLVLTWEDMSGKRVPAEYASFLPESESEYKLLQRYHGNAAGDSFTWNGKQFTLLD	420
Qy	421	RHDVYVTGCAHYQKQGMWYNACAHNSLNGVYRGGHRYRSYODQCVYAEFRGGSYSLKK	480
Db	421	RHDVYVTGCAHYQKQGMWYNACAHNSLNGVYRGGHRYRSYODQCVYAEFRGGSYSLKK	480
Qy	481	VVMVIRPNPNTFH 493	
Db	481	VVMVIRPNPNTFH 493	

RESULT 3
US-09-136-828-2
; Sequence 2, Application US/09136828

GENERAL INFORMATION:
APPLICANT: godowski, Paul J.
APPLICANT: Gurney, Austin L.
TITLE OF INVENTION: Tie ligands
NUMBER OF SEQUENCES: 17
CORRESPONDENCE ADDRESS:
ADDRESSER: Genentech, Inc.
STREET: 1 DNA Way
CITY: South San Francisco
STATE: California
COUNTRY: USA
ZIP: 94080
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Winpatin (Genentech)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/136, 828
FILING DATE:
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Dreyer, Ginger R.
REGISTRATION NUMBER: 33,055
REFERENCE/DOCKET NUMBER: P1130RIA
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650/225-3216
TELEFAX: 650/952-9881
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 493 amino acids
TYPE: Amino Acid

TOPOLOGY: Linear
US-09-136-828-2

Query Match 99.9%; Score 2682; DB 4; Length 493;
Best Local Similarity 99.8%; Pred. No. 4.8e-220;
Matches 492; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

```
QY 1 MRPLCTCMWLGILAAAGVAGGDEGEGTEGSPREFTYLNRYKAGSODKCTYFTIV 60
DB 1 MRPLCTCMWLGILAAAGVAGGDEGEGTEGSPREFTYLNRYKAGSODKCTYFTIV 60
QY 61 POORVTGALCVNSKEPEVLLNRYVHKOELINNNELKOKROETLQOLVAVDGIYSEV 120
DB 61 POORVTGALCVNSKEPEVLLNRYVHKOELINNNELKOKROETLQOLVAVDGIYSEV 120
QY 121 KILKESRNMSRVTLQYLMOLHEIIRKDNALISOLENRIINOTADMQLASKYKDL 180
DB 121 KILKESRNMSRVTLQYLMOLHEIIRKDNALISOLENRIINOTADMQLASKYKDL 180
QY 181 HKYQHLATLANQSEIIIAQLBEHCORVPSARVPQPPAPPRVYQPTNRIINQISTN 240
DB 181 HKYQHLATLANQSEIIIAQLBEHCORVPSARVPQPPAPPRVYQPTNRIINQISTN 240
QY 241 EIQSDQNLKVLPEPLPTMTLTSPPSSTDKPSGWRDCLQALBDGHTSSIYLVKPENTN 300
DB 241 EIQSDQNLKVLPEPLPTMTLTSPPSSTDKPSGWRDCLQALBDGHTSSIYLVKPENTN 300
QY 301 RLMQWCDQRPDGGWTVIQRLDGSVNFRRMNETYKQSGNIDGEYWLGENIYWLTNQ 360
DB 301 RLMQWCDQRPDGGWTVIQRLDGSVNFRRMNETYKQSGNIDGEYWLGENIYWLTNQ 360
QY 361 GNYKLVTMEDWSGRKVFAYASFLPESEYYKLRLGRYHGNAGDSFTWNGKQFTLLD 420
DB 361 GNYKLVTMEDWSGRKVFAYASFLPESEYYKLRLGRYHGNAGDSFTWNGKQFTLLD 420
QY 421 RDHDVYTGNCAYKQGGWYNACASHNLNGVYRGHYSRYYODGYVMAEFRGGSYSLLK 480
DB 421 RDHDVYTGNCAYKQGGWYNACASHNLNGVYRGHYSRYYODGYVMAEFRGGSYSLLK 480
QY 481 VMMIRPNPNTFH 493
DB 481 VMMIRPNPNTFH 493
```

RESULT 4
US-09-332-928A-2
Sequence 2, Application US/09332928A
Patent No. 6368853

GENERAL INFORMATION:

APPLICANT: Godowski, Paul J.
TITLE OF INVENTION: Tie Ligands
NUMBER OF SEQUENCES: 17
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Genentech, Inc.
STREET: 1 DNA Way
CITY: South San Francisco
STATE: California
COUNTRY: USA
ZIP: 94080
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WinPatIn (Genentech)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/332,928A
FILING DATE: 14-Jun-1999
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/933,821
FILING DATE: <Unknown>
ATTORNEY/AGENT INFORMATION:

NAME: Dreger, Ginger R.
REGISTRATION NUMBER: 33,055
REFERENCE/DOCKET NUMBER: P1130
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650/225-3216
TELEFAX: 650/952-9881
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 493 amino acids
TYPE: Amino Acid
TOPOLOGY: Linear
SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Query Match 99.9%; Score 2682; DB 4; Length 493;
Best Local Similarity 99.8%; Pred. No. 4.8e-220;
Matches 492; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

```
QY 1 MRPLCTCMWLGILAAAGVAGGDEGEGTEGSPREFTYLNRYKAGSODKCTYFTIV 60
DB 1 MRPLCTCMWLGILAAAGVAGGDEGEGTEGSPREFTYLNRYKAGSODKCTYFTIV 60
QY 61 POORVTGALCVNSKEPEVLLNRYVHKOELINNNELKOKROETLQOLVAVDGIYSEV 120
DB 61 POORVTGALCVNSKEPEVLLNRYVHKOELINNNELKOKROETLQOLVAVDGIYSEV 120
QY 121 KILKESRNMSRVTLQYLMOLHEIIRKDNALISOLENRIINOTADMQLASKYKDL 180
DB 121 KILKESRNMSRVTLQYLMOLHEIIRKDNALISOLENRIINOTADMQLASKYKDL 180
QY 181 HKYQHLATLANQSEIIIAQLBEHCORVPSARVPQPPAPPRVYQPTNRIINQISTN 240
DB 181 HKYQHLATLANQSEIIIAQLBEHCORVPSARVPQPPAPPRVYQPTNRIINQISTN 240
QY 241 EIQSDQNLKVLPEPLPTMTLTSPPSSTDKPSGWRDCLQALBDGHTSSIYLVKPENTN 300
DB 241 EIQSDQNLKVLPEPLPTMTLTSPPSSTDKPSGWRDCLQALBDGHTSSIYLVKPENTN 300
QY 301 RLMQWCDQRPDGGWTVIQRLDGSVNFRRMNETYKQSGNIDGEYWLGENIYWLTNQ 360
DB 301 RLMQWCDQRPDGGWTVIQRLDGSVNFRRMNETYKQSGNIDGEYWLGENIYWLTNQ 360
QY 361 GNYKLVTMEDWSGRKVFAYASFLPESEYYKLRLGRYHGNAGDSFTWNGKQFTLLD 420
DB 361 GNYKLVTMEDWSGRKVFAYASFLPESEYYKLRLGRYHGNAGDSFTWNGKQFTLLD 420
QY 421 RDHDVYTGNCAYKQGGWYNACASHNLNGVYRGHYSRYYODGYVMAEFRGGSYSLLK 480
DB 421 RDHDVYTGNCAYKQGGWYNACASHNLNGVYRGHYSRYYODGYVMAEFRGGSYSLLK 480
QY 481 VMMIRPNPNTFH 493
DB 481 VMMIRPNPNTFH 493
```

RESULT 5
US-09-136-801-2
Sequence 2, Application US/09136801
Patent No. 6413770

GENERAL INFORMATION:

APPLICANT: Godowski, Paul J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth
APPLICANT: Botstein, David
APPLICANT: Goddard, Audrey
APPLICANT: Roy, Margaret
APPLICANT: Ferrara, Napoleone
APPLICANT: Tumas, Daniel
APPLICANT: Schwalli, Ralph
TITLE OF INVENTION: Tie Ligand Homologues
NUMBER OF SEQUENCES: 35
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Genentech, Inc.

STREET: 1 DNA Way
CITY: South San Francisco
STATE: California
COUNTRY: USA
ZIP: 94080
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WinPac (Genentech)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/136,801
FILING DATE:
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Dreger, Ginger R.
REGISTRATION NUMBER: 33,055
REFERENCE/DOCKET NUMBER: P130P2
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650/952-9881
TELEFAX: 650/225-3216
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 493 amino acids
TYPE: Amino Acid
TOPOLOGY: linear
US-09-136-801-2

Query Match 99.9%; Score 2682; DB 4; Length 493;
Best Local Similarity 99.8%; Pred. No. 4,8e-220;
Matches 492; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRPLCTCWMGLGILAMGAVAGQEDGFEETEGESPREFIYLRKVRAGSSQCKCTYTFIV 60
DB 1 MRPLCTCWMGLGILAMGAVAGQEDGFEETEGESPREFIYLRKVRAGSSQCKCTYTFIV 60
QY 61 PQORVTGALCVNSKEBEVLLERNVHKQELINNELKQKQIETLQOLVVDGIVSEV 120
DB 61 PQORVTGALCVNSKEBEVLLERNVHKQELINNELKQKQIETLQOLVVDGIVSEV 120
QY 121 KILRKESRMNSRVTLQYQLLHEIIRKDNALLESQLENRIINOTADMLQASRYKDL 180
DB 121 KILRKESRMNSRVTLQYQLLHEIIRKDNALLESQLENRIINOTADMLQASRYKDL 180
QY 181 HKYQHLATLAHNSQSEIIAQLHEHCQVPSARVPQPPAPPRVYQPTYNRIINQISTN 240
DB 181 HKYQHLATLAHNSQSEIIAQLHEHCQVPSARVPQPPAPPRVYQPTYNRIINQISTN 240
QY 241 EIQSDONLKVLPPLPTMPTLTSLPSTDKPSGPMRDCLQALDGDHDTSSIYLKPEENTN 300
DB 241 EIQSDONLKVLPPLPTMPTLTSLPSTDKPSGPMRDCLQALDGDHDTSSIYLKPEENTN 300
QY 301 RLMQWCDQRHDPGQMTVIQRRLDGSVNFRRMWTYKQFGNIDGYWLGLENITWLTNQ 360
DB 301 RLMQWCDQRHDPGQMTVIQRRLDGSVNFRRMWTYKQFGNIDGYWLGLENITWLTNQ 360
QY 361 GNYKLLVTMEDWSGRKVPFAEYASFRLEPSESEYKRLGRYHGNAGDSFTWNGKQFTTLD 420
DB 361 GNYKLLVTMEDWSGRKVPFAEYASFRLEPSESEYKRLGRYHGNAGDSFTWNGKQFTTLD 420
QY 421 RHDVYTGCAHYQKGGWYNAQAHNSNNGWYRGSHYRSRYODGVYAAEFRRGGSYSILKX 480
DB 421 RHDVYTGCAHYQKGGWYNAQAHNSNNGWYRGSHYRSRYODGVYAAEFRRGGSYSILKX 480
QY 481 VVMIRPNPNTFH 493
DB 481 VVMIRPNPNTFH 493

RESULT 6
US-09-332-929-2
Sequence 2, Application US/09332929
Patent No. 6420542

GENERAL INFORMATION:
APPLICANT: Godowski, Paul J.
APPLICANT: Gurney, Austin L.
TITLE OF INVENTION: The ligands
NUMBER OF SEQUENCES: 17
CORRESPONDENCE ADDRESSES:
ADDRESS: Genentech, Inc.
STREET: 1 DNA Way
CITY: South San Francisco
STATE: California
COUNTRY: USA
ZIP: 94080
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WinPac (Genentech)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/332,929
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/933,821
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Dreger, Ginger R.
REGISTRATION NUMBER: 33,055
REFERENCE/DOCKET NUMBER: P130
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650/952-9881
TELEFAX: 650/225-3216
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 493 amino acids
TYPE: Amino Acid
TOPOLOGY: linear
US-09-332-929-2

Query Match 99.9%; Score 2682; DB 4; Length 493;
Best Local Similarity 99.8%; Pred. No. 4,8e-220;
Matches 492; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRPLCTCWMGLGILAMGAVAGQEDGFEETEGESPREFIYLRKVRAGSSQCKCTYTFIV 60
DB 1 MRPLCTCWMGLGILAMGAVAGQEDGFEETEGESPREFIYLRKVRAGSSQCKCTYTFIV 60
QY 61 PQORVTGALCVNSKEBEVLLERNVHKQELINNELKQKQIETLQOLVVDGIVSEV 120
DB 61 PQORVTGALCVNSKEBEVLLERNVHKQELINNELKQKQIETLQOLVVDGIVSEV 120
QY 121 KILRKESRMNSRVTLQYQLLHEIIRKDNALLESQLENRIINOTADMLQASRYKDL 180
DB 121 KILRKESRMNSRVTLQYQLLHEIIRKDNALLESQLENRIINOTADMLQASRYKDL 180
QY 181 HKYQHLATLAHNSQSEIIAQLHEHCQVPSARVPQPPAPPRVYQPTYNRIINQISTN 240
DB 181 HKYQHLATLAHNSQSEIIAQLHEHCQVPSARVPQPPAPPRVYQPTYNRIINQISTN 240
QY 241 EIQSDONLKVLPPLPTMPTLTSLPSTDKPSGPMRDCLQALDGDHDTSSIYLKPEENTN 300
DB 241 EIQSDONLKVLPPLPTMPTLTSLPSTDKPSGPMRDCLQALDGDHDTSSIYLKPEENTN 300
QY 301 RLMQWCDQRHDPGQMTVIQRRLDGSVNFRRMWTYKQFGNIDGYWLGLENITWLTNQ 360
DB 301 RLMQWCDQRHDPGQMTVIQRRLDGSVNFRRMWTYKQFGNIDGYWLGLENITWLTNQ 360
QY 361 GNYKLLVTMEDWSGRKVPFAEYASFRLEPSESEYKRLGRYHGNAGDSFTWNGKQFTTLD 420
DB 361 GNYKLLVTMEDWSGRKVPFAEYASFRLEPSESEYKRLGRYHGNAGDSFTWNGKQFTTLD 420
QY 421 RHDVYTGCAHYQKGGWYNAQAHNSNNGWYRGSHYRSRYODGVYAAEFRRGGSYSILKX 480
DB 421 RHDVYTGCAHYQKGGWYNAQAHNSNNGWYRGSHYRSRYODGVYAAEFRRGGSYSILKX 480

QY 481 VMMIRPNPTFH 493
DB 481 VMMIRPNPTFH 493

RESULT 7
US-09-333-075-2
Sequence 2, Application US/09333075
Patent No. 6482331
GENERAL INFORMATION:
APPLICANT: Godowski, Paul J.
APPLICANT: Gurney, Austin L.
TITLE OF INVENTION: Tie Ligands
NUMBER OF SEQUENCES: 17
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genentech, Inc.
STREET: 1 DNA Way
CITY: South San Francisco
STATE: California
COUNTRY: USA
ZIP: 94080

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WinPatIn (Genentech)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/333,075
FILING DATE:
CLASSIFICATION:
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: 08/933,821
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Dreger, Ginger R.
REGISTRATION NUMBER: 33,055
REFERENCE/DOCKET NUMBER: P1130
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650/225-3216
TELEFAX: 650/952-9881
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 493 amino acids
TYPE: Amino Acid
TOPOLOGY: Linear
US-09-333-075-2

Query Match 99.9%; Score 2682; DB 4; Length 493;
Best Local Similarity 99.8%; Pred. No. 4.8e-220;
Matches 492; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRPLCTCWLGLLAAGAVAGQEDGEGTEEGSPREFIYLNRYKAGESQDKCTYTFIV 60
DB 1 MRPLCTCWLGLLAAGAVAGQEDGEGTEEGSPREFIYLNRYKAGESQDKCTYTFIV 60

QY 61 POORVTGALCVNSKEPEVLLNRYVHKOELLNELLKOKROIETLQOLVEVDGIVSEV 120
DB 61 POORVTGALCVNSKEPEVLLNRYVHKOELLNELLKOKROIETLQOLVEVDGIVSEV 120

QY 121 KLIRKESRNNSRVTOLYMOLEHIIIRKDNALBELSOLNRIINQADMLQASXYKDL 180
DB 121 KLIRKESRNNSRVTOLYMOLEHIIIRKDNALBELSOLNRIINQADMLQASXYKDL 180

QY 181 HKYOHATLANOSEIILAOLEEHQORVPASRPVQPPAPPRVYQPTNYRIINQISTN 240
DB 181 HKYOHATLANOSEIILAOLEEHQORVPASRPVQPPAPPRVYQPTNYRIINQISTN 240

QY 241 EIISDQNLKVLPPPLPTMPTLTSIPSSDTRKSGPWRDCLQALEDHGHTSSIYLVKPENTN 300
DB 241 EIISDQNLKVLPPPLPTMPTLTSIPSSDTRKSGPWRDCLQALEDHGHTSSIYLVKPENTN 300

QY 301 RLMQVWCDQRHDPGQWTVIQRRLDGSVNFPRNWTYKQGFNGINDGEYWLGLENIYWLTLNQ 360

DB 301 RLMQVWCDQRHDPGQWTVIQRRLDGSVNFPRNWTYKQGFNGINDGEYWLGLENIYWLTLNQ 360

QY 361 GNYKLVTMEDWSGRKYFAEYASFRLEPSEYKRLGRYHGNAGDSFTYHNGKQFTTLD 420
DB 361 GNYKLVTMEDWSGRKYFAEYASFRLEPSEYKRLGRYHGNAGDSFTYHNGKQFTTLD 420

QY 421 RDHDVYTGNCANHYQKGGWYNACASHNLNGWYRGHRSRYODGVYMAEFRRGGSYSLKK 480
DB 421 RDHDVYTGNCANHYQKGGWYNACASHNLNGWYRGHRSRYODGVYMAEFRRGGSYSLKK 480

QY 481 VMMIRPNPTFH 493
DB 481 VMMIRPNPTFH 493

RESULT 8
US-09-202-088A-2
Sequence 2, Application US/09202088A
Patent No. 6551822
GENERAL INFORMATION:
APPLICANT: Godowski, Paul J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth
APPLICANT: Boctstein, David
APPLICANT: Goddard, Audrey
APPLICANT: Roy, Margaret
APPLICANT: Ferrara, Napoleone
APPLICANT: Tumas, Daniel
APPLICANT: Schwall, Ralph
TITLE OF INVENTION: TIE LIGAND HOMOLOGUES
FILE REFERENCE: P1130P3US
CURRENT APPLICATION NUMBER: US/09/202,088A
CURRENT FILING DATE: 1998-12-08
PRIOR APPLICATION NUMBER: PCT/US98/19093
PRIOR FILING DATE: 1998-09-14
NUMBER OF SEQ ID NOS: 35
SEQ ID NO 2
LENGTH: 493
TYPE: PRT
ORGANISM: Homo Sapiens
US-09-202-088A-2

Query Match 99.9%; Score 2682; DB 4; Length 493;
Best Local Similarity 99.8%; Pred. No. 4.8e-220;
Matches 492; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRPLCTCWLGLLAAGAVAGQEDGEGTEEGSPREFIYLNRYKAGESQDKCTYTFIV 60
DB 1 MRPLCTCWLGLLAAGAVAGQEDGEGTEEGSPREFIYLNRYKAGESQDKCTYTFIV 60

QY 61 POORVTGALCVNSKEPEVLLNRYVHKOELLNELLKOKROIETLQOLVEVDGIVSEV 120
DB 61 POORVTGALCVNSKEPEVLLNRYVHKOELLNELLKOKROIETLQOLVEVDGIVSEV 120

QY 121 KLIRKESRNNSRVTOLYMOLEHIIIRKDNALBELSOLNRIINQADMLQASXYKDL 180
DB 121 KLIRKESRNNSRVTOLYMOLEHIIIRKDNALBELSOLNRIINQADMLQASXYKDL 180

QY 181 HKYOHATLANOSEIILAOLEEHQORVPASRPVQPPAPPRVYQPTNYRIINQISTN 240
DB 181 HKYOHATLANOSEIILAOLEEHQORVPASRPVQPPAPPRVYQPTNYRIINQISTN 240

QY 241 EIISDQNLKVLPPPLPTMPTLTSIPSSDTRKSGPWRDCLQALEDHGHTSSIYLVKPENTN 300
DB 241 EIISDQNLKVLPPPLPTMPTLTSIPSSDTRKSGPWRDCLQALEDHGHTSSIYLVKPENTN 300

QY 301 RLMQVWCDQRHDPGQWTVIQRRLDGSVNFPRNWTYKQGFNGINDGEYWLGLENIYWLTLNQ 360
DB 301 RLMQVWCDQRHDPGQWTVIQRRLDGSVNFPRNWTYKQGFNGINDGEYWLGLENIYWLTLNQ 360

QY 361 GNYKLVTMEDWSGRKYFAEYASFRLEPSEYKRLGRYHGNAGDSFTYHNGKQFTTLD 420

Db 361 GNYKLVTWEDWSGRKVFAYASFRLEPSEYYKTLGRYHGNAGDSFTWHNGKQFTTLD 420
Qy 421 RDHDVYTGNCAYHOKGGMWYNACAHSNLNGWYRGHYRSRYODGYVMAEFRRGSYSLLK 480
Db 421 RDHDVYTGNCAYHOKGGMWYNACAHSNLNGWYRGHYRSRYODGYVMAEFRRGSYSLLK 480
Qy 481 VMMIRPNPNTFH 493
Db 481 VMMIRPNPNTFH 493

RESULT 9

US-09-333-077-2
; Sequence 2, Application US//09333077
; Patent No. 6586397
; GENERAL INFORMATION:
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; TITLE OF INVENTION: Tie Ligands
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Genentech, Inc.
; STREET: 1 DNA Way
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WinPacIn (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/333,077
; FILING DATE:
; CLASSIFICATION:
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: 08/933,821
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Dreger, Ginger R.
; REGISTRATION NUMBER: 33,055
; REFERENCE/DOCKET NUMBER: P1130
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650/225-3216
; TELEFAX: 650/952-9881
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 493 amino acids
; TYPE: Amino Acid
; TOPOLOGY: linear
; US-09-333-077-2

Query Match 99.9%; Score 2682; DB 4; Length 493;
Best Local Similarity 99.8%; Pred. No. 4,8e-220;
Matches 492; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MRPICVTCWMLGLLAAGVAGQEDGFEGSTEGSPREFIYNRYRABESODKCYTFIV 60
Db 1 MRPICVTCWMLGLLAAGVAGQEDGFEGSTEGSPREFIYNRYRABESODKCYTFIV 60
Qy 61 PQQRVTGACVNSKEPEVLLNRVAKQELINNELLNKQKQIETLQQLVYDGGIVSEV 120
Db 61 PQQRVTGACVNSKEPEVLLNRVAKQELINNELLNKQKQIETLQQLVYDGGIVSEV 120
Qy 121 KILRKESRMNSRVTLQVQLLHEIIRKDNALLESQLENRLINQTAMLQLASKYKDL 180
Db 121 KILRKESRMNSRVTLQVQLLHEIIRKDNALLESQLENRLINQTAMLQLASKYKDL 180
Qy 181 HKYQHLATLAHQSEIIAQLEEHQCVPSARVPQPPAPPRVYQPTVRIINQISTN 240
Db 181 HKYQHLATLAHQSEIIAQLEEHQCVPSARVPQPPAPPRVYQPTVRIINQISTN 240

Qy 241 EIQSDQNLKYLPPPLPTMPTLTSLPSTDKPSGPMWDCQALBEDGHTSIVLKEPNTN 300
Db 241 EIQSDQNLKYLPPPLPTMPTLTSLPSTDKPSGPMWDCQALBEDGHTSIVLKEPNTN 300
Qy 301 RLMOVWCDQHRHDPGCVTVIQRIDGSVNFPRMETTKQGFNGINDGYWLGLENTVLTNQ 360
Db 301 RLMOVWCDQHRHDPGCVTVIQRIDGSVNFPRMETTKQGFNGINDGYWLGLENTVLTNQ 360
Qy 361 GNYKLVTWEDWSGRKVFAYASFRLEPSEYYKTLGRYHGNAGDSFTWHNGKQFTTLD 420
Db 361 GNYKLVTWEDWSGRKVFAYASFRLEPSEYYKTLGRYHGNAGDSFTWHNGKQFTTLD 420
Qy 421 RDHDVYTGNCAYHOKGGMWYNACAHSNLNGWYRGHYRSRYODGYVMAEFRRGSYSLLK 480
Db 421 RDHDVYTGNCAYHOKGGMWYNACAHSNLNGWYRGHYRSRYODGYVMAEFRRGSYSLLK 480
Qy 481 VMMIRPNPNTFH 493
Db 481 VMMIRPNPNTFH 493

RESULT 10

US-08-933-821-4
; Sequence 4, Application US//08933821
; Patent No. 5972338
; GENERAL INFORMATION:
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; TITLE OF INVENTION: Tie Ligands
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Genentech, Inc.
; STREET: 1 DNA Way
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WinPacIn (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/933,821
; FILING DATE:
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Dreger, Ginger R.
; REGISTRATION NUMBER: 33,055
; REFERENCE/DOCKET NUMBER: P1130
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650/225-3216
; TELEFAX: 650/952-9881
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 491 amino acids
; TYPE: Amino Acid
; TOPOLOGY: linear
; US-08-933-821-4

Query Match 56.1%; Score 1507.5; DB 2; Length 491;
Best Local Similarity 58.6%; Pred. No. 5e-120;
Matches 290; Conservative 69; Mismatches 109; Indels 27; Gaps 9;

Qy 9 WILGLLAAGVAGQSDGFEGTEGSPREF---IYNRYKRABESOD---KCTYTFIVP 61
Db 6 WILGLVLFLLVDTGHRG-----GQFKIKKINQRYPPATDKEAKKCAVTFIVP 56
Qy 62 QQRVTGACVNSKEPEV-ILNRVAKQELINNELLNKQKQIETLQQLVYDGGIVSEV 120
Db 57 QQRVTGACVNSKEPEV-ILNRVAKQELINNELLNKQKQIETLQQLVYDGGIVSEV 116
Qy 121 KILRKESRMNSRVTLQVQLLHEIIRKDNALLESQLENRLINQTAMLQLASKYKDL 180


```

Db      117 KLLRKESRRNNNSYVVLTQLYMWLLHETIRKDDNSLETSQENKILVMTTEMKMMATRYRELE 176
Qy      181 HKYQHATLTAHNSSEIIAQLSEHCORVDSAREVPQPP---AAPRYQVPPYVNRILINQI 237
Db      177 VKYASLTLDLVNNGSVMTLLEQGRIRFQRQDTHSPRYLVGVQGH--PNSQYPTPGLL 234
Qy      238 STNEIGSDQNL--KVLPP-LETPMLLT--SLPSSTDKPSSPMNDCCIALDEGHDHSII 232
Db      235 GGNELIRDPQYPPRDLMPRPDLATISPTKPSFKIPVPTFINEBPFXDCQQAERAGSVSGIY 294
Qy      293 LVPEPENTNRLMWQVWCQORHDPGQWTVYQRLDGSVNFPEMNETYKOGFGINDGYWGLGE 352
Db      295 MIREPNSNGMQLMGCNLSLDPGSWTVYQRLTQDGSVNFPEMNETYKKGFGINDGYWGLGE 354
Qy      353 NIYWLNLQNGYKALLVTMEDMSGKRYFAEYASRLPESEYIKLRLGRYHGNAGDSFYWHN 412
Db      355 NIYMLNSODNYKLLILEMDSKRYAEYSFRLPESEFYRLRLGYTQNGNAGDSMMWHN 414
Qy      413 GKQFTLLDRHDVYTCNCAHYKQGGWNYAACASHSLNGLVWVRGGGHYRSRYODGVYWAFFR 472
Db      415 GKQFTLLDRKQDMYLAQNCAPHFKGGMWNYAACASHSLNGLVWVRGGGHYRSKQDDGIFAEYR 474
Qy      473 GGSYSLSKRYVMIRP 487
Db      475 GGSYSLSRAVQMMIKP 489

```

```

1      RESULT 1
2      US-08-960-507-4
3      Sequence 4, Application US/08960507
4      Patent No. 6057435
5      GENERAL INFORMATION:
6      APPLICANT: Godowski, Paul J.
7      APPLICANT: Gurney, Austin L.
8      TITLE OF INVENTION: Tie ligands
9      NUMBER OF SEQUENCES: 24
10     CORRESPONDENCE ADDRESS:
11     ADDRESS: Genentech, Inc.
12     STREET: 1 DNA Way
13     CITY: South San Francisco
14     STATE: California
15     COUNTRY: USA
16     ZIP: 94080
17
18     COMPUTER READABLE FORM:
19     MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
20     COMPUTER: IBM PC compatible
21     OPERATING SYSTEM: PC-DOS/MS-DOS
22     SOFTWARE: Winpatin (Genentech)
23     CURRENT APPLICATION DATA:
24     APPLICATION NUMBER: US/08/960.507
25     FILING DATE:
26     CLASSIFICATION: 536
27     ATTORNEY/AGENT INFORMATION:
28     NAME: Dreyer, Ginger R.
29     REGISTRATION NUMBER: 33,055
30     REFERENCE/DOCKET NUMBER: P1130P1
31     TELECOMMUNICATION INFORMATION:
32     TELEPHONE: 650/952-3216
33     TELEFAX: 650/952-9881
34     INFORMATION FOR SEQ ID NO: 4:
35     SEQUENCE CHARACTERISTICS:
36     LENGTH: 491 amino acids
37     TYPE: Amino Acid
38     TYPE: Acid
39     TOPOLOGY: linear
40
41     US-08-960-507-4

```

Query Match 56.1%; Score 1507.5; DB 3; Length 491;
 Best Local Similarity 58.6%; Pred. No. 5e-120;
 Matches 290; Conservative 69; Mismatches 109; Indels 27; Gaps 9;

[illegible]

RESULT 12
 US-09-136-828-4
 Sequence 4, Application US/09136828
 Patent No. 6350450
 GENERAL INFORMATION:
 APPLICANT: Godowski, Paul J.
 APPLICANT: Gurney, Austin L.
 TITLE OF INVENTION: Tie ligands
 NUMBER OF SEQUENCES: 17
 CORRESPONDENCE ADDRESSES:
 ADDRESSEE: Genentech, Inc.
 STREET: 1 DNA Way
 CITY: South San Francisco
 STATE: California
 COUNTRY: USA
 ZIP: 94080
 COMPUTER READABLE FORM:
 MEDIUM TYPE: 3.5 inch, 1.44 MB floppy disk
 COMPUTES: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: WinPatIn (Genentech)
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/09/136,828
 FILING DATE:
 CLASSIFICATION:
 ATTORNEY/AGENT INFORMATION:
 NAME: Dreger, Ginger R.
 REGISTRATION NUMBER: 33,055
 REFERENCE/DOCKET NUMBER: P1130RIA
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 650/225-9881
 TELEFAX: 650/952-9881
 INFORMATION FOR SEQ ID NO: 4:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 491 amino acids
 TYPE: Amino Acid
 TOPOLOGY: Linear

```

; INFORMATION FOR SEQ ID NO: 4:
;   SEQUENCE CHARACTERISTICS:
;     LENGTH: 491 amino acids
;     TYPE: Amino Acid
;     TOPOLOGY: Linear
US-09-136-828-4

```

Query Match 56.1%; Score 1507.5; DB 4; Length 491;
Best Local Similarity 58.6%; Pred. No. 5e-120;
Matches 290; Conservative 69; Mismatches 109; Indels 27; Gaps 9;

9 WMLGLAAGAVAGGDEGFEETEGSPREF---YLNRYKAGESOD---KCTYFTVP 61
6 WTLGVLFLLVDTGHRG-----GQFKIKINQRRYPRATGKEAKKCAVFLVP 56
62 QQRVTGALCVNSKEPEV-LLENRVKQELINNELKQKQIETLQOLVYDGIIVSEV 120
57 EQRITGPICVNTKGQDASTIKDMITRMDLENLKDVLSRQREIDVLQVVDGNTVNEV 116
121 KLRKESRNNNSRVTLQVQLHETIRKQDNALFESOLENRIINOTADMQLASKYKYLE 180
117 KLRKESRNNNSRVTLQVQLHETIRKQDNALFESOLENRIINOTADMQLASKYKYLE 176
181 HKYQHLATLANQSEITIAOLEEHQORVPSARPVQPP--AAPRVYQPTYNRIINQI 237
177 VKYASLTDLVNNSQVMTLLEEQCLRIFSRQDTHVSPPLVQVYVPOHI--PNSQYTPGLL 234
238 STNEIOSDNL--KVLPP-LPTMPTLT--SLPSTDKPSGPMRDCQLALBDGHTSSLY 292
235 GGEIQRDPGYPRDLPPDLATSPKSPFKIPVTFINEGPFKDCQAKKAGHSVSGIY 294
293 LVKPEENTNRLMOVWCQDQRBHDPGWTVIQRLDGSVNFPMNWTYKQGFNIDGEEYVLGL 352
295 MKPENSNGPMQJMCENSJDPGWTVIQKRTDGSVNFPMNWTYKQGFNIDGEEYVLGL 354
353 NIYMLTNGQNYKLLVTMEDWNGRKYFAEYASFLRPESEYKRLGRHYGNAQDSFTW 412
355 NIYMLTNGQNYKLLVTMEDWNGRKYFAEYASFLRPESEYKRLGRHYGNAQDSFTW 414
413 GKQFTLDRDHDVYTGNCACHYQKGMWYNACAHSNLNGVWYRGHRSRYQDGVYAEFR 472
415 GKQFTLDRDHDVYTGNCACHYQKGMWYNACAHSNLNGVWYRGHRSRYQDGVYAEFR 474
473 GGSYSLKVVMMIRP 487
475 GGSYSLRAYQMMIKP 489

RESULT 13
US-09-332-928A-4
Sequence 4, Application US/09332928A
Patent No. 6368853
GENERAL INFORMATION:
APPLICANT: Godowski, Paul J.
Gurney, Austin L.
TITLE OF INVENTION: Tie Ligands
NUMBER OF SEQUENCES: 17
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genentech, Inc.
STREET: 1 DNA Way
CITY: South San Francisco
STATE: California
COUNTRY: USA
ZIP: 94080
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Winpatin (Genentech)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/332,928A
FILING DATE: 14-Jun-1999
CLASSIFICATION: <Unknown>
PRIOR APPLICATION NUMBER: 08/933,821
FILING DATE: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: Diegel, Ginger R.
REGISTRATION NUMBER: 33,055

REFERENCE/DOCKET NUMBER: P1130
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650/225-3216
TELEFAX: 650/952-9881
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 491 amino acids
TYPE: Amino Acid
TOPOLOGY: Linear
SEQUENCE DESCRIPTION: SEQ ID NO: 4:
US-09-332-928A-4

Query Match 56.1%; Score 1507.5; DB 4; Length 491;
Best Local Similarity 58.6%; Pred. No. 5e-120;
Matches 290; Conservative 69; Mismatches 109; Indels 27; Gaps 9;

9 WMLGLAAGAVAGGDEGFEETEGSPREF---YLNRYKAGESOD---KCTYFTVP 61
6 WTLGVLFLLVDTGHRG-----GQFKIKINQRRYPRATGKEAKKCAVFLVP 56
62 QQRVTGALCVNSKEPEV-LLENRVKQELINNELKQKQIETLQOLVYDGIIVSEV 120
57 EQRITGPICVNTKGQDASTIKDMITRMDLENLKDVLSRQREIDVLQVVDGNTVNEV 116
121 KLRKESRNNNSRVTLQVQLHETIRKQDNALFESOLENRIINOTADMQLASKYKYLE 180
117 KLRKESRNNNSRVTLQVQLHETIRKQDNALFESOLENRIINOTADMQLASKYKYLE 176
181 HKYQHLATLANQSEITIAOLEEHQORVPSARPVQPP--AAPRVYQPTYNRIINQI 237
177 VKYASLTDLVNNSQVMTLLEEQCLRIFSRQDTHVSPPLVQVYVPOHI--PNSQYTPGLL 234
238 STNEIOSDNL--KVLPP-LPTMPTLT--SLPSTDKPSGPMRDCQLALBDGHTSSLY 292
235 GGEIQRDPGYPRDLPPDLATSPKSPFKIPVTFINEGPFKDCQAKKAGHSVSGIY 294
293 LVKPEENTNRLMOVWCQDQRBHDPGWTVIQRLDGSVNFPMNWTYKQGFNIDGEEYVLGL 352
295 MKPENSNGPMQJMCENSJDPGWTVIQKRTDGSVNFPMNWTYKQGFNIDGEEYVLGL 354
353 NIYMLTNGQNYKLLVTMEDWNGRKYFAEYASFLRPESEYKRLGRHYGNAQDSFTW 412
355 NIYMLTNGQNYKLLVTMEDWNGRKYFAEYASFLRPESEYKRLGRHYGNAQDSFTW 414
413 GKQFTLDRDHDVYTGNCACHYQKGMWYNACAHSNLNGVWYRGHRSRYQDGVYAEFR 472
415 GKQFTLDRDHDVYTGNCACHYQKGMWYNACAHSNLNGVWYRGHRSRYQDGVYAEFR 474
473 GGSYSLKVVMMIRP 487
475 GGSYSLRAYQMMIKP 489

RESULT 14
US-09-136-801-4
Sequence 4, Application US/09136801
Patent No. 6413770
GENERAL INFORMATION:
APPLICANT: Godowski, Paul J.
Gurney, Austin L.
TITLE OF INVENTION: Tie Ligand Homologues
NUMBER OF SEQUENCES: 35
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genentech, Inc.
STREET: 1 DNA Way
CITY: South San Francisco

```

STATE: California
COUNTRY: USA
ZIP: 94080
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Winpatin (Genentech)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/136,801
FILING DATE:
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Dreger, Ginger R.
REGISTRATION NUMBER: 33,055
REFERENCE/DOCKET NUMBER: P1130P2
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650/952-9881
TELEFAX: 650/952-3216
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 491 amino acids
TYPE: Amino Acid
TOPOLOGY: Linear
US-09-136-801-4

```

```

Query Match      56.1%; Score 1507.5; DB 4; Length 491;
Best Local Similarity 58.6%; Pred. No. 58-120;
Matches 290; Conservative 69; Mismatches 109; Indels 27; Gaps 9;

```

```

9 WMLGLAAMGAVAGQDEGFEETEGSPREF---IYNRYKAGESQD---KCTYFTIVP 61
6 WTLGVLFLLVDTGHCGRG-----GQFKIKINRRPRATDGEKKAQATFLVP 56
62 QQRVGAICVNSKEPEV-LEENRVHKOELLNELIKQKROLETTLOQLYKVDGIVSEV 120
57 EGRITGICVNTKQDASTIKDMITRMDLENLKDVLSRQREIDVLQLVVDVGNIVNEV 116
121 KLRKESRNMNSRVTLQYMLLHEIRKRDNALELSQLENRIINQTDMLQLASKYKDL 180
117 KLRKESRNMNSRVTLQYMLLHEIRKRDNSLELSQLENKILNVTTEMLKATRYELE 176
181 HKYQHLATLANOSEIIAOLEEHQORVPSARVPQPP---AAPRYOPTYNRIINQI 237
177 VKYASLIDLVNNSQWVITLLEEQCLRFISRODTHVSPPLVQVYQHI--PNSQOYTPGL 234
238 STNEIQSQDNL--KVLPP-LPTMPTLT--SLPSTDKSGPWRDCLQALDEGHTSSIT 292
235 GGNELIQRDGYPRDLMPPLDLSPTKSPFKIPVTFINEGPFKCCQQAKEGHSVSGIT 294
293 LVKPEENTRLMQVCDQRHDPGWTVIQRLDGSVNFPRWETTYKQGFNIDGEYWLGLE 352
295 MIKPENSNGPQMLCENSIDPGWTVIQKRTDGSVNFPRWENYKKGFGNIDGEYWLGLE 354
353 NIYWLINQGNKYLLVLTMEDWSGRKVPFAEYASFLEPSESEYKRLRGYHGNAGSFTWHN 412
355 NIYWLINQGNKYLLLEEDWSDKRYAEYSFLEPSESEYKRLRGYHGNAGSFTWHN 414
413 GKQFTLDRDHDVYTGNCAYQKQGWVYNACASHNLNGVWYRGHYRSRYQDGVYMAEFR 472
415 GKQFTLDRDHDVYTGNCAYQKQGWVYNACASHNLNGVWYRGHYRSRYQDGVYMAEFR 474
473 GGSYSLLKKVVMIRP 487
475 GGSYSLLRAVQMMIKP 489

```

```

RESULT 15
US-09-332-929-4
Sequence 4, Application US/09332929
Patent No. 6420542
GENERAL INFORMATION:
APPLICANT: Godowski, Paul J.

```

```

APPLICANT: Gurney, Austin L.
TITLE OF INVENTION: The Ligands
NUMBER OF SEQUENCES: 17
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genentech, Inc.
STREET: 1 DNA Way
CITY: South San Francisco
STATE: California
COUNTRY: USA
ZIP: 94080
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Winpatin (Genentech)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/332,929
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/933,821
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Dreger, Ginger R.
REGISTRATION NUMBER: 33,055
REFERENCE/DOCKET NUMBER: P1130
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650/952-9881
TELEFAX: 650/952-3216
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 491 amino acids
TYPE: Amino Acid
TOPOLOGY: Linear
US-09-332-929-4

```

```

Query Match      56.1%; Score 1507.5; DB 4; Length 491;
Best Local Similarity 58.6%; Pred. No. 58-120;
Matches 290; Conservative 69; Mismatches 109; Indels 27; Gaps 9;

```

```

9 WMLGLAAMGAVAGQDEGFEETEGSPREF---IYNRYKAGESQD---KCTYFTIVP 61
6 WTLGVLFLLVDTGHCGRG-----GQFKIKINRRPRATDGEKKAQATFLVP 56
62 QQRVGAICVNSKEPEV-LEENRVHKOELLNELIKQKROLETTLOQLYKVDGIVSEV 120
57 EGRITGICVNTKQDASTIKDMITRMDLENLKDVLSRQREIDVLQLVVDVGNIVNEV 116
121 KLRKESRNMNSRVTLQYMLLHEIRKRDNALELSQLENRIINQTDMLQLASKYKDL 180
117 KLRKESRNMNSRVTLQYMLLHEIRKRDNSLELSQLENKILNVTTEMLKATRYELE 176
181 HKYQHLATLANOSEIIAOLEEHQORVPSARVPQPP---AAPRYOPTYNRIINQI 237
177 VKYASLIDLVNNSQWVITLLEEQCLRFISRODTHVSPPLVQVYQHI--PNSQOYTPGL 234
238 STNEIQSQDNL--KVLPP-LPTMPTLT--SLPSTDKSGPWRDCLQALDEGHTSSIT 292
235 GGNELIQRDGYPRDLMPPLDLSPTKSPFKIPVTFINEGPFKCCQQAKEGHSVSGIT 294
293 LVKPEENTRLMQVCDQRHDPGWTVIQRLDGSVNFPRWETTYKQGFNIDGEYWLGLE 352
295 MIKPENSNGPQMLCENSIDPGWTVIQKRTDGSVNFPRWENYKKGFGNIDGEYWLGLE 354
353 NIYWLINQGNKYLLVLTMEDWSGRKVPFAEYASFLEPSESEYKRLRGYHGNAGSFTWHN 412
355 NIYWLINQGNKYLLLEEDWSDKRYAEYSFLEPSESEYKRLRGYHGNAGSFTWHN 414
413 GKQFTLDRDHDVYTGNCAYQKQGWVYNACASHNLNGVWYRGHYRSRYQDGVYMAEFR 472
415 GKQFTLDRDHDVYTGNCAYQKQGWVYNACASHNLNGVWYRGHYRSRYQDGVYMAEFR 474
473 GGSYSLLKKVVMIRP 487

```

Db 475 GGSYSLRAYQMMKP 489

Search completed: July 30, 2004, 12:38:31
Job time : 21 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: July 30, 2004, 12:37:34 ; Search time 46 Seconds
(without alignments)
3361.863 Million cell updates/sec

Title: US-10-018-386-2

Sequence: 1 MRPLCVTCMWGLLAAMGAV.....GSYSLKRVVMIRNPNTFH 493

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1291235 seqs, 313682936 residues

Total number of hits satisfying chosen parameters: 1291235

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

Published Applications AA:*

- 1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep:*
- 2: /cgn2_6/ptodata/1/pubpaa/PCF_NEW_PUB.pep:*
- 3: /cgn2_6/ptodata/1/pubpaa/US06_NEW_PUB.pep:*
- 4: /cgn2_6/ptodata/1/pubpaa/US06_PUBCOMB.pep:*
- 5: /cgn2_6/ptodata/1/pubpaa/US07_NEW_PUB.pep:*
- 6: /cgn2_6/ptodata/1/pubpaa/PCFUS_PUBCOMB.pep:*
- 7: /cgn2_6/ptodata/1/pubpaa/US08_NEW_PUB.pep:*
- 8: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep:*
- 9: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep:*
- 10: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep:*
- 11: /cgn2_6/ptodata/1/pubpaa/US09_NEW_PUB.pep:*
- 12: /cgn2_6/ptodata/1/pubpaa/US10_PUBCOMB.pep:*
- 13: /cgn2_6/ptodata/1/pubpaa/US10_PUBCOMB.pep:*
- 14: /cgn2_6/ptodata/1/pubpaa/US10_PUBCOMB.pep:*
- 15: /cgn2_6/ptodata/1/pubpaa/US10_PUBCOMB.pep:*
- 16: /cgn2_6/ptodata/1/pubpaa/US10_NEW_PUB.pep:*
- 17: /cgn2_6/ptodata/1/pubpaa/US60_NEW_PUB.pep:*
- 18: /cgn2_6/ptodata/1/pubpaa/US60_PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	2682	99.9	493	9	US-09-818-143-23
2	2682	99.9	493	10	US-09-833-355A-113
3	2682	99.9	493	10	US-09-983-000A-8
4	2682	99.9	493	12	US-10-147-493-268
5	2682	99.9	493	12	US-10-145-127-268
6	2682	99.9	493	12	US-10-160-503-268
7	2682	99.9	493	12	US-10-143-118-268
8	2682	99.9	493	12	US-10-144-993-268
9	2682	99.9	493	12	US-10-158-787-268
10	2682	99.9	493	12	US-10-140-024-268
11	2682	99.9	493	12	US-10-140-808-268
12	2682	99.9	493	12	US-10-157-405-268
13	2682	99.9	493	12	US-10-127-852A-268
14	2682	99.9	493	12	US-10-127-900A-268
15	2682	99.9	493	12	US-10-128-685A-268

16	2682	99.9	493	12	US-10-131-820A-268	Sequence 268, App
17	2682	99.9	493	12	US-10-142-866-268	Sequence 268, App
18	2682	99.9	493	12	US-10-146-728-268	Sequence 268, App
19	2682	99.9	493	12	US-10-146-786-268	Sequence 268, App
20	2682	99.9	493	12	US-10-147-499-268	Sequence 268, App
21	2682	99.9	493	12	US-10-157-798-268	Sequence 268, App
22	2682	99.9	493	13	US-10-066-500-4	Sequence 4, Appl
23	2682	99.9	493	14	US-10-028-072-268	Sequence 268, App
24	2682	99.9	493	14	US-10-121-045-268	Sequence 268, App
25	2682	99.9	493	14	US-10-123-904-268	Sequence 268, App
26	2682	99.9	493	14	US-10-140-470-268	Sequence 268, App
27	2682	99.9	493	14	US-10-175-746-268	Sequence 268, App
28	2682	99.9	493	14	US-10-176-918-268	Sequence 268, App
29	2682	99.9	493	14	US-10-176-921-268	Sequence 268, App
30	2682	99.9	493	14	US-10-002-796-4	Sequence 4, Appl
31	2682	99.9	493	14	US-10-066-273-4	Sequence 4, Appl
32	2682	99.9	493	14	US-10-066-494-4	Sequence 4, Appl
33	2682	99.9	493	14	US-10-137-865-268	Sequence 268, App
34	2682	99.9	493	14	US-10-140-474-268	Sequence 268, App
35	2682	99.9	493	14	US-10-142-431-268	Sequence 268, App
36	2682	99.9	493	14	US-10-143-114-268	Sequence 268, App
37	2682	99.9	493	14	US-10-140-002-268	Sequence 268, App
38	2682	99.9	493	14	US-10-066-263-4	Sequence 4, Appl
39	2682	99.9	493	14	US-10-066-211-4	Sequence 4, Appl
40	2682	99.9	493	14	US-10-066-193-4	Sequence 4, Appl
41	2682	99.9	493	14	US-10-142-419-268	Sequence 268, App
42	2682	99.9	493	14	US-10-123-262-268	Sequence 268, App
43	2682	99.9	493	14	US-10-142-423-268	Sequence 268, App
44	2682	99.9	493	14	US-10-121-050-268	Sequence 268, App
45	2682	99.9	493	14	US-10-141-735-268	Sequence 268, App

ALIGNMENTS

RESULT 1
US-09-818-143-23
Sequence 23, Application US/09818143
Patent No. US2002019000A1
GENERAL INFORMATION:
APPLICANT: Walker, Michael G.
APPLICANT: Volkman, Wayne
TITLE OF INVENTION: POLYNUCLEOTIDES COEXPRESSED WITH MATRIX-REMODELING GENES
FILE REFERENCE: PB-0004 CIP
CURRENT APPLICATION NUMBER: US/09/818,143
CURRENT FILING DATE: 2001-03-26
NUMBER OF SEQ ID NOS: 23
SOFTWARE: PERL Program
SEQ ID NO 23
LENGTH: 493
TYPE: PRT
ORGANISM: Homo sapiens
FEATURE:
OTHER INFORMATION: 2268890C01
US-09-818-143-23

Query Match 99.9%; Score 2682; DB 9; Length 493;
Best Local Similarity 99.8%; Pred. No. 4.9e-210;
Matches 492; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY	1	MRPLCVTCMWGLLAAMGAVAGQEDGEGEGESPREFITYLNRYKAGSODKCTYTFIV	60
DB	1	MRPLCVTCMWGLLAAMGAVAGQEDGEGEGESPREFITYLNRYKAGSODKCTYTFIV	60
QY	61	POQRTGATVNSKEPEVLLIENRYKQELIENNELIKQROJETIQQVYKVGIVSEV	120
DB	61	POQRTGATVNSKEPEVLLIENRYKQELIENNELIKQROJETIQQVYKVGIVSEV	120
QY	121	KLRKESRNNSRYTQIYVQLLHEITRKRDNALELSQLEIRIINQTDAMQLASKYKDL	180
DB	121	KLRKESRNNSRYTQIYVQLLHEITRKRDNALELSQLEIRIINQTDAMQLASKYKDL	180

QY 181 HKYCHLALAHNQSSEIIAQLSEHCORVPSARVPQPPAAPRVYQPEPTYNRIINOISTN 240
DB 181 HKYCHLALAHNQSSEIIAQLSEHCORVPSARVPQPPAAPRVYQPEPTYNRIINOISTN 240
QY 241 EIQSDONLKVLPPLPTMTLTSLPSSTDKPSGPRDCLQALDGDHDTSSIYLVPENTN 300
DB 241 EIQSDONLKVLPPLPTMTLTSLPSSTDKPSGPRDCLQALDGDHDTSSIYLVPENTN 300
QY 301 RLMQVWCORHDPGPGMTVYQRLLDSGVNFFRWMEYTKOGFGNIDDEYLGENTYMLNQ 360
DB 301 RLMQVWCORHDPGPGMTVYQRLLDSGVNFFRWMEYTKOGFGNIDDEYLGENTYMLNQ 360
QY 361 GNYKLLVTMEDWSGKRVFAEYASFRLEPESEYKLLRGYHGNAGDSFTWHNGKQFTLLD 420
DB 361 GNYKLLVTMEDWSGKRVFAEYASFRLEPESEYKLLRGYHGNAGDSFTWHNGKQFTLLD 420
QY 421 RDHDVYTGNCAYHQKGMWYNACAHSNLNGWYRGCHYRSRYQDGYVAEFPGGSYSLKX 480
DB 421 RDHDVYTGNCAYHQKGMWYNACAHSNLNGWYRGCHYRSRYQDGYVAEFPGGSYSLKX 480
QY 481 VMMWIRPNPTFH 493
DB 481 VMMWIRPNPTFH 493

RESULT 2

US-09-832-355A-113
; Sequence 113, Application US/09832355A
; Publication No. US20030027751A1
; GENERAL INFORMATION:
; APPLICANT: Kovesdi, Imre
; APPLICANT: Kessler, Paul
; TITLE OF INVENTION: VEGF FUSION PROTEINS
; FILE REFERENCE: 205654
; CURRENT APPLICATION NUMBER: US/09/832,355A
; CURRENT FILING DATE: 2001-04-10
; NUMBER OF SEQ ID NOS: 126
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 113
; LENGTH: 493
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-832-355A-113

Query Match 99.9%; Score 2662; DB 10; Length 493;
Best Local Similarity 99.8%; Pred. No. 4,9e-210;
Matches 492; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRPLVCVTGWLGLLAAAGVAGQDGFEGTEGSPREFIYLNRYKRGESODKCTYTFIV 60
DB 1 MRPLVCVTGWLGLLAAAGVAGQDGFEGTEGSPREFIYLNRYKRGESODKCTYTFIV 60
QY 61 POORVTGALCVNSKEPEVLLENRVHAKQELLLNNELLNKQKQIETLQQLVYDGGIVSEV 120
DB 61 POORVTGALCVNSKEPEVLLENRVHAKQELLLNNELLNKQKQIETLQQLVYDGGIVSEV 120
QY 121 KILRKESRMNRSRYQLVYQMLLHEIRKRDNLLEISQLENRIINQADMLQASXYKDL 180
DB 121 KILRKESRMNRSRYQLVYQMLLHEIRKRDNLLEISQLENRIINQADMLQASXYKDL 180
QY 181 HKYCHLALAHNQSSEIIAQLSEHCORVPSARVPQPPAAPRVYQPEPTYNRIINOISTN 240
DB 181 HKYCHLALAHNQSSEIIAQLSEHCORVPSARVPQPPAAPRVYQPEPTYNRIINOISTN 240
QY 241 EIQSDONLKVLPPLPTMTLTSLPSSTDKPSGPRDCLQALDGDHDTSSIYLVPENTN 300
DB 241 EIQSDONLKVLPPLPTMTLTSLPSSTDKPSGPRDCLQALDGDHDTSSIYLVPENTN 300
QY 301 RLMQVWCORHDPGPGMTVYQRLLDSGVNFFRWMEYTKOGFGNIDDEYLGENTYMLNQ 360
DB 301 RLMQVWCORHDPGPGMTVYQRLLDSGVNFFRWMEYTKOGFGNIDDEYLGENTYMLNQ 360
QY 361 GNYKLLVTMEDWSGKRVFAEYASFRLEPESEYKLLRGYHGNAGDSFTWHNGKQFTLLD 420

DB 361 GNYKLLVTMEDWSGKRVFAEYASFRLEPESEYKLLRGYHGNAGDSFTWHNGKQFTLLD 420
QY 421 RDHDVYTGNCAYHQKGMWYNACAHSNLNGWYRGCHYRSRYQDGYVAEFPGGSYSLKX 480
DB 421 RDHDVYTGNCAYHQKGMWYNACAHSNLNGWYRGCHYRSRYQDGYVAEFPGGSYSLKX 480
QY 481 VMMWIRPNPTFH 493
DB 481 VMMWIRPNPTFH 493

RESULT 3

US-09-983-000A-8
; Sequence 8, Application US/0983000A
; Publication No. US20030118585A1
; GENERAL INFORMATION:
; APPLICANT: Agi Therapeutics
; APPLICANT: Melcher, Thorsten
; APPLICANT: Mueller, Sabine
; APPLICANT: Chin, Daniel
; TITLE OF INVENTION: USE OF PROTEIN BIOMOLECULAR TARGETS IN THE TREATMENT AND VISUALIZA
; TITLE OF INVENTION: OF BRAIN TUMORS
; FILE REFERENCE: 263/180 -- P8agلمان -- AGY
; CURRENT APPLICATION NUMBER: US/09/983,000A
; CURRENT FILING DATE: 2001-10-17
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
; LENGTH: 493
; TYPE: PRT
; ORGANISM: Homo sapiens

FEATURE:
; NAME/KEY: gene (1)..(493)
; LOCATION: (1)..(493)
; OTHER INFORMATION: Angiopoietin-like 2 (ANGPTL2), protein
; NAME/KEY: SIGNAL
; LOCATION: (1)..(22)
; OTHER INFORMATION: Potential
; NAME/KEY: CHAIN
; LOCATION: (23)..(493)
; OTHER INFORMATION: Angiopoietin-related protein 2
; NAME/KEY: DOMAIN
; LOCATION: (76)..(115)
; OTHER INFORMATION: Coiled Coil (potential)
; NAME/KEY: DOMAIN
; LOCATION: (152)..(206)
; OTHER INFORMATION: Coiled Coil (potential)
; NAME/KEY: DOMAIN
; LOCATION: (438)..(450)
; OTHER INFORMATION: Fibrinogen C-terminal
; NAME/KEY: CARBOHYD
; LOCATION: (164)..(164)
; OTHER INFORMATION: N-linked (GLCNAC...) (potential)
; NAME/KEY: CARBOHYD
; LOCATION: (192)..(192)
; OTHER INFORMATION: N-linked (GLCNAC...) (potential)
US-09-983-000A-8

Query Match 99.9%; Score 2662; DB 10; Length 493;
Best Local Similarity 99.8%; Pred. No. 4,9e-210;
Matches 492; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRPLVCVTGWLGLLAAAGVAGQDGFEGTEGSPREFIYLNRYKRGESODKCTYTFIV 60
DB 1 MRPLVCVTGWLGLLAAAGVAGQDGFEGTEGSPREFIYLNRYKRGESODKCTYTFIV 60
QY 61 POORVTGALCVNSKEPEVLLENRVHAKQELLLNNELLNKQKQIETLQQLVYDGGIVSEV 120
DB 61 POORVTGALCVNSKEPEVLLENRVHAKQELLLNNELLNKQKQIETLQQLVYDGGIVSEV 120
QY 121 KILRKESRMNRSRYQLVYQMLLHEIRKRDNLLEISQLENRIINQADMLQASXYKDL 180

Db 121 KLRKESRNNNSRVTOLYMQLLHEIRKRDNALELSQLENRLINQADMLQASRYKDL 180
Qy 181 HKYQHLATLANHOSSEIIAQLEEHQCRVPSARVPVPPAPAPRVYQPTYNRIINQISTN 240
Db 181 HKYQHLATLANHOSSEIIAQLEEHQCRVPSARVPVPPAPAPRVYQPTYNRIINQISTN 240
Qy 241 EIOSDQNLKVLPPPLPTMPTLTSLPSSTDKPSGPMWDCQALDGHDTSSIIYVKPEENTN 300
Db 241 EIOSDQNLKVLPPPLPTMPTLTSLPSSTDKPSGPMWDCQALDGHDTSSIIYVKPEENTN 300
Qy 301 RIMQVWCQQRHDPGQWTVIQRRLDGSVNFERNMETYKQFGNIDGEYWLGLENIYWLTLNQ 360
Db 301 RIMQVWCQQRHDPGQWTVIQRRLDGSVNFERNMETYKQFGNIDGEYWLGLENIYWLTLNQ 360
Qy 361 GNYKLVMTMEDSGRKYFAEYASFRLEPSEYYKRLGRYHGNAGDSFTWNGKQFTTLD 420
Db 361 GNYKLVMTMEDSGRKYFAEYASFRLEPSEYYKRLGRYHGNAGDSFTWNGKQFTTLD 420
Qy 421 RDHDVYTGNCAYHOKGWMYNACAHSNLNGWYRGHYRSRYODGVYMAEFRGGSYSLKK 480
Db 421 RDHDVYTGNCAYHOKGWMYNACAHSNLNGWYRGHYRSRYODGVYMAEFRGGSYSLKK 480
Qy 481 VVMIRPNPNTFH 493
Db 481 VVMIRPNPNTFH 493

RESULT 4

US-10-147-493-268
; Sequence 268, Application US/10147493
; Publication No. US20040029217A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Tumas, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C345
; CURRENT APPLICATION NUMBER: US/10/147,493
; CURRENT FILING DATE: 2002-05-17
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 268
; LENGTH: 493
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-147-493-268

Query Match 99.9%; Score 2682; DB 12; Length 493;
Best Local Similarity 99.8%; Pred. No. 4,9e-210;
Matches 492; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MRPLCTCWMGLGLAAGVAGQEDGEGTEBGSPPREFIYNRYKRAGSODKCTYTFIV 60
Db 1 MRPLCTCWMGLGLAAGVAGQEDGEGTEBGSPPREFIYNRYKRAGSODKCTYTFIV 60
Qy 61 POORVTGATCVNSKEPEVILENRVHKQELLELNELKQKROIFTLQQLVYDGGIVSEV 120
Db 61 POORVTGATCVNSKEPEVILENRVHKQELLELNELKQKROIFTLQQLVYDGGIVSEV 120

Qy 121 KLRKESRNNNSRVTOLYMQLLHEIRKRDNALELSQLENRLINQADMLQASRYKDL 180
Db 121 KLRKESRNNNSRVTOLYMQLLHEIRKRDNALELSQLENRLINQADMLQASRYKDL 180
Qy 181 HKYQHLATLANHOSSEIIAQLEEHQCRVPSARVPVPPAPAPRVYQPTYNRIINQISTN 240
Db 181 HKYQHLATLANHOSSEIIAQLEEHQCRVPSARVPVPPAPAPRVYQPTYNRIINQISTN 240
Qy 241 EIOSDQNLKVLPPPLPTMPTLTSLPSSTDKPSGPMWDCQALDGHDTSSIIYVKPEENTN 300
Db 241 EIOSDQNLKVLPPPLPTMPTLTSLPSSTDKPSGPMWDCQALDGHDTSSIIYVKPEENTN 300
Qy 301 RIMQVWCQQRHDPGQWTVIQRRLDGSVNFERNMETYKQFGNIDGEYWLGLENIYWLTLNQ 360
Db 301 RIMQVWCQQRHDPGQWTVIQRRLDGSVNFERNMETYKQFGNIDGEYWLGLENIYWLTLNQ 360
Qy 361 GNYKLVMTMEDSGRKYFAEYASFRLEPSEYYKRLGRYHGNAGDSFTWNGKQFTTLD 420
Db 361 GNYKLVMTMEDSGRKYFAEYASFRLEPSEYYKRLGRYHGNAGDSFTWNGKQFTTLD 420
Qy 421 RDHDVYTGNCAYHOKGWMYNACAHSNLNGWYRGHYRSRYODGVYMAEFRGGSYSLKK 480
Db 421 RDHDVYTGNCAYHOKGWMYNACAHSNLNGWYRGHYRSRYODGVYMAEFRGGSYSLKK 480
Qy 481 VVMIRPNPNTFH 493
Db 481 VVMIRPNPNTFH 493

RESULT 5

US-10-145-127-268
; Sequence 268, Application US/10145127
; Publication No. US2004003558A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Tumas, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C252
; CURRENT APPLICATION NUMBER: US/10/145,127
; CURRENT FILING DATE: 2002-05-13
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 268
; LENGTH: 493
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-145-127-268

Query Match 99.9%; Score 2682; DB 12; Length 493;
Best Local Similarity 99.8%; Pred. No. 4,9e-210;
Matches 492; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MRPLCTCWMGLGLAAGVAGQEDGEGTEBGSPPREFIYNRYKRAGSODKCTYTFIV 60
Db 1 MRPLCTCWMGLGLAAGVAGQEDGEGTEBGSPPREFIYNRYKRAGSODKCTYTFIV 60

QY 61 POORVTGALCVNSKEPEVLENNRVHKOELLENNELLKOKROJETLQOLVKVDGIVSEV 120
DB 61 POORVTGALCVNSKEPEVLENNRVHKOELLENNELLKOKROJETLQOLVKVDGIVSEV 120
QY 121 KLIRKSRNNNSRVYQOLYVQLLHEIIRKDNALIELSOLENNRILNQTADMLQOLASKYKYLE 180
DB 121 KLIRKSRNNNSRVYQOLYVQLLHEIIRKDNALIELSOLENNRILNQTADMLQOLASKYKYLE 180
QY 181 HKYQHLATLANHNOSEIIAOLEEHCORVPSPARVPVOPPPAPPPVOPPTYNRIINOISTN 240
DB 181 HKYQHLATLANHNOSEIIAOLEEHCORVPSPARVPVOPPPAPPPVOPPTYNRIINOISTN 240
QY 241 EIQSDQNLKVLPPPLPTMPTLTSLPSTDKPSGPMWDCIQALEDGHTSSILYVKEBNTN 300
DB 241 EIQSDQNLKVLPPPLPTMPTLTSLPSTDKPSGPMWDCIQALEDGHTSSILYVKEBNTN 300
QY 301 RLQVWCDQHRDPGGMTVIOQLRDLGGSVNFRRMNETYKQGFNGIDGYWLGLENIYWLINO 360
DB 301 RLQVWCDQHRDPGGMTVIOQLRDLGGSVNFRRMNETYKQGFNGIDGYWLGLENIYWLINO 360
QY 361 GNYKLVTMEDWSGRKVFAYASFRLPESEYKRLGRYHGNAGDSFTWNGKQFTTLD 420
DB 361 GNYKLVTMEDWSGRKVFAYASFRLPESEYKRLGRYHGNAGDSFTWNGKQFTTLD 420
QY 421 RHDVYTGNCAYHOKGGMWYNACAHSNLNGWYRGHYSRYQDGYVMAEPRGGSYSLKX 480
DB 421 RHDVYTGNCAYHOKGGMWYNACAHSNLNGWYRGHYSRYQDGYVMAEPRGGSYSLKX 480
QY 481 VMMIRPNPTFH 493
DB 481 VMMIRPNPTFH 493

RESULT 6

US-10-160-503-268
; Sequence 268, Application US/10160503
; Publication No. US20040033559A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P333ORIC466
; CURRENT APPLICATION NUMBER: US/10/160,503
; CURRENT FILING DATE: 2002-05-30
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 268
; LENGTH: 493
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-160-503-268

Query Match 99.9%; Score 2682; DB 12; Length 493;
Best Local Similarity 99.8%; Pred. No. 4,9e-210;
Matches 492; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

1 MRPLCYTCWMLGLLAAGVAGQEDGFEGTEEGSPREFTYLNRYKRAESODKCTYTFIV 60
|||||

DB 1 MRPLCYTCWMLGLLAAGVAGQEDGFEGTEEGSPREFTYLNRYKRAESODKCTYTFIV 60
QY 61 POORVTGALCVNSKEPEVLENNRVHKOELLENNELLKOKROJETLQOLVKVDGIVSEV 120
DB 61 POORVTGALCVNSKEPEVLENNRVHKOELLENNELLKOKROJETLQOLVKVDGIVSEV 120
QY 121 KLIRKSRNNNSRVYQOLYVQLLHEIIRKDNALIELSOLENNRILNQTADMLQOLASKYKYLE 180
DB 121 KLIRKSRNNNSRVYQOLYVQLLHEIIRKDNALIELSOLENNRILNQTADMLQOLASKYKYLE 180
QY 181 HKYQHLATLANHNOSEIIAOLEEHCORVPSPARVPVOPPPAPPPVOPPTYNRIINOISTN 240
DB 181 HKYQHLATLANHNOSEIIAOLEEHCORVPSPARVPVOPPPAPPPVOPPTYNRIINOISTN 240
QY 241 EIQSDQNLKVLPPPLPTMPTLTSLPSTDKPSGPMWDCIQALEDGHTSSILYVKEBNTN 300
DB 241 EIQSDQNLKVLPPPLPTMPTLTSLPSTDKPSGPMWDCIQALEDGHTSSILYVKEBNTN 300
QY 301 RLQVWCDQHRDPGGMTVIOQLRDLGGSVNFRRMNETYKQGFNGIDGYWLGLENIYWLINO 360
DB 301 RLQVWCDQHRDPGGMTVIOQLRDLGGSVNFRRMNETYKQGFNGIDGYWLGLENIYWLINO 360
QY 361 GNYKLVTMEDWSGRKVFAYASFRLPESEYKRLGRYHGNAGDSFTWNGKQFTTLD 420
DB 361 GNYKLVTMEDWSGRKVFAYASFRLPESEYKRLGRYHGNAGDSFTWNGKQFTTLD 420
QY 421 RHDVYTGNCAYHOKGGMWYNACAHSNLNGWYRGHYSRYQDGYVMAEPRGGSYSLKX 480
DB 421 RHDVYTGNCAYHOKGGMWYNACAHSNLNGWYRGHYSRYQDGYVMAEPRGGSYSLKX 480
QY 481 VMMIRPNPTFH 493
DB 481 VMMIRPNPTFH 493

RESULT 7

US-10-143-118-268
; Sequence 268, Application US/10143118
; Publication No. US2004003835A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P333ORIC228
; CURRENT APPLICATION NUMBER: US/10/143,118
; CURRENT FILING DATE: 2002-05-09
; Prior Application removed - See Palm or File Wrapper
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 268
; LENGTH: 493
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-143-118-268

Query Match 99.9%; Score 2682; DB 12; Length 493;
Best Local Similarity 99.8%; Pred. No. 4,9e-210;
Matches 492; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRPLVTCWMLGLIAAMGAVAGQEDGEGTEGSGPREFIYLNRYKRGESQDKCTYFTIV 60
Db 1 MRPLVTCWMLGLIAAMGAVAGQEDGEGTEGSGPREFIYLNRYKRGESQDKCTYFTIV 60
QY 61 POORVTGALCVNSKEPEVLLNNRVHVKQELINNELLKQKROJETTLQOLVKGIVSEV 120
Db 61 POORVTGALCVNSKEPEVLLNNRVHVKQELINNELLKQKROJETTLQOLVKGIVSEV 120
QY 121 KLLKESRRMNSRVTLQYMLLHEIIRKDNALLESQENRIINQADMLQASKYKDL 180
Db 121 KLLKESRRMNSRVTLQYMLLHEIIRKDNALLESQENRIINQADMLQASKYKDL 180
QY 181 HKYQHLATLANQSEIIAQLSEHCQVPSARVPVQPPAPPRVYQPTYNRIINQISTN 240
Db 181 HKYQHLATLANQSEIIAQLSEHCQVPSARVPVQPPAPPRVYQPTYNRIINQISTN 240
QY 241 EIQSDQNLKVLPPPLPTMPTLTS,PSSTDKPSGPMWDCI,QLALDGHDTSS,ILVKPENNTN 300
Db 241 EIQSDQNLKVLPPPLPTMPTLTS,PSSTDKPSGPMWDCI,QLALDGHDTSS,ILVKPENNTN 300
QY 301 RLMQVWCDQHDHDPGQMTVIO,RLDGSVNFPRNMETTKQGFNIDGEYWLGLENIYWLTLNQ 360
Db 301 RLMQVWCDQHDHDPGQMTVIO,RLDGSVNFPRNMETTKQGFNIDGEYWLGLENIYWLTLNQ 360
QY 361 GNYKLVTMEDSGRKVFAYASFLPESEYYKLRGRHGNAGDSFTWNGKQFTLLD 420
Db 361 GNYKLVTMEDSGRKVFAYASFLPESEYYKLRGRHGNAGDSFTWNGKQFTLLD 420
QY 421 RDHDVYTGNCARHKGGMWYNACAHSNLNGWYRGHTRSRQDGYMAEFPGSSYSLK 480
Db 421 RDHDVYTGNCARHKGGMWYNACAHSNLNGWYRGHTRSRQDGYMAEFPGSSYSLK 480
QY 481 VMMIRPNENTFH 493
Db 481 VMMIRPNENTFH 493

RESULT 8
US-10-144-993-268
; Sequence 268, Application US/10144993
; Publication No. US20040038336A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: Deforge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Zhang, William
; APPLICANT: Wood, William
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C261
; CURRENT APPLICATION NUMBER: US/10/144,993
; PRIOR FILING DATE: 2002-05-13
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 268
; LENGTH: 493
; TYPE: PRF
; ORGANISM: Homo Sapien
US-10-144-993-268

Query Match 99.9%; Score 2682; DB 12; Length 493;
Best Local Similarity 99.8%; Pred. No. 4,9e-210;
Matches 492; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1 MRPLVTCWMLGLIAAMGAVAGQEDGEGTEGSGPREFIYLNRYKRGESQDKCTYFTIV 60
Db 1 MRPLVTCWMLGLIAAMGAVAGQEDGEGTEGSGPREFIYLNRYKRGESQDKCTYFTIV 60
QY 61 POORVTGALCVNSKEPEVLLNNRVHVKQELINNELLKQKROJETTLQOLVKGIVSEV 120
Db 61 POORVTGALCVNSKEPEVLLNNRVHVKQELINNELLKQKROJETTLQOLVKGIVSEV 120
QY 121 KLLKESRRMNSRVTLQYMLLHEIIRKDNALLESQENRIINQADMLQASKYKDL 180
Db 121 KLLKESRRMNSRVTLQYMLLHEIIRKDNALLESQENRIINQADMLQASKYKDL 180
QY 181 HKYQHLATLANQSEIIAQLSEHCQVPSARVPVQPPAPPRVYQPTYNRIINQISTN 240
Db 181 HKYQHLATLANQSEIIAQLSEHCQVPSARVPVQPPAPPRVYQPTYNRIINQISTN 240
QY 241 EIQSDQNLKVLPPPLPTMPTLTS,PSSTDKPSGPMWDCI,QLALDGHDTSS,ILVKPENNTN 300
Db 241 EIQSDQNLKVLPPPLPTMPTLTS,PSSTDKPSGPMWDCI,QLALDGHDTSS,ILVKPENNTN 300
QY 301 RLMQVWCDQHDHDPGQMTVIO,RLDGSVNFPRNMETTKQGFNIDGEYWLGLENIYWLTLNQ 360
Db 301 RLMQVWCDQHDHDPGQMTVIO,RLDGSVNFPRNMETTKQGFNIDGEYWLGLENIYWLTLNQ 360
QY 361 GNYKLVTMEDSGRKVFAYASFLPESEYYKLRGRHGNAGDSFTWNGKQFTLLD 420
Db 361 GNYKLVTMEDSGRKVFAYASFLPESEYYKLRGRHGNAGDSFTWNGKQFTLLD 420
QY 421 RDHDVYTGNCARHKGGMWYNACAHSNLNGWYRGHTRSRQDGYMAEFPGSSYSLK 480
Db 421 RDHDVYTGNCARHKGGMWYNACAHSNLNGWYRGHTRSRQDGYMAEFPGSSYSLK 480
QY 481 VMMIRPNENTFH 493
Db 481 VMMIRPNENTFH 493

RESULT 9
US-10-158-787-268
; Sequence 268, Application US/10158787
; Publication No. US20040039164A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: Deforge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C449
; CURRENT APPLICATION NUMBER: US/10/158,787
; PRIOR FILING DATE: 2003-04-03
; CURRENT APPLICATION NUMBER: 60/045911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113

```

PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059115
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059117
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059122
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059184
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059263
PRIOR FILING DATE: 1997-09-18
PRIOR APPLICATION NUMBER: 60/059352
PRIOR FILING DATE: 1997-09-19
PRIOR APPLICATION NUMBER: 60/059588
PRIOR FILING DATE: 1997-09-19
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 550
SEQ ID NO 268
LENGTH: 493
TYPE: PR
ORGANISM: Homo Sapien
US-10-156-787-268

```

Query Match 99.9%; Score 2682; DB 12; Length 493;

Best Local Similarity 99.8%; Pred. No. 4.9e-210; Matches 492; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

```

QY 1 MRPLCTCWMGLGLAAMGAVAGDEGFEETGEGSPREFYILNRYKAGSODKCTYTFIV 60
DB 1 MRPLCTCWMGLGLAAMGAVAGDEGFEETGEGSPREFYILNRYKAGSODKCTYTFIV 60
QY 61 POORVTGALCVNSKEPEVLENNVHKQBELNNELNKKQKQIETLQOLVVDGIVSEV 120
DB 61 POORVTGALCVNSKEPEVLENNVHKQBELNNELNKKQKQIETLQOLVVDGIVSEV 120
QY 121 KILRKESRNNSRVTLQVQLHEITRKDNALIELSOLNRIINOTADMLQASXYKDE 180
DB 121 KILRKESRNNSRVTLQVQLHEITRKDNALIELSOLNRIINOTADMLQASXYKDE 180
QY 121 KILRKESRNNSRVTLQVQLHEITRKDNALIELSOLNRIINOTADMLQASXYKDE 180
DB 121 KILRKESRNNSRVTLQVQLHEITRKDNALIELSOLNRIINOTADMLQASXYKDE 180
QY 181 HKYQHLATLANHOSSEIIAQLBEHCORVPAPPOPPAPPRVYQPTYNRIINOISTN 240
DB 181 HKYQHLATLANHOSSEIIAQLBEHCORVPAPPOPPAPPRVYQPTYNRIINOISTN 240
QY 241 EIQSDONLKVLPPLPTMTLTSLSSTDXSGPWRDCLQALBDHDTSSIYLKPEENTN 300
DB 241 EIQSDONLKVLPPLPTMTLTSLSSTDXSGPWRDCLQALBDHDTSSIYLKPEENTN 300
QY 301 RLMQWVCDQHDHGGWTVIQRLDGSVNFPRMWTYKQGFNGIDGYWLGLENIYWLINQ 360
DB 301 RLMQWVCDQHDHGGWTVIQRLDGSVNFPRMWTYKQGFNGIDGYWLGLENIYWLINQ 360
QY 361 GNYKLLVTMEDWSGRVFAEYASFLPESEYKRLGRYHGNAGDSFTWNGKQFTLLD 420
DB 361 GNYKLLVTMEDWSGRVFAEYASFLPESEYKRLGRYHGNAGDSFTWNGKQFTLLD 420
QY 421 RDHDVYTGNCAYHOKGGMWYNACAHSNLNGVYRGHYSRKYODGYVMAEFGGSYSLLK 480
DB 421 RDHDVYTGNCAYHOKGGMWYNACAHSNLNGVYRGHYSRKYODGYVMAEFGGSYSLLK 480
QY 481 VVMIRPNPTFH 493
DB 481 VVMIRPNPTFH 493

```

RESULT 10
US-10-140-024-268
Sequence 268, Application US/10140024
Publication No. US2004005842A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Beresini, Maureen
APPLICANT: DeForge, Laura
APPLICANT: Desnoyers, Luc

```

APPLICANT: Filvaroff, Ellen
APPLICANT: Gao, Mei-Qiang
APPLICANT: Gerilsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Gueney, Austin L.
APPLICANT: Sherwood, Steven
APPLICANT: Smith, Victoria
APPLICANT: Stewart, Timothy A.
APPLICANT: Tamas, Daniel
APPLICANT: Watanabe, Colin K
APPLICANT: Wood, William
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
FILE REFERENCE: P330R1C69
CURRENT FILING DATE: 2002-05-06
NUMBER OF SEQ ID NOS: 550
SEQ ID NO 268
LENGTH: 493
TYPE: PR
ORGANISM: Homo Sapien
US-10-140-024-268

```

Query Match 99.9%; Score 2682; DB 12; Length 493;

Best Local Similarity 99.8%; Pred. No. 4.9e-210; Matches 492; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

```

QY 1 MRPLCTCWMGLGLAAMGAVAGDEGFEETGEGSPREFYILNRYKAGSODKCTYTFIV 60
DB 1 MRPLCTCWMGLGLAAMGAVAGDEGFEETGEGSPREFYILNRYKAGSODKCTYTFIV 60
QY 61 POORVTGALCVNSKEPEVLENNVHKQBELNNELNKKQKQIETLQOLVVDGIVSEV 120
DB 61 POORVTGALCVNSKEPEVLENNVHKQBELNNELNKKQKQIETLQOLVVDGIVSEV 120
QY 121 KILRKESRNNSRVTLQVQLHEITRKDNALIELSOLNRIINOTADMLQASXYKDE 180
DB 121 KILRKESRNNSRVTLQVQLHEITRKDNALIELSOLNRIINOTADMLQASXYKDE 180
QY 121 KILRKESRNNSRVTLQVQLHEITRKDNALIELSOLNRIINOTADMLQASXYKDE 180
DB 121 KILRKESRNNSRVTLQVQLHEITRKDNALIELSOLNRIINOTADMLQASXYKDE 180
QY 181 HKYQHLATLANHOSSEIIAQLBEHCORVPAPPOPPAPPRVYQPTYNRIINOISTN 240
DB 181 HKYQHLATLANHOSSEIIAQLBEHCORVPAPPOPPAPPRVYQPTYNRIINOISTN 240
QY 241 EIQSDONLKVLPPLPTMTLTSLSSTDXSGPWRDCLQALBDHDTSSIYLKPEENTN 300
DB 241 EIQSDONLKVLPPLPTMTLTSLSSTDXSGPWRDCLQALBDHDTSSIYLKPEENTN 300
QY 301 RLMQWVCDQHDHGGWTVIQRLDGSVNFPRMWTYKQGFNGIDGYWLGLENIYWLINQ 360
DB 301 RLMQWVCDQHDHGGWTVIQRLDGSVNFPRMWTYKQGFNGIDGYWLGLENIYWLINQ 360
QY 361 GNYKLLVTMEDWSGRVFAEYASFLPESEYKRLGRYHGNAGDSFTWNGKQFTLLD 420
DB 361 GNYKLLVTMEDWSGRVFAEYASFLPESEYKRLGRYHGNAGDSFTWNGKQFTLLD 420
QY 421 RDHDVYTGNCAYHOKGGMWYNACAHSNLNGVYRGHYSRKYODGYVMAEFGGSYSLLK 480
DB 421 RDHDVYTGNCAYHOKGGMWYNACAHSNLNGVYRGHYSRKYODGYVMAEFGGSYSLLK 480
QY 481 VVMIRPNPTFH 493
DB 481 VVMIRPNPTFH 493

```

RESULT 11
US-10-140-808-268
Sequence 268, Application US/10140808
Publication No. US20030017563A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.

APPLICANT: Beresini, Maureen
APPLICANT: Deforge, Laura
APPLICANT: Desnoyers, Luc
APPLICANT: Filvaroff, Ellen
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Gurney, Austin L.
APPLICANT: Sherwood, Steven
APPLICANT: Smith, Victoria
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K
APPLICANT: Wood, William
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
FILE REFERENCE: P3330R1C182
CURRENT FILING DATE: 2002-05-07
CURRENT APPLICATION NUMBER: US/10/140,808
Prior Application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 550
SEQ ID NO 268
LENGTH: 493
TYPE: PRT
ORGANISM: Homo Sapien
US-10-140-808-268

Query Match 99.9%; Score 2682; DB 12; Length 493;
Best Local Similarity 99.8%; Pred. No. 4.9e-210;
Matches 492; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRPLCTTCWMLGLLAAGAVAGDEGEGTEGSPREFIYLNRKRGESQDKCTYTFIV 60
DB 1 MRPLCTTCWMLGLLAAGAVAGDEGEGTEGSPREFIYLNRKRGESQDKCTYTFIV 60
QY 61 POORVTGATCVNSKEPEVLEENRVHKOELINNELLKOKROITLQOLVAVDGIYSEV 120
DB 61 POORVTGATCVNSKEPEVLEENRVHKOELINNELLKOKROITLQOLVAVDGIYSEV 120
QY 121 KILRKESRNNSRVTLQYMLLHEIIRKSDNAELISQLENRIINQTDMLQASKYKDL 180
DB 121 KILRKESRNNSRVTLQYMLLHEIIRKSDNAELISQLENRIINQTDMLQASKYKDL 180
QY 181 HKYOHATLANOSEIILAOLEHRCORVPAPVOPPPAPPRVYOPTVNRINQISTN 240
DB 181 HKYOHATLANOSEIILAOLEHRCORVPAPVOPPPAPPRVYOPTVNRINQISTN 240
QY 241 EIQSDONLKVPLPLPTMTLTSLSSTDKSGPWRDCLQALEDHGHTSSILVYKPENTN 300
DB 241 EIQSDONLKVPLPLPTMTLTSLSSTDKSGPWRDCLQALEDHGHTSSILVYKPENTN 300
QY 301 RLMQVACDQRHDPGQWTVIQRRLDGSVNFPRNMTYKQGFNIDGEYWLGIENIYWLTLNQ 360
DB 301 RLMQVACDQRHDPGQWTVIQRRLDGSVNFPRNMTYKQGFNIDGEYWLGIENIYWLTLNQ 360
QY 361 GNYKLIVTMEDWSGRKFAEYASFRLEPSEYYKRLGRYHGNAGDSFTWHNGQFTTLD 420
DB 361 GNYKLIVTMEDWSGRKFAEYASFRLEPSEYYKRLGRYHGNAGDSFTWHNGQFTTLD 420
QY 421 RDHDVYTGNCANHYQKGGWYNACAHSNLNGWYRGHYSRQYODGYWAAEFPGGSYSLSLK 480
DB 421 RDHDVYTGNCANHYQKGGWYNACAHSNLNGWYRGHYSRQYODGYWAAEFPGGSYSLSLK 480
QY 481 VVMWIRPNPTTFH 493
DB 481 VVMWIRPNPTTFH 493

RESULT 12
US-10-152-405-268
Sequence 268, Application US/10152405

Publication No. US20030211571A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Beresini, Maureen
APPLICANT: Deforge, Laura
APPLICANT: Desnoyers, Luc
APPLICANT: Filvaroff, Ellen
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Gurney, Austin L.
APPLICANT: Sherwood, Steven
APPLICANT: Smith, Victoria
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K
APPLICANT: Wood, William
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
FILE REFERENCE: P3330R1C383
CURRENT FILING DATE: 2002-05-20
CURRENT APPLICATION NUMBER: US/10/152,405
Prior Application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 550
SEQ ID NO 268
LENGTH: 493
TYPE: PRT
ORGANISM: Homo Sapien
US-10-152-405-268

Query Match 99.9%; Score 2682; DB 12; Length 493;
Best Local Similarity 99.8%; Pred. No. 4.9e-210;
Matches 492; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRPLCTTCWMLGLLAAGAVAGDEGEGTEGSPREFIYLNRKRGESQDKCTYTFIV 60
DB 1 MRPLCTTCWMLGLLAAGAVAGDEGEGTEGSPREFIYLNRKRGESQDKCTYTFIV 60
QY 61 POORVTGATCVNSKEPEVLEENRVHKOELINNELLKOKROITLQOLVAVDGIYSEV 120
DB 61 POORVTGATCVNSKEPEVLEENRVHKOELINNELLKOKROITLQOLVAVDGIYSEV 120
QY 121 KILRKESRNNSRVTLQYMLLHEIIRKSDNAELISQLENRIINQTDMLQASKYKDL 180
DB 121 KILRKESRNNSRVTLQYMLLHEIIRKSDNAELISQLENRIINQTDMLQASKYKDL 180
QY 181 HKYOHATLANOSEIILAOLEHRCORVPAPVOPPPAPPRVYOPTVNRINQISTN 240
DB 181 HKYOHATLANOSEIILAOLEHRCORVPAPVOPPPAPPRVYOPTVNRINQISTN 240
QY 241 EIQSDONLKVPLPLPTMTLTSLSSTDKSGPWRDCLQALEDHGHTSSILVYKPENTN 300
DB 241 EIQSDONLKVPLPLPTMTLTSLSSTDKSGPWRDCLQALEDHGHTSSILVYKPENTN 300
QY 301 RLMQVACDQRHDPGQWTVIQRRLDGSVNFPRNMTYKQGFNIDGEYWLGIENIYWLTLNQ 360
DB 301 RLMQVACDQRHDPGQWTVIQRRLDGSVNFPRNMTYKQGFNIDGEYWLGIENIYWLTLNQ 360
QY 361 GNYKLIVTMEDWSGRKFAEYASFRLEPSEYYKRLGRYHGNAGDSFTWHNGQFTTLD 420
DB 361 GNYKLIVTMEDWSGRKFAEYASFRLEPSEYYKRLGRYHGNAGDSFTWHNGQFTTLD 420
QY 421 RDHDVYTGNCANHYQKGGWYNACAHSNLNGWYRGHYSRQYODGYWAAEFPGGSYSLSLK 480
DB 421 RDHDVYTGNCANHYQKGGWYNACAHSNLNGWYRGHYSRQYODGYWAAEFPGGSYSLSLK 480
QY 481 VVMWIRPNPTTFH 493
DB 481 VVMWIRPNPTTFH 493

RESULT 13
US-10-127-852A-268
; Sequence 268, Application US/10127852A
; Publication No. US20030203428A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Thomas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C8
; CURRENT APPLICATION NUMBER: US/10/127,852A
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining prior application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 268
; LENGTH: 493
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-127-852A-268

Query Match 99.9%; Score 2682; DB 12; Length 493;
Best Local Similarity 99.8%; Pred. No. 4,9e-210;
Matches 492; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRPLCTCWMGLIAGAVAGCGEFGTEGSGREFLYNRYKRGESQKCYTYIV 60
DB 1 MRPLCTCWMGLIAGAVAGCGEFGTEGSGREFLYNRYKRGESQKCYTYIV 60
QY 61 PQRVYTGATCVNSKEPEVLLENRVHVKQSELINNELLKQKQIETLQOLVYKDGIVSEV 120
DB 61 PQRVYTGATCVNSKEPEVLLENRVHVKQSELINNELLKQKQIETLQOLVYKDGIVSEV 120
QY 121 KLIRKSRNNSRVYQLYVQMLHEIIRKDNALLESQLENRLINTQADMQLASKYKYLE 180
DB 121 KLIRKSRNNSRVYQLYVQMLHEIIRKDNALLESQLENRLINTQADMQLASKYKYLE 180
QY 181 HKYOHATLAHNOSEIIAQLEEHQVRPSARVPVQPPAPPRVYQPTYNRIINOISTN 240
DB 181 HKYOHATLAHNOSEIIAQLEEHQVRPSARVPVQPPAPPRVYQPTYNRIINOISTN 240

RESULT 14
US-10-127-900A-268
; Sequence 268, Application US/10127900A
; Publication No. US20030203428A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Thomas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C81
; CURRENT APPLICATION NUMBER: US/10/127,900A
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining prior application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 268

DB 181 HKYOHATLAHNOSEIIAQLEEHQVRPSARVPVQPPAPPRVYQPTYNRIINOISTN 240
QY 241 EIOSDQNLKYLPPPLPTMTSLPSSSTDKSPGWRDCQALBEGHDTSSIVLVKPEENTN 300
DB 241 EIOSDQNLKYLPPPLPTMTSLPSSSTDKSPGWRDCQALBEGHDTSSIVLVKPEENTN 300
QY 301 RLMOVWCDQDRHDPGCVTVIORLDGSVNFRRMETTKQGFNGINDGYSWGLNITVLTNQ 360
DB 301 RLMOVWCDQDRHDPGCVTVIORLDGSVNFRRMETTKQGFNGINDGYSWGLNITVLTNQ 360
QY 361 GNYGLVLTMDWSGRKFAEYASFRLEPESEYYKLIRGYHGNAGDSFTWNGKQFTTLD 420
DB 361 GNYGLVLTMDWSGRKFAEYASFRLEPESEYYKLIRGYHGNAGDSFTWNGKQFTTLD 420
QY 421 RDHDVYTGCAHYQKGGWYNACAHSNLNGVYRGGHYRSRYODGYWMAEFRCGSYSLKX 480
DB 421 RDHDVYTGCAHYQKGGWYNACAHSNLNGVYRGGHYRSRYODGYWMAEFRCGSYSLKX 480
QY 481 VVMWIRPNPTFH 493
DB 481 VVMWIRPNPTFH 493

Mon Aug 9 10:30:09 2004

us-10-018-386-2.rapb

Page 9

```

; LENGTH: 493
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-127-900A-268

Query Match      99.9%; Score 2682; DB 12; Length 493;
Best Local Similarity 99.8%; Pred. No. 4.9e-210;
Matches 492; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRPLCTCWMGLIAGAVAGDEGEGTEGSPREFIYLNRYKRGESQDKTYTIV 60
DB 1 MRPLCTCWMGLIAGAVAGDEGEGTEGSPREFIYLNRYKRGESQDKTYTIV 60
QY 61 POORVTGAI CYN SKEPEVLL ENRVAKO ELLNNEL LKORQIETLQOLVKVGGIVSEV 120
DB 61 POORVTGAI CYN SKEPEVLL ENRVAKO ELLNNEL LKORQIETLQOLVKVGGIVSEV 120
QY 121 KILRKESRNNNSRVYQ LYMQLHEIIRKDNAL ELSQENRIINQADMLQASKYKOLE 180
DB 121 KILRKESRNNNSRVYQ LYMQLHEIIRKDNAL ELSQENRIINQADMLQASKYKOLE 180
QY 181 HKYOH LATAHNOSEIIAOLEEHCORVPSARVPQPPAPPRVYQPTYNRIINQISTN 240
DB 181 HKYOH LATAHNOSEIIAOLEEHCORVPSARVPQPPAPPRVYQPTYNRIINQISTN 240
QY 241 EIQSDQNLKVLPPPLPTMTLTS LPSSTDKPSGFWRDCLQALBDGHTSSIYLVKPEPTN 300
DB 241 EIQSDQNLKVLPPPLPTMTLTS LPSSTDKPSGFWRDCLQALBDGHTSSIYLVKPEPTN 300
QY 301 RLMQWCDQDRHDPGWTIVIQRLDGSVNFRRMNETYKQSGNIDGEMVGLENIYMLNQ 360
DB 301 RLMQWCDQDRHDPGWTIVIQRLDGSVNFRRMNETYKQSGNIDGEMVGLENIYMLNQ 360
QY 361 GNYKLVITMEDWSGRKFAEYASFRLEPSEYYKLRIGRYHGNAGDSFTWHNGKQFTLLD 420
DB 361 GNYKLVITMEDWSGRKFAEYASFRLEPSEYYKLRIGRYHGNAGDSFTWHNGKQFTLLD 420
QY 421 RHDVYITGNCAYOKGGMWYNACAHSLNNGWYRGHYSRYQDGYVMAEFRGGSYSLSKK 480
DB 421 RHDVYITGNCAYOKGGMWYNACAHSLNNGWYRGHYSRYQDGYVMAEFRGGSYSLSKK 480
QY 481 VMMIRPNPTFH 493
DB 481 VMMIRPNPTFH 493

RESULT 15
US-10-128-685A-268
; Sequence 268, Application US/10128685A
; Publication No. US20030203430A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C116
; CURRENT APPLICATION NUMBER: US/10/128,685A
; CURRENT FILING DATE: 2002-04-23
```

```

; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 268
; LENGTH: 493
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-128-685A-268

Query Match      99.9%; Score 2682; DB 12; Length 493;
Best Local Similarity 99.8%; Pred. No. 4.9e-210;
Matches 492; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
```

```

QY 1 MRPLCTCWMGLIAGAVAGDEGEGTEGSPREFIYLNRYKRGESQDKTYTIV 60
DB 1 MRPLCTCWMGLIAGAVAGDEGEGTEGSPREFIYLNRYKRGESQDKTYTIV 60
QY 61 POORVTGAI CYN SKEPEVLL ENRVAKO ELLNNEL LKORQIETLQOLVKVGGIVSEV 120
DB 61 POORVTGAI CYN SKEPEVLL ENRVAKO ELLNNEL LKORQIETLQOLVKVGGIVSEV 120
QY 121 KILRKESRNNNSRVYQ LYMQLHEIIRKDNAL ELSQENRIINQADMLQASKYKOLE 180
DB 121 KILRKESRNNNSRVYQ LYMQLHEIIRKDNAL ELSQENRIINQADMLQASKYKOLE 180
QY 181 HKYOH LATAHNOSEIIAOLEEHCORVPSARVPQPPAPPRVYQPTYNRIINQISTN 240
DB 181 HKYOH LATAHNOSEIIAOLEEHCORVPSARVPQPPAPPRVYQPTYNRIINQISTN 240
QY 241 EIQSDQNLKVLPPPLPTMTLTS LPSSTDKPSGFWRDCLQALBDGHTSSIYLVKPEPTN 300
DB 241 EIQSDQNLKVLPPPLPTMTLTS LPSSTDKPSGFWRDCLQALBDGHTSSIYLVKPEPTN 300
QY 301 RLMQWCDQDRHDPGWTIVIQRLDGSVNFRRMNETYKQSGNIDGEMVGLENIYMLNQ 360
DB 301 RLMQWCDQDRHDPGWTIVIQRLDGSVNFRRMNETYKQSGNIDGEMVGLENIYMLNQ 360
QY 361 GNYKLVITMEDWSGRKFAEYASFRLEPSEYYKLRIGRYHGNAGDSFTWHNGKQFTLLD 420
DB 361 GNYKLVITMEDWSGRKFAEYASFRLEPSEYYKLRIGRYHGNAGDSFTWHNGKQFTLLD 420
QY 421 RHDVYITGNCAYOKGGMWYNACAHSLNNGWYRGHYSRYQDGYVMAEFRGGSYSLSKK 480
DB 421 RHDVYITGNCAYOKGGMWYNACAHSLNNGWYRGHYSRYQDGYVMAEFRGGSYSLSKK 480
QY 481 VMMIRPNPTFH 493
DB 481 VMMIRPNPTFH 493
```

Search completed: July 30, 2004, 12:43:16
Job time : 47 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: July 30, 2004, 12:32:34 ; Search time 18 Seconds
(without alignments)
2634.579 Million cell updates/sec

Title: US-10-018-386-2

Perfect score: 2666

Sequence: 1 MRPLCTCMTGLIAMGAV.....GSYSIKVVMIRNPNTFH 493

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283366 seqs, 96191526 residues

Total number of hits satisfying chosen parameters: 283366

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

1: PIR1:
2: PIR2:
3: PIR3:
4: PIR4:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	533	19.8	312	2 JN0596	fibrinogen-related
2	526.5	19.6	491	1 FGHUB	fibrinogen beta ch
3	524.5	19.5	468	1 FGBOB	fibrinogen beta ch
4	520.5	19.4	866	2 D44234	fibrinogen alpha c
5	512.5	19.1	479	2 A25052	fibrinogen beta ch
6	503	18.7	463	2 A38463	fibrinogen beta ch
7	501	18.7	437	1 FGHUG	fibrinogen gamma-A
8	501	18.7	453	1 FGHUGB	fibrinogen gamma-B
9	500	18.6	328	2 A05299	fibrinogen beta ch
10	485	18.4	282	2 A35084	fibrinogen-related
11	489.5	18.2	438	2 A32670	fibrinogen gamma c
12	488	18.2	1356	2 A45445	janusin precursor,
13	484.5	18.0	326	2 B47172	ficolin-beta - pig
14	483.5	18.0	326	2 S61517	ficolin-1 precursor
15	483.5	18.0	432	2 A27447	cytotoxic T-lympho
16	483.5	18.0	323	2 A47172	transforming growt
17	482.5	18.0	334	2 UCS580	ficolin-A precursors
18	480.5	17.9	439	2 I37391	fibrinogen-like pr
19	480.5	17.9	1353	1 JH0675	restrictin-like pr
20	479.5	17.9	432	2 I56934	fibrinogen-like pr
21	476.5	17.7	444	2 S05313	fibrinogen gamma-B
22	465.5	17.3	641	2 A41932	fibrinogen alpha-I
23	463.5	17.3	432	1 FGLMG	fibrinogen gamma c
24	459	17.1	437	1 FGRUGA	fibrinogen gamma-A
25	459	17.1	445	1 FGRUGB	fibrinogen gamma-B
26	455.5	17.0	417	2 S65944	tenascin-X - pig (
27	452	16.8	860	2 I48839	tenascin-X - mouse
28	451.5	16.8	3566	1 A40701	tenascin-X precurs
29	451.5	16.8	4135	2 T42629	tenascin-X - bovin

30	450.5	16.8	1810	1 A32230	tenascin precursor
31	448	16.7	4006	2 T09070	probbble tenascin
32	444.5	16.5	220	2 S28170	tenascin homolog -
33	443.5	16.2	1746	1 S19694	tenascin precursor
34	423.5	15.8	2019	1 J01322	tenascin precursor
35	421.5	15.7	2201	2 A32160	tenascin-C - human
36	391.5	14.6	1914	2 T42635	tenascin Y precurs
37	388.5	14.5	774	2 A39832	scabrous locus (sc
38	257.5	9.6	463	2 T15876	hypothetical prote
39	235.5	8.8	127	2 PC2036	microfibril-associ
40	188.5	7.0	431	2 T29680	hypothetical prote
41	174	6.5	452	2 T26827	hypothetical prote
42	172.5	6.4	933	2 A31930	cytoactin - chick
43	156.5	5.8	777	2 I51647	tenascin - African
44	155	5.8	146	2 T32255	hypothetical prote
45	153	5.7	744	2 F95013	pneumococcal surfa

ALIGNMENTS

```
RESULT 1
JN0596
fibrinogen-related protein HFRP-1 precursor - human
C:Species: Homo sapiens (man)
C:Date: 03-Feb-1994 #sequence_revision 03-Feb-1994 #text_change 21-Jul-2000
C:Accession: JN0596
R:Yamamoto, T.; Gotoh, M.; Sasaki, H.; Terada, M.; Kitejima, M.; Hirohashi, S.
Biochem. Biophys. Res. Commun. 193, 661-687, 1993
A:Title: Molecular cloning and initial characterization of a novel fibrinogen-related ge
A:Reference number: JN0596; MUID:33290661; PMID:8390249
A:Accession: JN0596
A:Molecule type: mRNA
A:Residues: 1-312 <YAM>
A:Cross-references: GS:D1446; NID:G393314; PIDN:BA03336.1; PID:G393315
A:Experimental source: liver
C:Superfamily: fibrinogen beta/gamma homology
F.1-17/Domain: signal sequence #status predicted <SIG>
F.18-312/Product: fibrinogen-related protein HFRP-1 #status predicted <MAT>
F.80-305/Domain: fibrinogen beta/gamma homology <FBG>

Query Match          19.8%; Score 533; DB 2; Length 312;
Best local similarity 39.3%; Pred. No. 1.9e-27;
Matches 110; Conservative 41; Mismatches 69; Indels 40; Gaps 9;

QY 232 RIINGISTNEIQ-----SPDNKVLPPPLPTMTLSIPSSNDKPSGPRDCLQALDGH 287
DB 50 KIKQLQENEVQFLDKGDED-----TVVDLSKRGQ-----YADSEIFNDGYK 92
QY 288 TSSIVLVKPEENTNRLMOYWCDDQRHDPGQWTVIQRLDGSVNFPMNMTYKGFQNI---D 344
DB 93 LSGFYKIKPILQSPAEFSYCDM-SDGGGWTVIQRRSGSENFNGMDYENGFNFOVKH 151
QY 345 GEYHIGLENTWLNQGVKYLVTMEDSGKVAEVAEFLSESESEYKRLRYGNA 404
DB 152 GEYWGKXKHLFTLQEDYTLKIDLADPEKRSRAQYKXNFVGEKXFLTEANIGESGA 211
QY 405 GDSFT-----W--HNGKQFTLLDHDVDTGNCAPHYKGGWYNAACHSNLNGVY 453
DB 212 GDSLAGNHPREVQWASHQRMKFTWDRDHNDYNGCAEFDQSGWWEFNRCHSAVLNGVY 271
QY 444 RGRHRSRYQDGVVAEFRGGSYSLSIKVVMIRNP---PN 490
DB 272 -SGPYTAKTDNGIWMYTWGHGWSLSKSVMKIRPNDFTPN 310

RESULT 2
FGHUB
fibrinogen beta chain precursor [validated] - human
N:Alternate names: coagulation factor I
N:Contains: fibrinopeptide B
C:Species: Homo sapiens (man)
C:Date: 24-Apr-1984 #sequence_revision 31-Mar-1993 #text_change 08-Dec-2000
```

C,Accession: B43568; A90469; B90469; I37389; A94433; A94309; G54223; A03121; B37
R,Chung, D.W.; Harris, J.E.; Davie, E.W.
Adv. Exp. Med. Biol. 281, 39-48, 1990
A,Title: Nucleotide sequences of the three genes coding for human fibrinogen.
A,Reference number: A43568; PMID:91344740; PMID:2102623
A,Accession: B43568
A,Molecule type: DNA
A,Residues: 9-191, 'P', 193-491 <CHU>
R,Chung, D.W.; Que, B.G.; Rixon, M.W.; Mace Jr., M.; Davie, E.W.
Biochemistry 22, 3244-3250, 1983
A,Title: Characterization of complementary deoxyribonucleic acid and genomic deoxyribon
A,Reference number: A90469; PMID:8323433; PMID:6688356
A,Accession: A90469
A,Molecule type: DNA
A,Residues: 1-38 <CHI>
A,Accession: B90469
A,Molecule type: mRNA
A,Residues: 9-191, 'A', 193-491 <CH2>
A,Cross-references: GB:J00129; NID:G182429; PIDN:AAA52429.1; PID:G182430
R,Huber, P.; Dalmont, J.; Courtois, G.; Laurent, M.; Assouline, Z.; Marguerie, G.
Nucleic Acids Res. 15, 1615-1625, 1987
A,Title: Characterization of the 5'-flanking region for the human fibrinogen beta gene.
A,Reference number: I37389; PMID:87146483; PMID:3029722
A,Accession: I37389
A,Status: translated from GB/EMBL/DBJ
A,Molecule type: DNA
A,Residues: 1-38 <HNB>
A,Cross-references: EMBL:X05018; NID:G31400; PIDN:CAA28674.1; PID:G31401
R,Henschen, A.; Lottspeich, F.; Southan, C.; Topfer-Petersen, E.
in Products of the Biological Fluids, Proc. 28th Colloq., Peeters, H., ed., pp.51-56, Pe
A,Title: Human fibrinogen: sequence, sulfur bridges, glycosylation and some structural v
A,Reference number: A94433
A,Contents: carbohydrate binding
A,Accession: A94433
A,Molecule type: protein
A,Residues: 31-137, 'Q', 140-144, 'Q', 147-491 <HEN>
R,Watt, K.W.K.; Takagi, T.; Doellittle, R.F.
Biochemistry 18, 68-76, 1979
A,Title: Amino acid sequence of the beta chain of human fibrinogen.
A,Reference number: A90437; PMID:79124640; PMID:420779
A,Accession: A90437
A,Molecule type: protein
A,Residues: 31-144, 'Q', 147-231, 'D', 233-330, 'E', 332-491 <WAT>
R,Blomback, B.; Hessel, B.; Hoger, D.
Thromb. Res. 8, 639-658, 1976
A,Title: Disulfide bridges in NH-2-terminal part of human fibrinogen.
A,Reference number: A94309; PMID:76225080; PMID:936108
A,Contents: disulfide bonds
A,Accession: A94309
A,Molecule type: protein
A,Residues: 31-112, 'E', 114-137, 'Q', 140-144, 'Q', 147-148 <BLO>
R,Kuntake, S.T.; Carilli, C.T.; Lau, K.; Procter, A.A.; Naya-Vigne, J.; Kane, J.P.
Biochemistry 33, 1988-1993, 1994
A,Title: Identification of proteins associated with apolipoprotein A-I-containing lipopr
A,Reference number: A54223; PMID:94162201; PMID:8117655
A,Accession: G54223
A,Molecule type: protein
A,Residues: 164-174 <KUN>
A,Note: Identification of tryptic peptides from high-density lipoproteins
R,Henschen, A.; Lottspeich, F.; Kehl, M.; Southan, C.
Am. N. Y. Acad. Sci. 408, 28-43, 1983
A,Title: Covalent structure of fibrinogen.
A,Reference number: A90037; PMID:83234370; PMID:6575689
A,Contents: annotation; review, disulfide bonds
R,Gardlund, B.; Hessel, B.; Marguerie, G.; Murano, G.; Blomback, B.
Eur. J. Biochem. 77, 595-610, 1977
A,Title: Primary structure of human fibrinogen. Characterization of disulfide-containing
A,Reference number: A91249; PMID:7745899; PMID:891553
A,Contents: annotation, disulfide bonds
R,Doellittle, R.F.; Takagi, T.; Watt, K.; Bouma III, H.; Cottrell, B.A.; Caesman, K.G.; G
in Regulatory Proteolytic Enzymes and Their Inhibitors, Magnusson, S., Ottesen, M., Folt
A,Title: The structures of fibrinogen and fibrin.
A,Reference number: A94437

A,Contents: annotation; disulfide bonds
R,Doellittle, R.F.
Annu. Rev. Biochem. 53, 195-229, 1984
A,Title: Fibrinogen and fibrin.
A,Reference number: A90041; PMID:84305751; PMID:6383194
A,Contents: annotation; review, EM structure, polymerization, ligands
R,Chung, D.W.; Rixon, M.W.; Que, B.G.; Davie, E.W.
Am. N. Y. Acad. Sci. 408, 449-456, 1983
A,Title: Cloning of fibrinogen genes and their cDNA.
A,Reference number: A90038; PMID:83254384; PMID:6575700
A,Contents: annotation
R,Kirsbaum, N.E.; Budzynski, A.Z.
J. Biol. Chem. 265, 13669-13676, 1990
A,Title: A unique proteolytic fragment of human fibrinogen containing the Aalpha COOH-te
A,Reference number: A37117; PMID:90337977; PMID:2143188
A,Contents: annotation; hementin cleavage site
A,Note: hementin, a protease from Haemaphysa gillmanii, the giant South American leech,
C,Comment: The conversion of fibrinogen to fibrin is triggered by thrombin, which cleave
ization sites responsible for the formation of the soft clot.
C,Comment: The soft clot is converted into the hard clot by factor XIIIa (fibrin-stabili
ger) and between alpha chains (weaker) of different monomers.
A,Comment: All fibrinogen chains are synthesized in the liver.
A,Genetics:
A,Gene: GDB:FCB
A,Cross-references: GDB:119130; OMIM:134830
A,Map position: 4q28-4q28
A,Intons: 38/3, 102/3, 164/1, 240/1, 278/1, 320/1, 415/2
C,Complex: The fibrinogen molecule is a hexamer containing two sets of alpha (see PIR:FG
ins are contained in the core. Two three-chain coiled coils emerge from this core and co
from the distal domain nodes.
C,Function:
A,Description: fibrinogen cleaved by thrombin yields monomers that are polymerized into
A,Pathway: blood coagulation
C,Superfamily: fibrinogen beta chain; fibrinogen beta/gamma homology; fibrinogen disulf
C,Keywords: blood coagulation; coiled coil; glycoprotein; liver; plasma; pyroglyutamic ac
F,1-30/Domain: (or 4-30 or 15-30) signal sequence #status predicted <SIG>
F,31-491/Product: fibrinogen beta chain #status experimental <WAT>
F,31-44/Product: fibrinopeptide B #status experimental <APT>
F,45-491/Product: fibrin beta chain #status experimental <APT>
F,45-47/Region: polymerization site
F,99-228/Domain: fibrinogen disulfide ring homology <FDR>
F,238-467/Domain: fibrinogen beta/gamma homology <FBG>
F,31/Modified site: pyroglutamate carboxylic acid (Gln) (in mature form) #status experimen
F,44-45/Cleavage site: Arg-Gly (thrombin) #status experimental
F,95/Disulfide bonds: interchain (to alpha-55) #status experimental
F,110/Disulfide bonds: interchain (to alpha-68) #status experimental
F,110/Disulfide bonds: interchain (to gamma-45) #status experimental
F,223/Disulfide bonds: interchain (to alpha-184) #status experimental
F,227/Disulfide bonds: interchain (to gamma-161) #status experimental
F,231-316,241-270,424-437/Disulfide bonds: #status experimental
F,394/Binding site: carbohydrate (Asn) (covalent) #status experimental
Query Match 19.6%; Score 526.5; DB 1; Length 491;
Best Local Similarity 30.3%; Pred. No. 9,2e-27;
Matches 139; Conservative 64; Mismatches 114; Indels 139; Gaps 16;
QY 92 LNNELLKQKQIETTLQOLVKGIVSGVSEVXKLKRSRNNNSRYTQI-----YMLLHEI 145
DB 112 LQBALIQQEBPIRN-----SVD-----ELNNVAVSQSSSSFPQMYLLKDL 154
QY 146 IRRKDNALF-----LSQLENRTL-----NQTADMQLASKYKDLKHXOHLAT 188
DB 155 WQKQKQVQNDENVVNEVSELEKQLYIDETVNSIIPNLVLRSLKLSKQKL-- 212
QY 189 LANQSEIIAQLSEHCQRPVSARPVQPPAPRVYQPPYRNRIINOISTNEIGSDQNL 248
DB 213 -----ESDVASQW-EYC-FRPPCT-----VSCN----- 232
QY 249 KVLPPPLPMTPLTSLPSSTDKPQSGPWRDCLQLEDGHTSSLYLKPENTRLNQWCD 308
DB 233 -----IPVV-----SG--KECEIIRKQSEMYLQPPSSVQPPRVYQCD 271
QY 309 QRHDPGQMTVLIQRLLDGSVNFRRNMEYKQSGNI-----DGEYWLGLNIY 356


```

Db      272  MNTENGWTVI|QNRDGGVDFGRKMDPYKQGFNATVTDKQVCG|PGEYTLANDKISQ 331
      357  LTNOGNYKLIVTMEWMSRKYVFAEYASFLPESEYYKLRLGRYGNAGD----- 406
      332  LTRMGPTTELLIMEMWKKDKYAHYGGFTVQNEANKYQISVYKRGTKGNALMGASQIM 391
      407  ----SFTWNGKQFTLLDRHDVYTG-----CAHYQKGGMWYNACAHSNLNGVYRGCH 457
      392  GENRTMTLHNGMFFSTYDRDNDGMLTSPRKQCSKEDGGWYNRCHANNPGRYWGQ 451
      458  Y-----RSRYQDGYVMAEPRGGSYSLKRYVMIRP 487
      452  YTWMAKHGTTDGVVWMMKSGWSYMRKMSKIRP 486

```

RESULT 3

RGOB

fibrinogen beta chain - bovine

N:Contains: fibrinopeptide B

C:Species: Bos primigenius taurus (cattle)

C>Date: 29-Jul-1981 #sequence_revision 29-Jul-1981 #text_change 13-Sep-1996

C:Accession: A03122; B03117; B37507; A37513; S02443

R:Blomback, B.; Doellittle, R.F.

Acta Chem. Scand. 17, 1816-1819, 1963

A>Title: The sequence of amino acids at the N-terminal end of bovine fibrinopeptide B.

A:Reference number: A03122

A:Accession: A03122

A:Molecule type: protein

A:Residues: 1-4 <BLO>

R:Stojaniet, J.; Blomback, B.; Wallen, P.

Ark. Kent 16, 425-436, 1960

A>Title: Amino acid sequence of bovine fibrinopeptides.

A:Reference number: A03117

A:Accession: B03117

A:Molecule type: protein

A:Residues: 5-21 <STO>

R:Marinelli, R.A.; Inglis, A.S.; Rubira, M.R.; Hageman, T.C.; Hurrell, J.G.R.; Leach, S.

Arch. Biochem. Biophys. 192, 27-32, 1979

A>Title: Amino acid sequences of portions of the alpha and beta chains of bovine fibrin

A:Reference number: A37507; MUID:79164394; PMID:434821

A:Accession: B37507

A:Molecule type: protein

A:Residues: 22-53 <MAR>

R:Chung, D.W.; Rixon, M.W.; MacGillivray, R.T.A.; Davie, E.W.

Proc. Natl. Acad. Sci. U.S.A. 78, 1466-1470, 1981

A>Title: Characterization of a cDNA clone coding for the beta chain of bovine fibrinogen

A:Reference number: A37513; MUID:81199473; PMID:6262803

A:Accession: A37513

A:Molecule type: mRNA

A:Residues: 44-468 <CHU>

R:Medred, L.V.; Platonova, T.N.; Litvinovich, S.V.; Lukinova, N.I.

FEBS Lett. 232, 56-60, 1988

A>Title: The cleavage of beta-chain in bovine fibrinogen D(H) fragment (95 kDa) leads to

A:Reference number: S02443; MUID:8821875; PMID:296748

A:Accession: S02443

A:Molecule type: protein

A:Residues: 373-374 <MED>

C:Comment: Thrombin cleaves the bond between Arg-21 and Gly-22 to release fibrinopeptide

C:Comment: Fibrinogen is a hexamer containing two sets of three nonidentical chains (alpha

C:Keywords: blood coagulation; glycoprotein; plasma; pyroglyutamic acid; sulfoliprotein

F:76-205/Domain: fibrinogen disulfide ring homology <FDR>

F:215-464/Domain: fibrinogen beta/gamma homology <FBG>

F:1/Modified site: pyroglutamate carboxylic acid (Gln) #status experimental

F:6/Binding site: sulfate (Tyr) (covalent) #status experimental

F:21-22/Cleavage site: Arg-Gly (thrombin) #status experimental

F:371/Binding site: carboxylate (Asn) (covalent) #status predicted

F:372-373/Cleavage site: Arg-Thr (plasmin) #status experimental

```

      92  LNNELLKQK-----QIETLQQLVKGIVSEVYKLRLKSRMNSRYTQYMLHEIR 147
      89  LQDTLVROEERPIKRSIEDLNTV-----DSVSTSSSTQYITLLNNMK 133
      148  KDNVALELSQENRILNQADMLQASKYKDEHKYQHLATLHNOSEIIAQLEHCORV 207
      134  GRQNV-----QDNENVAEYSHLEKQLYTD-----ETVKN----- 167
      208  PSARVPVQPPAAPPRVYQPPYRIINQISTN-----ETQSDQNLKVLPELPMPIL 261
      168  -----IPTKLRLVRLSILENIRSKIQLESDVSTQMEYCRTPCTVT- 207
      262  TSLPSSITDKRSGPRDCLQALEDHGPDSSIVLVKPENTNVMWQDQRPDGMVYQR 321
      208  CNLPVYSGK-----ECKIIRNEGTSMTLLQPEDSSKPYRYVYCDMKTEKGMVYQN 261
      322  RLDSVNFPPNWEYKQGFNI-----DGEYTLGLENIYWLINOYNYKLIVT 369
      262  RQDSGLDFGRKMDPYKQGFNATVNAEKKYCGVPGRYWLGNDRIQLTNMGPTKLIIEM 321
      370  EDMSGRVYFAEYASFLPESEYYKLRLGRYGNAGD-----SFTWNGKQ 415
      322  EDWKGDKVTALYEGFTVQNEANKYQLSVSKYKGTAGNALLIGASQLVGENRTMTIHSMF 381
      416  FTTLDPRHDVY-----TGNCAYQKGGMWYNACAHSNLNGVYRGCHY-----RSRYQDG 465
      382  FSTYDRDNDGKTTDPRKQCSKEDGGWYNRCHANNPGRYWGAYTWMAKHGTTDGG 441
      466  YVMAEPRGGSYSLKRYVMIRP 487
      442  VVMMWQSGWSYMRKMSKIRP 463

```

RESULT 4

fibrinogen alpha chain precursor, extended splice form - human

N:Alternate names: coagulation factor I

N:Contains: fibrinopeptide A

C:Species: Homo sapiens (man)

C>Date: 10-Jun-1993 #sequence_revision 06-Sep-1996 #text_change 19-Jan-2001

C:Accession: B44234; B44234

R:Fu, Y.; Weissbach, L.; Plant, P.W.; Oddoux, C.; Cao, Y.; Liang, T.J.; Roy, S.N.; Redma

Biochemistry 31, 11968-11972, 1992

A>Title: Carboxy-terminal-extended variant of the human fibrinogen alpha subunit: a novel

A:Reference number: A44234; MUID:91907025; PMID:1457396

A:Accession: D44234

A:Status: translated from GB/EMBL/DBJ

A:Molecule type: mRNA; DNA

A:Residues: 1-866 <FU>

A:Cross-references: GB:M58569; NID:G182406; PID:G182407

A:Note: neither the complete nucleic acid sequence nor the complete translation are shown

A:Accession: B44234

A:Molecule type: mRNA; DNA

A:Residues: 605-866 <FU2>

A:Note: sequence extracted from NCBI backbone (NCBI:119917)

C:Comment: The alpha chain binds by 2-4 cross-links to the amino end of fibrinectin.

C:Comment: The conversion of fibrinogen to fibrin is triggered by thrombin, which cleave

C:Comment: The soft clot is converted into the hard clot by factor XIIIa (fibrin-stabiliz

C:Comment: The soft clot is converted into the hard clot by factor XIIIa (fibrin-stabiliz

C:Comment: All fibrinogen chains (weaker) of different monomers.

C:Comment: See PIR:FGHVA for the major splice form. It is not known whether this form is

C:Genetics:

A:Gene: GDB:FGA

A:Cross-references: GDB:119129; OMIM:134820

A:Map position: 4q28-4q28

A:Introns: 18/3; 60/3; 122/1; 171/2

A:Note: The list of introns is incomplete

C:Complex: The fibrinogen molecule is a hexamer containing two sets of three nonidentical

C:Function: The fibrinogen molecule is a hexamer containing two sets of three nonidentical

C:Function: The fibrinogen molecule is a hexamer containing two sets of three nonidentical

A,Description: fibrinogen cleaved by thrombin yields monomers that are polymerized into A,Pathway: blood coagulation
C,Superfamily: human extended splice form fibrinogen alpha chain; fibrinogen beta/gamma
C,Keywords: alternative splicing; blood coagulation; glycoprotein; liver; phosphoprotein
F:1-19/Domain: signal sequence #status predicted <SIG>
F:20-863/Product: fibrinogen alpha chain, extended splice form #status predicted <MAT>
F:20-35/Product: fibrinopeptide A #status experimental <APT>
F:36-863/Product: fibrin alpha chain, extended splice form #status predicted <FCA>
F:57-185/Domain: fibrinogen disulfide ring homology <FDR>
F:591-593/Region: cell attachment (R-G-D) motif
F:629-663/Domain: fibrinogen beta/gamma homology <FBG>
F:22-460/Binding site: phosphate (Ser) (covalent) #status experimental
F:33-36/Cleavage site: Arg-Gly (thrombin) #status experimental
F:47/Disulfide bonds: interchain (to alpha-47) #status experimental
F:55/Disulfide bonds: interchain (to beta-95) #status experimental
F:64/Disulfide bonds: interchain (to gamma-49) #status experimental
F:66/Disulfide bonds: interchain (to beta-106) #status experimental
F:180/Disulfide bonds: interchain (to gamma-165) #status experimental
F:184/Disulfide bonds: interchain (to beta-223) #status experimental
F:288-419/Binding site: carbohydrate (Asn) (covalent) #status absent
F:322/cross-link: isopeptide (Lys) (interchain to Gln-41 of alpha-2-plasmin inhibitor) #
F:347-385/cross-link: isopeptide (Gln) (interchain to Lys N6-amino of alpha) #status exp
F:461-491/Disulfide bonds: #status experimental
F:527-558,575,581,599/Cross-link: isopeptide (Lys) (interchain to Gln of alpha) #status
F:686,831/Binding site: carbohydrate (Asn) (covalent) #status predicted

Query Match 19.4%; Score 520.5; DB 2; Length 866;
Best Local Similarity 43.3%; Pred. No. 4.9e-26;
Matches 104; Conservative 40; Mismatches 69; Indels 27; Gaps 7;
272 SCFWRC---LQALDEGHTSSIVLVKPNTRLMQWCDQRHDPGWTIQRLDGSVN 328
Db SRVRCDDVLQTHPSG-TQSGIFNFKLGSSKIFSVYDQETSLGMLIQRRDGLN 684
QY 329 FFRNMTYQGGNT---DGEVJGLENIYMLTNQNYKLLVYMEDSGRRVFAEYASF 384
Db 685 FRRWQDYKRGKSLNDEBEGFWLGNLYLHLTORGSV-LRVELDAGNAEYAEV-HF 742
QY 385 RLEPESEYKLRIGRHYNAGDS-----FPMHNGKQFTLLDPDHVYTCNGAHY 433
Db 743 RVGSEBAGALQVSSYEGTAGDALLRGSVEGAEYTSNNMWFSTFDADQWENCAEV 802
QY 434 QKGGWYNACAHSNLNGWYRGHYR---YQDGYVAEFGGYSYLKRYVMYMRP 487
Db 803 YGGGWYNNCOANLNGIYYPGGSYDPRNNSPYE-ENGWVWSPFGADYSLRAVMKIRP 862

RESULT 5

A25052
Fibrinogen beta chain - sea lamprey (fragments)
N:Contains: fibrinopeptide B
C:Species: Petromyzon marinus (sea lamprey)
C/Date: 25-Oct-1987 #sequence revision 19-Feb-1999 #text_change 13-Aug-1999
C/Accession: A25052; A03124; B03124
R:Biochem: V.L.; Doollittle, R.F.; Pontes, M.; Strong, D.D.
Biochemistry 25, 6512-6516, 1986
A>Title: Complementary DNA sequence of lamprey fibrinogen beta chain.
A/Reference number: A25052; MUID:87076582; PMID:3790537
A/Accession: A25052
A:Molecule type: mRNA
A/Residues: 39-479 <BOH>
A/Cross-references: GB:M4773; NID:9213191; PID:AAA49261.1; PID:9213192
R:Coltrrell, B.A.; Doollittle, R.F.
Biochem. Biophys. Acta 453, 426-438, 1976
A>Title: Amino acid sequences of lamprey fibrinopeptides A and B and characterization of
A/Reference number: A03120; MUID:77065679; PMID:399898
A/Accession: A03124
A:Molecule type: protein
A/Residues: 1-36 <COT1>
A/Accession: B03124
A:Molecule type: protein
A/Residues: 37-42 <COT2>
C:Superfamily: fibrinogen beta chain; fibrinogen beta/gamma homology; fibrinogen disulfide

C/Keywords: blood coagulation; glycoprotein; sulforprotein
F:1-36/Product: fibrinopeptide B #status experimental <FBP>
F:37-479/Product: fibrin beta chain #status experimental <MAT>
F:90-219/Domain: fibrinogen disulfide ring homology <FDR>
F:229-477/Domain: fibrinogen beta/gamma homology <FBG>
F:113/Binding site: sulfate (Tyr) (covalent) #status experimental
F:127/Binding site: carbohydrate (Asn) (covalent) #status experimental

Query Match 19.1%; Score 512.5; DB 2; Length 479;
Best Local Similarity 29.2%; Pred. No. 7.2e-26;
Matches 136; Conservative 64; Mismatches 136; Indels 128; Gaps 15;

QY 67 GATCNKRE-PEVLNR-----VHKELELNELLKQKQLETTQOLVKGIV 117
Db 94 GVLPTGCELRNEELKQRPVRYKISMLKQNTLYFINSFDRMSDNTLKO----- 144
QY 118 SEVLTKESNNRSTVQLYQMLHEITRRQNALESQENRILNQTMQLASKYK 177
Db 145 -NVQTLR---RLNRSRS-----THVNAOK-----EENR-----YK 172
QY 178 DLEHKYH-LATLAHQSEITIAOLEHQRPAPRPVOPPPAPRPVYOPPTYNRIHQ 236
Db 173 EVKIRISTVAGSIRSKSVLEHLRAQMEAKIKQKELCSAPCTV----- 220
QY 237 ISTNEISDQNLKVLPPPLPTMPTLTSPTSTKPSGPRWDCQALDEGHTSIYLVK 296
Db 221 -----NCRV-----PVSQM-----HCDIYRNGRTSEAYYIDP 250
QY 297 ENTNRMQWCDQRHDPGWTIQRLDGSVNFPRNMTYQGG-----NIDG 345
Db 251 DLSEBPYKFCDESHGGGWTVQNVYDGSNFAFMNTYKAFGNLARGNGKICNIG 310
QY 346 EYMLGLENIYMLTNQNYKLLVYMEDSGRRVFAEYASFLEPESEYKLRIGRHYNAG 405
Db 311 EYMLGTVQALTKQHTQVLPFMSDMEGSSVYAQVAFRPEADAGYRLWEDVAGNAG 370
QY 406 D-----SFTMNGKQFTLLDPDHVY-----TGCAHYQKGGWYNACAS 446
Db 371 NALLEGATQMGNRMTITNGQFSTFDRDNNMFGPPTGCSSEPDAGWYNRCHAA 430
QY 447 NLNGWYRGHYR---YQDGYVAEFGGYSYLKRYVMYMRP 487
Db 431 NPGRYVMGIIYTKQADYDGDGVVWNNWKGSMYEQAMKLRP 476

RESULT 6

A38463
Fibrinogen beta chain - chicken (fragment)
C/Species: Gallus gallus (chicken)
C/Date: 31-Jul-1991 #sequence revision 31-Jul-1991 #text_change 13-Aug-1999
C/Accession: A38463
R:Meisbach, L.; Oddoux, C.; Procyk, R.; Gieninger, G.
Biochemistry 30, 3290-3294, 1991
A>Title: The beta chain of chicken fibrinogen contains an atypical thrombin cleavage site
A/Reference number: A38463; MUID:91182745; PMID:2009266
A/Accession: A38463
A:Molecule type: preliminary
A:Molecule type: mRNA
A/Residues: 1-463 <MBI>
A/Cross-references: GB:M5614; NID:9211779; PID:AAA48770.1; PID:9211780
C:Superfamily: fibrinogen beta chain; fibrinogen beta/gamma homology; fibrinogen disulfide
F:73-202/Domain: fibrinogen disulfide ring homology <FDR>
F:212-460/Domain: fibrinogen beta/gamma homology <FBG>

Query Match 18.7%; Score 503; DB 2; Length 463;
Best Local Similarity 29.6%; Pred. No. 2.9e-25;
Matches 128; Conservative 63; Mismatches 146; Indels 96; Gaps 11;
QY 92 LNNELIKQKQLETTQOLVKGIVSEYKLRKESRNNSRYTQLYQMLHEITRKDN 151
Db 86 LQTTLLKQKQKTVAPVLRDLK-----DRVAKFSSTITWYQYVNMIDNKLVTQKQKDN 139
QY 152 ALELSQENRILNQTMQLASKYKDEHKYH-LATLAHQSEITIAOLEHQRPAPR 211

A/Contents: annotation, hementin cleavage site
 A/Note: hementin, a protease from Haemolysa ghiliani, the giant South American leech,
 C/Comment: The conversion of fibrinogen to fibrin is triggered by thrombin, which cleave
 ization sites responsible for the formation of the soft clot.
 C/Comment: The soft clot is converted into the hard clot by factor XIIIa (fibrin-stabiliz-
 ing) and between alpha chains (weaker) of different monomers.
 C/Comment: All fibrinogen chains are synthesized in the liver.
 C/Comment: The two forms of gamma chain, A and B (see PIR:FGHUB), arise by alternate sp-
 licing, which makes this chain different from the gamma-B chain at positions 434-437 and
 C/Genetics:
 A/Gene: GDB:FCG
 A/Cross-references: GDB:119132; OMIM:134850
 A/Map position: 4q28-4q28
 A/Intons: 26/3; 41/3; 103/1; 134/2; 178/1; 222/3; 284/2; 377/1; 433/3
 C/Complex: The fibrinogen molecule is a hexamer containing two sets of alpha (see PIR:FG
 ins are contained in the core. Two three-chain coiled coils emerge from this core and co-
 from the distal domain nodes.
 C/Function:
 A/Description: fibrinogen cleaved by thrombin yields monomers that are polymerized into
 C/Superfamily: fibrinogen gamma chain; fibrinogen beta/gamma homology
 C/Keywords: alternative splicing; blood coagulation; calcium; coiled coil; glycoprotein;
 F/1-26/Domain: signal sequence #status predicted <SIG>
 F/27-437/Product: fibrinogen gamma-A chain #status experimental <MPT>
 F/176-415/Domain: fibrinogen beta/gamma homology <FBG>
 F/341-355/Domain: calcium binding #status predicted <CB>
 F/400-422/Region: polymerization site, binding to the amino end of the alpha chain of an
 F/423-437/Region: platelet aggregation #status predicted
 F/54/Disulfide bonds: interchain (to gamma-35) #status experimental
 F/55/Disulfide bonds: interchain (to gamma-34) #status experimental
 F/49/Disulfide bonds: interchain (to beta-110) #status experimental
 F/48/Disulfide bonds: interchain (to alpha-64) #status experimental
 F/78/Binding site: carbohydrate (Asn) (covalent) #status experimental
 F/161/Disulfide bonds: interchain (to beta-227) #status experimental
 F/165/Disulfide bonds: interchain (to alpha-180) #status experimental
 F/179-208/355-365/Disulfide bonds: #status experimental
 F/424/Cross-link: isopeptide (Gln) (interchain to Lys-432 N6-amino) #status experimental
 F/432/Cross-link: isopeptide (Lys) (interchain to Gln-424) #status experimental

Query Match 18.7%; Score 50.1; DB 1; Length 437;
 Best local similarity 29.4%; Pred. No. 3.6e-25;
 Matches 128; Conservative 57; Mismatches 140; Indels 110; Gaps 11;

QY 90 ELINNELKOKRQIETLQOLVAVGDIYSEVFLRK-----ESRNNSRVTQY 138
 DB 53 DELSTVQTKVDDLOSLEDILHVENKTSSEVKQLIKAIQLTVPDESSKPMIDATLKS 112
 QY 139 MQLHEIIRKRDNAELSELQENRIINQADMLQLASKYKDLKHKKYCHLTLAHQSEIIA 198
 DB 113 RKLLEETMK-----YKASILTHDSIRYLOETINSNNQKTVN-----KXKVA 155
 QY 199 QLEHQRVPSARVPQPPAPRVYQPPYNNRIINOISTEIQSDNKLKVPPLPTM 258
 DB 156 QLEAQOE-----PCK 166
 QY 255 PLTSLPSSTDKPSGPMRDCLQALDEGHTSSIVYKENTRLMOWCDOHDPGCTV 318
 DB 167 DTV-GIHDITGK-----DCODIANKAKQSGLYIKPKANQOEFLVYCEIDGSGNGTIV 219
 QY 319 IORRLDGSVNFERNMETYKQGFNID-----GEWYGLENIYWLTFQO--NYKLVTWEDW 372
 DB 220 FQKRLDGSVDFKMMIYKEGFGHLSPTGTFEPMIENKIHISTQSAIPALVELEDW 279
 QY 373 SRKVFAYASFRLEPESSEYTLRLGRY-HGNAGDS-----FTWNGKQFT 417
 DB 280 NORTSTADYAMKVPBEADKRLTLAYFAGGACAFGPFQGDPSDKFTSHNGMFS 339
 QY 418 TLDRQHDVYTGCAHYQKGMVYNACASNLNNGVWYRGHRY-----SRYDDGYVMAEFR 472
 DB 340 TMDNDNDKFEKGCACQDQSGMMWAKCHAGHNGVYQGYTSKASTPNCYINGIIMATWK 399
 QY 473 GGSYSLEKVVMMIRP 487

DB 400 TRWYSKTKTWKTIIP 414

RESULT 8
 FGHUB
 fibrinogen gamma-B chain precursor [validated] - human
 N/Alternate names: coagulation factor I; fibrinogen gamma-55 chain
 C/Species: Homo sapiens (man)
 C/Date: 17-Mar-1997 #sequence revision 17-Mar-1997 #text change 08-Dec-2000
 C/Accession: A90494; A92448; A50453; A28203; B28203; I37390; A03126
 R/Rixon, M.W.; Chung, D.W.; Davie, E.W.
 Biochemistry 24, 2077-2086, 1985
 A/Title: Nucleotide sequence of the gene for the gamma chain of human fibrinogen.
 A/Reference numbers: A90494; MUID:85252774; PMID:290550
 A/Accession: A90494
 A/Molecule type: DNA
 A/Residues: 1-113; 'I', 115-453 <RIX>
 A/Cross-references: GB:M10014; GB:J00134; GB:J00135; GB:X00086; NID:9182438; PIDN:AAB595
 J/Fornace Jr., A.J.; Cummings, D.B.; Comeau, C.M.; Kant, J.A.; Crabtree, G.R.
 J. Biol. Chem. 259, 12826-12830, 1984
 A/Title: Structure of the human gamma-fibrinogen gene. Alternate mRNA splicing near the
 A/Reference number: A92448; MUID:85030379; PMID:6092346
 A/Accession: A92448
 A/Molecule type: DNA
 A/Residues: 286-453 <FOR>
 R/Mosesson, M.W.
 Biochemistry 20, 6146-6149, 1981
 A/Title: Carboxy-terminal amino acid sequence of a human fibrinogen gamma-chain variant
 A/Reference number: A90453; MUID:82068993; PMID:7306501
 A/Accession: A90453
 A/Molecule type: Protein
 A/Residues: 411-434; 'Y', 436-440; 'Z', 442; 'Z', 444; 'B', 446-447; 'R', 449; 'ZBB', 453 <WOL>
 R/Francis, C.W.; Mueller, E.; Henschel, A.; Simpson, P.J.; Marder, V.J.
 Proc. Natl. Acad. Sci. U.S.A. 85, 3358-3362, 1988
 A/Title: Carboxyl-terminal amino acid sequences of two variant forms of the gamma-chain
 A/Reference number: A9194; MUID:8821900; PMID:3368448
 A/Accession: A28203
 A/Molecule type: Protein
 A/Residues: 433-449 <FRA>
 A/Accession: B28203
 A/Molecule type: protein
 A/Residues: 433-453 <FR2>
 R/Marchetti, U.; Zanelli, T.; Malcovati, M.; Tenchini, M.L.
 DNA Seq. 1, 419-422, 1991
 A/Title: Polymorphism of the human gamma chain fibrinogen gene.
 A/Reference number: I37390; MUID:92119334; PMID:1685103
 A/Accession: I37390
 A/Status: translated from GB/EMBL/DBJ
 A/Molecule type: mRNA
 A/Residues: 75-286 <RES>
 A/Cross-references: EMBL:X51473; NID:G31410; PIDN:CAA35837.1; PID:G930064
 C/Comment: The two forms of gamma chain, A (see PIR:FGHUB) and B, arise by alternate sp-
 licing, which makes this chain different from the gamma-B chain at positions 434-437 and
 C/Comment: The gamma-B chain is present in about 10% of the fibrinogen molecules in plas-
 C/Genetics:
 A/Gene: GDB:FCG
 A/Cross-references: GDB:119132; OMIM:134850
 A/Map position: 4q28-4q28
 A/Intons: 26/3; 41/3; 103/1; 134/2; 178/1; 222/3; 284/2; 377/1
 C/Complex: The fibrinogen molecule is a hexamer containing two sets of alpha (see PIR:FG
 ins are contained in the core. Two three-chain coiled coils emerge from this core and co-
 from the distal domain nodes.
 C/Function:
 A/Description: fibrinogen cleaved by thrombin yields monomers that are polymerized into
 A/Pathway: blood coagulation
 C/Superfamily: fibrinogen gamma chain; fibrinogen beta/gamma homology
 C/Keywords: alternative splicing; blood coagulation; calcium; coiled coil; glycoprotein;
 F/1-26/Domain: signal sequence #status predicted <SIG>
 F/27-437/Product: fibrinogen gamma-A chain #status experimental <MPT>
 F/176-415/Domain: fibrinogen beta/gamma homology <FBG>
 F/341-355/Domain: calcium binding #status predicted <CB>
 F/400-422/Region: polymerization site, binding to the amino end of the alpha chain of an
 F/423-437/Region: platelet aggregation #status predicted

F;35/Disulfide bonds: interchain (to gamma-34) #status predicted
 F;45/Disulfide bonds: interchain (to beta-110) #status predicted
 F;49/Disulfide bonds: interchain (to alpha-64) #status predicted
 F;78/Binding site: carbohydrate (Asn) (covalent) #status predicted
 F;161/Disulfide bonds: interchain (to beta-227) #status predicted
 F;166/Disulfide bonds: interchain (to alpha-180) #status predicted
 F;179-208,352-365/Disulfide bonds: #status predicted
 F;424/Cross-link: isopeptide (Gln) (interchain to Lys-432 N6-amino) #status predicted
 F;432/Cross-link: isopeptide (Lys) (interchain to Gln-424) #status predicted

Query Match 18.7% Score 501; DB 1; Length 453;
 Best Local Similarity 29.4% Pred. No. 2; Length 328;
 Matches 128; Conservative 57; Mismatches 140; Indels 110; Gaps 11;

QY 90 ELNNELIKQRKQIETLQQLVKGIVGKIVSEYKLRK-----ESRMNSRYQLY 138
 DB 53 DFLSTYQTKVKDKDQLQSLDILHQYENKTSYKQLIKAIQLTYPNDESSKPMNIDATLKS 112
 QY 139 MQLHEIRKRDNALELSQLENRLNQADMLQASKYKDLHKYQHLATLANSQSEILA 198
 DB 113 RKMEEIMK-----YEASILTHSSIRYLOEITNSNNQKIVNL-----KEKVA 155
 QY 199 QLEHCQVPASRPVPPPPAPPRVYQPTNYRINQISTNEIQSDQNLKVLPPPLPTM 258
 DB 156 QLEAQCOE-----PCK 166
 QY 259 PVLTLSPSTDPKSPGWMDCLQLEDGHTSSIVLKPENTNRLMQWCDORHDPGWTY 318
 DB 167 DTV-IIDHITGK-----DCQDIANKGAKQSGLYTKPKANQGLVCEIDSGSNGWTY 219
 QY 319 IQRLDGSVNFPRNMTYKQSGFNID---GEYWLGLENIYWLINQG---NYKLVTWMDW 372
 DB 220 FQKRLDGSVDFKKNMIOYKEGFGHLSPTGTEFWMGNKIHLSQSAIPYALVELBDW 279
 QY 373 SGRKVPFAEYASFLPESEYKLRGLGRY-HGNAGS-----FTWNGKQFT 417
 DB 280 NKRSTIADYAMFKVGEADKRYRLTYAVFAGDAGAGAFDFGDDPSDKFFTSNKGWPS 339
 QY 418 TLDRHDVYTGNCAYKQKGMWYNACAHNLNGWYRGSHYR-----SRYPQGVYMAEFR 472
 DB 340 TWDNDKREKNGCAEDDGSQWMMNKGHAGLNGVYQSGTYKASTPNQYDGIIMATMX 399
 QY 473 GGSYSLKRYVMIRP 487
 DB 400 TWYSWKTKTKIP 414

RESULT 9

A05299
 fibrinogen beta chain precursor - rat (fragments)
 N:Contains: fibrinopeptide B
 C:Species: Rattus norvegicus (Norway rat)
 C>Date: 05-Jun-1987 #sequence_revision 10-Mar-1994 #text_change 13-Aug-1999
 C/Accession: A05299; PEO010
 R:Protein: D.M.; Mullis, N.T.; Comeau, C.M.; Cabriere, G.R.
 Proc. Natl. Acad. Sci. U.S.A. 81, 2313-2316, 1984
 A>Title: Potential basis for regulation of the coordinately expressed fibrinogen genes:
 A/Reference number: A93989; PMID:84194000; PMID:6232608
 A/Accession: A05299
 A/Molecule type: DNA
 A/Residues: 1-32 <FOM>
 R:Residues: E.M.; Gilula, N.B.
 Gene 79, 151-158, 1989
 A>Title: Cloning and characterization of a cDNA for the B beta chain of rat fibrinogen:
 A/Reference number: PEO010; PMID:89378771; PMID:2673932
 A/Accession: PEO010
 A/Molecule type: mRNA
 A/Residues: 35-328 <EAS>
 A/Cross-references: GB:M27220; NID:g529585; PIDN:AAA41160.1; PID:g529586
 C/Superfamily: fibrinogen beta chain; fibrinogen beta/gamma homology; fibrinogen disulfide
 C/Keywords: blood coagulation; glycoprotein; liver; plasma
 F;33-65/Domain: fibrinogen disulfide ring homology (fragment) <FDR>
 F;75-324/Domain: fibrinogen beta/gamma homology <FBG>

F;231/Binding site: carbohydrate (Asn) (covalent) #status predicted

Query Match 18.6% Score 500; DB 2; Length 328;

Best Local Similarity 31.2% Pred. No. 2, 8e-25;

Matches 118; Conservative 54; Mismatches 100; Indels 106; Gaps 9;

QY 153 LELSQLENRLNQADMLQ-----LASKYKDLHKYQHLATLANSQSEILAQLHEHCQ 205
 DB 9 LSVSLVQTAATDSKVDILSARVLRSLIEDLRSKQKL-----ESDISHQ-TEYC- 60
 QY 206 RVDSARPVPVPPAPPRVYQPTNYRINQISTNEIQSDQNLKVLPPPLPTMTLSLP 265
 DB 61 -----HTPCTVNCNIPVSGKE----- 77
 QY 266 SSTDKSPWRDCLQLEDGHTSSIVLKPENTNRLMQWCDORHDPGWTYIQRLDQ 325
 DB 78 -----CEIIRKGFISEMYLLOPTDSSKPRVYQDMKTENGQWTVIQRRQD 125
 QY 326 SYNFFRMETKYQSGFNI-----DGYYWLGLENIYWLINQGYKLVMTWEDMS 373
 DB 126 SYDFGRKMDYKKGFGNIAINEDTKYCGLPGEYWLGNKISQLTRIGPTLLEIMEDWK 185
 QY 374 GRKVPFAEYASFLPESEYKLRGLGRYHGNAGD-----SFTWNGKQFTLL 419
 DB 186 GDRKPAHYGFTVQTEANKYQVSNKYKGTAGNALMEGASQLVGENRTMTIHNGMFFSY 245
 QY 420 DRHDVYT-----GNCAHYKQGMWYNACAHNLNGWYRGSHY-----RSRYQGVYMA 469
 DB 246 DRDNDGVTTDPRKQCKEDGGGWYRCHAAPNGRYGGYGLYSMDMSHGDTDDGVYMW 305
 QY 470 EFRGGSYSLKRYVMIRP 487
 DB 306 NWKGSWYSMRMSKIRP 323

RESULT 10

A35084
 fibrinogen-related protein A precursor - sea cucumber (Parastichopus parvimensis)
 C/Species: Parastichopus parvimensis
 C>Date: 03-Aug-1990 #sequence_revision 03-Aug-1990 #text_change 09-Sep-1997
 C/Accession: A35084
 R:Xu, X.; Doellittle, R.F.
 Proc. Natl. Acad. Sci. U.S.A. 87, 2097-2101, 1990
 A>Title: Presence of a vertebrate fibrinogen-like sequence in an echinoderm.
 A/Reference number: A35084; PMID:90192754; PMID:2315305
 A/Accession: A35084
 A/Status: preliminary
 A/Molecule type: mRNA
 A/Residues: 1-282 <XUX>
 A/Cross-references: GB:M31326; NID:g161164; PID:g161165
 C/Superfamily: fibrinogen beta/gamma homology
 F;67-280/Domain: fibrinogen beta/gamma homology <FBG>

Query Match 18.4% Score 495; DB 2; Length 282;

Best Local Similarity 34.6% Pred. No. 4, 8e-25;

Matches 104; Conservative 45; Mismatches 96; Indels 56; Gaps 6;

QY 152 NQSEIADLEHCQVPASRPVPPPPAPPRVYQPTNYRINQISTNEIQSDQNLKVL 251
 DB 28 NESITFEREERSLADPPGRQKROSGLSCKPISHSPY----- 67
 QY 252 PPPLPTMTLSLPSSTDPKSPGWMDCLQLEDGHTSSIVLKPENTNRLMQWCD 308
 DB 68 -----RDYDILQSCSGGPPSGQYIIPDGDN-LIKYVCD 102
 QY 309 QHHDGQWTVQRLDGSVNFPRNMTYKQSGFNIDGYYWLGLENIYWLINQGYKLV 368
 DB 103 METDEGQWTVQRLDGINFRRSWSYQGTGGINLTFWLGNDIATLISQGYELAVE 162
 QY 369 MEDWGRKVPFAEYASFLPESEYKLRGLGRYHGNAGDSFTWNGKQFTLLDRHDVYTG 428
 DB 163 LNTIGNHYAKYNFRIGDSSESLVLVLGAVSGTAGDSLAVHNTMRSTYDNDNDVYSI 222

QY 429 NCA--HYOKGWMYNAACHSNLNGVWYRGHYRSHYODGVWAEFRGSGYSILKVVMMI 485
 Db 223 NCASHSSYSGAMWYNSCLSLNNGQY---DYSG--APSIWYSYLPQNDQIPFAEMKL 277
 QY 486 R 486
 Db 278 R 278

RESULT 11

A32670
 A:Accession: A32670
 A:Status: preliminary
 A:Molecule type: mRNA
 A:Residues: 1-438 <PAS>
 A:Cross-references: GB:J02894; NID:G21413; PIDN:AAA49709.1; PID:G21410
 R:Bhatnagar, A.; Shepard, A.R.; Moser, D.R.; Holland, L.J.
 Mol. Cell. Endocrinol. 72, 213-220, 1990
 A:Title: Isolation and characterization of cDNA clones for the gamma subunit of Xenopus
 A:Reference number: 151416; MUID:91146806; PMID:2289632
 A:Accession: 151416
 A:Status: preliminary; translated from GB/EMBL/DBJ
 A:Molecule type: mRNA
 A:Residues: 1-58 <BHA>
 A:Cross-references: GB:M35548; NID:G21414; PIDN:AAA03247.1; PID:G214142
 C:Superfamily: fibronogen gamma chain; fibronogen beta/gamma homology
 C:Keywords: blood coagulation
 F:173-413/Domain: fibronogen beta/gamma homology <FBG>

Query Match 18.2%; Score 489.5; DB 2; Length 438;
 Best Local Similarity 31.4%; Pred. No. 2e-24;
 Matches 125; Conservative 54; Mismatches 154; Indels 65; Gaps 13;

QY 145 IIRKDNALLESQENRILNQTADMLQASRYK---DLEHKYQHLATLAHQSEI1A9 199
 Db 25 IIPNTNCCILDRGEYCEPTTCGISDFLNRYQENVDTLQY-LENLLTQISNSTSGTTI 83
 QY 200 LEEHQGVPSA-RPVQPPAPAPRVYQPT-----YKRIINQISTNIGSDN 247
 Db 84 IVEHL--IDSGKKPATSPOTAIIDPVTQKSKTCMKLTDKNVYQYEENILYLQEVYSSNQ 141
 QY 248 LKV-----LPPPLPTMPTLTSPPSSTDKXSGPWRDCLQALDGHDTSS1YLVP 296
 Db 142 NKIFLTKOKIANLELQCCQPCRDIV-QIQEFTGK-----DQGVANKGAMLSGLYIKP 194
 QY 297 ENTNRLNMQWDDQRRDPGWTVIQRLDGSVNFRRNMTYQSGF---NIDGYWGLLE 352
 Db 195 LKAKQQLVYCEIEBSSGAMVTIORLDGSVNFHKNWQYEEGGLYSPDKTEFFWVGN 254
 QY 353 NIWYLTNNGN--YKLLVTMEDSGRKVFAEYASFLPESESEYKLRGRY-HGNAGDSF- 408
 Db 255 KIHLLSTQSTIPYWRILEDMNSGKSTADYSTRLSGEKNNYFTAYAFIGDAGAFD 314
 QY 409 -----TWANGKOTTLDRDHVYTGCAHYQKGGWYNAACHSNLNGVWYRG 455
 Db 315 GFDGDDPSDKFYTSNMGQSTFCDKNDKEDGCAODSGGMMNRCFAAHNLGKYYQG 374
 QY 456 GHYR-----SRYODGVWAEFRGSGYSILKVVMMIRP 487
 Db 375 GTYSEADSGPSGYNGLIATWRKRWYSKSVTKMIP 412

RESULT 12
 A45445
 Janusin precursor, long form - rat

N:Alternate names: neural recognition glycoprotein J1-160/180, long form
 N:Contents: neural recognition glycoprotein J1-160/180, short form
 C:Species: Rattus norvegicus (Norway rat)
 C:Date: 03-May-1994 #sequence_revision 03-May-1994 #text_change 20-Aug-1999
 C:Accession: A45445; B45445; S32023
 R:Fuss, B.; Wintergerst, E.S.; Bartsch, U.; Schachner, M.
 J. Cell Biol. 120, 1237-1249, 1993
 A:Title: Molecular characterization and in situ mRNA localization of the neural recognit
 A:Reference number: A45445; MUID:9311267; PMID:769676

A:Accession: A45445
 A:Status: preliminary
 A:Molecule type: mRNA
 A:Residues: 1-1356 <FUS>
 A:Cross-references: GB:218630; NID:G57961; PIDN:CAA79229.1; PID:G57962
 A:Accession: B45445
 A:Status: preliminary
 A:Molecule type: mRNA
 A:Residues: 1-772,863-1356 <FUD>
 A:Cross-references: GB:218630
 R:Fuss, B.; Wintergerst, E.; Bartsch, U.; Schachner, M.
 submitted to the EMBL Data Library, November 1992
 A:Description: Molecular characterization and in situ mRNA localization of the neural re

A:Reference number: S32023
 A:Accession: S32023
 A:Status: preliminary
 A:Molecule type: mRNA
 A:Residues: 1-1356 <FUS2>
 A:Cross-references: EMBL:218630; NID:G57961; PIDN:CAA79229.1; PID:G57962
 C:Superfamily: restrictin; EGF homology; fibronogen beta/gamma homology; fibronectin typ
 C:Keywords: alternative splicing; duplication; extracellular matrix; glycoprotein; oligo
 F:1-1356/Product: janusin, long form #status experimental <XAT>
 F:1-772,863-1356/Product: janusin, short form #status experimental <ALT>
 F:204-230/Domain: EGF homology <EG1>
 F:235-261/Domain: EGF homology <EG2>
 F:266-292/Domain: EGF homology <EG3>
 F:297-323/Domain: EGF homology <EG4>
 F:325-405/Domain: fibronectin type III repeat homology <FN1>
 F:413-494/Domain: fibronectin type III repeat homology <FN2>
 F:502-584/Domain: fibronectin type III repeat homology <FN3>
 F:582-576/Domain: fibronectin type III repeat homology <FN4>
 F:684-764/Domain: fibronectin type III repeat homology <FN5>
 F:772-854/Domain: fibronectin type III repeat homology <FN6>
 F:1038-1118/Domain: fibronectin type III repeat homology <FN7>
 F:1133-1341/Domain: fibronogen beta/gamma homology <FBG>

Query Match 18.2%; Score 488; DB 2; Length 1356;
 Best Local Similarity 36.2%; Pred. No. 1.2e-23;
 Matches 109; Conservative 41; Mismatches 103; Indels 49; Gaps 7;

QY 215 OPPAPAPRVYQPTNRIINQISTNEIGSDNKLVLPPPLPTMPTLNSPSTDKP--- 271
 Db 1060 QPPRAA-----IENVLYTKSITDGRKELIVDAEDTWRLEGLSENIDYTVLL 1107
 QY 272 -----SGPWRDCLQALDGHDTSS1YLVP--KPENTNRLMQVW 306
 Db 1108 QAAQEAATRSLSITSTFTTGRVFSHP-DCAQHLLNNGDTLSGVYITFINGLSHKL-QVY 1165
 QY 307 CQGRHDPGWTVIQRLDGSVNFRRNMTYQSGF---NIDGYWGLLE 366
 Db 1166 CMTTDDGGWIVQFRQNGQTDPRFKMADYRGFNLDEDEFLGJDNHRTTAAQRYELR 1225
 QY 367 VTMEDSGRKVFAEYASFLPESESEYKLRGRYHGNAGDSFTWANGKOTTLDRDHVY 426
 Db 1226 VDMRD-GQEAVALYVDKFAVEDSRSLYKRLRGVYGTAGDLSHYQGRPFSTEDNDNVA 1284
 QY 427 TGNCAHYQKGGWYNAACHSNLNGVWYRGHYRSHYODGVWAEFRGSGYSILKVVMMIR 486
 Db 1285 VTNCAMSYKGAMWYNCHRTYLN-----GKYGBSRHSGIWMYHWKGFESIPVEMQCR 1339
 QY 487 P 487
 Db 1340 P 1340

QY 406 DSFTW-----HNGKQFTTLDHDDVY-TGNCAPHYKQGGWVYNACAHSNLNGWVYRGHVR 459
Db 334 DALRFSRHVYHDLRFPTTDPDNDRIYPSGNGGLYSSGWFDSCLSANLNGKY---HOK 390
QY 460 SR-YQDGVYWAFFRG-----GSY--SLKKVMMIRP 487
Db 391 YKGVNNGIFWGTWPGINQAPGGYKSSFKQAKMMIRP 427

Search completed: July 30, 2004, 12:38:01
Job time : 19 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: July 30, 2004, 12:19:33 ; Search time 13 Seconds
(without alignments)
1974.660 Million cell updates/sec

Title: US-10-018-386-2
Perfect score: 2666
Sequence: 1 MRPLCTGWLGLIANGAV.....GSYSLKRYVMIRNPPTPH 493

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 141681 seqs, 52070155 residues

Total number of hits satisfying chosen parameters: 141681

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : SwissProt_42.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	2682	99.9	493	1 ANL2_HUMAN	Q9ak99 homo sapien
2	2550	94.9	493	1 ANL2_MOUSE	Q91045 mus musculu
3	577	21.5	497	1 AGP1_RAT	O35460 rattus norv
4	575.5	21.4	498	1 AGP1_MOUSE	O08538 mus musculu
5	574	21.4	496	1 AGP2_HUMAN	O15123 homo sapien
6	572.5	21.3	498	1 AGP1_HUMAN	O15389 homo sapien
7	558	20.8	509	1 AGP4_MOUSE	Q9y764 homo sapien
8	541	20.1	503	1 AGP4_HUMAN	O08630 homo sapien
9	537	20.0	312	1 FGL1_HUMAN	Q9b4y7 sus scrofa
10	537	20.0	496	1 AGP2_PIG	O18920 bos taurus
11	536.5	20.0	481	1 AGP1_BOVIN	O35608 mus musculu
12	535.5	19.9	496	1 AGP2_MOUSE	P02675 bos taurus
13	527.5	19.6	468	1 FIBB_BOVIN	P02675 bos taurus
14	526.5	19.6	491	1 FIBB_HUMAN	P14448 gallus gall
15	524	19.5	741	1 FIBB_CHICK	P14480 rattus norv
16	522.5	19.5	479	1 FIBB_RAT	P02671 homo sapien
17	520.5	19.4	866	1 FIBB_HUMAN	P02671 homo sapien
18	512.5	18.9	477	1 FIBB_PETMA	P02673 petromyzon
19	506.5	18.9	299	1 FCN3_HUMAN	O75636 homo sapien
20	505	18.8	782	1 FIBB_RAT	P06399 rattus norv
21	504.5	18.8	375	1 AGP2_BOVIN	O70497 mus musculu
22	503.5	18.7	306	1 FCN2_MOUSE	O15485 homo sapien
23	503.5	18.7	313	1 FCN2_HUMAN	Q02020 gallus gall
24	503	18.7	463	1 FIBB_CHICK	Q02020 gallus gall
25	501	18.7	453	1 FIBB_HUMAN	P19477 parastichop
26	495	18.4	282	1 FIBB_PARPA	P19477 parastichop
27	489.5	18.2	438	1 FIBB_HUMAN	P19477 parastichop
28	488.5	18.2	326	1 FCN1_HUMAN	P55083 homo sapien
29	486.5	18.1	255	1 MPA4_HUMAN	P12804 mus musculu
30	483.5	18.0	432	1 FGL2_MOUSE	O70165 mus musculu
31	482.5	18.0	334	1 FCN1_MOUSE	O14314 homo sapien
32	480.5	17.9	439	1 FGL2_HUMAN	P57756 rattus norv
33	479.5	17.9	319	1 FCN2_RAT	

34	476.5	17.7	444	1 FIBB_BOVIN	P12799 bos taurus
35	473	17.6	335	1 FCN1_RAT	Q9wrs8 rattus norv
36	471	17.5	445	1 FIBB_RAT	P02680 rattus norv
37	465.5	17.3	641	1 FIBB_PETMA	P33573 petromyzon
38	463.5	17.3	432	1 FIBB_CHICK	P04115 petromyzon
39	450.5	16.8	1808	1 TENX_CHICK	P10039 gallus gall
40	450	16.8	4289	1 TENX_HUMAN	P22105 homo sapien
41	434.5	16.2	1746	1 TENX_PIG	Q29116 sus scrofa
42	430.5	16.0	1294	1 TENX_HUMAN	Q9upd3 homo sapien
43	424.5	15.8	1560	1 TENX_MOUSE	O80271 mus musculu
44	423	15.7	406	1 ANL4_HUMAN	Q9b4y7 homo sapien
45	421.5	15.7	2201	1 TENX_HUMAN	P24821 homo sapien

ALIGNMENTS

RESULT 1
ANL2_HUMAN STANDARD; PRT; 493 AA.
ID ANL2_HUMAN
AC Q9ak99
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DT 15-MAR-2004 (Rel. 43, Last annotation update)
DE Angiopoietin-related protein 2 precursor (Angiopoietin-like 2)
DE (UNQ170/PRO196).
DN ANGP2L2 OR ANP2.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Heart;
RX MEDLINE=99403103; PubMed=10473614;
RA Kim I., Moon S.-O., Koh K.N., Kim H., Uhm C.-S., Kwak H.J., Kim N.-G.,
RA Koh G.Y.,
RA "Molecular cloning, expression, and characterization of angiopoietin-
RA related protein. angiopoietin-related protein induces endothelial cell
RA sprouting.";
RL J. Biol. Chem. 274:26523-26528(1999).
[2]
RP SEQUENCE FROM N.A.
RX MEDLINE=22887296; PubMed=12975309;
RA Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D., Brush J.,
RA Chen J., Chow B., Chui C., Crowley C., Currell B., Dewald P.,
RA Bacon D., Foster J., Grimaldi C., Gu O., Hass P.E., Helens S.,
RA Huang A., Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J.,
RA Lewis L., Liao D., Mark M., Robbie E., Sanchez C., Schoenfeld J.,
RA Sestagiri S., Simmons L., Singh J., Smith V., Stinson J., Vagts A.,
RA Vanden R., Watanabe C., Wleand D., Woods K., Xie M.-H., Yamsura D.,
RA Yi S., Yu G., Yuan J., Zhang W., Zhang Z., Goddard A., Wood W.I.,
RA Godowski P.,
RA "The secreted protein discovery initiative (SPDI), a large-scale
RA effort to identify novel human secreted and transmembrane proteins: a
RA bioinformatics assessment.";
RL Genome Res. 13:2265-2270(2003).
[3]
RP SEQUENCE FROM N.A.
RC TISSUE=Ovary;
RX MEDLINE=22388257; PubMed=12477932;
RA Strassberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shemmen C.M., Schuler G.D.,
RA Altshul S.F., Zerbe B., Buetow K.H., Schaefer C.F., Bat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Wax S.I., Wang J., Hsieh F.,
RA Diachenko L., Marusha K., Farmer A.A., Rubin G.M., Hong L.,
RA Stappleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Schetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loguettano N.A., Peters G.J., Abramson R.D., Mullany S.J.,
RA Bosh S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hilyk S.W.,
RA Villalon D.K., Wozny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahy J., Helton E., Ketterman M., Madan A., Rodriguez S., Sanchez A.,

RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
 RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalins D.E.,
 RA Schneringer A., Schein U.E., Jones S.J.M., Maira W.A.,
 RT Generation and initial analysis of more than 15,000 full-length
 RT human and mouse cDNA sequences."
 CC Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 CC -1- FUNCTION: Induces sprouting in endothelial cells through an
 CC autocrine and paracrine action.
 CC -1- SUBCELLULAR LOCATION: Secreted.
 CC -1- TISSUE SPECIFICITY: Widely expressed in heart, small intestine,
 CC spleen and stomach. Also found in lower levels in colon, ovary,
 CC adrenal gland, skeletal muscle and in prostate.
 CC -1- PTM: N-glycosylated.
 CC -1- SIMILARITY: Contains 1 fibrinogen C-terminal domain.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL: AF125175; AAD55357.1; -;
 DR EMBL: AF36274; AAO8641.1; -;
 DR EMBL: BC013368; AAI12368.1; -;
 DR HSSP: P02671; 1FZD.
 DR GeneW: HGNC:490; ANGP2L2.
 DR MIM: 605001; -;
 DR GO: GO:0005615; Cytoplasmic space; TAS.
 DR GO: GO:0005102; F:receptor binding; TAS.
 DR GO: GO:0007275; P:development; TAS.
 DR InterPro: IPR002181; Fibrinogen_C.
 DR Pfam: PF00147; fibrinogen_C_1.
 DR SMART: SM00186; FBG; 1.
 DR PROSITE: PS00514; FIBRIN AG C DOMAIN; 1.
 DR KEGG: K04401; Fibrinogen; 1.
 KM Signal: coiled coil, Glycoprotein.
 FT SIGNAL: 1
 FT CHAIN: 23
 FT DOMAIN: 76 493
 FT DOMAIN: 152 206
 FT DOMAIN: 438 450
 FT DISULFID: 278 307
 FT DISULFID: 430 443
 FT CARBOHYD: 164 164
 FT CARBOHYD: 192 192
 SQ SEQUENCE 493 AA; 57104 MW; 0F2ADECB3D185CA CRC64;
 Query Match 99.9%; Score 2682; DB 1; Length 493;
 Best Local Similarity 99.8%; Pred. No. 1,3e-159;
 Matches 492; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 Db 1
 QY 1 MRPLCVTGMWGLLAAGVAGQEDGPFGEFGSFRFETINRYKRAESGQDKCTYFTIV 60
 DB 1 MRPLCVTGMWGLLAAGVAGQEDGPFGEFGSFRFETINRYKRAESGQDKCTYFTIV 60
 QY 61 POORVTGAIQVNSKEPEVLLENRYKQELNNELLKQKQITLQOYKVDGIVSEV 120
 DB 61 POORVTGAIQVNSKEPEVLLENRYKQELNNELLKQKQITLQOYKVDGIVSEV 120
 QY 121 KLRRKESNNNSRVYQVLMQLHEIRKRDNALELSQLENNILNQTDMLQASKYDLE 180
 DB 121 KLRRKESNNNSRVYQVLMQLHEIRKRDNALELSQLENNILNQTDMLQASKYDLE 180
 QY 181 HKYGLATLANQSEITIAQLEHQCQVPSAPVQPPAPAPRYQPTNRIINQISTN 240
 DB 181 HKYGLATLANQSEITIAQLEHQCQVPSAPVQPPAPAPRYQPTNRIINQISTN 240
 QY 241 EIQSDONIKVLPPLPTWPTLTSPSSSTDKPSGPMRQCLQALEGDHTSSIVYKPPENTN 300
 DB 241 EIQSDONIKVLPPLPTWPTLTSPSSSTDKPSGPMRQCLQALEGDHTSSIVYKPPENTN 300

QY 301 RIMQVGDQDRDPCGWTVIQRIIDGSVNFRRMNEYKQSGNIDGVEYLGLENIYMLTNO 360
 DB 301 RIMQVGDQDRDPCGWTVIQRIIDGSVNFRRMNEYKQSGNIDGVEYLGLENIYMLTNO 360
 QY 361 GNYLLATVMEQSGRKYFAEYASFRLEPSEYKRLGRYHGNACDSFTWHNKQFTLLD 420
 DB 361 GNYLLATVMEQSGRKYFAEYASFRLEPSEYKRLGRYHGNACDSFTWHNKQFTLLD 420
 QY 421 RDHVVYTGNCAYHKGSGMTYNACSHNLNGVTRGCHYRSRYDDGYWAEFRGGSYLKK 480
 DB 421 RDHVVYTGNCAYHKGSGMTYNACSHNLNGVTRGCHYRSRYDDGYWAEFRGGSYLKK 480
 QY 481 VVMMIRPNPTFF 493
 DB 481 VVMMIRPNPTFF 493
 RESULT 2
 ANL2_MOUSE STANDARD; PRT; 493 AA.
 ID ANL2_MOUSE
 AC Q9R045;
 DT 16-OCT-2001 (Rel. 40, Last sequence update)
 DT 28-FEB-2003 (Rel. 41, Last annotation update)
 DE Angiopoietin-related protein 2 precursor (Angiopoietin-like 2).
 GN ANGP2L2 OR ARP2.
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathia; Muridae; Murinae; Mus.
 OX NCBI_TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Heart;
 RX MEDLINE=99403103; PubMed=10473614;
 RA Kim I., Moon S.-O., Koh K.N., Kim H., Uhm C.-S., Kwak H.J., Kim N.-G.,
 RA Koh G.Y.;
 RT "Molecular cloning, expression, and characterization of angiopoietin-
 RT related protein, angiopoietin-related protein induces endothelial cell
 RT sprouting."
 RL J. Biol. Chem. 274:26523-26528(1999).
 CC -1- FUNCTION: Induces sprouting in endothelial cells through an
 CC autocrine and paracrine action (By similarity).
 CC -1- SUBCELLULAR LOCATION: Secreted (By similarity).
 CC -1- TISSUE SPECIFICITY: WIDELY EXPRESSED IN HEART, TONGUE, LUNG AND
 CC SKELETAL MUSCLE. ALSO FOUND IN LOWER LEVELS IN KIDNEY, EPIDIDYMUS
 CC AND TESTIS.
 CC -1- SIMILARITY: Contains 1 fibrinogen C-terminal domain.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL: AF125176; AAD55358.1; -;
 DR HSSP: P02671; 1FZD.
 DR MGD: MGI:1347002; Angp2l2.
 DR InterPro: IPR002181; Fibrinogen_C.
 DR Pfam: PF00147; fibrinogen_C_1.
 DR SMART: SM00186; FBG; 1.
 DR PROSITE: PS00514; FIBRIN AG C DOMAIN; 1.
 KM Signal: coiled coil, Glycoprotein.
 FT SIGNAL: 1
 FT CHAIN: 20 493
 FT DOMAIN: 77 115
 FT DOMAIN: 152 202
 FT DOMAIN: 438 450
 FT DISULFID: 278 307
 FT DISULFID: 430 443
 FT CARBOHYD: 164 164
 N-LINKED (GLCNAC...) (POTENTIAL).

FT CARBOHYD 192 192 N-LINKED (GLCNAC...) (POTENTIAL)
 SEQ SEQUENCE 493 AA; 57118 MW; 228855ABEF0746BF2 CRC64;
 Query Match 94.9%; Score 2550; DB 1; Length 493;
 Best Local Similarity 94.7%; Pred. No. 2.1e-151;
 Matches 467; Conservative 10; Mismatches 16; Indels 0; Gaps 0;

QY 1 MRPLCTWMLGLAMGAVAGQEDGPGTEEGSPREFTYINRYRAESQDKTYFTIV 60
 DB 1 MRPLCTWMLGLATVGAATGPEADVGTEGDSQREFTYINRYRAESQDKTYFTIV 60
 QY 61 PQRVTGALCVNSKEPEVLENRVAKOELINNELKOKQOIEFTLOOLVYKGVGIVSEV 120
 DB 61 PQRVTGALCVNSKEPEVLENRVAKOELINNELKOKQOIEFTLOOLVYKGVGIVSEV 120
 QY 121 KLRKESRNMNSRVTLQVYMLHEIRKRDNALELSQENRIINQADMLQASKYKDL 180
 DB 121 KLRKESRNMNSRVTLQVYMLHEIRKRDNALELSQENRIINQADMLQASKYKDL 180
 QY 181 HKYGLATLANQSEITIAQLEHCQVPSARVPVPPAPAPRYVQPTNRIINQSTN 240
 DB 181 HKYGLATLANQSEITIAQLEHCQVPSARVPVPPAPAPRYVQPTNRIINQSTN 240
 QY 241 EIOSQNLKVLPPPLPTMEFTLTSLPSSTDKPSGPRDCLQALEDHGHTSSILVYKPENTN 300
 DB 241 EIOSQNLKVLPPPLPTMEFTLTSLPSSTDKPSGPRDCLQALEDHGHTSSILVYKPENTN 300
 QY 301 RIMQVWCDQDRHDPGQMTVIQRRLDGSVNFERNWETKYGFGNIDEGYMLGLENITWLNQ 360
 DB 301 RIMQVWCDQDRHDPGQMTVIQRRLDGSVNFERNWETKYGFGNIDEGYMLGLENITWLNQ 360
 QY 361 GNYKLVLMEDMSGRVFAEYASFRLEPSEYKRLRGYHGNAGDSFTWNGKQFTLTD 420
 DB 361 GNYKLVLMEDMSGRVFAEYASFRLEPSEYKRLRGYHGNAGDSFTWNGKQFTLTD 420
 QY 421 RDHDVYTGCAHYQKQGMWYNAQHSNLTNGVYRGHYSRYQDGYVAEFGGSSYSIKK 480
 DB 421 RDHDVYTGCAHYQKQGMWYNAQHSNLTNGVYRGHYSRYQDGYVAEFGGSSYSIKK 480
 QY 481 VMMATIRPNTFH 493
 DB 481 VMMATIRPNTFH 493

RESULT 3
 AGPL RAT STANDARD; PRT; 497 AA.
 ID AGPL RAT STANDARD; PRT; 497 AA.
 AC 035460; Q8K4Q4;
 DT 16-OCT-2001 (Rel. 40, Created)
 DT 28-FEB-2003 (Rel. 41, Last sequence update)
 DT 28-FEB-2003 (Rel. 41, Last annotation update)
 DE Angiotensin-1 precursor (ANG-1).
 GN ANGPL.
 OS Rattus norvegicus (Rat).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathu; Muridae; Rattus.
 OX NCBI_TaxID=10116;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=Water; TISSUE=Placenta;
 RX MEDLINE=2236496; PubMed=12458684;
 RA Tizasa H., Bae S.H., Asashima T., Kitano T., Matsunaga N.,
 RA Teraaki T., Kang Y.S., Nakashima E.,
 RT "Augmented expression of the tight junction protein occludin in brain
 RT endothelial cell line TR-bBB by rat angiotensin-1 expressed in
 RT baculovirus-infected sf plus insect cells.";
 RL Pharm. Res. 19:1757-1760(2002).
 RN [2]
 RP SEQUENCE OF 91-200 FROM N.A.
 RC STRAIN=Sprague-Dawley; TISSUE=Placenta;
 RX MEDLINE=98451564; PubMed=976732;
 RA Mandiata S.J., Pepper M.S.;
 RT "Regulation of angiotensin-2 mRNA levels in bovine microvascular

RT endothelial cells by cytokines and hypoxia.";
 RL Circ. Res. 83:852-859(1998).
 CC -1- FUNCTION: BINDS AND ACTIVATES TIE2 RECEPTOR BY INDUCING ITS
 CC TYROSINE PHOSPHORYLATION. IMPLICATED IN ENDOTHELIAL DEVELOPMENTAL
 CC PROCESSES LATER AND DISTINCT FROM THAT OF VEGF. APPEARS TO PLAY A
 CC CRUCIAL ROLE IN MEDIATING RECIPROCAL INTERACTIONS BETWEEN THE
 CC ENDOTHELIUM AND SURROUNDING MATRIX AND MESENCHYME. MEDIATES BLOOD
 CC VESSEL MATURATION/STABILITY. IT MAY PLAY AN IMPORTANT ROLE IN THE
 CC HEART EARLY DEVELOPMENT.
 CC -1- SUBCELLULAR LOCATION: Contains 1 fibrinogen C-terminal domain.
 CC -1- SIMILARITY: Contains 1 fibrinogen C-terminal domain.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 CC EMBL; AB080023; BAC10290.1;
 CC InterPro; IPR002181; Fibrinogen_C.
 CC Pfam; PF00147; fibrinogen_C.1.
 CC SMART; SM00186; FBG.1.
 CC PROSITE; PS00514; FIBRIN AG C DOMAIN; 1.
 CC KEGG; Angiogenesis; Glycoprotein; Coiled coil; Signal.
 CC SIGNAL 1 19
 CC CHAIN 20 497
 CC DOMAIN 81 119
 CC DOMAIN 153 261
 CC DOMAIN 283 497
 CC DISULFID 285 314
 CC DISULFID 438 451
 CC CARBOHYD 92 92
 CC CARBOHYD 122 122
 CC CARBOHYD 154 154
 CC CARBOHYD 243 243
 CC CARBOHYD 294 294
 CC CONFLICT 98 98
 CC CONFLICT 172 172
 CC CONFLICT 189 189
 CC SEQUENCE 497 AA; 57461 MW; 08E6A8B8FDD68AF CRC64;
 Query Match 21.5%; Score 577; DB 1; Length 497;
 Best Local Similarity 29.5%; Pred. No. 8.7e-29;
 Matches 149; Conservative 84; Mismatches 170; Indels 102; Gaps 14;

QY 43 RYKRGESQDKCTYFTIV-----QQRVTGALCVNSKEPEV-----L 79
 DB 32 RYNIQHQQ-CATYFTLPEHDGNGRSATIEQVYTNALQDPAPVETDFSSQKQIHEHV 89
 QY 80 LENRVHKOELINNELK-OKRQIEFTLOQ-----LVKQGVSEVKKLRKESRN 129
 DB 90 MEN-VYQWLOKLENYIVENKSEMAQIQCAVQNTATMLIGTSLSQT---AEQTRK 144
 QY 130 MNSRYTQLYMLHEIRKRDNALELSQENRIINQADMLQASKYKDLHKY----- 183
 DB 145 LTDEVTQVNLQTSRLIEQLNLSLYLEKQLOLQNTNLIKQKSLLEHKLLENGK 204
 QY 184 -----CHLATLANQSEITIAQLEHCQVPSARVPVPPAPAPRYVQPTN 231
 DB 205 HKEELDTKEKENLQGLVTRQRTIIGLEBQQLSRA----- 240
 QY 232 RIINQISNIEQSQNLKVLPPPLPTMEFTLTSLPSSTDKPSG-----PWRDCLQALD 284
 DB 241 -----TSNNSVLQKQOEL-----MDYANIVLSLQTKVELLKGGRBEERKPRDCAVYQA 291
 QY 285 GHDTSIYLVKPENTNRLMQVWCDQDRHDPGQMTVIQRRLDGSVNFERNWETKYGFGNID 344
 DB 292 GPNNSGIITTYFNNMPEPKYFCAMDVNEGMTVIQRHEDSLDFQGWKEXKYGFGNPS 351
 QY 345 GEYMLGLENITWLNQNYKLVLMEDMSGRVFAEYASFRLEPSEYKRLRGYHGN 404

```

Db 352 GEXWLNNEFIATISQROQWLRLEIMDEGNRAVSQYDFHIGNQONRYLTKHGTGA 411
Qy 405 G--DSTFWNGKQFTLLDHDVYTGNCNCHYQKGGWYNYACASHNNGWYHGGHRSRY 462
Db 412 GROSSLIH-GADFSFKDADNDNCMKCALMLTGWFDACGSPSLNMGFYTAGNHGKL 470
Qy 463 QDGVWAEPFGSGSYLKYVMWIRP 487
Db 471 -NGIKWHYFKGPGYSLSRTTMMIRP 494

RESULT 4
AGP1 MOUSE STANDARD; PRT; 498 AA.
ID AGP1 MOUSE
AC 008538;
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Angiopoietin-1 precursor (ANG-1).
GN ANGPT1 OR AGPT.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=9734663; PubMed=8980223;
RA Davis S., Aldrich T.H., Jones P.F., Acheson A., Compton D.L., Jain V.,
RA Ryan T.E., Bruno J., Radziejewski C., Malsompierre P.C.,
RA Yancopoulos G.D.;
RT "Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by
RT secretion-trap expression cloning."
RL Cell 87:1161-1169(1996).

-1- FUNCTION: BINDS AND ACTIVATES TIE2 RECEPTOR BY INDUCING ITS
CC TYROSINE PHOSPHORYLATION. IMPLICATED IN ENDOTHELIAL DEVELOPMENTAL
CC PROCESSES LATER AND DISTINCT FROM THAT OF VEGF. APPEARS TO PLAY A
CC CRUCIAL ROLE IN MEDIATING RECIPROCAL INTERACTIONS BETWEEN THE
CC ENDOTHELIUM AND SURROUNDING MATRIX AND MESENCHYME. MEDIATES BLOOD
CC VESSEL MATURATION/STABILITY. IT MAY PLAY AN IMPORTANT ROLE IN THE
CC HEART EARLY DEVELOPMENT.
CC -1- SUBCELLULAR LOCATION: Secreted.
CC -1- DEVELOPMENTAL STAGE: EARLY IN DEVELOPMENT, AT E9 TO E11, IT IS
CC FOUND MOST PROMINENTLY IN THE HEART MYOCARDIUM SURROUNDING THE
CC ENDOCARDIUM. LATER, IT BECOMES MORE WIDELY DISTRIBUTED, MOST OFTEN
CC IN THE MESENCHYME SURROUNDING DEVELOPING VESSELS, IN CLOSE
CC ASSOCIATION WITH ENDOTHELIAL CELLS.
CC -1- SIMILARITY: Contains 1 fibronogen C-terminal domain.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL: U83509; A835058.1;
DR HSSP: P02671; 1PZD.
DR MCD: MGI:108448; Agpt.
DR GO: GO:007163; P:transmembrane receptor protein tyrosine kin. . . ; IDA.
DR InterPro: IPR002181; Fibronogen_C.
DR Pfam: PF00147; fibronogen_C; 1.
DR SMART: SMC0186; FBG; 1.
DR PROSITE: PS00514; FIBRIN-AG_C DOMAIN; 1.
KM Angiogenesis; Glycoprotein; Coiled coil; Signal.
FT SIGNAL 1 13
FT CHAIN 20 498
FT DOMAIN 81 119
FT DOMAIN 153 261
FT DISULFID 286 315
FT DISULFID 439 452
BY SIMILARITY.
BY SIMILARITY.

```

```

FT CARBOHD 92 92 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHD 122 122 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHD 154 154 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHD 243 243 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHD 295 295 N-LINKED (GLCNAC. . .) (POTENTIAL).
SQ SEQUENCE 498 AA; 57505 MW; 285B4FDEC26D800 CRC64;

Query Match 21.4%; Score 575.5; DB 1; Length 498;
Best Local Similarity 29.8%; Pred. No. 1.1e-28;
Matches 151; Conservative 83; Mismatches 169; Indels 103; Gaps 15;

Qy 43 RYKRGESQDKCTYFTVP-----QQRVGAICVSKR-EP-----EVL 79
Db 32 RYMRICHQG--CAVFTFLPEHGDNCRESATEQYNTNALQRDAPHYVPESSQYLQHLEHY 89
Qy 80 LERNVHKQELINNELTK-QKROETLQO-----LVKDGIVSEVKLRKESRN 129
Db 90 MEN--YVQWLQKLENYIVENKSEMAQIQNAVQNTATVLEIGTSLSTQ--ABQTRK 144
Qy 130 MNSRVQLVYQQLLHEIRKDNALDELQLENRIINOTADMLQASRYKYLEHRY----- 183
Db 145 LTVETQVNLQTSRLLEIQLNLSLTYKLEKQLQQTNEILTKIKHNSLLEHKLMEBK 204
Qy 184 -----QHATLANQSEITIAQLSEHQQRPSARPVQPPAPRVQPPPTN 231
Db 205 HKEELDTLKEEKNLQGLSVRSQTFITQLELKQLSRA----- 240
Qy 232 RIINQSTNEIQSDONLKVLPPLPTMPTLTS-----LPSTDKPGPMRDCQALE 283
Db 241 -----TNNSILQKQLEL-----MDVHNLVSLCTEGVLLKNGKKEEKPRFDCADVQ 291
Qy 284 DGHDTSSIVYKPEENTRLMQWCGDQHDGCTVIGRLDGSVNFRRMETYKQGFQNI 343
Db 292 AGFNKSGIYITVYNNNPPEPKVFCNNDVNGGQTVIAQHEEDSLDPQRQMKEXKMGFGNP 351
Qy 344 DGEVYGLENIYVLTQNGVYKLVITMEDSGKRVFSEYAFSPRESEYKRLGRYGN 403
Db 352 GEXWLNNEFIATISQROQWLRLEIMDEGNRAVSQYDFHIGNQONRYLTKHGTGA 411
Qy 404 G--DSTFWNGKQFTLLDHDVYTGNCNCHYQKGGWYNYACASHNNGWYHGGHRSRY 461
Db 412 GROSSLIH-GADFSFKDADNDNCMKCALMLTGWFDACGSPSLNMGFYTAGNHGKL 470
Qy 462 QDGVWAEPFGSGSYLKYVMWIRP 487
Db 471 L-NGIKWHYFKGPGYSLSRTTMMIRP 495

RESULT 5
AGP2 HUMAN STANDARD; PRT; 496 AA.
ID AGP2 HUMAN
AC O15123; Q9NRR7; Q9P217;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Angiopoietin-2 precursor (ANG-2).
GN ANGPT2.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A. (ISOFORM 1).
RC TISSUE=Lung;
RX MEDLINE=97349327; PubMed=9204896;
RA Malsompierre P.C., Suri C., Jones P.F., Bartunkova S., Wiegand S.J.,
RA Radziejewski C., Compton D., McClain J., Aldrich T.H.,
RA Yancopoulos N., Daly T.J., Davis S., Sato T.N., Yancopoulos G.D.;
RT "Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo
RT angiogenesis."
RL Science 277:55-60(1997).
RP SEQUENCE FROM N.A. (ISOFORM 1).

```

Matches	149;	Conservative	86;	Mismatches	163	Indels	124;	Gaps	15;
QY	42	NRYKRGASGQK-----	CTYTFVPGQRTGALCVNSKEPFLLENRHK-----						86
Db	20	NNFRKMSDISCKKQYOVGHGSCSYTFLLPEM----	DNCRSSSPFY--SNAVQRPAPLEY						73
QY	87	-----QELTLNN-----	ELTK-----						120
Db	74	DDSVORLVLENINENNTOYMLKLENTIQDMKKEMWELIQNVAVQGTAVMEIGTNLLN							133
QY	121	-----KILKESRRNNNSRVTOYLWOLHEIRKRDNALESQLENRIINQADMLQLA							173
Db	134	QTAEQRTKLTVEAQVNLN-QTTRELEQL-----	EHSISTKLEKQILIDQTSLEINKQ						185
QY	174	SKYKOLEHY-----	QHATLANHQSSEIIIAQLEEHQCRVPASRPVQ						215
Db	186	DNKSFLFKVLAMEDKHIITQLQSIKEKQDQLQVLSQNSIIIELEK-----							232
QY	216	PPAPAPPVYQEPPTYNRIINQISTNEIQSDQNLKVLPPPLPTPLTSLPSSIDKSGP							274
Db	233	-----KIVTATVNSVYLQKQOHDL-----	MEYVNNILITWMTSTNSAKDPT						272
QY	275	-----WRDQLALEDHQDTSIYLYKRPENTRILMWQCDQRPDPGGTVLQRLDGS							326
Db	273	VAKERQISRPDAEFKSGHTTNGIYTLTPNSYEEIKAYCDMEAGGGWITIIQRDSDS							332
QY	327	VNFPRMWEYVYKGFNIDGEYWLGLLENITWLTNQCANKLLVTMEDWSGRKVPAYASPRI							386
Db	333	VDFQRWMEYKYPGNPBGSEYWLGNFVPSQLTNQRVYLKILKDWEGNAVSLYEHFYI							392
QY	387	EPESEYKRLRLGRYHGNAD-SFTWHNKGQTTILDRHDVYTGNCAYQKGGWYVNAQAH							445
Db	393	SSEHLNLYRTHLGLTGTAGKISSISQPNDSITDQNDKCTCKSQMLTGWMPDAGCP							452
QY	446	SNLNGYVWYRGHYRSRYODGVYMAEFRCGSYSLKXVVMIRP							487
Db	453	SNLNGYVYPRQRTNKF--NGIKRYWYKSGSGLKATITMIRP							493
RESULT 6									
AGPL HUMAN	ID	AGPL HUMAN	STANDARD:	PRT:	498	AA.			
AC	Q15389;								
DT	16-OCT-2001 (Rel. 40, Created)								
DT	16-OCT-2001 (Rel. 40, Last sequence update)								
DT	28-FEB-2003 (Rel. 41, Last annotation update)								
DE	Angiopoietin-1 precursor (ANG-1).								
CN	ANGPT1 OR KIAA0003.								
OS	Homo sapiens (Human).								
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;								
OC	Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.								
OX	NCBI_TaxID=9606;								
RN	[1]								
RP	SEQUENCE FROM N.A., AND VARIANT GUY-269 DEL.								
RC	TISSUE=Fetal lung;								
FX	MEDLINE=97134663; PubMed=8980223;								
RA	David S., Aldrich T.H., Jones P.F., Acheson A., Compson D.L., Jain V.,								
RA	Ryan T.E., Bruno D., Radziejewski C., Matsuopietre P.C.,								
RA	Yancopoulos G.D.;								
RT	"Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by								
RT	secretion-trap expression cloning."								
RL	Cell 87:1161-1169(1996).								
RN	[2]								
RP	SEQUENCE FROM N.A.								
FX	MEDLINE=22158633; PubMed=12168954;								
RA	Nakajima D., Okazaki N., Yarakawa H., Kiyuno R., Ohara O., Nagase T.;								
RT	"Construction of expression-ready cDNA clones for KIAA genes: manual								
RT	curation of 330 KIAA cDNA clones."								
RL	DNA Res. 9:99-106(2002).								
RN	[3]								
RP	SEQUENCE OF								

RA Nomura N., Miyajima N., Sazuka T., Tanaka A., Kwarabayashi Y.,
 RA Sato S., Naease T., Seki N., Ishikawa K.-I., Tabata S.;
 RT Prediction of the coding sequences of unidentified human genes. I.
 RT The coding sequences of 40 new genes (K1A0001-K1A0040) deduced by
 RT analysis of randomly sampled cDNA clones from human immature myeloid
 RT cell line KG-1.";
 RL DNA Res. 1:27-35(1994).
 RN (4)
 RP SEQUENCE FROM N.A., AND VARIANT GLY-269 DEL.
 RA Stan Z.X., Yu X.Y., Lin Q.Y., Fu Y.H., Tan H.H., Zheng M., Lin S.G.;
 RT "Human angiotensin II mRNA variant forms.";
 RL Submitted (APR-2002) to the EMBL/GenBank/DBJ databases.
 RN [5]
 RP SEQUENCE FROM N.A., AND VARIANT GLY-269 DEL.
 RA Stan Z.X., Yu X.Y., Lin Q.Y., Fu Y.H., Tan H.H., Zheng M., Lin S.G.;
 RT "Human angiotensin II mRNA variant forms.";
 RL Submitted (JUN-2002) to the EMBL/GenBank/DBJ databases.
 CC -1- FUNCTION: BINDS AND ACTIVATES TIE2 RECEPTOR BY INDUCING ITS
 CC TYROSINE PHOSPHORYLATION, IMPLICATED IN ENDOTHELIAL DEVELOPMENTAL
 CC PROCESSES LATER AND DISTINCT FROM THAT OF VEGF. APPEARS TO PLAY A
 CC CRUCIAL ROLE IN MEDIATING RECIPROCAL INTERACTIONS BETWEEN THE
 CC ENDOTHELIUM AND SURROUNDING MATRIX AND MESENCHYME. MEDIATES BLOOD
 CC VESSEL MATURATION/STABILITY. IT MAY PLAY AN IMPORTANT ROLE IN THE
 CC HEART EARLY DEVELOPMENT.
 CC -1- SUBCELLULAR LOCATION: Secreted.
 CC -1- PTM: Glycosylated.
 CC -1- MISCELLANEOUS: IT MAY HAVE A POTENTIAL THERAPEUTIC UTILITY SINCE
 CC IT CAN BE USED FOR SPECIFICALLY TARGETING TUMOR VASCULATURE OR FOR
 CC PROMOTING ANGIOGENIC PROCESSES IN CERTAIN ORGANS SUCH AS AN
 CC ISCHEMIC HEART.
 CC -1- SIMILARITY: Contains 1 fibrinogen C-terminal domain.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@sib.ch).
 CC -----
 DR EMBL: U83508; AAB50557.1; -
 DR EMBL: D13628; BAA02793.2; ALT_INIT.
 DR EMBL: AB084454; BAB91325.1; -
 DR EMBL: AY121504; AAM81745.1; -
 DR EMBL: AY124380; AAM92271.1; -
 DR HSSP: P02671; 1FZD.
 DR GeneW: HGNC:484; ANGPT1.
 DR MIM: 601667;
 DR GO: GO:0005102; F:receptor binding; TAS.
 DR GO: GO:0007165; P:signal transduction; TAS.
 DR InterPro: IPR002181; Fibrinogen_C.
 DR Pfam: PF00147; fibrinogen_C_1.
 DR SMART: SMO0186; FBG; 1.
 DR PROSITE: PS00514; FIBRIN_AG_C_DOMAIN; 1.
 KM Angiogenesis; Glycoprotein; Coiled coil; Signal; Polymorphism.
 FT SIGNAL 1 15
 FT CHAIN 16 498
 FT DOMAIN 81 119
 FT DOMAIN 153 261
 FT DOMAIN 284 498
 FT DISULFID 286 315
 FT DISULFID 439 452
 FT CAROXYD 92 92
 FT CAROXYD 122 122
 FT CAROXYD 154 154
 FT CAROXYD 243 243
 FT CAROXYD 295 295
 FT VARIANT 269 269
 FT Missing (in cell line 198G; may be due to
 FT exon skipping).
 FT /FTID=VAR_009940.
 SQ SEQUENCE 498 AA; 57513 MW; 5D5FA63AEF6E920 CRC64;
 Query Match 21.3%; Score 572.5; DB 1; Length 498;

Best Local Similarity 29.4%; Pred. No. 1.7e-28;
 Matches 149; Conservative 85; Mismatches 169; Indels 103; Gaps 15;
 QY 43 RYKAGSDQDCTFTFVPO-----QRTGALCVNSK-EE-----EVL 79
 DB 32 RYRIQHQC-CATYFLPEHDGNCRESTDQYNTNALQDAPVPEDEFSQKLOHLEHV 89
 QY 80 LENEHKOQELLENELNLK-QKQIETLQO-----LVKDGIVSEVKLLRKSER 129
 DB 90 MEN--YQWQLOKLENYIVENKSKMAQIQNAVGNHTAMLEIGTSLSTQ---AEQTR 144
 QY 130 MNSRTQLYQNLHETTRKDNALLESQLENRIINOTADMLQASKYKLEHY----- 183
 DB 145 LTVDETQVNLQTSRLLEQLLENSLSTYKLEKQLQCTNEILKIKHKSLLHEKILEMEG 204
 QY 184 -----OHLATLANOSRIQLSEHCORVASRPVQPPAPRPVYQPTVN 231
 DB 205 HKELDLTKKEKXELQGLVRYQRTYLOELKQNLRA----- 240
 QY 232 RIINOISTNEIQSDQNLKVLPPPLTPMPTLS-----LPSTDKPSGPMRDLQALE 283
 DB 241 -----TTNNSVLQKQLEL-----MDIVHNLVNLCTKEGVLLKGGKEEKEPFDCADVYQ 291
 QY 284 DGHDTSIYLVKPEENTRLMQWQDQHDGSGMTVIGRLDGSVNFRRMETYKQSGFNI 343
 DB 292 AGFKSGITVITYNNPPEPKVFCNMDVNGGQMTVIOHREDGLDFQKGKEXMGFGNP 351
 QY 344 DGEYWGLENLYWLTNGQNYKLLVTWEDWSGRKFAEYASFRLEPSEYKRLIGRHGN 403
 DB 352 SGEYWLLENFIFAITSRQRYMLRIELMDWEGNNAQYQYRFHIGNEKQYRLYLKSHGT 411
 QY 404 AG--DFTWNGKQFTLDRDHYVTGNCANHYKGGWYNACASHLNLGVYRGHYSR 461
 DB 412 AGQSSLIILH-GADFTKQDNDNCCKCALMLTGMPWDACGPNLNGMFTYAGGNHK 470
 QY 462 YQDGYVAEPRGSGYSILKKVYMWIR 487
 DB 471 L-NGIKWHYKPSYLSRSTTWIR 495
 RESULT 7
 AGP4_MOUSE STANDARD; PRT; 509 AA.
 ID AGP4_MOUSE
 AC OSWVH6;
 DT 28-FEB-2003 (Rel. 41, Created)
 DT 28-FEB-2003 (Rel. 41, Last sequence update)
 DT 28-FEB-2003 (Rel. 41, Last annotation update)
 DE Angiotensin-4 precursor (ANG-4) (ANG-3).
 GN ANGPT4 OR AGPT4 OR ANG3.
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 OC NCBI_TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Myoblasts, and Uterus;
 RX MEDLINE=9162530; PubMed=10051567;
 RA Valenzuela D.M., Griffiths J.A., Rojas J., Aldrich T.H., Jones P.F.,
 RA Zhou H., McLain J., Copeland N.G., Gilbert D.J., Jenkins N.A.,
 RA Huang T., Papadopoulos N., Maisonneuve P.C., Davis S.,
 RA Yancopoulos G.D.;
 RT Angiotensins 3 and 4: diverging gene counterparts in mice and
 RT humans.";
 RL Proc. Natl. Acad. Sci. U.S.A. 96:1904-1909(1999).
 CC -1- FUNCTION: BINDS TO TYROSINE-PROTEIN KINASE RECEPTOR TIE2 AND MAY
 CC ACT AS AN ANTAGONIST.
 CC -1- SUBCELLULAR LOCATION: Secreted (probable).
 CC -1- TISSUE SPECIFICITY: Widely expressed.
 CC -1- SIMILARITY: Contains 1 fibrinogen C-terminal domain.
 CC -1- CAUTION: Was originally (Ref.1) called angiotensin-3.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -

the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to license@isb-sib.ch).

EMBL, AF113707; AAD21586.1; -
DR HSBP; P02671; 1F2D.
DR MGD; WGI:1336887; Agpt4.
DR InterPro; IPR002181; Fibrinogen_C.
DR Pfam; PF00147; fibrinogen_C_1.
DR SMART; SM00186; FBG; 1.
DR PROSITE; PS00514; FIBRIN_AG_C_DOMAIN; 1.
KM Coiled coil; Signal.
FT SIGNAL 1 21 POTENTIAL.
FT CHAIN 22 509 ANGIOPOIETIN-4.
FT DOMAIN 181 269 COILED COIL (POTENTIAL).
FT DOMAIN 294 480 FIBRINOGEN-LIKE.
FT DISULFID 297 326 BY SIMILARITY.
FT DISULFID 450 463 BY SIMILARITY.
SQ SEQUENCE 509 AA; 57805 MW; 9B5A74A20A6664F6 CRC64;

Query Match 20.8%; Score 558; DB 1; Length 509;
Best Local Similarity 29.1%; Pred. No. 1.4e-27;
Matches 154; Conservative 90; Mismatches 195; Indels 90; Gaps 16;

13 LLAAGVAVGDDGEGTGGSPREFIYINRKAGSGDCTYTFITPQGRVGAIC-- 70
14 LLAATVAAAO--HRGPGAGSHRQIHQVRR--GQSYTFVVRP--DICOI 56
71 VNSKEPEV--LENNRKHQDELLNNE--ILKQRQ 102
57 APTAPAEALGGSNSQGRDIPASRLHITWRAGRAQARQVSGLEKILENNTQMLKLBOS 116
103 I-----ETLQO--LVKVDGIVSEYKYLKSRNNNSKVTQVMQLHEI 145
117 IKVNRSHLVQAQODITQNTTMTALGANLNQTK--AQCHKLTAVEAQVNLQTLHK 173
146 IKRRUNALELSQLENNILNQTADMLQASKYKDLKHEKYOHLLATLHNSSEITAEHQ 205
174 TQMLNSLSTNKLKRMQMSRELQLOGRNALLETQALE--AQHQAG--LNSLOKRE 230
206 RVPSARFVYQPPAPRPVYQPPYTR--INQISTNEI--QSDQMLKVLPPPLTMP 259
231 QHSHLIG--HQTGLTANLKNHIALSSNSSLQOQOQOQITFEVQRLVIV 278
260 TLTSLPSTDKSPGWRDCLQMLEGSHDSSIVLVKPEPNTNLMQVWCDQRHDPGQWTVI 319
279 ADDQHVSILKTPREVQDCAETKRSQVNSGVYTTIETMTKPLKVFCDMETDGGWTII 338
320 QRRLDGSVNFPRNWTETKQGFNGIDGEMVIGLENTYMLTNGQNYKLLVTMEDWGRKYFA 379
339 QHREGDSVNFQRTWEYKEGFGVNAHEHLGNEAVHRLTSFAYLLRVELHDMEGRQSI 398
380 EYASRFLRESESYKRLRGTRYGNAG--DSFTWNGQFOTLDRHDVYTGNAHAKQKGM 438
399 QYENFOLGSEORYSLSVNDSSSSAKRKNSLAPQGRKFTKMDNDNCKCKAQVLSGM 458
439 WYNACGSHNLNGWYRGHYRGRYQGVYWAFFRGGSYSLLKTYVMNIRP 487
459 WPDAGCLSLNLNGIY--SVQHKLKINGIMHFRGSSYSLHGRVWLRP 506

RESULT 8
AGP4 HUMAN STANDARD; PRT; 503 AA.
ID AGP4 HUMAN
IC 09Y264; 09H424;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Angiopoietin-4 precursor (ANG-4) (ANG-3).
GN ANGP4 OR ANG4 OR ANG3.
OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
CC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
CX NCBI_TaxId=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Aorta;
RX MEDLINE=99232854; PubMed=10218486;
RA Nishimura M., Miki T., Yashima R., Yokoi N., Yano H., Sato Y.,
RA Seino S.;
RT "Angiopoietin-3, a novel member of the angiopoietin family.";
RL FEBS Lett. 448:254-256 (1999).
[2]
RP SEQUENCE FROM N.A.
RC TISSUE=Ovary;
RX MEDLINE=9916530; PubMed=10051567;
RA Valenzuela D.M., Griffiths J.A., Rojas J., Aldrich T.H., Jones P.F.,
RA Zhou H., McClain U., Copeland N.G., Gilbert D.J., Jenkins N.A.,
RA Huang T., Papadopoulos N., Maisonneuve P.C., Davis S.,
RA Yancopoulos G.D.;
RT "Angiopoietins 3 and 4: diverging gene counterparts in mice and humans.";
RL Proc. Natl. Acad. Sci. U.S.A. 96:1904-1909 (1999).
[3]
RP SEQUENCE FROM N.A.
RX MEDLINE=21638749; PubMed=11780052;
RA Deloukas P., Matthews L.H., Ashurst J., Burton J., Gilbert J.G.R.,
RA Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M.,
RA Beasley C.P., Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J.,
RA Buck D., Burrill W.D., Butler A.P., Gardner C., Carter N.P.,
RA Chapman J.C., Clamp M., Clark G., Clark L.N., Clark S.Y., Clee C.M.,
RA Chigss S., Cobley V.E., Collier R.E., Connor R.E., Corby N.R.,
RA Coulson A.G., Coville G.J., Deadman R., Dhami P.D., Dunn M.,
RA Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA Hammond S., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA Huckle E., Hunt A.R., Hunt S.B., Jekosch K., Johnson C.M., Johnson D.,
RA Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA Leivasalaho M.H., Leverisa M.A., Lloyd C., Lloyd D.W., Lovell J.D.,
RA Marsh V.L., Martin S.L., McConachie L.J., McKay K., McMurtry A.A.,
RA Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsey H.,
RA Rice C.M., Ross M.T., Scott C.E., Senra H.K., Shownkeen R., Sims S.,
RA Skuse C.D., Smith M.L., Soderlund C., Steward C.A., Sultson J.E.,
RA Swann R.M., Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A.,
RA Tracey A., Tromans A.C., Vaudin M., Wall M., Wallis J.M.,
RA Whitehead S.L., Whitaker P., Willey D.L., Williams L., Williams S.A.,
RA Wilming L., Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S.,
RA Rogers J.;
RT "The DNA sequence and comparative analysis of human chromosome 20.";
RL Nature 414:865-871 (2001).
[4]
RP FUNCTION: BINDS TO TYROSINE-PROTEIN KINASE RECEPTOR TIE2 AND
ACTIVATES IT.
CC -1- SUBCELLULAR LOCATION: Secreted (Probable).
CC -1- TISSUE SPECIFICITY: HIGHLY EXPRESSED IN THE LUNG WITH MUCH LOWER
LEVELS FOUND IN OTHER TISSUES.
CC -1- CAUTION: Was originally (Ref.1) called angiopoietin-3.
CC -1- SIMILARITY: Contains 1 fibrinogen C-terminal domain.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
or send an email to license@isb-sib.ch).

EMBL, AF074332; AAD31728.1; -
EMBL, AF113708; AAD21587.1; -
EMBL, AL161939; CAC09933.1; -
DR HSBP; P02671; 1F2D.
DR Genew; HGNC:487; ANGP4.

SO SEQUENCE 312 AA; 36391 MW; 26BC82124E6660C2 CRC64;
 Query Match 20.0%; Score 537; DB 1; Length 312;
 Best Local Similarity 39.6%; Pred. No. 1.5e-26;
 Matches 111; Conservative 40; Mismatches 89; Indels 40; Gaps 9;

QY 232 RIINOISTNEIQ-----SDQNTKVLPPPLPTMTLTPSSSTDKSGSPRDCLOALDGDH 287
 DB 50 KIKQLOENBVOFLKGDEN-----TVIDLGSKQ-----YADCELENDGYK 92
 QY 288 TSSITLVLPENRNLMOYWCQORHDPGGTIVIGRLDSVSPFFRWERYKQGFNI---D 344
 DB 93 LSGFYKIRPLOSPPAFSVYCDM-SDGGQWTVYQSRSDSESNFRNGKDYENGFNFYK 151
 QY 345 GEYMLGLENIYVLTNGQYKLVITMEDWSGRKVAEYAFLEPESEYKRLGRYHNA 404
 DB 132 GEYMLGNKRLHFLTTOEDYTLKIDLADPEKNSRYAQYKNFKYGDENKPYELNIGYSGTA 211
 QY 405 GDSFT-----N-HNGKQFTLLDRDHDVYTGCAHYQKGGWYNAKAHSLNIGVY 453
 DB 212 GDSLGNFPEYQWNAHQMKFSTWDRDHDYBGNCAEEDQSGWVFRCSANLNGVY 271
 QY 454 RGGHYRSRYQDGVYAAEFRRGSGYSLKRYVMIRPN---FN 490
 DB 272 -SGPYTAKTDNGIWTWTHGWMYSLKSYVMKIRPNDFTN 310

RESULT 10
 AGP2_PIG STANDARD; PRT; 496 AA.
 AC Q9BD7;
 DT 28-FEB-2003 (Rel. 41, Created)
 DT 28-FEB-2003 (Rel. 41, Last sequence update)
 DT 28-FEB-2003 (Rel. 41, Last annotation update)
 DE Angiopoietin-2 precursor (ANG-2).
 GN ANGPT2;
 OS Sus scrofa (Pig).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.
 OX NCBI_TaxID=9823;
 RN [1]
 RP MEDLINE FROM N.A. Pubmed=11230987;
 RX MEDLINE=21153163;
 RA Kim I., Moon S.O., Han C.Y., Pak Y.K., Moon S.K., Kim J.J., Koh G.Y.;
 RT "The angiopoietin-tie2 system in coronary artery endothelium prevents
 oxidized low-density lipoprotein-induced apoptosis.";
 RL Cardiovasc. Res. 49:872-881(2001).
 CC -1- FUNCTION: BINDS TO TIE2 RECEPTOR AND COUNTERACTS BLOOD VESSEL
 MATURATION/STABILITY MEDIATED BY ANGIOPOIETIN-1. ITS FUNCTION MAY
 BE CONTEXT-DEPENDENT. IN THE ABSENCE OF ANGIOGENIC INDUCERS, SUCH
 AS VEGF, ANG2-MEDIATED LOOSENING OF CELL-MATRIX CONTACTS MAY
 INDUCE ENDOTHELIAL CELL APOPTOSIS WITH CONSEQUENT VASCULAR
 REGRESSION. IN CONCERT WITH VEGF, IT MAY FACILITATE ENDOTHELIAL
 CELL MIGRATION AND PROLIFERATION, THUS SERVING AS A PERMISSIVE
 ANGIOGENIC SIGNAL (BY SIMILARITY).
 CC -1- SUBCELLULAR LOCATION: Secreted.
 CC -1- SIMILARITY: Contains 1 fibrinogen C-terminal domain.

 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 between the Swiss Institute of Bioinformatics and the EMBL outstation -
 the European Bioinformatics Institute. There are no restrictions on its
 use by non-profit institutions as long as its content is in no way
 modified and this statement is not removed. Usage by and for commercial
 entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 or send an email to license@isb-sib.ch).

 CC EMBL; AF233228; AAK14993.1; -
 DR HSSP; P02671; 1FZD.
 DR InterPro; IPR002181; Fibrinogen_C.
 DR Pfam; PF00147; fibrinogen_C; 1.
 DR SMART; SM00186; FBG; 1.
 DR PROSITE; PS00514; FIBRIN AG C DOMAIN; 1.
 KW Angiogenesis; Glycoprotein; Coiled coil; signal.

FT SIGNAL 1 18 POTENTIAL.
 FT CHAIN 19 496 ANGIOPOETIN-2.
 FT DOMAIN 130 255 COILED COIL (POTENTIAL).
 FT DOMAIN 280 496 FIBRINOGEN C-TERMINAL.
 FT DISULFID 284 313 BY SIMILARITY.
 FT DISULFID 437 450 BY SIMILARITY.
 FT CARBOHYD 89 89 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 119 119 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 133 133 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 151 151 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 240 240 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 304 304 N-LINKED (GLCNAC. . .) (POTENTIAL).
 SO SEQUENCE 496 AA; 56911 MW; 33802BE224FE659D CRC64;

Query Match 20.0%; Score 537; DB 1; Length 496;
 Best Local Similarity 28.1%; Pred. No. 2.6e-26;
 Matches 141; Conservative 95; Mismatches 182; Indels 84; Gaps 12;

QY 42 NRYKAGESQDK-----CTYFIVPQ-----QRYTGAICVNSKEPEVLLNRYHKOE 88
 DB 20 NRPKMSDSTGKQYQYQHGPCSYTFLEPTDNCRSPSSSYVNAVQRPALDYDSVRR 79
 QY 89 LELLNN-----ELK-----OKROIEFLQQLVKYDGSIVSV----- 120
 DB 80 LOVLLENIMENNTQWLMLLESYIODNMKKEVEIQQNAVQNTAVMLHIGTNLLNQTAEO 139
 QY 121 -KILKRESRMNNSRVQLVQWQLLEIRKRDNALELSQLENRLINQTAQMLQASKYKDL 179
 DB 140 RKLTDVEAQVILN-OTTLIELQL-----EHSITKTLKQLIDQTSINKLQDKNSFL 191
 QY 180 EHKYQHLATLANQSEIIIAOLEHQYVSPARVPVPPAPPAVRVQPPYNNRIINOIST 239
 DB 192 EKVYLDMEDEKIIIVQLQSIKEKQDQLVAVSKQ-----NSLIELEK 232
 QY 240 NEIOSDQMLKLPFP-----LPTMPTLSLPSSTDXSGP-----WRDCCALDGH 286
 DB 233 QLVATVYNSVLQROQHDLETVNHLMTSTNSAHSVLAKSEQLIIFRDCAEAFKSG 292
 QY 287 DTSSIVLVKPPENTRLMOVWCQORHDPGGTIVIGRLDSVSPFFRWERYKQGFNIDGE 346
 DB 293 TTSQGYTLTFPNSIEETKAYCDMETGGGWTIVIQREDGSYDFQRTWEKYMGFGSPSGE 352
 QY 347 YMLGLENITVLTNGQYKLVITMEDWSGRKVAEYAFLEPESEYKRLGRYHNA 406
 DB 353 HMLGNFEPYQVYTNQRYVTLKHLRDWEGNEAYSLYEHYLSSEFPNRIHLKGLTGK 412
 QY 407 -SFTWHNGKQFTLLDRDHDVYTGCAHYQKGGWYNAKAHSLNIGVYRGHYRSRYQDG 465
 DB 413 ISSISQPSNDSTGDADNDKICQSQWLTGGMWFDACGSPNLNGMYVPQQTNTKF-NG 471
 QY 466 YVMAEFRRGSGYSLKRYVMIRP 487
 DB 472 IKWYMKSGSGYSLKATMMIRP 493

RESULT 11
 AGP1_BOVIN STANDARD; PRT; 481 AA.
 AC O18920;
 DT 16-OCT-2001 (Rel. 40, Created)
 DT 16-OCT-2001 (Rel. 40, Last sequence update)
 DT 28-FEB-2003 (Rel. 41, Last annotation update)
 DE Angiopoietin-1 precursor (ANG-1) (Fragment).
 GN ANGPT1 OR ANG1.
 OS Bos taurus (Bovine).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidea;
 OC Bovidae; Bovinae; Bos.
 OX NCBI_TaxID=9913;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Ovary;
 RX MEDLINE=99054348; Pubmed=9840613;

RA Geede V., Schmidt T., Kimmina S., Kozian D., Augustin H.G.;
 RT "Analysis of blood vessel maturation processes during cyclic ovarian
 RT angiogenesis.";
 RN Lab. Invest. 78:1385-1394(1998).
 CC [2]
 CC SEQUENCE OF 91-200 FROM N.A.
 CC TISSUE-Liver.
 CC MEDLINE=98451564; Pubmed=9776732;
 CC Mandriota S.J., Pepper M.S.;
 CC "Regulation of angiopoietin-2 mRNA levels in bovine microvascular
 CC endothelial cells by cytokines and hypoxia.";
 CC Circ. Res. 83:852-859(1998).
 CC -1- FUNCTION: BINDS AND ACTIVATES TIE2 RECEPTOR BY INDUCING ITS
 CC TYROSINE PHOSPHORYLATION IMPLICATED IN ENDOTHELIAL DEVELOPMENTAL
 CC PROCESSES LATER AND DISTINCT FROM THAT OF VEGF. APPEARS TO PLAY A
 CC CRUCIAL ROLE IN MEDIATING RECIPROCAL INTERACTIONS BETWEEN THE
 CC ENDOTHELIUM AND SURROUNDING MATRIX AND MESENCHYME. MEDIATES BLOOD
 CC VESSEL MATURATION/STABILITY. IT MAY PLAY AN IMPORTANT ROLE IN THE
 CC HEART EARLY DEVELOPMENT (BY SIMILARITY).
 CC -1- SUBCELLULAR LOCATION: Secreted.
 CC -1- DEVELOPMENTAL STAGE: Found to be expressed throughout the ovarian
 CC cycle.
 CC -1- SIMILARITY: Contains 1 fibrinogen C-terminal domain.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 CC EMBL: AF093573; AAC61872.1; -
 CC EMBL: AF032923; AAC78245.1; -
 CC HSSP: P02671; IFZD.
 CC InterPro: IPR002181; Fibrinogen_C.
 CC Pfam: PF00147; fibrinogen_C.1.
 CC SMART: SM00186; FBG; 1.
 CC PROSITE: PS00514; FIBRIN_AG_C_DOMAIN; 1.
 CC KW Angiogenesis; Glycoprotein; Coiled coil; signal.
 CC DR Angiogenesis; Glycoprotein; Coiled coil; signal.
 CC FT SIGNAL 1 15
 CC FT CHAIN 1 15
 CC FT DOMAIN 153 261
 CC FT DOMAIN 283 481
 CC FT DISULFID 285 314
 CC FT DISULFID 438 451
 CC FT CARBOHYD 92 92
 CC FT CARBOHYD 122 122
 CC FT CARBOHYD 154 154
 CC FT CARBOHYD 243 243
 CC FT CARBOHYD 294 294
 CC FT NON_TER 481
 CC SQ SEQUENCE 481 AA; 55556 MW; 88EC9ED84FC2B850 CRC64;
 CC -----
 CC Query Match 20.0%; Score 536.5; DB 1; Length 481;
 CC Best Local Similarity 28.5%; Pred.No. 2.7e-26;
 CC Matches 146; Conservative 86; Mismatches 186; Indels 95; Gaps 16;
 CC -----
 CC 14 LAAMGAVAGDEGFEETGEGSPREFIYARRYKAGESQDKCTYFIVPQ-----QRTG 67
 CC 10 LAAILTHIGSNQSRSPENGG-----RRYNRIGHQ--CAYFIPIDHNGCRSESTID 60
 CC 68 AICVNSKE---PEV-----LLENRYHKQELLLNNELK-QRQIETTLQO- 108
 CC 61 QYNTALORDAPHVQDSSQKLOLHEHVMEN--YTOWLQKIEVYIENKMSMAQIQON 118
 CC 109 -----LVKVDGIVSEVLLKRSKNSRVTOLYMLHLIRKRDVALLSQLEN 160
 CC 119 AVQNHATMELTIGLSLSQT---AEQTKLTDVETVNLQNSRIELQLENSLSTYKLEK 175
 CC 161 RILNQTADMLQSLASYKQLEHKY-----QHLATLHNSQSELIAGLE 202
 CC 176 QLLQGTNELLKIKHKNLSLEHKIFEMEGKHKEIDTLKEKENIQGLVTSQTYIIQLEK 235

QY 203 HQQRVPSARPVPPPPAPPRVYQPTYNRIINOISTNEIQSDNKLKVLPPPLPTMPTLT 262
 DB 236 QLNATITNSVLQ-----KQLEMDIVYHNLVN-LCKREV----- 269
 QY 263 SLPSSTDXKSPGPMWDCIQALDGHDTSSIVLVEKENTRLMQWCDGRHPDGGTIVIQR 322
 DB 270 LLKGGKREKEKPEFDDCADVYQAGFNKSGIYIYINNPEPKVFCDDMDLNGGGTIVIQH 329
 QY 323 LDGSVNFPRNWEYTKQSGFNIDGFWLGLNIVLNTQNGYKLLVTMEDWSGKVPFEYA 382
 DB 330 EDGSLDQKQKKEKMGKPGNPSGTYWLGNEFIFATISQROTYRIELLDWEGNAYSYD 389
 QY 383 SFRLPSESEYKYLGRYHGNAG--DSFTWNGKQFTLLDRDHDVYTGNCAYHOKGGMWY 440
 DB 390 RFHIGNKQVRYLKLKHTGTAGKQSSLIH-GADFSTKXADNDNCMKCALMTGGWVF 448
 QY 441 NAGASHNLNGVWYGGHYRERYQDGVYMAFRG 473
 DB 449 DACGSPNLNGMFTYAGNHGKL-NGIKWHYFKG 480
 CC -----
 CC RESULT 12
 CC AGP2_MOUSE STANDARD; PRT; 496 AA.
 CC ID AGP2_MOUSE
 CC AC O35608;
 CC DT 16-OCT-2001 (Rel. 40, Created)
 CC DT 16-OCT-2001 (Rel. 40, Last sequence update)
 CC DT 28-FEB-2003 (Rel. 41, Last annotation update)
 CC DE Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo
 CC ANGP2 OR AGP2.
 CC GN Mus musculus (Mouse).
 CC OS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 CC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 CC NCBI_Taxid=10090;
 CC RX [1]
 CC RA Madsen-Petersen P.C., Sui C., Jones P.F., Bartunkova S., Wiesgang S.J.,
 CC Radziejewski C., Compton D.L., McClain J., Aldrich T.H.,
 CC Papadopoulos N., Daly T.J., Davis S., Sato T.N., Yancopoulos G.D.;
 CC "Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo
 CC angiogenesis.";
 CC Science 277:55-60(1997).
 CC -1- FUNCTION: BINDS TO TIE2 RECEPTOR AND COUNTERACTS BLOOD VESSEL
 CC MATURATION/STABILITY MEDIATED BY ANGIOPOIETIN-1. ITS FUNCTION MAY
 CC BE CONTEXT-DEPENDENT. IN THE ABSENCE OF ANGIOGENIC INDUCERS, SUCH
 CC AS VEGF, ANG2-MEDIATED LOOSENING OF CELL-MATRIX CONTACTS MAY
 CC INDUCE ENDOTHELIAL CELL APOPTOSIS WITH CONSEQUENT VASCULAR
 CC REGRESSION. IN CONCERT WITH VEGF, IT MAY FACILITATE ENDOTHELIAL
 CC CELL MIGRATION AND PROLIFERATION, THUS SERVING AS A PERMISSIVE
 CC ANGIOGENIC SIGNAL.
 CC -1- SUBCELLULAR LOCATION: Secreted.
 CC -1- TISSUE SPECIFICITY: Expressed only at sites of vascular
 CC remodeling.
 CC -1- SIMILARITY: Contains 1 fibrinogen C-terminal domain.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 CC EMBL: AF004326; AAB63189.1; -
 CC HSSP: P02671; IFZD.
 CC GMD; MGI:1202890; Asptc2.
 CC InterPro: IPR002181; Fibrinogen_C.
 CC Pfam: PF00147; fibrinogen_C.1.
 CC SMART: SM00186; FBG; 1.
 CC PROSITE: PS00514; FIBRIN_AG_C_DOMAIN; 1.

KW Angiogenesis; Glycoprotein; Coiled coil; Signal.
 FT SIGNAL 1 18 POTENTIAL.
 FT CHAIN 19 496 ANGIOPOIETIN-2.
 FT DOMAIN 159 256 COILED COIL (POTENTIAL).
 FT DOMAIN 280 496 FIBRINOGEN C-TERMINAL.
 FT DISULFID 284 313 BY SIMILARITY.
 FT DISULFID 437 450 BY SIMILARITY.
 FT CARBOHYD 89 89 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 119 119 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 133 133 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 151 151 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 240 240 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 304 304 N-LINKED (GLCNAC. . .) (POTENTIAL).
 SQ SEQUENCE 496 AA; 5666 MW; FA3021FE4E01C410 CRC64;

Query Match 19.9%; Score 535.5; DB 1; Length 496;
 Best Local Similarity 28.9%; Pred. No. 3.3e-26;
 Matches 144; Conservative 82; Mismatches 163; Indels 109; Gaps 15;

QY 54 CTYTFVPOQRVTGALCVNSKEPVLLENKHK-----QELSLNN-----EL 96
 DB 41 CSYTFPLPPT---DSCRSSSP--YMSNAVQRDAPLDYDSDVORLOVLENNLTOWL 94
 QY 97 LK-----OKROJETLOQLVKVGDGIVSEV-----KLKESRMNNSRV 134
 DB 95 MLENYIQNMKKEMWEIQNVVQNTAVMIEIGSLNQTAAQTRKLDVAQVLYN-QT 153
 QY 135 TOLVNLHEIRKRDNALELSQENRIINQPADMLQASKYKDLHKY----- 183
 DB 154 TRLEQLT-----CHSISTNLEKQILDQTSINKQNKSPLEQKYLDMEGKHSQ 206
 QY 184 -----QHATLANQSEILNQLEHOCQVPSARVPQPPAAPRVYQPTVRIINQ 236
 DB 207 QSMKEQKDELQVLYVKSQSVIDELE---KKLVTA-----TANSLIQ 245
 QY 237 ISTNEIQSDQNLKVLPPPLPPTLTSLPSSTD-----KPSGPMWDCLOLEDHDTSS 290
 DB 246 KOQHDLMETVN-----SLTVMSSPNSKSSVAIRKEQOTPRDCAIEFKSGITSG 296
 QY 291 IYLVKRNENRMLQVWCQDRHDPGQWTYQRLDGVNFRFWETVKQFGNIDSEYWG 350
 DB 297 IYLVKRNENRMLQVWCQDRHDPGQWTYQRLDGVNFRFWETVKQFGNIDSEYWG 356
 QY 351 LENIYVLTQNGYKLVLTWEDWSGRKVFAYASFRLEPSESEYKRLGTHGNAGD-SFT 409
 DB 357 NERVQSGLTQGHRYVLTQKLDWEGNFAHSLYDHFTYLAGESNVRILHTGLTAKISST 416
 QY 410 WANGKQFTLLDRDHDVYTGNCAYQKGGWYNVNAHNSNNGVYRGHRSYQDGYWA 469
 DB 417 SQPGSFSFTRSDNDNDKICCKSCQMLSGWVPDACPSPNNGVYQKQNTNKF-NGIKWY 475
 QY 470 BFRGGSYSLKAYVMRMP 487
 DB 476 YMKGSYSLKATMMIRP 493

RESULT 13
 FIBB BOVIN STANDARD; PRT; 468 AA.
 AC P02676;
 DT 21-UTL-1986 (Rel. 01, Created)
 DT 01-FEB-1996 (Rel. 33, Last sequence update)
 DT 10-OCT-2003 (Rel. 42, Last annotation update)
 DE Fibrinogen beta chain precursor [Contains: Fibrinopeptide B].
 GN FGB.
 OS Bos taurus (Bovine).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
 OC Bovidae; Bovinae; Bos.
 OX NCBI_TaxID=9913;
 RN [1]
 RP SEQUENCE OF 1-4.
 RA Blomback B., Doolittle R.F.;

RT "The sequence of amino acids at the N-terminal end of bovine
 RT fibrinopeptide B.";
 RL Acta Chem. Scand. 17:1816-1819 (1963).
 RN [2]
 RP SEQUENCE OF 5-21.
 RT Sjoquist J., Blomback B., Wallen P.;
 RT "Amino acid sequence of bovine fibrinopeptides.";
 RL Ark. Kemt 16:425-436 (1960).
 RN [3]
 RP SEQUENCE OF 22-53.
 RX MEDLINE=79164394; PubMed=434821;
 RA Martindale R.A., Ingles A.S., Rubira M.R., Hageman T.C.,
 RA Hurrell J.G.R., Leach S.J., Scheraga H.A.;
 RT "Amino acid sequences of portions of the alpha and beta chains of
 RT bovine fibrinogen.";
 RL Arch. Biochem. Biophys. 192:27-32 (1979).
 RN [4]
 RP SEQUENCE OF 44-468 FROM N.A.
 RX MEDLINE=81199473; PubMed=6262803;
 RA Chung D.W., Rixon M.W., McGillivray R.T.A., Davie E.W.;
 RT "Characterization of a cDNA clone coding for the beta chain of bovine
 RT fibrinogen.";
 RL Proc. Natl. Acad. Sci. U.S.A. 78:1466-1470 (1981).
 CC -1- FUNCTION: Fibrinogen has a double function: yielding monomers that
 CC polymerize into fibrin and acting as a cofactor in platelet
 CC aggregation.
 CC -1- SUBUNIT: HEXAMER CONTAINING 2 SETS OF 3 NONIDENTICAL CHAINS
 CC (ALPHA, BETA AND GAMMA), LINKED TO EACH OTHER BY DISULFIDE BONDS.
 CC -1- PM: Conversion of fibrinogen to fibrin is triggered by thrombin,
 CC which cleaves fibrinopeptides A and B from alpha and beta chains,
 CC and thus exposes the N-terminal polymerization sites responsible
 CC for the formation of the soft clot. The soft clot is converted
 CC into the hard clot by factor XIIIa which catalyzes the epsilon-
 CC (gamma-glutamyl)lysine cross-linking between gamma chains
 CC (stronger) and between alpha chains (weaker) of different
 CC monomers.
 CC -1- SIMILARITY: Contains 1 fibrinogen C-terminal domain.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (see <http://www.ebi.ac.uk/announcements/>
 CC or send an email to license@ebi.ac.uk).
 CC -----
 CC EMBL: V00110; CAA23444.1; -.
 DR PDB: 1JY2; 22-MAY-02.
 DR PDB: 1JY3; 22-MAY-02.
 DR InterPro: IPR002181; Fibrinogen_C.
 DR Pfam: PF00147; fibrinogen_C, 1.
 DR SMART: SM00186; FBC, 1.
 DR PROSITE: PS00514; FIBRIN AG C DOMAIN, 1.
 KM Blood coagulation; Plasma; Platelet; Glycoprotein; Sulfation;
 KM Pyrolydione carboxylic acid; 3D-structure.
 FT PEPTIDE 1 21 FIBRINOPEPTIDE B.
 FT CHAIN 22 468 FIBRINOGEN BETA CHAIN.
 FT MOD RES 1 1 PYRROLIDONE CARBOXYLIC ACID.
 FT MOD RES 6 6 SULFATION.
 FT SITE 21 22 CLEAVAGE (BY THROMBIN; RELEASE
 FT FIBRINOPEPTIDE B).
 FT DISULFID 72 72 INTERCHAIN (WITH ALPHA).
 FT DISULFID 83 83 INTERCHAIN (WITH ALPHA).
 FT DISULFID 87 87 INTERCHAIN (WITH GAMMA).
 FT DISULFID 200 200 INTERCHAIN (WITH ALPHA).
 FT DISULFID 204 204 INTERCHAIN (WITH GAMMA).
 FT DISULFID 208 293 BY SIMILARITY.
 FT DISULFID 218 247 BY SIMILARITY.
 FT DISULFID 401 414 BY SIMILARITY.
 FT CARBOHYD 371 371 N-LINKED (GLCNAC. . .) (PROBABLE).
 SQ SEQUENCE 468 AA; 53340 MW; 2DEDA2F443AA4B37 CRC64;

Query Match 19.6%; Score 527.5; DB 1; Length 468;

RP X-RAY CRYSTALLOGRAPHY (2.3 350PROXS) OF 164-491.
 RX MEDLINE=98292395; PubMed=9628725;
 RA Everse S.J., Spraggan G., Veerapandian L., Riley M., Doolittle R.F.;
 RT "Crystal structure of fragment double-D from human fibrin with two
 RT different bound ligands";
 RL Biochemistry 37:8637-8642(1998).
 RN [16]
 RP X-RAY CRYSTALLOGRAPHY.
 RX MEDLINE=99175089; PubMed=10074346;
 RA Everse S.J., Spraggan G., Veerapandian L., Doolittle R.F.;
 RT "Conformational changes in fragments D and double-D from human
 RT fibrin(ogen) upon binding the peptide ligand Gly-His-Arg-Pro-amide";
 RL Biochemistry 38:2941-2946(1999).
 RN [17]
 RP INTERACTION WITH FBLN1.
 RX MEDLINE=95370284; PubMed=7642629;
 RA Tian H., Tanaka A., Litvinovich S.V., Medved L.V., Haudenschild C.C.,
 RA Argyres W.S.;
 RT "The interaction of fibrulin-1 with fibrinogen. A potential role in
 RT hemostasis and thrombosis";
 RL J. Biol. Chem. 270:19458-19464(1995).
 RN [18]
 RP VARIANT BALTIMORE-2 IYS-478.
 RX MEDLINE=89086942; PubMed=3194892;
 RA Schmeizer C.H., Ebert R.F., Bell W.R.;
 RT "A polymorphism at B beta 448 of fibrinogen identified during
 RT structural studies of fibrinogen Baltimore II";
 RL Thromb. Res. 52:173-177(1988).
 RN [19]
 RP VARIANT ISE ARG-45.
 RX MEDLINE=91208409; PubMed=2018836;
 RA Yoshida N., Wada H., Morita K., Hirata H., Matsuda M., Yamazumi K.,
 RA Asakura S., Shirakawa S.;
 RT "A new congenital abnormal fibrinogen Ise characterized by the
 RT replacement of B beta glycine-45 by cysteine";
 RL Blood 77:1958-1963(1991).
 RN [20]
 RP VARIANT NAPLES THR-98.
 RX MEDLINE=92340664; PubMed=1634610;
 RA Koopman J., Haverkate F., Lord S.T., Grimbergen J., Mannucci P.M.;
 RT "Molecular basis of fibrinogen Naples associated with defective
 RT thrombin binding and thrombophilia. Homozygous substitution of B beta
 RT 68 Ala-->Thr.";
 RL J. Clin. Invest. 90:238-244(1992).
 RN [21]
 RP VARIANTS IUMIDEN CYS-44 AND NITMEGEN CYS-74.
 RX MEDLINE=92228809; PubMed=1565641;
 RA Koopman J., Haverkate F., Grimbergen J., Engesser L., Novakova I.,
 RA Kerst A.F.J.A., Lord S.T.;
 RT "Abnormal fibrinogens Iumiden (B beta Arg14-->Cys) and Nijmegen (B
 RT beta Arg44-->Cys) form disulfide-linked fibrinogen-albumin
 RT complexes";
 RL Proc. Natl. Acad. Sci. U.S.A. 89:3478-3482(1992).
 RN [22]
 RP VARIANT NEW YORK-1 39-GLY--LEU-102 DEL.
 RX MEDLINE=85157605; PubMed=3156856;
 RA Liu C.Y., Koehn J.A., Morgan F.J.;
 RT "Characterization of fibrinogen New York 1. A dysfunctional
 RT fibrinogen with a deletion of B beta(9-72) corresponding exactly to
 RT exon 2 of the gene";
 RL J. Biol. Chem. 260:4390-4396(1985).
 RN [23]
 RP VARIANTS GLU-2; LEU-265 AND IYS-478.
 RX MEDLINE=99318093; PubMed=10381209;
 RA Casgill M., Altschuler D., Iteland J., Sklar P., Ardle K., Patil N.,
 RA Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemes J., Zlaugra L.,
 RA Friedland L., Rolfe A., Warrington J., Lipschutz R., Daley G.Q.,
 RA Lander E.S.;
 RT "Characterization of single-nucleotide polymorphisms in coding regions
 RT of human genes";
 RL Nat. Genet. 22:231-238(1999).
 RN [24]
 RP ERRATUM.

RA Casgill M., Altschuler D., Ireland D., Sklar P., Ardlie K., Patil N.,
 RA Shaw N., Lane C.R., Lim E.P., Kalyanarman M., Nemes J., Ziaura L.,
 RA Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.O.,
 RA Lander E.S.;
 RL Nat. Genet. 23:373-373(1999).
 RN [25]
 RP VARIANTS CONGENITAL AFIBRINOGENEMIA ARG-383 AND ASP-430.
 RX MEDLINE=20128589; PubMed=1066289;
 RX Dusa S., Asselta R., Santagostino E., Zeinelli S., Simoncic T.,
 RA Malcovati G.M., Mannucci P.M., Turchini M.L.;
 RT "Missense mutations in the human beta fibrinogen gene cause
 RT congenital afibrinogenemia by impairing fibrinogen secretion.";
 RL Blood 95:1336-1341(2000).
 RN [26]
 RN VARIANT CONGENITAL AFIBRINOGENEMIA CYS-196.
 RP MEDLINE=21361164; PubMed=1146616;
 RX Lounes K.C., Lefkowitz J.B., Herschen-Edman A.H., Coates A.I.,
 RA Hantgan R.R., Lord S.T.;
 RT "The impaired polymerization of fibrinogen Longmont

[illegible]

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: July 30, 2004, 12:30:59 / Search time 44 Seconds
(without alignments)
3535.238 Million cell updates/sec

Title: US-10-018-386-2

Perfect score: 2666
Sequence: 1 MRPLCTWMLGLAANGAV.....GSYLKRVMMIRPNPTFH 493

Scoring table: BLOSUM62
Gapop 10.0, Gapext 0.5

Searched: 1017041 seqs, 315518202 residues

Total number of hits satisfying chosen parameters: 1017041

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database:

1: SPREMBL.25:*
2: sp_archaea:*
3: sp_bacteria:*
4: sp_fungi:*
5: sp_human:*
6: sp_invertebrate:*
7: sp_mammal:*
8: sp_mhc:*
9: sp_organelle:*
10: sp_plant:*
11: sp_ricent:*
12: sp_virus:*
13: sp_vertebrate:*
14: sp_unclassified:*
15: sp_virus:*
16: sp_bacteriap:*
17: sp_archaeap:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	2561	95.3	493	11	Q8BM09
2	2546	94.8	493	11	Q8BU03
3	1507.5	56.1	491	4	Q98841
4	1353	50.4	236	4	Q8N2J9
5	1296	48.3	332	11	Q9C2Z8
6	1245.5	46.4	484	13	Q7SXV7
7	1110	41.3	191	4	Q8NCH7
8	1094.5	40.7	470	4	Q8N199
9	1090.5	40.6	470	4	Q9BZ20
10	987	36.7	457	11	Q8R0Z6
11	929	34.6	200	11	Q8BMV1
12	906.5	33.7	197	13	Q98UE9
13	588.5	21.9	513	13	Q90Z19
14	571.5	21.3	498	11	Q8C2K6
15	565	21.0	498	6	Q9BDY8
16	558	20.8	461	4	Q8N5J9

17	552	20.6	269	11	Q8BU07	Q8BU07 mus musculus
18	550	20.5	269	11	Q8BU54	Q8BU54 mus musculus
19	549.5	20.5	431	6	Q95LU3	Q95LU3 macaca fasc
20	539.5	20.1	493	13	Q9DER2	Q9DER2 gallus gall
21	538	20.0	312	4	Q8N332	Q8N332 homo sapien
22	536.5	20.0	337	11	Q8R1Q3	Q8R1Q3 mus musculus
23	536.5	20.0	496	11	Q9D2D2	Q9D2D2 mus musculus
24	535	19.9	316	5	Q9U8W7	Q9U8W7 tachyples
25	534.5	19.9	314	11	Q8VC25	Q8VC25 mus musculus
26	530.5	19.8	308	5	Q9U8W6	Q9U8W6 tachyples
27	530.5	19.8	481	11	Q8K0E8	Q8K0E8 mus musculus
28	523.5	19.5	346	4	Q438Z7	Q438Z7 homo sapien
29	523.5	19.5	488	13	Q915B9	Q915B9 xenopus lae
30	522.5	19.5	441	13	Q9DER0	Q9DER0 gallus gall
31	518	19.3	343	13	Q7ZXL3	Q7ZXL3 xenopus lae
32	518	19.3	760	13	Q7ZTR1	Q7ZTR1 xenopus lae
33	513.5	19.1	489	13	Q90Z18	Q90Z18 brachydantio
34	511.5	19.0	407	13	Q9DER1	Q9DER1 gallus gall
35	510	19.0	235	6	Q287E3	Q287E3 papio cynoc
36	510	19.0	782	11	Q7T070	Q7T070 rattus norv
37	509.5	19.0	435	13	Q93568	Q93568 gallus gall
38	501.5	18.7	399	4	Q7Z664	Q7Z664 homo sapien
39	499.5	18.6	407	13	Q9PU54	Q9PU54 gallus gall
40	499	18.6	439	13	Q7SZ13	Q7SZ13 xenopus lae
41	498	18.5	321	13	Q7SYN8	Q7SYN8 xenopus lae
42	497.5	18.5	431	13	Q7ZYG7	Q7ZYG7 brachydantio
43	494	18.4	503	11	Q7TME5	Q7TME5 rattus norv
44	494	18.4	1358	4	Q92752	Q92752 homo sapien
45	494	18.4	1358	4	Q15568	Q15568 homo sapien

ALIGNMENTS

RESULT 1	Q8BM09	PRELIMINARY;	PRT;	493 AA.
ID	Q8BM09			
AC	Q8BM09			
AD	01-MAR-2003 (TRENBLREL. 23, Created)			
DT	01-MAR-2003 (TRENBLREL. 23, Last sequence update)			
DT	01-OCT-2003 (TRENBLREL. 25, Last annotation update)			
DE	Angiotensin-related protein 2 precursor.			
GN	ANGPTL2.			
OS	Mus musculus (Mouse).			
OC	Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;			
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.			
OX	NCBI_TaxID=10090;			
RN	(1)			
RP	SEQUENCE FROM N.A.			
RC	STRAIN=C57BL/6J; TISSUE=Thymus;			
RX	MEDLINE=22354683; PubMed=12466851;			
RA	The FANTOM Consortium.			
RA	the RIKEN Genome Exploration Research Group Phase I & II Team;			
RT	"Analysis of the mouse transcriptome based on functional annotation of			
RT	60,770 full-length cDNAs."			
RL	Nature 420:563-573(2002).			
DR	EMBL; AK037265; BAC29780.1; -			
DR	MGI; MGI:1347002; Angptl2.			
DR	InterPro; IPR002181; Fibrinogen_C.			
DR	Pfam; PF00147; fibrinogen_C; 1.			
DR	SMART; SM00186; Fbg; 1.			
DR	PROSITE; PS00514; FIBRIN_AG_C_DOMAIN; 1.			
DR	SEQUENCE 493 AA; 57105 MW; 2288484010746BF2 CRC64;			
SO	SEQUENCE			
Query Match	95.3%; Score 2561; DB 11; Length 493;			
Best local similarity	95.1%; Pred. No. 5.4e-171;			
Matches	469; Conservative 15; Mismatches 15; Indels 0; Gaps 0;			
QY	1 MRPLCTWMLGLAANGAVAGQEDGEGEGEESPREFTIYNRKAKGSGSDKCTYTFIV 60			
DB	1 MRPLCTWMLGLAANGAVAGQEDGEGEGEESPREFTIYNRKAKGSGSDKCTYTFIV 60			
QY	61 PQQRTVGAICVNSKEPEVLENRVHKQELLENNELLKQKQIETLQQLVVDGIVSEV 120			

```

Db 61 POORVTGAI CVNSKEPEVHL ENRVHKOELINNELLKOKQOIEITLQOLVEVDGIVSEV 120
Qy 121 KILRKESRRNNNSRVTLQYMWQLLHEIIRKRDNALELSOLENRIINQPADMLQLASKYKDE 180
Db 121 KILRKESRRNNNSRVTLQYMWQLLHEIIRKRDNALELSOLENRIINQPADMLQLASKYKDE 180
Qy 181 HKYOHATLTAHNOSEIIAOLEEHCOQVPASRPVOPPPAPPRVYQPPYRNIIINOISTN 240
Db 181 HKFOHLMHLAHNOSEVIAOLEEHCOQVPAPRPVOPPPAPPRVYQPPYRNIIINOISTN 240
Qy 241 EIOSDQNLKYLPPPLPTMPTLSLPSTDKPSGPMWDCIQALEDGHTSSIIYLKPEENTN 300
Db 241 EIOSDQNLKYLPPSLPTMPTLSLPSTDKPSGPMWDCIQALEDGHTSSIIYLKPEENTN 300
Qy 301 RLMQVWCDDQHDHDPGWTVIQRRLDGSVNFPRNMEYTKQGFNIDGEMYLGLENIYMLTNO 360
Db 301 RLMQVWCDDQHDHDPGWTVIQRRLDGSVNFPRNMEYTKQGFNIDGEMYLGLENIYMLTNO 360
Qy 361 GNYKLIVTMEDMSGRKVFAPFAEYASFLPESEYKRLGRYHGNAGDSFTWNGKQPTTLD 420
Db 361 GNYKLIVTMEDMSGRKVFAPFAEYASFLPESEYKRLGRYHGNAGDSFTWNGKQPTTLD 420
Qy 421 RDHDVYTGNCAYHQKGGWYNNACAHSNLNGVWYRGGHYRSRYQDGYVMAEFRGGSYLK 480
Db 421 RDHDVYTGNCAYHQKGGWYNNACAHSNLNGVWYRGGHYRSRYQDGYVMAEFRGGSYLK 480
Qy 481 VVMIMIRPNPTFH 493
Db 481 VVMIMIRPNPTFH 493

```

RESULT 2

```

ID 09J03 PRELIMINARY; PRT; 493 AA.
AC 09J03;
DT 01-OCT-2000 (TREMBlrel. 15, Created)
DT 01-OCT-2000 (TREMBlrel. 15, Last sequence update)
DT 01-JUN-2003 (TREMBlrel. 24, Last annotation update)
DE Angiotensin II type 1a receptor associated protein.
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OX NCB1_TaxID=10116;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Mistar-Kyoto; TISSUE=Vascular smooth muscle;
RA Guo D.F., Baranes D., Ono Y., Porter J.P., Abi-Jaoude E., Orlov S.N.,
RA Inagami T.;
RT "ARAP1 is required for recycling and resensitization of angiotensin II
RT type 1a receptor."
RL Submitted (JUN-1999) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF159049; AAF80364.1; -
DR HSSP; P02671; 1FZD.
DR GO; GO:0004872; F:receptor activity; IEA.
DR InterPro; IPR002181; Fibrinogen_C.
DR Pfam; PF00147; Fibrinogen_C; 1.
DR SMART; PS00514; FIBRIN_AG_C_DOMAIN; 1.
DR PROSITE; PS00514; FIBRIN_AG_C_DOMAIN; 1.
KM Receptor.
SQ SEQUENCE 493 AA; 57159 MW; 7C37652C47282341 CRC64;

```

```

Query Match 94.8%; Score 2546; DB 11; Length 493;
Best Local Similarity 94.5%; Pred. No. 66-170;
Matches 466; Conservative 9; Mismatches 18; Indels 0; Gaps 0;
Qy 1 MRPLCTVCMWLGILAMGAVAGQEDGFEGTEGSPREFYILNRYRAGESQDKCTYPTIV 60
Db 1 MRPLCTVCMWLGILATVGAIVTGPEDVBAEDSGREFYILNRYRGADESPPKCTYPTIV 60
Qy 61 POORVTGAI CVNSKEPEVHL ENRVHKOELINNELLKOKQOIEITLQOLVEVDGIVSEV 120
Db 61 POORVTGAI CVNSKEPEVHL ENRVHKOELINNELLKOKQOIEITLQOLVEVDGIVSEV 120

```

```

Qy 121 KILRKESRRNNNSRVTLQYMWQLLHEIIRKRDNALELSOLENRIINQPADMLQLASKYKDE 180
Db 121 KILRKESRRNNNSRVTLQYMWQLLHEIIRKRDNALELSOLENRIINQPADMLQLASKYKDE 180
Qy 181 HKYOHATLTAHNOSEIIAOLEEHCOQVPASRPVOPPPAPPRVYQPPYRNIIINOISTN 240
Db 181 HKFOHLMHLAHNOSEVIAOLEEHCOQVPAPRPVOPPPAPPRVYQPPYRNIIINOISTN 240
Qy 241 EIOSDQNLKYLPPPLPTMPTLSLPSTDKPSGPMWDCIQALEDGHTSSIIYLKPEENTN 300
Db 241 EIOSDQNLKYLPPSLPTMPTLSLPSTDKPSGPMWDCIQALEDGHTSSIIYLKPEENTN 300
Qy 301 RLMQVWCDDQHDHDPGWTVIQRRLDGSVNFPRNMEYTKQGFNIDGEMYLGLENIYMLTNO 360
Db 301 RLMQVWCDDQHDHDPGWTVIQRRLDGSVNFPRNMEYTKQGFNIDGEMYLGLENIYMLTNO 360
Qy 361 GNYKLIVTMEDMSGRKVFAPFAEYASFLPESEYKRLGRYHGNAGDSFTWNGKQPTTLD 420
Db 361 GNYKLIVTMEDMSGRKVFAPFAEYASFLPESEYKRLGRYHGNAGDSFTWNGKQPTTLD 420
Qy 421 RDHDVYTGNCAYHQKGGWYNNACAHSNLNGVWYRGGHYRSRYQDGYVMAEFRGGSYLK 480
Db 421 RDHDVYTGNCAYHQKGGWYNNACAHSNLNGVWYRGGHYRSRYQDGYVMAEFRGGSYLK 480
Qy 481 VVMIMIRPNPTFH 493
Db 481 VVMIMIRPNPTFH 493

```

RESULT 3

```

ID 095841 PRELIMINARY; PRT; 491 AA.
AC 095841;
DT 01-MAY-1999 (TREMBlrel. 10, Created)
DT 01-MAY-1999 (TREMBlrel. 10, Last sequence update)
DT 01-OCT-2003 (TREMBlrel. 25, Last annotation update)
DE Angiotensin Y1 (Df595C2.2) (Angiotensin-related protein 1 precursor)
DE (Angiotensin-like 1).
GN Df595C2.2 OR ARP1.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
OX NCB1_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Heart;
RA Kim T., Kwak H.-J., Ahn J.E., So J.N., Liu M., Koh K.N., Koh G.Y.;
RT "Molecular cloning and characterization of a novel angiotensin family
RT protein, angiotensin-3."
RL FEBS Lett. 443:353-356 (1999).
RN [2]
RP SEQUENCE FROM N.A.
RA Cobley V.;
RL Submitted (OCT-2000) to the EMBL/GenBank/DBJ databases.
RN [3]
RP SEQUENCE FROM N.A.
RA Ota T., Nishikawa T., Kawai Y., Suzuki Y., Ishii S., Saito K.,
RA Yamamoto J., Sugano S., Isogai T.;
RT "HRI human cDNA sequencing project."
RL Submitted (FEB-2001) to the EMBL/GenBank/DBJ databases.
RN [4]
RP SEQUENCE FROM N.A.
RA Ito Y., Oike Y., Yasunaga K., Matsumoto S., Ota T., Nishikawa T.,
RA Kawai Y., Isogai T., Hamada K., Saito Y., Miyata K., Masuno Y.,
RA Suda T.;
RT "Molecular cloning and characterization of novel angiotensin-related
RT protein (ARP4)."
RL Submitted (FEB-2001) to the EMBL/GenBank/DBJ databases.
RN [5]

```


RT "Functional annotation of a full-length mouse cDNA collection."
 RL NATURE 409:685-690(2001).
 DR EMBL, AK011976; BAB27951.1; -
 SQ SEQUENCE 332 AA; 37221 MW; 9A6B464FC613038 CRC64;

Query Match 48.3%; Score 1296; DB 11; Length 332;
 Best Local Similarity 91.6%; Pred. No. 1.1e-82;
 Matches 250; Conservative 9; Mismatches 14; Indels 0; Gaps 0;

QY 1 MRLCYTCWMLGLAANGAVAGGDEGFEETBEGSPREFFILNRYKRAGESQDKCTYFTIV 60
 DB 1 MRLCYTCWMLGLAANGAVAGGDEGFEETBEGSPREFFILNRYKRAGESQDKCTYFTIV 60
 QY 61 PQRVVGALCVNSKEPEVLENNRVKHOELNNELNKKOKROETTLQOLVKVGGIVSEVKLRKES 120
 DB 61 PQRVVGALCVNSKEPEVLENNRVKHOELNNELNKKOKROETTLQOLVKVGGIVSEVKLRKES 120
 QY 121 KLRKESRNNSRVTLQYMLLHEIIRKDNALFELSOLENRIINOTADMQLASRYKXKLE 180
 DB 121 KLRKESRNNSRVTLQYMLLHEIIRKDNALFELSOLENRIINOTADMQLASRYKXKLE 180
 QY 181 HKYQHTATLAHNOSEITIAOLEEHCORVPSPAPPPAPPPRYQPTNRIINQISTN 240
 DB 181 HKYQHTATLAHNOSEITIAOLEEHCORVPSPAPPPAPPPRYQPTNRIINQISTN 240
 QY 241 EIQSDONLKVLPPLPTMPTLTSLPSSIDKPSG 273
 DB 241 EIQSDONLKVLPPLPTMPTLTSLPSSIDKPSG 273

RESULT 6
 Q7SXV7 PRELIMINARY; PRT; 484 AA.

ID Q7SXV7
 AC Q7SXV7;
 DT 01-OCT-2003 (T-EMBLrel. 25, Created)
 DT 01-OCT-2003 (T-EMBLrel. 25, Last sequence update)
 DT 01-OCT-2003 (T-EMBLrel. 25, Last annotation update)
 DE Hypothetical protein (Fragment).
 OS Brachydanio rerio (Zebrafish); (Danio rerio).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes;
 OC Cyprinidae; Danio.
 OX NCBI_TaxID=7955;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=AB; TISSUE=Body;
 RX MEDLINE=22368257; PubMed=12477932;
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
 RA Hapkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh L.,
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
 RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
 RA Brownstein M.J., Ustin T.B., Toshiyuki S., Carninci P., Frange C.,
 RA Raha S.S., Loughran N.A., Peters G.J., Abramson R.D., Mullenb S.J.,
 RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
 RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
 RA Fahy J., Helton E., Kettelman W., Madan A., Rodriguez S., Sanchez A.,
 RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butcherfield Y.S.,
 RA Krzywinski M.I., Skalska U., Smalins D.E., Scherch A., Schein J.E.,
 RA Jones S.J., Marra M.A.;
 RT "Generation and initial analysis of more than 15,000 full-length human
 and mouse cDNA sequences."
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 RP SEQUENCE FROM N.A.
 RC STRAIN=AB; TISSUE=Body;
 RL Strausberg R.;
 DR Submitted (JUL-2003) to the EMBL/GenBank/DBJ databases.
 DR EMBL, BC055229; AAH55229.1; -.

KW Hypothetical protein.
 RT NON_TER 1
 SQ SEQUENCE 484 AA; 53444 MW; FDC397A6E741768 CRC64;

Query Match 46.4%; Score 1245.5; DB 13; Length 484;
 Best Local Similarity 49.0%; Pred. No. 6e-79;
 Matches 236; Conservative 85; Mismatches 138; Indels 23; Gaps 5;

QY 8 CWMLGLAANGAVAGGDEGFEETBEGSPREFFILNRYKRAGESQDKCTYFTIVPQRYVG 67
 DB 22 CWMLGLAANGAVAGGDEGFEETBEGSPREFFILNRYKRAGESQDKCTYFTIVPQRYVG 67
 QY 68 AICVNSKEPEVLENNRVKHOELNNELNKKOKROETTLQOLVKVGGIVSEVKLRKES 127
 DB 68 AICVNSKEPEVLENNRVKHOELNNELNKKOKROETTLQOLVKVGGIVSEVKLRKES 127
 QY 69 PICASRGPELPPERTRTDMSELQTLRSQREHETLRLMYDVGDVQVQEKLRKES 127
 DB 69 PICASRGPELPPERTRTDMSELQTLRSQREHETLRLMYDVGDVQVQEKLRKES 127
 QY 128 RNNSRVTLQYMLLHEIIRKDNALFELSOLENRIINOTADMQLASRYKXKLEHKYQHLA 187
 DB 128 RNNSRVTLQYMLLHEIIRKDNALFELSOLENRIINOTADMQLASRYKXKLEHKYQHLA 187
 QY 188 TLAHNOSEITIAOLEEHCORV--PSAPVPQPPAPPPRYQPTNRIINQISTN 245
 DB 188 TLAHNOSEITIAOLEEHCORV--PSAPVPQPPAPPPRYQPTNRIINQISTN 245
 QY 188 ERYNSQAEELLALBERCVRYGQSDPPELPPVLENT--PVFVRVNSNISNSWTEE 245
 DB 188 ERYNSQAEELLALBERCVRYGQSDPPELPPVLENT--PVFVRVNSNISNSWTEE 245
 QY 246 QNLKVLPPPLPTMPTLTSLPSSIDKPSGPRDCLQALEGCHDTSIYLVKPENTNLMQV 305
 DB 246 QNLKVLPPPLPTMPTLTSLPSSIDKPSGPRDCLQALEGCHDTSIYLVKPENTNLMQV 305
 QY 306 WCDGRHDPGGWTYIQSRLOSVPFNNWYKGFQNGFNGEYKLGENTYMLNQNAYL 365
 DB 306 WCDGRHDPGGWTYIQSRLOSVPFNNWYKGFQNGFNGEYKLGENTYMLNQNAYL 365
 QY 301 WCEHDVVRGWTLLQKRKDAVNFSDWQSYKGFSDVDGEMHGLDTYLSLGRQEEYKL 360
 DB 301 WCEHDVVRGWTLLQKRKDAVNFSDWQSYKGFSDVDGEMHGLDTYLSLGRQEEYKL 360
 QY 366 LVYTMEDWGRKVEFAEYAFSLPESEYKRLRLGRYHGNAGDSFTWNGKQFTLLDRHDV 425
 DB 366 LVYTMEDWGRKVEFAEYAFSLPESEYKRLRLGRYHGNAGDSFTWNGKQFTLLDRHDV 425
 QY 361 LVYEMDEWMEKXYAAVSSFLPEESQSYRLRLGLYGNAGDSFTSHNGQFTLLDRHDA 420
 DB 361 LVYEMDEWMEKXYAAVSSFLPEESQSYRLRLGLYGNAGDSFTSHNGQFTLLDRHDA 420
 QY 426 YTGNCAYQKQGWNNYNAACHASNNGWYRGGRHSYQGVYAEFRGGSYSLSKKYVMMI 485
 DB 426 YTGNCAYQKQGWNNYNAACHASNNGWYRGGRHSYQGVYAEFRGGSYSLSKKYVMMI 485
 QY 421 FSNQCAHFOKRGWYNACQNTLNGVSGGYRSPFGIFWADYGGFYSKWSYRMMI 480
 DB 421 FSNQCAHFOKRGWYNACQNTLNGVSGGYRSPFGIFWADYGGFYSKWSYRMMI 480
 QY 486 RP 487
 DB 481 RP 482

RESULT 7

Q8NCH7 PRELIMINARY; PRT; 191 AA.

ID Q8NCH7
 AC Q8NCH7;
 DT 01-OCT-2002 (T-EMBLrel. 22, Created)
 DT 01-OCT-2002 (T-EMBLrel. 22, Last sequence update)
 DT 01-MAR-2003 (T-EMBLrel. 23, Last annotation update)
 DE Hypothetical protein FLJ90245.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=AB; TISSUE=Body;
 RX MEDLINE=12477932; PubMed=12477932;
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
 RA Hapkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh L.,
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
 RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
 RA Brownstein M.J., Ustin T.B., Toshiyuki S., Carninci P., Frange C.,
 RA Raha S.S., Loughran N.A., Peters G.J., Abramson R.D., Mullenb S.J.,
 RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
 RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
 RA Fahy J., Helton E., Kettelman W., Madan A., Rodriguez S., Sanchez A.,
 RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butcherfield Y.S.,
 RA Krzywinski M.I., Skalska U., Smalins D.E., Scherch A., Schein J.E.,
 RA Jones S.J., Marra M.A.;
 RT "Generation and initial analysis of more than 15,000 full-length human
 and mouse cDNA sequences."
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 RP SEQUENCE FROM N.A.
 RC STRAIN=AB; TISSUE=Body;
 RL Strausberg R.;
 DR Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
 DR EMBL, AK074726; BA01164.1; -
 DR InterPro: IPR002181; Fibrinogen_C.
 DR Pfam: PF00147; Fibrinogen_C.1.
 DR SMART: SM00186; FBG.1.
 DR PROSITE: PS00514; FIBRIN_AG_C_DOMAIN; 1.
 KW Hypothetical protein.
 SQ SEQUENCE 191 AA; 22717 MW; D050F4E25A571F6A CRC64;

Query Match 41.3%; Score 1110; DB 4; Length 191;
 Best Local Similarity 100.0%; Pred. No. 5.3e-70;
 Matches 191; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 303 MOVWCDQRRDPCGWTYQIRLDGVSVPFNNMETYKQGFNIDGFWLGLNLYMTLNGN 362
 DB 1 MOVWCDQRRDPCGWTYQIRLDGVSVPFNNMETYKQGFNIDGFWLGLNLYMTLNGN 60

QY 363 YKLLVYTMEDWSGRKVAEYASFLBESYYKLRGRYHGNAGDSFTWNGKQFTLLDRD 422
 DB 61 YKLLVYTMEDWSGRKVAEYASFLBESYYKLRGRYHGNAGDSFTWNGKQFTLLDRD 120

QY 423 HGVYVNGCAHYQKGGWVNAACHSNLNGVYRGHYSRKYQDGYVMAEPRGGSYLKKVY 482
 DB 121 HGVYVNGCAHYQKGGWVNAACHSNLNGVYRGHYSRKYQDGYVMAEPRGGSYLKKVY 180

QY 483 MMIRPNPNTFH 493
 DB 181 MMIRPNPNTFH 191

RESULT 8

Q8N199 PRELIMINARY; PRT; 470 AA.
 AC Q8N199;
 DT 01-OCT-2002 (TREMBlrel. 22, Created)
 DT 01-OCT-2002 (TREMBlrel. 22, Last sequence update)
 DT 01-MAR-2003 (TREMBlrel. 23, Last annotation update)
 DE ARP3.
 GN ARP3.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
 NC NCB1_Taxid=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Matsumoto S., Saito Y., Masuho Y., Yasunaga K., Oike Y., Suda T.;
 RL Submitted (JAN-2001) to the EMBL/GenBank/DBJ databases.
 RN [2]
 RP SEQUENCE FROM N.A.
 RA Oike Y., Suda T.;
 RT "Molecular cloning of ARP3."
 RT Submitted (MAY-2002) to the EMBL/GenBank/DBJ databases.
 DR EMBL; AB054064; BAB91248.1; -
 DR InterPro; IPR002181; Fibrinogen_C.
 DR Pfam; PF00147; fibrinogen_C.1.
 DR SMART; SM00186; FBG; 1.
 DR PROSITE; PS00514; FIBRIN_AG_C_DOMAIN; 1.
 DR PROSITE; PS00514; FIBRIN_AG_C_DOMAIN; 1.
 SQ SEQUENCE 470 AA; 51694 MW; FAD20B1B00965239 CRC64;

Query Match 40.7%; Score 1094.5; DB 4; Length 470;
 Best Local Similarity 46.3%; Pred. No. 2.1e-68;
 Matches 213; Conservative 73; Mismatches 147; Indels 27; Gaps 7;

QY 44 YKRAESQDKCTYTFIVPQRTVGAICVNSKEPEVLLNRYKQELNELLKQKQRI 103
 DB 19 WARAQ--APRCTYTFVLPQKFTGAVCWGSPASTRATPEAANASBLALRMVGRHEELL 76

QY 104 ETLQOVLVVGIGTSEVKLRKESRNNSRYTQLYMQLHE-----IIRKDNAL 155
 DB 77 RELQRLAADAAGAVAGVRAALRKESRGLSARLQGLRQLOHEHGPAGDGAEPAAAL 136

QY 156 SQLENRIINQADMLQASKYKDLNRYKQHLATLANQSEIILQLEHQRVPASRPVQ 215
 DB 137 ALLGERVLNASEAQAARAFHQLDVKFRLEAQLVTQSSLIARLERLCPGAGAGQOQVL 196

QY 216 PPPAAPRVYQPPRYNRIINQISTN-----EIOSDNKLVLPPLPTPTLSLPS 267
 DB 197 PPPPLPVV---PV---RLVGSSTSDSRMLDPAEPQDQTORQOEPMASPMF--AGHPAV 249

QY 268 TDKPSGWRDCLQALEDHDTSSIIYVKEPENTNRLMQWCDQRRDPCGWTYQIRLDGVS 327

DB 250 PTKFVGPWQDCAEABARQAGHEQSGVYELRV--GHHVSVWCEQQLLEGGWTYQIRLDGVS 307
 QY 328 NFFNNMETYKQGFNIDGFWLGLNLYMTLNGVNYLLVYTMEDWSGRKVAEYASFLB 387
 DB 308 NFFTTQHYKAGFRRPDEYVWLGLEPYQLTSGDHLLVLLLEHWDGGRGARAHYDGSLE 367

QY 388 PESSEYKLRGRYHGNAGDSFTWNGKQFTLLDRDHDVYVNGCAHYQKGGWVNAACHSN 447
 DB 368 PESDHYKLRGQHYHGDGDSLSMNDKPFSTVDRDRDSYGNCLLYRGGWVNAACHSN 427

QY 448 LNVGYVYRGHYSRKYQDGYVMAEPRGGSYLKKVYMMIRP 487
 DB 428 LNVGYVYRGHYSRKYQDGYVMAEPRGGSYLKKVYMMIRP 467

RESULT 9

Q9B220 PRELIMINARY; PRT; 470 AA.
 AC Q9B220;
 DT 01-JUN-2001 (TREMBlrel. 17, Created)
 DT 01-JUN-2001 (TREMBlrel. 17, Last sequence update)
 DT 01-DEC-2001 (TREMBlrel. 19, Last annotation update)
 DE Angiotensin-related protein 5.
 GN ARP5.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
 NC NCB1_Taxid=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Samal B., Wu C., Dias P., Singh S.;
 RT "Molecular cloning of a novel angiotensin-related protein."
 RT Submitted (FEB-2000) to the EMBL/GenBank/DBJ databases.
 DR EMBL; AF230330; AAK06404.1; -
 DR HSSP; P02671; IPRD.
 DR InterPro; IPR002181; Fibrinogen_C.
 DR Pfam; PF00147; fibrinogen_C.1.
 DR SMART; SM00186; FBG; 1.
 DR PROSITE; PS00514; FIBRIN_AG_C_DOMAIN; 1.
 DR PROSITE; PS00514; FIBRIN_AG_C_DOMAIN; 1.
 SQ SEQUENCE 470 AA; 51693 MW; FD64AABDA6B6518F CRC64;

Query Match 40.6%; Score 1090.5; DB 4; Length 470;
 Best Local Similarity 46.1%; Pred. No. 4.1e-68;
 Matches 212; Conservative 74; Mismatches 147; Indels 27; Gaps 7;

QY 44 YKRAESQDKCTYTFIVPQRTVGAICVNSKEPEVLLNRYKQELNELLKQKQRI 103
 DB 19 WARAQ--APRCTYTFVLPQKFTGAVCWGSPASTRATPEAANASBLALRMVGRHEELL 76

QY 104 ETLQOVLVVGIGTSEVKLRKESRNNSRYTQLYMQLHE-----IIRKDNAL 155
 DB 77 RELQRLAADAAGAVAGVRAALRKESRGLSARLQGLRQLOHEHGPAGDGAEPAAAL 136

QY 156 SQLENRIINQADMLQASKYKDLNRYKQHLATLANQSEIILQLEHQRVPASRPVQ 215
 DB 137 ALLGERVLNASEAQAARAFHQLDVKFRLEAQLVTQSSLIARLERLCPGAGAGQOQVL 196

QY 216 PPPAAPRVYQPPRYNRIINQISTN-----EIOSDNKLVLPPLPTPTLSLPS 267
 DB 197 PPPPLPVV---PV---RLVGSSTSDSRMLDPAEPQDQTORQOEPMASPMF--AGHPAV 249

QY 268 TDKPSGWRDCLQALEDHDTSSIIYVKEPENTNRLMQWCDQRRDPCGWTYQIRLDGVS 327
 DB 250 PTKFVGPWQDCAEABARQAGHEQSGVYELRV--GHHVSVWCEQQLLEGGWTYQIRLDGVS 307

QY 328 NFFNNMETYKQGFNIDGFWLGLNLYMTLNGVNYLLVYTMEDWSGRKVAEYASFLB 387
 DB 308 NFFTTQHYKAGFRRPDEYVWLGLEPYQLTSGDHLLVLLLEHWDGGRGARAHYDGSLE 367

QY 388 PESSEYKLRGRYHGNAGDSFTWNGKQFTLLDRDHDVYVNGCAHYQKGGWVNAACHSN 447
 DB 368 PESDHYKLRGQHYHGDGDSLSMNDKPFSTVDRDRDSYGNCLLYRGGWVNAACHSN 427

QY 448 LNCVWYRGHYSRYODGYMAEFRCGSYSLKVMYMR 487
 DB 428 LNCVWHGHYSRYODGYMAEFRCGASLSKRAMLIRP 467

RESULT 10
 Q8R026 PRELIMINARY; PRT; 457 AA.

ID Q8R026; AC Q8R026; DT 01-JUN-2002 (TEMBLrel. 21, Created)
 DT 01-JUN-2002 (TEMBLrel. 21, Last sequence update)
 DT 01-MAR-2003 (TEMBLrel. 23, Last annotation update)
 DE Similar to angiotensin-related protein 5 (ARP3).
 GN 6330404E1IRIK OR ARP3.
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 CC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 NX NCBI_TaxID=10090;
 RN (1)
 RP SEQUENCE FROM N.A.
 RC TISSUE=Liver;
 RA Strausberg R.;
 RL Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
 RN (2)
 RP SEQUENCE FROM N.A.
 RA Watsmota S., Salto Y., Masuho Y., Yasunaga K., Oike Y., Suda T.;
 RL Submitted (JAN-2001) to the EMBL/GenBank/DBJ databases.
 RN (3)
 RP SEQUENCE FROM N.A.
 RA Oike Y., Suda T.;
 RT "Molecular cloning of ARP3."
 RL Submitted (MAY-2002) to the EMBL/GenBank/DBJ databases.
 DR EMBL; BC025904; AAH25904.1; -;
 DR EMBL; AB054065; BAB91249.1; -;
 DR MGI; MGI:1917976; 6330404E1IRIK.
 DR InterPro; IPR002181; Fibrinogen_C.
 DR Pfam; PF00147; fibrinogen_C.1.
 DR PROSITE; PS00514; FIBRIN_AG_C_DOMAIN; 1.
 SQ SEQUENCE 457 AA; 51095 MW; B7C4289E3FECC3E CRC64;

Query Match 36.7%; Score 987; DB 11; Length 457;
 Best Local Similarity 44.0%; Pred. No. 6.9e-61;
 Matches 195; Conservative 78; Mismatches 146; Indels 24; Gaps 7;

QY 53 KTYTFIVPQGVYTAICVNSKEPEVLENRHKELEINNELIKORQJETIQOLVKV 112
 DB 26 RCRVTVLSPQKATSAVCGSSSEATQ-----DSELATLWRGHEHLLRALQRAAE 77
 QY 113 DGIIVSEVLLKESRNMNSRYTQLYMQLHEILIRKDNAL-----LSQLENRLINQAD 168
 DB 78 GGALADDEVRAUREHSLTINTRLGQLRAQLQGEARAPDLGAPPAALGLARLDAEAE 137
 QY 169 MQLASKYKDLHKYQHLATLAHNOSEIIAOLEBHCQVPSARPVPQPPAP---PRV 224
 DB 138 ARRTTARQQDAQLEHAQLMSCHSLGRIGRACAPREGQQQVLPPLAPVPLSLV 197
 QY 225 YQPTFNRLINQISTNEIQSDONLKVLPPLPTMPT-LTSPSSDKSGPMDCLQALE 283
 DB 198 GSASVTSRLQD--TPHQREGSLRQGPSSLPFTGLHAPVT---RVGWRRCALAHG 252
 QY 284 DGHDTSSILYKPEENTLMQVCDQRHDPGGVTVIQRLDGSVNFRRMWTYKQGFNI 343
 DB 253 AGHMOSGYVDFR--LGRVVAVVWCQQOEGGQMTVIGRQDGSVNFRRMWHYVAGGRP 310
 QY 344 DGEVYLGLENYVWLNQGNKYLLVTMEDMSGRKVFAYASRLPESSEYKRLRGVHGN 403
 DB 311 ESEVYLGLEPVHGVTSRQDHELLILLEMGGAARAHDSLSLSPESHVRLRGVYHD 370
 QY 404 AGDSFTWNGKQFTLLDRDHDVYTGNCAYQKGGWYNACAHSNLNGWYRGHYSRYQ 463
 DB 371 AGDSLSMHNDRKPSFVDRDSDYSNCALYHRCGWYHACAHSNLNGWYRGHYSRYQ 430
 QY 464 DGVTYAEFRGGSYSLSKVMYMR 486

DB 431 DGVTYAEFRGGAYSLSKAVMLTR 453

RESULT 11
 Q8BMV1 PRELIMINARY; PRT; 200 AA.

ID Q8BMV1; AC Q8BMV1; DT 01-MAR-2003 (TEMBLrel. 23, Created)
 DT 01-MAR-2003 (TEMBLrel. 23, Last sequence update)
 DT 01-OCT-2003 (TEMBLrel. 25, Last annotation update)
 DE Weakly similar to angiotensin Y1 (fragment).
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 CC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 NX NCBI_TaxID=10090;
 RN (1)
 RP SEQUENCE FROM N.A.
 RC STRAIN=CS7BL/6J; TISSUE=Body;
 RX MEDLINE=22354683; PubMed=12466851;
 RA The FANTOM Consortium,
 RL the RIKEN Genome Exploration Research Group Phase I & II Team;
 RT "Analysis of the mouse transcriptome based on functional annotation of
 60,776 full-length cDNAs."
 RL Nature 420:563-573(2002).
 DR EMBL; AK027978; BAC25687.1; -;
 DR InterPro; IPR002181; Fibrinogen_C.
 DR Pfam; PF00147; fibrinogen_C.1.
 DR SMART; SM00186; FBG; 1.
 DR PROSITE; PS00514; FIBRIN_AG_C_DOMAIN; 1.
 RN NON TIR
 FT SEQUENCE 200 AA; 22518 MW; E1FE92E20171F54 CRC64;

Query Match 34.6%; Score 929; DB 11; Length 200;
 Best Local Similarity 77.7%; Pred. No. 2.6e-57;
 Matches 153; Conservative 25; Mismatches 19; Indels 0; Gaps 0;

QY 291 IYVKEENTRLMOWCDDQHRDGGTVYQRLDGSVNFRRMWTYKQGFNIDGHYMG 350
 DB 2 IYVKEENTRLMOWCDDQHRDGGTVYQRLDGSVNFRRMWTYKQGFNIDGHYMG 61
 QY 351 LENIYVLTQGNKYLLVTMEDMSGRKVFAYASRLPESSEYKRLRGVHGNAGDSFTW 410
 DB 62 LDNIYVLTQGNKYLLVTMEDMSGRKVFAYASRLPESSEYKRLRGVHGNAGDSFTW 121
 QY 411 HNGKQFTLLDRDHDVYTGNCAYQKGGWYNACAHSNLNGWYRGHYSRYQDGYMAE 470
 DB 122 HNGKQFTLLDRDHDVYTGNCAYQKGGWYNACAHSNLNGWYRGHYSRYQDGYMAE 181
 QY 471 FRGGSYSLSKVMYMR 487
 DB 182 YRGGSYSLSKVMYMR 198

RESULT 12
 Q98U9 PRELIMINARY; PRT; 197 AA.

ID Q98U9; AC Q98U9; DT 01-JUN-2001 (TEMBLrel. 17, Created)
 DT 01-JUN-2001 (TEMBLrel. 17, Last sequence update)
 DT 01-DEC-2001 (TEMBLrel. 19, Last annotation update)
 DE Fibrinogen-like protein (fragment).
 OS Xenopus laevis (African clawed frog).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 CC Amphibia; Batrachia; Anura; Mesobatrachia; Pipidae; Pipidae;
 OC Xenopodinae; Xenopus.
 NX NCBI_TaxID=8355;
 RN (1)
 RP SEQUENCE FROM N.A.
 RA Amano T., Yoshizato K.;
 RT "Isolation of genes involved in intestinal remodeling during anuran
 metamorphosis."
 RL Submitted (JUL-1999) to the EMBL/GenBank/DBJ databases.

DR EMBL; AF170323; AAK1499.1; -.
DR HSSP; P02671; 1PZD.
DR InterPro; IPR002181; Fibrinogen_C.
DR Pfam; PF00147; fibrinogen_C.1.
DR SMART; SM00186; FBG; 1.
FT NON_TER
FT 1
FT 197
SQ SEQUENCE 197 AA; 22954 MW; 3409C6314E853896 CRC64;

Query Match 33.7%; Score 906.5; DB 13; Length 197;
Best Local Similarity 84.9%; Pred. No. 9,6e-56;
Matches 163; Conservative 11; Mismatches 15; Indels 3; Gaps 2;

QY 198 AQLSEHCQRP--SARVPQPPPAAPRVYQPTNRIINOISTNEIOSDONLKYLPPL 255
DB 1 SOLSEHCRRKVPPTQKPLPQ--PPQPNKYNPPNRIINOISTNEIOGDONLKYLPPL 59
QY 256 PTMPLTSLPSSTDKSPGWRDCLALPDGHTSIIYVKPENTRMLQWCDORHDPG 315
DB 60 PTMPLTSTNSSTDKSPGWRDCLALPDGHTSIIYVKPENTRMLQWCDORHDPG 119
QY 316 WTVIQRRLDGSVNFPRNMEYKQGFNIDGEYMLGLENIYMLTNQGNKLLVTMEDWSGR 375
DB 120 WTVIQRRLDGSVNFPRNMEYKLGFGNIGHGEYMLGLENIYMLTNQGNKLLITMEDWSGR 179
QY 376 KYFAFYASFRLE 387
DB 180 KMFAFYASFRLE 191

RESULT 13

Q80219 PRELIMINARY; PRT; 513 AA.
ID 090219
AC Q90219;
DT 01-DEC-2001 (TREMBlrel. 19, Created)
DT 01-DEC-2001 (TREMBlrel. 19, Last sequence update)
DT 01-MAR-2003 (TREMBlrel. 23, Last annotation update)
DE Angiopoietin-1.
GN ANGPT1 OR ANG1.
OS Brachydanio rerio (Zebrafish) (Danio rerio).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes;
OC Cyprinidae; Danio.
OX NCBI_TaxID=7955;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=21391693; PubMed=11500985;
RA Pham V.N., Roman B.L., Weinstein B.M.;
RT "Isolation and expression analysis of three zebrafish angiopoietin
genes.";
RT Dev. Dyn. 221:470-474 (2001).
DR EMBL; AF379602; AAK93347.1; -.
DR ZFIN; ZDB-GENE-010817-1; angpt1.
DR InterPro; IPR002181; Fibrinogen_C.
DR Pfam; PF00147; fibrinogen_C.1.
DR SMART; SM00186; FBG; 1.
DR PROSITE; PS00514; FIBRIN AG_C DOMAIN; 1.
SQ SEQUENCE 513 AA; 58360 MW; 0627777A39847D8B CRC64;

Query Match 21.9%; Score 588.5; DB 13; Length 513;
Best Local Similarity 30.5%; Pred. No. 6,2e-33;
Matches 163; Conservative 87; Mismatches 200; Indels 85; Gaps 19;

QY 9 WVLGF-LIAMGAVA---GQDGFEGTEEGSPREFIYLN-----RYKRAGESQDKTYTFI 59
DB 2 WVGCLFLALLVVAOCGVQKTDIGWSTPKS-----NSSGRRTYHRIOHQ--CSYTFI 55
QY 60 VPOQRTGAIQVNSKEPEVLENNRYHQ---ELELNELLIKQKQRIETLQO-LVKYDG 114
DB 56 LDES--DGNTCREFFSGTAYNANALQRDAPQPEALSNQKIQQLHEWVENYTWQLOKLEN 113
QY 115 GIVSEYKL-----LRKESRMNSRVLTQYMLLHEI-----IR 147

DB 114 YIKDNKTEWVOUQGSVAHNHTAMLEMGTSILISQTAOBTIKLTVEYVNLQTSRLBIQ 173
QY 148 KRDALELSQLENRIINQTAQMDLQASKYKDLERKQHLATLANOSEIIAQLSEHCQRPV 207
DB 174 LLENSLSTNLEKQMIQINEIKIHDKNGFLEKNOELE-----DRRQEL 220
QY 208 PSARVPQPPPAAPRVYQPTNRIINOISTNEIOSDONLKYLPPLPTMPLTSL 264
DB 221 ESILRTEKSDIQALVSR--QSSVIRELENQLSRATGNSTALQROQODLMEBSRLSLCAK 278
QY 265 -----PSSTDK--DSGWRDCLQALPDGHTSIIYL--VKPENTRMLQWCDORHDP 313
DB 279 DATAVEPNSTKQADERKRRDCAQLYQAGFQNGVYTTINISQETRK--YVCWESAG 335
QY 314 GGVTVIQRLDGSVNFPRNMEYKQGFNIDGEYMLGLENIYMLTNQGNKLLVTMEDWS 373
DB 336 GGVTVIQRLDGTVDYFQKTWKYKMGFGSGVSGEHLGNFVHVLTNQROHGLRVELSDWD 395
QY 374 GRKYFAFYASFRLEPESEYKLLGRYHGNAG--DSFTWANGKQFTLDRHDHYVGNCA 431
DB 396 GHQAFSQYDSFHDSEKQKRLFLKTHSGTAGSQSLAVH-GADFTKVDNDNCTCKA 454
QY 432 HYQKGGWYNACAHSNLNGVYRGHYRSRYQGVYMAERGGSYSLKRYVMIR 486
DB 455 LMSGGWYDACGPNLNGVYRQGHVQKF-NGIKMHYEKGPSYSLRSTVMIR 508

RESULT 14

Q8C2K6 PRELIMINARY; PRT; 498 AA.
ID Q8C2K6
AC Q8C2K6;
DT 01-MAR-2003 (TREMBlrel. 23, Created)
DT 01-MAR-2003 (TREMBlrel. 23, Last sequence update)
DT 01-OCT-2003 (TREMBlrel. 25, Last annotation update)
DE Angiopoietin.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RX STRAIN=NOD; TISSUE=Thymus;
RX MEDLINE=22354683; PubMed=12466851;
RA The FANTOM Consortium.
RT "Analysis of the mouse transcriptome based on functional annotation of
60,770 full-length cDNAs.";
RL Nature 420:563-573 (2002).
DR EMBL; AK088439; BAC40354.1; -.
DR InterPro; IPR002181; Fibrinogen_C.
DR Pfam; PF00147; fibrinogen_C.1.
DR SMART; SM00186; FBG; 1.
DR PROSITE; PS00514; FIBRIN AG_C DOMAIN; 1.
SQ SEQUENCE 498 AA; 57475 MW; 285D957468C5D800 CRC64;

Query Match 21.3%; Score 571.5; DB 11; Length 498;
Best Local Similarity 29.7%; Pred. No. 9,2e-32;
Matches 149; Conservative 83; Mismatches 175; Indels 95; Gaps 14;

QY 43 RYKRAGESQDKTYTFIVP-----QQVTVGAIQVNSK--RP-----EVL 79
DB 32 RYNIHQGQ--CAVTFILPEHDGNCRESATQNTNNAQDADHVEBDSQQLQHLHEV 89
QY 80 LENRVKQELLELNELIK-QKQRIETLQO-----LVKVDGIVSEYKLLRKESRN 129
DB 90 MEN--YTQWLQKLENYIVENWKSMAQIQNAVONHTATMLEIGTSLSGT--AEQTRK 144
QY 130 MNSRVTLQYMLLHEIRKRDNALELSQLENRIINQTAQMDLQASKYKDLERK 163
DB 145 LTVDETQVNLQTSRLBIQLLENSLSTYKLEKQLLQQTNELIKHEKNSLLEHKILEMEGK 204
QY 184 -----CHLATLANOSEIIAQLSEHCQRPVAPQPPPAAPRVYQPTYN 231

```

Db 205 HHEEDLTKEEKENIQLVSRQTFIIQLEKQLSPA-----240
Qy 232 RIINOISTEIOSDONKXLPPLPTMPLTSS---LPSSDTPKSPGWRDCLQALDGDH 287
Db 241 -----TNNNSILOKQOLEMDAVHNLVSLCTKEGVLLKGGKKEEKPRDCAVYQAGFN 295
Qy 288 TSSIVYKRENTNRLMQWCDQGRHDPGWTIVQRLDGSVNFPRWERYKQGFNDGEX 347
Db 296 KSGITVITYNNPEPKVFCNMDVNGGWTIVIQHEDSLDFQRMKSEYKMGFNPSEY 355
Qy 348 WGLENIYWLITNOGNKYLVTMEDWSGRKVAEYASFLEPSEYKRLGRYHGNAG-- 405
Db 356 WIGNERIFAITSQORQWMLRIELMDWEGNRAYSQYDRFPHGNKQNYRLYLKGHTJAKQ 415
Qy 406 DSFTWNGKQFTLLDRHDVYTGNCAHYQKGGWYNACASHNLNCAVTRGHHYSRYDG 465
Db 416 SSLILH-GADFTKADNDNMCCKCALMLTGWMPDAGPSNLNMFYTAQNHKL-NG 473
Qy 466 VYMAEPFGSGSYLSKKYVMYIRP 487
Db 474 IKMHYFKGPSYSLRSTTMYIRP 495

```

RESULT 15

```

Q9BDY8
AC Q9BDY8: PRELIMINARY: PRT: 498 AA.
DT 01-JUN-2001 (TREMblrel. 17, Created)
DT 01-JUN-2001 (TREMblrel. 17, Last sequence update)
DT 01-DEC-2001 (TREMblrel. 19, Last annotation update)
DE Angiopoietin 1.
OS Sus scrofa (Pig).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.
OX NCBI_TaxID=9823;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=2153163; PubMed=11230987;
RA Kim I., Moon S.O., Han C.Y., Pak Y.K., Moon S.K., Kim J.Y., Koh G.Y.;
RT "The angiopoietin-tie2 system in coronary artery endothelium prevents
RT oxidized low-density lipoprotein-induced apoptosis.";
RL Cardiovasc. Res. 49:872-881(2001).
DR EMBL; AF235227; AK14992.1; -.
DR HSSP; P02671; 1F2D.
DR InterPro; IPR002181; Fibrinogen_C.
DR Pfam; PF00147; fibrinogen_C; 1.
DR SMART; SM00186; FBG; 1.
DR PROSITE; PS00514; FIBRIN_AG_C DOMAIN; 1.
SQ SEQUENCE 498 AA; 57413 MW; A8C1C8BF66061876 CRC64;

```

Query Match

21.0%; Score 565; DB 6; Length 498;

Best Local Similarity 28.9%; Pred. No. 2,6e-31;

Matches 151; Conservative 92; Mismatches 195; Indels 84; Gaps 16;

```

Qy 14 LAAMGAVNGDEGFGTEGSPREFTIYLNRYKAGESODKCTYFTIVPQ-----QRYTG 67
Db 10 LAAILTHIGCSNQRSPENG-----RRYRIQHGO-CAYTFILPEHDGNCRESSTTD 60
Qy 68 ALCVNSKE---PEV-----LLENRVAKOLELLENNELK-QKQIETTLQO- 108
Db 61 QYNTNALQRDAPHVQDPSQKLOHLEHVEN--YTQWLKINENYVENMKSEWAQIQON 118
Qy 109 -----LVKVDGIVSEVKLLRKESENNNSRVYQLYMQLLHEIRKRDVALSOLDN 160
Db 119 AVQNHATATMLEIGTSLSQT--AEQTRKLTIDVETQVNLQTSRLIQLENSLSYKLEK 175
Qy 161 RIINOTADMLQASKYKDLHENYCHLATHANQSEIIQALEHSCQVPSARVPQPPAA 220
Db 176 QLLQGTNELKHEKNSLHEKILMEGKHKEELDTLKEEKENIQLVSR----- 225
Qy 221 PPRVQPTNYRIINQISTNE--IOSDONKXLPPLPTMPLTSLPSSTDXPS----- 272
Db 226 --QTYIIQELKQLNRATTNNSVLQKQO-----LEIMDTVHNLVNLCTKEGVLLKGG 275

```

```

Qy 273 -----GWRDCLQALDGDHDTSSIYVKRENTNRLMQWCDQGRHDPGWTIVQRLDGSV 327
Db 276 KKEEVKPFPRDCAVYQAGFNKSGITVITYINNPEPKVFCNMDLNGGWTIVIQHREDGSL 335
Qy 328 NFRNMEITYQGFNDGEYWLLENIYWLITNOGNKYLVTMEDWSGRKVAEYASFLE 387
Db 336 DFORMKKEYMGGNFSGEYWLGNERTFAITSQRYTLTTELMDEGNRAYSQYDRFHIG 395
Qy 388 PSEYKRLGRYHGNAG--DSFTWNGKQFTLLDRHDVYTGNCAHYQKGGWYNACAH 445
Db 396 NEKQNYRLYLKGHTJAKQSSILH-GADFTKADNDNMCCKCALMLTGWMPDAGCP 454
Qy 446 SNLNGVWYRGHYSRYQDGVYMAEPFGSGSYLSKKYVMYIRP 487
Db 455 SNLNGWFTYTAQNHKL-NGIKMHYFKGPSYSLRSTTMYIRP 495

```

Search completed: July 30, 2004, 12:37:32
Job time : 46 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 6, 2004, 12:25:23 ; Search time 860 Seconds
(without alignments)

10734.110 Million cell updates/sec

Title: US-10-018-386-1

Perfect score: 2173
Sequence: 1 gaaatgagctgctgcgga.....aaaaaaaaaaaaaaaaaaaa 2173

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 3373863 seqs, 2124039041 residues

Total number of hits satisfying chosen parameters: 6747726

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Database : N_Geneseq_25Jan04:*

1: geneseqn1980s:*\n2: geneseqn1990s:*\n3: geneseqn2000s:*\n4: geneseqn2001as:*\n5: geneseqn2001bs:*\n6: geneseqn2002as:*\n7: geneseqn2003as:*\n8: geneseqn2003bs:*\n9: geneseqn2003cs:*\n10: geneseqn2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	2173	100.0	2173	4	AAf29738 Human ang
2	2146.2	98.8	2288	3	AA252359 NSBO gene
3	2146.2	98.8	2288	6	AA142455 Human mat
4	2134.2	98.1	2154	3	AA172856 CDNA c10n
5	2132.6	98.1	2290	2	AAx36341 Human T1E
6	2132.6	98.1	2290	4	AAc86961 Nucleotid
7	2132.6	98.1	2290	4	AA821377 Human CDN
8	2132.6	98.1	2290	6	AB865529 Human T1E
9	2132.6	98.1	2290	6	AA031563 Human T1E
10	2132.6	98.1	2290	7	ACD23986 Novel hum
11	2132.6	98.1	2290	7	ACd42312 Novel hum
12	2132.6	98.1	2290	7	ACa67117 CDNA enco
13	2132.6	98.1	2290	7	ACa03736 CDNA enco
14	2132.6	98.1	2290	7	ACa04921 Novel hum
15	2132.6	98.1	2290	7	ABx89274 DNA enco
16	2132.6	98.1	2290	7	ACd41928 Human sec
17	2132.6	98.1	2290	7	ACa60451 Novel hum
18	2132.6	98.1	2290	7	ACa04441 Novel hum
19	2132.6	98.1	2290	7	ACa04157 Human CDN
20	2132.6	98.1	2290	8	ACa65582 Human CDN
21	2132.6	98.1	2290	8	ADA45786 Novel hum
22	2132.6	98.1	2290	8	ADA76217 Human PRO
23	2132.6	98.1	2290	8	ADA18867 Human PRO

24	2132.6	98.1	2290	8	ADA61490 Homo sapi
25	2132.6	98.1	2290	8	ADB19275 Novel hum
26	2132.6	98.1	2290	8	ADB27816 CDNA enco
27	2132.6	98.1	2290	8	ADA86295 Novel hum
28	2132.6	98.1	2290	8	ADB15859 Human PRO
29	2132.6	98.1	2290	8	ADA47645 Human PRO
30	2132.6	98.1	2290	8	ADA67440 Human PRO
31	2132.6	98.1	2290	8	ADB30447 CDNA enco
32	2132.6	98.1	2290	8	ADA85743 Novel hum
33	2132.6	98.1	2290	8	ADA96955 Human PRO
34	2132.6	98.1	2290	8	ADA79259 Human PRO
35	2132.6	98.1	2290	8	ADA87398 Novel hum
36	2132.6	98.1	2290	8	ADA16600 Human PRO
37	2132.6	98.1	2290	8	ADA91692 Novel hum
38	2132.6	98.1	2290	8	ADB14755 Human PRO
39	2132.6	98.1	2290	8	ADA47327 Human sec
40	2132.6	98.1	2290	8	ADB18716 Novel hum
41	2132.6	98.1	2290	8	ADA93931 Human PRO
42	2132.6	98.1	2290	8	ADB19827 Novel hum
43	2132.6	98.1	2290	8	ADB31319 Human PRO
44	2132.6	98.1	2290	8	ACD98557 Novel hum
45	2132.6	98.1	2290	8	ADA74393 Human PRO

ALIGNMENTS

RESULT 1	AAf29738	standard; CDNA; 2173 BP.
XX	AAf29738;	
XX	05-APR-2001	(first entry)
DE	Human angiotensin-7 (ANG-7) coding sequence.	
XX	Human; angiotensin-7; ANG-7; angiogenesis; cancer; wound healing;	
KW	diabetic retinopathy; macular degeneration; cardiovascular disease;	
KV	reproductive system; ss.	
OS	Homo sapiens.	
XX	WC0200102434-A1.	
PD	11-JAN-2001.	
XX	30-JUN-2000; 2000WC-US018170.	
PF	02-JUL-1999; 99EP-00113502.	
XX	(FARB) BAYER AG.	
PA	Friedrich G, Hagen G, Wick M, Zubov D, Dubois-Stringfellow N;	
PI	WPI; 2001-123103/13.	
DR	P-PSDB; AAB66340.	
XX	Inhibiting angiogenesis for treating cancer, wound healing, diabetic	
PT	retinopathies, macular degeneration, cardiovascular diseases, by	
PT	administering angiotensin-7 polypeptide or its fragments.	
PS	Claim 13; Fig 1; 86pp; English.	
XX	The present invention describes a method of preventing angiogenesis by	
CC	administering angiotensin-7 (ANG-7) nucleic acid, protein, fragment or	
CC	derivative. This can be used in the treatment of angiogenesis-related	
CC	diseases, including cancer, wound healing, macular degeneration,	
CC	cardiovascular diseases, diabetic retinopathies, infections and	
CC	conditions of the reproductive system such as regulation of placental	
CC	vascularization, and also may be used as an abortifacient. Note: in the	
CC	specification, ANG-7 is also referred to as being angiotensin-7	

QY	1021	CCCCCGCTGCCCCCGCCGGGCTTACCAACCAACCACCTTAACCGCATATATCAACAGA	108
Db	1021	CCCCCGCTGCCCCCGCCGGGCTTACCAACCAACCACCTTAACCGCATATCAACAGA	108
QY	1081	TCTCTACCAAGAGATCCAGAGTGCAGAACTGAAGGTCTGCCACCCCTCTGCCA	1140
Db	1081	TCTCTACCAAGAGATCCAGAGTGCAGAACTGAAGGTCTGCCACCCCTCTGCCA	1140
QY	1141	CTATGCCACTCTCAACAGCCTCCCATTTCCATCCGACAAACCGTTCGGGCCCATAGAGAG	1200
Db	1141	CTATGCCACTCTCAACAGCCTCCCATTTCCATCCGACAAACCGTTCGGGCCCATAGAGAG	1200
QY	1201	ACTGCTGTCAGAGCCCTGGAGAGTGGCCAGACACAGCTCCATCTACTCTGATGAAGCCGG	1260
Db	1201	ACTGCTGTCAGAGCCCTGGAGAGTGGCCAGACACAGCTCCATCTACTCTGATGAAGCCGG	1260
QY	1261	AGAACACCAACCCGCTCATGCAAGTGTGTGTGCCACAGAGACAGACCCCGGGGGCTGGA	1320
Db	1261	AGAACACCAACCCGCTCATGCAAGTGTGTGTGCCACAGAGACAGACCCCGGGGGCTGGA	1320
QY	1321	CCGATCATCAGAGACGCTGTAGTGGCTGTGTAATCTTTGAGAACTGGAGAGAGTACA	1380
Db	1321	CCGATCATCAGAGACGCTGTAGTGGCTGTGTAATCTTTGAGAACTGGAGAGAGTACA	1380
QY	1381	AGCAAGGTTTGGGAACATTGACGGCCGAATCTGGCTGGGCTTGGAGAACTTTACTGGC	1440
Db	1381	AGCAAGGTTTGGGAACATTGACGGCCGAATCTGGCTGGGCTTGGAGAACTTTACTGGC	1440
QY	1441	TGACGAACCAAGGCAACTACAACTCCCTGGTGAACATGAGAGACTGGTCCGACGCAAG	1500
Db	1441	TGACGAACCAAGGCAACTACAACTCCCTGGTGAACATGAGAGACTGGTCCGACGCAAG	1500
QY	1501	TCTTTGCAAAATACCCAGATTCCGCTCGACCTGAGACCTGAGACGAGATTTATTAAGCTGGGC	1560
Db	1501	TCTTTGCAAAATACCCAGATTCCGCTCGACCTGAGACCTGAGACGAGATTTATTAAGCTGGGC	1560
QY	1561	TGGGCGCGTACCATGAGCAATCGGGGTACTCTTTAATGGCAACAACGCAAGCAGTTCA	1620
Db	1561	TGGGCGCGTACCATGAGCAATCGGGGTACTCTTTAATGGCAACAACGCAAGCAGTTCA	1620
QY	1621	CCACCTGAGACAGATCATATGATCTCAACAGGAAACTGTGCCACTACAGAAAGGAG	1680
Db	1621	CCACCTGAGACAGATCATATGATCTCAACAGGAAACTGTGCCACTACAGAAAGGAG	1680
QY	1681	GCTGATGGTATPAAAGCCTGTGSCCACTCCAACTCAACGGGGGTCTGGTACCGCGGGGGCC	1740
Db	1681	GCTGATGGTATPAAAGCCTGTGSCCACTCCAACTCAACGGGGGTCTGGTACCGCGGGGGCC	1740
QY	1741	ATTACCGGAGCGCTTACCAGAGACGAGCTTACTGGGCTGAGTTCCGAGAGAGCTCTTACT	1800
Db	1741	ATTACCGGAGCGCTTACCAGAGACGAGCTTACTGGGCTGAGTTCCGAGAGAGCTCTTACT	1800
QY	1801	CACATCAAGAAAGTGTGATGATGATCCGACCGAACCACCAACACTTCCACTAACCAGCT	1860
Db	1801	CACATCAAGAAAGTGTGATGATGATCCGACCGAACCACCAACACTTCCACTAACCAGCT	1860
QY	1861	CCCCCTCTGACTCTCTGTGGCAATTGCCAGAGACCCACCTTGCTACAGCTGGCCACAGC	1920
Db	1861	CCCCCTCTGACTCTCTGTGGCAATTGCCAGAGACCCACCTTGCTACAGCTGGCCACAGC	1920
QY	1921	ACAAAGAACAACTGCTCACCAGATTACCTGAGGCTGGAGAGACCGGGATGCTGGATTCT	1980
Db	1921	ACAAAGAACAACTGCTCACCAGATTACCTGAGGCTGGAGAGACCGGGATGCTGGATTCT	1980
QY	1981	GTTTTCCGAAGTCACTCAGCGGAGTGTGGAACAGAACTCAATGAGGTGTTTTCTGTCCCT	2040
Db	1981	GTTTTCCGAAGTCACTCAGCGGAGTGTGGAACAGAACTCAATGAGGTGTTTTCTGTCCCT	2040
QY	2041	CTTACTTTCTTCCACACCAAGACCCCTCATGTCTCCAGGACAGGACAGGACTACAGAC	2100
Db	2041	CTTACTTTCTTCCACACCAAGACCCCTCATGTCTCCAGGACAGGACAGGACTACAGAC	2100

Db 1153 TCTACCAAGAGATCCAGAGTGAACGAACTGAAAGTGTGCAACCCCTCTGTGCCACT 1212
QY 1143 ATGCCCACTCTCACAGAGCTCCATCTTCCACGACCAAGCCGCGGCCCATGAGAGAC 1202
Db 1213 ATGCCCACTCTCACAGAGCTCCATCTTCCACGACCAAGCCGCGGCCCATGAGAGAC 1272
QY 1203 TGCCTGAGAGCCCTGAGAGATGGCCACGACCAAGCTTCATCTTCTGTGAAGCCGAG 1262
Db 1273 TGCCTGAGAGCCCTGAGAGATGGCCACGACCAAGCTTCATCTTCTGTGAAGCCGAG 1332
QY 1263 AACACCAACCGCTCTATGAGAGTGTGTGCGACGACGACGACCCCGGCGGCTGAGAC 1322
Db 1333 AACACCAACCGCTCTATGAGAGTGTGTGCGACGACGACGACCCCGGCGGCTGAGAC 1392
QY 1323 GTTCATCCAGAGAGCGCTGAGTGGCTCTGTAACTTCTTCAAGAACTGAGAGCTGAC 1382
Db 1393 GTTCATCCAGAGAGCGCTGAGTGGCTCTGTAACTTCTTCAAGAACTGAGAGCTGAC 1452
QY 1383 CAAGGGTTTGGGAACTTGAACGGCGAATATCTGGCTGGGCTGAGAACTTATCTGGGCTG 1442
Db 1453 CAAGGGTTTGGGAACTTGAACGGCGAATATCTGGCTGGGCTGAGAACTTATCTGGGCTG 1512
QY 1443 ACGAACCAAGGCAACTACAACTCTGTGATGACCATGAGAGAGTGTGCGCGCAAAAGTC 1502
Db 1513 ACGAACCAAGGCAACTACAACTCTGTGATGACCATGAGAGAGTGTGCGCGCAAAAGTC 1572
QY 1503 TTTTGCAATATAGCCAGTTTCCGCTTGAACCTGAGAGAGATTTATTAAGTGTGGGCTG 1562
Db 1573 TTTTGCAATATAGCCAGTTTCCGCTTGAACCTGAGAGAGATTTATTAAGTGTGGGCTG 1632
QY 1563 GGGCGCTACCATGAGAGTGTGAGTGTGATCTTTAATGACCAAGGAGAGAGTTCACC 1622
Db 1633 GGGCGCTACCATGAGAGTGTGAGTGTGATCTTTAATGAGCAAGGAGAGAGTTCACC 1692
QY 1623 ACCCTGAGAGAGATGATGATGTCTTACACAGGAACTGTGCCCATCTACCAAGAGAGAGC 1682
Db 1693 ACCCTGAGAGAGATGATGATGTCTTACACAGGAACTGTGCCCATCTACCAAGAGAGAGC 1752
QY 1683 TGGTGTATTAAGCGCTGTGCGCACTCCCACTCAACCGGGGTGTGTACCGGGGGGGCAT 1742
Db 1753 TGGTGTATTAAGCGCTGTGCGCACTCCCACTCAACCGGGGTGTGTACCGGGGGGGCAT 1812
QY 1743 TACCGGAGCGCTTACAGAGCGAGTCTAATGAGGCTGAGTTCCAGAGAGGCTCTTACTCA 1802
Db 1813 TACCGGAGCGCTTACAGAGCGAGTCTAATGAGGCTGAGTTCCAGAGAGGCTCTTACTCA 1872
QY 1803 CTCAGAAAGTGTGATGATGATTCGAGCCGAAACCCCAACCTTCCATAGCCAGGCTCC 1862
Db 1873 CTCAGAAAGTGTGATGATGATTCGAGCCGAAACCCCAACCTTCCATAGCCAGGCTCC 1932
QY 1863 CCCTCTGACCTCTGTGCGCATTTGCCAGAGAGCCCACTGGTCAAGCTGCGCAAGAGAC 1922
Db 1933 CCCTCTGACCTCTGTGCGCATTTGCCAGAGAGCCCACTGGTCAAGCTGCGCAAGAGAC 1992
QY 1923 AAAGAAACAATCTCTCAACGATTCATCTGAGGCTGGGAGAGCCGGAGATGCTGATTCGT 1982
Db 1993 AAAGAAACAATCTCTCAACGATTCATCTGAGGCTGGGAGAGCCGGAGATGCTGATTCGT 2052
QY 1983 TTTCCGAGTCACTGAGCGAGTGAATGAATGAACTGATGATGATGATGATGATGATGATG 2042
Db 2053 TTTCCGAGTCACTGAGCGAGTGAATGAATGAACTGATGATGATGATGATGATGATGATG 2112
QY 2043 TACTTTCTTCAACACGAGAGCCCTCATGTCTCCAGAGACGAGAGCTACAGACAA 2102
Db 2113 TACTTTCTTCAACACGAGAGCCCTCATGTCTCCAGAGACGAGAGCTACAGACAA 2172
QY 2103 CTCTTTCTTAAATTAATTAAGTCTCTCAATTAATAAACAACAGTGAAGTAAATAAATAA 2162
Db 2173 CTCTTTCTTAAATTAATTAAGTCTCTCAATTAATAAACAACAGTGAAGTAAATAAATAA 2232
QY 2163 AAAAAA 2169
Db 2233 ATATACA 2239

RESULT 3
ID AAL42455
AC AAL42455;
XX 11-JUL-2002 (first entry)
XX Human matrix-remodeling-associated nucleotide 11.
XX
XX Human; ds: matrix-remodeling gene; extracellular matrix; gene;
XX matrix-remodeling-associated nucleotide; screening;
XX matrix remodeling-associated disease; angiogenesis; arthritis;
XX atherosclerosis; cancer; cardiomyopathy; diabetic necrosis; fibrosis;
XX ulceration.
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX CDS 442..1923
XX FT /*tag= a
XX FT /product= "Human matrix-remodeling-associated protein 3"
XX
XX US2002019000-A1.
XX
XX 14-FEB-2002.
XX
XX 26-MAR-2001; 2001US-00818143.
XX
XX 09-OCT-1998; 98US-00169289.
XX
XX (WALKER M G.
XX (VOLK W.
XX (KLINGLER T M.
XX
XX Walker MG, Volkmueth W, Klingler TM;
XX
XX WPI: 2002-338319/37.
XX
XX DR P-PSDB; AAO14786.
XX
XX
XX PT New isolated polynucleotide coexpressed with matrix-remodeling genes,
XX PT useful in diagnosis, prognosis, prevention and treatment of diseases
XX PT associated with matrix-remodeling such as angiogenesis, arthritis and
XX PT cancer.
XX
XX PS Claim 1; Fig 3; 63pp; English.
XX
XX CC The invention comprises human nucleotide sequences which are co-expressed
XX CC with matrix-remodeling genes. Matrix-remodeling is associated with the
XX CC construction, destruction and reorganization of extracellular matrix
XX CC components. The matrix-remodeling-associated nucleotides of the invention
XX CC are useful for screening for and purifying ligands that specifically bind
XX CC to the nucleotides of the invention. The matrix-remodeling-associated
XX CC nucleotides of the invention are also useful in the diagnosis, prognosis,
XX CC prevention, treatment and evaluation of therapies for diseases associated
XX CC with matrix remodeling (e.g. angiogenesis, arthritis, atherosclerosis,
XX CC cancer, cardiomyopathy, diabetic necrosis, fibrosis and ulceration). The
XX CC present DNA sequence represents a human matrix-remodeling-associated
XX CC nucleotide of the invention
XX
XX SQ Sequence 2288 BP; 548 A; 689 C; 647 G; 404 T; 0 U; 0 Other;
Query Match 98.8%; Score 2146.2; DB 6; Length 2288;
Best Local Similarity 99.4%; Pred. No. 0;
Matches 2154; Conservative 0; Mismatches 13; Indels 0; Gaps 0;
QY 3 AATGAGGCTGCTGCGGAGCGGCTGAGATGAACCCCAAGCCCTGAGCTGCGGAGCGTG 62
Db 73 AATGAGGCTGCTGCGGAGCGGCTGAGATGAACCCCAAGCCCTGAGCTGCGGAGCGTG 132
QY 63 GCAGTACGAGCGGCTGAGCTGATGATGAGGAAAGAGTTGTGAGAGCCCGCAGG 122

Db 123 GACAGAGGACAGGAGCTGACGCTACTGTGAGGAAAGAGGTTGAGACACGCCCCGAG 192
Qy 123 ACCCTGAGCAGCCCTGAGCCCTGAGCCCTGAGCCCTGAGAGGAGAGCAGATG 182
Db 123 ACCCTGAGCAGCCCTGAGCCCTGAGCCCTGAGCCCTGAGAGGAGAGCAGATG 252
Qy 123 GAGCCCAAGAGGAGGAGGCTGCTGAGAGGAGAGGAGAGGAGAGGAGAGGAGAG 242
Db 253 GAGCCCAAGAGGAGGAGGCTGCTGAGAGGAGAGGAGAGGAGAGGAGAGGAGAG 312
Qy 243 AGGCAATGAGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 302
Db 313 AGGCAATGAGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 372
Qy 303 AGGCAATGAGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 362
Db 373 AGGCAATGAGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 432
Qy 363 GGAAGAGAGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 422
Db 433 GGAAGAGAGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 492
Qy 423 GGAAGAGAGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 482
Db 493 GGAAGAGAGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 552
Qy 483 TTGATTTAG 542
Db 553 TTGATTTAG 612
Qy 543 TTGATTTAG 602
Db 613 TTGATTTAG 672
Qy 603 GTGCTTTAG 662
Db 673 GTGCTTTAG 732
Qy 663 AAGCAAG 722
Db 733 AAGCAAG 792
Qy 723 AAGCAAG 782
Db 793 AAGCAAG 852
Qy 783 AAGCAAG 842
Db 853 AAGCAAG 912
Qy 843 CTGAG 902
Db 913 CTGAG 972
Qy 903 GACCTGAG 962
Db 973 GACCTGAG 1032
Qy 963 GGGAG 1022
Db 1033 GGGAG 1092
Qy 1023 CCGGCTGAG 1082
Db 1093 CCGGCTGAG 1152
Qy 1083 TTGATTTAG 1142
Db 1153 TTGATTTAG 1212
Qy 1143 ATGCAAG 1202

Db 1213 ATGCAAG 1272
Qy 1203 TGCTGAG 1262
Db 1273 TGCTGAG 1332
Qy 1263 AAGCAAG 1322
Db 1333 AAGCAAG 1392
Qy 1323 GTCATCAG 1382
Db 1393 GTCATCAG 1452
Qy 1383 CAAGGAG 1442
Db 1453 CAAGGAG 1512
Qy 1443 AAGCAAG 1502
Db 1513 AAGCAAG 1572
Qy 1503 TTGATTTAG 1562
Db 1573 TTGATTTAG 1632
Qy 1563 GGGAG 1622
Db 1633 GGGAG 1692
Qy 1623 ACCCTGAG 1682
Db 1693 ACCCTGAG 1752
Qy 1683 TGCTGAG 1742
Db 1753 TGCTGAG 1812
Qy 1743 TACCGAG 1802
Db 1813 TACCGAG 1872
Qy 1803 CTGAG 1862
Db 1873 CTGAG 1932
Qy 1863 CCGCTGAG 1922
Db 1933 CCGCTGAG 1992
Qy 1923 AAGCAAG 1982
Db 1993 AAGCAAG 2052
Qy 1983 TTGATTTAG 2042
Db 2053 TTGATTTAG 2112
Qy 2043 TACCTTCTGAG 2102
Db 2113 TACCTTCTGAG 2172
Qy 2103 CTGCTTTTAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 2162
Db 2173 CTGCTTTTAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 2232
Qy 2163 AAAAAA 2169
Db 2233 ATATACA 2239

RESULT 4
AA17856

AA172856 standard; cDNA; 2154 BP.
 AA172856;
 12-AUG-2002 (first entry)
 cDNA clone AR3, ATCC 207063.
 Gene: angiotensin-like protein 2; AR2; angiotensin-like protein 3; AR3;
 apple crisp protein; APPLE; cocoa crisp protein; COCO;
 signal sequence cloning; secretory leader motif; angiogenesis;
 wound healing; transplantation; ss.
 Homo sapiens.
 Key Location/Qualifiers
 CDS 358..183
 /tag_a
 /product= "Angiotensin-like protein-3"
 WO200059938-A1.
 12-OCT-2000.
 31-MAR-2000; 2000WO-US008832.
 01-APR-1999; 99US-0126366P.
 29-MAR-2000; 2000US-00538361.
 (GENY) GENETICS INST INC.
 Racie-Collins LA, Lavallie ER;
 WPI; 2000-664990/64.
 P-PSDB; AAB47997.
 New angiotensin-like proteins 2 and 3, apple crisp and cocoa crisp
 proteins and polynucleotides, useful in treating e.g. autoimmune
 diseases, cancer, or central and peripheral nervous system disorders and
 neuropathies.
 Claim 24; Page 70-71; 84pp; English.
 The sequences given in AA172855-58 encode angiotensin-like protein 2
 (AR2), angiotensin-like 3 protein (AR3), apple crisp protein (APPLE), or
 cocoa crisp protein (COCO), respectively. These sequences were isolated
 by indirect cloning techniques, e.g. signal sequence cloning, which
 isolates DNA based on the presence of well known secretory leader motifs.
 AR2 and AR3 promote angiogenesis and may therefore be used in wound
 healing and transplantation
 Sequence 2154 BP; 528 A; 657 C; 607 G; 362 T; 0 U; 0 Other;

	Query Match	98.2%	Score 2134.2	DB 3	Length 2154
	Best Local Similarity	99.9%	Pred. No. 0		
	Matches 2156	Conservative 0	Mismatches 3	Indels 0	Gaps 0
QY	30	GATGAACCCCAAGCCCTGAGACTGGACGCTGCACCTGACGACTGACCTACTG	89		
Db	16	GATGAGACCCCAAGCCCTGAGACTGGACGCTGCACTGAGGACGAGCGCTGAGCTACTG	75		
QY	90	TGAGGGAAGAAGGTGTGTGACAGCGCCCGACAGACCCCTTGAGCGACCTTGACCCACCT	149		
Db	76	TGAGGGAAGAAGGTGTGTGACAGCGCCCGACAGACCCCTTGAGCGACCTTGACCCACCT	135		
QY	150	CTGCCGAGACCCCTCTGTGAGAGCAAGGCACTGAGGCCCAGTAGGCAAGGCTGCTTGGC	209		
Db	136	CTGCCGAGACCCCTCTGTGAGAGCAAGGCACTGAGGCCCAGTAGGCAAGGCTGCTTGGC	195		
QY	210	AGCCACCGGCTCTGCAACTCAGAAACCCCTCCAGAGGCAATGACAGGACGCGCCCGGTAC	269		
Db	196	AGCCACCGGCTCTGCAACTCAGAAACCCCTCCAGAGGCAATGACAGGACGCGCCCGGTAC	255		

QY	270	GGCACAGGTGAAGCACTGTGAAGAGCCGCGCCGGAGCCAGCAGAGGGGAAGAGCTTTCA	329
Db	256	GGCACAGGTGAAGCACTGTGAAGAGCCGCGCCGGAGCCAGAGGAGGGAAGAGGCTTTCA	315
QY	330	TAGATTTCTATTCACAAAAGATTACACCATTTTGCAAAAGACAAAGAGGCCACTGTGGTGTG	389
Db	316	TAAATTTCTATTCACAAAAGATTACACCATTTTGCAAAAGACAAAGAGGCCACTGTGGTGTG	375
QY	390	ACATGTGCTGTGCTCGACTGTGCTGTGCCATGGAGAGTGTTCGAGGCCAGAGAGCGAT	449
Db	376	ACATGTGCTGTGCTCGACTGTGCTGTGCCATGGAGAGTGTTCGAGGCCAGAGAGCGAT	435
QY	450	TTTTGAGGGCACTGAGAGAGGGCTTCGCCAAGAAGATTCAATTACCTTAACAGATTACAGCGG	509
Db	436	TTTTGAGGGCACTGAGAGAGGGCTTCGCCAAGAAGATTCAATTACCTTAACAGATTACAGCGG	495
QY	510	GGGGGGAGTCCACAGAGCAAGTGCACCTACACTTTCATTGTGGCCCCAGACGGGGTCAACG	569
Db	496	GGGGGGAGTCCACAGAGCAAGTGCACCTACACTTTCATTGTGGCCCCAGACGGGGTCAACG	555
QY	570	GGTGCCATCTGCTCACTCCAAAGAGGCTGAGGTGCTTTGTGAAACCGATGTGCATAG	629
Db	556	GGTGCCATCTGCTCACTCCAAAGAGGCTGAGGTGCTTTGTGAAACCGATGTGCATAG	615
QY	630	CAGAGCTGTAGACTCTCTAACAATGAGTGTCTCAAGAGAAAGGGGCGAGTCGAGAGCGTG	689
Db	616	CAGAGACTGTAGACTCTCTAACAATGAGTGTCTCAAGAGAAAGGGGCGAGTCGAGAGCGTG	675
QY	690	CAGCACTGTGTAAAGTGTGACCGCGGCATTGTGTGACGAGGTGAAGCTCTGCGCAAGAG	749
Db	676	CAGCACTGTGTGAAGTGTGAACGGCGGCAATTGTGACGAGGTGAAGCTCTGCGCAAGAG	735
QY	750	AGCCGCACTATGAATCTCGCGGGTCAACGCACTCTACATGCAGCTCTCTGCACAGATATCTC	809
Db	736	AGCCGCACTATGAATCTCGCGGGTCAACGCACTCTACATGCAGCTCTCTGCACAGATATCTC	795
QY	810	CGCAACCGGGACAACGCGTTGGAGTCTCCAGCTGTGAGAAACAGGATCTCGAACCAAGACA	869
Db	796	CGCAACCGGGACAACGCGTTGGAGTCTCCAGCTGTGAGAAACAGGATCTCGAACCAAGACA	855
QY	870	GCCGACATGCTGACAGCTGGCCAGCAAGTACAAAGACCTGAGACCAAGTACCAAGCACTTG	929
Db	856	GCCGACATGCTGACAGCTGGCCAGCAAGTACAAAGACCTGAGACCAAGTACCAAGCACTTG	915
QY	930	GCCACATGGGCCCAACAACCAATCAGAGATTCATCGCGACCTGTGAGAGCACTGCGAGAG	989
Db	916	GCCACATGGGCCCAACAACCAATCAGAGATTCATCGCGACCTGTGAGAGCACTGCGAGAG	975
QY	990	GTTGCCCTCGGACAGGCGCGTCCGCCAGCACCCCGCGCTGCCCGCCCGGAGTCTACAA	1044
Db	976	GTTGCCCTCGGACAGGCGCGTCCGCCAGCACCCCGCGCGTCCCGGAGTCTACAA	1033
QY	1050	CCACCCACTTAACAACCGCATATCAACCAATCTCTACCAACGAGATCCAGATTAACCAAG	1104
Db	1036	CCACCCACTTAACAACCGCATATCAACAAGATCTCTACCAACGAGATCCAGATTAACCAAG	1099
QY	1110	AACCTGAAGTCTGCAACCCCGCTGTGGCCACTATGACCACTCTCAACCACTCTCCATCT	1166
Db	1096	AACCTGAAGTCTGCAACCCCGCTGTGGCCACTATGACCACTCTCAACCACTCTCCATCT	1155
QY	1170	TCCACCGACAGACCGTCTGGGCCCCATGAGAGACTGCTTGCAGGCGCTGTGAGGATGGCCAC	1222
Db	1156	TCCACCGACAGACCGTCTGGGCCCCATGAGAGACTGCTTGCAGGCGCTGTGAGGATGGCCAC	1211
QY	1230	GACACCAAGTTCATTTACCTGGTGAAGCCGGAGAAACCAACCGGCTCAATGACAGGTGTG	1288
Db	1216	GACACCAAGTTCATTTACCTGGTGAAGCCGGAGAAACCAACCGGCTCAATGACAGGTGTG	1277
QY	1290	TGCGAACCAAGACACGAGCCCGCGGGGCTGGAACGTTCAATCCAGAGACGCTGTGATGGCTCT	1344
Db	1276	TGCGAACCAAGACACGAGCCCGCGGGGCTGGAACGTTCAATCCAGAGACGCTGTGATGGCTCT	1333
QY	1350	GTTAACTTCTTCAGGAACCTGGAGACGTACCAAGCAAGGGTTTGGGAACATTGACGCGGA	1404

Db	1336	GTTAACCTCTTCAGGAACCTGGGAGACGTAACAAGCAAGGTTTGGAACTTGAACGGCGAA	1395
QY	1410	TACTGGCTGGGCTCGAGAACATTTACTGGCTGACGAACCAAGGCACTACAAACTCCTG	1469
Db	1396	TACTGGCTGGGCTCGAGAACATTTACTGGCTGACGAACCAAGGCACTACAAACTCCTG	1455
QY	1470	GTGACCATAGGAGGACTGGTCCGGCCGCAAACTCTTGTAGAAATAGCGAGTTCCGCTG	1529
Db	1456	GTACCAATGAGAGACTGGTCCGGCCGCAAACTCTTGTAGAAATAGCGAGTTCCGCTG	1515
QY	1530	GAACCTGAGACGAGTATTATAGCTGGCGCTGGGCGCTTCCATGAGCAATGCGGATGAC	1589
Db	1516	GAACCTGAGACGAGTATTATAGCTGGCGCTGGGCGCTTCCATGAGCAATGCGGATGAC	1575
QY	1550	TCCCTTAAATGGCAACGGGACAGATTCACACCTCTGACAGAGATCAATGATGCTAC	1649
Db	1576	TCCCTTAAATGGCAACGGGACAGATTCACACCTCTGACAGAGATCAATGATGCTAC	1635
QY	1650	ACAGAAACTGTGCCACTTACACAGAGGAGGCTGTGTGTAAAGCTGTGCCCACTCC	1709
Db	1636	ACAGAAACTGTGCCCACTTACACAGAGGAGGCTGTGTGTAAAGCTGTGCCCACTCC	1695
QY	1710	AACTCTCAACGGGGTCTGGTACCGCGGGGGCCATTACCGAGCCGCTACACGAGCGATC	1769
Db	1696	AACTCTCAACGGGGTCTGGTACCGGGGGCCATTACCGAGCCGCTACACGAGCGAGTC	1755
QY	1770	TACTGGCTGAGTTCGAGAGAGCTCTTACTCACTCAAGAAAGTGATGATGATCCGA	1829
Db	1756	TACTGGCTGAGTTCGAGAGAGCTCTTACTCACTCAAGAAAGTGATGATGATCCGA	1815
QY	1830	CCGAACCCCAACACCTTCCACTAAGCCAGCTCCCTCTTCGACTCTTGCGCCATTTGCC	1889
Db	1816	CCGAACCCCAACACCTTCCACTAAGCCAGCTCCCTCTTCGACTCTTGCGCCATTTGCC	1875
QY	1890	AGGAGCCCAACCTGGTCAACGCTGGCCACAGCAAAAGAACATCTCACAGTCAATCC	1949
Db	1876	AGGAGCCCAACCTGGTCAACGCTGGCCACAGCAAAAGAACATCTCACAGTCAATCC	1935
QY	1950	TGAGGCTGGAGAGACCGGGATGCTGATCTTGTTTTCCGAAGTCACTGACGCGATGATG	2009
Db	1936	TGAGGCTGGAGAGACCGGGATGCTGATCTTGTTTTCCGAAGTCACTGACGCGATGATG	1995
QY	2010	GAATGGAATGATACGATACGATGTTTTCTGTGTCCTCTCACTTTCTTTACACACGAGCCCT	2069
Db	1996	GAATGGAATGATACGATACGATGTTTTCTGTGTCCTCTCACTTTCTTTACACACGAGCCCT	2055
QY	2070	CATGTCTTCAGAGACAGACAGACTACAGACAACTCTTTCTTTAAATTAATGATCTCT	2129
Db	2056	CATGTCTTCAGAGACAGAGACTACAGACAACTCTTTCTTTAAATTAATGATCTCT	2115
QY	2130	ACAAATAAAAACACAACCTGCAAAAGTAAAAAATAAAAA 2168	
Db	2116	ACAAATAAAAACACAACCTGCAAAAGTAAAAAATAAAAA 2154	

RESULT 5	
AA36341	
ID	AA36341 standard; DNA; 2290 BP.
XX	
AC	AA36341;
XX	
DT	01-JUL-1999 (first entry)
XX	
DE	Human TIE ligand NLI coding sequence.
XX	
KW	Human TIE ligand; NLI; NT4; NL5; NL8; Ig homology domain; angiogenesis;
KW	EGF homology domain; receptor tyrosine kinase; vascular endothelial cell;
KW	early haemopoietic cell; haemopoiesis; neovascularisation; wound healing;
KW	endothelial cell; growth inhibitor; apoptosis inducer; tumour cell;
KW	vasculogenesis; detection; diagnosis; therapy; ss.
XX	
OS	Homo sapiens.

XX	
PN	W09915653-A2.
XX	
PD	01-APR-1999.
XX	
PF	14-SEP-1998; 98WO-US019093.
XX	
PR	19-SEP-1997; 97US-00933821.
XX	
PA	29-OCT-1997; 97US-00960507.
XX	
(GETH) GENENTECH INC.	
PI	Godowski PJ, Gurney AL, Hillan K, Botstein D, Goddard A, Roy M,
PL	Ferrara N, Tumas D, Schwall R;
XX	
DR	WPI; 1999-263480/22.
XX	
PT	P-PSDB; AA050396.
XX	
PT	New isolated TIE ligand homologs for, e.g. developing products for
XX	treatment of tumors.
XX	
CS	Claim 3, Fig 2, 132pp; English.

CC This sentence encodes the human tyrosine kinase containing IY and EGF
CC homology domains (TIE) ligand of the invention, designated N1L. The TIE
CC receptors are receptor tyrosine kinases which are expressed in vascular
CC endothelial cells and early haemopoietic cells. The TIE receptors are
CC believed to be actively involved in angiogenesis, and may play a role in
CC haemopoiesis as well. The TIE ligand homologs can promote the survival
CC and/or growth and/or differentiation of TIE receptor expressing cells.
CC They can be used for promoting neovascularisation in wound healing and
CC for promoting angiogenic processes, such as for inducing collateral
CC vascularisation in an ischaemic heart or limb, or for promoting bone
CC development and/or maturation and/or growth in a patient or muscle growth
CC and development. The TIE ligand homologs and antibodies can inhibit the
CC growth of endothelial cells and induce apoptosis of cells, particularly
CC tumour cells. They can inhibit vasculogenesis, particularly the
CC vascularisation of tumour cells. The antibodies can also inhibit
CC vascularisation of a cell in which a gene encoding an N1L, N2S, N4S or
CC N14 polypeptide is amplified. The products can also be used for
CC detection, diagnosis, drug screening and production of transgenic animals
XX
XX Sequence 2290 BP; 537 A; 692 C; 668 G; 393 T; 0 U; 0 Other;

Query Match	98.1%	Score 2132.6	DB 2	Length 2290
Best Local Similarity	99.8%	Pred. No. 0		
Matches 2135	Conservative	0	Mismatches 4	Indels 0
			Gaps	0
QY	3	AAATGAGCTGTGTGGCAGCGCCTGAGGATGAAACCCCAAGCCCTGGACCTGCGCAGCGTG	62	
Db	151	AAATGAGCTGTGTGGCAGCGCCTGAGGATGAAACCCCAAGCCCTGGACCTGCGCAGCGTG	210	
QY	63	GCACTGAGGCGAGCGCTACCGTACTGTGAGGGAAAGAGTTGTGACAGCCCGCAGG	122	
Db	211	GCACTGAGGCGAGCGCTACCGTACTGTGAGGGAAAGAGTTGTGACAGCCCGCAGG	270	
QY	123	ACCCCTGGCGAAGCCCTGGCCCGCAGCGCTGTGCGCGGAGGCGCTCTGTGAGGAGAGCCAGTG	182	
Db	271	ACCCCTGGCGAAGCCCTGGCCCGCAGCGCTGTGCGCGGAGGCGCTCTGTGAGGAGAGCCAGTG	330	
QY	183	GAGCCAGTGAAGGAGGAGGCTCTTGTGCGAGCCACGCGCTGCAACTGAGAAACCCCTCCAG	242	
Db	331	GAGCCAGTGAAGGAGGAGGCTCTTGTGCGAGCCACGCGCTGCAACTGAGAAACCCCTCCAG	390	
QY	243	AGGCATGAGAGGCTGCGCCCGCTGACGCGCCAGGAGTGAAGCATGTGAGAGGCCGCCCGG	302	
Db	391	AGGCATGAGAGGCTGCGCCCGCTGACGCGCCAGGAGTGAAGCATGTGAGAGGCCGCCCGG	450	
QY	303	AGCCAGAGCGAGAGGGGAAAGGCTTTCAATGATTTATTTCAAAAGATTAACCACTTTT	362	
Db	451	AGCCAGAGCGAGAGGGGAAAGGCTTTCAATGATTTATTTCAAAAGATTAACCACTTTT	510	
QY	363	GCAAGAGCCATGAGGCGACTGTGCGTGAACATGTGAGTGGCTGCGAGCTGCTGAGCTGCATG	422	

Db	511	GCAAGACCAATGAGAGCCACTGTGGGTGACATGCTGTGGCTCGGACTGTGGCTGCATG	570
QY	423	GGAGCTGTTGCAAGCCCAAGAGACGCTTTTAAGGGCACTGAGAGAGGCTCGCCAAAGAG	482
Db	571	GGAGCTGTGGCAAGCCCAAGAGACGCTTTTAAGGGCACTGAGAGAGGCTCGCCAAAGAG	630
QY	483	TTCAATTTAACCTAAACAGGTACAAAGCGGGCGGACAGTCCCAAGACAAGTGAACCTACAC	542
Db	631	TTCAATTTAACCTAAACAGGTACAAAGCGGGCGGACAGTCCCAAGACAAGTGAACCTACAC	690
QY	543	TTCAATTTGCCCCCAGCAGCGGGTCAAGGGTCCATCTTGCTCAATCCCAAGAGCTTGAG	602
Db	691	TTCAATTTGCCCCCAGCAGCGGGTCAAGGGTCCATCTTGCTCAATCCCAAGAGCTTGAG	750
QY	603	GTCCTTCCTGGAGAACCCAGATGCATTAAGAGAGAGCTAAGAGTGCCTCAACATAGACTGTC	662
Db	751	GTCCTTCCTGGAGAACCCAGATGCATTAAGAGAGAGCTAAGAGTGCCTCAACATAGACTGTC	810
QY	663	AAGCAGAAAGCCGACAGATCGAGACGCTGCAGCAGCTGTGAAGGTGAACGGCGGATTGTG	722
Db	811	AAGCAGAAAGCCGACAGATCGAGACGCTGCAGCAGCTGTGAAGGTGAACGGCGGATTGTG	870
QY	723	AGCGAGTGAAGCTGTCTCCGCAAGAGACCCGCAACATGAACCTGCGGGTCAAGCAGACTC	782
Db	871	AGCGAGTGAAGCTGTCTCCGCAAGAGACCCGCAACATGAACCTGCGGGTCAAGCAGACTC	930
QY	783	TACATGCAAGCTCTGCGACGAGATCATCCGCAAGCGGACCAACGCGTTGAGCTCTCCAG	842
Db	931	TACATGCAAGCTCTGCGACGAGATCATCCGCAAGCGGACCAACGCGTTGAGCTCTCCAG	990
QY	843	CTGGAGAACAGGATCTTGAAACCAAGCAGCCCAATGCTGCAGCTGGCCAGCAATACAG	902
Db	991	CTGGAGAACAGGATCTTGAAACCAAGCAGCCCAATGCTGCAGCTGGCCAGCAATACAG	1050
QY	903	GACCTGGAGCAACAGTACACAGACCTGGCCCACTGGGCCCAACCAATCAGATCATC	962
Db	1051	GACCTGGAGCAACAGTACACAGACCTGGCCCACTGGGCCCAACCAATCAGATCATC	1110
QY	963	GCGCAGCTTGAAGAGCACTGCGCAGAGGGTGCCCTGGCCAGAGCCCGTCCCGACCAACC	1022
Db	1111	GCGCAGCTTGAAGAGCACTGCGCAGAGGGTGCCCTGGCCAGAGCCCGTCCCGACCAACC	1170
QY	1023	CCCGCTGCCCCCGCCCGGCTTACCAACCACTCACTTCAACCCGATATTAACCAAGATC	1082
Db	1171	CCCGCTGCCCCCGCCCGGCTTACCAACCACTCACTTCAACCCGATATTAACCAAGATC	1230
QY	1083	TCTACCAAGAGATCCAGAGTGAACCAAGACTGAAGGTGCTGCAACCCCTCTGCCACT	1142
Db	1231	TCTACCAAGAGATCCAGAGTGAACCAAGACTGAAGGTGCTGCAACCCCTCTGCCACT	1290
QY	1143	ATGCCCACTTCAACAGGCTCCCATCTTTCACCCGAACAGCGGTGGGCTCCATGAGAGAC	1202
Db	1291	ATGCCCACTTCAACAGGCTCCCATCTTTCACCCGAACAGCGGTGGGCTCCATGAGAGAC	1350
QY	1203	TGCGTCGAGAGCCCTGAGAGATGAGGACCAAGACACAGCTCCATCTACTGTTAAGCCGAG	1262
Db	1351	TGCGTCGAGAGCCCTGAGAGATGAGGACCAAGACACAGCTCCATCTACTGTTAAGCCGAG	1410
QY	1263	AAACACCAACCGGCTTCAATCAGGTGTGATGCGACCAAGACACGACCCCGGGGGCTGAC	1322
Db	1411	AAACACCAACCGGCTTCAATCAGGTGTGATGCGACCAAGACACGACCCCGGGGGCTGAC	1470
QY	1323	GTCATCCAGAGACGCTGAGATGCTCTGTTAACCTTTCACAGAACTGGGAACGTACAG	1382
Db	1471	GTCATCCAGAGACGCTGAGATGCTCTGTTAACCTTTCACAGAACTGGGAACGTACAG	1530
QY	1383	CAAGGTTTGGGAACATTGACGGCAATATCTGAGCTGAGGACTGAGAACATTTACTGAGCTG	1442
Db	1531	CAAGGTTTGGGAACATTGACGGCAATATCTGAGCTGAGGACTGAGAACATTTACTGAGCTG	1590
QY	1443	ACGAACCAAGGCACTAACAACTCCTGGTACATGAGAGATGCTCCGCGCCGAAGTC	1502

	Accession	Gene	Protein	Length
Db	1591	ACGAACCAAGGCAACTACAAACCTCCTGATGACATGAGAGACTGGTCCGGCCGCAAAAGTC	1562	
Qy	1503	TTTGAGAAATACGGCAAGTTTCCGCTTGGAACCTGAGACGAGATTTTAAGCTGCGGCTG	1562	
Db	1651	TTTCCAGAAATACGGCAAGTTTCCGCTTGGAACCTGAGACGAGATTTTAAGCTGCGGCTG	1710	
Qy	1563	GGGCGCTAACATGGCAATGCGGGAGACTCCTTTTACATGAGCAACCGGCAAGCACTTCAAC	1622	
Db	1711	GGGCGCTAACATGGCAATGCGGGAGACTCCTTTTACATGAGCAACCGGCAAGCACTTCAAC	1770	
Qy	1623	ACCTTGACAGAGATCATGATGTCTTACACAGAAAATGTGCCACTACACGAAAGGAGGC	1682	
Db	1771	ACCTTGACAGAGATCATGATGTCTTACACAGAAAATGTGCCACTACACGAAAGGAGGC	1830	
Qy	1683	TGGTGGTATACGCTGTGGCCACTCCAACTCAACGGGGTCTGTATCCGGGGGGCAT	1742	
Db	1831	TGGTGGTATACGCTGTGGCCACTCCAACTCAACGGGGTCTGTATCCGGGGGGCAT	1890	
Qy	1743	TACCGAGCCGCTACACGAGCGAGTCTACTGSGCTGATGTTCCGAGAGGCTCTTACTCA	1802	
Db	1891	TACCGAGCCGCTACACGAGCGAGTCTACTGSGCTGATGTTCCGAGAGGCTCTTACTCA	1950	
Qy	1803	CTCAAGAAAGTGGATGATGATGATCGAACCGAACCCCAACCTTCCACTAAGCCAGCTCC	1862	
Db	1951	CTCAAGAAAGTGGATGATGATGATCGAACCGAACCCCAACCTTCCACTAAGCCAGCTCC	2010	
Qy	1863	CCCTCCTGACCTCTCGTGGCCATTGCCAGAGACCACCCCTGGTCAACGCTGSCCAACAGAC	1922	
Db	2011	CCCTCCTGACCTCTCGTGGCCATTGCCAGAGACCACCCCTGGTCAACGCTGSCCAACAGAC	2070	
Qy	1923	AAAGAAACACTCTTCACCAAGTTTCACTCTGAGAGCTGGAGAGACCGGGATGCTGATTCGT	1982	
Db	2071	AAAGAAACACTCTTCACCAAGTTTCACTCTGAGAGCTGGAGAGACCGGGATGCTGATTCGT	2130	
Qy	1983	TTTCGGAAGTCACTGACGAGCGGATATGAGAACTGATCGATACGATGTTTCTGTCCCTCC	2042	
Db	2131	TTTCGGAAGTCACTGACGAGCGGATATGAGAACTGATCGATACGATGTTTCTGTCCCTCC	2190	
Qy	2043	TACTTCTCTTACACACGACAGCCCTCATGTCTTCAGGACAGACAGACTTAAGACAA	2102	
Db	2191	TACTTCTCTTACACACGACAGCCCTCATGTCTTCAGGACAGACAGACTTAAGACAA	2250	
Qy	2103	CTCTTCTTTAAATTAATTAAGTCTCTCAATTAATAACA	2141	
Db	2251	CTCTTCTTTAAATTAATTAAGTCTCTCAATTAATAAAA	2289	
RESULT 6				
AAC86961				
ID	AAC86961	standard; CDNA; 2290 BP.		
XX	AAC86961;			
XX	20-APR-2001	(first entry)		
DE	Nucleotide sequence of human polypeptide PRO196.			
XX	Human; secreted protein, transmembrane protein; PRO196; PRO444; PRO183;			
KW	PRO185; PRO210; PRO215; PRO217; PRO288; PRO365; PRO361; PRO1308;			
KW	PRO1183; PRO1172; PRO1419; PRO4999; PRO1170; PRO248; PRO353; PRO1318;			
KW	PRO1600; PRO3940; PRO533; PRO301; PRO187; PRO337; PRO1411; PRO4356;			
KW	PRO246; PRO265; PRO941; PRO10096; PRO6003; PRO6004; PRO350; PRO2630;			
KW	PRO6309; cell death; genetic disorder; transgenic animal; gene therapy;			
OS	Homo sapiens.			
XX				
XX	Key	Location/Qualifiers		
XX	CDS	520..2001		
XX	sig_peptide	/*tag= a		
XX		520..585		
XX		/*tag= b		

PN WO200077037-A2.
 XX 21-DEC-2000.
 XX 22-MAY-2000; 2000WO-US014042.
 XX 15-JUN-1999; 99US-0139695P.
 PR 20-JUL-1999; 99US-0145070P.
 PR 26-JUL-1999; 99US-0145698P.
 PR 17-AUG-1999; 99US-0149396P.
 PR 01-SEP-1999; 99WO-US020111.
 PR 08-SEP-1999; 99WO-US020594.
 PR 15-SEP-1999; 99WO-US021090.
 PR 30-NOV-1999; 99WO-US028313.
 PR 01-DEC-1999; 99WO-US028301.
 PR 02-DEC-1999; 99US-0169495P.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US007377.
 PR 20-MAR-2000; 2000WO-US008439.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 15-MAY-2000; 2000WO-US013358.
 PR 17-MAY-2000; 2000WO-US013705.
 XX (GENTH) GENENTECH INC.
 PA Ashkenazi AJ, Baker KP, Bolstein DA, Desnoyers L, Eaton DL;
 PI Ferrara N, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
 PI Godowski PJ, Gurney AL, Kljavin IJ, Mather JP, Napier MA, Pan J;
 PI Paoni NF, Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM;
 PI Wood WI, Zhang Z;
 XX WPI, 2001-050091/06.
 DR P-PSDB; AAB31179.
 XX Isolated nucleic acid molecule encoding a PRO polypeptide which is a
 PT transmembrane polypeptide is useful for gene therapy and identification
 of related polypeptides.
 XX Claim 2; Fig 1; 244pp; English.
 XX The present sequence encodes a human secreted and transmembrane
 CC polypeptide. The specification describes human polypeptides, designated
 CC PRO196, PRO444, PRO183, PRO185, PRO210, PRO215, PRO242, PRO288,
 CC PRO365, PRO366, PRO368, PRO183, PRO1272, PRO1419, PRO4999, PRO7170,
 CC PRO288, PRO353, PRO1318, PRO1600, PRO3940, PRO533, PRO301, PRO187,
 CC PRO337, PRO1411, PRO3356, PRO246, PRO265, PRO941, PRO1096, PRO6003,
 CC PRO6004, PRO350, PRO2630, and PRO6309. The biological activity of cells
 CC can be modulated with agents that bind to these polypeptides, resulting
 CC in the death of the cells. The polynucleotides encoding these
 CC polypeptides are useful in the recombinant production of the
 CC polypeptides, as a hybridisation probe to screen libraries to isolate
 CC homologous sequences, or to map the gene. They may also be used for
 CC analysing genetic disorders, and to produce transgenic animals which are
 CC useful for the development and screening of therapeutically useful
 CC reagents. The polynucleotides can also be used in gene therapy e.g. to
 CC replace a defective gene
 XX
 SO Sequence 2250 BP; 537 A; 692 C; 668 G; 393 T; 0 U; 0 Other;
 Query Match 98.1%; Score 2132.6; DB 4; Length 2250;
 Best Local Similarity 99.8%; Pred. No. 0;
 Matches 2135; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 QY 3 AAATGAGGCTGCTGCGAGCGGCTGAGATGAACCCCAAGCCCTGAGCCTGCGAGCGTG 62
 Db 151 AAATGAGGCTGCTGCGAGCGGCTGAGATGAACCCCAAGCCCTGAGCCTGCGAGCGTG 210

QY 63 GCACTGAGGCGAGGCTGAGAGCTACTGTGTAGAGGAAGAAGTTGTGAGAGGCCCGCAGG 122
 Db 211 GCACTGAGGCGAGGCTGAGAGCTACTGTGTAGAGGAAGAAGTTGTGAGAGGCCCGCAGG 270
 QY 123 ACCCTGAGGCGAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGG 182
 Db 271 ACCCTGAGGCGAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGG 330
 QY 183 GAGCCAGTGAAGGCGAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGG 242
 Db 331 GAGCCAGTGAAGGCGAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGG 390
 QY 243 AGGCGATGAGGCGAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGG 302
 Db 391 AGGCGATGAGGCGAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGG 450
 QY 303 AGGCGATGAGGCGAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGG 362
 Db 451 AGGCGATGAGGCGAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGG 510
 QY 363 GCAAGAGGCGAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGG 422
 Db 511 GCAAGAGGCGAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGG 570
 QY 423 GAGGCTGTCAGAGGCGAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGG 482
 Db 571 GAGGCTGTCAGAGGCGAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGG 630
 QY 483 TTCAATTTACCTTAAACAGTGAACAGGCGGCGAGTGTGAGAGGAGGAGGAGGAGGAGGAGGAGGAGG 542
 Db 631 TTCAATTTACCTTAAACAGTGAACAGGCGGCGAGTGTGAGAGGAGGAGGAGGAGGAGGAGGAGG 690
 QY 543 TTCAATTTACCTTAAACAGTGAACAGGCGGCGAGTGTGAGAGGAGGAGGAGGAGGAGGAGGAGG 602
 Db 691 TTCAATTTACCTTAAACAGTGAACAGGCGGCGAGTGTGAGAGGAGGAGGAGGAGGAGGAGGAGG 750
 QY 603 GTGCTTGTGAGAGGCGAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGG 662
 Db 751 GTGCTTGTGAGAGGCGAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGG 810
 QY 663 AAGCAGAGGCGAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGG 722
 Db 811 AAGCAGAGGCGAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGG 870
 QY 723 AGCAGGTGAAGCTGCTGCGCAGAGGAGGCGGCAACATGAATCTGCGGATCAGCAGCTC 782
 Db 871 AGCAGGTGAAGCTGCTGCGCAGAGGAGGCGGCAACATGAATCTGCGGATCAGCAGCTC 930
 QY 783 TACATGAGGCTGCTGCGCAGAGGAGGCGGCAACATGAATCTGCGGATCAGCAGCTC 842
 Db 931 TACATGAGGCTGCTGCGCAGAGGAGGCGGCAACATGAATCTGCGGATCAGCAGCTC 990
 QY 843 CTGAGAGGAGGAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGG 902
 Db 991 CTGAGAGGAGGAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGG 1050
 QY 903 GACCTGAGGAGGAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGG 962
 Db 1051 GACCTGAGGAGGAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGG 1110
 QY 963 GCGCAGGCTGAGAGGAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGG 1022
 Db 1111 GCGCAGGCTGAGAGGAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGG 1170
 QY 1023 CCCGCTGCGCGCGCGCGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGG 1082
 Db 1171 CCCGCTGCGCGCGCGCGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGG 1230
 QY 1083 TCTACCAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1142
 Db 1231 TCTACCAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1290
 QY 1143 ATGCCACTTACAGGCTGCGCAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGGCTGAGAGGCCCGCAGG 1202

Db 1291 ATGCCAATCTTCCAGCCCTCCATCTTCCACGACACACCGCTCGGCCCATGAGAGAC 1350
 QY 1203 TCCCTCAGGCTCTGAGGATGCGACGACACAGCTCCATCTACCTGGTGAAGCCGAG 1262
 Db 1351 TGCCTCAGGCTCTGAGGATGCGACGACACAGCTCCATCTACCTGGTGAAGCCGAG 1410
 QY 1263 AATACCAACCGCTCTGAGGATGCGACGACACAGCTCCATCTACCTGGTGAAGCCGAG 1322
 Db 1411 AATACCAACCGCTCTGAGGATGCGACGACACAGCTCCATCTACCTGGTGAAGCCGAG 1470
 QY 1323 GTTCATCAGAGAGCGCTGATGGCTCTGTTAACTTCTTGAGAACTGGAGAGCTACAAG 1382
 Db 1471 GTTCATCAGAGAGCGCTGATGGCTCTGTTAACTTCTTGAGAACTGGAGAGCTACAAG 1530
 QY 1383 CAAGGCTTTGGAGAACTTGAAGCGCAATCTGGCTGGGCTTGAAGAACTTTACTGGCTG 1442
 Db 1531 CAAGGCTTTGGAGAACTTGAAGCGCAATCTGGCTGGGCTTGAAGAACTTTACTGGCTG 1590
 QY 1443 ACGAACAAGGCACTACAACTCTGAGCACTGAGCACTGAGCACTGAGCACTGAGCACTG 1502
 Db 1591 ACGAACAAGGCACTACAACTCTGAGCACTGAGCACTGAGCACTGAGCACTGAGCACTG 1650
 QY 1503 TTTTGGAATACGCCAGTTTCCGCTGGAACCTGAGCGAGTATTATTAAGCTGGGCTG 1562
 Db 1651 TTTTGGAATACGCCAGTTTCCGCTGGAACCTGAGCGAGTATTATTAAGCTGGGCTG 1710
 QY 1563 GGGCGCTACCATGGAATGCGGCTGACTCTTGAATGAGCAACGGAAGAGTTTACC 1622
 Db 1711 GGGCGCTACCATGGAATGCGGCTGACTCTTGAATGAGCAACGGAAGAGTTTACC 1770
 QY 1623 ACCCTGAGCAGATCATGATGTCTACACAGGAACTGCTGCCACTACAGAGGAGGC 1682
 Db 1771 ACCCTGAGCAGATCATGATGTCTACACAGGAACTGCTGCCACTACAGAGGAGGC 1830
 QY 1683 TGGTGGTAAAGCGCTGCGCCCACTCAACCGGAGTGTGTAACCGGGGGGCGCAT 1742
 Db 1831 TGGTGGTAAAGCGCTGCGCCCACTCAACCGGAGTGTGTAACCGGGGGGCGCAT 1890
 QY 1743 TACCGGAGCGCTTACAGAGCGAGTCTACTGAGCTGAGTCCGAGAGGCTCTTACTCA 1802
 Db 1891 TACCGGAGCGCTTACAGAGCGAGTCTACTGAGCTGAGTCCGAGAGGCTCTTACTCA 1950
 QY 1803 CTGAAGAAAGTGTATGATGATCCGACCGAAACCCCAACCTTCACTAAGCAGCTCC 1862
 Db 1951 CTGAAGAAAGTGTATGATGATCCGACCGAAACCCCAACCTTCACTAAGCAGCTCC 2010
 QY 1863 CCTCTGACCTCTGCTGAGCCATTGSCAGAGCGCCAGCCCTGCTACGCTGGCCACAGAC 1922
 Db 2011 CCTCTGACCTCTGCTGAGCCATTGSCAGAGCGCCAGCCCTGCTACGCTGGCCACAGAC 2070
 QY 1923 AAAGAACTCTCTCAGCAGATTCATCTGAGGCTGGAGGACCGGAGTGTGATTCGT 1982
 Db 2071 AAAGAACTCTCTCAGCAGATTCATCTGAGGCTGGAGGACCGGAGTGTGATTCGT 2130
 QY 1983 TTTCCGAGTCACTGAGCGAGTGTGATGATGATGATGATGATGATGATGATGATGATGAT 2042
 Db 2131 TTTCCGAGTCACTGAGCGAGTGTGATGATGATGATGATGATGATGATGATGATGATGAT 2190
 QY 2043 TACTTTCCTTCACTCAGCAGAGCGCCCTGATCTTCCAGAGCAGAGCAGAGCAGAGCAG 2102
 Db 2191 TACTTTCCTTCACTCAGCAGAGCGCCCTGATCTTCCAGAGCAGAGCAGAGCAGAGCAG 2250
 QY 2103 CTCTTCTTCTTAAATTAATTAAGTCTCTTAATTAATTAATTAATTAATTAATTAAT 2141
 Db 2251 CTCTTCTTCTTAAATTAATTAAGTCTCTTAATTAATTAATTAATTAATTAATTAAT 2289

RESULT 7
 AAS21377
 ID AAS21377 standard; CDNA, 2290 BP.
 XX
 AC AAS21377;

XX 24-OCT-2001 (first entry)
 XX
 DE Human CDNA sequence encoding for PRO196 polypeptide.
 XX
 KW Human secretory and tumour membrane; PRO; mammalian; cancer; lung; breast;
 KW prostate; cervical; tumour necrosis factor- α ; TNF- α ; cartilage;
 KW ear; proliferation; glucose; free fatty acid; skeletal muscle; adipocyte;
 KW A-peptide; factor VIIa; gene therapy; ss.
 XX
 OS Homo sapiens.
 XX
 PN W0200140466-A2.
 XX
 PD 07-JUN-2001.
 XX
 PF 01-DEC-2000; 2000MO-US032678.
 XX
 PR 01-DEC-1999; 99MO-US028301.
 PR 01-DEC-1999; 99MO-US028634.
 PR 02-DEC-1999; 99MO-US028551.
 PR 02-DEC-1999; 99MO-US028564.
 PR 02-DEC-1999; 99MO-US028565.
 PR 09-DEC-1999; 99US-0170262P.
 PR 16-DEC-1999; 99MO-US030095.
 PR 20-DEC-1999; 99MO-US030911.
 PR 20-DEC-1999; 99MO-US030999.
 PR 30-DEC-1999; 99MO-US031243.
 PR 30-DEC-1999; 99MO-US031274.
 PR 05-JAN-2000; 2000MO-US000219.
 PR 06-JAN-2000; 2000MO-US000277.
 PR 06-JAN-2000; 2000MO-US000376.
 PR 11-FEB-2000; 2000MO-US003565.
 PR 18-FEB-2000; 2000MO-US004341.
 PR 18-FEB-2000; 2000MO-US004342.
 PR 22-FEB-2000; 2000MO-US004414.
 PR 24-FEB-2000; 2000MO-US004914.
 PR 24-FEB-2000; 2000MO-US005004.
 PR 01-MAR-2000; 2000MO-US005841.
 PR 02-MAR-2000; 2000MO-US005841.
 PR 03-MAR-2000; 2000MO-US005841.
 PR 10-MAR-2000; 2000MO-US006319.
 PR 15-MAR-2000; 2000MO-US006884.
 PR 20-MAR-2000; 2000MO-US007377.
 PR 21-MAR-2000; 2000MO-US007532.
 PR 30-MAR-2000; 2000MO-US008439.
 PR 17-MAY-2000; 2000MO-US013705.
 PR 22-MAY-2000; 2000MO-US014042.
 PR 30-MAY-2000; 2000MO-US014941.
 PR 02-JUN-2000; 2000MO-US015264.
 PR 05-JUN-2000; 2000MO-US019832P.
 PR 28-JUL-2000; 2000MO-US020710.
 PR 11-AUG-2000; 2000MO-US020231.
 PR 23-AUG-2000; 2000MO-US023522.
 PR 24-AUG-2000; 2000MO-US023528.
 PR 08-NOV-2000; 2000MO-US030952.
 PR 10-NOV-2000; 2000MO-US030873.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 DR WPI; 2001-408281/43.
 DR P-PSDB; AAU12305.
 XX
 PT Isolated, secretory and transmembrane PRO polypeptide used to detect
 PT other PRO polypeptides, link bioactive molecules to cells expressing PRO
 PT polypeptides, and detect the presence of mammalian tumors e.g. lung,
 PT breast, prostate, cervical.
 XX
 PS Claim 3; Fig 267; 813pp; English.

XX AAS21244-AAS21518 encode for novel human secretory and transmembrane PRO
CC polypeptides. The PRO polypeptides are useful to detect other PRO
CC polypeptides, to link bioactive molecules to cells expressing PRO
CC polypeptides, to modulate biological activities of cells expressing PRO
CC polypeptides, and to detect the presence of mammalian lung, colon,
CC breast, prostate, rectal, cervical or liver tumours by comparing PRO
CC polypeptide expression in a cell sample to that in a control sample. Some
CC of the 275 sequences are also useful to stimulate the release of tumour
CC necrosis factor-alpha (TNF-alpha) from human blood, the proliferation or
CC differentiation of chondrocytes, the proliferation or gene expression in
CC pericyte cells, the release of proteoglycans from cartilage, the
CC proliferation of inner ear utricular supporting cells or of T-
CC lymphocytes, the release of a cytokine from peripheral blood monocytes
CC (PMNCs) or the proliferation of endothelial cells. Some of the PRO
CC polypeptides may modulate glucose or free fatty acid uptake by skeletal
CC muscle cells or by adipocytes; or inhibit binding of A-peptide to factor
CC VIIA. The PRO polypeptides can be used in assays to identify molecules
CC involved in binding interactions. The polynucleotides encoding PRO
CC polypeptides can be used to generate probes, antisense RNA/DNA,
CC transgenic or knock out animals and can be used in gene therapy
CC
SQ Sequence 2290 BP; 537 A; 692 C; 668 G; 393 T; 0 U; 0 Other;

Query Match 98.1%; Score 2132.6; DB 4; Length 2290;
Best Local Similarity 99.8%; Pred. No. 0;
Matches 2135; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 3 AATATAGGCTGTGGGAGCGGCTGAGATGAAACCCAGCCCTGAGCTGCGGAGCTG 62
Db 151 AATATAGGCTGTGGGAGCGGCTGAGATGAAACCCAGCCCTGAGCTGCGGAGCTG 210
QY 63 GCAGTGAAGGAGCGGCTGACGCTACTGTAGAGGAAAGAGTTGTAGACAGCCCGCAGG 122
Db 211 GCAGTGAAGGAGCGGCTGACGCTACTGTAGAGGAAAGAGTTGTAGACAGCCCGCAGG 270
QY 123 ACCCTGCGCAGCCCTGCGCCCAAGCTTCTGCGGAGCCCTCTGTGAGAGCAGAGCAGT 182
Db 271 ACCCTGCGCAGCCCTGCGCCCAAGCTTCTGCGGAGCCCTCTGTGAGAGCAGAGCAGT 330
QY 183 GAGCCAGTGAAGGAGCGGCTGTGGAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 242
Db 331 GAGCCAGTGAAGGAGCGGCTGTGGAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 390
QY 243 AGGCGATGAGAGGCTGCGCTGACGCGCCAGGCTGAAAGCATGTGAGAGCTCGCCCGG 302
Db 391 AGGCGATGAGAGGCTGCGCTGACGCGCCAGGCTGAAAGCATGTGAGAGCTCGCCCGG 450
QY 303 AACCAAGCAGGAGGAGGAGGCTTCATGATTCTATTACAAAGAAATTAACCACTTT 362
Db 451 AACCAAGCAGGAGGAGGAGGCTTCATGATTCTATTACAAAGAAATTAACCACTTT 510
QY 363 GCAAGAACCATGAGGCACTGTGCTGACATGCTGTGCTGGAATGCTGCTGCCATG 422
Db 511 GCAAGAACCATGAGGCACTGTGCTGACATGCTGTGCTGGAATGCTGCTGCCATG 570
QY 423 GAGAGCTGTGACAGCCAGAGAGACGTTTGAAGGCGATGAGAGGCTCGGCAAGAG 482
Db 571 GAGAGCTGTGACAGCCAGAGAGACGTTTGAAGGCGATGAGAGGCTCGGCAAGAG 630
QY 483 TTCAATTACCTTAAACAGTAAACAGCGGCGGCGAGTCCACAGACAAAGTGACCTTAAC 542
Db 631 TTCAATTACCTTAAACAGTAAACAGCGGCGGCGAGTCCACAGACAAAGTGACCTTAAC 690
QY 543 TTCAATTGTGCCCCAGAGAGGCGGTCAAGGCTGCTCACTCCAGAGAGCTGAG 602
Db 691 TTCAATTGTGCCCCAGAGAGGCGGTCAAGGCTGCTCACTCCAGAGAGCTGAG 750
QY 603 GTGCTTCTGAGAAACGAGTGCATAAGCAGAGAGCTGAGCTGCTCAACATGAGCTGCTC 662
Db 751 GTGCTTCTGAGAAACGAGTGCATAAGCAGAGAGCTGAGCTGCTCAACATGAGCTGCTC 810
QY 663 AAGCAGAAAGCGAGATCGAGAGCTGACAGAGCTGTGAAAGTGAAGCGGCGCATTTG 722

Db 811 AAGCAGAAAGCGAGATCGAGAGCTGACAGAGCTGTGAGAGGTGAGCGGCGCATTTG 870
QY 723 AGGAGGTGAGAGTGTGTGGCAAGAGAGAGCCGCAATGAACTCGGCGGCTCAAGCAGCTC 782
Db 871 AGGAGGTGAGAGTGTGTGGCAAGAGAGAGCCGCAATGAACTCGGCGGCTCAAGCAGCTC 930
QY 783 TACATGAGCTCTGTGACAGAGATCATCCGACGAGGAGCAACGCTTGAAGCTTCTCCAG 842
Db 931 TACATGAGCTCTGTGACAGAGATCATCCGACGAGGAGCAACGCTTGAAGCTTCTCCAG 990
QY 843 CTGAGAAACAGATCTCTGAACCAAGACCGCAATCTCTGAGCTGCGCAAGTACAG 902
Db 991 CTGAGAAACAGATCTCTGAACCAAGACCGCAATCTCTGAGCTGCGCAAGTACAG 1050
QY 903 GACCTGAGACAGATGACAGACAGCACTGACCACTGAGCCCAACCAATCAGAGATCATC 962
Db 1051 GACCTGAGACAGATGACAGACAGCACTGACCACTGAGCCCAACCAATCAGAGATCATC 1110
QY 963 GCGAGCTTGAAGAGCACTGCGAGAGGCTGCTGCGGCGGCGGCTGCGGCGGCGGCGG 1022
Db 1111 GCGAGCTTGAAGAGCACTGCGAGAGGCTGCTGCGGCGGCGGCTGCGGCGGCGGCGG 1170
QY 1023 CCGGCTGCGGCGGCGGCGGCTGCTGCGGCGGCGGCTGCGGCGGCGGCGGCGGCGGCGG 1082
Db 1171 CCGGCTGCGGCGGCGGCGGCTGCTGCGGCGGCGGCTGCGGCGGCGGCGGCGGCGGCGG 1230
QY 1083 TCTACCAAGAGATTCAGAGTGAACAGAACCTGAGGTGCTGACCCCTCTGCGCACT 1142
Db 1231 TCTACCAAGAGATTCAGAGTGAACAGAACCTGAGGTGCTGACCCCTCTGCGCACT 1290
QY 1143 ATGCGCACTCTCACAGCTTCCATCTTCCACCGAACAGCCGCGGCGGCGGCGGCGGCGG 1202
Db 1291 ATGCGCACTCTCACAGCTTCCATCTTCCACCGAACAGCCGCGGCGGCGGCGGCGGCGG 1350
QY 1203 TGCGCTGAGGCGCTGAGAGTGAAGCAGCAGCAGCTCATCTTACCTGTGAGAGCGGAG 1262
Db 1351 TGCGCTGAGGCGCTGAGAGTGAAGCAGCAGCAGCTCATCTTACCTGTGAGAGCGGAG 1410
QY 1263 AACACCAACCGCTCATGACAGGTGTGTGTCGACCAAGAACAGAACCCCGGCGGCTGAGAC 1322
Db 1411 AACACCAACCGCTCATGACAGGTGTGTGTCGACCAAGAACAGAACCCCGGCGGCTGAGAC 1470
QY 1232 GTCAATCAGAGAGCGCTGAGTGTGCTGTTAACTTCTTACAGAACTGAGAGCTGACAG 1382
Db 1471 GTCAATCAGAGAGCGCTGAGTGTGCTGTTAACTTCTTACAGAACTGAGAGCTGACAG 1530
QY 1383 CAAGGCTTGGGAACATTGAACGAGAACTGCTGCGGCTGAGAAACATTACTGCGCTG 1442
Db 1531 CAAGGCTTGGGAACATTGAACGAGAACTGCTGCGGCTGAGAAACATTACTGCGCTG 1590
QY 1443 ACGAACAAGGCAATCAATCAATCTGTGAGACATGAGAGAGTGTGCGGCGGCAAGTGC 1502
Db 1591 ACGAACAAGGCAATCAATCAATCTGTGAGACATGAGAGAGTGTGCGGCGGCAAGTGC 1650
QY 1503 TTTGACAGAAATACGCACTTTCGCGCTGGAACCTGAGACGAGTATTAAGCTGCGGCTG 1562
Db 1651 TTTGACAGAAATACGCACTTTCGCGCTGGAACCTGAGACGAGTATTAAGCTGCGGCTG 1710
QY 1563 GGGCGCTACATGACATGCGGAGTGAATCTCTTTCATGAGGACAAAGGCAAGAGCTTAC 1622
Db 1711 GGGCGCTACATGACATGCGGAGTGAATCTCTTTCATGAGGACAAAGGCAAGAGCTTAC 1770
QY 1623 ACCCTGACAGAGATCATGATGTCTACACAGAAACTGTGCGCACTACAGAAAGGAGGC 1682
Db 1771 ACCCTGACAGAGATCATGATGTCTACACAGAAACTGTGCGCACTACAGAAAGGAGGC 1830
QY 1683 TGTGTATTAACGCTGCTGCTGCTCACTCAACTCAAGGCTGTGTACCGGCGGCGCAT 1742
Db 1831 TGTGTATTAACGCTGCTGCTGCTCACTCAACTCAAGGCTGTGTACCGGCGGCGCAT 1890
QY 1743 TACGAGAGCGCTACAGAGAGAGTCTACTGAGCTGAGGCTTCTACTCA 1802

QY 3 AAATGAGCTGCTGCGGAGACGAGCTGAGATGAATCCCAAGCCCTGAGACCTGCGAGCTG 62
 Db 151 AAATGAGCTGCTGCGGAGACGAGCTGAGATGAATCCCAAGCCCTGAGACCTGCGAGCTG 210
 QY 63 GCACTGAGGACGCGGTGACGCTACTGTGAGGAGAAAGAGGTTGTGACACGCCCCGAGG 122
 Db 211 GCACTGAGGACGCGGTGACGCTACTGTGAGGAGAAAGAGGTTGTGACACGCCCCGAGG 270
 QY 123 ACCCGTGGCAGCCCTGGGCCCCAGGCTGCGGAGGAGCCCTGTGTGAGAGGACGACATG 182
 Db 271 ACCCGTGGCAGCCCTGGGCCCCAGGCTGCGGAGGAGCCCTGTGTGAGAGGACGACATG 330
 QY 183 GAGCCAGTGAAGCAGAGGCTGCTTGTGACAGCCACGCGCTGCAACTCAGAAAACCCCTCCAG 242
 Db 331 GAGCCAGTGAAGCAGAGGCTGCTTGTGACAGCCACGCGCTGCAACTCAGAAAACCCCTCCAG 390
 QY 243 AAGCCATGGAACAGGCTGCCCCGCTGACGCGCCAGGGGTGAAGCATGTGAAGAGCCGCCGG 302
 Db 391 AAGCCATGGAACAGGCTGCCCCGCTGACGCGCCAGGGGTGAAGCATGTGAAGAGCCGCCGG 450
 QY 303 AGCCAGACGAGAGGAGAGGCTTTCATAGATTCTTATTCACAAAGATTAACACCATTT 362
 Db 451 AGCCAGACGAGAGGAGAGGCTTTCATAGATTCTTATTCACAAAGATTAACACCATTT 510
 QY 363 GCAAGACCATGAGGCTGCTGCTGACATGCTGTGCTGAGCTGCTGCTGCTGCTGCTGCTG 422
 Db 511 GCAAGACCATGAGGCTGCTGCTGACATGCTGTGCTGAGCTGCTGCTGCTGCTGCTGCTG 570
 QY 423 GAGGCTGTTGACAGGCGAGAGAGCGTTTGTGAGGACCTGAAGAGAGGCTCGCAGAGAG 482
 Db 571 GAGGCTGTTGACAGGCGAGAGAGCGTTTGTGAGGACCTGAAGAGAGGCTCGCAGAGAG 630
 QY 483 TTCAATTTAATTAAGATTAAGAGGAGGCGGAGGAGTCCAGAGCAATGACCTTCAAC 542
 Db 631 TTCAATTTAATTAAGATTAAGAGGAGGCGGAGGAGTCCAGAGCAATGACCTTCAAC 690
 QY 543 TTCAATTTGCCCCACAGAGGAGTCAAGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 602
 Db 691 TTCAATTTGCCCCACAGAGGAGTCAAGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 750
 QY 603 GTGCTTTGAGAGAACGAGAGTGCATTAAGACAGAGAGTGTCTCAACATGAGAGTGTG 662
 Db 751 GTGCTTTGAGAGAACGAGAGTGCATTAAGACAGAGAGTGTCTCAACATGAGAGTGTG 810
 QY 663 AAGCAGAGCGGACGATGACAGCTGACAGCTGTGTGAAGGTGGAAGCGGCAATTTG 722
 Db 811 AAGCAGAGCGGACGATGACAGCTGACAGCTGTGTGAAGGTGGAAGCGGCAATTTG 870
 QY 723 AAGCAGAGTGAAGCTGCTGCGCAAGAGAGCGCAATGAACTGCGGGGTCAAGAGCTG 782
 Db 871 AAGCAGAGTGAAGCTGCTGCGCAAGAGAGCGCAATGAACTGCGGGGTCAAGAGCTG 930
 QY 783 TACATGACGCTCTGACAGAGATCATCCGCAAGCGGAGCAACGCGTTGAGAGCTTCCAG 842
 Db 931 TACATGACGCTCTGACAGAGATCATCCGCAAGCGGAGCAACGCGTTGAGAGCTTCCAG 990
 QY 843 CTGAGAGACAGGATCTGTAACAGACAGCGCATGCTGACAGCTGCGCAGAGAGTAAAG 902
 Db 991 CTGAGAGACAGGATCTGTAACAGACAGCGCATGCTGACAGCTGCGCAGAGAGTAAAG 1050
 QY 903 GACCTGAGACCAAGTACAGGACCTGAGCAACTGAGCCCAACCAATCAGAGATCATC 962
 Db 1051 GACCTGAGACCAAGTACAGGACCTGAGCAACTGAGCCCAACCAATCAGAGATCATC 1110
 QY 963 GGGCAGCTTTGAGAGACATGCGCAGAGGAGTCCCTGTGCGCAGAGCCCTCCAGCAGCC 1022
 Db 1111 GGGCAGCTTTGAGAGACATGCGCAGAGGAGTCCCTGTGCGCAGAGCCCTCCAGCAGCC 1170
 QY 1023 CCGGCTGCGCCCGCCGCGGTCTACCAACACCACTCAACCGGATCATCAACAGATC 1082
 Db 1171 CCGGCTGCGCCCGCCGCGGTCTACCAACACCACTCAACCGGATCATCAACAGATC 1230

QY 1083 TTTACCAACGAGATTCAGAGTGAACAGAACTTGAAGTGTGACCAACCCCTCTGCCACT 1142
 Db 1231 TTTACCAACGAGATTCAGAGTGAACAGAACTTGAAGTGTGACCAACCCCTCTGCCACT 1290
 QY 1143 ATGCCACTCTCAACAGGCTTCCATTTTCCACCGCAAGCCGTCGGGCCCATGAGAGAC 1202
 Db 1291 ATGCCACTCTCAACAGGCTTCCATTTTCCACCGCAAGCCGTCGGGCCCATGAGAGAC 1350
 QY 1203 TGCCTGAGAGCCCTGAGAGATGAGCAACAGGCTCCATCTTCACTGAGTGAAGCCGAG 1262
 Db 1351 TGCCTGAGAGCCCTGAGAGATGAGCAACAGGCTCCATCTTCACTGAGTGAAGCCGAG 1410
 QY 1263 AAGCAACCCGCTCATGAGAGTGTGTGTGACAGAGACAGACCCCGGGGCTGAGAC 1322
 Db 1411 AAGCAACCCGCTCATGAGAGTGTGTGTGACAGAGACAGACCCCGGGGCTGAGAC 1470
 QY 1323 GTCATCCAGAGAGCCCTGAGAGTGTGTGTGACAGAGACAGACCCCGGGGCTGAGAC 1382
 Db 1471 GTCATCCAGAGAGCCCTGAGAGTGTGTGTGACAGAGACAGACCCCGGGGCTGAGAC 1530
 QY 1383 CAAAGGTTTGGAGAACATTAAGCGGAAATCTGCTGAGGCTGAGAGAACATTTAGCTG 1442
 Db 1531 CAAAGGTTTGGAGAACATTAAGCGGAAATCTGCTGAGGCTGAGAGAACATTTAGCTG 1590
 QY 1443 AGCAACCAAGGCAACTTAACATCTGCTGAGACCATGAGAGAGTGTGCGGCGGCAAGTC 1502
 Db 1591 AGCAACCAAGGCAACTTAACATCTGCTGAGACCATGAGAGAGTGTGCGGCGGCAAGTC 1650
 QY 1503 TTGCAAGAAATACGCAATTTCCGCTGAGAACCTGAGAGAGAGATTAATTAAGCTGAG 1562
 Db 1651 TTGCAAGAAATACGCAATTTCCGCTGAGAACCTGAGAGAGAGATTAATTAAGCTGAG 1710
 QY 1563 GGGCGCTACCATGAGCAATGCGGAGTCTCTTTACATGAGCAACAGGCAAGATTTAC 1622
 Db 1711 GGGCGCTACCATGAGCAATGCGGAGTCTCTTTACATGAGCAACAGGCAAGATTTAC 1770
 QY 1623 ACCCTGACAGAGATCATGATGTCTACACAGAGAACTGTGCCACTACAGAGAGAGAG 1682
 Db 1771 ACCCTGACAGAGATCATGATGTCTACACAGAGAACTGTGCCACTACAGAGAGAGAG 1830
 QY 1683 TGGTGGATTAACGCTGTGCCACTTCAACCTTCAACGAGGAGTGTGATCCGCGGGGCA 1742
 Db 1831 TGGTGGATTAACGCTGTGCCACTTCAACCTTCAACGAGGAGTGTGATCCGCGGGGCA 1890
 QY 1743 TACCGAGCGCTACAGAGAGAGTCTACTGGGCTGAGTTCGAGAGAGGCTCTTAATCA 1802
 Db 1891 TACCGAGCGCTACAGAGAGAGTCTACTGGGCTGAGTTCGAGAGAGGCTCTTAATCA 1950
 QY 1803 CTCAGAAAGTGTGATGATGATCCGACCGAAACCCCAACACCTTCCACTTAAGCACTCC 1862
 Db 1951 CTCAGAAAGTGTGATGATGATCCGACCGAAACCCCAACACCTTCCACTTAAGCACTCC 2010
 QY 1863 CCTCTCTGACCTTCTGTGCAATGCTGAGAGAGCCCAACCTTCCACTTAAGCACTCC 1922
 Db 2011 CCTCTCTGACCTTCTGTGCAATGCTGAGAGAGCCCAACCTTCCACTTAAGCACTCC 2070
 QY 1923 AAGAGCAACTCTCTCAACAGTTCATCTGAGGCTGAGAGAGCCGAGATCTGATTTCT 1982
 Db 2071 AAGAGCAACTCTCTCAACAGTTCATCTGAGGCTGAGAGAGCCGAGATCTGATTTCT 2130
 QY 1983 TTTCCGAAGTCACTGAGAGAGATGATGAATGAATGATGATGATGATGATGATGATGAT 2042
 Db 2131 TTTCCGAAGTCACTGAGAGAGATGATGAATGAATGATGATGATGATGATGATGATGAT 2190
 QY 2043 TACTTCTCTTACACAGAGAGAGGCTCTATGCTCCAGAGACAGAGAGAGAGAGAGAG 2102
 Db 2191 TACTTCTCTTACACAGAGAGAGGCTCTATGCTCCAGAGACAGAGAGAGAGAGAGAG 2250
 QY 2103 CTCTTTCTTAAATAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 2141
 Db 2251 CTCTTTCTTAAATAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 2289

RESULT 10
ACD23986
ID ACD23986 standard; cDNA, 2290 BP.
XX
AC ACD23986;
XX
DT 26-AUG-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO196 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; antiinflammatory;
KW antiarteriosclerotic; cardiant; anti-infectivity; anti-HIV; cytostatic;
KW antidiabetic; gene therapy; tumour necrosis factor (TNF)-alpha release;
KW TNF-alpha release; cell proliferation; cell differentiation;
KW gene expression modulator; proteoglycan release; cytokine release;
KW tumour; inflammatory disease; organ failure; atherosclerosis;
KW cardiac injury; infertility; birth defect; premature aging; AIDS;
KW acquired immunodeficiency syndrome; cancer; diabetic complication;
KW chromosome mapping; gene mapping; pharmaceutical; diagnostic; biosensor;
KW bio reactor; tissue typing; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003032156-A1.
XX
PD 13-FEB-2003.
XX
PF 06-MAY-2002; 2002US-00140474.
XX
PR 31-MAR-1997; 97WO-US0052230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019099.
PR 14-SEP-1998; 98WO-US019177.
PR 14-SEP-1998; 98WO-US019330.
PR 16-SEP-1998; 98WO-US019437.
PR 17-SEP-1998; 98WO-US021144.
PR 07-OCT-1998; 98WO-US022999.
PR 29-OCT-1998; 98WO-US023992.
PR 29-OCT-1998; 98WO-US024855.
PR 20-NOV-1998; 98WO-US025106.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008613.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028554.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 22-DEC-1999; 99WO-US030999.
PR 23-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.

PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUN-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US032678.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00864280.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017830.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882536.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-009308827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W,
PI Gerlitsen ME, Geddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI, 2003-341980/32.
DR P-PSDB; ABO17749.
XX
PT New secreted and transmembrane PRO nucleic acids, for treating
PT inflammation, organ failure, atherosclerosis, cardiac injury,
PT infertility, birth defects, premature aging, acquired immunodeficiency
PT syndrome (AIDS), or cancer.
XX
PS Claim 2; Fig 267; 660pp; English.
XX
CC The invention describes an isolated nucleic acid (I) comprising, or which

CC has 80 % sequence identity to, or the full-length coding sequence of, one
CC of 275 nucleotide sequences, and which encodes a corresponding
CC polypeptide selected from 275 amino acid sequences, where all sequences
CC are given in the specification. The polypeptide encoded by (1) is used to
CC detect PRO polypeptides, link a bioactive molecule to a cell expressing a
CC PRO polypeptide, modulate a biological activity of a cell, stimulate the
CC release of tumour necrosis factor (TNF)-alpha from human blood, modulate
CC the uptake of glucose or free fatty acid by cells, stimulate or inhibit
CC the proliferation or differentiation of cells or gene expression,
CC stimulate the release of proteoglycans, stimulate the release of cytokine
CC from peripheral blood mononuclear cells, inhibit the binding of A-peptide
CC to factor VIIa, or detect the presence of tumour in a mammal. The nucleic
CC acid and polypeptide encoded by it, are useful for treating inflammatory
CC diseases, organ failure, atherosclerosis, cardiac injury, infertility,
CC birth defects, premature aging, acquired immunodeficiency syndrome
CC (AIDS), cancer, or diabetic complications. The nucleic acid is useful as
CC hybridisation probes, in chromosome and gene mapping, and in generating
CC antisense RNA or DNA. The polypeptides are useful as pharmaceuticals,
CC diagnostics, biosensors or bioreactors. Both are useful in tissue typing.
CC This sequence encodes a novel human secreted and transmembrane PRO
CC polypeptide
XX

Sequence 2290 BP; 537 A; 692 C; 668 G; 393 T; 0 U; 0 Other;

Query Match 98.1%; Score 2132.6; DB 7; Length 2290;

Best Local Similarity 99.8%; Pred. No. 0;

Matches 2135; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```
QY 3 AATGAGGCTGCTGCGGAGAGGCTGAGATGAACCCCAAGCCCTGAGACTGCGGAGCTG 62
DB 151 AATGAGGCTGCTGCGGAGAGGCTGAGATGAACCCCAAGCCCTGAGACTGCGGAGCTG 210
QY 63 GCACTGAGGACAGCGGCTGAGCTGCTGAGGAGAAAGAGTTTGAGCAGACCCCGCAGG 122
DB 211 GCACTGAGGACAGCGGCTGAGCTGCTGAGGAGAAAGAGTTTGAGCAGACCCCGCAGG 270
QY 123 ACCCTGCGCAGCCCTGCGGCTGAGCTGCTGCGGAGCCCTCTGTGAGAGCGAGCAGTG 182
DB 271 ACCCTGCGCAGCCCTGCGGCTGAGCTGCTGCGGAGCCCTCTGTGAGAGCGAGCAGTG 330
QY 183 GAGCCAGTGAAGGAGGAGGCTGCTGAGCAGCCAGCCGCTGCACTCAGGAACCCCTCAG 242
DB 331 GAGCCAGTGAAGGAGGAGGCTGCTGAGCAGCCAGCCGCTGCACTCAGGAACCCCTCAG 390
QY 243 AGGCCATGAGCAGGCTGCTGCGGCTGAGCGGCAAGGCTGAGAGTGAAGAGCGCCCGG 302
DB 391 AGGCCATGAGCAGGCTGCTGCGGCTGAGCGGCAAGGCTGAGAGTGAAGAGCGCCCGG 450
QY 303 AGCCAGAGGAGGAGGAGGCTTCAATGATTTCAATTCATCAAGAAATTAACCACTTTT 362
DB 451 AGCCAGAGGAGGAGGAGGCTTCAATGATTTCAATTCATCAAGAAATTAACCACTTTT 510
QY 363 GCAAGAGCATTGAGGCACTGCTGCTGAGCATGCTGCTGCTGCTGCTGCTGCTGCTGCTG 422
DB 511 GCAAGAGCATTGAGGCACTGCTGCTGAGCATGCTGCTGCTGCTGCTGCTGCTGCTGCTG 570
QY 423 GAGAGCTGTTGAGAGGCAAGAGGCTTTTGAAGGCACTGAGAGGCTGCTGCTGCTGCTG 482
DB 571 GAGAGCTGTTGAGAGGCAAGAGGCTTTTGAAGGCACTGAGAGGCTGCTGCTGCTGCTG 630
QY 483 TTCATTATTAACCTAAACAGGTACAAAGGCGGCGGAGCTCCAGAGCAAGTGAACCTAAC 542
DB 631 TTCATTATTAACCTAAACAGGTACAAAGGCGGCGGAGCTCCAGAGCAAGTGAACCTAAC 690
QY 543 TTCATTGTTGCGCCAGAGCGGCTGACCGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 602
DB 691 TTCATTGTTGCGCCAGAGCGGCTGACCGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 750
QY 603 GTGCTTCTGAGAAACCGAGTCAATAGCAGAGGCTGCTGCTGCTGCTGCTGCTGCTGCTG 662
DB 751 GTGCTTCTGAGAAACCGAGTCAATAGCAGAGGCTGCTGCTGCTGCTGCTGCTGCTGCTG 810
QY 663 AAGCAGAAAGCGGAGATGAGACGCTGAGCAAGCTGCTGCTGCTGCTGCTGCTGCTGCTG 722
```

```
DB 811 AAGCAGAAAGCGGAGATGAGACGCTGAGCAAGCTGCTGCTGCTGCTGCTGCTGCTGCTG 870
QY 723 AGCAGGTGAAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 782
DB 871 AGCAGGTGAAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 930
QY 783 TACATGAGCTCTGTCAGAGATCATTCGGAACGGGAGCAAGCTTGGAGCTCTCCAG 842
DB 931 TACATGAGCTCTGTCAGAGATCATTCGGAACGGGAGCAAGCTTGGAGCTCTCCAG 990
QY 843 CTGAGAGACAGAGATCTGCAACAGAGCCGATGCTGAGCTGCGCAGAGTCAAG 902
DB 991 CTGAGAGACAGAGATCTGCAACAGAGCCGATGCTGAGCTGCGCAGAGTCAAG 1050
QY 903 GACTGAGACCAAGTACCGAGCACTGCGCACTGCGCCACCAACCAATGAGATCATC 962
DB 1051 GACTGAGACCAAGTACCGAGCACTGCGCACTGCGCCACCAACCAATGAGATCATC 1110
QY 963 GCGAGCTTGAAGAGACATGCGCAGAGGCTGCTGCGGAGCGGCTGCGGAGCGGAGCGG 1022
DB 1111 GCGAGCTTGAAGAGACATGCGCAGAGGCTGCTGCGGAGCGGCTGCGGAGCGGAGCGG 1170
QY 1023 CCGGCTGCGGCGGCGGCTGCTGCAACCAAGCCGATGCTGAGCTGCTGAGTCAAGATC 1082
DB 1171 CCGGCTGCGGCGGCGGCTGCTGCAACCAAGCCGATGCTGAGCTGCTGAGTCAAGATC 1230
QY 1083 TCTACCAAGAGATCCAGAGTGAAGAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGT 1142
DB 1231 TCTACCAAGAGATCCAGAGTGAAGAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGT 1290
QY 1143 ATGCCACTCTCAACAGCTCTCCATCTTCCACAGCAACCGCTGCGGAGCCATGAGAGAC 1202
DB 1291 ATGCCACTCTCAACAGCTCTCCATCTTCCACAGCAACCGCTGCGGAGCCATGAGAGAC 1350
QY 1203 TGCTGAGAGCTCTGAGAGATGCGCAGACACCAAGTCAATCTTCTGAGTGAAGCGGAG 1262
DB 1351 TGCTGAGAGCTCTGAGAGATGCGCAGACACCAAGTCAATCTTCTGAGTGAAGCGGAG 1410
QY 1263 AACCAACCGGCTCTGAGAGTGTGCTGAGACAGAGACAGACCGCGGAGGCTGAGAC 1322
DB 1411 AACCAACCGGCTCTGAGAGTGTGCTGAGACAGAGACAGACCGCGGAGGCTGAGAC 1470
QY 1323 GTCATCAAGAGCGCTGAGTGGCTGTGTTAACTTCTTCAAGAACTGAGAGAGTCAAG 1382
DB 1471 GTCATCAAGAGCGCTGAGTGGCTGTGTTAACTTCTTCAAGAACTGAGAGAGTCAAG 1530
QY 1383 CAAGGCTTGGAGAACTGAAGGCAATCTGCTGAGGCTGAGGAACTTAACTGAGGCTG 1442
DB 1531 CAAGGCTTGGAGAACTGAAGGCAATCTGCTGAGGCTGAGGAACTTAACTGAGGCTG 1590
QY 1443 ACGAACCAAGGCAATCAAACTCTGCTGAGCAATGAGAGTGTGCGGCGCAAGATC 1502
DB 1591 ACGAACCAAGGCAATCAAACTCTGCTGAGCAATGAGAGTGTGCGGCGCGCAAGATC 1650
QY 1503 TTTGCAAGTAAAGCCAGCTTCCGCTGAGAACTGAGAGCGAGTATTAAGTGGGCTG 1562
DB 1651 TTTGCAAGTAAAGCCAGCTTCCGCTGAGAACTGAGAGCGAGTATTAAGTGGGCTG 1710
QY 1563 GGGCGCTACCATGAGCATGCGGCTGCTCTTAAATGAGCAACGCGAAGAGTTCACC 1622
DB 1711 GGGCGCTACCATGAGCATGCGGCTGCTCTTAAATGAGCAACGCGAAGAGTTCACC 1770
QY 1623 ACCCTGAGACAGATCATGATGTCTTACACAGAGAACTGTGCCATTAACAGAGGAGGC 1682
DB 1771 ACCCTGAGACAGATCATGATGTCTTACACAGAGAACTGTGCCATTAACAGAGGAGGC 1830
QY 1683 TGTGTATTAACGCTGCTGCGCAGTCAACCTCAACGCGGCTGCTGCTGCTGCTGCTGCTG 1742
DB 1831 TGTGTATTAACGCTGCTGCGCAGTCAACCTCAACGCGGCTGCTGCTGCTGCTGCTGCTG 1890
QY 1743 TACCGAGCGCTTACAGAGCGAGTCTTCTGAGGCTGAGGCTTCTTACTCA 1802
```


CC amino acid sequence identity to 30 secreted and transmembrane
 CC polypeptides. PRO polypeptides are also useful for stimulating
 CC hypertrophy of adult heart, for inhibiting vascular endothelial growth
 CC factor stimulated proliferation of endothelial cells, stimulating
 CC proliferation of stimulated T-lymphocytes and for inducing proliferation
 CC of PD12 pancreatic ductal cells and are thus useful in the treatment of
 CC disorders which involve protein secretion by the pancreas, including
 CC diabetes. PRO polypeptides are useful for inducing vascular permeability
 CC and in enhancing survival of retinal neurons cells and are thus useful
 CC for the treatment of retinal disorders. PRO polypeptides are also useful
 CC for stimulating an immune response and inducing inflammation by inducing
 CC mononuclear cell and eosinophil infiltration at the site of infection of
 CC an animal. The PRO polypeptides are further useful for inducing apoptosis
 CC in endothelial cells for inhibiting neoplastic growth. This sequence
 CC encodes a novel human secreted and transmembrane PRO polypeptide
 XX
 SQ Sequence 2290 BP; 537 A; 692 C; 668 G; 393 T; 0 U; 0 Other;

Query Match 98.1%; Score 2132.6; DB 7; Length 2290;
 Best Local Similarity 99.8%; Pred. No. 0;
 Matches 2135; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 3 AATGAGGCTGCTGGGAGCGCTTGAAGTGAACCCCAAGCCCTGAGACTGCGGAGCGTG 62
 DB 151 AATGAGGCTGCTGGGAGCGCTTGAAGTGAACCCCAAGCCCTGAGACTGCGGAGCGTG 210
 QY 63 GAGCTGAGGAGCGGCTGAGCTGAGTGAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 122
 DB 211 GAGCTGAGGAGCGGCTGAGCTGAGTGAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 270
 QY 123 ACCCTGAGGAGCGGCTGAGCTGAGTGAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 182
 DB 271 ACCCTGAGGAGCGGCTGAGCTGAGTGAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 330
 QY 183 GAGCCAGTGAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 242
 DB 331 GAGCCAGTGAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 390
 QY 243 AGGCGATGAGAGGCTGCGCCGCTGAGCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 302
 DB 391 AGGCGATGAGAGGCTGCGCCGCTGAGCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 450
 QY 303 AGCCAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 362
 DB 451 AGCCAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 510
 QY 363 GGAAGAGCATGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 422
 DB 511 GGAAGAGCATGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 570
 QY 422 GAGCTGTTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 482
 DB 571 GAGCTGTTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 630
 QY 483 TTCAATTTAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 542
 DB 631 TTCAATTTAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 690
 QY 543 TTCAATTTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 602
 DB 691 TTCAATTTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 750
 QY 603 GTGCTTTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 662
 DB 751 GTGCTTTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 810
 QY 663 AAGCAGAGCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 722
 DB 811 AAGCAGAGCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 870
 QY 723 AGCGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 782
 DB 871 AGCGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 930

QY 783 TACATGAGGCTCTGCAACGAGATCATCCGAGCGGAGCAAGCGCTTGGAGCTCTCCAG 842
 DB 931 TACATGAGGCTCTGCAACGAGATCATCCGAGCGGAGCAAGCGCTTGGAGCTCTCCAG 990
 QY 843 CTGAGAGAGGAGATCTGGAACGAGAGCGAGATGATGAGTGGAGGAGGAGGAGGAGGAGG 902
 DB 991 CTGAGAGAGGAGATCTGGAACGAGAGCGAGATGATGAGTGGAGGAGGAGGAGGAGGAGG 1050
 QY 903 GACCTGAGAGCAAGTACGAGACCTGGCCACCTGGCCACCAATCAATGAGATCATC 962
 DB 1051 GACCTGAGAGCAAGTACGAGACCTGGCCACCTGGCCACCAATCAATGAGATCATC 1110
 QY 963 GCGCAGTTGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1022
 DB 1111 GCGCAGTTGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1170
 QY 1023 CCGCTGCCCCCGCCGCTTACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 1082
 DB 1171 CCGCTGCCCCCGCCGCTTACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 1230
 QY 1083 TCTACCAAGAGATCCAGAGTGAACGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1142
 DB 1231 TCTACCAAGAGATCCAGAGTGAACGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1290
 QY 1143 ATGCCACTCTACAGAGCTCCCATCTTCCACGAGAGGAGGAGGAGGAGGAGGAGGAGGAG 1202
 DB 1291 ATGCCACTCTACAGAGCTCCCATCTTCCACGAGAGGAGGAGGAGGAGGAGGAGGAGGAG 1350
 QY 1203 TGCTTGAGGAGGCTGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1262
 DB 1351 TGCTTGAGGAGGCTGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1410
 QY 1263 AACCAACCGGCTTACAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1322
 DB 1411 AACCAACCGGCTTACAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1470
 QY 1471 GTCATCAGAGAGCGCTGAGATGCTCTTAACTTTCAGAGAGCTGGAGAGGAGGAGGAG 1530
 DB 1383 CAAGGAGTTGGAGAGCTTGAACGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1442
 DB 1531 CAAGGAGTTGGAGAGCTTGAACGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1590
 QY 1443 ACGAACCAAGGAGCACTAACAATCTGATGAGCAGATGAGAGCTGTCGCGCGCAAGTC 1502
 DB 1591 ACGAACCAAGGAGCACTAACAATCTGATGAGCAGATGAGAGCTGTCGCGCGCAAGTC 1650
 QY 1503 TTTGCAAGATAGCCAGTTTCCGCTGGAACCTGAGAGGAGGAGGAGGAGGAGGAGGAGG 1562
 DB 1651 TTTGCAAGATAGCCAGTTTCCGCTGGAACCTGAGAGGAGGAGGAGGAGGAGGAGGAGG 1710
 QY 1563 GGGCGCTACATGAGCAATGCGGAGTCTCTTAACTGAGCAACGAGGAGGAGGAGGAGGAG 1622
 DB 1711 GGGCGCTACATGAGCAATGCGGAGTCTCTTAACTGAGCAACGAGGAGGAGGAGGAGGAG 1770
 QY 1623 ACCCTGAGAGAGATCATGATGCTTACACAGAGAACTGTGCCACTTACAGAGAGGAGG 1682
 DB 1771 ACCCTGAGAGAGATCATGATGCTTACACAGAGAACTGTGCCACTTACAGAGAGGAGG 1830
 QY 1683 TGGTGTATTAAGCGCTGTGCGCACTCCAACTGAGAGGAGGAGGAGGAGGAGGAGGAGGAG 1742
 DB 1831 TGGTGTATTAAGCGCTGTGCGCACTCCAACTGAGAGGAGGAGGAGGAGGAGGAGGAGGAG 1890
 QY 1743 TACCGAGCGCTACAGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1802
 DB 1891 TACCGAGCGCTACAGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1950
 QY 1803 CTCAGAAAGTGTATGATGATCCGAGCGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1862
 DB 1951 CTCAGAAAGTGTATGATGATCCGAGCGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 2010

QY 1863 CCTCTGCTCTCTGTCGATGTCAGAGAGCCACCTGTCAGCGTGGCCACAGC 1922
| | | | |
Db 2011 CCTCTGCTCTCTGTCGATGTCAGAGAGCCACCTGTCAGCGTGGCCACAGC 2070
| | | | |
QY 1923 AAGAACAATCTCTCAGCAGTTCATCTGAGGCTGGAGAGCCGGAGTCTGATTTCTGT 1982
| | | | |
Db 2071 AAGAACAATCTCTCAGCAGTTCATCTGAGGCTGGAGAGCCGGAGTCTGATTTCTGT 2130
| | | | |
QY 1983 TTTCGAGTCACTGAGCGGATGATGAGACTGATTCATGAGTCTGTCCTCC 2042
| | | | |
Db 2131 TTTCGAGTCACTGAGCGGATGATGAGACTGATTCATGAGTCTGTCCTCC 2190
| | | | |
QY 2043 TACTTCTCTTCCAGCAGCAGCCCTCATGTCCTCAGAGACAGAGACTACAGACA 2102
| | | | |
Db 2191 TACTTCTCTTCCAGCAGCAGCCCTCATGTCCTCAGAGACAGAGACTACAGACA 2250
| | | | |
QY 2103 CTCTTCTTTAATAATTAACTCTCTACATAAAAACA 2141
| | | | |
Db 2251 CTCTTCTTTAATAATTAACTCTCTACATAAAAACA 2289
| | | | |
RESULT 12
ACA67127
ID ACA67127 standard; cDNA; 2290 BP.
XX
XX
AC ACA67127;
XX
XX
DT 23-JUN-2003 (first entry)
XX
XX
DE cDNA encoding human PRO polypeptide #134.
XX
XX
KW Human; PRO polypeptide; secreted and transmembrane protein;
KW anti-PRO antibody; diagnostic assay; gene expression; diabetes;
KW bone disorder; cartilage disorder; rheumatoid arthritis; obesity;
KW sports injury; osteoarthritis; hyper-insulinaemia; hypo-insulinaemia;
KW hearing loss; coagulation disorder; stroke; heart attack; candidant;
KW antidiabetic; anorectic; vulnary; arthritis; osteopathic;
KW antihemetic; auditory; cerebroprotective; angiogenic; gene; ss.
XX
XX
OS Homo sapiens.
XX
XX
PN US2003004311-A1.
XX
PD 02-JAN-2003.
XX
PF 19-DEC-2001; 2001US-00028072.
XX
XX
PR 18-JUN-1997; 97US-0049911P.
PR 26-AUG-1997; 97US-0056974P.
PR 17-SEP-1997; 97US-0059113P.
PR 17-SEP-1997; 97US-0059115P.
PR 17-SEP-1997; 97US-0059117P.
PR 17-SEP-1997; 97US-0059122P.
PR 17-SEP-1997; 97US-0059184P.
PR 18-SEP-1997; 97US-0059263P.
PR 19-SEP-1997; 97US-0059352P.
PR 19-SEP-1997; 97US-0059588P.
PR 24-SEP-1997; 97US-0059836P.
PR 17-OCT-1997; 97US-0062250P.
PR 17-OCT-1997; 97US-0062285P.
PR 17-OCT-1997; 97US-0062287P.
PR 17-OCT-1997; 97US-0063755P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0062816P.
PR 24-OCT-1997; 97US-0063845P.
PR 24-OCT-1997; 97US-0063882P.
PR 24-OCT-1997; 97US-0063127P.
PR 27-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-006350P.
PR 28-OCT-1997; 97US-006351P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063733P.

PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066433P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 11-DEC-1997; 97US-0069212P.
PR 11-DEC-1997; 97US-0069278P.
PR 16-DEC-1997; 97US-0069634P.
PR 23-JAN-1998; 97US-0072330P.
PR 04-FEB-1998; 97US-0073612P.
PR 09-FEB-1998; 97US-0074086P.
PR 09-FEB-1998; 97US-0074092P.
PR 12-MAR-1998; 97US-007791P.
PR 20-MAR-1998; 97US-0078910P.
PR 25-MAR-1998; 97US-0079294P.
PR 27-MAR-1998; 97US-0079663P.
PR 31-MAR-1998; 97US-0080165P.
PR 12-JUN-1998; 97US-0081245P.
PR 14-JUL-1998; 97US-00814552.
PR 28-AUG-1998; 97US-00817888.
PR 10-SEP-1998; 97US-00818824.
PR 14-SEP-1998; 97US-00819093.
PR 14-SEP-1998; 97US-00819094.
PR 14-SEP-1998; 97US-00819177.
PR 16-SEP-1998; 97US-00819330.
PR 17-SEP-1998; 97US-00819437.
PR 07-OCT-1998; 97US-00821141.
PR 29-OCT-1998; 97US-00822991.
PR 29-OCT-1998; 97US-00822992.
PR 20-NOV-1998; 97US-00824855.
PR 01-DEC-1998; 97US-00825106.
PR 05-JAN-1999; 97US-00800106.
PR 08-MAR-1999; 97US-00805028.
PR 10-MAR-1999; 97US-00805190.
PR 20-APR-1999; 97US-00808615.
PR 14-MAY-1999; 97US-00810733.
PR 02-JUN-1999; 97US-00812252.
PR 01-SEP-1999; 97US-00820111.
PR 08-SEP-1999; 97US-00820594.
PR 13-SEP-1999; 97US-00820944.
PR 15-SEP-1999; 97US-00821090.
PR 05-OCT-1999; 97US-00821089.
PR 29-NOV-1999; 97US-00828214.
PR 30-NOV-1999; 97US-00828313.
PR 30-NOV-1999; 97US-00828419.
PR 01-DEC-1999; 97US-00828301.
PR 01-DEC-1999; 97US-00828634.
PR 02-DEC-1999; 97US-00828551.
PR 02-DEC-1999; 97US-00828564.
PR 02-DEC-1999; 97US-00828565.
PR 16-DEC-1999; 97US-00830095.
PR 20-DEC-1999; 97US-00830911.
PR 20-DEC-1999; 97US-00830999.
PR 30-DEC-1999; 97US-00831243.
PR 30-DEC-1999; 97US-00831274.
PR 05-JAN-2000; 97US-00800219.
PR 06-JAN-2000; 97US-00800277.
PR 06-JAN-2000; 97US-00800376.
PR 11-FEB-2000; 97US-00800356.
PR 18-FEB-2000; 97US-00804341.
PR 18-FEB-2000; 97US-00804342.
PR 22-FEB-2000; 97US-00804414.
PR 24-FEB-2000; 97US-00804914.
PR 01-MAR-2000; 97US-00805004.
PR 01-MAR-2000; 97US-00805601.

PR 02-MAR-2000; 2000MO-US005746.

XX (GERTH) GENENTECH INC.

XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filaro E, Gao W;

XX Geritsen ME, Goddard A, Godowski PJ, Gunney AL, Sherwood S;

XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI: 2003-352836/33.

XX P-PSDB; AB081003.

XX New isolated PRO polypeptide useful for treating diabetes, rheumatoid

XX arthritis, sports injuries, obesity, hearing loss in mammals, stroke, or

XX heart attack.

XX Claim 2; Fig 267; 643pp; English.

XX The present invention relates to the isolation of novel human PRO
 CC polypeptides, and the polynucleotide sequences encoding them. The PRO
 CC polypeptides are secreted and transmembrane proteins. The PRO
 CC polypeptides and polynucleotides are useful for preparing a medicament
 CC useful in the treatment of diabetes, bone and/or cartilage disorders
 CC (e.g. rheumatoid arthritis, sports injuries, osteoarthritis), obesity,
 CC hyper- or hypo-insulinaemia, hearing loss, and coagulation disorders
 CC (e.g. stroke, heart attack). Anti-PRO antibodies are useful in diagnostic
 CC assays for PRO. By detecting its expression in specific cells, tissues or
 CC serum, and for affinity purification of PRO from recombinant cell culture
 CC or natural sources. ACA6599-ACA67268 represent cDNA sequences encoding
 CC the human PRO polypeptides of the invention. Note: The sequence data for
 CC this patent was obtained in electronic format directly from the USPTO web
 CC site at seqdata.uspto.gov/bpseqidbentry.html

XX Sequence 2290 BP; 537 A; 692 C; 668 G; 393 T; 0 U; 0 Other;

Query Match 98.1%; Score 2132.6; DB 7; Length 2290;
 Best Local Similarity 99.8%; Pred No. 0;
 Matches 2155; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 3 AAATAGGCTGCTCGGACGCGCTTGAAGTGAACCCCAAGCCCTTGACCTGCGAGCTG 62
 Db 151 AATAGGCTGCTCGGACGCGCTTGAAGTGAACCCCAAGCCCTTGACCTGCGAGCTG 210
 QY 63 GGACGTGAGGCGAGCGCTGCGCTGCTGAGGAGGAGAGGTTGAGACAGCCCGCAGG 122
 Db 211 GACTGAGGCGAGCGCTGCGCTGCTGAGGAGGAGAGGTTGAGACAGCCCGCAGG 270
 QY 123 ACCCTGCGCAGCCCTGCGCAGCCCTCTGCGAGCCCTCTGTGAGGCGAGGCACTG 182
 Db 271 ACCCTGCGCAGCCCTGCGCAGCCCTCTGCGAGCCCTCTGTGAGGCGAGGCACTG 330
 QY 183 GAGCCCACTGAGGCGAGGCTGTTGGCAGCCAGCCGCTGCAACTCAAGAAACCCCTCAG 242
 Db 331 GAGCCCACTGAGGCGAGGCTGTTGGCAGCCAGCCGCTGCAACTCAAGAAACCCCTCAG 390
 QY 243 AGGCATGAGCAGGCTGCGCCGCTGACGCGCAGGCTGGAAGCATGAGAGACCGCCCGG 302
 Db 391 AGGCATGAGCAGGCTGCGCCGCTGACGCGCAGGCTGGAAGCATGAGAGACCGCCCGG 450
 QY 303 AGCCAAAGCAGGAGGAGGCTTTCATGATTTCTATTCAACAAGATTAACCACTTTT 362
 Db 451 AGCCAAAGCAGGAGGAGGCTTTCATGATTTCTATTCAACAAGATTAACCACTTTT 510
 QY 363 GGAAGAGCAGGAGCAGCTGCTGCTGAGCATGCTGTGAGCTCGAGCTCTGAGCTGCTG 422
 Db 511 GGAAGAGCAGGAGCAGCTGCTGCTGAGCATGCTGTGAGCTCGAGCTCTGAGCTGCTG 570
 QY 423 GAGAGCTTTGCAAGCCAGAGAGCGTTTGAAGGCACTGAGAGAGGCTCGCAAGAGAG 482
 Db 571 GAGAGCTTTGCAAGCCAGAGAGCGTTTGAAGGCACTGAGAGAGGCTCGCAAGAGAG 630
 QY 483 TTCAATTTACCTTAAGAGTGAAGAGGCGCGCGCGCTCCCAAGAGAGAG 542
 Db 631 TTCAATTTACCTTAAGAGTGAAGAGGCGCGCGCGCTCCCAAGAGAGAG 690

QY 543 TTCAATTTGCCCCAGAGAGGCGGCTGACGAGGAGGAGGATGCTGATCACTCAAGAGCTGAG 602
 Db 691 TTCAATTTGCCCCAGAGAGGCGGCTGACGAGGAGGAGGATGCTGATCACTCAAGAGCTGAG 750
 QY 603 GTGCTTTGAGAGACCGAGTGCATTAAGCAGAGTGAAGCTGCTCAACATGAGCTGCTC 662
 Db 751 GTGCTTTGAGAGACCGAGTGCATTAAGCAGAGTGAAGCTGCTCAACATGAGCTGCTC 810
 QY 663 AAGCAGAGGCGAGATTCAGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCGGCAATTG 722
 Db 811 AAGCAGAGGCGAGATTCAGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCGGCAATTG 870
 QY 723 AGCAGAGTGAAGCTGCTGCGCAAGAGAGCCGCAATGAGTCTGCGGCTCAAGAGCTC 782
 Db 871 AGCAGAGTGAAGCTGCTGCGCAAGAGAGCCGCAATGAGTCTGCGGCTCAAGAGCTC 930
 QY 783 TACATGAGTCTCTGCAAGAGATCATCCGCAAGCGGGAACAAGCGTTGAGCTTCCCG 842
 Db 931 TACATGAGTCTCTGCAAGAGATCATCCGCAAGCGGGAACAAGCGTTGAGCTTCCCG 990
 QY 843 CTGAGAGACAGATCTCTGCAAGAGATCATCCGCAAGCGGGAACAAGCGTTGAGCTTCCCG 902
 Db 991 CTGAGAGACAGATCTCTGCAAGAGATCATCCGCAAGCGGGAACAAGCGTTGAGCTTCCCG 1050
 QY 903 GACCTGAGACCAAGTACAGACACTGCGCAACTGCGCCCAACCAATCAAGATCATC 962
 Db 1051 GACCTGAGACCAAGTACAGACACTGCGCCCAACCAATCAAGATCATC 1110
 QY 963 GCGCAGCTTGAAGAGAGTGCAGAGAGGAGGCTGCGGCGGAGCGGCGGCGGAGCACC 1022
 Db 1111 GCGCAGCTTGAAGAGAGTGCAGAGAGGAGGCTGCGGCGGAGCGGCGGCGGAGCACC 1170
 QY 1023 CCGCTGCCCCCGCGGCTCTACCAACCAACCCATCAACCGATCAACCAAGATC 1082
 Db 1171 CCGCTGCCCCCGCGGCTCTACCAACCAACCCATCAACCGATCAACCAAGATC 1230
 QY 1083 TCTACCAAGAGTCCAGAGTACCAAGAGTCCAGAGTCCAGAGTCCAGAGTCCAGAGT 1142
 Db 1231 TCTACCAAGAGTCCAGAGTACCAAGAGTCCAGAGTCCAGAGTCCAGAGTCCAGAGT 1290
 QY 1143 ATGCCACTCTCAACAGCTCTCCATCTTCAACCAAGAGTCCAGAGTCCAGAGTCCAGAGT 1202
 Db 1291 ATGCCACTCTCAACAGCTCTCCATCTTCAACCAAGAGTCCAGAGTCCAGAGTCCAGAGT 1350
 QY 1203 TGCCTGAGGCTCTGAGAGTGCAGAGTGCAGAGTGCAGAGTGCAGAGTGCAGAGTGCAG 1262
 Db 1351 TGCCTGAGGCTCTGAGAGTGCAGAGTGCAGAGTGCAGAGTGCAGAGTGCAGAGTGCAG 1410
 QY 1263 AACACCAACCGCTCTCAAGAGTGCAGAGTGCAGAGTGCAGAGTGCAGAGTGCAGAGTGCAG 1322
 Db 1411 AACACCAACCGCTCTCAAGAGTGCAGAGTGCAGAGTGCAGAGTGCAGAGTGCAGAGTGCAG 1470
 QY 1323 GTCATCAAGAGCGCTGAGAGTGCAGAGTGCAGAGTGCAGAGTGCAGAGTGCAGAGTGCAG 1382
 Db 1471 GTCATCAAGAGCGCTGAGAGTGCAGAGTGCAGAGTGCAGAGTGCAGAGTGCAGAGTGCAG 1530
 QY 1383 CAAGGCTTGGAGACATTAAGCGGAGTGCAGAGTGCAGAGTGCAGAGTGCAGAGTGCAGAGTGCAG 1442
 Db 1531 CAAGGCTTGGAGACATTAAGCGGAGTGCAGAGTGCAGAGTGCAGAGTGCAGAGTGCAGAGTGCAG 1590
 QY 1443 ACGAACCAAGGCACTCAAACTCTGATGACATGAGAGTGCAGAGTGCAGAGTGCAGAGTGCAG 1502
 Db 1591 ACGAACCAAGGCACTCAAACTCTGATGACATGAGAGTGCAGAGTGCAGAGTGCAGAGTGCAG 1650
 QY 1503 TTTGCAAGATAGCCAGCTTCCGCTGAGACCTGAGAGGAGATTAATTAAGCTGCGGCTG 1562
 Db 1651 TTTGCAAGATAGCCAGCTTCCGCTGAGACCTGAGAGGAGATTAATTAAGCTGCGGCTG 1710
 QY 1563 GGGCGCTACCATGAGCATGCGGAGTGCAGAGTGCAGAGTGCAGAGTGCAGAGTGCAGAGTGCAG 1622
 Db 1711 GGGCGCTACCATGAGCATGCGGAGTGCAGAGTGCAGAGTGCAGAGTGCAGAGTGCAGAGTGCAG 1770

PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-0087879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Geritsen ME, Goddard A, Godowski PJ, Gunney AU, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;
XX
XX WPI; 2003-332040/31.
DR P-PsDB; ABU66703.
XX
PT New secreted and transmembrane PRO nucleic acids, useful for gene
PT therapy, in chromosome and gene mapping, as chromosome markers, in tissue
PT typing, and in chromosome identification.
XX
XX Claim 2; Fig 267; 660pp; English.
XX
XX The present invention relates to the isolation of novel human PRO
XX polypeptides, and the polynucleotide sequences encoding them. The PRO
XX polypeptides are secreted and transmembrane proteins. The PRO
XX polypeptides are useful for detecting other PRO polypeptides, for linking
XX bioactive molecules to cells expressing PRO polypeptides, for modulating
XX biological activities of cells expressing PRO polypeptides, and for
XX identifying agonists or antagonists. The PRO polypeptides are useful for
XX for stimulating the release of tumour necrosis factor (TNF)-alpha from
XX human blood, for stimulating the proliferation or differentiation of
XX chondrocytes, and detecting the presence of tumours. The polynucleotide
XX sequences encoding PRO polypeptides are useful as hybridisation probes,
XX in chromosome and gene mapping, in the generation of antisense RNA and
XX DNA, in the preparation of PRO polypeptides, for generating transgenic
XX animals or knockout animals, for the genetic analysis of individuals with
XX genetic disorders, and in gene therapy. ACA03603-ACA03877 represent cDNAs
XX encoding the human PRO polypeptides of the invention. Note: The sequence
XX data for this patent was obtained in electronic format directly from the
XX USPTO web site at seqdata.uspto.gov/?spsid=IDEntry.html
SQ Sequence 2290 BP; 537 A; 692 C; 668 G; 393 T; 0 U; 0 Other;
Query Match 98.1%; Score 2132.6; DB 7; Length 2290;
Best Local Similarity 99.8%; Pred. No. 0;
Matches 2135; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 3 AAATGAGCTGCTGGAGAGCGGCTGAGATGAACCCCAAGCCTGAGACCTGCGAGCGTG 62
Db 151 AAATGAGCTGCTGGAGAGCGGCTGAGATGAACCCCAAGCCTGAGACCTGCGAGCGTG 210
QY 63 GCACTGAGGACAGCGGCTGACCTACTGAGGAGAAAGAGTTGTGACAGACCCCGCAGG 122
Db 211 GCACTGAGGACAGCGGCTGACCTACTGAGGAGAAAGAGTTGTGACAGACCCCGCAGG 270
QY 123 ACCCTGAGCAGCCCTGAGCCCGCAGGCTGTGCGGAGCCCTGTGTGAGAGGAGAGCCAGTG 182
Db 271 ACCCTGAGCAGCCCTGAGCCCGCAGGCTGTGCGGAGCCCTGTGTGAGAGGAGAGCCAGTG 330
QY 183 GAGCCCAATGAGGAGGAGGCTGTTGAGAGCAGCCGCGCTGCACTAGAAACCCCTCAG 242
Db 331 GAGCCCAATGAGGAGGAGGCTGTTGAGAGCAGCCGCGCTGCACTAGAAACCCCTCAG 390
QY 243 AGGCAATGAGAGAGGCTGCGCGCTGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 302
Db 391 AGGCAATGAGAGAGGCTGCGCGCTGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 450

QY 303 AGCCAGAGAGAGAGAGAGGCTTTCACTAGATTCTATTCAGAAAGATTAACCAATTTT 362
Db 451 AGCCAGAGAGAGAGAGAGGCTTTCACTAGATTCTATTCAGAAAGATTAACCAATTTT 510
QY 363 GCAAGAGCATTGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 422
Db 511 GCAAGAGCATTGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 570
QY 423 GAGCTTTGTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 482
Db 571 GAGCTTTGTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 630
QY 483 TTCACTTACCTAAACAGGATCAAGCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 542
Db 631 TTCACTTACCTAAACAGGATCAAGCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 690
QY 543 TTCACTTACCTAAACAGGATCAAGCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 602
Db 691 TTCACTTACCTAAACAGGATCAAGCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 750
QY 603 GTGCTTTGTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 662
Db 751 GTGCTTTGTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 810
QY 663 AAGCAGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 722
Db 811 AAGCAGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 870
QY 723 AGGAG 782
Db 871 AGGAG 930
QY 783 TACATGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 842
Db 931 TACATGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 990
QY 843 CTGAGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 902
Db 991 CTGAGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1050
QY 903 GACCTGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 962
Db 1051 GACCTGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1110
QY 963 GCGCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1022
Db 1111 GCGCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1170
QY 1023 CCGGCTGCG 1082
Db 1171 CCGGCTGCG 1230
QY 1083 TCTACCAAGAGATCCAGAGTACCAAGATCCAGAGTACCAAGATCCAGAGTACCAAGATCCAG 1142
Db 1231 TCTACCAAGAGATCCAGAGTACCAAGATCCAGAGTACCAAGATCCAGAGTACCAAGATCCAG 1290
QY 1143 ATGCCACTCTCAACAGGCTCCCAATCTTCAACGCAAAAGCGTGGGCGCATGAGAGAC 1202
Db 1291 ATGCCACTCTCAACAGGCTCCCAATCTTCAACGCAAAAGCGTGGGCGCATGAGAGAC 1350
QY 1203 TGCGTCAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1262
Db 1351 TGCGTCAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1410
QY 1263 AACACCAACCGGCTCATGAGGAGTGTGTGCAACAGAGACAGACCGCGGGGAGTGAAC 1322
Db 1411 AACACCAACCGGCTCATGAGGAGTGTGTGCAACAGAGACAGACCGCGGGGAGTGAAC 1470
QY 1323 GTCACTCAAGAGAGGCTGAGT 1382
Db 1471 GTCACTCAAGAGAGGCTGAGT 1530

Mon Aug 9 10:30:08 2004

us-10-018-386-1.rng

Page 23

QY	1383	TAAGGTTTGGGAACATTGACGGGGAATACGTGCGGGCTGGGGAACATTACCTGGCTG	1442
Db	1531	CAAGGGTTTGGGAACATTGACGGGGAATACGTGCGGGCTGGGGAACATTACCTGGCTG	1590
QY	1443	ACGAACCAAGCACTACAACTACCTGGTGACATGAGAGCATGGTCCGGCCGAAATGC	1502
Db	1591	ACGAACCAAGCACTACAACTACCTGGTGACATGAGAGCATGGTCCGGCCGAAATGC	1650
QY	1503	TTTGGCAGATACGCCAGTTTCCGCTGGAACTTGAGACGAGTATTAATACCTGGCGTG	1562
Db	1651	TTTGGCAGATACGCCAGTTTCCGCTGGAACTTGAGACGAGTATTAATACCTGGCGTG	1710
QY	1563	GGGCGCTCCATGAGCAATGCGGGGTACCTCTTATCATGGACCAACGCAACAGATTCAC	1622
Db	1711	GGGCGCTCCATGAGCAATGCGGGGTACCTCTTATCATGGACCAACGCAACAGATTCAC	1770
QY	1623	ACCTGACAGAGATCATGATGTCTTACACAGAAACTGTGCCACTACACAGAGGAGGC	1682
Db	1771	ACCTGACAGAGATCATGATGTCTTACACAGAAACTGTGCCACTACACAGAGGAGGC	1830
QY	1663	TGTGTGTATACGCTGTGGCCACTCCAACTCAACGGGGTCTGGTACCGGGGGGGCAT	1742
Db	1831	TGTGTGTATACGCTGTGGCCACTCCAACTCAACGGGGTCTGGTACCGGGGGGGCAT	1890
QY	1743	TACCGGACCCGCTACACAGACGAGATCTACCTGAGGCTGATTCGAGAGGCTTTACTCA	1802
Db	1891	TACCGGACCCGCTACACAGACGAGATCTACCTGAGGCTGATTCGAGAGGCTTTACTCA	1950
QY	1803	CTCAAGAAATGTGTGATGATGATCCGACCGAACCCCAACCTTCCACTAAGCCAGCTCC	1862
Db	1951	CTCAAGAAATGTGTGATGATGATCCGACCGAACCCCAACCTTCCACTAAGCCAGCTCC	2010
QY	1863	CCCTCCCTACCTCTGTGGCCATTGSCCAGAGGCCACCCCTGGTCAACGCTGGCCACAGAC	1922
Db	2011	CCCTCCCTACCTCTGTGGCCATTGSCCAGAGGCCACCCCTGGTCAACGCTGGCCACAGAC	2070
QY	1923	AAAGAAACAATCTCTCACCAGATTCATCTGAGGCTGGAGGACCGGGATGCTGGATTCTGT	1982
Db	2071	AAAGAAACAATCTCTCACCAGATTCATCTGAGGCTGGAGGACCGGGATGCTGGATTCTGT	2130
QY	1963	TTTCCGAAGTCACTGACAGCGGATGATGGAATCGATACGGTGTTTCTGTCCCTCC	2044
Db	2131	TTTCCGAAGTCACTGACAGCGGATGATGGAATCGATACGGTGTTTCTGTCCCTCC	2190
QY	2043	TACTTCTCTCAACACAGACAGCCCTCATGTCTCCAGACAGGACAGACTACAGACAA	2102
Db	2191	TACTTCTCTCAACACAGACAGCCCTCATGTCTCCAGACAGGACAGACTACAGACAA	2250
QY	2103	CTCTTTCTTTAAATAATTAACTCTCTACATTAATAA	2141
Db	2251	CTCTTTCTTTAAATAATTAACTCTCTACATTAATAA	2289
RESULT 14			
ACA04921	ID	ACA04921 standard; cDNA; 2290 BP.	
XX	ACA04921;		
AC			
XX			
DT	28-MAY-2003	(first entry)	
XX			
DE	Novel human secreted and transmembrane protein PRO196 cDNA.		
XX			
KW	Secreted and transmembrane polypeptide; PRO polypeptide; PRO533; PRO301;		
KW	PRO187; PRO337; PRO1411; PRO10096; PRO246; PRO6307; PRO6003; PRO6004;		
KW	PRO3356; PRO2630; PRO265; PRO941; FGFR; bioactive molecule;		
KW	fibroblast growth factor receptor; cell death; chromosome mapping;		
KW	gene mapping; transgenic anemia; knockout animal; gene therapy; tumour;		
KW	obesity; diabetes; insulinemia; vascular permeability;		
KW	cardiac insufficiency disorder; immune response; hearing loss;		
KW	auditory hair cell regeneration; bone disorder; cartilage disorder;		
KW	sports injury; arthritis; gene; ss.		
XX			

OS	Homo sapiens.	
XX	US:003032063-A1.	
XX		
XX	13-FEB-2003.	
XX		
XX	01-FEB-2002; 2002US-00066494.	
XX		
PR	26-AUG-1997;	97US-0056974P
PR	17-SEP-1997;	97US-0059115P
PR	18-SEP-1997;	97US-0059263P
PR	19-SEP-1997;	97US-0059688P
PR	17-OCT-1997;	97US-0062285P
PR	24-OCT-1997;	97US-0062815P
PR	24-OCT-1997;	97US-0063082P
PR	27-OCT-1997;	97US-0063329P
PR	29-OCT-1997;	97US-0063733P
PR	21-NOV-1997;	97US-0066546P
PR	21-NOV-1997;	97US-0066640P
PR	16-DEC-1997;	97US-0069694P
PR	09-FEB-1998;	98US-0074086P
PR	09-FEB-1998;	98US-0074409P
PR	25-MAR-1998;	98US-0079294P
PR	08-APR-1998;	98US-0081049P
PR	10-AUG-1998;	98US-0095598P
PR	18-AUG-1998;	98US-0097000P
PR	09-SEP-1998;	98US-0098601P
PR	10-SEP-1998;	98US-0098803P
PR	10-SEP-1998;	98US-0098911P
PR	10-SEP-1998;	98US-0099812P
PR	14-SEP-1998;	98US-00103933.
PR	16-SEP-1998;	98US-00103330.
PR	17-SEP-1998;	98US-0100658P
PR	17-SEP-1998;	98US-0101322P
PR	24-SEP-1998;	98US-0106032P
PR	28-OCT-1998;	98US-01093040.
PR	20-NOV-1998;	98US-01034855.
PR	25-NOV-1998;	98US-01052190P
PR	01-DEC-1998;	98US-01052108
PR	08-MAR-1999;	99US-0105578P
PR	23-MAR-1999;	99US-0105702P
PR	02-JUN-1999;	99US-01012252.
PR	15-JUN-1999;	99US-0139659P
PR	15-JUN-1999;	99US-0145070P
PR	26-JUL-1999;	99US-0145936P
PR	17-AUG-1999;	99US-0149996P
PR	17-SEP-1999;	99US-01502011.
PR	08-SEP-1999;	99US-0150594
PR	15-SEP-1999;	99US-015021090
PR	30-SEP-1999;	99US-015021547
PR	15-OCT-1999;	99US-015028313
PR	01-DEC-1999;	99US-015028301.
PR	02-DEC-1999;	99US-015028565
PR	07-DEC-1999;	99US-0169495P
PR	20-DEC-1999;	99US-01693099
PR	05-JAN-2000;	2000US-00002019
PR	18-FEB-2000;	2000US-00004341.
PR	18-FEB-2000;	2000US-00004432.
PR	22-FEB-2000;	2000US-00004414
PR	01-MAR-2000;	2000US-00005601.
PR	02-MAR-2000;	2000US-00005841.
PR	09-MAR-2000;	2000US-00006771
PR	09-MAR-2000;	2000US-00007377
PR	30-MAR-2000;	2000US-00008439
PR	15-MAY-2000;	2000US-00013358
PR	17-MAY-2000;	2000US-00013705
PR	22-MAY-2000;	2000US-00014042.
PR	30-MAY-2000;	2000US-00014841.
PR	02-JUN-2000;	2000US-00015664
PR	11-AUG-2000;	2000US-00020231.
PR	23-AUG-2000;	2000US-00023328
PR	24-AUG-2000;	2000US-00023328

PR 01-DEC-2000; 2000MC-US032678.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 30-MAY-2001; 2001WO-US017442.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 15-NOV-2001; 2001US-00002796.
 XX (GENT) GENENTECH INC.
 PA Ashkenazi AJ, Baker KP, Botstein DA, Desnoyers L, Eaton DL;
 PI Ferreira N, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
 PI Godowski PJ, Gurney AL, Kijavita J, Mather JP, Napier MA, Pan J;
 PI Paoni NF, Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM;
 PI Wood WI, Zhang Z;
 XX WPI; 2003-341964/32.
 DR P-PSDB; AB067268.
 XX
 PT Thirty seven nucleic acids encoding novel secreted and transmembrane PRO
 PT polypeptides, useful for modulating biological activity of cell
 PT expressing the polypeptide, and in chromosome and gene mapping.
 XX
 PS Claim 2; Fig 1; 255pp; English.
 CC The invention describes an isolated, secreted and transmembrane
 CC polypeptide (I), termed PRO polypeptide. (II) is useful for detecting
 CC PRO533, PRO301, PRO187, PRO337, PRO1411, PRO10095, PRO246, PRO6307,
 CC PRO6003, PRO6004, PRO4356, PRO2630, PRO265, PRO941, fibroblast growth
 CC factor receptor (FGFR)-4, FGFR-3, FGFR-2 or FGFR-1 polypeptide, and for
 CC linking a bioactive molecule e.g. toxin, radiolabel or antibody, to a
 CC cell expressing the polypeptides. The bioactive molecule causes cell
 CC death. (III) is useful as hybridisation probes, in chromosome and gene
 CC mapping, in generation of antisense RNA and DNA, in the preparation of
 CC PRO polypeptide, for generating transgenic animals or knock-out animals
 CC which in turn are useful in the development and screening of
 CC therapeutically useful reagents, and for the genetic analysis of
 CC individuals with genetic disorders, in gene therapy, and for chromosome
 CC identification. (I) Or Ab is useful for the preparation of medicament for
 CC treating conditions which are responsive to the PRO polypeptide or anti-
 CC PRO antibody e.g. a tumour. (II) is useful for treating obesity, diabetes
 CC or hypo- or hyper-insulinaemia, and cardiac insufficiency disorders, for
 CC inhibiting tumour growth, enhances vascular permeability and immune
 CC response, for inducing regeneration of auditory hair cells and for
 CC treating hearing loss in mammals, and for treating bone and/or cartilage
 CC disorders such as sports injuries and arthritis. This sequence encodes a
 CC novel human secreted and transmembrane polypeptide associated
 CC oligonucleotide
 CC
 SQ Sequence 2290 BP; 537 A; 692 C; 668 G; 393 T; 0 U; 0 Other;
 Query Match 98.1%; Score 2132.6; DB 7; Length 2290;
 Best Local Similarity 99.8%; Pred. No. 0;
 Matches 2135; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 QY 3 AANTAGGCTGCTGGGAGGCGCTGAGANTGACCCCAAGCCCTGGAGCTGCGAGGCTG 62
 DB 151 AATAGAGGCTGCTGGGAGGCGCTGAGANTGACCCCAAGCCCTGGAGCTGCGAGGCTG 210
 QY 63 GCACTGAGGCAAGCGGCTGACGCTACTGTGAGGGAAGAAGTGTGACAGACCCCGAGAG 122
 DB 211 GCACGAGGCAAGCGGCTGACGCTACTGTGAGGGAAGAAGTGTGACAGACCCCGAGAG 270
 QY 123 ACCCTTGAGCAGGCTGAGCCGCTGAGGAGGAGCCCTCTGTGAGAGGCAAGACGAGTG 182
 DB 271 ACCCTTGAGCAGGCTGAGCCGCTGAGGAGGAGCCCTCTGTGAGAGGCAAGACGAGTG 330
 QY 183 GAGCCCAAGTGAAGGAGGAGGCTGTTGGAGGCAAGCCGAGCTTGAACCTCAGAGAACCCCTCAG 242
 DB 331 GAGCCCAAGTGAAGGAGGAGGCTGTTGGAGGCAAGCCGAGCTTGAACCTCAGAGAACCCCTCAG 390
 QY 243 AGGCCATGAGAGGCTGCCCCGCTGACGCGCAAGGCTGAAGCATGTGAGAGACCCCGCCGCG 302

DB 391 AGGCCATGAGAGGCTGCCCCGCTGACGCGCAGAGGTGAAGCATGTGAGAGACCCCGCG 450
 QY 303 AGCCAAAGCAGAGGAGGAGAGGCTTTATATAGATTCTTACAAAGATATACCAATTTT 362
 DB 451 AGCCAAAGCAGAGGAGGAGGCTTTATATAGATTCTTACAAAGATATACCAATTTT 510
 QY 363 GCAAAGACATGAGGCACTGTGCGTGAATGTGTGAGCTGCGAATGCTGAGCTGCATG 422
 DB 511 GCAAGACATGAGGCACTGTGCGTGAATGTGTGAGCTGCGAATGCTGAGCTGCATG 570
 QY 423 GGAAGCTGTTGACAGGAGGAGAGAGAGAGGCTTTTGAAGGCACTGAGAGGAGCTGCGCAAGAG 482
 DB 571 GGAAGCTGTTGACAGGAGGAGAGAGAGGCTTTTGAAGGCACTGAGAGGAGCTGCGCAAGAG 630
 QY 483 TTGATTACTTAACAGATTAACAGGCGGCGGAGATCCAGAGCAAGTGCACTTACAC 542
 DB 631 TTGATTACTTAACAGATTAACAGGCGGCGGAGATCCAGAGCAAGTGCACTTACAC 690
 QY 543 TTGATTGTCGCCAGAGAGCGGATCAAGGAGTGCATGCTGCACTCCAGAGAGCTGAG 602
 DB 691 TTGATTGTCGCCAGAGAGCGGATCAAGGAGTGCATGCTGCACTCCAGAGAGCTGAG 750
 QY 603 GTGCTTCTGAGAGAACGAGTGCTAAGCAGAGAGCTGAGCTGCTCAACATAGCTGCTC 662
 DB 751 GTGCTTCTGAGAGAACGAGTGCTAAGCAGAGAGCTGAGCTGCTCAACATAGCTGCTC 810
 QY 663 AAGCAGAGGCGCAGATGCAAGAGAGCTGACAGAGCTGTAAGGAGGAGCGGCAATTTGTG 722
 DB 811 AAGCAGAGGCGCAGATGCAAGAGAGCTGACAGAGCTGTAAGGAGGAGCGGCAATTTGTG 870
 QY 723 AGCAGAGTGAAGCTGTGCGCAAGAGAGAGCCGCAATGAACTGCGGAGTCAAGCACTC 782
 DB 871 AGCAGAGTGAAGCTGTGCGCAAGAGAGAGCCGCAATGAACTGCGGAGTCAAGCACTC 930
 QY 783 TACATGAGTCTCTGACAGAGATCAATCGCAAGCGGAGCAAGCGCTGAGAGCTGCCAG 842
 DB 931 TACATGAGTCTCTGACAGAGATCAATCGCAAGCGGAGCAAGCGCTGAGAGCTGCCAG 990
 QY 843 CTGAGAGAACAGATCTCTGACAGAGAGAGCGGCAATGCTGAGCTGCGCAGAGTACAG 902
 DB 991 CTGAGAGAACAGATCTCTGACAGAGAGAGCGGCAATGCTGAGCTGCGCAGAGTACAG 1050
 QY 903 GACCTGAGACAGAGTACAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGATC 962
 DB 1051 GACCTGAGACAGAGTACAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGATC 1110
 QY 963 GCGCAAGTGAAG 1022
 DB 1111 GCGCAAGTGAAG 1170
 QY 1023 CCGCTGCCCCCGCCCGGCTTACACAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1082
 DB 1171 CCGCTGCCCCCGCCCGGCTTACACAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1230
 QY 1083 TCTACCAAGAGATCCAG 1142
 DB 1231 TCTACCAAGAGATCCAG 1290
 QY 1143 ATGCGCACTCTACAGAGCTTCCATCTTCCACAGAGAGAGAGAGAGAGAGAGAGAGAG 1202
 DB 1291 ATGCGCACTCTACAGAGCTTCCATCTTCCACAGAGAGAGAGAGAGAGAGAGAGAGAG 1350
 QY 1203 TGCCTGCAAGGCTGAG 1262
 DB 1351 TGCCTGCAAGGCTGAG 1410
 QY 1263 AACACCAAGAGCTCTATGAGAGTGTGTGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1322
 DB 1411 AACACCAAGAGCTCTATGAGAGTGTGTGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1470
 QY 1323 GTATCTCAAGAGAGCTGTGATGCTGTGTTAATCTTCTTCAAGAGAGAGAGAGAGAGAG 1382

Db 1471 GTGATCCAGAGACGCTGGATGGCTCTGTATTAATTCTTCAGGAACCTGGAGACGTACAAAG 1530
 QY 1383 CAAGGGTTTGGAGACATTGAGCGGGGAATTAAGTGGCTGGAGACATTACTAGGCTG 1442
 Db 1531 CAAGGGTTTGGAGACATTGAGCGGGGAATTAAGTGGCTGGAGACATTACTAGGCTG 1590
 QY 1443 ACGAACCAAGGCACTACAACTCTGTGTGACATGAGAGAGATGGTCCGGCCGCAAGTTC 1502
 Db 1591 ACGAACCAAGGCACTACAACTCTGTGTGACATGAGAGAGATGGTCCGGCCGCAAGTTC 1650
 QY 1503 TTTGCAAGATAGCCAGATTTCCGCTGGAACCTGAGACGAGATTAATTAAGTGGGCTG 1562
 Db 1651 TTTGCAAGATAGCCAGATTTCCGCTGGAACCTGAGACGAGATTAATTAAGTGGGCTG 1710
 QY 1563 GGGCGCTACATGAGCAATCGGGTGAATCTCTTATCATGAGCAACGCGACAGATTCAAC 1622
 Db 1711 GGGCGCTACATGAGCAATCGGGTGAATCTCTTATCATGAGCAACGCGACAGATTCAAC 1770
 QY 1623 ACCCTGACAGATCATGATGATCTTACACAGAGAACTGTGCCACTTACCCAGAGGAGGC 1682
 Db 1771 ACCCTGACAGATCATGATGATCTTACACAGAGAACTGTGCCACTTACCCAGAGGAGGC 1830
 QY 1683 TGGGTGTAATACGCGTGGCCCACTCCAACTCCAAAGGGGTCTGGTACCGCGGGGGCCAT 1742
 Db 1831 TGGGTGTAATACGCGTGGCCCACTCCAACTCCAAAGGGGTCTGGTACCGCGGGGGCCAT 1890
 QY 1743 TACCGAGCGCGCTACACAGACGAGAGTCTACTGGGCTGAGTTCCAGAGAGCTTTACTCA 1802
 Db 1891 TACCGAGCGCGCTACACAGACGAGAGTCTACTGGGCTGAGTTCCAGAGAGCTTTACTCA 1950
 QY 1803 CTCAGAGAGTGGTATGATGATCCGACCGGACCCCACTTCCACTAAGCCAGCTCC 1862
 Db 1951 CTCAGAGAGTGGTATGATGATCCGACCGGACCCCACTTCCACTAAGCCAGCTCC 2010
 QY 1863 CCTCTGCTGCTCTGTGGCCATTCGACGAGACCCACCTGTGTACGCTGGCCAGAGCAG 1922
 Db 2011 CCTCTGCTGCTCTGTGGCCATTCGACGAGACCCACCTGTGTACGCTGGCCAGAGCAG 2070
 QY 1923 AAGAGCAACTCTCTCAACCACTTCATCTGAGGCTGGAGAGACCGGAGTGTGATTTCTGT 1982
 Db 2071 AAGAGCAACTCTCTCAACCACTTCATCTGAGGCTGGAGAGACCGGAGTGTGATTTCTGT 2130
 QY 1983 TTTCCGAGTCACTGAGCGAGATGATGAGTGAATGATGATGATGATGATGATGATGATGAT 2042
 Db 2131 TTTCCGAGTCACTGAGCGAGATGATGAGTGAATGATGATGATGATGATGATGATGATGAT 2190
 QY 2043 TACTTTCTCTTCAACCCAGACAGCCCTCATGTTCTCCAGAGACGAGACGACTACAGACAA 2102
 Db 2191 TACTTTCTCTTCAACCCAGACAGCCCTCATGTTCTCCAGAGACGAGACGACTACAGACAA 2250
 QY 2103 CTCCTTCTTAAATTAATTAAGTCTTCAATTAATAAC 2141
 Db 2251 CTCCTTCTTAAATTAATTAAGTCTTCAATTAATAAC 2289

RESULT 15
 ABX89274
 ID ABX89274 standard; cDNA; 2290 BP.
 AC ABX89274;
 XX 13-MAY-2003 (first entry)
 DE DNA encoding novel secreted and transmembrane protein PRO196.
 XX
 XX Human, PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
 KW Cardiac insufficiency disorder; cancer; tumor; immune response;
 KW adrenal cortical capillary endothelial growth; c-fos induction;
 KW vascular endothelial growth factor inhibition; VEGF inhibition;
 KW endothelial cell growth inhibitor; T-lymphocytes stimulation;
 KW retinal neurons cell survival; rod photoreceptor cell survival;
 KW retinal disorder; retinitis pigmentosa; kidney disease;
 KW mammalian kidney mesangial cell proliferation; Berger disease;

KW dermatitis; herpeticiformis; Crohn's disease; chondrocyte proliferation;
 KW chondrocyte redifferentiation; sports injury; arthritis; gene; ss.
 XX Homo sapiens.
 EN US2003017563-A1.
 PD 23-JAN-2003.
 PF 07-MAY-2002; 2002US-00140808.
 XX 31-MAR-1997; 97WO-US005230.
 PR 12-JUN-1998; 98WO-US012456.
 PR 14-JUL-1998; 98WO-US014552.
 PR 28-AUG-1998; 98WO-US017888.
 PR 10-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98WO-US019093.
 PR 14-SEP-1998; 98WO-US019094.
 PR 14-SEP-1998; 98WO-US019177.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US021141.
 PR 07-OCT-1998; 98WO-US021141.
 PR 29-OCT-1998; 98WO-US022991.
 PR 29-OCT-1998; 98WO-US022992.
 PR 20-NOV-1998; 98WO-US024855.
 PR 01-DEC-1998; 98WO-US025108.
 PR 05-JAN-1999; 99WO-US000106.
 PR 08-MAR-1999; 99WO-US005028.
 PR 10-MAR-1999; 99WO-US005190.
 PR 20-APR-1999; 99WO-US006615.
 PR 14-MAY-1999; 99WO-US010733.
 PR 02-JUN-1999; 99WO-US012252.
 PR 01-SEP-1999; 99WO-US020111.
 PR 08-SEP-1999; 99WO-US020594.
 PR 13-SEP-1999; 99WO-US020944.
 PR 15-SEP-1999; 99WO-US021090.
 PR 15-SEP-1999; 99WO-US021547.
 PR 05-OCT-1999; 99WO-US023089.
 PR 29-NOV-1999; 99WO-US028214.
 PR 30-NOV-1999; 99WO-US028313.
 PR 30-NOV-1999; 99WO-US028409.
 PR 01-DEC-1999; 99WO-US028301.
 PR 01-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028651.
 PR 02-DEC-1999; 99WO-US028654.
 PR 02-DEC-1999; 99WO-US031274.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003365.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004814.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007277.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.

28-JUL-2000; 2000MO-US020710.
 11-AUG-2000; 2000MO-US022031.
 23-AUG-2000; 2000MO-US023522.
 24-AUG-2000; 2000MO-US023328.
 08-NOV-2000; 2000MO-US030952.
 10-NOV-2000; 2000MO-US030873.
 01-DEC-2000; 2000MO-US032678.
 20-DEC-2000; 2000MO-US034956.
 28-FEB-2001; 2001MO-US036498.
 28-FEB-2001; 2001MO-US006520.
 01-MAR-2001; 2001MO-US006666.
 09-MAR-2001; 2001US-00802706.
 14-MAR-2001; 2001US-00808689.
 22-MAR-2001; 2001US-00816744.
 05-APR-2001; 2001US-00828366.
 10-MAY-2001; 2001US-00854208.
 18-MAY-2001; 2001US-00854280.
 25-MAY-2001; 2001US-00860216.
 25-MAY-2001; 2001US-00866028.
 25-MAY-2001; 2001US-00866034.
 25-MAY-2001; 2001MO-US017092.
 01-JUN-2001; 2001US-00872035.
 05-JUN-2001; 2001MO-US017800.
 14-JUN-2001; 2001US-00874503.
 19-JUN-2001; 2001US-00882636.
 20-JUN-2001; 2001MO-US019692.
 21-JUN-2001; 2001US-00887879.
 22-JUN-2001; 2001MO-US020116.
 29-JUN-2001; 2001MO-US021066.
 09-JUL-2001; 2001MO-US021735.
 18-JUL-2001; 2001US-00908827.
 06-AUG-2001; 2001US-00924419.
 09-AUG-2001; 2001US-00927796.
 16-AUG-2001; 2001US-00931836.
 19-DEC-2001; 2001US-00028072.
 (GENE) GENENTECH INC.
 Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W,
 Gerdtzen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S,
 Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WT, Zhang Z;
 WPI; 2003-148238/14.
 P-PSDB; ABUS9784.
 Two hundred and seventy five nucleic acids encoding PRO polypeptides,
 useful for treating pericyte-associated tumors, diabetes and various bone
 and/or cartilage disorders, e.g. arthritis.
 Claim 2; Fig 267; 659pp; English.

disorders of injuries, e.g. retinitis pigmentosum, AMD, PRO819, PRO813
 and PRO1066 induce proliferation of mammalian kidney mesangial cells,
 and therefore are useful for treating kidney disorders associated with
 decreased mesangial cell function such as Berger disease or other
 nephropathies associated with dermatitis, herpiformis or Crohn's
 disease, PRO1310, PRO844, PRO1312, PRO1392 and PRO1387 induce the
 proliferation and/or redifferentiation of chondrocytes in culture and are
 thus useful for treating sports injuries, and arthritis. This sequence
 encodes a novel human PRO protein
 SQ Sequence 2290 BP; 537 A; 692 C; 666 G; 393 T; 0 U; 0 Other;
 Query Match 98.1%; Score 2132.6; DB 7; Length 2290;
 Best Local Similarity 99.8%; Pred. No. 0;
 Matches 2135; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 3 AATGAGGCTGCTGCGAGCGGCTGAGTGAACCCAGCCCTGAGCTGCGGAGCTG 62
 151 AATGAGGCTGCTGCGAGCGGCTGAGTGAACCCAGCCCTGAGCTGCGGAGCTG 210
 63 GCACTGAGGAGGCGGCTGAGTGAACCCAGCCCTGAGCTGCGGAGCTG 122
 211 GCACTGAGGAGGCGGCTGAGTGAACCCAGCCCTGAGCTGCGGAGCTG 270
 123 ACCCTGAGGAGGCGGCTGAGTGAACCCAGCCCTGAGCTGCGGAGCTG 182
 271 ACCCTGAGGAGGCGGCTGAGTGAACCCAGCCCTGAGCTGCGGAGCTG 330
 183 GAGCCAGTGAAGGAGGCGGCTGAGTGAACCCAGCCCTGAGCTGCGGAGCTG 242
 331 GAGCCAGTGAAGGAGGCGGCTGAGTGAACCCAGCCCTGAGCTGCGGAGCTG 390
 243 AGGCAATGAGGAGGCGGCTGAGTGAACCCAGCCCTGAGCTGCGGAGCTG 302
 391 AGGCAATGAGGAGGCGGCTGAGTGAACCCAGCCCTGAGCTGCGGAGCTG 450
 303 AGGCAATGAGGAGGCGGCTGAGTGAACCCAGCCCTGAGCTGCGGAGCTG 362
 451 AGGCAATGAGGAGGCGGCTGAGTGAACCCAGCCCTGAGCTGCGGAGCTG 510
 363 GCAAGACATGAGGAGGCGGCTGAGTGAACCCAGCCCTGAGCTGCGGAGCTG 422
 511 GCAAGACATGAGGAGGCGGCTGAGTGAACCCAGCCCTGAGCTGCGGAGCTG 570
 423 GAGAGTGTGAGGAGGCGGCTGAGTGAACCCAGCCCTGAGCTGCGGAGCTG 482
 571 GAGAGTGTGAGGAGGCGGCTGAGTGAACCCAGCCCTGAGCTGCGGAGCTG 630
 483 TTGATTACTTAACAGGATGACAGGCGGCGGAGGCTGAGTGAACCCAGCTG 542
 631 TTGATTACTTAACAGGATGACAGGCGGCGGAGGCTGAGTGAACCCAGCTG 690
 543 TTGATTACTTAACAGGATGACAGGCGGCGGAGGCTGAGTGAACCCAGCTG 602
 691 TTGATTACTTAACAGGATGACAGGCGGCGGAGGCTGAGTGAACCCAGCTG 750
 603 GTGCTTGTGAGAGCCGAGTGTGAGTGAACCCAGCCCTGAGCTGCGGAGCTG 662
 751 GTGCTTGTGAGAGCCGAGTGTGAGTGAACCCAGCCCTGAGCTGCGGAGCTG 810
 663 AAGCAGAGGAGGAGTGTGAGTGAACCCAGCCCTGAGCTGCGGAGCTG 722
 811 AAGCAGAGGAGGAGTGTGAGTGAACCCAGCCCTGAGCTGCGGAGCTG 870
 723 AAGCAGAGGAGGAGTGTGAGTGAACCCAGCCCTGAGCTGCGGAGCTG 782
 871 AAGCAGAGGAGGAGTGTGAGTGAACCCAGCCCTGAGCTGCGGAGCTG 930
 783 TACATGAGTGTGAGTGTGAGTGAACCCAGCCCTGAGCTGCGGAGCTG 842
 931 TACATGAGTGTGAGTGTGAGTGAACCCAGCCCTGAGCTGCGGAGCTG 990
 843 CTGAGAGAGGATCTGAGTGAACCCAGCCCTGAGCTGCGGAGCTG 902

Db 991 CTGGAGAACAGGATCTCTGACACGACGACGACATGCTGACGCTGGCCAGAGATGACAG 1050
 Qy 903 GACCTGGAGCACAAGTATCCAGCAGCTGGCCACACTGGCCCAACACCAATCAGAGATCATC 962
 Db 1051 GACCTGGAGCACAAGTATCCAGCAGCTGGCCACACTGGCCCAACACCAATCAGAGATCATC 1110
 Qy 963 GCGCAGCTTGAAGGACATGCGCAGAGGGTGGCCCTGGCCAGCCCGTCCCGACGACCC 1022
 Db 1111 GCGCAGCTTGAAGGACATGCGCAGAGGGTGGCCCTGGCCAGCCCGTCCCGACGACCC 1170
 Qy 1023 CCCGCTGCCCCGCCCCGGGCTCTACCCACACCCCACTTACCAACCGCATCATCAGCAGATC 1082
 Db 1171 CCCGCTGCCCCGCCCCGGGCTCTACCCACACCCCACTTACCAACCGCATCATCAGCAGATC 1230
 Qy 1083 TCTACCAACGAGATCCAGAGTGAACGAGAACTGAGAGTGTGCTGCCACCCCTCTGCCCCACT 1142
 Db 1231 TCTACCAACGAGATCCAGAGTGAACGAGAACTGAGAGTGTGCTGCCACCCCTCTGCCCCACT 1290
 Qy 1143 ATGCCACTCTCACCAGCCTCCCATCTTCCACCCGACAGCCGTGGGCCCATGAGAGAC 1202
 Db 1291 ATGCCACTCTCACCAGCCTCCCATCTTCCACCCGACAGCCGTGGGCCCATGAGAGAC 1350
 Qy 1203 TGCTTGCAGGCTCTGAGAGATGCGCAGACACACAGCTCATCTTACCTGTGTAAGCCGAG 1262
 Db 1351 TGCTTGCAGGCTCTGAGAGATGCGCAGACACACAGCTCATCTTACCTGTGTAAGCCGAG 1410
 Qy 1263 AACACCAACCGGCTCATGAGAGTGTGTCGACGAGACAGACGACCCCGGGGGCTGGAGC 1322
 Db 1411 AACACCAACCGGCTCATGAGAGTGTGTCGACGAGACAGACGACCCCGGGGGCTGGAGC 1470
 Qy 1323 GTCATCCAGAGACGCTGATGATGCTGTGTAACCTTTCAGAGAACTGGAGACGTACAG 1382
 Db 1471 GTCATCCAGAGACGCTGATGATGCTGTGTAACCTTTCAGAGAACTGGAGACGTACAG 1530
 Qy 1383 CAAGGCTTTGGGAAATGAGACGCGCAATACGTGGCTGGGGCTGGAGAACTTTACTGGCTG 1442
 Db 1531 CAAGGCTTTGGGAAATGAGACGCGCAATACGTGGCTGGGGCTGGAGAACTTTACTGGCTG 1590
 Qy 1443 ACGAACCAAGGCACTACAAACTCCTGTGACCAATGAGAGACTGGTCCGCGCGCAAAATC 1502
 Db 1591 ACGAACCAAGGCACTACAAACTCCTGTGACCAATGAGAGACTGGTCCGCGCGCAAAATC 1650
 Qy 1503 TTTGCAAAATAGCCAGTTTCCGCTGGAACTTGAGACGAGATATTAAGCTCGGCTG 1562
 Db 1651 TTTGCAAAATAGCCAGTTTCCGCTGGAACTTGAGACGAGATATTAAGCTCGGCTG 1710
 Qy 1563 GGGCGCTACATGGCAATGCGGGTGAATCCTTTACATGGCAAAAGGCAAGCAGTTCAAC 1622
 Db 1711 GGGCGCTACATGGCAATGCGGGTGAATCCTTTACATGGCAAAAGGCAAGCAGTTCAAC 1770
 Qy 1623 ACCCTGACAGAGATCATGATGTCTTACACAGAGAACTGTGCCCACTACACAGAGGAGGC 1682
 Db 1771 ACCCTGACAGAGATCATGATGTCTTACACAGAGAACTGTGCCCACTACACAGAGGAGGC 1830
 Qy 1683 TGGTGTATTAAGCTGTGCGCACTCCAACTCAACGCGGGTCTGTTACCGCGGGGGCCAT 1742
 Db 1831 TGGTGTATTAAGCTGTGCGCACTCCAACTCAACGCGGGTCTGTTACCGCGGGGGCCAT 1890
 Qy 1743 TACCGGACCGCTACACAGAGCGAGTCTTACTGGCTGAGTTCGAGAGAGGCTTTACTCA 1802
 Db 1891 TACCGGACCGCTACACAGAGCGAGTCTTACTGGCTGAGTTCGAGAGAGGCTTTACTCA 1950
 Qy 1803 CTCAGAGAAAGTGTATGATGATGATCGAGACCAACCCCAACCTTCCACTAAGCCAGCTCC 1862
 Db 1951 CTCAGAGAAAGTGTATGATGATGATCGAGACCAACCCCAACCTTCCACTAAGCCAGCTCC 2010
 Qy 1863 CCTCTGACCTCTGTGGCCATTGCGAGAGCCACACCTGTGATCAGCTGGCCACAGAC 1922
 Db 2011 CCTCTGACCTCTGTGGCCATTGCGAGAGCCACACCTGTGATCAGCTGGCCACAGAC 2070
 Qy 1923 AAAGAACAACTCTCAACAGTTCACTGAGCTGGAGAGACCGGAGTCTGGAATCTGT 1982

Db 2071 AAAGAACAACTCTCAACAGTTCACTGAGCTGGAGAGACCGGAGTGTGATCTGT 2130
 Qy 1983 TTTCCGAAATGCTGACGCGGATGATGAACTGAATCGATACGCTGTTTCTGTCCCTCC 2042
 Db 2131 TTTCCGAAATGCTGACGCGGATGATGAACTGAATCGATACGCTGTTTCTGTCCCTCC 2190
 Qy 2043 TACTTCTCTTACACACAGACAGCCCTCATGTCTCCAGAGCAGAGACGACTACAGACAA 2102
 Db 2191 TACTTCTCTTACACACAGACAGCCCTCATGTCTCCAGAGCAGAGACGACTACAGACAA 2250
 Qy 2103 CTCTTCTTTAAATAATTAAGTCTCTTACAAATAAAAA 2141
 Db 2251 CTCTTCTTTAAATAATTAAGTCTCTTACAAATAAAAA 2289

Search completed: August 6, 2004, 14:23:31
 Job time : 874 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 6, 2004, 12:27:03 ; Search time 8364 Seconds

(without alignments)
11260.690 Million cell updates/sec

Title: US-10-018-386-1

Perfect score: 2173

Sequence: 1 gaaatgagcgtctgctgca.....aaaaaaaaaaaaaaaaaa 2173

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 1.0

Searched: 3470272 seqs, 21671516395 residues

Total number of hits satisfying chosen parameters: 6940544

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

GenEmbl:*

1: gb_ba:*

2: gb_hg:*

3: gb_in:*

4: gb_om:*

5: gb_ov:*

6: gb_pal:*

7: gb_ph:*

8: gb_pl:*

9: gb_pr:*

10: gb_ro:*

11: gb_sy:*

12: gb_un:*

13: gb_vl:*

14: gb_vl:*

15: em_ba:*

16: em_fun:*

17: em_hum:*

18: em_in:*

19: em_mu:*

20: em_om:*

21: em_or:*

22: em_ov:*

23: em_pat:*

24: em_pi:*

25: em_pl:*

26: em_ro:*

27: em_sts:*

28: em_un:*

29: em_vl:*

30: em_hg_hum:*

31: em_hg_inv:*

32: em_hg_other:*

33: em_hg_mus:*

34: em_hg_pdn:*

35: em_hg_rtd:*

36: em_hg_mam:*

37: em_hg_vrt:*

38: em_sy:*

39: em_hgo_hum:*

40: em_hgo_mus:*

41: em_hgo_other:*

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	* Match Length	DB ID	Description
1	2173	100.0	2173 6 AX069013	AX069013 Sequence
2	2156.6	99.2	2178 6 BC012368	BC012368 Homo sapi
3	2146.2	98.8	2288 6 BD260120	BD260120 Matrix-re
4	2133.2	98.2	3541 6 AX014413	AX014413 Sequence
5	2133.2	98.2	3541 6 BD222237	BD222237 Human nuc
6	2132.6	98.1	2290 6 AR081094	AR081094 Sequence
7	2132.6	98.1	2290 6 AR194809	AR194809 Sequence
8	2132.6	98.1	2290 6 AR205229	AR205229 Sequence
9	2132.6	98.1	2290 6 AR266344	AR266344 Sequence
10	2132.6	98.1	2290 6 AR307688	AR307688 Sequence
11	2132.6	98.1	2290 6 AR350376	AR350376 Sequence
12	2132.6	98.1	2290 6 AX403648	AX403648 Sequence
13	2132.6	98.1	2290 6 AX464138	AX464138 Sequence
14	2132.6	98.1	2290 6 BD076338	BD076338 Ligand ho
15	2132.6	98.1	2290 6 AY358274	AY358274 Homo sapi
16	2132.6	98.1	2290 6 AX750615	AX750615 Sequence
17	1511.6	69.6	1518 6 BD186034	BD186034 Methods o
18	1511.6	69.6	1518 6 AF125175	AF125175 Homo sapi
19	1478.8	68.1	1482 6 E64730	E64730 Proteins '4
20	1441.6	66.3	2784 6 AX014308	AX014308 Sequence
21	1441.6	66.3	2784 6 BD222187	BD222187 Human nuc
22	1343.4	61.8	2138 10 AF159049	AF159049 Rattus no
23	1239.2	57.0	1518 6 AX750616	AX750616 Sequence
24	1239.2	57.0	1518 10 AF125176	AF125176 Mus muscu
25	1082.4	49.8	2384 6 BD127427	BD127427 Primer fo
26	1082.4	49.8	2384 6 AK075026	AK075026 Homo sapi
27	976	44.9	1173 6 BD269693	BD269693 Protein a
28	970.4	44.7	2576 6 BD127752	BD127752 Primer fo
29	970.4	44.7	2576 6 AK074726	AK074726 Homo sapi
30	865.8	39.8	145481 9 AL356862	AL356862 Human DNA
31	703.4	32.4	747 6 BD125108	BD125108 Primer fo
32	703.4	32.4	747 6 BD126655	BD126655 Primer fo
33	685	31.5	263623 2 AC107560	AC107560 Rattus no
34	675.6	31.1	225087 10 AL845277	AL845277 Mouse DNA
35	572	26.3	660 6 BD269694	BD269694 Protein a
36	495	22.8	1877 5 BC055229	BC055229 Datto rer
37	491.8	22.6	1476 9 AF107253	AF107253 Homo sapi
38	491.8	22.6	2066 6 E39783	E39783 Protein par
39	491.8	22.6	2066 6 AX750614	AX750614 Sequence
40	491.8	22.6	2066 6 BD186033	BD186033 Methods o
41	491.8	22.6	2066 6 AB056476	AB056476 Homo sapi
42	491.8	22.6	2326 9 BC050640	BC050640 Homo sapi
43	491.8	22.6	3355 6 AR081095	AR081095 Sequence
44	491.8	22.6	3355 6 AR194810	AR194810 Sequence
45	491.8	22.6	3355 6 AR205230	AR205230 Sequence

ALIGNMENTS

RESULT 1	AX069013	2173 bp	DNA	linear	PAT 25-JAN-2001
LOCUS	AX069013				
DEFINITION	Sequence 1 from Patent WO0102434.				
ACCESSION	AX069013				
VERSION	AX069013.1				
KEYWORDS	GI:12578833				
SOURCE	Homo sapiens (human)				
ORGANISM	Homo sapiens				
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.				
AUTHORS	Friedrich, G., Hagen, G., Wick, M., Zubov, D. and Dubois-Stringfellow, N.				
TITLE	Methods for modulating angiogenesis by using the anti-angiogenic				

Qy		1503	TTTGCACAAATACGCGCATTTTCGGCTCGGAACCTCAGACGCGATTTTAAAGCTCCGGCTG	1562
Dd		1505	TTTGCAAGAATAACGCCAATTTCGGCTCGGAACCTCAGACGCGATTTTAAAGCTCCGGCTG	1564
Qy		1563	GGGCGCTAACCAATGCGCAATGCGGGTGACTCCTTTACATGAGCAACAACGCGAAGCAATTAACC	1622
Dd		1565	GGGGGCTAACCAATGCGCAATGCGGGTGACTCCTTTACATGAGCAACAACGCGAAGCAATTAACC	1624
Qy		1623	ACCGTGAACAGAGATCAATGATGTCTAACAAGAAAACCTGTGGCCCATCTCACAGGAGAGGC	1682
Dd		1625	ACCGTGAACAGAGATCAATGATGTCTAACAAGAAAACCTGTGGCCCATCTCACAGGAGAGGC	1684
Qy		1683	TGGTGATATAACGCTGTGGCCCACTCCAACCTCAAACGGGGTCTGTGTAACCGGGGGGCCAT	1742
Dd		1685	TGGTGATATAACGCTGTGGCCCACTCCAACCTCAAACGGGGTCTGTGTAACCGGGGGGCCAT	1744
Qy		1743	TACCGGAGCCGCTTACAGACAGAGATTAATCTGGGCTGATGTTCCGAGAGAGGCTCTTAATCA	1802
Dd		1745	TACCGGAGCCGCTTACAGACAGAGATTAATCTGGGCTGATGTTCCGAGAGAGGCTCTTAATCA	1804
Qy		1803	CTCAAGAAATGTGTGATGATGATCCGACCGAACCCCAACACTTCCACTAAGCCAGCTCC	1862
Dd		1805	CTCAAGAAATGTGTGATGATGATCCGACCGAACCCCAACACTTCCACTAAGCCAGCTCC	1864
Qy		1863	CCCTCTGACCTCTCGTGGCCATTGGCCAGGAGCCCACTCTGTGTAAGCTGGCCACAGCAC	1922
Dd		1865	CCCTCTGACCTCTCGTGGCCATTGGCCAGGAGCCCACTCTGTGTAAGCTGGCCACAGCAC	1924
Qy		1923	AAAGAACAACTCCCTCAACAGTTTCACTCTGAGGCTGGAGAGACCGGAGATTCGT	1982
Dd		1925	AAAGAACAACTCCCTCAACAGTTTCACTCTGAGGCTGGAGAGACCGGAGATTCGT	1984
Qy		1983	TTTTCCGAGTCACTGCAACGAGATGATGAACTGAATGATACGGTGTTCCTGTCCTCC	2042
Dd		1985	TTTTCCGAGTCACTGCAACGAGATGATGAACTGAATGATACGGTGTTCCTGTCCTCC	2044
Qy		2043	TACTTTCCTTCAACACGAGACAGCCCCCTCAAGTCTCCAGACAGGACAGGACTAAGACAA	2102
Dd		2045	TACTTTCCTTCAACACGAGACAGCCCCCTCAAGTCTCCAGACAGGACAGGACTAAGACAA	2104
Qy		2103	CTCTTTCTTTAAATTAATTAAGTCTCTACATATAAAAAACAACACTGCAAAAGTAAAAAAAA	2162
Dd		2105	CTCTTTCTTTAAATTAATTAAGTCTCTACATATAAAAAACAACACTGCAAAAGTAAAAAAAA	2164
Qy		2163	AAAAAAAAAAAAA 2173	
Dd		2165	AAAAAAAAAAAAA 2175	
RESULT 3				
LOCUS	BD260120	2288 bp	DNA	linear PAT 17-JUL-2003
DEFINITION	Matrix-remodeling genes.			
ACCESSION	BD260120			
VERSION	BD260120.1 GI:33069890			
KEYWORDS	JP 2002527054-A/11.			
SOURCE	Homo sapiens (human)			
ORGANISM	Homo sapiens			
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
	Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.			
REFERENCE	Walker,M.G., Volkmutz,W. and Klingler,T.M.			
AUTHORS	Matrix-remodeling genes			
TITLE	Patent: JP 2002527054-A 11 27-AUG-2002;			
JOURNAL	INOYTE PHARMACEUTICALS INC			
COMMENT	OS Homo sapiens (human) PN JP 2002527054-A/11 PD 27-AUG-2002 PF 06-OCT-1999 JP 2000575891 PR 09-OCT-1998 US 05/169289 PI MICHAEL G WALKER WAYNE VOLKMUH TOD M KLINGLER PC CI2N5/09,A6IK38/00,A6IK38/28,A6IK38/46,A6IK48/00,A6IP1/04,PC A6I9/10.			

PC A6IP9/10,A6IP17/02,A6IP19/02,A6IP35/00,C07K14/47,C07K16/18, PC
C12N1/15,
PC C12N1/19,C12N1/21,C12N5/10,C12Q1/68,G01N33/15,G01N33/50,G01N33/53,
G01N33/53//A6IK31/711,A6IK35/76,C12N15/00,C12N5/00,A6IK37/02,
PC A6IK37/26,
PC A6IK37/54
CC Incyte ID NO.: 2268890CE1
FH Key Location/Qualifiers
FT source 1..2288
/organism='Homo sapiens (human)'.
FEATURES
source location/Qualifiers
1..2288
/organism='Homo sapiens'
/mol_type='genomic DNA'
/db_xref='taxon:9606'

ORIGIN

Query Match 98.8%; Score 2146.2; DB 6; Length 2288;
Best Local Similarity 99.4%; Pred. No. 0;
Matches 2154; Conservative 0; Mismatches 13; Indels 0; Gaps 0;
3 AANTAGAGCTGCTGCGAGAGGCTGAGATGAACCCCAAGCCCTGACCTGCCAGCGCTG
73 AANTAGAGCTGCTGCGAGAGGCTGAGATGAACCCCAAGCCCTGACCTGCCAGCGCTG
63 GCACTGAGCGAGCGGCTGACCTGCTGAGAGGAAAGAGTTGTGAGCAGCCCGCAGG 122
133 GCACTGAGCGAGCGGCTGACCTGCTGAGAGGAAAGAGTTGTGAGCAGCCCGCAGG 192
123 ACCCTGCGAGCGCTGAGCGGCTGAGCGGCTGAGAGCGGCTGAGAGCGAGCGAGT 182
193 ACCCTGCGAGCGCTGAGCGGCTGAGCGGCTGAGAGCGGCTGAGAGCGAGCGAGT 252
183 GAGCCAGTGAAGGAGGAGCTGCTTGGCAGCCACCGGCTGCAACTCAGAAACCCCTCCAG 242
253 GAGCCAGTGAAGGAGGAGCTGCTTGGCAGCCACCGGCTGCAACTCAGAAACCCCTCCAG 312
243 AGGCGATGAGAGCGGCTGCGCGCGCTGACCGCGGCTGAGAGTGTGAGAGCGCGCGG 302
313 AGGCGATGAGAGCGGCTGCGCGCGCTGACCGCGGCTGAGAGTGTGAGAGCGCGCGG 372
303 AGCCAGAGAGAGGAGGCTTTCATAGATTCTATTCACAAAGATTAACACCATTTT 362
373 AGCCAGAGAGAGGAGGCTTTCATAGATTCTATTCACAAAGATTAACACCATTTT 432
363 GCAAGAGCATGAGGCTGCTGCTGAGATGCTGTGTGGCTGCACTGCTGGCTGCCATG 422
433 GCAAGAGCATGAGGCTGCTGCTGAGATGCTGTGTGGCTGCACTGCTGGCTGCCATG 492
423 GAGAGCTGTTGAGCGAGAGAGCGTTTTCAGGCACTGAGAGGCGCTCCCAAGAGAG 482
493 GAGAGCTGTTGAGCGAGAGAGCGTTTTCAGGCACTGAGAGGCGCTCCCAAGAGAG 552
483 TTTCATTTCCTTAACAAGTACAGCGGCGGCGAGTCCCAAGACAGTGCATCACCC 542
553 TTTCATTTCCTTAACAAGTACAGCGGCGGCGAGTCCCAAGACAGTGCATCACCC 612
543 TTTCATTTCCTTAACAAGTACAGCGGCGGCGAGTCCCAAGACAGTGCATCACCC 602
613 TTTCATTTCCTTAACAAGTACAGCGGCGGCGAGTCCCAAGACAGTGCATCACCC 672
603 GTGCTTTCGAGAACCGAGTGCATTAAGAGAGCTAGAGTCTTCAACAAATGAGTGTCTC 662
673 GTGCTTTCGAGAACCGAGTGCATTAAGAGAGCTAGAGTCTTCAACAAATGAGTGTCTC 732
663 AAGCAGAGCGGCGAGATGAGAGCGCTGAGAGCGTGTGAGAGTGTGAGAGCGGCGAGTGTG 722
733 AAGCAGAGCGGCGAGATGAGAGCGCTGAGAGCGTGTGAGAGTGTGAGAGCGGCGAGTGTG 792
723 AAGCAGAGCGGCGAGATGAGAGCGCTGAGAGCGTGTGAGAGTGTGAGAGCGGCGAGTGTG 782

Db 793 AGCAGGTGAAGCTGCTGCGCAGAGAGAGCGCGCAATGAATTCGCGGCTCAGCGAGCTC 852
Qy 783 TACATGAGCTCTCTGCAAGATCATCCGAGCGGAGCAACCGCTTGGAGCTCTCCAG 842
Db 853 TACATGAGCTCTCTGCAAGATCATCCGAGCGGAGCAACCGCTTGGAGCTCTCCAG 912
Qy 843 CTGAGAACAGATCTCTGAACCAAGACCGGAGCATGCTGTGAGCTGCTGAGCAAGTACAG 902
Db 913 CTGAGAACAGATCTCTGAACCAAGACCGGAGCATGCTGTGAGCTGCTGAGCAAGTACAG 972
Qy 903 GACTGAGACAGATCTCTGAGACAGACCTGAGCGAGCTGAGCGAGCGAGCGAGCGAGCT 962
Db 973 GACTGAGACAGATCTCTGAGACAGACCTGAGCGAGCTGAGCGAGCGAGCGAGCT 1032
Qy 963 GCGAGCTTGAAGAGCATGCTGCGAGAGGCTGCTGCGAGCGAGCGAGCGAGCGAGCT 1022
Db 1033 GCGAGCTTGAAGAGCATGCTGCGAGAGGCTGCTGCGAGCGAGCGAGCGAGCGAGCT 1092
Qy 1023 CCGGCTGCGCGCGCGCGGCTGCTGAGACAGCGAGCGAGCGAGCGAGCGAGCGAGCT 1082
Db 1093 CCGGCTGCGCGCGCGCGGCTGCTGAGACAGCGAGCGAGCGAGCGAGCGAGCGAGCT 1152
Qy 1083 TCTACCAAGAGATCCAGAGTGAACAGAACTGAGAGTGTGAGCGAGCGAGCGAGCT 1142
Db 1153 TCTACCAAGAGATCCAGAGTGAACAGAACTGAGAGTGTGAGCGAGCGAGCGAGCT 1212
Qy 1143 ATGCGCACTCTACAGAGCTCTCCATCTTCCAGCAAGCGGCTGAGCGAGCGAGCGAG 1202
Db 1213 ATGCGCACTCTACAGAGCTCTCCATCTTCCAGCAAGCGGCTGAGCGAGCGAGCGAG 1272
Qy 1203 TGCGTGAAGCGCTGAGAGTGAACAGCAAGCGAGCGAGCGAGCGAGCGAGCGAG 1262
Db 1273 TGCGTGAAGCGCTGAGAGTGAACAGCAAGCGAGCGAGCGAGCGAGCGAGCGAG 1332
Qy 1263 AACCAACCGCTCATGAGAGTGTGAGCGAGCGAGCGAGCGAGCGAGCGAGCGAG 1322
Db 1333 AACCAACCGCTCATGAGAGTGTGAGCGAGCGAGCGAGCGAGCGAGCGAGCGAG 1392
Qy 1323 GTATCCAGAGAGCGGCTGAGAGTGTGAGCGAGCGAGCGAGCGAGCGAGCGAG 1382
Db 1393 GTATCCAGAGAGCGGCTGAGAGTGTGAGCGAGCGAGCGAGCGAGCGAGCGAG 1452
Qy 1383 CAAGGCTTGGAGAACTTGAACGAGAGTGTGAGCGAGCGAGCGAGCGAGCGAG 1442
Db 1453 CAAGGCTTGGAGAACTTGAACGAGAGTGTGAGCGAGCGAGCGAGCGAGCGAG 1512
Qy 1443 ACGAAGCAAGGCAATCAACATCTGAGTGAACATGAGAGAGTGTGAGCGAGCGAG 1502
Db 1513 ACGAAGCAAGGCAATCAACATCTGAGTGAACATGAGAGAGTGTGAGCGAGCGAG 1572
Qy 1503 TTTCAGAAATACCGAGTTCGCGCTGGAACCTGAGAGCGAGTATTAAGTGCAGCTG 1562
Db 1573 TTTCAGAAATACCGAGTTCGCGCTGGAACCTGAGAGCGAGTATTAAGTGCAGCTG 1632
Qy 1563 GGGGCGCTACATGAGCAATGCGGCTGAGCTCTTACATGAGCAACGAGCAAGCTTCAAC 1622
Db 1633 GGGGCGCTACATGAGCAATGCGGCTGAGCTCTTACATGAGCAACGAGCAAGCTTCAAC 1692
Qy 1623 ACCCTGAGAGAGATCATGATGCTTCAACAGAGAACTGTGCCACTACAGAGAGAGG 1682
Db 1693 ACCCTGAGAGAGATCATGATGCTTCAACAGAGAACTGTGCCACTACAGAGAGAGG 1752
Qy 1683 TGGTGTATTAACCGCTGTGCTCACTCCACCTCAACGAGGCTGTGTAACGCGGCGAGCAT 1742
Db 1753 TGGTGTATTAACCGCTGTGCTCACTCCACCTCAACGAGGCTGTGTAACGCGGCGAGCAT 1812
Qy 1743 TACCGAGCGGCTACACAGAGCGAGTCTACTGAGCTGAGTTCGAGAGAGGCTTTACTCA 1802
Db 1813 TACCGAGCGGCTACACAGAGCGAGTCTACTGAGCTGAGTTCGAGAGAGGCTTTACTCA 1872
Qy 1803 CTCAGAGAGTGTGATGATTCGAGCGAGACCGCAACACTTTCACATTAAGCAGAGCTCC 1862
Db 1873 CTCAGAGAGTGTGATGATTCGAGCGAGACCGCAACACTTTCACATTAAGCAGAGCTCC 1932

QY 1863 CCTCTGACCTCTGTGGCCATTGTCAGAGAGCCACCTGTGTCACGCTGSCACAGAC 1922
DB 1933 CCTCTGACCTCTGTGGCCATTGTCAGAGAGCCACCTGTGTCACGCTGSCACAGAC 1992
QY 1933 AAAAGAACATCTCTCAACCAATTCTCTGAGGCTGGAGAGACCGGATGCTGATTTCT 1982
DB 1993 AAAAGAACATCTCTCAACCAATTCTCTGAGGCTGGAGAGACCGGATGCTGATTTCT 2052
QY 1983 TTTCGAAAGTCATCTGAGGAGATGATGGAATGATGATGATGATGATGATGATGATG 2042
DB 2053 TTTCGAAAGTCATCTGAGGAGATGATGGAATGATGATGATGATGATGATGATGATG 2112
QY 2043 TACTTCTCTCAACCAACAGCCCTCATGTCTTCAGAGACAGACAGACTACAGACAA 2102
DB 2113 TACTTCTCTCAACCAACAGCCCTCATGTCTTCAGAGACAGACAGACTACAGACAA 2172
QY 2103 CTCTTCTTTAAATTAATTAAGTCTCTCAATTAATAAACAACAGCAAGTAAATAA 2162
DB 2173 CTCTTCTTTAAATTAATTAAGTCTCTCAATTAATAAACAACAGCAAGTAAATAA 2232
QY 2163 AAAAAA 2169
DB 2233 AATATCA 2239

RESULT 4
AX014413 3541 bp DNA linear PAT 07-SEP-2000
LOCUS Sequence 125 from Patent WO9954353.
DEFINITION AX014413
ACCESSION AX014413
VERSION AX014413.1 GI:10040712
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
REFERENCE 1
AUTHORS Schmitt,A., Specht,T., Dahl,E., Hinzmann,B., Rosenthal,A. and
Piletsky,C.
TITLE Human nucleic acid sequences of normal uterus tissue
JOURNAL Patent: WO 9954353-A 125 28-OCT-1999;
SCHMITT ARMIN (DE); SPECHT THOMAS (DE); DAHL EDGAR (DE); HINZMANN
BERND (DE); ROSENTHAL ANDRE (DE); METAGEN GES FUER GENOMFORSCHUN
(DE); PILETSKY CHRISTIAN (DE)
FEATURES
source location/Qualifiers
1..3541
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

ORIGIN
Query Match 98.2%; Score 2133.2; DB 6; Length 3541;
Best Local Similarity 99.3%; Pred. No. 0;
Matches 2152; Conservative 0; Mismatches 14; Indels 1; Gaps 1;

DB 315 AGGCTATGACAGAGGCTGCCCCCTGACGACGAGGATGAAGCATGTGAGAGAGCGCCCG 374
QY 303 AGCCAGACAGAGAGAGAGAGGCTTTCAATGATTTCTATACAAAGATTAACCAATTTT 362
DB 375 AGCCAGACAGAGAGAGAGAGGCTTTCAATGATTTCTATACAAAGATTAACCAATTTT 434
QY 363 GCAAGACATGAGAGGCACTGTGCTGATGATGCTGTGCTGTGATCTGTGCTGTGCTG 422
DB 435 GCAAGACATGAGAGGCACTGTGCTGATGATGCTGTGCTGTGATCTGTGCTGTGCTG 494
QY 423 GAGCTGTTGGAGGAGGAGGAGGAGGCTTTGAGAGGCACTGAGAGAGGCTCGCAAGAG 482
DB 495 GAGCTGTTGGAGGAGGAGGAGGAGGCTTTGAGAGGCACTGAGAGAGGCTCGCAAGAG 554
QY 483 TTCAATTAACCTAAACAGATTAACAGCGGAGGAGGAGGCTTCAGAGACAGTGCATCAC 542
DB 555 TTCAATTAACCTAAACAGATTAACAGCGGAGGAGGAGGCTTCAGAGACAGTGCATCAC 614
QY 543 TTCAATTAACCTAAACAGATTAACAGCGGAGGAGGAGGCTTCAGAGACAGTGCATCAC 602
DB 615 TTCAATTAACCTAAACAGATTAACAGCGGAGGAGGAGGCTTCAGAGACAGTGCATCAC 674
QY 603 GTGCTTCTGAGAGACCGAGTGTATAGCAGAGCTAGAGCTGCTCAACATGAGCTGCTC 662
DB 675 GTGCTTCTGAGAGACCGAGTGTATAGCAGAGCTAGAGCTGCTCAACATGAGCTGCTC 734
QY 663 AACCAAGAGCGGAGATTCAGAGACGCTGACGAGCTGTGTAAGTGAACGCGCGCATTTG 722
DB 735 AACCAAGAGCGGAGATTCAGAGACGCTGACGAGCTGTGTAAGTGAACGCGCGCATTTG 794
QY 723 AGGAGGTGAAGCTGTGCGCAAGAGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 782
DB 795 AGGAGGTGAAGCTGTGCGCAAGAGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 854
QY 783 TACATGAGCTCTGTCAGAGATCATCGCAAGCGGAGACAGGCTGTGAGCTTCTCCAG 842
DB 855 TACATGAGCTCTGTCAGAGATCATCGCAAGCGGAGACAGGCTGTGAGCTTCTCCAG 914
QY 843 CTGGAAGACAGATCTCTGACAGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 902
DB 915 CTGGAAGACAGATCTCTGACAGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 974
QY 903 GACCTGAGACAGATTCAGAGACGCTGACAGAGGAGGAGGAGGAGGAGGAGGAGGAGG 962
DB 975 GACCTGAGACAGATTCAGAGACGCTGACAGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1034
QY 963 GCGCAGCTTGAAGAGACATGCGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1022
DB 1035 GCGCAG-TTGAAGAGACATGCGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1093
QY 1023 CCGCTGCCCCCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1082
DB 1094 CCGCTGCCCCCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1153
QY 1083 TCTACAGAGAGATTCAGAGATGACAGAGACCTGGAAGGCTGTCACACCCCTTGGCCACT 1142
DB 1154 TCTACAGAGAGATTCAGAGATGACAGAGACCTGGAAGGCTGTCACACCCCTTGGCCACT 1213
QY 1143 ATGCCACTCTACAGAGCTTCCATTTCCACGACCAAGCCCTGCGGAGGAGGAGAGAC 1202
DB 1214 ATGCCACTCTACAGAGCTTCCATTTCCACGACCAAGCCCTGCGGAGGAGGAGAGAC 1273
QY 1203 TGCTGAGAGGCTTGAAGAGATGAGCAGACAGAGTCCATTTACTTGTGTAAGCTGAGG 1262
DB 1274 TGCTGAGAGGCTTGAAGAGATGAGCAGACAGAGTCCATTTACTTGTGTAAGCTGAGG 1333
QY 1263 AAGACCAACGAGCTTGAAGAGATGAGCAGACAGAGTCCATTTACTTGTGTAAGCTGAGG 1322
DB 1334 AAGACCAACGAGCTTGAAGAGATGAGCAGACAGAGTCCATTTACTTGTGTAAGCTGAGG 1393
QY 1323 GTCATCAGAGAGCTGTGATGCTGTAACTTTGAGAACTGGAGAGCTGACAG 1382

Db 1394 GTGATCCAGAGACGGCTGATGCTCTGTTAACTTCTTACAGAACTGGGAGACGTACAG 1453
Qy 1383 CAAGGTTTGGGAACATTGACGGCGAATAGTGGCTGGGCTTGAGAACTTACTGGCTG 1442
Db 1454 CAAGGTTTGGGAACATTGATGCGCAATATCTGGGCTTGAGAACTTACTGGCTG 1513
Qy 1443 ACGAACCAGGGAATCAAACTCCTGGTGACATGAGGAGCTGGTCCGGCGGAAAGTC 1502
Db 1514 ACGAACCAGGGAATCAAACTCCTGGTGACATGAGGAGCTGGTCCGGCGGAAAGTC 1573
Qy 1503 TTTGAGAAATACGGCAGTTTCCGCTGGAACTGAGACGAGTATTATAGCTCGGCTG 1562
Db 1574 TTTGAGAAATACGGCAGTTTCCGCTGGAACTGAGACGAGTATTATAGCTCGGCTG 1633
Qy 1563 GGGGCGTACATGCGAATGCGGGTGATCTCTTTACATGCGCAACGCGAAGCACTTACC 1622
Db 1634 GGGGCGTACATGCGAATGCGGGTGATCTCTTTACATGCGCAACGCGAAGCACTTACC 1693
Qy 1623 ACCCTGACAGATCATGATGTCTACACAGGAACTGTGCCACTACAGAGGAGGC 1682
Db 1694 ACCCTGACAGATCATGATGTCTACACAGGAACTGTGCCACTACAGAGGAGGC 1753
Qy 1683 TGGTGTATTAACGCTGTGCCACTACCACTCAACGCGGTCTGCTACCGCGGGCCAT 1742
Db 1754 TGGTGTATTAACGCTGTGCCACTACCACTCAACGCGGTCTGCTACCGCGGGCCAT 1813
Qy 1743 TACCGGACCGGCTACAGAGCGGAGTCTACTGGGCTGAGTCCGAGAGGCTCTTACTCA 1802
Db 1814 TACCGGACCGGCTACAGAGCGGAGTCTACTGGGCTGAGTCCGAGAGGCTCTTACTCA 1873
Qy 1803 CTCAAGAAAGTGTATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1862
Db 1874 CTCAAGAAAGTGTATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1933
Qy 1863 CCTTCTTACCTCTCTGTGGCCATTGCGAGAGCCCACTCTGTACAGCTGGCCACAGAG 1922
Db 1934 CCTTCTTACCTCTCTGTGGCCATTGCGAGAGCCCACTCTGTACAGCTGGCCACAGAG 1993
Qy 1923 AAAAGAACACTCTCTACAGATTCATCTGAGGCTGGAGAGACCGGAGTGTGATTCGT 1982
Db 1994 AAAAGAACACTCTCTACAGATTCATCTGAGGCTGGAGAGACCGGAGTGTGATTCGT 2053
Qy 1983 TTTCCGAGTCACTGACGCGGATGATGATGATGATGATGATGATGATGATGATGATGAT 2042
Db 2054 TTTCCGAGTCACTGACGCGGATGATGATGATGATGATGATGATGATGATGATGATGAT 2113
Qy 2043 TACTTCTCTGACACAGACGCGCTGATGATGATGATGATGATGATGATGATGATGATGAT 2102
Db 2114 TACTTCTCTGACACAGACGCGCTGATGATGATGATGATGATGATGATGATGATGATGAT 2173
Qy 2103 CTCTTCTTAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 2162
Db 2174 CTCTTCTTAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 2233
Qy 2163 AAAAAA 2169
Db 2234 ATATACA 2240

RESULT 5
BD222237 3541 bp DNA linear PAT 17-JUN-2003
LOCUS BD222237
DEFINITION Human nucleic acid sequence originating in normal uterine tissue.
ACCESSION BD222237.1 GI:33032007
VERSION JP 2002512017-A/66
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
1 (bases 1 to 3541)
Specht, T., Hinzmann, B., Schmitt, A., Pilarsky, C., Dahl, E. and
Rosenthal, A.

TITLE Human nucleic acid sequence originating in normal uterine tissue
JOURNAL Patent: JP 2002512017-A 66 23-APR-2002;
MUTAGEN GESELLSCHAFT FUER GENOM FORSCHUNG MBH
COMMENT OS Homo sapiens (human)
PN JP 2002512017-A/66
PD 23-APR-2002
PF 15-APR-1999 JP 2000544691
PR 17-APR-1998 DE 198 17 946 4
PI THOMAS SPECHT, BERND HINZMANN, ARMIN SCHMITT, CHRISTIAN PILARSKY,
PI EDGAR DAHL,
PI ANDRE ROSENTHAL
PC C12N15/09, A61K38/00, A61P35/00, C07K14/47, C07K16/18,
PC C12N1/19,
PC C12N1/21, C12N5/00, C12P21/08, C12Q1/68, G01N33/68, C12N15/00, PC
A61K37/02,
PC C12N5/00
CC Human nucleic acid sequence originating in normal uterine tissue

FEATURES
FH Key Location/Qualifiers
FT source 1..3541
FT /organism="Homo sapiens (human)".
FT Location/Qualifiers
1..3541
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

ORIGIN
Query Match 98.2%; Score 2133.2; DB 6; Length 3541;
Best Local Similarity 99.3%; Pred. No. 0;
Matches 2152; Conservative 0; Mismatches 14; Indels 1; Gaps 1;
Qy 3 AAATGAGGCTGTGCGGACGCGCTGAGATGAACCCCAAGCCTGAGCCTGCGGACGTG 62
Db 75 AAATGAGGCTGTGCGGACGCGCTGAGATGAACCCCAAGCCTGAGCCTGCGGACGTG 134
Qy 63 GCACTGAGGCGGCGCTGACGCTACTGTGTAGGGAAGAAAGTTGTAGACACCCGCGAG 122
Db 135 GCACTGAGGCGGCGCTGACGCTACTGTGTAGGGAAGAAAGTTGTAGACACCCGCGAG 194
Qy 123 ACCGCTGGCAGCGCTGGGCGCCGAGCCTGCGCGGAGCCCTGTGAGAGGAGCCAGTG 182
Db 195 ACCGCTGGCAGCGCTGGGCGCCGAGCCTGCGCGGAGCCCTGTGAGAGGAGCCAGTG 254
Qy 183 GAGCCAGTGAAGGCGGCTGCTGTGACGCAACCGGCTGCAACTGAGAACCCCTCCAG 242
Db 255 GAGCCAGTGAAGGCGGCTGCTGTGACGCAACCGGCTGCAACTGAGAACCCCTCCAG 314
Qy 243 AGGCGATGGAACAGGCTGCCCCGCTGACGCGGAGGAGGATGAGAGCCGCGCCCG 302
Db 315 AGGCGATGGAACAGGCTGCCCCGCTGACGCGGAGGAGGATGAGAGCCGCGCCCG 374
Qy 303 AGCCAGAGGAGGAGGAGGCTTTCATAGATTCTATTCAAAAGATTAACCAACATTTT 362
Db 375 AGCCAGAGGAGGAGGAGGCTTTCATAGATTCTATTCAAAAGATTAACCAACATTTT 434
Qy 363 GCAAGACCATGAGGCGCATCTGTGCGTGAACATGCTGTGGTCTGCGATCTGCTGCGATG 422
Db 435 GCAAGACCATGAGGCGCATCTGTGCGTGAACATGCTGTGGTCTGCGATCTGCTGCGATG 494
Qy 423 GGAAGCTTGCAGGCGCAGAGGAGCGGTTTGAAGGCACTGAGAGGAGGCTGCGCAAGAG 482
Db 495 GGAAGCTTGCAGGCGCAGAGGAGCGGTTTGAAGGCACTGAGAGGAGGCTGCGCAAGAG 554
Qy 483 TTCAATTACTTAACAGGTACAAAGCGGCGGCGAGTCCAGGACAAAGTGCACCTTACAC 542
Db 555 TTCAATTACTTAACAGGTACAAAGCGGCGGCGAGTCCAGGACAAAGTGCACCTTACAC 614
Qy 543 TTCAATTGCGCCAGAGAGGCGGCTCAGCGGAGCCATGCGTCAACTGCAAGAGGCTGAG 602
Db 615 TTCAATTGCGCCAGAGAGGCGGCTCAGCGGAGCCATGCGTCAACTGCAAGAGGCTGAG 674
Qy 603 GTGCTTGTGAGAACCGAGTGCATTAAGCAGAGAGCTGACTGCTCAACATGAGTGTTC 662

Db	675	GTGCTTCTGGAGAACCGAGTGTGATTAAGCAGAGGCTTAGAGCTGCTCAACATAGAGCTGTC	734
QY	663	AAGCAGAAAGCGCAGATGAGACGCTGCAGAGCTGTGTGAGAGGTGAGACGGCAATTGTG	722
Db	735	AAGCAGAAAGCGCAGATGAGACGCTGTGCAGAGCTGTGTGAGAGGTGAGACGGCAGATTGTG	794
QY	723	AGCGAGGTGAAGCTCTGTGCAGAGAGAGCGCAACATGAATCTGGGGGTCAACGAGCTC	782
Db	795	AGCGAGGTGAAGCTCTGTGCAGAGAGAGCGCAACATGAATCTGGGGGTCAACGAGCTTC	854
QY	783	TACATGCAAGCTCTTGACAGAGATCATCCGCAAGCGGGAACACGCGTTGTGAGCTCTCCAG	842
Db	855	TACATGCAAGCTCTTGACAGAGATCATCCGCAAGCGGGAACACGCGTTGTGAGCTCTCCAG	914
QY	843	CTGGAGAACAGGATCTCTGAACCAAGACGCCACATGTCTGCACTGTGGCCAGGAAGTACAG	902
Db	915	CTGGAGAACAGGATCTCTGAACCAAGACGCCACATGTCTGCACTGTGGCCAGGAAGTACAG	974
QY	903	GACCTGGAGACAAGATACAGACCTGGCCACACTGCGCCACACCAACCAATCAGAGATCATC	962
Db	975	GACCTGGAGACAAGATACAGACCTGGCCACACTGCGCCACACCAACCAATCAGAGATCATC	103
QY	963	GCGCAGCTTTGAGAGACACTGCCAGAGGGTGCCTTGGCCAGGCGCTGCCCAAGCACCC	1022
Db	1035	GCGCAG- TTGAGAGACACTGCGCAGAGGGTGCCTTGGCCAGGCGCTGCCCAAGCACCC	1092
QY	1023	CCCGCTGGCCCCGCCCGGGGTCTACCAACCAACCCACCTCTCAACCGGATCATCAACAGATC	1082
Db	1094	CCCGCTGGCCCCGCCCGGGGTCTACCAACCAACCCACCTCTCAACCGGATCATCAACAGATC	1152
QY	1083	TCTACCAACGAGATCCAGAGTGACACAGAACTGAAAGTGTGTCACACCCCTCTGCTCACT	1142
Db	1154	TCTACCAACGAGATCCAGAGTGACACAGAACTGAAAGTGTGTCACACCCCTCTGCTCACT	1212
QY	1143	ATGGCCACTCTACACAGCTCCCACTCTTCCACCGACAGCGGTGGGGCCCATGGAGAGAC	1202
Db	1214	ATGGCCACTCTACACAGCTCCCACTCTTCCACCGACAGCGGTGGGGCCCATGGAGAGAC	1272
QY	1203	TGCTGTGAGCGCTCTGAGAGATGCGCACGACACCAAGCTCCATTTACTGTGTGAAGCCGAG	1262
Db	1274	TGCTGTGAGCGCTCTGAGAGATGCGCACGACACCAAGCTCCATTTACTGTGTGAAGCCGAG	1332
QY	1263	AACACCAACCGCTCTATGACAGGTGTGTGTGCGACCGAGACACAGACCCCGGGGGCTGAGAC	1322
Db	1334	AACACCAACCGCTCTATGACAGGTGTGTGTGCGACCGAGACACAGACCCCGGGGGCTGAGAC	1392
QY	1323	GTCACTCGAGAGACGCGCTGGATGGCTGTGTTAACTCTTCAGAGAACTGGGAGACGTACAG	1382
Db	1394	GTCACTCGAGAGACGCGCTGGATGGCTGTGTTAACTCTTCAGAGAACTGGGAGACGTACAG	1452
QY	1383	CAAGGGTTGGGACATTGACGCGCGAATATCGGCTGGGCTGTGAGAACATTATCTGCGCTG	1442
Db	1454	CAAGGGTTGGGACATTGATGGCGAATATCGGCTGGGCTGTGAGAACATTATCTGCGCTG	1512
QY	1443	ACGAACCAAGGAACTACAAACTCTGTGTGACATGGAGAGACTGTCCGCGCGCAAACTC	1502
Db	1514	ACGAACCAAGGAACTACAAACTCTGTGTGACATGGAGAGACTGTCCGCGCGCAAACTC	1572
QY	1503	TTTGCAGAAATACGACAGTTTCGCGCTGGAACCTGGAACGAGTATTAATAGCTGTGCGGCT	1562
Db	1574	TTTGCAGAAATACGACAGTTTCGCGCTGGAACCTGGAACGAGTATTAATAGCTGTGCGGCT	1632
QY	1563	GGGCGCTACATGGGAATGCGGGGTGACTCTTTTATATGGCAACAGCGAAGCATTTAC	1622
Db	1634	GGGCGCTACATGGGAATGCGGGGTGACTCTTTTATATGGCAACAGCGAAGCATTTAC	1692
QY	1623	ACCTCGACAGAGATCATGATGTCTACACAGAAACTGTGCCATCAACAGAGGAGAGC	1682
Db	1694	ACCTCGACAGAGATCATGATGTCTACACAGAAACTGTGCCATCAACAGAGGAGAGC	1752
QY	1683	TGTTGTATTAACGCTGTGCCACTCCAACCTCAACGGGGTGTGTACCGCGGGGCCAT	1742

Db	1754	TGGTGGATTAACGCGCTGGCCACTCCAACTCAACGGGGCTGTGTACCGGGGGGCAT	1813
QY	1743	TACCGGAGCGCTACCGAGCGAGTCTACTGGGCTGATTCGAGGAGGCTCTACTCA	1802
Db	1814	TACCGGAGCGCTACCGAGCGAGTCTACTGGGCTGATTCGAGGAGGCTCTACTCA	1873
QY	1803	CTCAAGAAAGTGTGATGATGATCGACCGAACCCCAACCTTCCAATAAGCCAGCTCC	1862
Db	1874	CTCAAGAAAGTGTGATGATGATCGACCGAACCCCAACCTTCCAATAAGCCAGCTCC	1933
QY	1863	CCCTTCCTGACCTCTCTGTGGCCATTGGCCAGAGCCCACTCTGTGTACGCTGGCCACAGCAC	1922
Db	1934	CCCTTCCTGACCTCTCTGTGGCCATTGGCCAGAGCCCACTCTGTGTACGCTGGCCACAGCAC	1993
QY	1923	AAAGAACACTCTCTCAACAGTTCACTCCCTGAGGCTGGAGAGACCGGAGTGCATTCGT	1952
Db	1994	AAAGAACACTCTCTCAACAGTTCACTCCCTGAGGCTGGAGAGACCGGAGTGCATTCGT	2053
QY	1983	TTTCCGAAGTCACTCGACGCGGATATGGAATCGATCGGTGTTTCTGTCCCTCC	2042
Db	2054	TTTCCGAAGTCACTCGACGCGGATATGGAATCGATCGGTGTTTCTGTCCCTCC	2113
QY	2043	TACTTCTCTCAACGAGACGCGCCCTCAAGTCTCCAGAGCAGGACAGCACTACAGCAA	2102
Db	2114	TACTTCTCTCAACGAGACGCGCCCTCAAGTCTCCAGAGCAGGACAGCACTACAGCAA	2173
QY	2103	CTCTTCTTTTAATTAATTAAGTCTTACATATAAAACAACACTGCAAAAGTAAAAAAA	2162
Db	2174	CTCTTCTTTTAATTAATTAAGTCTTACATATAAAACAACACTGCAAAAGTACTTCATA	2233
QY	2163	AAAAAA 2169	
Db	2234	ATATACA 2240	

RESULT 6	LOCUS	DEFINITION	ACCESSION	VERSION	KEYWORDS	SOURCE	ORGANISM	REFERENCE	AUTHORS	TITLE	JOURNAL	FEATURES
AR08.094	AR081094	Sequence 1 from patent US 5972338.	AR081094	AR081094.1	GI:10007822	Unknown.	Unknown.	1 (bases 1 to 2290)	Godowski, P.J. and Gurney, A.L.	Tie ligands homologues	Patent: US 5972338-A 1 26-OCT-1999;	location/Qualifiers 1..2290 /organism="unknown" /mol_type="unassigned DNA"

	Query Match	Similarity	98.1%	Score	2132.6	DB	6	Length	2290
	Best Local	Similarity	99.8%	Pred.	No				
	Matches	135	Conservative	0	Mismatches	4	Indels	0	Gaps
Qy	3	AAATGAGCGTCTGCGGACGGCCTGAGAGTAACCCAGCCCTGACCTGCGAGCGTG							62
Db	151	AAATGAGCGTCTGCGGACGGCCTGAGAGTAACCCAGCCCTGACCTGCGAGCGTG							210
Qy	63	GCACTGAGGAGCGCGCTGACGCTACTGTGAGGGAAMAAGTTGTGTGACGCCCCGAG							122
Db	211	GCACTGAGGAGCGCGCTGACGCTACTGTGAGGGAAMAAGTTGTGTGAGGCCCCGAG							270
Qy	123	ACCCCTGGCCAGCCCTGTGGCCCGACGCCCTGTGCGGAGCCCTGTGGAGGAGAGCCAGTG							182
Db	271	ACCCCTGGCCAGCCCTGTGGCCCGACGCCCTGTGTGAGGAGAGAGCCAGTG							330
Qy	183	GAGCCGATGAGGCGGCGCTGTGGCAGCCACCGCCTGCAACTCAGAAACCCCTCCAG							242

Db	331	GAGCCGATGAGGACAGGGCTGCTTTGGACAGCACCGGCTGTGCAGACTCGAGAAACCCCTCCAG	390
QY	243	AGGCGCATGACAGGCTGCCCGGCTGACGGCCAGGGTGAAGATGTGAGGACCGCCCGG	302
Db	391	AGGCCATGACAGGCTGCCCGCTACCGCCAGGGTGAAGATGTGAGGACCGCCCGG	450
QY	303	AGCCAGCAGGAGGGAGAGGGCTTTCATAGATTCTATTCACAAGAAATTAACACCATTTT	362
Db	451	AGCCAGACGAGAGGGAGAGGGCTTTCATAGATTCTATTCACAAGAAATTAACACCATTTT	510
QY	363	GCAAAAGCATTAGAGGCCATGTGGTGACATGCTGTGGCTCGACTGTGGCTGCCATG	422
Db	511	GCAAGGACATAGAGGCCACTGTGGTGACATGCTGTGGCTCGACTGTGGCTGCCATG	570
QY	423	GGAGCTGTGGCAGGGCAGAGGACGGTTTTAGGGCAGCTGAGGAGGGCTGCCAAGAGAG	482
Db	571	GGAGCTGTGGCAGGGCAGAGGACGGTTTTAGGGCAGCTGAGGAGGGCTGCCAAGAGAG	630
QY	483	TTTCATTTTACCTAAACAGGTACAAAGCGGGCGGAGAGTCCAGGACAAATGCACTCAAC	542
Db	631	TTTCATTTTACCTAAACAGGTACAAAGCGGGCGGAGAGTCCAGGACAAATGCACTCAAC	690
QY	543	TTTCATTTGCCCCCAGACAGCGGGTCAACGGGTGCCATCTGCGTCACTCCAAAGAACCTGAG	602
Db	691	TTTCATTTGCCCCCAGACAGCGGGTCAACGGGTGCCATCTGCGTCACTCCAAAGAACCTGAG	750
QY	603	GTGCTTTCGAGAAACCGAGTGCATTAAGCAGAGCTAGAGCTGCTCAACATAGACTGCTC	662
Db	751	GTGCTTTCGAGAAACCGAGTGCATTAAGCAGAGCTAGAGCTGCTCAACATAGACTGCTC	810
QY	663	AAGCAAAACGGCGAGATCGAACCGCTGCAGACGCTGTGAAGGTGACGGCGCATTTGTG	722
Db	811	AAGCAAAACGGCGAGATCGAACCGCTGCAGACGCTGTGAAGGTGACGGCGCATTTGTG	870
QY	723	AGCGAGGTGAAGCTGTGTCGCAAGAGAGCCGCAACATGAATCGCGGGTCAACGAGCTC	782
Db	871	AGCGAGGTGAAGCTGTGTCGCAAGAGAGCCGCAACATGAATCGCGGGTCAACGAGCTC	930
QY	783	TACATGCAGCTCTGCACGAGATCATCCGCAAGCGGGACAAACGGTTGAGCTTCCCGAG	842
Db	931	TACATGCAGCTCTGCACGAGATCATCCGCAAGCGGGACAAACGGTTGAGCTTCCCGAG	990
QY	843	CTGAGGAACAGAGTCTGTAACCAAGACCCCAACATGCTGCAGCTGCGCAGAAATGACAG	902
Db	991	CTGAGGAACAGAGTCTGTAACCAAGACCCCAACATGCTGCAGCTGCGCAGAAATGACAG	1050
QY	903	GACCTGAGGACCAAGTATCCAGACCTGTGCTCACTGTGGCCCAACCAATCCAGAGTATC	962
Db	1051	GACCTGAGGACCAAGTATCCAGACCTGTGCTCACTGTGGCCCAACCAATCCAGAGTATC	1110
QY	963	GCGCAGCTTGAAGAGCATCTGCCAAGGGTGCCTTGCCAGAGCCCGTCCCGACGCAACC	1022
Db	1111	GCGCAGCTTGAAGAGCATCTGCCAAGGGTGCCTTGCCAGAGCCCGTCCCGACGCAACC	1170
QY	1023	CCCGCTGCCCGCCCGCGGGTCTTACCAACCAACCACTTCAACCCGATCATCAACAGATC	1082
Db	1171	CCCGCTGCCCGCCCGCGGGTCTTACCAACCAACCACTTCAACCCGATCATCAACAGATC	1230
QY	1083	TTCTACCAACGAGATCCAGAGTACCCAGAACCTGAAGGTGTGTCGCAACCCCTCTGCCACT	1142
Db	1231	TTCTACCAACGAGATCCAGAGTACCCAGAACCTGAAGGTGTGTCGCAACCCCTCTGCCACT	1290
QY	1143	ATGCCCACTTCAACAGCTCCCATCTTCCACCCGACAGCGGTGGGGCCCATGAGAGAC	1202
Db	1291	ATGCCCACTTCAACAGCTCCCATCTTCCACCCGACAGCGGTGGGGCCCATGAGAGAC	1350
QY	1203	TGCTCTGACGCGCTCTGAGAGATGGCCACGACACCAAGCTCCATCTTACTCTGTGAAGCCGAG	1262
Db	1351	TGCTCTGACGCGCTCTGAGAGATGGCCACGACACCAAGCTCCATCTTACTCTGTGAAGCCGAG	1410
QY	1263	AACACCAACCGCTTATGACAGGTGTGTGTGCCACCAAGACACAGACCCCGGGGGCTGAGAC	1322
Db	1411	AACACCAACCGCTTATGACAGGTGTGTGTGCCACCAAGACACAGACCCCGGGGGCTGAGAC	1470

OY	1323	GTATCTCAGAGACGGCTCGATNNGCTCTGTATTACTTTCTTCAGAACTGGAGACGTACAAAG	1382
Dp	1471	GTCACTCAGAGACGGCTCGATNGCTCTGTATTACTTTCTTCAGAACTGGAGACGTACAAAG	1530
OY	1383	CAAGGCTTTGGGAACATTTGACCGCGGAATVACTGCTGCGCTCTGAGAACATTTACTGCGTG	1442
Dp	1531	CAAGGCTTTGGGAACATTTGACCGCGGAATVACTGCGCTGCGCTCTGAGAACATTTACTGCGTG	1590
OY	1443	ACGGAACCAAGGCACATTCANAACTCTGGTGAACCTGAGAGACCTGCTCCGCGCAAAAGTC	1502
Dp	1591	ACGGAACCAAGGCACATTCANAACTCTGGTGAACCTGAGAGACCTGCTCCGCGCAAAAGTC	1650
OY	1503	TTTTCAGAAATACGCGCACTTTCCGCTCGGAACCTGAGACGAGATTTATAAGTCGCGCTG	1562
Dp	1651	TTTTCAGAAATACGCGCACTTTCCGCTCGGAACCTGAGACGAGATTTATAAGCTGCGCTG	1710
OY	1563	GGGCGCTTACCATGGCAATGCGGGTGACTCCTTTACATGCGACAAAGCGCAGACGATTTCAAC	1622
Dp	1711	GGGCGCTTACCATGGCAATGCGGGTGACTCCTTTTACATGCGACAAAGCGCAGACGATTTCAAC	1770
OY	1623	ACCGTGAACAGAGATTCATGATGCTACACAGAAACCTGTCGCCACTCACAGAAAGGAGGC	1682
Dp	1771	ACCGTGAACAGAGATTCATGATGCTACACAGAAACCTGTCGCCACTCACAGAAAGGAGGC	1830
OY	1683	TGATGTATATACGCGCTGTGCCCACTCCAACTCAACGCGGGGTCTGGTAACCGCGGGGGCCAT	1742
Dp	1831	TGATGTATATACGCGCTGTGCCCACTCCAACTCAACGCGGGGTCTGGTAACCGCGGGGGCCAT	1890
OY	1743	TACCGGAGCGGCTTACCGAGACGAGTCTACTGCGGCTGAATTTCCAGAGAGGCTTTACTTCA	1802
Dp	1891	TACCGGAGCGGCTTACCGAGACGAGTCTACTGCGGCTGAATTTCCAGAGAGGCTTTACTTCA	1950
OY	1803	CTCAAGAAAGTGGTGAATGATGATCCGACCGAACCCCAACACTTCCACTAAAGCAGAGTCC	1852
Dp	1951	CTCAAGAAAGTGGTGAATGATGATCCGACCGAACCCCAACACTTCCACTAAAGCAGAGTCC	2010
OY	1863	CCCTCTGACCTCTCGTGGCCATTTGCCAGAGAGCCCACTGTGTCACGCTGSCACAGACAC	1922
Dp	2011	CCCTCTGACCTCTCGTGGCCATTTGCCAGAGAGCCCACTGTGTCACGCTGSCACAGACAC	2070
OY	1923	AAABAABAACTCCCTCACAGCTTCACTCTGAGGGCTGGAGAGACCGGGATGCTGGAATTCGT	1982
Dp	2071	AAABAABAACTCCCTCACAGCTTCACTCTGAGGGCTGGAGAGACCGGGATGCTGGAATTCGT	2130
OY	1983	TTTTCGGAAGTCACTGACAGCGGATATGAACTGAGTACGATACGGTGTGTTTCTGTCCTCC	2042
Dp	2131	TTTTCGGAAGTCACTGACAGCGGATATGAACTGAGTACGATACGGTGTGTTTCTGTCCTCC	2190
OY	2043	TACTTTCCTTACACCCAGACAGAGCCCTCTCATGTCCTCCAGAGACGAGACGAGATTAACAGCA	2102
Dp	2191	TACTTTCCTTACACCCAGACAGAGCCCTCTCATGTCCTCCAGAGACGAGACGAGATTAACAGCA	2250
OY	2103	CTCTTTCCTTAAATTAATTAAGTCTCTACAAATAAAAAA	2141
Dp	2251	CTCTTTCCTTAAATTAATTAAGTCTCTACAAATAAAAAA	2289

RESULT 7	AR194809	2290 bp	DNA	linear	PAT 20-APR-2002
LOCUS	AR194809				
DEFINITION	Sequence 1 from patent US 6350450.				
ACCESSION	AR194809				
VERSION	AR194809.1	GI:20244246			
KEYWORDS					
SOURCE	Unknown.				
ORGANISM	Unknown.				
	Unclassified.				
	1 (bases 1 to 2290)				
AUTHORS	Godowski, P.J., Gurney, A.L., Goddard, A. and Hillan, K.				
TITLE	The ligand homologous antibody				
JOURNAL	Patent: US 6350450-A 1 26-FEB-2002;				
FEATURES	Location/Qualifiers				

source 1..2290
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 98.1%; Score 2132.6; DB 6; Length 2290;
Best Local Similarity 99.8%; Pred. No. 0;
Matches 2135; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```
QY 3 AAATAGGCTGCTGGGACGGCTGAGATGAACCCCAAGCCCTGGAGCTTGGCCAGAGTG 62
DB |||||
QY 151 AAATAGGCTGCTGGGACGGCTGAGATGAACCCCAAGCCCTGGAGCTTGGCCAGAGTG 210
DB |||||
QY 63 GCACTGAGGACAGCGCTGACGCTACTGTGAGGAAAGAGGTTGTGACAGACCCCGACAG 122
DB |||||
QY 211 GCACTGAGGACAGCGCTGACGCTACTGTGAGGAAAGAGGTTGTGACAGACCCCGACAG 270
DB |||||
QY 123 ACCCTGGGACCGCTTGGCCCGCCAGCCTCTGCGAGAGCCCTCTGTGAGAGGACAGACAGTG 182
DB |||||
QY 271 ACCCTGGGACCGCTTGGCCCGCCAGCCTCTGCGAGAGCCCTCTGTGAGAGGACAGACAGTG 330
DB |||||
QY 183 GAGCCAGTGAAGGAGGAGGCTGTGGACAGCAACCGGCTTGCAACTGAGAGACCCCTCCAG 242
DB |||||
QY 331 GAGCCAGTGAAGGAGGAGGCTGTGGACAGCAACCGGCTTGCAACTGAGAGACCCCTCCAG 390
DB |||||
QY 243 AGGCTATGACAGGCTGCGCCGCTGACGCGCCAGGTTGAAGCATGTGAGAGACCCCGCCG 302
DB |||||
QY 391 AGGCTATGACAGGCTGCGCCGCTGACGCGCCAGGTTGAAGCATGTGAGAGACCCCGCCG 450
DB |||||
QY 303 AGGCTATGACAGGAGGAGGCTTCTATAGATTCTATTCAAGAAATTAACCAATTTT 362
DB |||||
QY 451 AGGCTATGACAGGAGGAGGCTTCTATAGATTCTATTCAAGAAATTAACCAATTTT 510
DB |||||
QY 363 GCAAGAGCCATGAGGCTGCTGCGTGAATGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 422
DB |||||
QY 511 GCAAGAGCCATGAGGCTGCTGCGTGAATGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 570
DB |||||
QY 423 GAGAGCTGTCAGGCGCAGAGAGAGCGTTTGAAGGCACTGAGAGAGGCTGCGCCAGAGAG 482
DB |||||
QY 571 GAGAGCTGTCAGGCGCAGAGAGAGCGTTTGAAGGCACTGAGAGAGGCTGCGCCAGAGAG 630
DB |||||
QY 483 TTCAATTTAACTAAAGGTTACAGAGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 542
DB |||||
QY 631 TTCAATTTAACTAAAGGTTACAGAGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 690
DB |||||
QY 543 TTCAATTTGCCCCCAGAGCGGCTCAAGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 602
DB |||||
QY 691 TTCAATTTGCCCCCAGAGCGGCTCAAGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 750
DB |||||
QY 603 GTCCTTCTGAGAGACGAGTGCATTAAGCAGAGAGCTAGAGCTGCTCAACATGAGCTGCTC 662
DB |||||
QY 751 GTCCTTCTGAGAGACGAGTGCATTAAGCAGAGAGCTAGAGCTGCTCAACATGAGCTGCTC 810
DB |||||
QY 663 AAAGAGAGCGGACAGATGAGACGCTGAGAGAGCTGTAAGGTTGAGAGCGGCGGCTGCTG 722
DB |||||
QY 811 AAAGAGAGCGGACAGATGAGACGCTGAGAGAGCTGTAAGGTTGAGAGCGGCGGCTGCTG 870
DB |||||
QY 723 AGGAGGTTGAGAGCTGCTGCGAGAGAGAGCGGCAACATGAACCTGCGGCTGAGAGAGCTG 782
DB |||||
QY 871 AGGAGGTTGAGAGCTGCTGCGAGAGAGAGCGGCAACATGAACCTGCGGCTGAGAGAGCTG 930
DB |||||
QY 783 TACATGACAGCTCTGTCAGAGATCATCCGCAAGCGGAGCAACGCGTTGAGAGCTTCCAG 842
DB |||||
QY 931 TACATGACAGCTCTGTCAGAGATCATCCGCAAGCGGAGCAACGCGTTGAGAGCTTCCAG 990
DB |||||
QY 843 CTGAGAGACAGATCTCTGAACCAAGAGAGCTGCTGAGAGCTGCTGAGAGAGCTGCTGAG 902
DB |||||
QY 991 CTGAGAGACAGATCTCTGAACCAAGAGAGCTGCTGAGAGCTGCTGAGAGAGCTGCTGAG 1050
DB |||||
QY 903 GACCTGAGAGCAAGATACAGAGCTGAGAGCTGAGAGCTGAGAGCTGAGAGCTGAGAGCTGAG 962
DB |||||
QY 1051 GACCTGAGAGCAAGATACAGAGCTGAGAGCTGAGAGCTGAGAGCTGAGAGCTGAGAGCTGAG 1110
DB |||||
```

```
QY 963 GCGACCTTGAGAGAGCTGCGAGAGAGGTTGCCCTGCGCCAGGCGGCTGCCCGACGACCC 1022
DB |||||
QY 1111 GCGACCTTGAGAGAGCTGCGAGAGAGGTTGCCCTGCGCCAGGCGGCTGCCCGACGACCC 1170
DB |||||
QY 1023 CCGCTGCCCCCGCCCGGCTCTACCAACCACTTAACCCGATCATCAACAGATC 1082
DB |||||
QY 1171 CCGCTGCCCCCGCCCGGCTCTACCAACCACTTAACCCGATCATCAACAGATC 1230
DB |||||
QY 1083 TCTACCAAGAGATCCAGAGTGCAGAGAGCTGAGAGCTGCTGCAACCCCTGCTGCACT 1142
DB |||||
QY 1231 TCTACCAAGAGATCCAGAGTGCAGAGAGCTGAGAGTCTGCTGCAACCCCTGCTGCACT 1290
DB |||||
QY 1143 ATGCCACTCTCAACGAGCTCCCATCTTCAACGACAGCCGCTGAGGCTGAGAGAGC 1202
DB |||||
QY 1291 ATGCCACTCTCAACGAGCTCCCATCTTCAACGACAGCCGCTGAGGCTGAGAGAGC 1350
DB |||||
QY 1203 TGCCTGACAGGCTTGAAGAGTGGCCACGACACAGCTGCTATCTACCTGTTGAGAGCGGAG 1262
DB |||||
QY 1351 TGCCTGACAGGCTTGAAGAGTGGCCACGACACAGCTGCTATCTACCTGTTGAGAGCGGAG 1410
DB |||||
QY 1263 AACACCAACCGCTCATGAGAGTGTGTGCGACAGAGACAGACCCCGGAGGCTGAGAC 1322
DB |||||
QY 1411 AACACCAACCGCTCATGAGAGTGTGTGCGACAGAGACAGACCCCGGAGGCTGAGAC 1470
DB |||||
QY 1323 GTGATCCAGAGAGCTGAGAGTGTGTGCTGTTACTTCTTCAAGAACTGGAGAGAGCTGACAG 1382
DB |||||
QY 1471 GTGATCCAGAGAGCTGAGAGTGTGTGCTGTTACTTCTTCAAGAACTGGAGAGAGCTGACAG 1530
DB |||||
QY 1383 CAAGGTTTGGAGAACTTGAACGCGCAATCTGAGCTGAGGCTGAGAGAACTTACTGAGCTG 1442
DB |||||
QY 1531 CAAGGTTTGGAGAACTTGAACGCGCAATCTGAGCTGAGGCTGAGAGAACTTACTGAGCTG 1590
DB |||||
QY 1443 AGCAACCAAGGCACTACAAATCTCTGTTGACATGAGAGAGTGTGCGGCGGCAAGTTC 1502
DB |||||
QY 1591 AGCAACCAAGGCACTACAAATCTCTGTTGACATGAGAGAGTGTGCGGCGGCAAGTTC 1650
DB |||||
QY 1503 TTGACAGAAATGCGCACTTCCGCTGAGAACCTGAGAGAGGATTTATTAAGCTGCGGCTG 1562
DB |||||
QY 1651 TTGACAGAAATGCGCACTTCCGCTGAGAACCTGAGAGAGGATTTATTAAGCTGCGGCTG 1710
DB |||||
QY 1563 GGGCGCTACCATGCAATGCGAGTGGGCTGATCTCTTAACTGAGCAGAGCAAGCTTCAAC 1622
DB |||||
QY 1711 GGGCGCTACCATGCAATGCGAGTGGGCTGATCTCTTAACTGAGCAGAGCAAGCTTCAAC 1770
DB |||||
QY 1623 ACCCTGAGAGAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1682
DB |||||
QY 1771 ACCCTGAGAGAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1830
DB |||||
QY 1683 TGGTGTATTAAGCGCTGTGCTGCTCAACTCAACGAGGCTGTGATGCTGAGAGCGGCGCAT 1742
DB |||||
QY 1831 TGGTGTATTAAGCGCTGTGCTGCTCAACTCAACGAGGCTGTGATGCTGAGAGCGGCGCAT 1890
DB |||||
QY 1743 TACCGAGCGGCTTACAGAGAGGAGTCTACTGAGGCTGAGTTCGAGAGAGCTTACTCA 1802
DB |||||
QY 1891 TACCGAGCGGCTTACAGAGAGGAGTCTACTGAGGCTGAGTTCGAGAGAGCTTACTCA 1950
DB |||||
QY 1803 CTCGAAGAAGTGTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1862
DB |||||
QY 1951 CTCGAAGAAGTGTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 2010
DB |||||
QY 1863 CCTCTGACCTCTGTGCTGCTATGTCAGAGAGCCCACTGCTGCTGCTGCTGCTGCTGCTGCTG 1922
DB |||||
QY 2011 CCTCTGACCTCTGTGCTGCTATGTCAGAGAGCCCACTGCTGCTGCTGCTGCTGCTGCTGCTG 2070
DB |||||
QY 1923 AAAGAACACTGCTCAACGAGTTCATGCTGAGGCTGGAGAGAGCGGAGATGCTGATTTCTGT 1982
DB |||||
QY 2071 AAAGAACACTGCTCAACGAGTTCATGCTGAGGCTGGAGAGAGCGGAGATGCTGATTTCTGT 2130
DB |||||
QY 1983 TTTCCGAGTCACTGAGAGGATGATGAACTGAATGATGATGATGATGATGATGATGATGATGATGAT 2042
DB |||||
QY 2131 TTTCCGAGTCACTGAGAGGATGATGAACTGAATGATGATGATGATGATGATGATGATGATGATGAT 2190
DB |||||
QY 2043 TACTTCTTCAACCAAGACAGCCCTCATGCTCTCAAGAGACAGAGACTACAGACAA 2102
DB |||||
```


QY 1383 CAAGGGTTTGGACATTGACGGCGAATPCTGGCTGGGCTTGAGACATTACTGGCTG 1442
DB 1531 CAAGGGTTTGGACATTGACGGCGAATPCTGGCTGGGCTTGAGACATTACTGGCTG 1590
QY 1443 AGGAACCAAGGCACTACAACTCTGTGTGACCATGAGAGACTGTCCGGCGCAAGTTC 1502
DB 1591 AGGAACCAAGGCACTACAACTCTGTGTGACCATGAGAGACTGTCCGGCGCAAGTTC 1650
QY 1503 TTTGGAGATATAGCCAGTTTCCGCTGGAACTTGAGACGAGATATTATAGCTGGGCTG 1562
DB 1651 TTTGGAGATATAGCCAGTTTCCGCTGGAACTTGAGACGAGATATTATAGCTGGGCTG 1710
QY 1563 GGGGCTACCATGAGCAATCGGGTGAATCTTTTACATGACCAACGCGACAGTTTCAAC 1622
DB 1711 GGGGCTACCATGAGCAATCGGGTGAATCTTTTACATGACCAACGCGACAGTTTCAAC 1770
QY 1623 ACCCTGACAGATCATGATGTCTTACACAGGAACTGTGCCACTTACCAAGAGGAGGC 1682
DB 1771 ACCCTGACAGATCATGATGTCTTACACAGGAACTGTGCCACTTACCAAGAGGAGGC 1830
QY 1683 TGGTGGTAAACGCTGTGGCCACTCCAACTCAACGAGGAGTGTGGTACCGGGGGGCGCAT 1742
DB 1831 TGGTGGTAAACGCTGTGGCCACTCCAACTCAACGAGGAGTGTGGTACCGGGGGGCGCAT 1890
QY 1743 TACCGGAGCGCTACACAGACCGAGTCTACTGGGCTGAGTTCCGAGAGGCTTTACTCA 1802
DB 1891 TACCGGAGCGCTACACAGACCGAGTCTACTGGGCTGAGTTCCGAGAGGCTTTACTCA 1950
QY 1803 CTCGAAGAAGTGTATGATGTCCGACCGAAACCCCAACCTTCCACTTAAGCCAGCTCC 1862
DB 1951 CTCGAAGAAGTGTATGATGTCCGACCGAAACCCCAACCTTCCACTTAAGCCAGCTCC 2010
QY 1863 CCTCTCTACCTCTCGTGGCCATTTGCGAGAGCCCACTGTGTACGCTGGCCACAGAC 1922
DB 2011 CCTCTCTACCTCTCGTGGCCATTTGCGAGAGCCCACTGTGTACGCTGGCCACAGAC 2070
QY 1923 AAAGAACAATCTCTACCAATTCATCTGAGGCTTGGAGAACCGGGAATGCTGATTTCTGT 1982
DB 2071 AAAGAACAATCTCTACCAATTCATCTGAGGCTTGGAGAACCGGGAATGCTGATTTCTGT 2130
QY 1983 TTTCCGAGTCACTGACGAGGATGATGGAATCGAATCGGATGCTTTCGTCCTCC 2042
DB 2131 TTTCCGAGTCACTGACGAGGATGATGGAATCGAATCGGATGCTTTCGTCCTCC 2190
QY 2043 TACTTCTTCAACACAGACAGCCCTCATGCTTCCAGAGACAGACAGACTTACAGCA 2102
DB 2191 TACTTCTTCAACACAGACAGCCCTCATGCTTCCAGAGACAGACAGACTTACAGCA 2250
QY 2103 CTCCTTCTTAAATTAATTAAGTCTCTTACATTAATAACA 2141
DB 2251 CTCCTTCTTAAATTAATTAAGTCTCTTACATTAATAACA 2289

RESULT 10
LOCUS AR307688 2290 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 1 from patent US 6551822.
ACCESSION AR307688
VERSION AR307688.1 GI:31698425
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
UNCLASIFIED.
REFERENCE 1 (bases 1 to 2290)
AUTHORS Godowski, P.J., Gurney, A.L., Hillan, K., Botstein, D., Goddard, A.,
Roy, N., Ferrara, N., Tumas, D., and Schwall, R.
TITLE NL4 tie ligand homologue
JOURNAL Patent: US 6551822-A 1 22-APR-2003;
FEATURES
Location/Qualifiers
1..2290
/organism="Unknown"
/mol_type="genomic DNA"

ORIGIN
Query Match 98.1%; Score 2132.6; DB 6; Length 2290;
Best Local Similarity 99.8%; Pred. No. 0;
Matches 2135; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 3 AAATGAGCTGTGCGGACGGCTGAGAGATGAACCCCAAGCCCTGAGACTGCGAGGCTG 62
DB 151 AAATGAGCTGTGCGGACGGCTGAGAGATGAACCCCAAGCCCTGAGACTGCGAGGCTG 210
QY 63 GCATGAGGCAAGGCTGACGCTACTGTGTGAGGAAAGAGTTGTGAGACGCCCGCAGG 122
DB 211 GCATGAGGCAAGGCTGACGCTACTGTGTGAGGAAAGAGTTGTGAGAGCCCGCAGG 270
QY 123 ACCCTGGCAGGCGCTGGGCCCAAGCTCTGCGGAGCGCTGTGAGAGGAGGAGGCTG 182
DB 271 ACCCTGGCAGGCGCTGGGCCCAAGCTCTGCGGAGCGCTGTGAGAGGAGGAGGCTG 330
QY 183 GAGCCAGTGAAGGAGGCTGCTTGGCAGCCACCGGCTTGCACTAGGAACCCCTCCAG 242
DB 331 GAGCCAGTGAAGGAGGCTGCTTGGCAGCCACCGGCTTGCACTAGGAACCCCTCCAG 390
QY 243 AGGCTATGACAGGCTGCCCCCTGACAGGCGCAGGCTGAGCATGTGAGAGAGCCCGCG 302
DB 391 AGGCTATGACAGGCTGCCCCCTGACAGGCGCAGGCTGAGCATGTGAGAGAGCCCGCG 450
QY 303 AGCCAAACAGAGGAAAGAGGCTTTCAATGATTTCTATTCACAAAGATAACCAATTTT 362
DB 451 AGCCAAACAGAGGAAAGAGGCTTTCAATGATTTCTATTCACAAAGATAACCAATTTT 510
QY 363 GCAAAGACATGAGGCCACTGTGCTGACATGCTGTGCTCGAGCTGCTGCTGCCATG 422
DB 511 GCAAAGACATGAGGCCACTGTGCTGACATGCTGTGCTCGAGCTGCTGCTGCCATG 570
QY 423 GAGGCTGTGACAGGCGCAGAGGAGCGGTTTGAAGGAGCTGAGAGAGGCGTGGCAAGAG 482
DB 571 GAGGCTGTGACAGGCGCAGAGGAGCGGTTTGAAGGAGCTGAGAGAGGCGTGGCAAGAG 630
QY 483 TTCAATTTACCTAAACAGGTACAGAGCGGCGGAGTCCCGAGCAAGTGCACCTACCC 542
DB 631 TTCAATTTACCTAAACAGGTACAGAGCGGCGGAGTCCCGAGCAAGTGCACCTACCC 690
QY 543 TTCAATTTGCCCCAGAGCGGCGTCAAGGCTGCTGCTGCTCACTCCAAAGAGCTGAG 602
DB 691 TTCAATTTGCCCCAGAGCGGCGTCAAGGCTGCTGCTGCTCACTCCAAAGAGCTGAG 750
QY 603 GTGCTTCTGAGAACCGAGTGCATTAAGCAGAGACTAGAGTGTCTCAACAATGAGTGTCT 662
DB 751 GTGCTTCTGAGAACCGAGTGCATTAAGCAGAGACTAGAGTGTCTCAACAATGAGTGTCT 810
QY 663 AAGCAGAGGCGGAGATCGAGACGCTGACAGACGCTGTGAAGTGAACGCGGCAATTGTG 722
DB 811 AAGCAGAGGCGGAGATCGAGACGCTGACAGACGCTGTGAAGTGAACGCGGCAATTGTG 870
QY 723 AGCAGGTGAAGTGTGCTGCGCAGAGAGGAGCGCAATGAATCTGGGGGTCAAGCAGCTC 782
DB 871 AGCAGGTGAAGTGTGCTGCGCAGAGAGGAGCGCAATGAATCTGGGGGTCAAGCAGCTC 930
QY 783 TAATGAGCTCTCTGACAGATCATTCGAGCGGAGCAACGCGTTGAGAGCTCTCCAG 842
DB 931 TAATGAGCTCTCTGACAGATCATTCGAGCGGAGCAACGCGTTGAGAGCTCTCCAG 990
QY 843 CTGAGAGAGAGATCTCGAACAGACAGACCGCATGCTGAGTGGCCAGAGATCAAG 962
DB 991 CTGAGAGAGAGATCTCGAACAGACAGACCGCATGCTGAGTGGCCAGAGATCAAG 1050
QY 903 GACCTGAGACAGATACAGACCTGTGGCCACCTGAGCCCAACCAATCAGAGATCATC 962
DB 1051 GACCTGAGACAGATACAGACCTGTGGCCACCTGAGCCCAACCAATCAGAGATCATC 1110
QY 963 GCGCAGCTTGAAGAGACTGCGAGAGGAGTCCCTGCGCAGAGGCGCTCCCGACCAAGCC 1022
DB 1111 GCGCAGCTTGAAGAGACTGCGAGAGGAGTCCCTGCGCAGAGGCGCTCCCGACCAAGCC 1170


```
QY 1023 CCGGTCGCCCCCGGGGCTCTACCAACCAACCACTTAACAACCGGCATCATCAACAGATC 1082
DB 1171 CCGGTCGCCCCCGGGGCTCTACCAACCAACCACTTAACAACCGGCATCATCAACAGATC 1230
QY 1083 TCTACCAACAGATCAGATGAGTGAACAGAACTGAAGTGTCTGCCACCCCTCTGCCCCACT 1142
DB 1231 TCTACCAACAGATCAGATGAGTGAACAGAACTGAAGTGTCTGCCACCCCTCTGCCCCACT 1290
QY 1143 ATGCCCACTCTACCAAGCTTCCCATCTTCCACCGAACAGCGGTGGGGCCCTAGAGAGAC 1202
DB 1291 ATGCCCACTCTACCAAGCTTCCCATCTTCCACCGAACAGCGGTGGGGCCCTAGAGAGAC 1350
QY 1203 TGCCCTGAGGCGCTGAGAGATGGCCAGACACAGCTCATCTACTGTTGAAGCCGAGAG 1262
DB 1351 TGCCCTGAGGCGCTGAGAGATGGCCAGACACAGCTCATCTACTGTTGAAGCCGAGAG 1410
QY 1263 AACACCAACCGCTCTCATGAGGTGTGTGCAACAGAGACACGACCCCGGGGGCTGAGAC 1322
DB 1411 AACACCAACCGCTCTCATGAGGTGTGTGCAACAGAGACACGACCCCGGGGGCTGAGAC 1470
QY 1323 GTCATCCAGAGACGCTGATGGCTCTGTAACTCTTCAAGAACTGGAGACGTACAG 1382
DB 1471 GTCATCCAGAGACGCTGATGGCTCTGTAACTCTTCAAGAACTGGAGACGTACAG 1530
QY 1383 CAAGGGTTTGGGAACATTGACGGCGAATATGCTGGGCTGAGAACTTTACTGCTG 1442
DB 1531 CAAGGGTTTGGGAACATTGACGGCGAATATGCTGGGCTGAGAACTTTACTGCTG 1590
QY 1443 ACGAACAAGGAACTTAACTCTGTGTACATGAGAGATGTCCGGCCGGAAGTGC 1502
DB 1591 ACGAACAAGGAACTTAACTCTGTGTACATGAGAGATGTCCGGCCGGAAGTGC 1650
QY 1503 TTTGAGAAATACGCGAGTTTCGCGCTGGAACTTGAGAGCGATATTAAGCTCGGCTG 1562
DB 1651 TTTGAGAAATACGCGAGTTTCGCGCTGGAACTTGAGAGCGATATTAAGCTCGGCTG 1710
QY 1563 GGGCGCTTACATGGAATGCGGGGTGATCTTTTACATGCGCAACCGGAAACAGATTCAAC 1622
DB 1711 GGGCGCTTACATGGAATGCGGGGTGATCTTTTACATGCGCAACCGGAAACAGATTCAAC 1770
QY 1623 ACCCTGACAGAGATCATGATGTCTACACAGAAACTGTGCCCACTACAGAAAGGAGGC 1682
DB 1771 ACCCTGACAGAGATCATGATGTCTACACAGAAACTGTGCCCACTACAGAAAGGAGGC 1830
QY 1683 TGGTGTATTAACGCTGTGCCACTCAACCTCAACGGGGTCTGGTACCGCGGGGGCCAT 1742
DB 1831 TGGTGTATTAACGCTGTGCCACTCAACCTCAACGGGGTCTGGTACCGCGGGGGCCAT 1890
QY 1743 TACCGGAGCGCTTACAGAGAGAGATCTACTGGGCTGATTCAGAGAGGCTTTACTCA 1802
DB 1891 TACCGGAGCGCTTACAGAGAGAGATCTACTGGGCTGATTCAGAGAGGCTTTACTCA 1950
QY 1803 CTCAAGAAAGTGTATGATGATCCGACCGAAACCCCAACACCTTTCACACTTAAGCAGCTCC 1862
DB 1951 CTCAAGAAAGTGTATGATGATCCGACCGAAACCCCAACACCTTTCACACTTAAGCAGCTCC 2010
QY 1863 CCCTCTGACCTCTGTGGCCATTGCCAGAGAGCCCAACCTGTGTACCGTGGCCACAGAC 1922
DB 2011 CCCTCTGACCTCTGTGGCCATTGCCAGAGAGCCCAACCTGTGTACCGTGGCCACAGAC 2070
QY 1923 AAAGAACAACTCTCAACGATCATCTGAGGCTGGAGAGACCGGGATGTCTGATTTCTGT 1982
DB 2071 AAAGAACAACTCTCAACGATCATCTGAGGCTGGAGAGACCGGGATGTCTGATTTCTGT 2130
QY 1983 TTTCCGAAGTCACTGACGAGCGATGAGAACTGAATGATAGGTGTTTCTGTCTCTCC 2042
DB 2131 TTTCCGAAGTCACTGACGAGCGATGAGAACTGAATGATAGGTGTTTCTGTCTCTCC 2190
QY 2043 TACTTTCTTCAACACAGACGCGCTCATGTCTGACAGAGACGAGACGAGACTACAGACA 2102
DB 2191 TACTTTCTTCAACACAGACGCGCTCATGTCTGACAGAGACGAGACGAGACTACAGACA 2250
```

```
QY 2103 CTCCTTCTTAATAATTAAGTCTCTACATTAATAAACA 2141
DB 2251 CTCCTTCTTAATAATTAAGTCTCTACATTAATAAACA 2289

RESULT 11
AR350376 2290 bp DNA linear PAT 17-AUG-2003
LOCUS Sequence 1 from patent US 6586397.
DEFINITION AR350376
ACCESSION AR350376
VERSION AR350376.1 GI:33751435
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 2290)
AUTHORS Godowski, P. J. and Gurney, A. L.
TITLES Tie ligand homologues
JOURNAL Patent: US 6586397-A 1 01-JUL-2003;
FEATURES
Location/Qualifiers
1..2290
/mol_type="genomic DNA"

ORIGIN
Query Match 98.1%; Score 2132.6; DB 6; Length 2290;
Best Local Similarity 99.8%; Pred. No. 0;
Matches 2135; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 3 AAATGAGGTCTGCTGCGAGCGGCTGAGATGAACCCAGCCCTGAGCTGCCAGCGTG 62
DB 151 AAATGAGGTCTGCTGCGAGCGGCTGAGATGAACCCAGCCCTGAGCTGCCAGCGTG 210
QY 63 GCACTGAGGCGAGCGCTGACGCTACTGTGAGGAAAAGAGTTGTGAGCAGCCCGCAGG 122
DB 211 GCACTGAGGCGAGCGGCTGACGCTACTGTGAGGAAAAGAGTTGTGAGCAGCCCGCAGG 270
QY 123 ACCCTGGGCGACGCTGCGCCGAGCGCTGCGCGAGCCCTGTGTGAGGCGAGCGAGTG 182
DB 271 ACCCTGGGCGACGCTGCGCCGAGCGCTGCGCGAGCCCTGTGTGAGGCGAGCGAGTG 330
QY 183 GAGCCAGTGAAGGCGAGGCTGTGAGCAGCAACCGGCTGCACTGAGAACTCCCTCCAG 242
DB 331 GAGCCAGTGAAGGCGAGGCTGTGAGCAGCAACCGGCTGCACTGAGAACTCCCTCCAG 390
QY 243 AGGCCATGAGCAGGCTGCGCCGCTGACGGCCAGGGGTAAGCATGTGAGAGCGCGCCGG 302
DB 391 AGGCCATGAGCAGGCTGCGCCGCTGACGGCCAGGGGTAAGCATGTGAGAGCGCGCCGG 450
QY 303 AGCCAAGCAGAGAGGAGAGGCTTTCATAGATTCTATTCAAAAGATTAACCACTTTT 362
DB 451 AGCCAAGCAGAGAGGAGAGGCTTTCATAGATTCTATTCAAAAGATTAACCACTTTT 510
QY 363 GCAAAAGCATGAGAGGCTGCTGCTGATGATGCTGTGGCTGGACTGTGCTGCCAATG 422
DB 511 GCAAAAGCATGAGAGGCTGCTGCTGATGATGCTGTGGCTGGACTGTGCTGCCAATG 570
QY 423 GAGAGTGTGACAGGCGCAGAGAGCGGTTTGAAGGCGCATGAGAGAGGCTGCGCAAGAG 482
DB 571 GAGAGTGTGACAGGCGCAGAGAGCGGTTTGAAGGCGCATGAGAGAGGCTGCGCAAGAG 630
QY 483 TTCAATTACCTAAACAGGTACAAAGCGGCGGAGTCCCAAGACAAAGTGCCTTAAC 542
DB 631 TTCAATTACCTAAACAGGTACAAAGCGGCGGAGTCCCAAGACAAAGTGCCTTAAC 690
QY 543 TTCAATTGCGCCCAAGAGAGGCGGTCAAGGCTGAGCATGTGGCTCAACCTCAAGAGCCTGAG 602
DB 691 TTCAATTGCGCCCAAGAGAGGCGGTCAAGGCTGAGCATGTGGCTCAACCTCAAGAGCCTGAG 750
QY 603 GTGCTTCTGAGAGAACGAGTGTGATTAAGCAGAGAGTGAAGCTGCTCTCAACATGACTGCTC 662
DB 751 GTGCTTCTGAGAGAACGAGTGTGATTAAGCAGAGAGTGAAGCTGCTCTCAACATGACTGCTC 810
```


QY 663 AAGCAGAGCGGAGATCGAGACGCTGACAGCTGTGAAGTGAACGCGGAGTGTG 722
 DB 811 AAGCAGAGCGGAGATCGAGACGCTGACAGCTGTGAAGTGAACGCGGAGTGTG 870
 QY 723 AGCGAGTGAAGCTGCTCGGCAAGGAGCGGCAACATGAACCTGCGGAGTACGAGCTC 782
 DB 871 AGCGAGTGAAGCTGCTCGGCAAGGAGCGGCAACATGAACCTGCGGAGTACGAGCTC 930
 QY 783 TACATGAGCTCTGCGACAGATCATCGGCAAGCGGCAACGCGTGAAGCTCTCCAG 842
 DB 931 TACATGAGCTCTGCGACAGATCATCGGCAAGCGGCAACGCGTGAAGCTCTCCAG 990
 QY 843 CTGAGAACAGAGATCTGAACAGACAGCGACATGCTGACGCTGCGGAGCAAGTACAG 902
 DB 991 CTGAGAACAGAGATCTGAACAGACAGCGACATGCTGACGCTGCGGAGCAAGTACAG 1050
 QY 903 GACCTGAGACATACATACAGACCTGCGCAACCTGCGGCAACATGAGATCATC 962
 DB 1051 GACCTGAGACATACATACAGACCTGCGCAACCTGCGGCAACATGAGATCATC 1110
 QY 963 GCGAGCTTGAAGAGACATGCGAGAGGCGCTGCGCAAGCGGCAAGCGGCAAGCGG 1022
 DB 1111 GCGAGCTTGAAGAGACATGCGAGAGGCGCTGCGCAAGCGGCAAGCGGCAAGCGG 1170
 QY 1023 CCGGCTGCGGCGCGCGGCTTACCAACGACCCATCTTCAACCGGATCATCAACGATC 1082
 DB 1171 CCGGCTGCGGCGCGCGGCTTACCAACGACCCATCTTCAACCGGATCATCAACGATC 1230
 QY 1083 TCTACCAACGAGATCGAGATGACAGACCTGGAAGTGTGCGCAACCGGCTCTGCGCACT 1142
 DB 1231 TCTACCAACGAGATCGAGATGACAGACCTGGAAGTGTGCGCAACCGGCTCTGCGCACT 1290
 QY 1143 ATGCCACTCTTCCAGCGCTCCCATCTTCAACCGCAACCGGCTGCGGCAATGAGAGAC 1202
 DB 1291 ATGCCACTCTTCCAGCGCTCCCATCTTCAACCGCAACCGGCTGCGGCAATGAGAGAC 1350
 QY 1203 TGCCTGAGCGGCGCTGAGAGTGGCCAGACACCACTCATCTTACCTGTGAAGCGGAG 1262
 DB 1351 TGCCTGAGCGGCGCTGAGAGTGGCCAGACACCACTCATCTTACCTGTGAAGCGGAG 1410
 QY 1263 AACACCAACCGGCTCATGAGAGTGTGTGCGACAGACAGACCGGCGGAGTGAAC 1322
 DB 1411 AACACCAACCGGCTCATGAGAGTGTGTGCGACAGACAGACCGGCGGAGTGAAC 1470
 QY 1323 GTCATTCAGAGACGCTGAGTGTGTGTTAACTTCTTCAAGAACTGGAGACGTAACAG 1382
 DB 1471 GTCATTCAGAGACGCTGAGTGTGTGTTAACTTCTTCAAGAACTGGAGACGTAACAG 1530
 QY 1383 CAAGGTTTGGGAACTTGAAGCGGCAATCTGCGGCGGAGCAATTTACTGCGTG 1442
 DB 1531 CAAGGTTTGGGAACTTGAAGCGGCAATCTGCGGCGGAGCAATTTACTGCGTG 1590
 QY 1443 ACGAACCAAGGCACTCAAACTCTGTGTGACATGAGAGACTGTGCGGCGCAAGTGC 1502
 DB 1591 ACGAACCAAGGCACTCAAACTCTGTGTGACATGAGAGACTGTGCGGCGCAAGTGC 1650
 QY 1503 TTTTGCAGATTAAGCAAGCTTCCGCTGGAACCTGAGAGAGATTTAATTAAGTGGGCTG 1562
 DB 1651 TTTTGCAGATTAAGCAAGCTTCCGCTGGAACCTGAGAGAGATTTAATTAAGTGGGCTG 1710
 QY 1563 GGGCGGTACATGAGCAATGCGGAGTCTCTTTAATGACACAGGCAAGCAAGTTCAAC 1622
 DB 1711 GGGCGGTACATGAGCAATGCGGAGTCTCTTTAATGACACAGGCAAGCAAGTTCAAC 1770
 QY 1623 ACCCTGAGACAGATATATATGTCTTCAAGAGAACTGTGCCCATTAACAGAGGAGAGC 1682
 DB 1771 ACCCTGAGACAGATATATATGTCTTCAAGAGAACTGTGCCCATTAACAGAGGAGAGC 1830
 QY 1683 TGGTGTATTAAGCGCTGTGCCCACTCAACGAGGCTGTGTTACGCGGAGGAGCAT 1742
 DB 1831 TGGTGTATTAAGCGCTGTGCCCACTCAACGAGGCTGTGTTACGCGGAGGAGCAT 1890
 QY 1743 TACCGAGCGGCTTACAGGACGAGTCTTCTGCGGCTGAGTCCGAGAGAGCTCTTACTCA 1802

DB 1891 TACCGAGCGGCTTACAGGACGAGTCTTACTGCGTGAAGTTCGAGAGGCTCTTACTCA 1950
 QY 1803 CTCAGAAAGTGTGTATGATCGAGACGAGACCCCAACCTTCCACTAGACAGCTCC 1862
 DB 1951 CTCAGAAAGTGTGTATGATCGAGACGAGACCCCAACCTTCCACTAGACAGCTCC 2010
 QY 1863 CCTCTGACCTCTGCGGCACTTGCAGAGAGCCCACTGTGTACGCTGCGGCAAGCAG 1922
 DB 2011 CCTCTGACCTCTGCGGCACTTGCAGAGAGCCCACTGTGTACGCTGCGGCAAGCAG 2070
 QY 1923 AAAGAACACTCTCTACCACTTATCTGAGGCTGGAGAGACCGGAGATGCTGATCTGT 1982
 DB 2071 AAAGAACACTCTCTACCACTTATCTGAGGCTGGAGAGACCGGAGATGCTGATCTGT 2130
 QY 1983 TTTCCGAGTCACTGAGCGGATGATGAACCTGAATCATGAGTGTCTTCTGTCTCCCTCC 2042
 DB 2131 TTTCCGAGTCACTGAGCGGATGATGAACCTGAATCATGAGTGTCTTCTGTCTCCCTCC 2190
 QY 2043 TACTTCTTCAACACAGACAGCGGCTCATGTCTCAAGACAGACAGACATCAAGACAA 2102
 DB 2191 TACTTCTTCAACACAGACAGCGGCTCATGTCTCAAGACAGACAGACATCAAGACAA 2250
 QY 2103 CTCTTCTTAAATAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 2141
 DB 2251 CTCTTCTTAAATAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 2289

RESULT 12
 AX403648 2290 bp DNA linear PAT 14-JUN-2002
 LOCUS AX403648
 DEFINITION Sequence 3 from Patent WO0077037.
 ACCESSION AX403648
 VERSION AX403648.1 GI:21437109
 KEYWORDS
 SOURCE
 ORGANISM
 Homo sapiens (human)
 Eukaryote; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
 1
 Ashkenazi, A., Baker, K., Botstein, D., Desnoves, L., Eaton, D. L.,
 Ferrara, N., Fong, S., Gao, W. Q., Gerber, H., Gerstl, M. E.,
 Goddard, A., Godowski, P., Gunney, A., Kijavini, J., Mather, J.,
 Napier, M., Pan, J., Paoni, N., Roy, M., Tuma, D., Watanabe, C.,
 Williams, P. M., Wood, W. I. and Zhang, Z.
 Secreted and transmembrane polypeptides and nucleic acids encoding
 the same
 Patent: WO 0077037-A 3 21-DEC-2000;
 Genentech Inc. (US)
 Location/Qualifiers
 1..2290
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

FEATURES
 source
 ORIGIN
 Query Match 98.1%; Score 2132.6; DB 6; Length 2290;
 Best Local Similarity 99.8%; Pred. No. 0;
 Matches 2135; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 3 AATGAGGCTGCTGCGGAGCGGCTGAGAGTGAACCCCAAGCCTGACCTGCGAGGCTG 62
 DB 151 AATGAGGCTGCTGCGGAGCGGCTGAGAGTGAACCCCAAGCCTGCGAGGCTG 210
 QY 63 GCATGAGGAGCGGCTGAGCGCTACTGTGAGGAGAAAGAGTGTGAGAGCCCGGAGG 122
 DB 211 GCATGAGGAGCGGCTGAGCGCTACTGTGAGGAGAAAGAGTGTGAGAGCCCGGAGG 270
 QY 123 ACCCTGAGCAAGCCTGAGGCGGCTGAGGCTGTGCGGAGGCTGTGTGAGGAGCAAGCTG 182
 DB 271 ACCCTGAGCAAGCCTGAGGCGGCTGAGGCTGTGCGGAGGCTGTGTGAGGAGCAAGCTG 330
 QY 183 GAGCCAGTGAAGGAGGCTGCTTGGAGGCAACCGGCTGCAACTGAGAACCCCTTCAAG 242

```

Db 331 GAGCCAGTGAAGGAGGCTGCTTGAACCCAGCCCTGCACTCAGAAACCTCTCAG 390
Qy 243 AGGCCATGACAGGCTCCCGCTGAACGCGCAAGGTGAAGATGTAGAGAGCCGCCG 302
Db 391 AGGCCATGACAGGCTCCCGCTGAACGCGCAAGGTGAAGATGTAGAGAGCCGCCG 450
Qy 303 AGCCAGACGAGGAGAGGCTTTCATAGATTTCATTCACAAATAATACCATTTT 362
Db 451 AGCCAGACGAGGAGAGGCTTTCATAGATTTCATTCACAAATAATACCATTTT 510
Qy 363 GCAAGACCATAGAGGCACTGTGCGTGAACATGCTGTGGCTGCGACTGCTGGCTCA 422
Db 511 GCAAGACCATAGAGGCACTGTGCGTGAACATGCTGTGGCTGCGACTGCTGGCTCA 570
Qy 423 GGAAGCTTTGACAGCCAGAGAGACGTTTGAAGGCACTGAAGAGGCTCCCAAGAG 482
Db 571 GGAAGCTTTGACAGCCAGAGAGACGTTTGAAGGCACTGAAGAGGCTCCCAAGAG 630
Qy 483 TTCAATTACCTTAAACAGGTACAAAGGCGGCGGCGAGTCCCAAGCAAGTGAACCT 542
Db 631 TTCAATTACCTTAAACAGGTACAAAGGCGGCGGCGAGTCCCAAGCAAGTGAACCT 690
Qy 543 TTCAATTGCGCCAGACGCGGTCAACGGTGCATCTGCTCAACTCCAAAGAGCTGAG 602
Db 691 TTCAATTGCGCCAGACGCGGTCAACGGTGCATCTGCTCAACTCCAAAGAGCTGAG 750
Qy 603 GTGCTTTGAGAGAACCGAGTGAATAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 662
Db 751 GTGCTTTGAGAGAACCGAGTGAATAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 810
Qy 663 AAGCAGAAACGCGCAGATCAGACGCTGAGCAGCTGTGAAGGTGAAGCGGAGATTGT 722
Db 811 AAGCAGAAACGCGCAGATCAGACGCTGAGCAGCTGTGTGAAGGTGAAGCGGAGATT 870
Qy 723 AAGCAGGTGAAGCTGTGCGGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 782
Db 871 AAGCAGGTGAAGCTGTGCGGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 930
Qy 783 TACATGACAGCTCTGCAACAGATCATCCGCAAGCGGAGCAACGCGTTGAGACTCT 842
Db 931 TACATGACAGCTCTGCAACAGATCATCCGCAAGCGGAGCAACGCGTTGAGACTCT 990
Qy 843 CTGAGAAACAGATCTCTGCAACAGATCATCCGCAAGCGGAGCAACGCGTTGAGACT 902
Db 991 CTGAGAAACAGATCTCTGCAACAGATCATCCGCAAGCGGAGCAACGCGTTGAGACT 1050
Qy 903 GACCTGAGACCAAGTACAGACAGCTGCGCAACTGCGCAACCAATCAGAGTATC 962
Db 1051 GACCTGAGACCAAGTACAGACAGCTGCGCAACTGCGCAACCAATCAGAGTATC 1110
Qy 963 GCGAGCTTGAAGACACTGCGCAAGGAGGCTGCGCAAGGAGGAGGAGGAGGAGG 1022
Db 1111 GCGAGCTTGAAGACACTGCGCAAGGAGGAGGCTGCGCAAGGAGGAGGAGGAGG 1170
Qy 1023 CCGCGTGGCCCGCCCGGCTTACCAACCAACCACTCAACCGATATATCAACCAATC 1082
Db 1171 CCGCGTGGCCCGCCCGGCTTACCAACCAACCACTCAACCGATATATCAACCAATC 1230
Qy 1083 TCTACCAACGAGATCAGAGTACAGAGTGAAGGTGTGCGCAACCCCTCTGCCACT 1142
Db 1231 TCTACCAACGAGATCAGAGTACAGAGTGAAGGTGTGCGCAACCCCTCTGCCACT 1290
Qy 1143 ATGCCACTCTTACCAAGCTCTCCATCTTTCACCGCAAGCGGTGGGCGCATGAGAG 1202
Db 1291 ATGCCACTCTTACCAAGCTCTCCATCTTTCACCGCAAGCGGTGGGCGCATGAGAG 1350
Qy 1203 TGCTGACAGGCTCTGAGAGTGGCAGACAGACAGCTCATCTTACTGTGAACCGGAG 1262
Db 1351 TGCTGACAGGCTCTGAGAGTGGCAGACAGACAGCTCATCTTACTGTGAACCGGAG 1410
Qy 1263 AAGACCAACCGCTCATGAGAGTGTGTGCGACAGAGACAGACCCCGGCGCTGAGAC 1322

```

```

Db 1411 AACACCAACCGCTCATGACAGTGTGTGCGACAGACAGACAGACCCCGGCGTGGAC 1470
Qy 1323 GTCAATCAGAGAGCGCTGATGAGTGTGTAACTTTTACCTTACAGAACTGGAGAGTACAG 1382
Db 1471 GTCAATCAGAGAGCGCTGATGAGTGTGTAACTTTTACAGAACTGGAGAGTACAG 1530
Qy 1383 CAAGGTTTGGAAACATTGACGCGGAAATCTGGCTGGGCTGGAGAACTTTACTGGCTG 1442
Db 1531 CAAGGTTTGGAAACATTGACGCGGAAATCTGGCTGGGCTGGAGAACTTTACTGGCTG 1590
Qy 1443 ACCAACCAAGCAACTACAACTCTGTGTACAGCATGAGAGAGAGAGAGAGAGAGAG 1502
Db 1591 ACCAACCAAGCAACTACAACTCTGTGTACAGCATGAGAGAGAGAGAGAGAGAGAG 1650
Qy 1503 TTTGCAAAATACGCGGCTTTCCGCTGGAACTGAGAGAGAGAGAGAGAGAGAGAGAG 1562
Db 1651 TTTGCAAAATACGCGGCTTTCCGCTGGAACTGAGAGAGAGAGAGAGAGAGAGAGAG 1710
Qy 1563 GGGCGTACCATGAGCATGCGGAGTGAACCTTTACATGAGCAACAGGCAAGAGTTCAC 1622
Db 1711 GGGCGTACCATGAGCATGCGGAGTGAACCTTTACATGAGCAACAGGCAAGAGTTCAC 1770
Qy 1623 ACCCTGACAGAGATCATGATGTCTACAGAGAACTGTGCCCATACAGAAAGGAGGC 1682
Db 1771 ACCCTGACAGAGATCATGATGTCTACAGAGAACTGTGCCCATACAGAAAGGAGGC 1830
Qy 1683 TGGGTGATPACGCTGTGCCCACTCAACCTCAACGCGGCTGTGGTACCGCGGAGCAT 1742
Db 1831 TGGGTGATPACGCTGTGCCCACTCAACCTCAACGCGGCTGTGGTACCGCGGAGCAT 1890
Qy 1743 TACCGAGCGGCTACAGAGAGAGTCTACTGCGCTGAGTTCGAGAGAGCTTTACTCA 1802
Db 1891 TACCGAGCGGCTACAGAGAGAGTCTACTGCGCTGAGTTCGAGAGAGCTTTACTCA 1950
Qy 1803 CTCAGAAAGTGTGTATGATTCGACAGCAACCCCAACCTTCACATTAAGCAGCTCC 1862
Db 1951 CTCAGAAAGTGTGTATGATTCGACAGCAACCCCAACCTTCACATTAAGCAGCTCC 2010
Qy 1863 CCCTCTGACCTCTGTGSCCAATTCGACAGAGCCCAACCTGTGACGCTGSCACAGAC 1922
Db 2011 CCCTCTGACCTCTGTGSCCAATTCGACAGAGCCCAACCTGTGACGCTGSCACAGAC 2070
Qy 1923 AAGAACAACTCTCTACCACTTATCTGAGTGTGAGAGAGAGAGAGAGAGAGAGAGAG 1982
Db 2071 AAGAACAACTCTCTACCACTTATCTGAGTGTGAGAGAGAGAGAGAGAGAGAGAGAG 2130
Qy 1983 TTTCCGAACTCACTGACGCGGATGATGAACTGAATCGATACAGTGTCTGTGCTCC 2042
Db 2131 TTTCCGAACTCACTGACGCGGATGATGAACTGAATCGATACAGTGTCTGTGCTCC 2190
Qy 2043 TACTTCTCTTACACCAAGAGCCCTCATGTCTCCAGACAGACAGAGACTACAGACA 2102
Db 2191 TACTTCTCTTACACCAAGAGCCCTCATGTCTCCAGACAGACAGAGACTACAGACA 2250
Qy 2103 CTCTTCTTTAATAATTAAGTCTCAATTAATAACA 2141
Db 2251 CTCTTCTTTAATAATTAAGTCTCAATTAATAAAA 2289

```

RESULT 13
AX464134 2290 bp DNA linear PAT 16-JUL-2002
LOCUS Sequence 267 from Patent WO0140466.
DEFINITION
ACCESSION AX464134
VERSION AX464134.1 GI:21899083
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
1 Baker, K.P., Beresini, M., Deforge, L., Desnoyers, L., Filvaroff, E.,
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
Gao, W.Q., Gerritsen, M.E., Goddard, A., Godowski, P.J., Guiney, A.L.,

Sherwood, S., Smith, V., Stewart, T.A., Tumas, D., Watanabe, C.K.,
Wood, W.L. and Zhang, Z.
Secreted and transmembrane polypeptides and nucleic acids encoding
same
Patent: WO 0140466-A 267 07-JUN-2001;
Genentech Inc. (US)
FEATURES
Source
1. 2230
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

ORIGIN

Query Match 98.1%; Score 2132.6; DB 6; Length 2290;
Best Local Similarity 99.8%; Pred. No. 0;
Matches 2135; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 3 AAATGAGGCTGCTGCGAGCGCTGAGAGTGAACCCCAAGCCCTGGAAGCTGCGAGCGTG 62
Db 151 AAATGAGGCTGCTGCGAGCGCTGAGAGTGAACCCCAAGCCCTGGAAGCTGCGAGCGTG 210
QY 63 GCACTGAGGCGGCTGACGCTACTGTGAGGAAAGAGGTGTGAGCAAGCCCGAGG 122
Db 211 GCACTGAGGCGGCTGACGCTACTGTGAGGAAAGAGGTGTGAGCAAGCCCGAGG 270
QY 123 ACCCTGCGCAGCCCTGCGCAGCTGCTGCGGAGCCCTCTGTGAGGCGAGAGCCAGTG 182
Db 271 ACCCTGCGCAGCCCTGCGCAGCTGCTGCGGAGCCCTCTGTGAGGCGAGAGCCAGTG 330
QY 183 GAGCCCACTGAGGCGGCTGCTGCGCAGCCCTGCGGAGCCCTCTGTGAGGCGAGAG 242
Db 331 GAGCCCACTGAGGCGGCTGCTGCGCAGCCCTGCGGAGCCCTCTGTGAGGCGAGAG 390
QY 243 AGGCCATGAGAGGCTGCGCGCTGAGAGCGGCGAGGATGTGAGGAGCCCGCGG 302
Db 391 AGGCCATGAGAGGCTGCGCGCTGAGAGCGGCGAGGATGTGAGGAGCCCGCGG 450
QY 303 AGCCAGCAGAGGAGGAGGCTTTCATGATTCATTACAAAGAAATTAACCAACATTTT 362
Db 451 AGCCAGCAGAGGAGGAGGCTTTCATGATTCATTACAAAGAAATTAACCAACATTTT 510
QY 363 GCAAGACCATGAGGCGCCTGCGGTGACATGCTGCTGCGGAGCTGCTGCGGAGCCAGT 422
Db 511 GCAAGACCATGAGGCGCCTGCGGTGACATGCTGCTGCGGAGCTGCTGCGGAGCCAGT 570
QY 423 GAGGCTGTGAGGCGCAGAGAGACGGTTTGAAGGCACTGAGAGGCGCTGCGCAAGAG 482
Db 571 GAGGCTGTGAGGCGCAGAGAGACGGTTTGAAGGCACTGAGAGGCGCTGCGCAAGAG 630
QY 483 TTCAATTACCTTAACAGGTACAAAGGCGGCGGAGTCCAGAGCAAGTGAACCTTAACC 542
Db 631 TTCAATTACCTTAACAGGTACAAAGGCGGCGGAGTCCAGAGCAAGTGAACCTTAACC 690
QY 543 TTCAATTGCGCCAGCAGCGGCTCAAGGCTGCACTGCTCAACTCCAGAGAGCTGAG 602
Db 691 TTCAATTGCGCCAGCAGCGGCTCAAGGCTGCACTGCTCAACTCCAGAGAGCTGAG 750
QY 603 GTGCTTCTGAGAACCGAGTGCATAGAGAGCTGAGAGCTGCTCAACATGAGTGTCTC 662
Db 751 GTGCTTCTGAGAACCGAGTGCATAGAGAGCTGAGAGCTGCTCAACATGAGTGTCTC 810
QY 663 AAGCAGAAAGCGGCAATGAGAGCGCTGAGAGCGTGTGAAGGTGAGAGCGGCGGATTTG 722
Db 811 AAGCAGAAAGCGGCAATGAGAGCGCTGAGAGCGTGTGTGAGGTGAGAGCGGCGGATTTG 870
QY 723 AGCGAGGTGAAGCTGCTGCGCAAGGAGCGCGCAATGAATCTGCGGCTCAAGCGAGCTC 782
Db 871 AGCGAGGTGAAGCTGCTGCGCAAGGAGCGCGCAATGAATCTGCGGCTCAAGCGAGCTC 930
QY 783 TACATGAGAGCTGCTGCGCAAGGATTCATCGCAAGCGGCGCAACGCGTTTGAAGCTTCCAG 842
Db 931 TACATGAGAGCTGCTGCGCAAGGATTCATCGCAAGCGGCGCAACGCGTTTGAAGCTTCCAG 990

QY 843 CTGAGAGACAGGATCTGTAACAGACAGCGGACATGCTGACAGCTGCGAGCAAGTACAAG 902
Db 991 CTGAGAGACAGGATCTGTAACAGACAGCGGACATGCTGACAGCTGCGAGCAAGTACAAG 1050
QY 903 GACCTGAGACACAGTACAGAGCCTGCGCAGCAGCTGCGGCGCAACCAATCAAGATCATC 962
Db 1051 GACCTGAGACACAGTACAGAGCCTGCGCAGCAGCTGCGGCGCAACCAATCAAGATCATC 1110
QY 963 GCGCAGCTTGAAGAGACCTGCCAGAGGAGGCTGCGGAGCGGCTGCCAGGACCC 1022
Db 1111 GCGCAGCTTGAAGAGACCTGCCAGAGGAGGCTGCGGAGCGGCTGCCAGGACCC 1170
QY 1023 CCGGCTGCCCGCGCGGCTTACCAACCAACCACTTCAACCGCATCATCAACAGATC 1082
Db 1171 CCGGCTGCCCGCGCGGCTTACCAACCAACCACTTCAACCGCATCATCAACAGATC 1230
QY 1083 TCTACCAAGAGATCCAGAGTACAGAGCCTGGAAGGTGTGCAACCCCTGCTGCCACT 1142
Db 1231 TCTACCAAGAGATCCAGAGTACAGAGCCTGGAAGGTGTGCAACCCCTGCTGCCACT 1290
QY 1143 ATGCCACTCTCACAGCTCCCATCTTCCACCGCAAGCCGTCGCGCCATGAGAGAGC 1202
Db 1291 ATGCCACTCTCACAGCTCCCATCTTCCACCGCAAGCCGTCGCGCCATGAGAGAGC 1350
QY 1203 TGCCTGAGGCGCTGAGAGATGCGCAGACCAACCACTTCACTCTGCTGAAAGCCGAG 1262
Db 1351 TGCCTGAGGCGCTGAGAGATGCGCAGACCAACCACTTCACTCTGCTGAAAGCCGAG 1410
QY 1263 AACACCAACCGGCTTATGAGAGGTGTGCGACCAAGACAAGACCCGCGGCTGAGAC 1322
Db 1411 AACACCAACCGGCTTATGAGAGGTGTGCGACCAAGACAAGACCCGCGGCTGAGAC 1470
QY 1323 GTCATCCAGAGAGCGCTGATGCTGTAACTTTCAAGAACTGGAGAGATGACAAG 1382
Db 1471 GTCATCCAGAGAGCGCTGATGCTGTAACTTTCAAGAACTGGAGAGATGACAAG 1530
QY 1383 CAAGGCTTTGGAGACATTAACCGCGGAACTACTGCTGCGGCTGAGAGCAATTAAGTGGCTG 1442
Db 1531 CAAGGCTTTGGAGACATTAACCGCGGAACTACTGCTGCGGCTGAGAGCAATTAAGTGGCTG 1590
QY 1443 ACAGAACAGAGCAACTACAACTCTGTGACCATGAGAGACTGTGCGGCGCAAGTTC 1502
Db 1591 ACAGAACAGAGCAACTACAACTCTGTGACCATGAGAGACTGTGCGGCGCAAGTTC 1650
QY 1503 TTTGCAAGATACCGCAGTTTCCGCTGGAACCTGAGAGCGAGATTAAGTCCGCTG 1562
Db 1651 TTTGCAAGATACCGCAGTTTCCGCTGGAACCTGAGAGCGAGATTAAGTCCGCTG 1710
QY 1563 GGGCGCTACCATGGCATGCGGCTGACTCTTTACATGAGCAACCGCAAGCACTTCAAC 1622
Db 1711 GGGCGCTACCATGGCATGCGGCTGACTCTTTACATGAGCAACCGCAAGCACTTCAAC 1770
QY 1623 ACCCTGAGCAGAGATCATGATGTCTACAGAGAACTGTGCGCACTTACAGAAAGGAGG 1682
Db 1771 ACCCTGAGCAGAGATCATGATGTCTACAGAGAACTGTGCGCACTTACAGAAAGGAGG 1830
QY 1683 TGGTGTATTAAGGCTGCTGCGCACTGCAACCTCAAGCGGCTGTGTAACCGCGGCGGCAAT 1742
Db 1831 TGGTGTATTAAGGCTGCTGCGCACTGCAACCTCAAGCGGCTGTGTAACCGCGGCGGCAAT 1890
QY 1743 TACCGAGCGGCTTACAGAGCAGAGTCTACTGCGCTGAGTTCCGAGAGGCTTTACTCA 1802
Db 1891 TACCGAGCGGCTTACAGAGCAGAGTCTACTGCGCTGAGTTCCGAGAGGCTTTACTCA 1950
QY 1803 CTCAAGAAATGATGATGATGATCCAGACCGCAACCACTTCAACTTAAGCAACTCC 1862
Db 1951 CTCAAGAAATGATGATGATGATCCAGACCGCAACCACTTCAACTTAAGCAACTCC 2010
QY 1863 CCTCTGACCTCTGCTGAGCATTTGCGAGAGGCCACCTGTGTCAAGCTGCGCAGAC 1922
Db 2011 CCTCTGACCTCTGCTGAGCATTTGCGAGAGGCCACCTGTGTCAAGCTGCGCAGAC 2070
QY 1923 AAAGAACCACTCTTCAACAGTTCATCTGAGGCTGAGAGACCGGAGATGCTGATTTCTGT 1982

Db 2071 AAGGAGCACTCTCTACCACTTCTGAGGCTGGAGAGACCGGAGAGCTGGATTCTGT 2130
 Qy 1983 TTTCGAGTCACTGACGAGATGATGAACTGAATCAATCGGTGTTTCTGTCTCC 2042
 Db 2131 TTTCGAGTCACTGACGAGATGATGAACTGAATCAATCGGTGTTTCTGTCTCC 2190
 Qy 2043 TACTTCTCTGACGAG 2102
 Db 2191 TACTTCTCTGACGAG 2250
 Qy 2103 CTCTTCTTAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 2141
 Db 2251 CTCTTCTTAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 2289
 RESULT 14
 BD076338 2290 bp DNA linear PAT 27-AUG-2002
 LOCUS BD076338
 DEFINITION L1gand homolog.
 ACCESSION BD076338.1 GI:22621941
 VERSION JP 2001517437-A/1.
 KEYWORDS Homo sapiens (human)
 SOURCE Homo sapiens
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 1 (bases 1 to 2290)
 Roy,M., Ferrara,N., Tumas,D. and Schwall,R.
 L1gand homolog
 Patent: JP 2001517437-A 1 09-OCT-2001;
 GENENTECH INC
 COMMENT OS Homo sapiens (human)
 PN JP 2001517437-A/1
 PD 09-OCT-2001
 PF 14-SEP-1998 JP 2000512945
 PR 19-SEP-1997 US 08/933821,29-OCT-1997 US 08/960507 PI
 PAUL J GODOWSKI, AUSTIN L GURNEY, KENNETH HILLAN, DAVID BOSTEIN, PI
 AUDLEY GODDARD, MARGARET ROY, NAPOLEONE FERRARA, DANIEL TOMAS, PI
 RALPH SCHWALL
 PC C12N15/09,A61K38/00,A61K39/395,A61K39/44,A61P35/00,C07K14/515,
 PC C07K16/18,
 PC C12N1/15,C12N1/19,C12N1/21,C12N5/10,C12O1/68,G01N33/53//C12P21/ PC
 08,
 CC C12N15/00,A61K37/02,C12N5/00
 CC L1gand homolog
 FH Key Location/Qualifiers
 FT source 1..2290
 Location/Qualifiers
 1..2290
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 ORIGIN
 Query Match 98.1%; Score 2132.6; DB 6; Length 2290;
 Best Local Similarity 99.8%; Pred. No. 0;
 Matches 2135; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 Db 3 AAATAGAGCTGCTGGAG 62
 Qy 151 AAATAGAGCTGCTGGAG 210
 Db 63 GCACTGAG 122
 Qy 211 GCACTGAG 270
 Db 123 ACCCTGGAG 182
 Qy 271 ACCCTGGAG 330

Qy 183 GAGCCAGTGAAG 242
 Db 331 GAGCCAGTGAAG 390
 Qy 243 AGGCAATGAG 302
 Db 391 AGGCAATGAG 450
 Qy 303 AGGCAATGAG 362
 Db 451 AGGCAATGAG 510
 Qy 363 GCAAGAGATGAG 422
 Db 511 GCAAGAGATGAG 570
 Qy 423 GAGAGTGTGAG 482
 Db 571 GAGAGTGTGAG 630
 Qy 483 TTGATTTACCTTAAACAGTACAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 542
 Db 631 TTGATTTACCTTAAACAGTACAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 690
 Qy 543 TTGATTTACCTTAAACAGTACAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 602
 Db 691 TTGATTTACCTTAAACAGTACAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 750
 Qy 603 GTGCTTCTGAG 662
 Db 751 GTGCTTCTGAG 810
 Qy 663 AAGCAG 722
 Db 811 AAGCAG 870
 Qy 723 AGGAGAGTGAAG 782
 Db 871 AGGAGAGTGAAG 930
 Qy 783 TACATGAG 842
 Db 931 TACATGAG 990
 Qy 843 CTGAG 902
 Db 991 CTGAG 1050
 Qy 903 GAGCTGAG 962
 Db 1051 GAGCTGAG 1110
 Qy 963 GCGCAG 1022
 Db 1111 GCGCAG 1170
 Qy 1023 CCGGCTGAG 1082
 Db 1171 CCGGCTGAG 1230
 Qy 1083 TCTACCAAG 1142
 Db 1231 TCTACCAAG 1290
 Qy 1143 ATGCCAG 1202
 Db 1291 ATGCCAG 1350
 Qy 1203 TGGCTGAG 1262
 Db 1351 TGGCTGAG 1410

QY 1263 AACACCAACCCGCTCATGAGTGTGTCGACAGACAGACACCCCGGGGCTGAGCC 1322
 DB 1411 AACACCAACCCGCTCATGAGTGTGTCGACAGACAGACACCCCGGGGCTGAGCC 1470
 QY 1323 GTCATCCAGAGACGCTGAGTGTGTCGACAGACAGACACCCCGGGGCTGAGCC 1382
 DB 1471 GTCATCCAGAGACGCTGAGTGTGTCGACAGACAGACACCCCGGGGCTGAGCC 1530
 QY 1383 CAAGGCTTTGGGAACTGAGAGCGGGAATCTGCTGAGGCTGAGGAACTTACCTGAGG 1442
 DB 1511 CAAGGCTTTGGGAACTGAGAGCGGGAATCTGCTGAGGCTGAGGAACTTACCTGAGG 1530
 QY 1443 AGCAACCAAGGCAATCAACAACTCTGCTGAGCAATGAGAGAGCTGCTGAGCAAGTC 1502
 DB 1521 AGCAACCAAGGCAATCAACAACTCTGCTGAGCAATGAGAGAGCTGCTGAGCAAGTC 1550
 QY 1503 TTTGCAAGATACGCGAGTTTCGCTGAGCAATGAGAGAGCTGCTGAGCAAGTC 1562
 DB 1651 TTTGCAAGATACGCGAGTTTCGCTGAGCAATGAGAGAGCTGCTGAGCAAGTC 1710
 QY 1563 GGGGCTGAGCAATGAGAGAGCTGCTGAGCAATGAGAGAGCTGCTGAGCAAGTC 1622
 DB 1711 GGGGCTGAGCAATGAGAGAGCTGCTGAGCAATGAGAGAGCTGCTGAGCAAGTC 1770
 QY 1623 ACCCTGAGCAGAGATCATGATGTCTACACAGAGAACTGTGCTGAGCAAGAGGAGGC 1682
 DB 1771 ACCCTGAGCAGAGATCATGATGTCTACACAGAGAACTGTGCTGAGCAAGAGGAGGC 1830
 QY 1683 TGTGTGTATACAGCTGTGCTGAGCAATGAGAGAGCTGCTGAGCAAGAGGAGGCAT 1742
 DB 1831 TGTGTGTATACAGCTGTGCTGAGCAATGAGAGAGCTGCTGAGCAAGAGGAGGCAT 1890
 QY 1743 TACCGAGCCGCTACAGAGAGAGCTGCTGAGCAATGAGAGAGCTGCTGAGCAATGAG 1802
 DB 1891 TACCGAGCCGCTACAGAGAGAGCTGCTGAGCAATGAGAGAGCTGCTGAGCAATGAG 1950
 QY 1803 CTCAGAGAGAGTGTATGATGTGTCGACAGAGAACTGCTGAGCAATGAGAGAGGAGGC 1862
 DB 1951 CTCAGAGAGAGTGTATGATGTGTCGACAGAGAACTGCTGAGCAATGAGAGAGGAGGC 2010
 QY 1863 CCTCTGAGCTGTGCTGAGCAATGAGAGAGCTGCTGAGCAATGAGAGAGGAGGC 1922
 DB 2011 CCTCTGAGCTGTGCTGAGCAATGAGAGAGCTGCTGAGCAATGAGAGAGGAGGC 2070
 QY 1923 AAAAGAACCTCTGAGCAATGAGAGAGCTGCTGAGCAATGAGAGAGGAGGC 1982
 DB 2071 AAAAGAACCTCTGAGCAATGAGAGAGCTGCTGAGCAATGAGAGAGGAGGC 2130
 QY 1983 TTTCCGAGTCACTGAGAGAGTGTGTCGAGAGAGAGCTGCTGAGCAATGAGAGAGGAGGC 2042
 DB 2131 TTTCCGAGTCACTGAGAGAGTGTGTCGAGAGAGAGCTGCTGAGCAATGAGAGAGGAGGC 2190
 QY 2043 TACTTCTCTTCAACAGAGAGAGCTGCTGAGAGAGAGCTGCTGAGCAATGAGAGAGGAGGC 2102
 DB 2191 TACTTCTCTTCAACAGAGAGAGCTGCTGAGAGAGAGCTGCTGAGCAATGAGAGAGGAGGC 2250
 QY 2103 CTCTTCTCTTCAATTAAGTCTGAGAGAGAGCTGCTGAGCAATGAGAGAGGAGGC 2141
 DB 2251 CTCTTCTCTTCAATTAAGTCTGAGAGAGAGCTGCTGAGCAATGAGAGAGGAGGC 2289
 RESULT 15
 AY358274 2290 bp mRNA linear PRI 03-OCT-2003
 DEFINITION Homo sapiens clone DNA22779 NLI (UNQ170) mRNA, complete cds.
 ACCESSION AY358274
 VERSION AY358274.1 GI:37181667
 KEYWORDS FLI CDNA.
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
 REFERENCE 1 (bases 1 to 2290)

AUTHORS Clark,H.F., Gurney,A.L., Abaya,E., Baker,K., Baldwin,D., Brush,J.,
 Chen,J., Chow,B., Chui,C., Crowley,C., Currell,B., Deuel,B.,
 Dowd,P., Eaton,D., Foster,J., Grimaldi,C., Gu,Q., Hass,P.E.,
 Heldens,S., Huang,A., Kim,H.S., Klimowski,L., Jin,Y., Johnson,S.,
 Lee,J., Lewis,L., Liao,D., Mark,M., Robbie,E., Sanchez,C.,
 Schoenfeld,J., Seshagiri,S., Simmons,L., Singh,J., Smith,V.,
 Stinson,J., Vagts,A., Vanden,R., Watanabe,C., Wiand,D., Woods,K.,
 Xie,M.H., Yansura,D., Yi,S., Yu,G., Yuan,J., Zhang,M., Zhang,Z.,
 Goddard,A., Wood,W.I. and Godowski,P.
 The Secreted Protein Discovery Initiative (SPDI), a Large-Scale
 Effort to Identify Novel Human Secreted and Transmembrane Proteins:
 A Bioinformatics Assessment
 Genome Res. 13 (10), 2265-2270 (2003)
 JOURNAL PUBLISHED 12975309
 REFERENCE 2 (bases 1 to 2290)
 AUTHORS Clark,H.F.
 TITLE Direct Submission
 JOURNAL Submitted (01-AUG-2003) Department of Bioinformatics, Genentech,
 Inc., 1 DNA Way, South San Francisco, CA 94080, USA
 FEATURES
 source
 1..2290
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /clone="DNA22779"
 1..2290
 /locus_tag="UNQ170"
 520..2001
 /locus_tag="UNQ170"
 /note="PRO196"
 /codon_start=1
 /product="NLI"
 /protein_id="AA08641.1"
 /db_xref="GI:37181668"
 /translation="MRPLVTCWMLILAMGAVAGQEDGFEETGSGSPRELYNRY
 KRAESQDCTYFIVPOQRTVGTALCVNSKEPEVLLENVHKOELINNELKQRO
 IETLOLEVDGIVSEVLEKESRNMSRVOLMOLHEIIRKDNALIEVSEPN
 RINQOAVMDALASKYKDLKHXOHLATLHNSSEIIAOLEHCOHSPARVPOPP
 AAPRYVQPTVYRIINQISTNBIOSDONLKYTPPLPTMPTLSLPSSTDRSGWR
 DCLOLEBDGHDISITLVKPEKNTNRLKQWCDORHPGRTVYQRLDSVNFPRWE
 TYQGFQNDIDSEIVLWGLNNTYVLTNGNKLTVTMEDSGKRVFAYASFRLEPSEY
 VKLRLRYHGNADSEFTWNGKQPTLDRHDVYTNCAHYQKGGWYNACAHNSING
 VMYRGHYRSRYODGYVMAEFRRGSYSILKVMVIRPNPTFH"
 ORIGIN
 Query Match 98.1%; Score 2132.6; DB 9; Length 2290;
 Best Local Similarity 99.8%; Pred. No. 0;
 Matches 2135; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 QY 3 AATGAGGCTGTGCGAGAGGCTGAGAGTAAACCCCAAGCCTGAGACTGCGAGGCTG 62
 DB 151 AATGAGGCTGTGCGAGAGGCTGAGAGTAAACCCCAAGCCTGAGACTGCGAGGCTG 210
 QY 63 GCACCTGAGGAGGCTGAGAGCTGAGAGTAAACCCCAAGGCTGAGAGGCTGAGAGG 122
 DB 211 GCACCTGAGGAGGCTGAGAGCTGAGAGTAAACCCCAAGGCTGAGAGGCTGAGAGG 270
 QY 123 ACCCGTGGCAGAGCCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGG 182
 DB 271 ACCCGTGGCAGAGCCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGG 330
 QY 183 GAGCCAGTGAAGGAGGCTGCTTGGAGAGCAGCCGCTGAGAGTAAACCCCAAGGCTGAG 242
 DB 331 GAGCCAGTGAAGGAGGCTGCTTGGAGAGCAGCCGCTGAGAGTAAACCCCAAGGCTGAG 390
 QY 243 AGGCAATGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAG 302
 DB 391 AGGCAATGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAG 450
 QY 303 AGCCAGCAGAGAGGAGAGGCTTTCATAGATTCTATTCACAAAGATTAACCAACATTTT 362
 DB 451 AGCCAGCAGAGAGGAGAGGCTTTCATAGATTCTATTCACAAAGATTAACCAACATTTT 510

1. *Chlorophyll a* (Chl *a*)
 2. *Chlorophyll b* (Chl *b*)
 3. *Chlorophyll c* (Chl *c*)
 4. *Chlorophyll d* (Chl *d*)
 5. *Chlorophyll e* (Chl *e*)
 6. *Chlorophyll f* (Chl *f*)
 7. *Chlorophyll g* (Chl *g*)
 8. *Chlorophyll h* (Chl *h*)
 9. *Chlorophyll i* (Chl *i*)
 10. *Chlorophyll j* (Chl *j*)
 11. *Chlorophyll k* (Chl *k*)
 12. *Chlorophyll l* (Chl *l*)
 13. *Chlorophyll m* (Chl *m*)
 14. *Chlorophyll n* (Chl *n*)
 15. *Chlorophyll o* (Chl *o*)
 16. *Chlorophyll p* (Chl *p*)
 17. *Chlorophyll q* (Chl *q*)
 18. *Chlorophyll r* (Chl *r*)
 19. *Chlorophyll s* (Chl *s*)
 20. *Chlorophyll t* (Chl *t*)
 21. *Chlorophyll u* (Chl *u*)
 22. *Chlorophyll v* (Chl *v*)
 23. *Chlorophyll w* (Chl *w*)
 24. *Chlorophyll x* (Chl *x*)
 25. *Chlorophyll y* (Chl *y*)
 26. *Chlorophyll z* (Chl *z*)
 27. *Chlorophyll aa* (Chl *aa*)
 28. *Chlorophyll ab* (Chl *ab*)
 29. *Chlorophyll ac* (Chl *ac*)
 30. *Chlorophyll ad* (Chl *ad*)
 31. *Chlorophyll ae* (Chl *ae*)
 32. *Chlorophyll af* (Chl *af*)
 33. *Chlorophyll ag* (Chl *ag*)
 34. *Chlorophyll ah* (Chl *ah*)
 35. *Chlorophyll ai* (Chl *ai*)
 36. *Chlorophyll aj* (Chl *aj*)
 37. *Chlorophyll ak* (Chl *ak*)
 38. *Chlorophyll al* (Chl *al*)
 39. *Chlorophyll am* (Chl *am*)
 40. *Chlorophyll an* (Chl *an*)
 41. *Chlorophyll ao* (Chl *ao*)
 42. *Chlorophyll ap* (Chl *ap*)
 43. *Chlorophyll aq* (Chl *aq*)
 44. *Chlorophyll ar* (Chl *ar*)
 45. *Chlorophyll as* (Chl *as*)
 46. *Chlorophyll at* (Chl *at*)
 47. *Chlorophyll au* (Chl *au*)
 48. *Chlorophyll av* (Chl *av*)
 49. *Chlorophyll aw* (Chl *aw*)
 50. *Chlorophyll ax* (Chl *ax*)
 51. *Chlorophyll ay* (Chl *ay*)
 52. *Chlorophyll az* (Chl *az*)
 53. *Chlorophyll aza* (Chl *aza*)
 54. *Chlorophyll abz* (Chl *abz*)
 55. *Chlorophyll acz* (Chl *acz*)
 56. *Chlorophyll adz* (Chl *adz*)
 57. *Chlorophyll aez* (Chl *aez*)
 58. *Chlorophyll afz* (Chl *afz*)
 59. *Chlorophyll agz* (Chl *agz*)
 60. *Chlorophyll ahz* (Chl *ahz*)
 61. *Chlorophyll aiz* (Chl *aiz*)
 62. *Chlorophyll ajz* (Chl *ajz*)
 63. *Chlorophyll akz* (Chl *akz*)
 64. *Chlorophyll alz* (Chl *alz*)
 65. *Chlorophyll amz* (Chl *amz*)
 66. *Chlorophyll anz* (Chl *anz*)
 67. *Chlorophyll aoz* (Chl *aoz*)
 68. *Chlorophyll apz* (Chl *apz*)
 69. *Chlorophyll aqz* (Chl *aqz*)
 70. *Chlorophyll arz* (Chl *arz*)
 71. *Chlorophyll asz* (Chl *asz*)
 72. *Chlorophyll atz* (Chl *atz*)
 73. *Chlorophyll auz* (Chl *auz*)
 74. *Chlorophyll avz* (Chl *avz*)
 75. *Chlorophyll awz* (Chl *awz*)
 76. *Chlorophyll axz* (Chl *axz*)
 77. *Chlorophyll ayz* (Chl *ayz*)
 78. *Chlorophyll ayz* (Chl *ayz*)
 79. *Chlorophyll azz* (Chl *azz*)
 80. *Chlorophyll azaa* (Chl *aza*)
 81. *Chlorophyll abz* (Chl *abz*)
 82. *Chlorophyll acz* (Chl *acz*)
 83. *Chlorophyll adz* (Chl *adz*)
 84. *Chlorophyll aez* (Chl *aez*)
 85. *Chlorophyll afz* (Chl *afz*)
 86. *Chlorophyll agz* (Chl *agz*)
 87. *Chlorophyll ahz* (Chl *ahz*)
 88. *Chlorophyll aiz* (Chl *aiz*)
 89. *Chlorophyll ajz* (Chl *ajz*)
 90. *Chlorophyll akz* (Chl *akz*)
 91. *Chlorophyll alz* (Chl *alz*)
 92. *Chlorophyll amz* (Chl *amz*)
 93. *Chlorophyll anz* (Chl *anz*)
 94. *Chlorophyll aoz* (Chl *aoz*)
 95. *Chlorophyll apz* (Chl *apz*)
 96. *Chlorophyll aqz* (Chl *aqz*)
 97. *Chlorophyll arz* (Chl *arz*)
 98. *Chlorophyll asz* (Chl *asz*)
 99. *Chlorophyll atz* (Chl *atz*)
 100. *Chlorophyll auz* (Chl *auz*)
 101. *Chlorophyll avz* (Chl *avz*)
 102. *Chlorophyll awz* (Chl *awz*)
 103. *Chlorophyll axz* (Chl *axz*)
 104. *Chlorophyll ayz* (Chl *ayz*)
 105. *Chlorophyll ayz* (Chl *ayz*)
 106. *Chlorophyll ayz* (Chl *ayz*)
 107. *Chlorophyll ayz* (Chl *ayz*)
 108. *Chlorophyll ayz* (Chl *ayz*)
 109. *Chlorophyll ayz* (Chl *ayz*)
 110. *Chlorophyll ayz* (Chl *ayz*)
 111. *Chlorophyll ayz* (Chl *ayz*)
 112. *Chlorophyll ayz* (Chl *ayz*)
 113. *Chlorophyll ayz* (Chl *ayz*)
 114. *Chlorophyll ayz* (Chl *ayz*)
 115. *Chlorophyll ayz* (Chl *ayz*)
 116. *Chlorophyll ayz* (Chl *ayz*)
 117. *Chlorophyll ayz* (Chl *ayz*)
 118. *Chlorophyll ayz* (Chl *ayz*)
 119. *Chlorophyll ayz* (Chl *ayz*)
 120. *Chlorophyll ayz* (Chl *ayz*)
 121. *Chlorophyll ayz* (Chl *ayz*)
 122. *Chlorophyll ayz* (Chl *ayz*)
 123. *Chlorophyll ayz* (Chl *ayz*)
 124. *Chlorophyll ayz* (Chl *ayz*)
 125. *Chlorophyll ayz* (Chl *ayz*)
 126. *Chlorophyll ayz* (Chl *ayz*)
 127. *Chlorophyll ayz* (Chl *ayz*)
 128. *Chlorophyll ayz* (Chl *ayz*)
 129. *Chlorophyll ayz* (Chl *ayz*)
 130. *Chlorophyll ayz* (Chl *ayz*)
 131. *Chlorophyll ayz* (Chl *ayz*)
 132. *Chlorophyll ayz* (Chl *ayz*

Db 211 GCACTGAGGACAGCGCTGACGCTACTGTGAGGGAAGAAAGGTTGTGACAGACCCCGGAGG 270
Qy 123 ACCCTTGGCCAGCCCTTGGCCCGCCAGCCTTGTGCGAGACCCCTTGTGAGGCGAGACCGAGT 182
Db 271 ACCCTTGGCCAGCCCTTGGCCCGCCAGCCTTGTGCGAGACCCCTTGTGAGGCGAGACCGAGT 330
Qy 183 GAGCCAGTGAAGGCGAGGCTGTGCGAGCCACCGGCTGTGCACTCAAGAAACCCCTCAG 242
Db 331 GAGCCAGTGAAGGCGAGGCTGTGCGAGCCACCGGCTGTGCACTCAAGAAACCCCTCAG 390
Qy 243 AGGCCATGGAACAGCTGCCCCGCTTGAAGGCTTGAAGATGTGAGAGAGCCGCCCGG 302
Db 391 AGGCCATGGAACAGCTGCCCCGCTTGAAGGCTTGAAGATGTGAGAGAGCCGCCCGG 450
Qy 303 AGCCAGAGGAGGAGGAGGCTTCAATAGATTTCAATTAATTAACCAATTAATTT 362
Db 451 AGCCAGAGGAGGAGGAGGCTTCAATAGATTTCAATTAATTAACCAATTAATTT 510
Qy 363 GCAAGACCATGAGGCGCTGTGCGTGAACATGTGTGCTGCGAGCTGTGCTGCGCATG 422
Db 511 GCAAGACCATGAGGCGCTGTGCGTGAACATGTGTGCTGCGAGCTGTGCTGCGCATG 570
Qy 423 GAGAGTGTGCGAGGCGAGGAGGCTTTTGAAGGCACTGAGAGAGGCTGCGCAAGAG 482
Db 571 GAGAGTGTGCGAGGCGAGGAGGCTTTTGAAGGCACTGAGAGAGGCTGCGCAAGAG 630
Qy 483 TTCAATTTAATTAACAGGTACAAAGCGGCGGCGAGTCCAGAGCAAGTGCACCTTAACC 542
Db 631 TTCAATTTAATTAACAGGTACAAAGCGGCGGCGAGTCCAGAGCAAGTGCACCTTAACC 690
Qy 543 TTCAATTTGCGCCAGACCGGCTGCAAGGCTGCACTGTGCTGCTGCTGCTGCTGCTG 602
Db 691 TTCAATTTGCGCCAGACCGGCTGCAAGGCTGCACTGTGCTGCTGCTGCTGCTGCTG 750
Qy 603 GTGCTTGTGAGAAACCGAGTGCATTAAGCAGAGAGTGAAGTGTCTCAACATGAGCTGCTC 662
Db 751 GTGCTTGTGAGAAACCGAGTGCATTAAGCAGAGAGTGAAGTGTCTCAACATGAGCTGCTC 810
Qy 663 AAGCAAGAGCGGCGAGATGAGACGCTGCGAGCAGCTGTGAGAGTGTGAGAGCGGAGTGTG 722
Db 811 AAGCAAGAGCGGCGAGATGAGACGCTGCGAGCAGCTGTGAGAGTGTGAGAGCGGAGTGTG 870
Qy 723 AGCGAGTGTGAGCTGCTGCGAGAGGAGCGCAACATGAATGCGGCTGCAACGAGCTC 782
Db 871 AGCGAGTGTGAGCTGCTGCGAGAGGAGCGCAACATGAATGCGGCTGCAACGAGCTC 930
Qy 783 TACATGACAGCTTGTGACAGAGATCAATCCGCAAGCGGAGCAACGCGTGTGAGCTTCTCCAG 842
Db 931 TACATGACAGCTTGTGACAGAGATCAATCCGCAAGCGGAGCAACGCGTGTGAGCTTCTCCAG 990
Qy 843 CTGAGGAACAGGATCTGTAACAGAGCAGCGACATGTGCGAGCTGCGAGCAAGTACAG 902
Db 991 CTGAGGAACAGGATCTGTAACAGAGCAGCGACATGTGCGAGCTGCGAGCAAGTACAG 1050
Qy 903 GACCTGAGACCAAGTACAGACCTGCGCAACTGTGCGCAACCAATCAGAGATCATC 962
Db 1051 GACCTGAGACCAAGTACAGACCTGCGCAACTGTGCGCAACCAATCAGAGATCATC 1110
Qy 963 GGGCAGCTTGAAGAGACATGCGCAGAGGCTGCTGCGAGGCGCGCTGCGCGAGCGCC 1022
Db 1111 GGGCAGCTTGAAGAGACATGCGCAGAGGCTGCTGCGAGGCGCGCTGCGCGAGCGCC 1170
Qy 1023 CCGCGTGGCCCGCCCGGGGTCTAACCAACCAACCTTCAACCGCATCATCAACAGATC 1082
Db 1171 CCGCGTGGCCCGCCCGGGGTCTAACCAACCAACCTTCAACCGCATCATCAACAGATC 1230
Qy 1083 TCTACCAACAGAGATCAAGATGACCAAGAACTGAAAGGTGCTGCGACCCCTCTGCGCACT 1142
Db 1231 TCTACCAACAGAGATCAAGATGACCAAGAACTGAAAGGTGCTGCGACCCCTCTGCGCACT 1290
Qy 1143 ATGCCCACTTCAACAGGCTCCCATCTTCAACCGACCAAGCGCTGCGGCGCATGAGAGAC 1202
Db 1291 ATGCCCACTTCAACAGGCTCCCATCTTCAACCGACCAAGCGCTGCGGCGCATGAGAGAC 1350

Qy 1203 TGCCTGACAGCCCTGAGAGATGAGGACAGACCAAGCTCCATCTTACCTGTGAGGCGGAG 1262
Db 1351 TGCCTGACAGCCCTGAGAGATGAGGACAGACCAAGCTCCATCTTACCTGTGAGGCGGAG 1410
Qy 1263 AACACCAACCGCTCACTGAGGTGTGTGCGACACAGAGACAGACCCCGGCGGCTGAGAC 1322
Db 1411 AACACCAACCGCTCACTGAGGTGTGTGCGACACAGAGACAGACCCCGGCGGCTGAGAC 1470
Qy 1323 GTCATCAGAGAGCGCTGAGTGGCTGTCTTAATCTTCAAGAACTGAGAGACGTACAAAG 1382
Db 1471 GTCATCAGAGAGCGCTGAGTGGCTGTCTTAATCTTCAAGAACTGAGAGACGTACAAAG 1530
Qy 1383 CAAGGTTTGGGAACAATTGACGCGGAATCTGCTGAGACCAAGAGAGCTGGTCCGCGCAAGTC 1442
Db 1531 CAAGGTTTGGGAACAATTGACGCGGAATCTGCTGAGACCAAGAGAGCTGGTCCGCGCAAGTC 1590
Qy 1443 ACGAACCAAGGACCACTCAAACTCTGCTGAGACCAAGAGAGCTGGTCCGCGCAAGTC 1502
Db 1591 ACGAACCAAGGACCACTCAAACTCTGCTGAGACCAAGAGAGCTGGTCCGCGCAAGTC 1650
Qy 1503 TTTGCAAAATACGCAATTTCCGCTGGAACCTGAGAGGAGTATTAATTAAGCTGCGGCTG 1562
Db 1651 TTTGCAAAATACGCAATTTCCGCTGGAACCTGAGAGGAGTATTAATTAAGCTGCGGCTG 1710
Qy 1563 GGGCGCTACCATGAGCAATGCGGCTGACTCTTCAATGAGCAACAGGCAAGCATTTCAAC 1622
Db 1711 GGGCGCTACCATGAGCAATGCGGCTGACTCTTCAATGAGCAACAGGCAAGCATTTCAAC 1770
Qy 1623 ACCCTGACAGAGATCATGATGTCTACACAGAGAACTGCGCCACTTACAGAGAGGAGGC 1682
Db 1771 ACCCTGACAGAGATCATGATGTCTACACAGAGAACTGCGCCACTTACAGAGAGGAGGC 1830
Qy 1683 TGTGTGTATTAAGCTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1742
Db 1831 TGTGTGTATTAAGCTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1890
Qy 1743 TACCGAGCGCTACACAGAGAGGAGTCACTGAGGCTGAGTCCAGAGAGGCTTACTCA 1802
Db 1891 TACCGAGCGCTACACAGAGAGGAGTCACTGAGGCTGAGTCCAGAGAGGCTTACTCA 1950
Qy 1803 CTCAGAAAGTGTGTATGATGATCCGACCGAACCCCAACCTTCACTAAGCAGCTCC 1862
Db 1951 CTCAGAAAGTGTGTATGATGATCCGACCGAACCCCAACCTTCACTAAGCAGCTCC 2010
Qy 1863 CCTCTGACCTCTGCTGCGCAATGCGAGAGCCCAACCTGCTGACAGCTGCGCAAGAC 1922
Db 2011 CCTCTGACCTCTGCTGCGCAATGCGAGAGCCCAACCTGCTGACAGCTGCGCAAGAC 2070
Qy 1923 AAAGAACCACTCCTCAACAGTTCATCTGAGCTGAGAGAGCGGAGTCTGATTTCTGT 1982
Db 2071 AAAGAACCACTCCTCAACAGTTCATCTGAGCTGAGAGAGCGGAGTCTGATTTCTGT 2130
Qy 1983 TTTCCGAAGTCACTGAGGAGTATGAGAACTGAATCGATTAAGGTGTTTCTGTCCCTCC 2042
Db 2131 TTTCCGAAGTCACTGAGGAGTATGAGAACTGAATCGATTAAGGTGTTTCTGTCCCTCC 2190
Qy 2043 TACTTCTTCAACAGACAGCCCTCATGTCTCAGAGACAGAGCAAGTACAGACAA 2102
Db 2191 TACTTCTTCAACAGACAGCCCTCATGTCTCAGAGACAGAGCAAGTACAGACAA 2250
Qy 2103 CTCTTCTTAAATAATTAATTAAGTCTTCAATTAATAAQA 2141
Db 2251 CTCTTCTTAAATAATTAATTAAGTCTTCAATTAATAAQA 2289

RESULT 2
US-08-960-507-1
; Sequence 1, Application US/08960507
; Patent No. 6057435
; GENERAL INFORMATION:
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.

Mon Aug 9 10:30:08 2004

us-10-018-386-1.rn1

Page 3

TITLE OF INVENTION: Tie Ligands
NUMBER OF SEQUENCES: 24
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genentech, Inc.
STREET: 1 DNA Way
CITY: South San Francisco
STATE: California
COUNTRY: USA
ZIP: 94080
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WinPatIn (Genentech)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/960,507
FILING DATE:
CLASSIFICATION: 536
ATTORNEY/AGENT INFORMATION:
NAME: Dregert, Ginger R.
REGISTRATION NUMBER: 33,055
REFERENCE/DOCKET NUMBER: P1130p1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650/225-3216
TELEFAX: 650/952-9881
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 2290 base pairs
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
US-08-960-507-1

Query Match 98.1%; Score 2132.6; DB 3; Length 2290;
Best Local Similarity 99.8%; Pred. No. 0;
Matches 2135; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 3 AAATGAGGCTGCTGGAGACGGCTGAGATGAAACCCCAAGCCCTGAGCTGCGCAGCTG 62
DB 151 AAATGAGGCTGCTGGAGACGGCTGAGATGAAACCCCAAGCCCTGAGCTGCGCAGCTG 210
QY 63 GCACTGAGGACGGCTGACGCTACTGTGAGGAAAGAAAGTTGTGAGACGCCCGCAGG 122
DB 211 GCACTGAGGACGGCTGACGCTACTGTGAGGAAAGAAAGTTGTGAGACGCCCGCAGG 270
QY 123 ACCCTGCGCAGCCCTGCGCCCGCAGCTGTGCGGAGCCCTGTGAGAGCAGAGCCAGTG 182
DB 271 ACCCTGCGCAGCCCTGCGCCCGCAGCTGTGCGGAGCCCTGTGAGAGCAGAGCCAGTG 330
QY 183 GAGCCAGTGAAGGAGGAGGCTGTGAGCAGCAGCGGCTGCACTCAGGAAACCCCTCCAG 242
DB 331 GAGCCAGTGAAGGAGGAGGCTGTGAGCAGCAGCGGCTGCACTCAGGAAACCCCTCCAG 390
QY 243 AGGCGATGAGCAGGCTGCGCCCGCTGACGCGCAGGAGTGAAGCATGTGAGAGCGCGCCG 302
DB 391 AGGCGATGAGCAGGCTGCGCCCGCTGACGCGCAGGAGTGAAGCATGTGAGAGCGCGCCG 450
QY 303 AGCCAGCAGAGGAGGAGGCTTTCAATGATTTCTATTCACAAAGATTAACCAACATTT 362
DB 451 AGCCAGCAGAGGAGGAGGCTTTCAATGATTTCTATTCACAAAGATTAACCAACATTT 510
QY 363 GAAAGAACCATGAGGACATGTGCTGACATGCTGTGCTGAGCTGCTGCTGCTGCTGCTG 422
DB 511 GAAAGAACCATGAGGACATGTGCTGACATGCTGTGCTGAGCTGCTGCTGCTGCTGCTG 570
QY 423 GAGAGCTGTGAGGCGCAGAGGAGCGTTTGGAGGCACTGAGAGGAGGCTGCGCAGAGAG 482
DB 571 GAGAGCTGTGAGGCGCAGAGGAGCGTTTGGAGGCACTGAGAGGAGGCTGCGCAGAGAG 630
QY 483 TTCAATTTACTTAAACAGGTACAGAGGAGGAGGAGGAGTCCAGAGCAAGTGACCTTACCC 542
DB 631 TTCAATTTACTTAAACAGGTACAGAGGAGGAGGAGGAGTCCAGAGCAAGTGACCTTACCC 690

QY 543 TTCAATTTGCCCCAGCAGCGGGGTACGGGTGCTTCTGCTCAACTCCAGAGACCTTGAG 602
DB 691 TTCAATTTGCCCCAGCAGCGGGGTACGGGTGCTTCTGCTCAACTCCAGAGAGCCCTGAG 750
QY 603 GTGCTTCTGAGAAACCGAGTGCATTAAGCAGAGAGTAGAGTGTCTCAACATTAAGCTCTC 662
DB 751 GTGCTTCTGAGAAACCGAGTGCATTAAGCAGAGAGTAGAGTGTCTCTCAACATTAAGCTCTC 810
QY 663 AAGCAGAGCGGCGAGATCGAGACGCTGACAGCTGTGAGAGGTGAACGCGCGCATTTGTG 722
DB 811 AAGCAGAGCGGCGAGATCGAGACGCTGACAGCTGTGAGAGGTGAACGCGCGCATTTGTG 870
QY 723 AGGAGGTGAAGGCTGCGCCAGAGAGAGCGGCAACATGAACTCGCGGGGTCAAGCAGCTC 782
DB 871 AGGAGGTGAAGGCTGCGCCAGAGAGAGCGGCAACATGAACTCGCGGGGTCAAGCAGCTC 930
QY 783 TACATGAGCTCTCTGACAGATCATCCGAGCGGAGCAACGCGTTGAGCTCTCCAG 842
DB 931 TACATGAGCTCTCTGACAGATCATCCGAGCGGAGCAACGCGTTGAGCTCTCCAG 990
QY 843 CTGAGAAACAGATCTCTGAACCGAGACCGGACATGTGACAGCTGCGCAGAGTACAG 902
DB 991 CTGAGAAACAGATCTCTGAACCGAGACCGGACATGTGACAGCTGCGCAGAGTACAG 1050
QY 903 GACCTGAGACCAAGTACCAAGACCTGCGCAGCTGCGCAGCAACCAATCAGAGATCATC 962
DB 1051 GACCTGAGACCAAGTACCAAGACCTGCGCAGCTGCGCAGCAACCAATCAGAGATCATC 1110
QY 963 GCGAGCTTGAAGAGCACTGCGCAGAGGAGTCCCTGCGCAGGCGCGTCCCTCCAGCCACC 1022
DB 1111 GCGAGCTTGAAGAGCACTGCGCAGAGGAGTCCCTGCGCAGGCGCGTCCCTCCAGCCACC 1170
QY 1023 CCGGCTGCCCCCGCGGGGTCTACCAACCAACCCAGCTCAACAGCGCATCATCAACCAATC 1082
DB 1171 CCGGCTGCCCCCGCGGGGTCTACCAACCAACCCAGCTCAACAGCGCATCATCAACCAATC 1230
QY 1083 TCTACCAACGAGATCCAGAGTGAACAGAACCTGAAGTGTGCGCAGCCCTGTGCCACT 1142
DB 1231 TCTACCAACGAGATCCAGAGTGAACAGAACCTGAAGTGTGCGCAGCCCTGTGCCACT 1290
QY 1143 ATGCCACTCTCAACAGCCTCCCATCTTCCACCGAGCAAGCGGTGCGCATGAGAGAC 1202
DB 1291 ATGCCACTCTCAACAGCCTCCCATCTTCCACCGAGCAAGCGGTGCGCATGAGAGAC 1350
QY 1203 TGCTGAGAGCCCTGAGAGATGAGCAGCAGCAGCAGCTCCATCTAAGCTGTGAAGCCGAG 1262
DB 1351 TGCTGAGAGCCCTGAGAGATGAGCAGCAGCAGCAGCTCCATCTAAGCTGTGAAGCCGAG 1410
QY 1263 AACCAACCGGCTCATGCAAGTGTGTGCGACAGACAGACAGACCCCGGGGCTGAGACC 1322
DB 1411 AACCAACCGGCTCATGCAAGTGTGTGCGACAGACAGACAGACCCCGGGGCTGAGACC 1470
QY 1323 GTCAATCAGAGAGCGCTGAGATGAGCTGTAACTTTCAGGAACTGAGAGAGTACAAG 1382
DB 1471 GTCAATCAGAGAGCGCTGAGATGAGCTGTAACTTTCAGGAACTGAGAGAGTACAAG 1530
QY 1383 CAAGGTTTGGGAACATGAACGCGGAATGAGCTGTGAGGAGGCTGTGAGAACATTTA 1442
DB 1531 CAAGGTTTGGGAACATGAACGCGGAATGAGCTGTGAGGAGGCTGTGAGAACATTTA 1590
QY 1443 ACGAACCAAGGCAACTCAACCTCCGAGTACCATGAGAGAGCTGCTCGGCGGCAAGTGC 1502
DB 1591 ACGAACCAAGGCAACTCAACCTCCGAGTACCATGAGAGAGCTGCTCGGCGGCAAGTGC 1650
QY 1503 TTTCAGAAATACGCAAGTTTCCGCTGGAACCTGAGAGCAGATTAATAAGCTGCGGCTG 1562
DB 1651 TTTCAGAAATACGCAAGTTTCCGCTGGAACCTGAGAGCAGATTAATAAGCTGCGGCTG 1710
QY 1563 GGGGCTACCATGAGCAATGGGGGTGACTCTTTTACATGAGCAACCGGCAAGAGCTTACCC 1622
DB 1711 GGGGCTACCATGAGCAATGGGGGTGACTCTTTTACATGAGCAACCGGCAAGAGCTTACCC 1770
QY 1623 ACCCTGACAGAGATCATGATGTCTTACACAGGAAAGTGTCCCACTACAGAAAGGAGGC 1682

Dp	1111	GGCGAGCTTGAAGAGACACTGGCCAGAGGGGgGccCTGGGCGAGGCGGTCCCGACGACC	1170
Qy	1023	CCCGCTGCCCGCCCCGGGTCTACCAACCAACCACTTCAACCGATCATCAACCAATC	1082
Dp	1171	CCCGGTGCCCGCCCCGGGTCTACCAACCAACCACTTCAACCGATCATCAACCAATC	1230
Qy	1083	TCTACCAACGAGATCTCAGAGTACCAAGAACTGAAGAGGCTGCACCCCTCTGGCCAT	1142
Dp	1231	TCTACCAACGAGATCTCAGAGTACCAAGAACTGAAGAGGCTGCACCCCTCTGGCCAT	1290
Qy	1143	ATGCCCACTCTCACCGAGCTTCCCATCTTTCCACCGCAAAAGCGTGGGCCCATGAGAGAC	1202
Dp	1291	ATGCCCACTCTCACCGAGCTTCCCATCTTTCCACCGCAAAAGCGTGGGCCCATGAGAGAC	1350
Qy	1203	TGCCCTGCAGGGCCCTGAGAGATGGCCAGACACACACTCATCTTACTCTGTAAAGCCGGAG	1262
Dp	1351	TGCCCTGCAGGGCCCTGAGAGATGGCCAGACACACACTCATCTTACTCTGTAAAGCCGGAG	1410
Qy	1263	AACACCAACCGGCTCATCGAGTGTGTGTGCGACACAGACACAGCCCCGGGGGCTGAGAC	1322
Dp	1411	AACACCAACCGGCTCATCGAGTGTGTGTGCGACACAGACACAGCCCCGGGGGCTGAGAC	1470
Qy	1323	GTCACTCCAGAGACGCGCTGGATGGCTCTGTAACTTCTCAGGAATCTGGGAACGTAAAG	1382
Dp	1471	GTCACTCCAGAGACGCGCTGGATGGCTCTGTAACTTCTCAGGAATCTGGGAACGTAAAG	1530
Qy	1383	CAAGGGTTTGGGAACATTGACGGCCAAATACCTGGGCGCTGGAGAACATTACCTGGCTG	1442
Dp	1531	CAAGGGTTTGGGAACATTGACGGCCAAATACCTGGGCGCTGGAGAACATTACCTGGCTG	1598
Qy	1443	ACGAACCAAGGCACCTACCAAACTCTGTGTACCATGAGAGACGTGTCCGGCCGCAAGTC	1502
Dp	1591	ACGAACCAAGGCACCTACCAAACTCTGTGTGTACCATGAGAGACGTGTCCGGCCGCAAGTC	1650
Qy	1503	TTTGAGAGATACGGCCAGTTTCGGCTGGAACTGTAGAGCCAGTAACTTAACCTCGGCTG	1562
Dp	1651	TTTGAGAGATACGGCCAGTTTCGGCTGGAACTGTAGAGCCAGTAACTTAACCTCGGCTG	1710
Qy	1563	GGGGCGCTACCATGGCCATGGCGGGTGACTCTTTATATGGGCACAAACGGCAACAGTTTAC	1622
Dp	1711	GGGGCGCTACCATGGCCATGGCGGGTGACTCTTTATATGGGCACAAACGGCAACAGTTTAC	1770
Qy	1623	ACCTGTGACAGAGATCATGATGTCTACACAGGAACCTGTGCCACTTACCAAGAGGAGGC	1682
Dp	1771	ACCTGTGACAGAGATCATGATGTCTACACAGGAACCTGTGCCACTTACCAAGAGGAGGC	1830
Qy	1683	TGATGTGTAAAGCCTGTGGCCCACTCCAACTCAAACGGGCTCTGGTACCGGGGGGGCAT	1742
Dp	1831	TGATGTGTAAAGCCTGTGGCCCACTCCAACTCAAACGGGCTCTGGTACCGGGGGGGCAT	1890
Qy	1743	TACGGGAGCGGCTACCAAGACGGAGTCTACTGTGGCTGAGTTTCCAGAGAGGCTCTTACTCA	1802
Dp	1891	TACGGGAGCGGCTACCAAGACGGAGTCTACTGTGGCTGAGTTTCCAGAGAGGCTCTTACTCA	1950
Qy	1803	CTCAAGAAAGTGGGATGATGATGATCCGACCGAAACCCAACTTCACTTAAGCCAGACTCC	1862
Dp	1951	CTCAAGAAAGTGGGATGATGATGATCCGACCGAAACCCAACTTCACTTAAGCCAGACTCC	2010
Qy	1863	CCCTTCTGACCTTCTGTGGCCATTGCCAGAGGCCAACCCCTGTGTCAACGTGGCCACAGAC	1922
Dp	2011	CCCTTCTGACCTTCTGTGGCCATTGCCAGAGGCCAACCCCTGTGTCAACCGTGGCCACAGAC	2070
Qy	1923	AAAGAACAACTCTCACCAAGTTCACTCGAAGGCTGGAGGACCGGGAATGCTGATTTCTGT	1982
Dp	2071	AAAGAACAACTCTCACCAAGTTCACTCGAAGGCTGGAGGACCGGGAATGCTGATTTCTGT	2130
Qy	1983	TTTCGGAAGTCACTGCAAGCGGATGTAGAACTGAATCATACGGTGTTTTCTGTCCCTCC	2042
Dp	2131	TTTCGGAAGTCACTGCAAGCGGATGTAGAACTGAATCATACGGTGTTTTCTGTCCCTCC	2190
Qy	2043	TACTTTCTTCAACACAGACAGCCCTCATGTCTTCCAGAGACAGACACAGATTAACAGACA	2102
Dp	2191	TACTTTCTTCAACACAGACAGCCCTCATGTCTTCCAGAGACAGACACAGATTAACAGACA	2250

Qy	2103	CTCTTCTTAAATAATTAAGTCTCTACATAAAAAACA	2141
Dp	2251	CTCTTCTTAAATAATTAAGTCTCTACATAAAAAAAA	2289

RESULT 4
US-09-332-928A-1
; Sequence 1, Application US/09332928A

GENERAL INFORMATION:

APPLICANT: Godowski Paul J

gurney, Austin L.
TITLE OF INVENTION: The Ligands

CORRESPONDENCE ADDRESS:

STREET: 1 DNA way

STATE: California
COUNTRY: USA

ZIP: 94080
COMPTON READABLE

COMPUTER: IBM PC compatible

SOFTWARE: WinPatIn (Genentech)

APPLICATION NUMBER: US/09/332,928A

```

; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:

```

APPLICATION NUMBER: 08/933,821
FILING DATE: <unknown>

NAME: Dreger, Ginger R

REFERENCE/DOCKET NUMBER: P1130

TELEPHONE: 650/225-3216

INFORMATION FOR SEQ ID NO: 1:

LENGTH: 2290 base pairs
TYPE: Nucleic Acid

TOPOLOGY: Linear

US-09-332-928A-1

Query Match	98.1%;	Score 2132.6;	DB 4;	Length 2290;
Best Local Similarity	99.8%;	Pred No. 0;		

```
Matches 2135; conservative 0; mismatches 4; indels 0; gaps 0;
```

2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 104

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
84

[illegible]

123 ACCCCCTGGCCAGCCCTCTGACCGGAGCCCTCTGTGAGGCGAGAGCCAGTG 182

Db 271 ACCCTGGCAGCCCTGGCCCAAGCCTCTGCCGAGCCCTCTGTGAGGCAAGCCAGTG 330

QY 183 GAGCCAGTGAGCAGGGCTGCTTGGCAGCCACCGGCTGCAACTCAGGAACCCCTCCAG 242

Db 331 GAGCCAGTGAGGCAGGGCTGCTTGCGACGCCACCGGCTGCAACTCAGGAACCCCTCCAG 390

243 AGGCCAIGACAGGCTGCCCCGCTGACCGCCAGGCTGAGCATGTGAGGAGCCGCCCGG 302

[illegible]

STATE: California
COUNTRY: USA
ZIP: 94080
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WinPatIn (Genentech)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/136,801
FILING DATE:
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Dreger, Ginger R.
REGISTRATION NUMBER: 33,055
REFERENCE/DOCKET NUMBER: P1130P2
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650/425-3216
TELEFAX: 650/952-9881
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 2290 base pairs
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
US-09-136-801-1

Query Match 98.1%; Score 2132.6; DB 4; Length 2290;
Best Local Similarity 99.8%; Pred. No. 0;
Matches 2135; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 3 AAATAGGTGCTGTGGGAGCGGCTTGAAGTAAACCCCAAGCCCTTGACCTGCGGAGCTG 62
DB 151 AAATAGGTGCTGTGGGAGCGGCTTGAAGTAAACCCCAAGCCCTTGACCTGCGGAGCTG 210
QY 63 GCACTGAGCGAGCGGCTGACCTACTGTGAGGGAAGAAGTTGTAGCAGAGCCCGCAGG 122
DB 211 GCACTGAGCGAGCGGCTGACCTACTGTGAGGGAAGAAGTTGTAGCAGAGCCCGCAGG 270
QY 123 ACCCTGTGCGAGCCCTTGCGCCCAAGCCTTGTGCGAGCCCTTGTGAGGCGAGAGCAATG 182
DB 271 ACCCTGTGCGAGCCCTTGCGCCCAAGCCTTGTGCGAGCCCTTGTGAGGCGAGAGCAATG 330
QY 183 GAGCCAGTGAAGGAGCGGCTGTGGCAAGCCAGGCGCTGCAACTCAGAGAACCCCTCCAG 242
DB 331 GAGCCAGTGAAGGAGCGGCTGTGGCAAGCCAGGCGCTGCAACTCAGAGAACCCCTCCAG 390
QY 243 AGGCCATGAGACAGGCTGCGCCGCTGACGCGCAGGCTGAAGCATGTGAGAGCCCGCCCGG 302
DB 391 AGGCCATGAGACAGGCTGCGCCGCTGACGCGCAGGCTGAAGCATGTGAGAGCCCGCCCGG 450
QY 303 AGCCAAAGCAGAGGGAAGAAGCTTTCATGATTTCTATTCAAAAGAAATTAACACCATTTT 362
DB 451 AGCCAAAGCAGAGGGAAGAAGCTTTCATGATTTCTATTCAAAAGAAATTAACACCATTTT 510
QY 363 GCAAAAGCAGTGAAGCGCACTGTGCTGACATGCTGGTGGCTGCGACTGCTGGCTGCCATG 422
DB 511 GCAAAAGCAGTGAAGCGCACTGTGCTGACATGCTGGTGGCTGCGACTGCTGGCTGCCATG 570
QY 423 GAGAGCTGTGCGAGCGCAGAGGACGCTTTTGAAGGCACTGAGAGAGGCTGCCCAAGAGAG 482
DB 571 GAGAGCTGTGCGAGCGCAGAGGACGCTTTTGAAGGCACTGAGAGAGGCTGCCCAAGAGAG 630
QY 483 TTCAATTACTTAACAGGTACAAAGCGGCGGCGAGTCCCAAGAGCAAGTGAACCTACACC 542
DB 631 TTCAATTACTTAACAGGTACAAAGCGGCGGCGAGTCCCAAGAGCAAGTGAACCTACACC 690
QY 543 TTCAATTGCGCCAGCAGAGCGGCTACGCGGTGCGATCTGCTCAACTCCAAAGAGCTTAG 602
DB 691 TTCAATTGCGCCAGCAGAGCGGCTACGCGGTGCGATCTGCTCAACTCCAAAGAGCTTAG 750
QY 603 GTGCTTGTGAGAACCGAGTGCATAGCAGAGAGCTGCTCAACAAATGAGGTGCTC 662

DB 751 GTGCTTGTGAGAACCGAGTGCATAGCAGAGAGCTGCTCAACAAATGAGGTGCTC 810
QY 663 AAGCAGAAAGCGGCGAGATTCGAGACGCTGACAGAGTGTGAAGTGAACGCGCGGATTTGTG 722
DB 811 AAGCAGAAAGCGGCGAGATTCGAGACGCTGACAGAGTGTGAAGTGAACGCGCGGATTTGTG 870
QY 723 AGCAGGTGAAGCTGCTGCGCAGAGAGAGCGGCAACATGAACCTGCGGGTTCACGACAGCTC 782
DB 871 AGCAGGTGAAGCTGCTGCGCAGAGAGAGCGGCAACATGAACCTGCGGGTTCACGACAGCTC 930
QY 783 TACATGACGCTCTGCGACAGATATCCGAAAGCGGAGCAACGCTTTGAGCTTCCGAG 842
DB 931 TACATGACGCTCTGCGACAGATATCCGAAAGCGGAGCAACGCTTTGAGCTTCCGAG 990
QY 843 CTGAGAAACAGATTCCTGAACCAAGACCGGACATGTGTGAGCTGGCGACCAAGTACAG 902
DB 991 CTGAGAAACAGATTCCTGAACCAAGACCGGACATGTGTGAGCTGGCGACCAAGTACAG 1050
QY 903 GACCTGAGACCAAGTACCAAGACCTTGCCCACTGACCACCAACCAATCAGAGATATC 962
DB 1051 GACCTGAGACCAAGTACCAAGACCTTGCCCACTGACCACCAACCAATCAGAGATATC 1110
QY 963 GCGGAGCTTGAAGAGCACTGCGAAGAGGTGCTGCGGCGAGGCGGCGGCGGCGGCGGCGG 1022
DB 1111 GCGGAGCTTGAAGAGCACTGCGAAGAGGTGCTGCGGCGAGGCGGCGGCGGCGGCGGCGG 1170
QY 1023 CCGGCTGCGGCGGCGGCGGCTTCAACCAAGCAACCACTTCAACAGCATCATCAACAGATC 1082
DB 1171 CCGGCTGCGGCGGCGGCGGCTTCAACCAAGCAACCACTTCAACAGCATCATCAACAGATC 1230
QY 1083 TCTTACCAAGATTCAGAGTGAACAGAACTTGAAGTGTGCGACCCCTTGTGCCACT 1142
DB 1231 TCTTACCAAGATTCAGAGTGAACAGAACTTGAAGTGTGCGACCCCTTGTGCCACT 1290
QY 1143 ATGCCACTCTCAACAGAGCTTCCCATCTTCCACGCAACAGCGCTGCGGCGGCGGCGGAG 1202
DB 1291 ATGCCACTCTCAACAGAGCTTCCCATCTTCCACGCAACAGCGCTGCGGCGGCGGAG 1350
QY 1203 TGCTGAGGCGCTTGAAGATGAGCAAGACCAAGCTCCATCTACTGTGAAAGCGGAG 1262
DB 1351 TGCTGAGGCGCTTGAAGATGAGCAAGACCAAGCTCCATCTACTGTGAAAGCGGAG 1410
QY 1263 AACCAACAGCGCTCATGAGAGTGTGTGCAACAGACAGCTCCATCTACTGTGAAAGCGGAG 1322
DB 1411 AACCAACAGCGCTCATGAGAGTGTGTGCAACAGACAGCTCCATCTACTGTGAAAGCGGAG 1470
QY 1323 GTATCCAGAGAGCGCTGATGAGCTCTGTAACTTTCAGGAACCTGAGAGAGTCAAG 1382
DB 1471 GTATCCAGAGAGCGCTGATGAGCTCTGTAACTTTCAGGAACCTGAGAGAGTCAAG 1530
QY 1383 CAAGGTTTGGGAACATTAAGCGCGGAATATGCTGCTGGCTGAGAAACATTTACTGGCTG 1442
DB 1531 CAAGGTTTGGGAACATTAAGCGCGGAATATGCTGCTGGCTGAGAAACATTTACTGGCTG 1590
QY 1443 ACBAACCAAGGCAACTCAAACTCTGTGTGACCATGAGAGAGCTGCGGCGGCAAGTGC 1502
DB 1591 ACBAACCAAGGCAACTCAAACTCTGTGTGACCATGAGAGAGCTGCGGCGGCAAGTGC 1650
QY 1503 TTTGAGAAATAGCGCAGTTTCCGCTGGAACCTGAGAGCGAGTATTAAGCTGCGGCTG 1562
DB 1651 TTTGAGAAATAGCGCAGTTTCCGCTGGAACCTGAGAGCGAGTATTAAGCTGCGGCTG 1710
QY 1563 GGGGCTTACCATGAGCAGTGGGCTGACTCTTTTACATGAGCAACGCGCAAGCTTCAAC 1622
DB 1711 GGGGCTTACCATGAGCAGTGGGCTGACTCTTTTACATGAGCAACGCGCAAGCTTCAAC 1770
QY 1623 ACCCTGAGCAGAGTATGATGTCTACAGAGAACTGTGCCACTTACAGAAAGGAGGC 1682
DB 1771 ACCCTGAGCAGAGTATGATGTCTACAGAGAACTGTGCCACTTACAGAAAGGAGGC 1830
QY 1683 TGGTGTATTAACCGCTGTGCGCACTCCAACTCAAGCGGAGTGTGTACCGGCGGCGGCGAT 1742
DB 1831 TGGTGTATTAACCGCTGTGCGCACTCCAACTCAAGCGGAGTGTGTACCGGCGGCGGCGAT 1890

Db 1171 CCCGCTGCCCCCGGGCTTACCAACCAACCACCTAACCGGATCATCAACGAGATC 1230
 QY 1083 TCTACCAACGAGATCCAGATGACCAAGAACTGAAGTGTGCGCAACCCCTCTGCCCCACT 1142
 Db 1231 TTTACCAACGAGATCCAGATGACCAAGAACTGAAGTGTGCGCAACCCCTCTGCCCCACT 1290
 QY 1143 ATGCCACTCTCCACAGAGCTCCCATCTTTCACCGAACAGCCGTCGGGCCCATGAGAGAC 1202
 Db 1291 ATGCCACTCTCCACAGAGCTCCCATCTTTCACCGAACAGCCGTCGGGCCCATGAGAGAC 1350
 QY 1203 TGGCTGAGAGCCCTGAGAGATGGCCACGACACCACTGCTTACTTGGTGAAGCCGAG 1262
 Db 1351 TGGCTGAGAGCCCTGAGAGATGGCCACGACACCACTGCTTACTTGGTGAAGCCGAG 1410
 QY 1263 AACACCAACCGGCTCATGAGAGTGTGTGCGACAGACAGACAGACCCCGGGGGCTGAGAC 1322
 Db 1411 AACACCAACCGGCTCATGAGAGTGTGTGCGACAGACAGACAGACCCCGGGGGCTGAGAC 1470
 QY 1323 GTGATCCAGAGACGCTGAGATGCTCTGTGTTAACTTCTTACGAACTGGAGACGTACAG 1382
 Db 1471 GTGATCCAGAGACGCTGAGATGCTCTGTGTTAACTTCTTACGAACTGGAGACGTACAG 1530
 QY 1383 CAAGGTTTGGGAACTTGAAGCGCGAATCTGCTGGGCTGGAGAACTTACTGGGCTG 1442
 Db 1531 CAAGGTTTGGGAACTTGAAGCGCGAATCTGCTGGGCTGGAGAACTTACTGGGCTG 1590
 QY 1443 ACGAACCAAGGCACTACAACTCTGTGTGATGACCATGAGAGCTGTCCGGCCGCAAAATC 1502
 Db 1591 ACGAACCAAGGCACTACAACTCTGTGTGATGACCATGAGAGCTGTGTCCGGCCGCAAAATC 1650
 QY 1503 TTTTGAAGATACGCCAGTTTCCGCTGGAACCTGAGAGAGATATTAAAGTGTGGGCTG 1562
 Db 1651 TTTTGAAGATACGCCAGTTTCCGCTGGAACCTGAGAGAGATATTAAAGTGTGGGCTG 1710
 QY 1563 GGGGCTACCATGAGCATGCGGGTACTCTTTAATGAGCAACGAGAGAGTTCAAC 1622
 Db 1711 GGGGCTACCATGAGCATGCGGGTACTCTTTAATGAGCAACGAGAGAGTTCAAC 1770
 QY 1623 ACCCTGAGACAGATCATGATGTCTTACACAGAGAACTGTGCCCATACCAAGAGGAGGC 1682
 Db 1771 ACCCTGAGACAGATCATGATGTCTTACACAGAGAACTGTGTGCCCATACCAAGAGGAGGC 1830
 QY 1683 TGGTGTATTAAGCGCTGTGCCACTCCACTCCAACTCAACGCGGGTGTGTACCGCGGGGCCAT 1742
 Db 1831 TGGTGTATTAAGCGCTGTGCCACTCCACTCCAACTCAACGCGGGTGTGTACCGCGGGGCCAT 1890
 QY 1743 TACCGGAGCGGTACACAGACGGAAGTCTACTGGGCTGAGTTCCGAGAGGCTCTTACTCA 1802
 Db 1891 TACCGGAGCGGTACACAGACGGAAGTCTACTGGGCTGAGTTCCGAGAGGCTCTTACTCA 1950
 QY 1803 CTCAGAGAAATGTGTATGTATGATCCGACCGGAACTCCCACTTCCACTTAAGCCAGCTCC 1862
 Db 1951 CTCAGAGAAATGTGTATGTATGATCCGACCGGAACTCCCACTTCCACTTAAGCCAGCTCC 2010
 QY 1863 CCTCTCTGACTCTGTGGGCTATGTCAGAGAGCCCACTGTGTCAAGCTGGCCACAGAC 1922
 Db 2011 CCTCTCTGACTCTGTGGGCTATGTCAGAGAGCCCACTGTGTCAAGCTGGCCACAGAC 2070
 QY 1923 AAAAGAACAACTCTCTCAACGATTCATCTGAGAGCTGGAGAGACCGGAGATGCTGATTCGT 1982
 Db 2071 AAAAGAACAACTCTCTCAACGATTCATCTGAGAGCTGGAGAGACCGGAGATGCTGATTCGT 2130
 QY 1983 TTTCCGAAGTCACTGAGAGGATGATGAGAACTGATGATGATGATGATGATGATGATGATGAT 2042
 Db 2131 TTTCCGAAGTCACTGAGAGGATGATGAGAACTGATGATGATGATGATGATGATGATGATGAT 2190
 QY 2043 TACTTTCTTCAACACAGACGCGCTTATGTCTCCAGAGACAGACAGACTACAGACAA 2102
 Db 2191 TACTTTCTTCAACACAGACGCGCTTATGTCTCCAGAGACAGACAGACTACAGACAA 2250
 QY 2103 CTCCTTCTTAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 2141

Db 2251 CTCCTTCTTAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 2289
 RESULT 7
 US-09-333-075-1
 ; Sequence 1, Application US/09333075
 ; Patent No. 6492331
 ; GENERAL INFORMATION:
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Gurney, Austin L.
 ; TITLE OF INVENTION: The Ligands
 ; NUMBER OF SEQUENCES: 17
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Genentech, Inc.
 ; STREET: 1 DNA Way
 ; CITY: South San Francisco
 ; STATE: California
 ; COUNTRY: USA
 ; ZIP: 94080
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: WinPatlin (Genentech)
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/09/333,075
 ; FILING DATE:
 ; CLASSIFICATION:
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: 08/933,821
 ; FILING DATE:
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Dreger, Ginger R.
 ; REGISTRATION NUMBER: 33,055
 ; REFERENCE/DOCKET NUMBER: P1130
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: 650/225-3216
 ; TELEFAX: 650/952-9881
 ; INFORMATION FOR SEQ ID NO: 1:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 2290 base pairs
 ; TYPE: Nucleic Acid
 ; STRANDEDNESS: Single
 ; TOPOLOGY: Linear
 ; US-09-333-075-1
 Query Match 98.1%; Score 2132.6; DB 4; Length 2290;
 Best Local Similarity 99.8%; Pred. No. 0;
 Matches 2135; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 QY 3 AAATGAGGCTGTGCGGAGCGGCTGAGGATGAACCCCAACCCCTGGAGCTGCGGAGGCTG 62
 Db 151 AAATGAGGCTGTGCGGAGCGGCTGAGGATGAACCCCAACCCCTGGAGCTGCGGAGGCTG 210
 QY 63 GCACTGAGGAGCGGCTGAGCTACTGTGAGGAGAAAGAGTTGTGAGACGCCCGAG 122
 Db 211 GCACTGAGGAGCGGCTGAGCTACTGTGAGGAGAAAGAGTTGTGAGACGCCCGAG 270
 QY 123 ACCCTGGCCAGCGCTGAGCGCCCAAGCTCTGCGGAGAGCCCTGTGAGAGGAGGCAAGTG 182
 Db 271 ACCCTGGCCAGCGCTGAGCGCCCAAGCTCTGCGGAGAGCCCTGTGAGAGGAGGCAAGTG 330
 QY 123 ACCCTGGCCAGCGCTGAGCGCCCAAGCTCTGCGGAGAGCCCTGTGAGAGGAGGCAAGTG 182
 Db 271 ACCCTGGCCAGCGCTGAGCGCCCAAGCTCTGCGGAGAGCCCTGTGAGAGGAGGCAAGTG 330
 QY 183 GAGCCAGTGAAGGAGGAGGCTGTGAGGAGCCACCGGCTGCACTAGAGAACCCCTTCAG 242
 Db 331 GAGCCAGTGAAGGAGGAGGCTGTGAGGAGCCACCGGCTGCACTAGAGAACCCCTTCAG 390
 QY 243 AGGCTATGACAGGCTGCCCCGCTGACAGCGCCAGAGTGAACATGTAGAGAGCCGCCCGG 302
 Db 391 AGGCTATGACAGGCTGCCCCGCTGACAGCGCCAGAGTGAACATGTAGAGAGCCGCCCGG 450
 QY 303 AGCCAGACGAGAGGAGAAAGGCTTTCAATGATTTCTATTCACAAAGATAACACCAATTTT 362
 Db 451 AGCCAGACGAGAGGAGAAAGGCTTTCAATGATTTCTATTCACAAAGATAACACCAATTTT 510

ORGANISM: Homo Sapiens
US-09-202-088A-1

Query Match 98.1%; Score 2132.6; DB 4; Length 2290;
Best Local Similarity 99.8%; Pred. No. 0;
Matches 2135; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

3 AAATAGAGCTGCTGCGAGCGGCTTGAAGATGAACCCCAAGCCCTGAGCTGCGAGCTG 62
151 AATATAGAGCTGCTGCGAGCGGCTTGAAGATGAACCCCAAGCCCTGAGCTGCGAGCTG 210
63 GCACTGAGGCGAGCGGCTGAGCTGCTGCTGAGGAGAAAGGTTGTGAGCAGCCCGCAGG 122
211 GCACTGAGGCGAGCGGCTGAGCTGCTGCTGAGGAGAAAGGTTGTGAGCAGCCCGCAGG 270
123 ACCCTGAGGCGAGCGGCTGAGCTGCTGCTGAGGAGGAGGAGGAGGAGGAGGAGGAGG 182
271 ACCCTGAGGCGAGCGGCTGAGCTGCTGCTGAGGAGGAGGAGGAGGAGGAGGAGGAGG 330
183 GAGCCGAGTGAAGCGAGGCTGCTGCTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 242
331 GAGCCGAGTGAAGCGAGGCTGCTGCTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 390
243 AGGCGATGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 302
391 AGGCGATGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 450
303 AGCCAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 362
451 AGCCAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 510
363 GCAAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 422
511 GCAAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 570
423 GAGGCTGTTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 482
571 GAGGCTGTTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 630
483 TTCAATTTAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 542
631 TTCAATTTAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 690
543 TTCAATTTAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 602
691 TTCAATTTAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 750
603 GTGCTTCTGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 662
751 GTGCTTCTGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 810
663 AAGCAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 722
811 AAGCAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 870
723 AGCGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 782
871 AGCGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 930
783 TACATGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 842
931 TACATGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 990
843 CTGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 902
991 CTGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1050
903 GACCTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 962
1051 GACCTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1110
963 GGGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1022

1111 GCGGAGCTTGAAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1170
1023 CCGGCTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1082
1171 CCGGCTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1230
1083 TCTACAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1142
1231 TCTACAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1290
1143 ATGCCCCCTCTCACAGGCTTCCATCTTCCACGAGCAGCCGCTGCGGAGGAGGAGGAGGAGG 1202
1291 ATGCCCCCTCTCACAGGCTTCCATCTTCCACGAGCAGCCGCTGCGGAGGAGGAGGAGGAGG 1350
1203 TGCCCTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1262
1351 TGCCCTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1410
1263 AACACAAACCGCTCATGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1322
1411 AACACAAACCGCTCATGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1470
1323 GTCAATCAGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1382
1471 GTCAATCAGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1530
1383 CAAGG 1442
1531 CAAGG 1590
1443 ACGAAGCAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1502
1591 ACGAAGCAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1550
1503 TTTCGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1562
1651 TTTCGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1710
1563 GGGGCTTACATGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1622
1711 GGGGCTTACATGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1770
1623 ACCCTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1682
1771 ACCCTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1830
1683 TGGTGTATTAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1742
1831 TGGTGTATTAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1890
1743 TACCGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1802
1891 TACCGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1950
1803 CTCAAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1862
1951 CTCAAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 2010
1863 CCTCTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1922
2011 CCTCTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 2070
1923 AAAGAACTCTCTCAACAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1982
2071 AAAGAACTCTCTCAACAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 2130
1983 TTTCGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 2042
2131 TTTCGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 2190
2043 TACTTTGCTTCAACAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 2102
2191 TACTTTGCTTCAACAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 2250

QY 2103 CTCCTTCTTAATAATTAGTCTCTACATATAACCA 2141
DB 2251 CTCCTTCTTAATAATTAGTCTCTACATATAACCA 2289

RESULT 9

US-09-333-077-1
Sequence 1, Application US/09333077
Patent No. 6586397
GENERAL INFORMATION:
APPLICANT: Godowski, Paul J.
APPLICANT: Gudney, Austin L.
TITLE OF INVENTION: Tie ligands
NUMBER OF SEQUENCES: 17
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genentech, Inc.
STREET: 1 DNA Way
CITY: South San Francisco
STATE: California
COUNTRY: USA
ZIP: 94080
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Winpatin (Genentech)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/333,077
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/933,821
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Dreger, Ginger R.
REGISTRATION NUMBER: 33,055
REFERENCE/DOCKET NUMBER: P1130
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650/952-9881
TELEFAX: 650/225-3216
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 2290 base pairs
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
US-09-333-077-1

Query Match 98.1%; Score 2132.6; DB 4; Length 2290;
Best Local Similarity 99.8%; Pred. No. 0;
Matches 2135; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 3 AATGAGGCTGCTGGGAGAGGCTGAGATGAACCCCAAGCCCTGAGACCTGCGGAGCTG 62
DB 151 AATGAGGCTGCTGGGAGAGGCTGAGATGAACCCCAAGCCCTGAGACCTGCGGAGCTG 210
QY 63 GCACTAGGAGCAGCGGCTGACGCTACTGTGAGGAGAAAGAGTTGTAGCAAGCCCGCAGG 122
DB 211 GCACTAGGAGCAGCGGCTGACGCTACTGTGAGGAGAAAGAGTTGTAGCAAGCCCGCAGG 270
QY 123 AACCCTGGGACAGCCCTGGGCGCCAGGCTCTGCGGAGAGCCCTCTGTGAGAGGAGAGCAGTG 182
DB 271 AACCCTGGGACAGCCCTGGGCGCCAGGCTCTGCGGAGAGCCCTCTGTGAGAGGAGAGCAGTG 330
QY 183 GAGCCAGTGAAGGAGGAGGCTGCTGAGCAAGCCAGCCCTGCAACTCAGAAACCCCTCCAG 242
DB 331 GAGCCAGTGAAGGAGGAGGCTGCTGAGCAAGCCAGCCCTGCAACTCAGAAACCCCTCCAG 390
QY 243 AGGCCATGAGAGGCTGCGCCGCTGAAGCCAGGAGTGAAGCATGTGAGAGAGCCGCGCCGG 302
DB 391 AGGCCATGAGAGGCTGCGCCGCTGAAGCCAGGAGTGAAGCATGTGAGAGAGCCGCGCCGG 450

QY 303 AGCCAGCAGGAGGAGGAGGAGGCTTCATGATTCCTATTGCAAAAGATATACCATTTT 362
DB 451 AGCCAGCAGGAGGAGGAGGAGGCTTCATGATTCCTATTGCAAAAGATATACCATTTT 510
QY 363 GCAAGAGCATGAGGAGGAGGAGGCTTCATGATTCCTATTGCAAAAGATATACCATTTT 422
DB 511 GCAAGAGCATGAGGAGGAGGAGGCTTCATGATTCCTATTGCAAAAGATATACCATTTT 570
QY 423 GAGGCTGTTGAGGAGGAGGAGGCTTCATGATTCCTATTGCAAAAGATATACCATTTT 482
DB 571 GAGGCTGTTGAGGAGGAGGAGGCTTCATGATTCCTATTGCAAAAGATATACCATTTT 630
QY 483 TTCAATTTACCTAAACAGTACAGGAGGAGGAGGCTTCATGATTCCTATTGCAAAAGATATACCATTTT 542
DB 631 TTCAATTTACCTAAACAGTACAGGAGGAGGAGGCTTCATGATTCCTATTGCAAAAGATATACCATTTT 690
QY 543 TTCAATTTGCTGAGGAGGAGGAGGCTTCATGATTCCTATTGCAAAAGATATACCATTTT 602
DB 691 TTCAATTTGCTGAGGAGGAGGAGGCTTCATGATTCCTATTGCAAAAGATATACCATTTT 750
QY 603 GTGCTTCTGAGAGAGGAGGAGGAGGCTTCATGATTCCTATTGCAAAAGATATACCATTTT 662
DB 751 GTGCTTCTGAGAGAGGAGGAGGAGGCTTCATGATTCCTATTGCAAAAGATATACCATTTT 810
QY 663 AAGCAGAGGAGGAGGAGGAGGCTTCATGATTCCTATTGCAAAAGATATACCATTTT 722
DB 811 AAGCAGAGGAGGAGGAGGAGGCTTCATGATTCCTATTGCAAAAGATATACCATTTT 870
QY 723 AAGCAGAGGAGGAGGAGGAGGCTTCATGATTCCTATTGCAAAAGATATACCATTTT 782
DB 871 AAGCAGAGGAGGAGGAGGAGGCTTCATGATTCCTATTGCAAAAGATATACCATTTT 930
QY 783 TACATGAGGAGGAGGAGGAGGCTTCATGATTCCTATTGCAAAAGATATACCATTTT 842
DB 931 TACATGAGGAGGAGGAGGAGGCTTCATGATTCCTATTGCAAAAGATATACCATTTT 990
QY 843 CTGAGAGAGGAGGAGGAGGCTTCATGATTCCTATTGCAAAAGATATACCATTTT 902
DB 991 CTGAGAGAGGAGGAGGAGGCTTCATGATTCCTATTGCAAAAGATATACCATTTT 1050
QY 903 GACCTGAGAGGAGGAGGAGGCTTCATGATTCCTATTGCAAAAGATATACCATTTT 962
DB 1051 GACCTGAGAGGAGGAGGAGGCTTCATGATTCCTATTGCAAAAGATATACCATTTT 1110
QY 963 GCGCAGGAGGAGGAGGAGGCTTCATGATTCCTATTGCAAAAGATATACCATTTT 1022
DB 1111 GCGCAGGAGGAGGAGGAGGCTTCATGATTCCTATTGCAAAAGATATACCATTTT 1170
QY 1023 CCGGCTGAGGAGGAGGAGGCTTCATGATTCCTATTGCAAAAGATATACCATTTT 1082
DB 1171 CCGGCTGAGGAGGAGGAGGCTTCATGATTCCTATTGCAAAAGATATACCATTTT 1230
QY 1083 TCTACCAAGAGATCCAGAGTACAGAACTGAGAGTCTGCAACCCCTCTGCGCACT 1142
DB 1231 TCTACCAAGAGATCCAGAGTACAGAACTGAGAGTCTGCAACCCCTCTGCGCACT 1290
QY 1143 ATGCCCACTGCAAGAGGCTTCATGATTCCTATTGCAAAAGATATACCATTTT 1202
DB 1291 ATGCCCACTGCAAGAGGCTTCATGATTCCTATTGCAAAAGATATACCATTTT 1350
QY 1203 TGCCTGAGGAGGAGGAGGCTTCATGATTCCTATTGCAAAAGATATACCATTTT 1262
DB 1351 TGCCTGAGGAGGAGGAGGCTTCATGATTCCTATTGCAAAAGATATACCATTTT 1410
QY 1263 AACACCAACCGCTCATGAGGAGTGTGTCGACAGAGCAAGACCAAGCCCGGAGGAGTGAAC 1322
DB 1411 AACACCAACCGCTCATGAGGAGTGTGTCGACAGAGCAAGACCAAGCCCGGAGGAGTGAAC 1470
QY 1323 GTCATCCAGAGAGGCTTCATGATTCCTATTGCAAAAGATATACCATTTT 1382
DB 1471 GTCATCCAGAGAGGCTTCATGATTCCTATTGCAAAAGATATACCATTTT 1530
QY 1383 CAAGGAGTTGGAGACATGAGGAGTACTGAGGAGTGTGAGAGACATTTACTGAGCTG 1442

QY 1525 GCTGGAACCTGAGAGCGATGATTATTAAGCTGCGGCTGGGCGGCTACCATGGAATGCGG 1584
 Db 1608 GTCTGGAACCTGGAAGTGAATTCATATAGACTGGCCCTGGGAATTTACAGGAAATGACG 1667
 QY 1555 GTGACTCTTTACATGACACACCGGCAAGGTTTACCACTTGGACAGATGATATGATG 1644
 Db 1668 GGGATTCTATGATGCGATATGATGTAACCAATTCACACACTGACAGAGATTAAGATA 1727
 QY 1645 TCTACAGAGAACTGTGCTCCCACTACACAGAGAGAGGCTGTGATTAACGCTGTGCCC 1704
 Db 1728 TGTATGACGAGAACTGCCCCCACTTCTATTAAGAGAGGCTGTGATGATGATGATG 1787
 QY 1705 ACTCCACCTTCAACGGGCTGTGATACCGCGGCGCATTTACCGAGCGCTACAGAGC 1764
 Db 1788 ATTCTAACCTTAATGAGTATGATGTAACAGAGAGGCGCATTTACAGAGAGCAGCAGATG 1847
 QY 1755 GAGTCTACGAGGCTGAGTTCCGAGAGGCTCTTACTCACTCAAGAAATGATGATGATG 1824
 Db 1848 GAATTTCTGGGCGCAATACAGAGGCGGCTACTCTCTTAAGACAGCTTCAATGATG 1907
 QY 1825 TCCGACCGA 1833
 Db 1908 TCAAGCTTA 1916

RESULT 13

US-09-332-928A-3
 Sequence 3, Application US/09332928A
 Patent No. 6368853

GENERAL INFORMATION:

APPLICANT: Godowski, Paul J.
 Garney, Austin L.
 TITLE OF INVENTION: Tie Ligands
 NUMBER OF SEQUENCES: 17
 CORRESPONDENCE ADDRESS:
 ADDRESSES: Genentech, Inc.
 STREET: 1 DNA Way
 CITY: South San Francisco
 STATE: California
 COUNTRY: USA

ZIP: 94080

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Winpatin (Genentech)

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/332,928A

FILING DATE: 14-Jun-1999

CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/933,821

FILING DATE: <Unknown>

ATTORNEY/AGENT INFORMATION:

NAME: Dreger, Ginger R.

REGISTRATION NUMBER: 33,055

REFERENCE/DOCKET NUMBER: P1130

TELECOMMUNICATION INFORMATION:

TELEPHONE: 650/225-3216

TELEFAX: 650/952-9881

INFORMATION FOR SEQ ID NO: 3:

SEQUENCE CHARACTERISTICS:

LENGTH: 3355 base pairs

TYPE: Nucleic Acid

STRANDEDNESS: Single

TOPOLOGY: Linear

SEQUENCE DESCRIPTION: SEQ ID NO: 3:

US-09-332-928A-3

Query Match 22.6%; Score 491.8; DB 4; Length 3355;
 Best Local Similarity 62.9%; Pred. No. 1e-105;
 Matches 836; Conservative 0; Mismatches 472; Indels 21; Gaps 4;

QY 526 ACAAGTGCACCTTACACCTTCAATTTGTCCTCCAGCAGCGGGGTACGGGTGCAATCTGCTCA 585
 Db 588 AGAATAATGTCATACATCTTCCTGATCTGTAACAAAGATTAACAGGCGCAATCTGTGTCA 647
 QY 586 ACTCCAGAGGCTGAGGCTTC---TGAAGAACCGAGTGCATTAAGCAGAGAGCTAGAGC 642
 Db 648 AACACAGGCGCAAGATGCAATTAACATTAAGATATATACACAGATGAGACCTTGAAA 707
 QY 643 TGTCAACAAATGAGCTGCTCAAGCAAGAACGGCAGATGAGACCTGCAAGCCTGTGCA 702
 Db 708 ACTGAGAGATGTGCTCTCCAGGCAAGACGGGAATGATGTTCTGCAACTGTGGTGTG 767
 QY 703 AGGTGAGCGGGGCAATGTGAGCGGAGTGAAGCTCTGCGCAAGAGAGCGCAATGA 762
 Db 768 ATGTATATGAGAAACATTTGATGATGATGATGATGATGATGATGATGATGATGATG 827
 QY 763 ACTGCGGCTCAACGAGCTTACATGACAGCTCTGACAGATATCCGCAAGCGGCA 822
 Db 828 ACTCTGTGTACTCACTCTATGATGATGATGATGATGATGATGATGATGATGATG 887
 QY 823 ACGGTTGAGCTTCTCCAGCTGAGAAACAGATCTCTGACACGACGCGCATGTGCG 882
 Db 888 ATTCACTTGAACCTTCCCACTGAGAAACAAATCTCAATGTCCACACAGAAATGTGA 947
 QY 883 AGCTGCGCAGAGTACAAAGACCTGAGACACAGTACAGACCTGCGCACACTGAGCC 942
 Db 948 AGATGCGCAACAGATACAGGGAACCTAGAGGTGAATAGCTTCTTGAATGATGATG 1007
 QY 943 ACAACCAATGAGATATGCGCAGCTTGAAGAGACCTGCGAGAGGCTGCGGCA 1002
 Db 1008 ATAAACCAATGTGATGATGATGATGATGATGATGATGATGATGATGATGATG 1067
 QY 1003 GGGCGGTCCCGACGACCGCCCGGCTGCGCGC-----CCCGGGTCTACCAACACCC 1055
 Db 1068 AAGACACCATGTGTCTCCCACTTGTCCAGTGTGTCACAAATATCTTAACAGCG 1127
 QY 1056 ACCTACACCGCATATCAACAGATCTTCAACACAGATCAAGATGACAGAACTG 1115
 Db 1128 AACAGTATCTCTGTGTGTGAGAGGTAAAGAAATTCAGAGGATCCAGGTTATCCA 1187
 QY 1116 AAGC-----TGTGCGCACCCCTGCGCCACTGATGCGCCACTCTCAACAGCTC-----C 1164
 Db 1188 GAAATTAAGTACACACCTGATCTGGAACCTTCTCCACCAAAAGCCCTTCAAGATAC 1247
 QY 1165 CATCTTCAACCGACGACCGGCGGCGCAATGAGAGACTGCTGAGCGCTGAGAGATG 1224
 Db 1248 CACCGGTAACCTTCAATCAATGAGAGCAATTCAGAGACTGTCAGAGCAAGAAAGAGCTG 1307
 QY 1225 GCGACAGACAGCTCATCTACCTGTGTAAGCCGAGAAACCAACGCGCTCATGCGAG 1284
 Db 1308 GGCATTCGCTCACTGAGTATTAATGATTAACCTGAAACAGCAATGCAATGCACT 1367
 QY 1285 TGTGTGCGACAGAGACGACGACCGCGGGGCTGACCTGATCCAGAGACCGCTGATG 1344
 Db 1368 TATGTGTGAAAACAATTTGAGACCTGCGGGTTGAGCTGTATTCAGAAAAGACAGAG 1427
 QY 1345 GCTCTGTAACTTCTTCAAGAACTGGGAGACGTAACAGAAAGGTTTGGGAATTTGAG 1404
 Db 1428 GCTCTGTCAACTTCTTCAAGAAATTTGGAAATTTAAGAAAGGTTTGGAAACATTTGAG 1487
 QY 1405 GCGAATACGCGCTGAGGCTGAGAACTTACTGTGCTGAGCAACAGGCAACTACAAAC 1464
 Db 1488 GAGAAATACGCTTGTGAGCTGAGAAATATCTATATGTTGCAATGAGTAATTTCAAGT 1547
 QY 1465 TCTGTGTGACATGAGAGATGCTGCGCGGCAAACTCTTTGCAAGATGCGCAATTTCC 1524
 Db 1548 TATTTGATGATTAAGAGACTGAGATGATTAAGAAAGTCTATGCAAGATGACAGAGTTTC 1607
 QY 1525 GCTGGAACCTGAGAGCGATATTAAGACTGCGGCTGAGAGAGCGGCTACATGCAATGCGG 1584
 Db 1608 GTCTGGAACCTGGAAGTGAATTCATATAGACTGGCCCTGGGAATTTACAGGAAATGACG 1667
 QY 1585 GTGACTCTTTACATGACACACCGGCAAGGTTTACCACTTGGACAGATGATATGATG 1644

Db 1668 GGGATTCTATGATGTGGCATTAATGTAACCAATTACCCACTGGACAGAGATAAGATA 1727
 Qy 1645 TCTACACAGGAAGTGTGCTCCACTACAGAGAGAGGCTGTGTATTAAGCTTGTGCC 1704
 Db 1728 TGTATGCGAGAACTGCGCCCACTTTCATTAAGAGAGGCTGTGTATCAATGCTGTGCAC 1787
 Qy 1705 ACTCCAACTCAACGGGCTGTGTACCGCGGGGCGCATTAACGAGCGGCTACAGAGC 1764
 Db 1788 ATTCTAATTAATGAGATATGTACAGAGAGCGCATTAACAGACCAAGCATG 1847
 Qy 1765 GAGTCTACTGGGCTGATGCTCCAGAGAGGCTCTTACTCACTCAAGAAAGTGATGATGA 1824
 Db 1848 GAATTTTCTGGGCGCAATACAGAGGCGGCTACTCTTAAGAGCAGTTGATGATGA 1907
 Qy 1825 TCCGACCGA 1833
 Db 1908 TCAGCCTTA 1916

RESULT 14

US-09-136-801-3
 ; Sequence 3, Application US/09136801
 ; Patent No. 6413770

GENERAL INFORMATION:

APPLICANT: Godowski, Paul J.
 APPLICANT: Gurney, Austin
 APPLICANT: Hillan, Kenneth
 APPLICANT: Botstein, David
 APPLICANT: Goddard, Audrey
 APPLICANT: Roy, Margaret
 APPLICANT: Ferrara, Napoleone
 APPLICANT: Tumas, Daniel
 APPLICANT: Schwall, Ralph
 TITLE OF INVENTION: Tie Ligand Homologues
 NUMBER OF SEQUENCES: 35
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Genentech, Inc.
 STREET: 1 DNA Way
 CITY: South San Francisco
 STATE: California
 COUNTRY: USA
 ZIP: 94080
 COMPUTER READABLE FORM:
 MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: WinPatIn (Genentech)
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/09/136,801
 FILING DATE:
 CLASSIFICATION:
 ATTORNEY/AGENT INFORMATION:
 NAME: Dreger, Ginger R.
 REGISTRATION NUMBER: 33,055
 REFERENCE/DOCKET NUMBER: P1130P2
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 650/225-3216
 TELEFAX: 650/952-9881
 INFORMATION FOR SEQ ID NO: 3:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 3355 base pairs
 TYPE: Nucleic Acid
 STRANDEDNESS: Single
 TOPOLOGY: Linear

US-09-136-801-3

Query Match 22.6%; Score 491.8; DB 4; Length 3355;
 Best Local Similarity 62.9%; Pred.No. 1e-105;
 Matches 836; Conservative 0; Mismatches 472; Indels 21; Gaps 4;

Qy 526 ACAAGTGAACCTTCACTTGTGCCCCAGACGGGCTCAACGGGCTTGTGCTCA 585

Db 588 AGAATGTCATACATTCCTGTGACCTGAACAAAGATTAACAGGGCCAATGTGTCA 647
 Qy 586 ACTCCAGAGAGCTGAGGTCTTC---TGAGAACCCAGATGTCATTAAGAGCTAGAGC 642
 Db 648 ACACCAAGGGGCAAGAGAGATACCAATTAAGACATGATCACCGATGAGACCTTGAAA 707
 Qy 643 TGCTCAACATGAGCTGCTCAAGAGAGGCGGATCGAGCGCTCAGAGCTGTGTA 702
 Db 708 ACCGAAAGATGTCTCTCCAGCAGAGCGGAGATAGATGTTTCTGCACTGTGTGG 767
 Qy 703 AGGTGACGCGGCAATTTGTAGCGAGGTGAAGCTGTGCGCAAGAGAGCCGCAATGA 762
 Db 768 ATGTAGATGAGAACTGTGATGAGGTAAAGCTGTGAGAAAGAGGCGTAAACATGA 827
 Qy 763 ACTGGGGGTCAAGAGCTCTAATGAGTCTCTGCAAGATCATCCGGAACCGGAGCA 822
 Db 828 ACTCTGTGTACTCACTCTATATGCAATTAATTAATGAGATTAATCCGTAAGGGATA 887
 Qy 823 ACGGTTGAGGCTCTCCAGCTGAGAACAGATCTGAACAGACAGCCGCAATGCTGC 882
 Db 888 ATTCATTGAACCTTCCCACTGGAAAACAAATTCCTCAATGTCAACAGAAATGTGA 947
 Qy 883 AGCTGGCCAGCAATTAAGAGCTGTGAGACAGATCCAGACCTGTGCGCACTGCGCC 942
 Db 948 AGATGGCAACAAAGTACAGAGGAATGAGGTGAATACGCTTCTTGACTGATCTGTCA 1007
 Qy 943 ACAACCAATCAGAGATCATGCGCAGCTTGAGAGCACTCCAGAGGCTGCCCGCA 1002
 Db 1008 ATTAACCAATCTGTGATATATCACTTTGTGAAAGAACAGTCTTGAGATATTTTCCGAC 1067
 Qy 1003 GGGCCGTCCCAAGCAACCCCGCTGCGCCG-----CCCGGGTCTTCAACCAACC 1055
 Db 1068 AAGCAACCATGTGTCTCCCACTTGTCCAGGTGTGCCAACAAATATCTTAACAGCC 1127
 Qy 1056 ACCTACAGCGCAATCAACCAAGATCTTACCAAGATCCAGATGACCAAGACTG 1115
 Db 1128 AACGATTAATCTCTGCTGTGTGTGAGAGTACAGATTAAGAGGATCCAGTTATCCA 1187
 Qy 1116 AAGG-----TGCTGCCAACCCTCTGCGCACTATGCGCACTTACAGAGCTC-----C 1164
 Db 1188 GAGATTAATGCGACCACTGATCTGCAACTTCTCCACAAAGCCCTTCAAGATAC 1247
 Qy 1165 CATCTTCCACCGAAGCCGCTCGGCGCCATGAGAGATCTGCGAGGCTGTGAGATG 1224
 Db 1248 CACCGTAATCTTATCAATGAAGAACCAATTAACATGTCGACAAAGCAAGAGCTG 1307
 Qy 1225 GCAACGACACAGCTCCATCTACCTGTGAGCGGAGAACACCAACCGCTCATGAGG 1284
 Db 1308 GGCATTGCGTCAATGGGATTTATATGATTAACCTGAAACAGCAATGACCAATGCAGT 1367
 Qy 1285 TGTGTGCGACAGAGACGAGACCCCGGGGGCTGACCGTATCCAGAGCGCTGATG 1344
 Db 1368 TATGTGTGAAAACAGTTGGAACCTGCGGGGTGGACTGTATTCAGAAAAGACAGAG 1427
 Qy 1345 GCTCTGTAATCTTCTCAGAGACTGGAGACGACAGCAAGGCTTGGAGAACTATGAGC 1404
 Db 1428 GCTCTGCAACTCTTTCAGAAATTGGAAATTAATTAAGAAAGGTTTGGAAACATTTGACG 1487
 Qy 1405 GCGAATACGTGCTGGGCTTGAGAACATTTACTGTGTCGAAACCAAGGCACTACAAAC 1464
 Db 1488 GAGAAATACGTGCTGAGCAAGAAATATCTATGTGCTTGAATCAAGATTAATCAAGT 1547
 Qy 1465 TCGTGGAGCAATGAGAGAGTGTGCGGCGCAAAATCTTTGAGAAATGCGCAGTTCC 1524
 Db 1548 TATTTGATTAATTAAGAGCTGAGTGAATTAAGAAATGCTATGAGATACAGACCTTTC 1607
 Qy 1525 GCCTGGAACCTGAGACGAGATTTATTAAGCTGTGCGGCTGAGCCCTTCAATGCAATGCG 1584
 Db 1608 GTCTGGAACCTGAAGATTAATTAAGACTGTGCGGCTGAGAACTTACAGAGGAAATGAG 1667
 Qy 1585 GTGACTCTTTAATGAGCAACGAGCAAGCTTCAACCTGTCGACAGAGATCAATGATG 1644
 Db 1668 GGGATTCTATGATGTGCAATTAATGTAACCAATTCACCACTGACAGAGATTAAGATA 1727

QY 1645 TCTACACGAAACTGTGCTCCCACTACGAGAGAGGCTGTGTATTAACGCTGTGCCC 1704
DB 1728 TGTATGACGAGAACTGCGCCCACTTCTATTAAGAGAGCTGTGTATGCTGTGTAC 1787
QY 1705 ACTCCAACTCAACGCGGCTGTGTATCCGCGGCGCACTTACCGAGCCGCTACGAGAGC 1764
DB 1788 ATTCTAACCTTAATGTAGATATGTATGATACAGAGAGGCACTTACAGAGACCAAGATG 1847
QY 1765 GAGTCTACTGCGCTGAGTTCGAGAGAGGCTTCTACTACTCAAGAAAGTGTATGTGA 1824
DB 1848 GAAATTTCTGCGCGCCGATACAGAGCGGCTACTCTCTTAAGACAGTTCAGATGTGA 1907
QY 1825 TCCGACCGA 1833
DB 1908 TCAAGCTTA 1916

RESULT 15

US-09-332-929-3
Sequence 3, Application US/09332929

Patent No. 6420542
GENERAL INFORMATION:

APPLICANT: Godowski, Paul J.
APPLICANT: Gurney, Austin L.

TITLE OF INVENTION: Tie Ligands
NUMBER OF SEQUENCES: 17

CORRESPONDENCE ADDRESS:
ADDRESSEE: Genentech, Inc.

STREET: 1 DNA Way
CITY: South San Francisco

STATE: California
COUNTRY: USA

ZIP: 94080

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk

OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Winpatin (Genentech)

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/332,929

FILING DATE:
CLASSIFICATION:

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/933,821

FILING DATE:
ATTORNEY/AGENT INFORMATION:

NAME: Dregar, Ginger R.
REGISTRATION NUMBER: 33,055

REFERENCE/DOCKET NUMBER: P1130
TELECOMMUNICATION INFORMATION:

TELEPHONE: 650/225-3216
TELEFAX: 650/952-9881

INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:

LENGTH: 355 base pairs
TYPE: Nucleic Acid

STRANDEDNESS: Single
TOPOLOGY: Linear

US-09-332-929-3

Query Match 22.6%; Score 491.8; DB 4; Length 3355;
Best Local Similarity 62.9%; Pred. No. 1e-105;
Matches 836; Conservative 0; Mismatches 472; Indels 21; Gaps 4;

QY 526 ACAAGTACCTCAACCTTCAATGTGCCCCAGACCGGGTCAAGGGTCCATCTGCGTCA 585
DB 588 AGAAATGTGATACATCTCTGTACCTGAACAAGAAATACAGGGCAATCTGTGTCA 647
QY 586 ACTCCAGAGAGCTGAGTGTCTTC---TGGAGAACGAGTGCATTAAGAGAGGCTAGAGC 642
DB 648 ACACCAAGGGGAGATGCAAGTACCATTAAGACATGATCACCGAGATGAACCTTGAAA 707

QY 643 TGTCAACAATGAGTGTCTCAAGCAGAAAGCGAGATGAGACGCTGACAGACTGTGA 702
DB 708 ACTGAGAGATGTGCTCTCAGGACAGAGCGGAGATATGATGTCTGCAACTGTGTGG 767
QY 703 AGGTGACCGCGCATTTGTGACGAGTGAAGTCTCTCGCAAGAGAGCGGCAATGA 762
DB 768 ATGTAGATGAAACATGTGAATGAGTAACTCTGAGAAAGGAGGCTTAACATGA 827
QY 763 ACTGCGGCTCAGCAGCTCTACATGACAGCTCTGACAGATTCATCCGCAAGCGGCA 822
DB 828 ACTCTGTGTACTCACTCTATATGCAATTTATACATGAGATTTATCCGTAAAGAGATA 887
QY 823 AGCGTTGAGCTCTCCAGCTGTGAGAACAGATCTTGAACCAAGACAGCCATGCTGC 882
DB 888 ATCACTTGAATCTTCCCACTGGAACCAATCTCTCATCTCAACAGAAATGTGA 947
QY 883 AGCTGCGCAGCAAGTACAGAGACTGAGACCAAGATACAGCACTGTGCGCACTGCGCC 942
DB 948 AGATGCAACAGATACAGGAACTTAGAGTGAATACGCTTCTTGAATGATCTGTGA 1007
QY 943 ACAACCAATCAGAGATCATGCGCAGCTTGAAGAGCACTGCCAGAGGCTGCGGCA 1002
DB 1008 ATACCAATCTGTGATGATCACTTGTGGAAGAACAGTGTGAGGATATTTCCGAC 1067
QY 1003 GCGCCGTCGCCAGACCCCGCGCTGCGCCG-----CGCGGCTACCAACACCC 1055
DB 1068 AAGACACCATGTGTCTCCCACTTGTACAGGTGTGACCAACATATCTTAACAGC 1127
QY 1056 ACCTACACCGCATCATCAACCAAGATCTTACCAACAGATCCAGATGACCAAGCTG 1115
DB 1128 AACAGATATCTCTGTGTGTGAGAGTAAAGATTAAGAGGATCCAGGATATCCCA 1187
QY 1116 AAG-----TGTGCGCAACCCCTCTGCGCACTATGCGCATCTCAACAGCTC-----C 1164
DB 1188 GAAATTTAATGCGACACCTGATCTGCAACTCTTCCCAACAAAGCCTTTCAAGATC 1247
QY 1165 CATCTTCAACCGACAGACCGCTGCGGCGCATGAGAGACTGCTGAGGCGCTGAGAGT 1224
DB 1248 CACCGGTAATCTTCAATCAATGAAGACATTAAGAGCTGTACGAGAGAAAGAGCTG 1307
QY 1225 GCCAGACACCACTTCATCTACTGTGTAAAGCGGAGAACCAACCGCTCATGACG 1284
DB 1308 GGCATTCGGTCAAGTGGATTTATATGATTAACCTGTAAACAGCAATGACCAATGCA 1367
QY 1285 TGTGTGCGACCAAGACAGACCGCGGGGCTGAGCGCTCATCCAGAGACGCTGAGT 1344
DB 1368 TATGTGTGAAACAGCTTTGACCTGTGGGCTTGAATCTTTATGAAAGAAACAGAG 1427
QY 1345 GCTGTGTAATCTTCAAGAACTGAGACGTACAGCAAGCGTTTGGAACTTTGACG 1404
DB 1428 GCTGTGCAACTCTTCAAGAAATTTGAAATTTAAGAAAGGTTTGGAAACATTTGAG 1487
QY 1405 GCGAATATCTGCTGGGCTGTGAGAAATTTACTGTGTGACCAAGGCACTCAAC 1464
DB 1488 GAGAAATACGCTGTGAGAAATATCTATATGTGTGCAATCAAGATTAATTAACAT 1547
QY 1465 TCTGTGACCATGAGAGACTGTGCGCGGCAAGTCTTTGAGATTAAGCAAGTTTCC 1524
DB 1548 TATTGATGATTAAGAACTGAGATGATTAAGAAATCTATGAGATTAACAGAGCTTTC 1607
QY 1525 GCTGGAACCTGAGAGCGATTAATTAAGCTGTGCGGCTGAGGCTTACATGCAATGCG 1584
DB 1608 GTCTGGAACCTGAAATGATTAATTAAGCTGTGAGGCTTGAACCTTACAGGAAATGCA 1667
QY 1585 GTGACCTCTTACATGAGCAACGCAAGAGTTCACCACTGTGACAGAGATCATGATG 1644
DB 1668 GGAATTTGTATGATGTGATTAAGTAAATTAATTAATTAATTAATTAATTAATTA 1727
QY 1645 TCTACACGAGAACTGTGCCACTACCAAGAGAGGCTGTGTGTAAAGCTGTGCGCC 1704
DB 1728 TGTATGAGAGAACTGCGCCACTTTCATTAAGAGAGGCTGTGTGTAAAGCTGTGCGAC 1787
QY 1705 ACTCCAACTCAACGCGGCTGTGTACCGGGGCGCACTTAACGGAACGCGCTACAGAGC 1764

Mon Aug 9 10:30:08 2004

us-10-018-386-1.rni

Page 19

Db	1788	ATTCTAACCTAAATGAGATATGTTACAGAGAGGCCATTACAGAAAGCAAGCACCAAGATG	1847
QY	1765	GAGTCTACTGGGCTGAGTTCCGAGGAGGCTTTACTCACTCAAGAAAGTGTGATGATGA	1824
Db	1848	GAATTTCTGGGGCGAATACAGAGCGGGTCACTACTCTTAAGAGCAGTTTCAGATGATGA	1907
QY	1825	TCCGACCGA	1833
Db	1908	TCAAGCCTA	1916

Search completed: August 6, 2004, 18:18:56
Job time : 172 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Comugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 6, 2004, 16:43:28 ; Search time 976 Seconds
(without alignments)
10916.520 Million cell updates/sec

Title: US-10-018-386-1
Perfect score: 2173
Sequence: 1 gaaatgagctgctgcgga.....aaaaaaaaaaaaaaaaaa 2173

Scoring table: IDENTITY NUC
Gapop 10.0, Gapext 1.0

Searched: 3222919 seqs, 2451570024 residues

Total number of hits satisfying chosen parameters: 6445838

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database: / Published Applications NA:*

- 1: /cgn2_6/ptodata/1/pubpna/US07_PUBCOMB.seq:*
- 2: /cgn2_6/ptodata/1/pubpna/ECT_NEW_PUB.seq:*
- 3: /cgn2_6/ptodata/1/pubpna/US06_NEW_PUB.seq:*
- 4: /cgn2_6/ptodata/1/pubpna/US06_PUBCOMB.seq:*
- 5: /cgn2_6/ptodata/1/pubpna/US07_NEW_PUB.seq:*
- 6: /cgn2_6/ptodata/1/pubpna/ECTUS_PUBCOMB.seq:*
- 7: /cgn2_6/ptodata/1/pubpna/US08_NEW_PUB.seq:*
- 8: /cgn2_6/ptodata/1/pubpna/US08_PUBCOMB.seq:*
- 9: /cgn2_6/ptodata/1/pubpna/US09A_PUBCOMB.seq:*
- 10: /cgn2_6/ptodata/1/pubpna/US09B_PUBCOMB.seq:*
- 11: /cgn2_6/ptodata/1/pubpna/US09C_PUBCOMB.seq:*
- 12: /cgn2_6/ptodata/1/pubpna/US09_NEW_PUB.seq:*
- 13: /cgn2_6/ptodata/1/pubpna/US09_PUBCOMB.seq:*
- 14: /cgn2_6/ptodata/1/pubpna/US10A_PUBCOMB.seq:*
- 15: /cgn2_6/ptodata/1/pubpna/US10B_PUBCOMB.seq:*
- 16: /cgn2_6/ptodata/1/pubpna/US10C_PUBCOMB.seq:*
- 17: /cgn2_6/ptodata/1/pubpna/US10_NEW_PUB.seq:*
- 18: /cgn2_6/ptodata/1/pubpna/US60_NEW_PUB.seq:*
- 19: /cgn2_6/ptodata/1/pubpna/US60_PUBCOMB.seq:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	2146.2	98.8	2288	9 US-09-818-143-11	Sequence 11, Appl
2	2132.6	98.1	2290	13 US-10-147-493-267	Sequence 267, App
3	2132.6	98.1	2290	13 US-10-145-127-267	Sequence 267, App
4	2132.6	98.1	2290	13 US-10-160-503-267	Sequence 267, App
5	2132.6	98.1	2290	13 US-10-143-118-267	Sequence 267, App
6	2132.6	98.1	2290	13 US-10-144-993-267	Sequence 267, App
7	2132.6	98.1	2290	13 US-10-158-787-267	Sequence 267, App
8	2132.6	98.1	2290	13 US-10-140-024-267	Sequence 267, App
9	2132.6	98.1	2290	13 US-10-140-808-267	Sequence 267, App
10	2132.6	98.1	2290	13 US-10-152-405-267	Sequence 267, App
11	2132.6	98.1	2290	13 US-10-127-852A-267	Sequence 267, App
12	2132.6	98.1	2290	13 US-10-127-900A-267	Sequence 267, App
13	2132.6	98.1	2290	13 US-10-128-685A-267	Sequence 267, App
14	2132.6	98.1	2290	13 US-10-131-820A-267	Sequence 267, App

15	2132.6	98.1	2290	13 US-10-142-886-267	Sequence 267, App
16	2132.6	98.1	2290	13 US-10-146-728-267	Sequence 267, App
17	2132.6	98.1	2290	13 US-10-146-786-267	Sequence 267, App
18	2132.6	98.1	2290	13 US-10-147-499-267	Sequence 267, App
19	2132.6	98.1	2290	13 US-10-157-798-267	Sequence 267, App
20	2132.6	98.1	2290	14 US-10-066-500-3	Sequence 3, Appl
21	2132.6	98.1	2290	15 US-10-028-072-267	Sequence 267, App
22	2132.6	98.1	2290	15 US-10-121-049-267	Sequence 267, App
23	2132.6	98.1	2290	15 US-10-123-904-267	Sequence 267, App
24	2132.6	98.1	2290	15 US-10-140-470-267	Sequence 267, App
25	2132.6	98.1	2290	15 US-10-175-746-267	Sequence 267, App
26	2132.6	98.1	2290	15 US-10-176-918-267	Sequence 267, App
27	2132.6	98.1	2290	15 US-10-176-921-267	Sequence 267, App
28	2132.6	98.1	2290	15 US-10-002-796-3	Sequence 3, Appl
29	2132.6	98.1	2290	15 US-10-066-273-3	Sequence 3, Appl
30	2132.6	98.1	2290	15 US-10-066-494-3	Sequence 3, Appl
31	2132.6	98.1	2290	15 US-10-137-865-267	Sequence 267, App
32	2132.6	98.1	2290	15 US-10-140-474-267	Sequence 267, App
33	2132.6	98.1	2290	15 US-10-142-431-267	Sequence 267, App
34	2132.6	98.1	2290	15 US-10-143-114-267	Sequence 267, App
35	2132.6	98.1	2290	15 US-10-140-002-267	Sequence 267, App
36	2132.6	98.1	2290	15 US-10-066-269-3	Sequence 3, Appl
37	2132.6	98.1	2290	15 US-10-066-211-3	Sequence 3, Appl
38	2132.6	98.1	2290	15 US-10-066-193-3	Sequence 3, Appl
39	2132.6	98.1	2290	15 US-10-142-419-267	Sequence 267, App
40	2132.6	98.1	2290	15 US-10-123-262-267	Sequence 267, App
41	2132.6	98.1	2290	15 US-10-142-423-267	Sequence 267, App
42	2132.6	98.1	2290	15 US-10-121-050-267	Sequence 267, App
43	2132.6	98.1	2290	15 US-10-141-755-267	Sequence 267, App
44	2132.6	98.1	2290	15 US-10-143-032-267	Sequence 267, App
45	2132.6	98.1	2290	15 US-10-123-108-267	Sequence 267, App

ALIGNMENTS

RESULT 1
US-09-818-143-11
Sequence 11, Application US/09818143
Patent No. US20020019000A1
GENERAL INFORMATION:
APPLICANT: Walkers, Michael G.
APPLICANT: Volkmar, Wayne
APPLICANT: Klingler, Tod M.
TITLE OF INVENTION: POLYNUCLEOTIDES COEXRESSED WITH MATRIX-REMODELING GENES
FILE REFERENCE: PB-0004 CIP
CURRENT APPLICATION NUMBER: US/09/818,143
CURRENT FILING DATE: 2001-03-26
NUMBER OF SEQ ID NOS: 23
SOFTWARE: PERL Program
SEQ ID NO 11
LENGTH: 2288
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
OTHER INFORMATION: 2268990CB1
US-09-818-143-11

Query Match 98.8%; Score 2146.2; DB 9; Length 2288;
Best local similarity 99.4%; Pred. No. 0;
Matches 2154; Conservative 0; Mismatches 13; Indels 0; Gaps 0;
QY 3 AAATGAGGCTGCTGGGAGGCGCTGAGGATGAGACCCCAAGCCCTGAGCCCGGAGG 62
DB 73 AATGAGGCTGCTGGGAGGCGCTGAGGATGAGACCCCAAGCCCTGAGCCCGGAGG 132
QY 63 GCACTGAGGAGCGGCTGAGGCTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 122
DB 133 GCACTGAGGAGCGGCTGAGGCTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 192
QY 123 ACCCTGGGAGGCGGCTGAGGCGGCTGAGGCGGAGGCGGCTGAGGAGGAGGAGG 182
DB 193 ACCCTGGGAGGCGGCTGAGGCGGCTGAGGCGGAGGCGGCTGAGGAGGAGGAGG 252

QY 183 GAGCCCATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 242
 DB 253 GAGCCCATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 312
 QY 243 AGGCGATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 302
 DB 313 AGGCGATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 372
 QY 303 AGGCGATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 362
 DB 432 AGGCGATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 492
 QY 423 AGGCGATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 482
 DB 493 AGGCGATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 552
 QY 483 AGGCGATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 542
 DB 553 AGGCGATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 612
 QY 543 AGGCGATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 602
 DB 613 AGGCGATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 672
 QY 603 AGGCGATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 662
 DB 673 AGGCGATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 732
 QY 663 AGGCGATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 722
 DB 733 AGGCGATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 792
 QY 723 AGGCGATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 782
 DB 793 AGGCGATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 852
 QY 783 AGGCGATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 842
 DB 853 AGGCGATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 912
 QY 843 AGGCGATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 902
 DB 913 AGGCGATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 972
 QY 903 AGGCGATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 962
 DB 973 AGGCGATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 1032
 QY 963 AGGCGATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 1022
 DB 1033 AGGCGATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 1092
 QY 1023 AGGCGATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 1082
 DB 1093 AGGCGATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 1152
 QY 1083 AGGCGATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 1142
 DB 1153 AGGCGATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 1212
 QY 1143 AGGCGATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 1202
 DB 1213 AGGCGATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 1272
 QY 1203 AGGCGATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 1262
 DB 1273 AGGCGATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 1332

QY 1263 AACACCAACCGGCTCATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 1322
 DB 1333 AACACCAACCGGCTCATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 1392
 QY 1323 AACACCAACCGGCTCATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 1382
 DB 1393 AACACCAACCGGCTCATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 1452
 QY 1383 AACACCAACCGGCTCATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 1442
 DB 1453 AACACCAACCGGCTCATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 1512
 QY 1443 AACACCAACCGGCTCATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 1502
 DB 1513 AACACCAACCGGCTCATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 1572
 QY 1503 AACACCAACCGGCTCATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 1562
 DB 1573 AACACCAACCGGCTCATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 1632
 QY 1563 AACACCAACCGGCTCATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 1622
 DB 1633 AACACCAACCGGCTCATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 1692
 QY 1623 AACACCAACCGGCTCATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 1682
 DB 1693 AACACCAACCGGCTCATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 1752
 QY 1683 AACACCAACCGGCTCATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 1742
 DB 1753 AACACCAACCGGCTCATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 1812
 QY 1743 AACACCAACCGGCTCATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 1802
 DB 1813 AACACCAACCGGCTCATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 1872
 QY 1803 AACACCAACCGGCTCATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 1862
 DB 1873 AACACCAACCGGCTCATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 1932
 QY 1863 AACACCAACCGGCTCATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 1922
 DB 1933 AACACCAACCGGCTCATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 1992
 QY 1923 AACACCAACCGGCTCATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 1982
 DB 1993 AACACCAACCGGCTCATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 2052
 QY 1983 AACACCAACCGGCTCATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 2042
 DB 2053 AACACCAACCGGCTCATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 2112
 QY 2043 AACACCAACCGGCTCATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 2102
 DB 2113 AACACCAACCGGCTCATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 2172
 QY 2103 AACACCAACCGGCTCATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 2162
 DB 2173 AACACCAACCGGCTCATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 2232
 QY 2163 AACACCAACCGGCTCATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 2222
 DB 2233 AACACCAACCGGCTCATGAGGAGGAGGCTGTTGGCAGCCACCGGCTGCACTCAGGAAACCCCTCCAG 2292

RESULT 2
 US-10-147-493-267
 ; Sequence 267, Application US/10147493
 ; Publication No. US20040029217A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Baker, Kevin P.
 ; APPLICANT: Beresini, Maureen
 ; APPLICANT: Deforse, Laura

/ APPLICANT: Desnoyers, Luc
 / APPLICANT: Filvaroff, Ellen
 / APPLICANT: Gao, Wei-Qiang
 / APPLICANT: Gerritsen, Mary E.
 / APPLICANT: Goddard, Audrey
 / APPLICANT: Godowski, Paul J.
 / APPLICANT: Gurney, Austin L.
 / APPLICANT: Sherwood, Steven
 / APPLICANT: Smith, Victoria
 / APPLICANT: Stewart, Timothy A.
 / APPLICANT: Tumas, Daniel
 / APPLICANT: Matanabe, Colin K
 / APPLICANT: Wood, William
 / APPLICANT: Zhang, Zemin
 / TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
 / FILE REFERENCE: P3330R1C345
 / CURRENT APPLICATION NUMBER: US/10/147,493
 / CURRENT FILING DATE: 2002-05-17
 / Prior Application removed - See File Wrapper or Palm
 / NUMBER OF SEQ ID NOS: 550
 / SEQ ID NO 267
 / LENGTH: 2290
 / TYPE: DNA
 / ORGANISM: Homo Sapien
 / US-10-147-493-267

Query Match 98.1%; Score 2132.6; DB 13; Length 2290;
 Best Local Similarity 99.8%; Pred. No. 0;
 Matches 2135; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY	3	AAATAGAGTGTGTCGCGGACGCGCTGAGATGAAACCCCAAGCCCTGACCTGCGAGCGTG	62
DB	151	AAATAGAGTGTGTCGCGGACGCGCTGAGATGAAACCCCAAGCCCTGACCTGCGAGCGTG	210
QY	63	GCACTGAGGACGCGCTGAGCGCTACTGTGAGGAAAGAGTTGTGAGAGCCCGCAGG	122
DB	211	GCAGTGAAGGACGCGCTGAGCGCTACTGTGAGGAAAGAGTTGTGAGAGCCCGCAGG	270
QY	123	ACCCTGCGGACGCGCTGCGGCCCAAGCTTCTGCGAGCCCTCTGTGAGGACGAGCGAGT	182
DB	271	ACCCTGCGGACGCGCTGCGGCCCAAGCTTCTGCGAGCCCTCTGTGAGGACGAGCGAGT	330
QY	183	GAGCCAGTGAAGGACGCGCTGCTGCGACGACCGGCTGCAACTCAGGAAACCCCTCGAG	242
DB	331	GAGCCAGTGAAGGACGCGCTGCTGCGACGACCGGCTGCAACTCAGGAAACCCCTCGAG	390
QY	243	AGGCGATGAGACGCGCTGCGGCCCAAGCTTCTGCGAGCCCTCTGTGAGGACGAGCGAGT	302
DB	391	AGGCGATGAGACGCGCTGCGGCCCAAGCTTCTGCGAGCCCTCTGTGAGGACGAGCGAGT	450
QY	303	AGCCAGAGGAGGAGGAGGAGGCTTCATGATTTCTATTCAACAAGAAATTAACCATTTT	362
DB	451	AGCCAGAGGAGGAGGAGGAGGCTTCATGATTTCTATTCAACAAGAAATTAACCATTTT	510
QY	363	GCAAAAGACCATGAGGCACTGTGCGTGAATGCTGTGAGTCTGCGAGTCTGCGTGCATG	422
DB	511	GCAAAAGACCATGAGGCACTGTGCGTGAATGCTGTGAGTCTGCGAGTCTGCGTGCATG	570
QY	423	GGAGCTGTGACGAGGACGAGTGTGAGGAGCACTGAGAGGAGGCTCCCAAGAGAG	482
DB	571	GGAGCTGTGACGAGGACGAGTGTGAGGAGCACTGAGAGGAGGCTCCCAAGAGAG	630
QY	483	TTTCATTTCCTTAAACAGATCAAGAGGAGGAGGAGTCCCAAGAGAGTGCACCTACCC	542
DB	631	TTTCATTTCCTTAAACAGATCAAGAGGAGGAGGAGTCCCAAGAGAGTGCACCTACCC	690
QY	543	TTTCATTTCCTTAAACAGATCAAGAGGAGGAGTCCCAAGAGAGTGCACCTACCC	602
DB	691	TTTCATTTCCTTAAACAGATCAAGAGGAGGAGTCCCAAGAGAGTGCACCTACCC	750
QY	603	GTGCTTCTGAGAACCGAGTGCATAGAGGAGGAGTGCCTCAACATGAGGCTGTC	662

DB	751	GTGCTTCTGAGAACCGAGTGCATAGAGGAGGAGTGCCTCAACATGAGGCTGTC	810
QY	663	AAGCAGAAAGCGCGGATGAGACCGCTGAGACGCTGTGAGAGTGTGAGCGGGATTTGTG	722
DB	811	AAGCAGAAAGCGCGGATGAGACCGCTGAGACGCTGTGAGAGTGTGAGCGGGATTTGTG	870
QY	723	AGCGAGTGAAGCTGCTGCGCAAGAGAGCGGCAACATGAATCTGCGGGATCAGCAGCTC	782
DB	871	AGCGAGTGAAGCTGCTGCGCAAGAGAGCGGCAACATGAATCTGCGGGATCAGCAGCTC	930
QY	783	TACATGACGCTTCTGCAAGAGATCATCGCAAGGAGGCAACCGGTTGAGCTCTCCAG	842
DB	931	TACATGACGCTTCTGCAAGAGATCATCGCAAGGAGGCAACCGGTTGAGCTCTCCAG	990
QY	843	CTGAGAACAGGATCTGAAACGAGACCGGACATGTGCGAGTGTGCGAGCAGATCAAG	902
DB	991	CTGAGAACAGGATCTGAAACGAGACCGGACATGTGCGAGTGTGCGAGCAGATCAAG	1050
QY	903	GACCTGAGACCAAGATACGACACCTGCGCACACTGCGCCCAACCAATCAGAGATATC	962
DB	1051	GACCTGAGACCAAGATACGACACCTGCGCACACTGCGCCCAACCAATCAGAGATATC	1110
QY	963	GCGCAGCTTGAAGGACCTGCGCAGAGGAGTGCCTTGGCGAGGCGCGTCCCGACGACCC	1022
DB	1111	GCGCAGCTTGAAGGACCTGCGCAGAGGAGTGCCTTGGCGAGGCGCGTCCCGACGACCC	1170
QY	1023	CCGCTGCGCGCGCGCGGCTTACCAACCAACCCACTTACCAACGCGATCATCAACAGATC	1082
DB	1171	CCGCTGCGCGCGCGCGGCTTACCAACCAACCCACTTACCAACGCGATCATCAACAGATC	1230
QY	1083	TCTACCAACGAGATTCAGAGTGAACCAAGACTGAAGTGTGCTGCCACCCCTTCCCACT	1142
DB	1231	TCTACCAACGAGATTCAGAGTGAACCAAGACTGAAGTGTGCTGCCACCCCTTCCCACT	1290
QY	1143	ATGCCACTCTCAGCAGCTCCATCTTCCACGACGAGCGTGGGCGCATGTGAGAGAC	1202
DB	1291	ATGCCACTCTCAGCAGCTCCATCTTCCACGACGAGCGTGGGCGCATGTGAGAGAC	1350
QY	1203	TGCTGCAAGGCGCTGAGAGTGGCCACGACCAACGCTTCACTTCTGTGAAAGCCGAG	1262
DB	1351	TGCTGCAAGGCGCTGAGAGTGGCCACGACCAACGCTTCACTTCTGTGAAAGCCGAG	1410
QY	1263	AACACCAACGCGCTCATGAGGAGTGTGCGACCAAGAGACACGCGCGGGGCTGAGAC	1322
DB	1411	AACACCAACGCGCTCATGAGGAGTGTGCGACCAAGAGACACGCGCGGGGCTGAGAC	1470
QY	1323	GTCAATCAGAGACGCTGAGTGTGCTGTGTAATCTTTCAGGAATGTGGAGACGTACAG	1382
DB	1471	GTCAATCAGAGACGCTGAGTGTGCTGTGTAATCTTTCAGGAATGTGGAGACGTACAG	1530
QY	1383	CAAGGTTTGGGAACATTTGACGCGGAATACTGCTGAGGCTGTGAGAACATTTTACTGCTG	1442
DB	1531	CAAGGTTTGGGAACATTTGACGCGGAATACTGCTGAGGCTGTGAGAACATTTTACTGCTG	1590
QY	1443	ACGAACCAAGGCAATCAAACTCTGTGTGACCATGAGAGATGTGCTGCGCCCAAGATC	1502
DB	1591	ACGAACCAAGGCAATCAAACTCTGTGTGACCATGAGAGATGTGCTGCGCCCAAGATC	1560
QY	1503	TTTGCAAGATACGCGAGTTTCCGCTGGAACCTGAGAGCGAGTATTAAGTGTGCGCTG	1562
DB	1651	TTTGCAAGATACGCGAGTTTCCGCTGGAACCTGAGAGCGAGTATTAAGTGTGCGCTG	1710
QY	1563	GGGCGCTAACATGGCAATGCGGGTGACTCCTTTAATGAGCAAGGCAAGCATGCTCACG	1622
DB	1711	GGGCGCTAACATGGCAATGCGGGTGACTCCTTTAATGAGCAAGGCAAGCATGCTCACG	1770
QY	1623	ACCTGGAACAGATCATGATGTCTACACAGAAACCTGTGCGCACTACAGAAAGGAGGC	1682
DB	1771	ACCTGGAACAGATCATGATGTCTACACAGAAACCTGTGCGCACTACAGAAAGGAGGC	1830
QY	1683	TGGTGTATTAAGGCTGTGCGCACTCCCACTCAAGGAGGCTGTGTAACCGCGGGGCGCAT	1742
DB	1831	TGGTGTATTAAGGCTGTGCGCACTCCCACTCAAGGAGGCTGTGTAACCGCGGGGCGCAT	1890

[REDACTED]

QY	63	GCACGTGAGCAGCGCGCTGACGTACTGTGAGGAAAGAAAGTTGTGACAGCCCCGACG	122
Db	211	GCACTGAGGAGCGCGCTGACGTACTGTGAGGAAAGAAAGTTGTGACAGCCCCGACG	270
QY	123	ACCCCTGGCCACGCCCTGGCCCCACGCTCTGGAGCCCTCTGTGAGGCGAGACCAATG	182
Db	271	ACCCCTGGCCACGCCCTGGCCCCACGCTCTGGAGCCCTCTGTGAGGCGAGACCAATG	330
QY	183	GAGCCCAAGTGAAGCGCGCTGTGGCAGCCACCGGCGCTGGCACTCAAGAAACCCCTCAG	242
Db	331	GAGCCCAAGTGAAGCGCGCTGTGGCAGCCACCGGCGCTGGCACTCAAGAAACCCCTCAG	390
QY	243	AGGCCATGGAACGGCTGGCCCCGTGACCGCCAGGGTGAAGCATGTGAGAGCCGCCCGG	302
Db	391	AGGCCATGGAACGGCTGGCCCCGTGACCGCCAGGGTGAAGCATGTGAGAGCCGCCCGG	450
QY	303	AGCCAAACAGAGGAGGAAAGGCTTTCATAGATTCAATTCACAAGAAATTAACCAATTT	362
Db	451	AGCCAAACAGAGGAGGAAAGGCTTTCATAGATTCAATTCACAAGAAATTAACCAATTT	510
QY	363	GCAAAAGCCATGAGGCCACTGTGCGTGACATGTGTGTGGCTGGGACTGTGGCTGGCAG	422
Db	511	GCAAAAGCCATGAGGCCACTGTGCGTGACATGTGTGTGGCTGGGACTGTGGCTGGCAG	570
QY	423	GGAGCTTTGCAAGGCCAGAGGACGGTTTGAAGGCACTGAGAGGGCTCGCCAAAGAG	482
Db	571	GGAGCTTTGCAAGGCCAGAGGACGGTTTGAAGGCACTGAGAGGGCTCGCCAAAGAG	630
QY	483	TTCAATTAACCTAAACAGGTACAAAGGGGCGGGCGAGTCCAGGACAAATGTACACTAC	542
Db	631	TTCAATTAACCTAAACAGGTACAAAGGGGCGGGCGAGTCCAGGACAAATGTACACTAC	690
QY	543	TTCAATGTGCCCCAGCAGCGGGTCAACGGGTGCACTCTGCTCACTCAAGAGAGCTGAG	602
Db	691	TTCAATGTGCCCCAGCAGCGGGTCAACGGGTGCACTCTGCTCACTCAAGAGAGCTGAG	750
QY	603	GTGCTCTGAGAAACCGAGTGCATTAAGAGAGAGCTAAAGTGTCAACAAATGAGCTGTC	662
Db	751	GTGCTCTGAGAAACCGAGTGCATTAAGAGAGAGCTAAAGTGTCAACAAATGAGCTGTC	810
QY	663	AAGCAGAAAGCGCAGATCGAGCGCTGCGAGCAGCTGTGAAAGTGAACGGCGCATTTGT	722
Db	811	AAGCAGAAAGCGCAGATCGAGCGCTGCGAGCAGCTGTGAAAGTGAACGGCGCATTTGT	870
QY	723	AGGAGGTGAAGTGTGTGGCAAGGAGACCGCAACATGAACCTCGGGGTCAAGCAGCTC	782
Db	871	AGGAGGTGAAGTGTGTGGCAAGGAGACCGCAACATGAACCTCGGGGTCAAGCAGCTC	930
QY	783	TACATGACGCTCTGACGAGATCACTCGCAAGCGGAGCAACCGTGTGAGCTCTCCAG	842
Db	931	TACATGACGCTCTGACGAGATCACTCGCAAGCGGAGCAACCGTGTGAGCTCTCCAG	990
QY	843	CTGGAAGACAGATCTTGAACCAAGACCGGCACTGTGTGAGTGTGGCCAGCAAGTAAAG	902
Db	991	CTGGAAGACAGATCTTGAACCAAGACCGGCACTGTGTGAGTGTGGCCAGCAAGTAAAG	1052
QY	903	GACCTGAGCAACAGTACCAAGCACTGTGCAACTGTGGCCCAACCAATCAGAGATCATC	962
Db	1051	GACCTGAGCAACAGTACCAAGCACTGTGCAACTGTGGCCCAACCAATCAGAGATCATC	1110
QY	963	GCCACACTTGAAGAGCACTGCAAGAGGGTGCCTCGGCCAGGCGGTGCCCAAGCAACC	1022
Db	1111	GCCACACTTGAAGAGCACTGCAAGAGGGTGCCTCGGCCAGGCGGTGCCCAAGCAACC	1170
QY	1023	CCCGCTGCCCGCCCGGGTCTTACCAACCAACCACTTCAACCGCATCATCAACAGATC	1088
Db	1171	CCCGCTGCCCGCCCGGGTCTTACCAACCAACCACTTCAACCGCATCATCAACAGATC	1230
QY	1083	TTCAACAAAGAGATCAAGATGACAGAAACCTGAAGTGTGTGCAACCCCTCTGGCAAT	1144
Db	1231	TTCAACAAAGAGATCAAGATGACAGAAACCTGAAGTGTGTGCAACCCCTCTGGCAAT	1292
QY	1143	ATGCGCACTTCCACAGCTTCCATCTTCCACGCAACAGCGTGGGCGCCATGAGAGAC	1202

Db 1291 ATGCCACCTCTCAACGAGCCCTCCCATCTTCCACCGACAGACGCGGCGGCCCCATGAGAGAC 1350
 Qy 1203 TGCCTGAGGCGCTTGGAGATGAGCCACGACAGCTCCATCTTACTGCTGAAGCCGAG 1262
 Db 1351 TGCCTGAGGCGCTTGGAGATGAGCCACGACAGCTCCATCTTACTGCTGAAGCCGAG 1410
 Qy 1263 AACACCAACCGCTCAATGACGAGTGTGTCACAGACAGACCCCGGCGGCTGAGAC 1322
 Db 1411 AACACCAACCGCTCAATGACGAGTGTGTCACAGACAGACCCCGGCGGCTGAGAC 1470
 Qy 1323 GTCATCAAGAGAGCGCTGATGAGCTCTGTAACTTCTTCAAGAACTGGAGAGCTACAG 1382
 Db 1471 GTCATCAAGAGAGCGCTGATGAGCTCTGTAACTTCTTCAAGAACTGGAGAGCTACAG 1530
 Qy 1383 CAAGGCTTGGAGACATGACGCGCAATCTGCTGAGGCTGAGACATTTTACTGCTG 1442
 Db 1531 CAAGGCTTGGAGACATGACGCGCAATCTGCTGAGGCTGAGACATTTTACTGCTG 1590
 Qy 1443 ACGAACCAAGGCAACTACAACTCTGTGACCATGAGAGCTGTCCGCGCAAGTC 1502
 Db 1591 ACGAACCAAGGCAACTACAACTCTGTGACCATGAGAGCTGTCCGCGCAAGTC 1650
 Qy 1503 TTTGCGAATACGCCCGCTTCCGCTGAGAACTGAGAGCGAGTATTATAAGCTGGCGCTG 1562
 Db 1651 TTTGCGAATACGCCCGCTTCCGCTGAGAACTGAGAGCGAGTATTATAAGCTGGCGCTG 1710
 Qy 1563 GGAGCGCTACATGAGCAATGAGGAGTGAATCTTCTTACATGAGCAACGAGAGAGTTCACC 1622
 Db 1711 GGAGCGCTACATGAGCAATGAGGAGTGAATCTTCTTACATGAGCAACGAGAGAGTTCACC 1770
 Qy 1623 ACCCTGAGACAGATCATGATGATCTTACACAGAACTGTGCCACTTACCAAGAGAGAGC 1682
 Db 1771 ACCCTGAGACAGATCATGATGATCTTACACAGAACTGTGCCACTTACCAAGAGAGAGC 1830
 Qy 1683 TGGTGGTAAAGCGCTGTGCCCACTCCACACCTTCCACAGGAGTGTGTTCCGCGGAGCCAT 1742
 Db 1831 TGGTGGTAAAGCGCTGTGCCCACTCCACACCTTCCACAGGAGTGTGTTCCGCGGAGCCAT 1890
 Qy 1743 TACCGAGAGCGCTTACAGAGACGAGTCTTACTGAGGCTGAGTCCAGAGAGCTCTTACTCA 1802
 Db 1891 TACCGAGAGCGCTTACAGAGACGAGTCTTACTGAGGCTGAGTCCAGAGAGCTCTTACTCA 1950
 Qy 1803 CTCAGAGAAAGTGTGATGATTCGACCGAAACCCCAACACCTTCCACTAAGCCAGCTCC 1862
 Db 1951 CTCAGAGAAAGTGTGATGATTCGACCGAAACCCCAACACCTTCCACTAAGCCAGCTCC 2010
 Qy 1863 CCTCTCTGACTCTGCTGAGCAATGTCAGAGAGCCCAACCTGCTGAGCTGAGCCAGAGAC 1922
 Db 2011 CCTCTCTGACTCTGCTGAGCAATGTCAGAGAGCCCAACCTGCTGAGCTGAGCCAGAGAC 2070
 Qy 1923 AAAAGAACCTCTCTCAACAGTTCATCTGAGGCTGAGAGACCGGAGTCTGAGTTCGT 1982
 Db 2071 AAAAGAACCTCTCTCAACAGTTCATCTGAGGCTGAGAGACCGGAGTCTGAGTTCGT 2130
 Qy 1983 TTTCCGAGTCACTGAGAGGAGTGAATGAACTGAATTCGATTCGATTCGATTCGATTCG 2042
 Db 2131 TTTCCGAGTCACTGAGAGGAGTGAATGAACTGAATTCGATTCGATTCGATTCGATTCG 2190
 Qy 2043 TACTTCTCTTCAACACAGACAGCCCTCATGCTCTCAGAGACAGAGACAGACTACAGAA 2102
 Db 2191 TACTTCTCTTCAACACAGACAGCCCTCATGCTCTCAGAGACAGAGACAGACTACAGAA 2250
 Qy 2103 CTCCTTCTTAAATAATTAATTAAGTCTCTACATTAATAA 2141
 Db 2251 CTCCTTCTTAAATAATTAATTAAGTCTCTACATTAATAA 2289

RESULT 4
 US-10-160-503-267
 ; Sequence 267 Application US/10160503
 ; Publication No. US20040033559A1
 ; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.
 ; APPLICANT: Beresini, Maureen
 ; APPLICANT: Deforge, Laura
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Filvaroff, Ellen
 ; APPLICANT: Gao, Wei-Qiang
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, Audrey
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Sherwood, Steven
 ; APPLICANT: Smith, Victoria
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Matanabe, Colin K
 ; APPLICANT: Wood, William
 ; APPLICANT: Zhang, Zemin
 ; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
 ; FILE REFERENCE: P3330R1C446
 ; CURRENT APPLICATION NUMBER: US/10/160,503
 ; CURRENT FILING DATE: 2002-05-30
 ; NUMBER OF SEQ ID NOS: 550
 ; SEQ ID NO 267
 ; LENGTH: 2290
 ; TYPE: DNA
 ; ORGANISM: Homo Sapien
 ; US-10-160-503-267
 Query Match 98.1%; Score 2132.6; DB 13; Length 2290;
 Best Local Similarity 99.8%; Pred. No. 0;
 Matches 2135; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 3 AAATGAGGCGCTGTCGAGAGCGGCTGAGATGAGACCCCAAGCCCTGAGACTGCGGAGCTG 62
 Db 151 AAATGAGGCGCTGTCGAGAGCGGCTGAGATGAGACCCCAAGCCCTGAGACTGCGGAGCTG 210
 Qy 63 GCACCTGAGGAGCGGCTGAGCTTACTGTGAGAGGAAAGATTGTGAGAGAGCCCGAGG 122
 Db 211 GCATGAGGAGCGGCTGAGCTTACTGTGAGAGGAAAGATTGTGAGAGAGCCCGAGG 270
 Qy 123 ACCCTGAGGAGCGGCTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 182
 Db 271 ACCCTGAGGAGCGGCTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 330
 Qy 183 GAGCCAGTGAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 242
 Db 331 GAGCCAGTGAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 390
 Qy 243 AGGCGATGAGACAGGCTGCGGCTGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 302
 Db 391 AGGCGATGAGACAGGCTGCGGCTGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 450
 Qy 303 AGCCACAGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 362
 Db 451 AGCCACAGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 510
 Qy 423 GAGGCTTTCAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 482
 Db 511 GCAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 570
 Qy 483 GCAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 542
 Db 571 GCAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 630
 Qy 543 TTTATTTTACCTTAAACAGTACAGCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 602
 Db 631 TTTATTTTACCTTAAACAGTACAGCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 690
 Qy 602 TTTATTTTACCTTAAACAGTACAGCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 660
 Db 691 TTTATTTTACCTTAAACAGTACAGCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 750

Qy	603	GTGCTTTCTGGAGAACCGAGTGTCTATAGACGAGCTAGAGCTGCTCAACATAGAGCTGCT	662
Db	751	GTGCTTTCTGGAGAACCGAGTGTCTATAGACGAGCTAGAGCTGCTCAACATAGAGCTGCT	810
Qy	663	AAGCAGAACCGGCATCATGAGACGCTGACGAGCTGTGAGAGGTGAGACGGCGCATTTGT	722
Db	811	AAGCAGAACCGGCATCATGAGACGCTGACGAGCTGTGAGAGGTGAGACGGCGCATTTGT	870
Qy	723	AGCGAGGTGAAGCTCTGCTGCGCAGAGAGACCGGCACATGAACTGCGGGGTCAAGCAGCTC	782
Db	871	AGCGAGGTGAAGCTCTGCTGCGCAGAGAGACCGGCACATGAACTGCGGGGTCAAGCAGCTC	930
Qy	783	TACATGACAGCTCTCTGACAGATCATCTCCGACGCGGAGCAACGCGTTGAGACTTCCAG	842
Db	931	TACATGACAGCTCTCTGACAGATCATCTCCGACGCGGAGCAACGCGTTGAGACTTCCAG	990
Qy	843	CTGGAGAACAGGATCTTGAATCCAGACAGCCCATGCTGCACTGGCCACGCAATAAAG	902
Db	991	CTGGAGAACAGGATCTTGAATCCAGACAGCCCATGCTGCACTGGCCACGCAATAAAG	1050
Qy	903	GACCTGGAGCAACAGTACAGACGACTGGGCACACTGCGCCCAACCAATCAGATCATC	962
Db	1051	GACCTGGAGCAACAGTACAGACGACTGGGCACACTGCGCCCAACCAATCAGATCATC	1110
Qy	963	GCGCAGCTTGAAGAGCACTGCCAAGGGTGCCTCGCCAGGCCCGTCCCAAGCCACC	1022
Db	1111	GCGCAGCTTGAAGAGCACTGCCAAGGGTGCCTCGCCAGGCCCGTCCCAAGCCACC	1170
Qy	1023	CCCGCTGCCCCGCCCGGGTCTAACCAACCACTCACTCAACCGCATCATCAACAGATC	1082
Db	1171	CCCGCTGCCCCGCCCGGGTCTAACCAACCACTCACTCAACCGCATCATCAACAGATC	1230
Qy	1083	TCCTACCAACGAGATCCAGAGTACACAGAACTTGAAGGTCTGCCACCCCTCTGCCACT	1142
Db	1231	TCCTACCAACGAGATCCAGAGTACACAGAACTTGAAGGTCTGCCACCCCTCTGCCACT	1290
Qy	1143	ATGCCCACTCTCAACAGCTCCCATCTTTCACCCGACAGCCGTGGGGCCCATGGAGAGAC	1202
Db	1291	ATGCCCACTCTCAACAGCTCCCATCTTTCACCCGACAGCCGTGGGGCCCATGGAGAGAC	1350
Qy	1203	TGGCTTCAGAGCCCTGGAGGATGGCCACGACACCACTCCATCTACTTGGTGAACCCGAG	1262
Db	1351	TGGCTTCAGAGCCCTGGAGGATGGCCACGACACCACTCCATCTACTTGGTGAACCCGAG	1410
Qy	1263	AACACCAACCGCTCTCATGCAAGTGTGTGTGCGACAGAGACACGACCCCGGGGGCTGAC	1322
Db	1411	AACACCAACCGCTCTCATGCAAGTGTGTGTGCGACAGAGACACGACCCCGGGGGCTGAC	1470
Qy	1323	GTCAATCAGAGACCGCTGGATGGCTGTGTAACTTCTTCAGGAATCGGAGACGTACAG	1382
Db	1471	GTCAATCAGAGACCGCTGGATGGCTGTGTAACTTCTTCAGGAATCGGAGACGTACAG	1530
Qy	1383	CAAGGGTTTGGGAACATTGACGGCGAATATCTGGCTTGGGCTTGAGAACATTTACTGGCTG	1442
Db	1531	CAAGGGTTTGGGAACATTGACGGCGAATATCTGGCTTGGGCTTGAGAACATTTACTGGCTG	1590
Qy	1443	ACGAACCAAGGGAACCTACAACTCCCTGGAGACATAGAGGAATGTGTCGGCGCGCAAAATC	1502
Db	1591	ACGAACCAAGGGAACCTACAACTCCCTGGAGACATAGAGGAATGTGTCGGCGCGCAAAATC	1650
Qy	1503	TTTTCAGAAATAGCCCAATTTCCGCTGGAACCTGAGAGCGAATATTAAGCTGCGCTG	1562
Db	1651	TTTTCAGAAATAGCCCAATTTCCGCTGGAACCTGAGAGCGAATATTAAGCTGCGCTG	1710
Qy	1563	GGGCGCTACATGAGCAATGCGGGTGACTCTTTTACATGGCAAAAGGGAAGAGTTCAAC	1622
Db	1711	GGGCGCTACATGAGCAATGCGGGTGACTCTTTTACATGGCAAAAGGGAAGAGTTCAAC	1770
Qy	1623	ACCTTGAGACAGATCATGATGTCTACACAGGAACTGTGCCACTACCAAGAGGAGGC	1682
Db	1771	ACCTTGAGACAGATCATGATGTCTACACAGGAACTGTGCCACTACCAAGAGGAGGC	1830
Qy	1683	TGCTGTATTAACGCTGTGCGCACTCAACCTCAACGGGGGTCTGGTATCCGCGGGGCCAT	1742

Db	1831	TGCTGGATTAACCGCTGTGGCCACTCCAACCTCAACGGGGTCTGGTACCCGGGGGCAT	1890
QY	1743	TACCGAGCGCGTACACGAGCGGAGTCTACTGGCGTGAAGTTCGAGAGGCTCTACTCA	1802
Db	1891	TACCGAGCGCGTACACGAGCGGAGTCTACTGGCGTGAAGTTCGAGAGGCTCTACTCA	1950
QY	1803	CTCAAGAAAGTGGTGAATGATGATCCGACCGAACCCCAACACTTCCACTAAGCCAGCTCC	1862
Db	1951	CTCAAGAAAGTGGTGAATGATGATCCGACCGAACCCCAACACTTCCACTAAGCCAGCTCC	2010
QY	1863	CCCTCTGACCTCTCGTGGCCATTGGCCAGAGCCCACTCTGTCTACGCTGGCCACAGCAC	1922
Db	2011	CCCTCTGACCTCTCGTGGCCATTGGCCAGAGCCCACTCTGTCTACGCTGGCCACAGCAC	2070
QY	1923	AAGAACAACTCCTCAACCATTTATCTGAGGCTGGAGGACCGGGATGCTGAATTCGT	1982
Db	2071	AAGAACAACTCCTCAACCATTTATCTGAGGCTGGAGGACCGGGATGCTGAATTCGT	2130
QY	1983	TTTCCGAGTCACTGCAGCGGATGATGGAATCTGAATCAGGTGTTTTCTGTCTCTCC	2042
Db	2131	TTTCCGAGTCACTGCAGCGGATGATGGAATCTGAATCAGGTGTTTTCTGTCTCTCC	2190
QY	2043	TACTTTCCTTCACACCGACGAGCCCTCATGTCTCCAGACAGACACTACAGACAA	2102
Db	2191	TACTTTCCTTCACACCGACGAGCCCTCATGTCTCCAGACAGACACTACAGACAA	2250
QY	2103	CTCTTCTTTAAATTAATTAACTCTCTACATAAACA	2141
Db	2251	CTCTTCTTTAAATTAATTAACTCTCTACATAAACA	2289

RESULT 5

US-10-143-118-267

Sequence 267, Application US/10143118

Publication No. US20040038335A1

GENERAL INFORMATION:

APPLICANT: Baker, Kevin P

APPLICANT: Beresini, Maureen

APPLICANT: DeForge, Laura

APPLICANT: Desnoyers, Luc

APPLICANT: Filvaroff, Ellen

APPLICANT: Gao, Wei-Qiang

APPLICANT: Gerritsen, Mary E.

APPLICANT: Goddard, Audrey

APPLICANT: Godowski, Paul J.

APPLICANT: Gurney, Austin L.

APPLICANT: Sherwood, Steven

APPLICANT: Smith, Victoria

APPLICANT: Stewart, Timothy A.

APPLICANT: Tunas, Daniel

APPLICANT: Watanabe, Colin K

APPLICANT: Wood, William

APPLICANT: Zhang, Zhen

TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

TITLE OF INVENTION: ACIDS ENCODING THE SAME

FILE REFERENCE: P33081C28

CURRENT APPLICATION NUMBER: US/10/143,118

CURRENT FILING DATE: 2002-05-09

Prior Application removed - See Palm or File wrapper

NUMBER OF SEQ ID NOS: 550

SEQ ID NO 267

LENGTH: 2290

TYPE: DNA

ORGANISM: Homo Sapien

US-10-143-118-267

Query Match 98.1%, Score 2132.6, DB 13, Length 2290;

Best Local Similarity 99.8%, Pred. No. 0;

Matches 2135, Conservative 0, Mismatches 4, Indels 0, Gaps 0.

3 AATGAGGCTCTGCGAGCGGCTGAGGATGAACCCCAAGGCTGGAGCTGGCGAGCGTG 62

Mon Aug 9 10:30:08 2004

us-10-018-386-1.rmpb

Page 7

Db 151 AATATGAGGTGCTGCGGACGGCTGAGATGAGACCCCAAGCCCTGAGCCTGCGAGCTG 210
QY 63 GCACCTAGAGGAGGAGGCTGACGCTACTGTGAGGGAAGAGTTGTGAGAGGCCCGGACG 122
Db 211 GCACTAGAGGAGGAGGCTGAGCGTACTGTGAGGGAAGAGTTGTGAGAGGCCCGGACG 270
QY 123 ACCCTGAGCGAGCCTGAGCGCCCAAGCCTTGTGCGAGCCCTTGTGAGGCGAGAGCGAGT 182
Db 271 ACCCTGAGCGAGCCTGAGCGCCCAAGCCTTGTGCGAGCCCTTGTGAGGCGAGAGCGAGT 330
QY 183 GAGCCAGTGAAGGAGGAGGCTGCTGAGGAGCGACCGGCGTGAATTCAGGAACCCCTCCAG 242
Db 331 GAGCCAGTGAAGGAGGAGGCTGCTGAGGAGCGACCGGCGTGAATTCAGGAACCCCTCCAG 390
QY 243 AGGCGATGAGAGGCTGCGCCCGCTGACGGCGAGGAGTGAAGCATGTGAGAGCGCGCCCG 302
Db 391 AGGCGATGAGAGGCTGCGCCCGCTGACGGCGAGGAGTGAAGCATGTGAGAGCGCGCCCG 450
QY 303 AGCCAAAGCAGAGGAGGAGGCTTTGATGATTCTATTCAAAAGATTAACCACTTTT 362
Db 451 AGCCAAAGCAGAGGAGGAGGCTTTGATGATTCTATTCAAAAGATTAACCACTTTT 510
QY 363 GCAAAAGCATGAGGAGGCTGAGCGTGTGAGCATGTGTGAGCTGAGACTGCTGAGCTGCAATG 422
Db 511 GCAAGGACCATGAGGAGGCTGAGCGTGTGAGCATGTGTGAGCTGAGACTGCTGAGCTGCAATG 570
QY 423 GAGCTGTTGACAGCGCCAGAGAGAGCGGTTTGAAGGCGCTGAGAGAGGCTCGCCAAAGAG 482
Db 571 GAGCTGTTGACAGCGCCAGAGAGAGCGGTTTGAAGGCGCTGAGAGAGGCTCGCCAAAGAG 630
QY 483 TTCTATTACTTAAACAGATTAAGCGGAGGAGGAGTCCCAAGACAAAGTGCACCTAAC 542
Db 631 TTCTATTACTTAAACAGATTAAGCGGAGGAGGAGTCCCAAGACAAAGTGCACCTAAC 690
QY 543 TTCTATTGTCAGGAGGAGGAGGAGTCCCAAGTGCATGCTGCACTCAAGAGGCTGAG 602
Db 691 TTCTATTGTCAGGAGGAGGAGGAGTCCCAAGTGCATGCTGCACTCAAGAGGCTGAG 750
QY 603 GTGCTTCTGAGAGACCGAGTGCATTAAGCAGAGAGTGAAGCTGCTCAACATAGCTGCTC 662
Db 751 GTGCTTCTGAGAGACCGAGTGCATTAAGCAGAGAGTGAAGCTGCTCAACATAGCTGCTC 810
QY 663 AAGCAGAGAGGAGAGTGCAGAGCGTGCAGAGCTGTGAGAGTGAAGCGGCGCATTTG 722
Db 811 AAGCAGAGAGGAGAGTGCAGAGCGTGCAGAGCTGTGAGAGTGAAGCGGCGCATTTG 870
QY 723 AGGAGGTGAAGCTGTGCGCAAGAGAGCGGCAATGAATCTCGGAGTCAACGAGCTC 782
Db 871 AGGAGGTGAAGCTGTGCGCAAGAGAGCGGCAATGAATCTCGGAGTCAACGAGCTC 930
QY 783 TACATGACAGTCTGAGACGAGATCATCCGAGCGGAGCAAGCGTGTGAGAGCTCCCGAG 842
Db 931 TACATGACAGTCTGAGACGAGATCATCCGAGCGGAGCAAGCGTGTGAGAGCTCCCGAG 990
QY 843 CTGAGAGAGAGATCTCTGAACAGACGAGCGAGCTGAGCTGAGCGCAGAGTGAAG 902
Db 991 CTGAGAGAGAGATCTCTGAACAGACGAGCGAGCTGAGCTGAGCGCAGAGTGAAG 1050
QY 903 GACCTGAGAGCAAGTACCAAGACCTGAGCACTGTGCGCAACCAATCAAGAGATCATC 962
Db 1051 GACCTGAGAGCAAGTACCAAGACCTGAGCACTGTGCGCAACCAATCAAGAGATCATC 1110
QY 963 GCGCACTTGAAGAGACTGCGAGAGGAGTGCCTTGGCGAGGCGCTGCGCGAGCGACGC 1022
Db 1111 GCGCACTTGAAGAGACTGCGAGAGGAGTGCCTTGGCGAGGCGCTGCGCGAGCGACGC 1170
QY 1023 CCGCGTGCCTGCGCGCGGCTTACCAACCAAGCTTCAACCGCATCATCAACGAGATC 1082
Db 1171 CCGCGTGCCTGCGCGCGGCTTACCAACCAAGCTTCAACCGCATCATCAACGAGATC 1230
QY 1083 TCTACCAAGAGATTCAGAGTGAAGCAAGCTTGAAGTGTGCAACCCCTCTGAGCACT 1142
Db 1231 TCTACCAAGAGATTCAGAGTGAAGCAAGCTTGAAGTGTGCAACCCCTCTGAGCACT 1290

QY 1143 ATGCCACTCTACACAGGCTCCCATCTTCCACCGAAGACCGCTGCGGCCCATGAGAGAC 1202
Db 1291 ATGCCACTCTACACAGGCTCCCATCTTCCACCGAAGACCGCTGCGGCCCATGAGAGAC 1350
QY 1203 TGCTGAGGCGCTGAGAGATGCGCAAGACCAAGCTTCACTTGTGTGAAGCGGAG 1262
Db 1351 TGCTGAGGCGCTGAGAGATGCGCAAGACCAAGCTTCACTTGTGTGAAGCGGAG 1410
QY 1263 AAGACCAACCGCTCATGAGAGTGTGAGGAGCAAGAGACAGACCCCGGAGGCTGAGAC 1322
Db 1411 AAGACCAACCGCTCATGAGAGTGTGAGGAGCAAGAGACAGACCCCGGAGGCTGAGAC 1470
QY 1323 GTCATCCAGAGACCGCTGAGATGAGCTGTAACTTCTTCAAGAACTGAGAGACGTACAG 1382
Db 1471 GTCATCCAGAGACCGCTGAGATGAGCTGTAACTTCTTCAAGAACTGAGAGACGTACAG 1530
QY 1383 CAAGGTTTGGGAACTTGAAGGCGAATATCGCTGAGGCGCTGAGAACTTTAATGAGCTG 1442
Db 1531 CAAGGTTTGGGAACTTGAAGGCGAATATCGCTGAGGCGCTGAGAACTTTAATGAGCTG 1590
QY 1443 ACGAAGCAAGGCACTCAAACTCTGTGTGACATGAGAGAGCTGTCCGCGCAAGATC 1502
Db 1591 ACGAAGCAAGGCACTCAAACTCTGTGTGACATGAGAGAGCTGTCCGCGCAAGATC 1650
QY 1503 TTTGCAAGATACGCCAGTTTCCGCTTGAACCTGAGAGCGAGATTTATAGCTGCGCTG 1562
Db 1651 TTTGCAAGATACGCCAGTTTCCGCTTGAACCTGAGAGCGAGATTTATAGCTGCGCTG 1710
QY 1563 GGGGCTTACCATGAGCAATGCGGAGTGAAGCTTCAATGAGCAACCGGCAAGCACTTAC 1622
Db 1711 GGGGCTTACCATGAGCAATGCGGAGTGAAGCTTCAATGAGCAACCGGCAAGCACTTAC 1770
QY 1623 ACCCTGAGCAGAGATCATGATGTCTAACAAGAGAACTGTGCCACTAACAGAGGAGG 1682
Db 1771 ACCCTGAGCAGAGATCATGATGTCTAACAAGAGAACTGTGCCACTAACAGAGGAGG 1830
QY 1683 TGGTGTATTAACGCTGTGAGCCCACTCAACCGGAGTGTACCGGAGGAGGAGCAT 1742
Db 1831 TGGTGTATTAACGCTGTGAGCCCACTCAACCGGAGTGTACCGGAGGAGGAGCAT 1890
QY 1743 TACCGAGCCGCTACAGAGAGGAGTGTACTGTGAGCTGAGTCCGAGAGAGGCTTTACTCA 1802
Db 1891 TACCGAGCCGCTACAGAGAGGAGTGTACTGTGAGCTGAGTCCGAGAGAGGCTTTACTCA 1950
QY 1803 CTCAAGAAAGTGTGATGATATCCGACCGAAACCCCAACACTTCCACTAAGCGAGCTCC 1862
Db 1951 CTCAAGAAAGTGTGATGATATCCGACCGAAACCCCAACACTTCCACTAAGCGAGCTCC 2010
QY 1863 CCTCTGACCTCTGAGGAGTGTGAGAGGAGCCCACTGTGTACAGCTGAGCGACAGAC 1922
Db 2011 CCTCTGACCTCTGAGGAGTGTGAGAGGAGCCCACTGTGTACAGCTGAGCGACAGAC 2070
QY 1923 AAGAGCAACTCTTACCAAGTTCATCTGAGCTGAGAGAGCGGAGTGTGATTTCTGT 1982
Db 2071 AAGAGCAACTCTTACCAAGTTCATCTGAGCTGAGAGAGCGGAGTGTGATTTCTGT 2130
QY 1983 TTTCCGAGATGACAGCGAGCGAGTATGAGAACTGAATGATGATGATTTTGTGACCTCC 2042
Db 2131 TTTCCGAGATGACAGCGAGCGAGTATGAGAACTGAATGATGATGATTTTGTGACCTCC 2190
QY 2043 TACTTCTCTTCAACAGAGACCGCTCATGTCTTCAAGAGAGAGAGCTACAGACAA 2102
Db 2191 TACTTCTCTTCAACAGAGACCGCTCATGTCTTCAAGAGAGAGAGCTACAGACAA 2250
QY 2103 CTCTTTCTTAAATTAATTAAGTCTTCAATTAATAACA 2141
Db 2251 CTCTTTCTTAAATTAATTAAGTCTTCAATTAATAAAAA 2289

RESULT 6
US-10-144-993-267
; Sequence 267, Application US/10144993

```

; Publication NO. US20040038336A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Collin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C261
; CURRENT APPLICATION NUMBER: US/10/144,993
; PRIOR FILING DATE: 2002-05-13
; PRIOR APPLICATION removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 267
; LENGTH: 2290
; TYPE: DNA
; ORGANISM: Homo Sapien
; US-10-144-993-267

```

```

Query Match      98.1%; Score 2132.6; DB 13; Length 2290;
Best Local Similarity 99.8%; Pred. No. 0;
Matches 2155; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 3 AAATGAGGCTGCTGCGGAGCGGCTGAGATGAACCCCAAGCCCTGAGACTGCGGAGCGTG 62
DB 151 AAATGAGGCTGCTGCGGAGCGGCTGAGATGAACCCCAAGCCCTGAGACTGCGGAGCGTG 210
QY 63 GCACTAGGAGGAGGAGGCTGAGCGTACTGCTGAGGAGAAAGAGTTGTGAGAGCCCGCAGG 122
DB 211 GCACTAGGAGGAGGAGGCTGAGCGTACTGCTGAGGAGAAAGAGTTGTGAGAGCCCGCAGG 270
QY 123 ACCCTGAGCGAGCCCTGAGCGCCCAAGCCTCTGCGGAGCCCTCTGTGAGAGCAGAGCAAGT 182
DB 271 ACCCTGAGCGAGCCCTGAGCGCCCAAGCCTCTGCGGAGCCCTCTGTGAGAGCAGAGCAAGT 330
QY 183 GAGCCAGTGAAGGAGGAGGCTGCTGTGCAAGCAACCGGCTGCAACTCAGAGAACCCCTCCAG 242
DB 331 GAGCCAGTGAAGGAGGAGGCTGCTGTGCAAGCAACCGGCTGCAACTCAGAGAACCCCTCCAG 390
QY 243 AGGCGATGAGAGGCTGCGCCCGCTGACGGCCAGGGTGAAGCATGTGAGAGCGCCCGCG 302
DB 391 AGGCGATGAGAGGCTGCGCCCGCTGACGGCCAGGGTGAAGCATGTGAGAGCGCCCGCG 450
QY 303 AGCCAGAGGAGGAGGAGGCTTTTCAATGATTCTATTCAAAAGATTAACCAATTTT 362
DB 451 AGCCAGAGGAGGAGGAGGCTTTTCAATGATTCTATTCAAAAGATTAACCAATTTT 510
QY 363 GCAAGAGCATGAGGAGGAGGCTGTGCGTGAATGATGCTGTGAGTGTGCTGAGTGTGCTGAGT 422
DB 511 GCAAGAGCATGAGGAGGAGGCTGTGCGTGAATGATGCTGTGAGTGTGCTGAGTGTGCTGAGT 570
QY 423 GAGAGCTGTGAGAGGAGGAGGAGGCTTTTGAAGGCACTGAGAGAGGCTCGCAAGAGAG 482
DB 571 GAGAGCTGTGAGAGGAGGAGGAGGCTTTTGAAGGCACTGAGAGAGGCTCGCAAGAGAG 630
QY 483 TTGATTACTTAAGAGGATTAAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 542
DB 631 TTGATTACTTAAGAGGATTAAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 690
QY 543 TTGATTGTGCGCCAGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 602

```

```

DB 691 TTGATTGTGCGCCAGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 750
QY 603 GTGCTTGTGAGAGAGCCAGTGCATTAAGCAGAGCTGAGTGTCTCAACATAGCTGTCTC 662
DB 751 GTGCTTGTGAGAGAGCCAGTGCATTAAGCAGAGCTGAGTGTCTCAACATAGCTGTCTC 810
QY 663 AAGCAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 722
DB 811 AAGCAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 870
QY 723 AGCGAGGTGAAGTGTCTGCGCAAGAGAGGCGCAAGATGAATCTGCGGGGTCAAGAGCTC 782
DB 871 AGCGAGGTGAAGTGTCTGCGCAAGAGAGGCGCAAGATGAATCTGCGGGGTCAAGAGCTC 930
QY 783 TACATGAGCTCTCTGCAAGAGATTCATCCGGAACCGGAGCAAGCGGCTTGAAGCTCTCCAG 842
DB 931 TACATGAGCTCTCTGCAAGAGATTCATCCGGAACCGGAGCAAGCGGCTTGAAGCTCTCCAG 990
QY 843 CTGAGAGAGAGATCTCTGCAAGAGATTCATCCGGAACCGGAGCAAGCGGCTTGAAGCTCTCCAG 902
DB 991 CTGAGAGAGAGATCTCTGCAAGAGATTCATCCGGAACCGGAGCAAGCGGCTTGAAGCTCTCCAG 1050
QY 903 GACCTGAGAGCAAGATTCATCCGGAACCGGAGCAAGCGGCTTGAAGCTCTCCAG 962
DB 1051 GACCTGAGAGCAAGATTCATCCGGAACCGGAGCAAGCGGCTTGAAGCTCTCCAG 1110
QY 963 GCGAGCTTGAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1022
DB 1111 GCGAGCTTGAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1170
QY 1023 CCGGCTGCGCCCGCGGAGTCTTCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAGT 1082
DB 1171 CCGGCTGCGCCCGCGGAGTCTTCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAGT 1230
QY 1083 TCTACCAAGAGATTCAGAGATTCAGAGATTCAGAGATTCAGAGATTCAGAGATTCAGAGATTC 1142
DB 1231 TCTACCAAGAGATTCAGAGATTCAGAGATTCAGAGATTCAGAGATTCAGAGATTCAGAGATTC 1290
QY 1143 ATGCCCACTCTCAACCAAGCTCTCCATCTTCCACCAAGAGAGAGAGAGAGAGAGAGAGAG 1202
DB 1291 ATGCCCACTCTCAACCAAGCTCTCCATCTTCCACCAAGAGAGAGAGAGAGAGAGAGAGAGAG 1350
QY 1203 TGCTGTGAGGCTCTGAGAGATTCGACAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1262
DB 1351 TGCTGTGAGGCTCTGAGAGATTCGACAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1410
QY 1263 AACCAACAGGCTCTCAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1322
DB 1411 AACCAACAGGCTCTCAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1470
QY 1323 GTGATCGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1382
DB 1471 GTGATCGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1530
QY 1383 CAAGAGGTTGGAGAACATTTGACGGGCAATATCTGCTGGGCTGGAGAACATTTTCTGGCTG 1442
DB 1531 CAAGAGGTTGGAGAACATTTGACGGGCAATATCTGCTGGGCTGGAGAACATTTTCTGGCTG 1590
QY 1443 ACGAAGCAAGCACTAACAATCTCTGTGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1502
DB 1591 ACGAAGCAAGCACTAACAATCTCTGTGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1650
QY 1503 TTTCGAGAAATAGCCGAGTTTCCGCTGAGAACCTGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1562
DB 1651 TTTCGAGAAATAGCCGAGTTTCCGCTGAGAACCTGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1710
QY 1563 GGGGCTACCATGAGAGATGCGGGTGAATCTCTTTTCAATGAGCAACCGGCAAGAGATTCAC 1622
DB 1711 GGGGCTACCATGAGAGATGCGGGTGAATCTCTTTTCAATGAGCAACCGGCAAGAGATTCAC 1770
QY 1623 ACCCTGAGAGAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1682

```

Mon Aug 9 10:30:08 2004

us-10-018-386-1.rnpb

Page 9

Db 1771 ACCCTGACAGAGATCATGATGCTACAGAGAACTGTGCCACTACAGAGAGAGGC 1830
Qy 1683 TGGTGTATATACGCTGTGCGCCACTCAACCTCAACGAGGAGTGGTACCGAGGAGCAT 1742
Db 1831 TGGTGTATATACGCTGTGCGCCACTCAACCTCAACGAGGAGTGGTACCGAGGAGCAT 1890
Qy 1743 TACCGAGCGGCTACAGAGAGAGAGTCTAAGTGGTGAAGTCCAGAGAGCTTTACTCA 1802
Db 1891 TACCGAGCGGCTACAGAGAGAGAGTCTAAGTGGTGAAGTCCAGAGAGCTTTACTCA 1950
Qy 1803 CTCAGAAAGTGTATGATGATCCGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1862
Db 1951 CTCAGAAAGTGTATGATGATCCGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 2010
Qy 1863 CCCTCTGACCTCTCGTGGCCATTGGCAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1922
Db 2011 CCCTCTGACCTCTCGTGGCCATTGGCAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 2070
Qy 1923 AAGAGAACTCTCTCAACCACTTCTTCTAGGCTGGAGAGAGAGAGAGAGAGAGAGAG 1982
Db 2071 AAGAGAACTCTCTCAACCACTTCTTCTAGGCTGGAGAGAGAGAGAGAGAGAGAGAG 2130
Qy 1983 TTTCGAGATCACTGAG 2042
Db 2131 TTTCGAGATCACTGAG 2190
Qy 2043 TACTTCTCTCAACCACTTCTTCTAGGCTGGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 2102
Db 2191 TACTTCTCTCAACCACTTCTTCTAGGCTGGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 2250
Qy 2103 CTCTTCTCTTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 2141
Db 2251 CTCTTCTCTTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 2289

RESULT 7
US-10-158-787-267
Sequence 267, Application US/10158787
Publication No. US20040039164A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Beresini, Maureen
APPLICANT: DeForge, Laura
APPLICANT: Desnoyers, Luc
APPLICANT: Flivaioff, Ellen
APPLICANT: Gao, Wei-Qiang
APPLICANT: Geriltsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Gueney, Austin L.
APPLICANT: Sherwood, Steven
APPLICANT: Smith, Victoria
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K
APPLICANT: Wood, William
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
TITLE OF INVENTION: ACIDS ENCODING THE SAME
FILE REFERENCE: P330R1C449
CURRENT APPLICATION NUMBER: US/10/158,787
CURRENT FILING DATE: 2003-04-03
PRIOR APPLICATION NUMBER: 60/049911
PRIOR FILING DATE: 1997-06-18
PRIOR APPLICATION NUMBER: 60/056974
PRIOR FILING DATE: 1997-08-26
PRIOR APPLICATION NUMBER: 60/059113
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059115
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059117
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059122

Qy 3 AATGAGGCTGTGCGAG 62
Db 151 AATGAGGCTGTGCGAG 210
Qy 63 GCACTGAGGAG 122
Db 211 GCACTGAGGAG 270
Qy 123 ACCCTGCGAG 182
Db 271 ACCCTGCGAG 330
Qy 183 GAGCCAGTGAAG 242
Db 331 GAGCCAGTGAAG 390
Qy 243 AGGCGATGAG 302
Db 391 AGGCGATGAG 450
Qy 303 AGGCGATGAG 362
Db 451 AGGCGATGAG 510
Qy 363 GCAAGAGATGAG 422
Db 511 GCAAGAGATGAG 570
Qy 423 GAGAGCTGTGAG 482
Db 571 GAGAGCTGTGAG 630
Qy 483 TTCAATTAACCTTAACAG 542
Db 631 TTCAATTAACCTTAACAG 690
Qy 543 TTCAATTAACCTTAACAG 602
Db 691 TTCAATTAACCTTAACAG 750
Qy 603 GTGCTTGTGAG 662
Db 751 GTGCTTGTGAG 810
Qy 663 AAGGAG 722
Db 811 AAGGAG 870
Qy 723 AGGAGAGTGAAGTGTGCGAG 782
Db 871 AGGAGAGTGAAGTGTGCGAG 930

Query Match 98.1%; Score 2132.6; DB 13; Length 2290;
Best Local Similarity 99.8%; Pred. No. 0;
Matches 2135; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 783 TACATGACGCTCTCTGCAAGATATCTCCGCAAGCGGGAACAGCGCTTGAGACTCTCCAG 842
 DB 931 TACATGACGCTCTCTGCAAGATATCTCCGCAAGCGGGAACAGCGCTTGAGACTCTCCAG 990
 QY 843 CTGAGAACAGGATCTCTGCAAGATATCTCCGCAAGCGGGAACAGCGCTTGAGACTCTCCAG 902
 DB 991 CTGAGAACAGGATCTCTGCAAGATATCTCCGCAAGCGGGAACAGCGCTTGAGACTCTCCAG 1050
 QY 903 GACTGAGAACAGGATCTCTGCAAGATATCTCCGCAAGCGGGAACAGCGCTTGAGACTCTCCAG 962
 DB 1051 GACTGAGAACAGGATCTCTGCAAGATATCTCCGCAAGCGGGAACAGCGCTTGAGACTCTCCAG 1110
 QY 963 GGGGAGCTTGAGAGACGCTGCGAGAGGGGCTCTGCGAGAGCGGCTCCCGAGGACCC 1022
 DB 1111 GGGGAGCTTGAGAGACGCTGCGAGAGGGGCTCTGCGAGAGCGGCTCCCGAGGACCC 1170
 QY 1023 CCCGCTGCCCCCGCGGGGTCTTACCAACCAACCCATCTAACCGGATCATCAACCAATC 1082
 DB 1171 CCCGCTGCCCCCGCGGGGTCTTACCAACCAACCCATCTAACCGGATCATCAACCAATC 1230
 QY 1083 TCTACCAACAGATATCCAGATGACCAAGAACTGAGAGGCTGCGAGAGCGGCTCCCGAG 1142
 DB 1231 TCTACCAACAGATATCCAGATGACCAAGAACTGAGAGGCTGCGAGAGCGGCTCCCGAG 1290
 QY 1143 ATGCCACTCTCAGCAGCTCTCCATCTTCCACCGAGCGGTGCGGCGCATGAGAGAC 1202
 DB 1291 ATGCCACTCTCAGCAGCTCTCCATCTTCCACCGAGCGGTGCGGCGCATGAGAGAC 1350
 QY 1203 TGCCTGAGAGCGCTGAGAGATGCGCAACGACACTCTCATCTTACCTGTAAGCGGAG 1252
 DB 1351 TGCCTGAGAGCGCTGAGAGATGCGCAACGACACTCTCATCTTACCTGTAAGCGGAG 1410
 QY 1263 AACACCAACCGCTCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAG 1322
 DB 1411 AACACCAACCGCTCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAG 1470
 QY 1323 GTCATCCAGAGACGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAG 1382
 DB 1471 GTCATCCAGAGACGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAG 1530
 QY 1383 CAGGAGTTGGAGAACCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAG 1442
 DB 1531 CAGGAGTTGGAGAACCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAG 1590
 QY 1443 ACGAACCAAGGCACTACAACTCTGAGTACCATGAGAGGCTGAGAGGCTGAGAGGCTGAGAGG 1502
 DB 1591 ACGAACCAAGGCACTACAACTCTGAGTACCATGAGAGGCTGAGAGGCTGAGAGGCTGAGAGG 1650
 QY 1503 TTTGCAAGTATGCGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAG 1562
 DB 1651 TTTGCAAGTATGCGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAG 1710
 QY 1563 GGGCGCTACCATGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAG 1622
 DB 1711 GGGCGCTACCATGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAG 1770
 QY 1623 ACCCTGAGAGAGATCATGATCTTACACAGAGAACTGTGCTCCATCTACCAAGAGGAGG 1682
 DB 1771 ACCCTGAGAGAGATCATGATCTTACACAGAGAACTGTGCTCCATCTACCAAGAGGAGG 1830
 QY 1683 TGGTGGTATACGCGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGG 1742
 DB 1831 TGGTGGTATACGCGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGG 1890
 QY 1743 TACCGAGAGCGCTACCGAGAGGAGTCTAAGGAGTGAAGTTCGAGAGGCTTACTCA 1802
 DB 1891 TACCGAGAGCGCTACCGAGAGGAGTCTAAGGAGTGAAGTTCGAGAGGCTTACTCA 1950
 QY 1803 CTCAAGAAAGTGTGATGATCTGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1862
 DB 1951 CTCAAGAAAGTGTGATGATCTGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 2010
 QY 1863 CCTCTGACCTCTGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1922

DB 2011 CCTCTGACCTCTCTGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 2070
 QY 1923 AAGAGAACCTCTCTACCGAGTCTATGAGGCTGAGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1982
 DB 2071 AAGAGAACCTCTCTACCGAGTCTATGAGGCTGAGAGGAGGAGGAGGAGGAGGAGGAGGAGG 2130
 QY 1983 TTTCCGAGTCACTGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 2042
 DB 2131 TTTCCGAGTCACTGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 2190
 QY 2043 TACTTCTCTTACAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 2102
 DB 2191 TACTTCTCTTACAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 2250
 QY 2103 CTCTTCTTAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 2141
 DB 2251 CTCTTCTTAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 2289

RESULT 8
 US-10-140-024-267
 Sequence 267, Application US/10140024
 Publication No. US20040058424A1
 GENERAL INFORMATION:
 APPLICANT: Baker, Kevin P.
 APPLICANT: Beresini, Maureen
 APPLICANT: DeForge, Laura
 APPLICANT: Desnoyers, Luc
 APPLICANT: Filvaroff, Ellen
 APPLICANT: Gao, Wei-Qiang
 APPLICANT: Geriltsen, Mary E.
 APPLICANT: Goddard, Audrey
 APPLICANT: Godowski, Paul J.
 APPLICANT: Gurney, Austin L.
 APPLICANT: Sherwood, Steven
 APPLICANT: Smith, Victoria
 APPLICANT: Stewart, Timothy A.
 APPLICANT: Tumas, Daniel
 APPLICANT: Watanabe, Collin K
 APPLICANT: Wood, William
 APPLICANT: Zhang, Zemin
 TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
 FILE REFERENCE: P9330R1C69
 CURRENT APPLICATION NUMBER: US/10/140,024
 PRIOR APPLICATION: 2002-05-06
 NUMBER OF SEQ ID NOS: 550
 SEQ ID NO 267
 LENGTH: 2290
 TYPE: DNA
 ORGANISM: Homo Sapien
 US-10-140-024-267

Query Match 98.1%; Score 2132.6; DB 13; Length 2290;
 Best Local Similarity 99.8%; Pred. No. 0;
 Matches 2135; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 3 AAATGAGCTGCTGCGAGCGGCTGAGAGTAAACCCAGACCTTGAGCTGCGAGCGG 62
 DB 151 AAATGAGCTGCTGCGAGCGGCTGAGAGTAAACCCAGACCTTGAGCTGCGAGCGG 210
 QY 63 GCACTGAGGAGGAGGCTGAGAGGCTGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 122
 DB 211 GCACTGAGGAGGAGGCTGAGAGGCTGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 270
 QY 123 ACCCTGCGAGGCTGCGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 182
 DB 271 ACCCTGCGAGGCTGCGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 330
 QY 183 GAGCCAGTGAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 242

APPLICANT: Sherwood, Steven
 APPLICANT: Smith, Victoria
 APPLICANT: Stewart, Timothy A.
 APPLICANT: Tumas, Daniel
 APPLICANT: Watanabe, Colin K
 APPLICANT: Wood, William
 APPLICANT: Zhang, Zemin
 TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
 FILE REFERENCE: P3330R1C182
 CURRENT APPLICATION NUMBER: US/10/140,808
 PRIOR APPLICATION DATE: 2002-05-07
 NUMBER OF SEQ ID NOS: 550
 SEQ ID NO 267
 LENGTH: 2290
 TYPE: DNA
 ORGANISM: Homo Sapien
 US-10-140-808-267

Query Match 98.1%; Score 2132.6; DB 13; Length 2290;
 Best Local Similarity 99.8%; Pred. No. 0;
 Matches 2135; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 3 AATGAGGCTGCTGCGGAGGCGCTGAGATGAACCCCAAGCCCTGAGCTGCGGAGCGTG 62
 DB 151 AATGAGGCTGCTGCGGAGGCGCTGAGATGAACCCCAAGCCCTGAGCTGCGGAGCGTG 210
 QY 63 GCATGAGGCGGCGGCTGAGCTGCTGAGGAGAAAGAGTTGTAGAGAGCCCGCAGG 122
 DB 211 GCATGAGGCGGCGGCTGAGCTGCTGAGGAGAAAGAGTTGTAGAGAGCCCGCAGG 270
 QY 123 ACCCTGGCCAGCCCTGCGGAGGCGCTGCTGCGGAGGCGCTGCTGAGAGCGAGCGAGTG 182
 DB 271 ACCCTGGCCAGCCCTGCGGAGGCGCTGCTGCGGAGGCGCTGCTGAGAGCGAGCGAGTG 330
 QY 183 GAGCCAGTGAAGGCGAGGCGCTGCTGAGGAGCGAGGCGCTGAGAGCGAGGCGAGTG 242
 DB 331 GAGCCAGTGAAGGCGAGGCGCTGCTGAGGAGCGAGGCGCTGAGAGCGAGGCGAGTG 390
 QY 243 AGGCGATGAGCAAGGCTGCGGAGGCGCTGAGGAGCGAGGCGAGGCGAGTG 302
 DB 391 AGGCGATGAGCAAGGCTGCGGAGGCGCTGAGGAGCGAGGCGAGGCGAGTG 450
 QY 303 AGGCGATGAGCAAGGCTGCGGAGGCGCTGAGGAGCGAGGCGAGGCGAGTG 362
 DB 451 AGGCGATGAGCAAGGCTGCGGAGGCGCTGAGGAGCGAGGCGAGGCGAGTG 510
 QY 363 GCAAGAGCATGAGGCGAGGCGCTGAGGAGCGAGGCGAGGCGAGGCGAGTG 422
 DB 511 GCAAGAGCATGAGGCGAGGCGCTGAGGAGCGAGGCGAGGCGAGGCGAGTG 570
 QY 423 GAGGCTGTGAGGCGAGGCGAGGCGCTGAGGAGCGAGGCGAGGCGAGTG 482
 DB 571 GAGGCTGTGAGGCGAGGCGAGGCGCTGAGGAGCGAGGCGAGGCGAGTG 630
 QY 483 TTGATTTACCTTAACAGGCTGAGGAGGCGAGGCGAGGCGAGGCGAGTG 542
 DB 631 TTGATTTACCTTAACAGGCTGAGGAGGCGAGGCGAGGCGAGGCGAGTG 690
 QY 543 TTGATTTACCTTAACAGGCTGAGGAGGCGAGGCGAGGCGAGGCGAGTG 602
 DB 691 TTGATTTACCTTAACAGGCTGAGGAGGCGAGGCGAGGCGAGGCGAGTG 750
 QY 603 GTGCTTGTGAGGAGGCGAGGCGAGGCGAGGCGAGGCGAGGCGAGTG 662
 DB 751 GTGCTTGTGAGGAGGCGAGGCGAGGCGAGGCGAGGCGAGGCGAGTG 810
 QY 663 AAGCAGAGGCGAGGCGAGGCGAGGCGAGGCGAGGCGAGGCGAGTG 722
 DB 811 AAGCAGAGGCGAGGCGAGGCGAGGCGAGGCGAGGCGAGGCGAGTG 870
 QY 723 AGCGAGGCGAGGCGAGGCGAGGCGAGGCGAGGCGAGGCGAGTG 782

DB 871 AGCGAGGCGAGGCGAGGCGAGGCGAGGCGAGGCGAGGCGAGTG 930
 QY 783 TACATGAGGCTGCTGCGGAGGCGCTGAGATGATCCGGAAGCGGAGCAAGCGTTGAGCTGCCAG 842
 DB 931 TACATGAGGCTGCTGCGGAGGCGCTGAGATGATCCGGAAGCGGAGCAAGCGTTGAGCTGCCAG 990
 QY 843 CTGAGAGAGAGATCTCGAAGCGAGGCGAGGCGAGGCGAGGCGAGGCGAGTG 902
 DB 991 CTGAGAGAGAGATCTCGAAGCGAGGCGAGGCGAGGCGAGGCGAGGCGAGTG 1050
 QY 903 GACTGAGAGCAAGTACAGGAGGCGAGGCGAGGCGAGGCGAGGCGAGTG 962
 DB 1051 GACTGAGAGCAAGTACAGGAGGCGAGGCGAGGCGAGGCGAGGCGAGTG 1110
 QY 963 GCGAGGCTTGAAGAGGAGGCGAGGCGAGGCGAGGCGAGGCGAGGCGAGTG 1022
 DB 1111 GCGAGGCTTGAAGAGGAGGCGAGGCGAGGCGAGGCGAGGCGAGGCGAGTG 1170
 QY 1023 CCGGCTGCGGCGGCGGCTGAGCAAGCGAGGCGAGGCGAGGCGAGGCGAGTG 1082
 DB 1171 CCGGCTGCGGCGGCGGCTGAGCAAGCGAGGCGAGGCGAGGCGAGGCGAGTG 1230
 QY 1083 TCTACAGAGAGATCCAGAGGAGGCGAGGCGAGGCGAGGCGAGGCGAGTG 1142
 DB 1231 TCTACAGAGAGATCCAGAGGAGGCGAGGCGAGGCGAGGCGAGGCGAGTG 1290
 QY 1143 ATGCGCATCTCAACAGGCTGCGAGGCGAGGCGAGGCGAGGCGAGTG 1202
 DB 1291 ATGCGCATCTCAACAGGCTGCGAGGCGAGGCGAGGCGAGGCGAGTG 1350
 QY 1203 TGCTGAGAGGCGGCTGAGGAGGCGAGGCGAGGCGAGGCGAGGCGAGTG 1262
 DB 1351 TGCTGAGAGGCGGCTGAGGAGGCGAGGCGAGGCGAGGCGAGGCGAGTG 1410
 QY 1263 AACACCAAGCGCTCATGAGGAGGCGAGGCGAGGCGAGGCGAGGCGAGTG 1322
 DB 1411 AACACCAAGCGCTCATGAGGAGGCGAGGCGAGGCGAGGCGAGGCGAGTG 1470
 QY 1323 GTCATCCAGAGAGGCGCTGAGGAGGCGAGGCGAGGCGAGGCGAGTG 1382
 DB 1471 GTCATCCAGAGAGGCGCTGAGGAGGCGAGGCGAGGCGAGGCGAGTG 1530
 QY 1383 CAAAGGTTTGGGAAACATTAAGGCGAGGAGTATGAGGCGAGGCGAGTG 1442
 DB 1531 CAAAGGTTTGGGAAACATTAAGGCGAGGAGTATGAGGCGAGGCGAGTG 1590
 QY 1443 ACGAAGCAAGCACTAACAAGCTGAGGAGGCGAGGCGAGGCGAGTG 1502
 DB 1591 ACGAAGCAAGCACTAACAAGCTGAGGAGGCGAGGCGAGGCGAGTG 1650
 QY 1503 TTTGCAAAATTAAGGCGAGGCGAGGCGAGGCGAGGCGAGGCGAGTG 1562
 DB 1651 TTTGCAAAATTAAGGCGAGGCGAGGCGAGGCGAGGCGAGGCGAGTG 1710
 QY 1563 GGGCGCTACCATGAGGAGGCGAGGCGAGGCGAGGCGAGGCGAGTG 1622
 DB 1711 GGGCGCTACCATGAGGAGGCGAGGCGAGGCGAGGCGAGGCGAGTG 1770
 QY 1623 ACCCTGAGAGGAGATGATGATGCTTACAGGAGAACTGTGCGGAGGCGAGTG 1682
 DB 1771 ACCCTGAGAGGAGATGATGATGCTTACAGGAGAACTGTGCGGAGGCGAGTG 1830
 QY 1683 TGGTGATTAAGGCGCTGCGGAGGCGAGGCGAGGCGAGGCGAGTG 1742
 DB 1831 TGGTGATTAAGGCGCTGCGGAGGCGAGGCGAGGCGAGGCGAGTG 1890
 QY 1743 TACCGAGCGGCTTACAGAGGAGGCTTACAGGAGGCGAGGCGAGTG 1802
 DB 1891 TACCGAGCGGCTTACAGAGGAGGCTTACAGGAGGCGAGGCGAGTG 1950
 QY 1803 CTGAGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGTG 1862

1263 AACACCAACCGCTCATGCGAGTGTGTGCGACAGAGACACGACCCCGGGGGCTGTGACC 1322
 1411 AACACCAACCGCTCATGCGAGTGTGTGCGACAGAGACACGACCCCGGGGGCTGTGACC 1470
 1333 GTGATCCAGAGAGCGCTGTGATGCTGTGTAATCTTTCAGAGAACTGGGAGACGTAACAG 1382
 1471 GTATCCAGAGAGCGCTGTGATGCTGTGTAATCTTTCAGAGAACTGGGAGACGTAACAG 1530
 1383 CAAGGTTTGGGAGAACTTGAAGGCGGAAATATGAGTGGCTGGGCTGGAGAACTTATCTGAGT 1442
 1531 CAAGGTTTGGGAGAACTTGAAGGCGGAAATATGAGTGGCTGGGCTGGAGAACTTATCTGAGT 1590
 1443 ACGAACCAAGGCACTACAACTCTGTGTGACCATGTGAGAGAGATGCTCCGGCCGCAAGTTC 1502
 1591 ACGAACCAAGGCACTACAACTCTGTGTGACCATGTGAGAGAGATGCTCCGGCCGCAAGTTC 1650
 1503 TTTCAGAGAACTAGCCAGTTCCTGCTGTGAACTGTGAGAGAGATATTAATGAGTGGCTG 1562
 1651 TTTCAGAGAACTAGCCAGTTCCTGCTGTGAACTGTGAGAGAGATATTAATGAGTGGCTG 1710
 1563 GGGCGCTACCATGCGCAATGCGGATGACTCTTTTACATGGCAACGCGCAAGAGATTAC 1622
 1711 GGGCGCTACCATGCGCAATGCGGATGACTCTTTTACATGGCAACGCGCAAGAGATTAC 1770
 1623 ACCCTGAGACAGATCATATGATGTCTACACAGAGAACTGTGCTTACCTACCAAGAGAGAG 1682
 1771 ACCCTGAGACAGATCATATGATGTCTACACAGAGAACTGTGCTTACCTACCAAGAGAGAG 1830
 1683 TGGTGTATTAACGCTGTGCTCCCACTCAACCTCAACGCGGATCTGTACCTGCGCGGGCCAT 1742
 1831 TGGTGTATTAACGCTGTGCTCCCACTCAACCTCAACGCGGATCTGTACCTGCGCGGGCCAT 1890
 1743 TACCGAGGCGCTTACCAAGAGAGAGTCTATCTGAGGCTGAGTTCGAGAGAGCTTTACTCA 1802
 1891 TACCGAGGCGCTTACCAAGAGAGAGTCTATCTGAGGCTGAGTTCGAGAGAGCTTTACTCA 1950
 1803 CTCGAAGAAGTGTGTATGATGTATCCGACCGGAACTCCCAACCTTCCCACTTAAGCCAGCTCC 1862
 1951 CTCGAAGAAGTGTGTATGATGTATCCGACCGGAACTCCCAACCTTCCCACTTAAGCCAGCTCC 2010
 1863 CCCTCCTGACCTCTCTGTGCGCATTTGCGAGAGAGCCCACTCTGTGCTACGCTGGCGACAGAC 1922
 2011 CCCTCCTGACCTCTCTGTGCGCATTTGCGAGAGAGCCCACTCTGTGCTACGCTGGCGACAGAC 2070
 1923 AAGAGCAACTCTCTCAACGCTTATCTGTAGAGCTGGAGAGACCGGAGATCTGATTCGT 1982
 2071 AAGAGCAACTCTCTCAACGCTTATCTGTAGAGCTGGAGAGACCGGAGATCTGATTCGT 2130
 1983 TTCCGAGTCACTGAGCGAGATGATGAATGAACTGATGAGTGTGTTCTGTCTCTCC 2042
 2131 TTCCGAGTCACTGAGCGAGATGATGAATGAACTGATGAGTGTGTTCTGTCTCTCC 2190
 2043 TACTTCTCTTACACAGAGAGAGCTCTATGTCTCCAGAGACGAGACGAGACTACAGACAA 2102
 2191 TACTTCTCTTACACAGAGAGAGCTCTATGTCTCCAGAGACGAGACGAGACTACAGACAA 2250
 2103 CTCTTCTCTTAAATTAATTAAGTCTTACATTAATAACA 2141
 2251 CTCTTCTCTTAAATTAATTAAGTCTTACATTAATAAAAA 2289

RESULT 11
 US-10-127-852A-267
 Publication No. US20030203428A1
 GENERAL INFORMATION:
 APPLICANT: Baker, Kevin P.
 APPLICANT: Beresini, Maureen
 APPLICANT: DeForge, Laura
 APPLICANT: Desnoyers, Luc
 APPLICANT: Filvaroff, Ellen
 APPLICANT: Gao, Mei-Qiang
 APPLICANT: Gerlitsen, Mary E.

APPLICANT: Goddard, Audrey
 APPLICANT: Godowski, Paul J.
 APPLICANT: Gurney, Austin L.
 APPLICANT: Sherwood, Steven
 APPLICANT: Smith, Victoria
 APPLICANT: Stewart, Timothy A.
 APPLICANT: Tumas, Daniel
 APPLICANT: Watanabe, Colin K
 APPLICANT: Wood, William
 APPLICANT: Zhang, Zemin
 TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
 TITLE OR INVENTION: ACIDS ENCODING THE SAME
 FILE REFERENCE: B3330R0C8
 CURRENT APPLICATION NUMBER: US/10/127,852A
 PRIOR FILING DATE: 2002-10-15
 PRIOR APPLICATION NUMBER: 60/049911
 PRIOR FILING DATE: 1997-06-18
 PRIOR APPLICATION NUMBER: 60/056974
 PRIOR FILING DATE: 1997-08-26
 PRIOR APPLICATION NUMBER: 60/059113
 PRIOR FILING DATE: 1997-09-17
 PRIOR APPLICATION NUMBER: 60/059115
 PRIOR FILING DATE: 1997-09-17
 PRIOR APPLICATION NUMBER: 60/059117
 PRIOR FILING DATE: 1997-09-17
 PRIOR APPLICATION NUMBER: 60/059122
 PRIOR FILING DATE: 1997-09-17
 PRIOR APPLICATION NUMBER: 60/059184
 PRIOR FILING DATE: 1997-09-17
 PRIOR APPLICATION NUMBER: 60/059263
 PRIOR FILING DATE: 1997-09-18
 PRIOR APPLICATION NUMBER: 60/059352
 PRIOR FILING DATE: 1997-09-19
 PRIOR APPLICATION NUMBER: 60/059588
 PRIOR FILING DATE: 1997-09-19
 Remaining Prior Application data removed - See File Wrapper or PALM.
 NUMBER OF SEQ ID NOS: 550
 SEQ ID NO 267
 LENGTH: 2290
 TYPE: DNA
 ORGANISM: Homo Sapien
 US-10-127-852A-267
 Query Match 98.1%; Score 2132.6; DB 13; Length 2290;
 Best Local Similarity 99.8%; Pred. No. 0;
 Matches 2135; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 3 AATGAGGCTGCTGCGAGCGGCTTGAAGATGAACCCCAAGCCCTGAGCTGCGAGCGTG 62
 151 AATGAGGCTGCTGCGAGCGGCTTGAAGATGAACCCCAAGCCCTGAGCTGCGAGCGTG 210
 63 GCACTGAGGAGCGGCTGAGCGTACTGTGAGGAGAAAGGTTGTGAGAGAGCCCGCAG 122
 211 GCACTGAGGAGCGGCTGAGCGTACTGTGAGGAGAAAGGTTGTGAGAGAGCCCGCAG 270
 123 ACCCTGAGCAAGCCCTGAGCGCTTCTGCGAGAGCCCTCTGTGAGAGAGAGCCAG 182
 271 ACCCTGAGCAAGCCCTGAGCGCTTCTGCGAGAGCCCTCTGTGAGAGAGAGCCAG 330
 183 GAGCCAGTGAAGGAGGCTGTGAGAGAGCCAGCCAGCCCTCACTAGAGAACCCCTCCAG 242
 331 GAGCCAGTGAAGGAGGCTGTGAGAGAGCCAGCCAGCCCTCACTAGAGAACCCCTCCAG 390
 243 AGGCAATGAGAGGCTGCGCGCTGAGCGGCGAGGCTGAAGCATGTGAGAGAGCCCGCG 302
 391 AGGCAATGAGAGGCTGCGCGCTGAGCGGCGAGGCTGAAGCATGTGAGAGAGCCCGCG 450
 303 AGCCAGCAGAGAGGAGAGGCTTTCATGATTTCAATTCATCAAGATTAACCAATTTT 362
 451 AGCCAGCAGAGAGGAGAGGCTTTCATGATTTCAATTCATCAAGATTAACCAATTTT 510
 363 GCAAGACCATGAGGCGCACTGTGTGTGACATGTGTGTGTGTGTGTGTGTGTGTGTGT 422

Db 511 GCAGAGACCATGAGGCCACTGTGCTGACATGCTGNGGCTGGACTGCTGCTGCCATG 570
QY 423 GGAGCTGTGGCAGGCCAGAGAGAGCGGTTTGGAGGACCTGAGAGAGGGCTCCGCAAGAG 482
Db 571 GGAGCTGTGGCAGGCCAGAGAGAGCGGTTTGGAGGACCTGAGAGAGGGCTCCGCAAGAG 630
QY 483 TTGATTACTTAACAGAGTACAGAGCGGGGGGAGTCCAGAGCAAGTGCACCTACAC 542
Db 631 TTGATTACTTAACAGAGTACAGAGCGGGGGGAGTCCAGAGCAAGTGCACCTACAC 690
QY 543 TTGATTGTGCCCCAGAGAGCGGGGTCAAGGGTCCATCTGGTCAACTCCAGAGAGCTGAG 602
Db 691 TTGATTGTGCCCCAGAGAGCGGGGTCAAGGGTCCATCTGGTCAACTCCAGAGAGCTGAG 750
QY 603 GTGCTTCTGAGAGACCGAGTGCATTAAGCAGAGAGCTGAGCTGCTCAACATGAGCTGCTC 662
Db 751 GTGCTTCTGAGAGACCGAGTGCATTAAGCAGAGAGCTGAGCTGCTCAACATGAGCTGCTC 810
QY 663 AAGCAGAGCGGAGATCGAGAGCGCTGCAAGAGCTGAGAGAGTGAAGAGCGAGCATTTG 722
Db 811 AAGCAGAGCGGAGATCGAGAGCGCTGCAAGAGCTGAGAGAGTGAAGAGCGAGCATTTG 870
QY 723 AAGCAGAGTGAAGCTGTGCGCAGAGAGAGCGGCAATGTAATCTGCGGGGTCAAGAGCTC 782
Db 871 AAGCAGAGTGAAGCTGTGCGCAGAGAGAGCGGCAATGTAATCTGCGGGGTCAAGAGCTC 930
QY 783 TACATCAGCTCTGACAGAGATCATCCGCAAGCGGAGCAAGCGTTGAGCTCCAG 842
Db 931 TACATCAGCTCTGACAGAGATCATCCGCAAGCGGAGCAAGCGTTGAGCTCCAG 990
QY 843 CTGAGAGAAAGAGTCTCTGAACAGAGAGCGGAGATCTGAGTGGCCAGCAATGACAG 902
Db 991 CTGAGAGAAAGAGTCTCTGAACAGAGAGCGGAGATCTGAGTGGCCAGCAATGACAG 1050
QY 903 GACCTGAGAGCAAGATACAGAGAGCGGAGCAAGCTGAGCGGCAAGCAATGAGATGATC 962
Db 1051 GACCTGAGAGCAAGATACAGAGAGCGGAGCAAGCTGAGCGGCAAGCAATGAGATGATC 1110
QY 963 GCGAGCTTGAAGAGAGCTGCAAGAGAGGATGCGCTGCGGAGAGCGGCTCCAGCAAGC 1022
Db 1111 GCGAGCTTGAAGAGAGCTGCAAGAGAGGATGCGCTGCGGAGAGCGGCTCCAGCAAGC 1170
QY 1023 CCGGCTGCGCGCGCGCGGCTGTAACAGAGAGCGGAGAGCGGCTCCAGCAAGC 1082
Db 1171 CCGGCTGCGCGCGCGCGGCTGTAACAGAGAGCGGAGAGCGGCTCCAGCAAGC 1230
QY 1083 TCTACCAAGAGATCCAGAGTGAACAGAGCTGAGAGTGTGCTCAACCCCTGCTGCCACT 1142
Db 1231 TCTACCAAGAGATCCAGAGTGAACAGAGCTGAGAGTGTGCTCAACCCCTGCTGCCACT 1290
QY 1143 AAGCCCACTCTCAACAGAGCTCCATTTTCAACAGAGCGGCTGCGGCTCCAGAGAGAC 1202
Db 1291 AAGCCCACTCTCAACAGAGCTCCATTTTCAACAGAGCGGCTGCGGCTCCAGAGAGAC 1350
QY 1203 TGCCTGAGAGCGGCTGAGAGTGGCCAGAGCAAGAGTGTGCTCAACCTGCTGAGAGCGGAG 1262
Db 1351 TGCCTGAGAGCGGCTGAGAGTGGCCAGAGCAAGAGTGTGCTCAACCTGCTGAGAGCGGAG 1410
QY 1263 AACACCAACCGGCTCATGAGAGTGTGTGCGACAGAGAGAGCGAGCGGCGGAGCTGAGAC 1322
Db 1411 AACACCAACCGGCTCATGAGAGTGTGTGCGACAGAGAGAGCGAGCGGCGGAGCTGAGAC 1470
QY 1323 GTCATCAAGAGAGCGGCTGAGTGTGCTGTAACCTTCAAGAGAGCGGAGAGCGTACAG 1382
Db 1471 GTCATCAAGAGAGCGGCTGAGTGTGCTGTAACCTTCAAGAGAGCGGAGAGCGTACAG 1530
QY 1383 CAAGGGTTTGGAGAACTTGAAGCGGAGATCTGAGCTGAGGCTTGGAGAACTTTACTGCGTG 1442
Db 1531 CAAGGGTTTGGAGAACTTGAAGCGGAGATCTGAGCTGAGGCTTGGAGAACTTTACTGCGTG 1590
QY 1443 AAGAACCAAGAGCAATCAAACTCTGCTGAGAGCAATGAGAGTGTGCTGCGGCGGAGAGT 1502
Db 1591 AAGAACCAAGAGCAATCAAACTCTGCTGAGAGCAATGAGAGTGTGCTGCGGCGGAGAGT 1650

QY 1503 TTTGAGATATAGGCAAGTTTCCGCTGGAACCTGAGAGCGAGATATTAAGCTGCGGCTG 1562
Db 1651 TTTGAGATATAGGCAAGTTTCCGCTGGAACCTGAGAGCGAGATATTAAGCTGCGGCTG 1710
QY 1563 GGGCGCTACATGAGCAATGCGGAGTGAAGCTCTTACATGAGCAAGCGGAGAGAGTTCAC 1622
Db 1711 GGGCGCTACATGAGCAATGCGGAGTGAAGCTCTTACATGAGCAAGCGGAGAGAGTTCAC 1770
QY 1623 ACCCTGAGCAAGATCATGATGCTCAACAGAGAACTGTGCCCTACACAGAGAGAGG 1682
Db 1771 ACCCTGAGCAAGATCATGATGCTCAACAGAGAACTGTGCCCTACACAGAGAGAGG 1830
QY 1683 TGTGTGTATACGCTGTGAGCCCACTGCAAGCGGAGTGTGTGCTGCGGAGGAGCAT 1742
Db 1831 TGTGTGTATACGCTGTGAGCCCACTGCAAGCGGAGTGTGTGCTGCGGAGGAGCAT 1890
QY 1743 TACGAGAGCGGCTACAGAGAGAGTCTAGGCTGAGTTCAGAGAGGCTCTTACTCA 1802
Db 1891 TACGAGAGCGGCTACAGAGAGAGTCTAGGCTGAGTTCAGAGAGGCTCTTACTCA 1950
QY 1803 CTCAAGAGAGTGTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1862
Db 1951 CTCAAGAGAGTGTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 2010
QY 1863 CCTCTGAGCTCTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1922
Db 2011 CCTCTGAGCTCTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 2070
QY 1923 AAAGAACATCTCTCAGAGGATTCATCTGAGGCTGAGAGAGCGGAGAGTGTGATTTCTGT 1982
Db 2071 AAAGAACATCTCTCAGAGGATTCATCTGAGGCTGAGAGAGCGGAGAGTGTGATTTCTGT 2130
QY 1983 TTTCCGAAGTCACTGAGCGGAGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 2042
Db 2131 TTTCCGAAGTCACTGAGCGGAGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 2190
QY 2043 TACTTCTCTCAGAGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 2102
Db 2191 TACTTCTCTCAGAGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 2250
QY 2103 CTCTTCTTAAATTAATTAAGTCTCAATTAATAA 2141
Db 2251 CTCTTCTTAAATTAATTAAGTCTCAATTAATAA 2289

RESULT 12
US-10-127-900A-267
; Sequence 267, Application US/10127900A
; Publication No. US20030203429A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: Deforge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gettitsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P9330R1G81
; CURRENT APPLICATION NUMBER: US/10/127, 900A
; CURRENT FILING DATE: 2002-10-15

PRIOR APPLICATION NUMBER: 60/049911
 PRIOR FILING DATE: 1997-06-18
 PRIOR APPLICATION NUMBER: 60/056974
 PRIOR FILING DATE: 1997-08-26
 PRIOR APPLICATION NUMBER: 60/059113
 PRIOR FILING DATE: 1997-09-17
 PRIOR APPLICATION NUMBER: 60/059115
 PRIOR FILING DATE: 1997-09-17
 PRIOR APPLICATION NUMBER: 60/059117
 PRIOR FILING DATE: 1997-09-17
 PRIOR APPLICATION NUMBER: 60/059122
 PRIOR FILING DATE: 1997-09-17
 PRIOR APPLICATION NUMBER: 60/059184
 PRIOR FILING DATE: 1997-09-17
 PRIOR APPLICATION NUMBER: 60/059263
 PRIOR FILING DATE: 1997-09-18
 PRIOR APPLICATION NUMBER: 60/059352
 PRIOR FILING DATE: 1997-09-19
 PRIOR APPLICATION NUMBER: 60/059588
 PRIOR FILING DATE: 1997-09-19
 Remaining Prior Application data removed - See File Wrapper or PALM.
 NUMBER OF SEQ ID NOS: 550
 SEQ ID NO: 267
 LENGTH: 2290
 TYPE: DNA
 ORGANISM: Homo Sapien
 US-10-127-900A-267

Query Match 98.1%; Score 2132.6; DB 13; Length 2290;
 Best Local Similarity 99.8%; Pred. No. 0;
 Matches 215; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

3 AATGAGGCTGCTGCGAGCGGCTGAGATGAAACCCCAAGCCCTGAGCTGCGAGCGTG 62
 151 AATGAGGCTGCTGCGAGCGGCTGAGATGAAACCCCAAGCCCTGAGCTGCGAGCGTG 210
 63 GCATGAGGAGCGGCTGAGCTGAGTGAAGGAAAGAGTTGAGAGAGCCCGCAGG 122
 211 GCATGAGGAGCGGCTGAGCTGAGTGAAGGAAAGAGTTGAGAGAGCCCGCAGG 270
 123 ACCCTGAGCGAGCCCTGAGCCCAAGCTTGCAGAGCCCTCTGTGAGAGCAGAGCAGTG 182
 271 ACCCTGAGCGAGCCCTGAGCCCAAGCTTGCAGAGCCCTCTGTGAGAGCAGAGCAGTG 330
 183 GAGCCAGTGAAGCGGCTGCTGCTGAGCCCAAGCCCTGCAACTCAAGAGCCCTCCAG 242
 331 GAGCCAGTGAAGCGGCTGCTGCTGAGCCCAAGCCCTGCAACTCAAGAGCCCTCCAG 390
 243 AGGCAATGAGCGGCTGCGCCGCTGAGCGGCAAGGAGCATGTGAGAGAGCCCGCCG 302
 391 AGGCAATGAGCGGCTGCGCCGCTGAGCGGCAAGGAGCATGTGAGAGAGCCCGCCG 450
 303 AGCCAGCAGAGGAGGAGGCTTTTCATAGATTCTATTCACAAAGATTAACCAATTTT 362
 451 AGCCAGCAGAGGAGGAGGCTTTTCATAGATTCTATTCACAAAGATTAACCAATTTT 510
 363 GCAGAAACATGAGGCACTGTGCGCTGAGCATGTGAGGCTGAGAGCTGAGCTGCGAGT 422
 511 GCAGAAACATGAGGCACTGTGCGCTGAGCATGTGAGGCTGAGAGCTGAGCTGCGAGT 570
 423 GAGAGCTTGAAGCGGAGGAGCGGTTTGAAGGCACTGAGAGAGGCTGCGCAAGAG 482
 571 GAGAGCTTGAAGCGGAGGAGCGGTTTGAAGGCACTGAGAGAGGCTGCGCAAGAG 630
 483 TTCAATTACCTAAACAGGTACAAAGCGGCGGCGGAGTCCCAAGACAAAGTCACTTAAC 690
 631 TTCAATTACCTAAACAGGTACAAAGCGGCGGCGGAGTCCCAAGACAAAGTCACTTAAC 690
 543 TTCAATTGTCGCGAGAGCGGCTCAAGGAGGCTGAGTCACTTCAAGAGAGCTGAG 602
 691 TTCAATTGTCGCGAGAGCGGCTCAAGGAGGCTGAGTCACTTCAAGAGAGCTGAG 750
 603 GTGCTTCTGAGAACCGAGTGCATTAAGCAGAGGCTGAGCTGCTCAACATGAGCTGCT 662

751 GTGCTTCTGAGAACCGAGTGCATTAAGCAGAGGCTGAGCTGCTCAACATGAGCTGCTC 810
 663 AAGCAAGAGGAGGAGTCCAGAGCGGCTGAGCTGAGTGAAGTGAAGCGGCGCAATTG 722
 811 AAGCAAGAGGAGGAGTCCAGAGCGGCTGAGCTGAGTGAAGTGAAGCGGCGCAATTG 870
 723 AGCAGAGTGAAGTGTGCGCAAGAGAGCGGCAATGAACCTGCGGAGTCAAGCAGCTC 782
 871 AGCAGAGTGAAGTGTGCGCAAGAGAGCGGCAATGAACCTGCGGAGTCAAGCAGCTC 930
 783 TACATGAGCTCTGCAAGAGATTCATCCGCAAGCGGAGCAAGCGGCTTGAAGCTTCCAG 842
 931 TACATGAGCTCTGCAAGAGATTCATCCGCAAGCGGAGCAAGCGGCTTGAAGCTTCCAG 990
 843 CTGAGAGACAGATCTGAGACAGAGCGGAGCATGCTGAGTGCAGCAAGTCAAG 902
 991 CTGAGAGACAGATCTGAGACAGAGCGGAGCATGCTGAGTGCAGCAAGTCAAG 1050
 903 GACCTGAGAGCAAGTACCAAGACCTGAGCCCACTGAGCCCAACCAATCAAGATCAATC 962
 1051 GACCTGAGAGCAAGTACCAAGACCTGAGCCCACTGAGCCCAACCAATCAAGATCAATC 1110
 963 GCGAGCTTGAAGAGAGCTGCGCAGAGGAGTCCCTGCGCCAGCGGCTGCGCCAGCCACC 1022
 1111 GCGAGCTTGAAGAGAGCTGCGCAGAGGAGTCCCTGCGCCAGCGGCTGCGCCAGCCACC 1170
 1023 CCGGCTGCGCCCGCGGAGTCTTCAACCAAGCCCACTTCAAGCGGATCAATCAAGATC 1082
 1171 CCGGCTGCGCCCGCGGAGTCTTCAACCAAGCCCACTTCAAGCGGATCAATCAAGATC 1230
 1083 TCTACCAAGAGATCCAGAGTACCAAGACCTGAGAGTGTGCAAGCCCTGCGCCACT 1142
 1231 TCTACCAAGAGATCCAGAGTACCAAGACCTGAGAGTGTGCAAGCCCTGCGCCACT 1290
 1143 ATGCCCACTCTCAACAGAGCTCCCATCTTCCAGCAGAGCGGCTGCGCCCATGAGAGAG 1202
 1291 ATGCCCACTCTCAACAGAGCTCCCATCTTCCAGCAGAGCGGCTGCGCCCATGAGAGAG 1350
 1203 TGCTGCAAGGCTGAGAGATGAGCAGAGACAGAGCTTCACTTCACTGAGTGAAGCGGAG 1262
 1351 TGCTGCAAGGCTGAGAGATGAGCAGAGACAGAGCTTCACTTCACTGAGTGAAGCGGAG 1410
 1263 AACACCAAGCGCTCATGAGAGTGTGAGTGAAGCAGAGACAGAGCCCGGAGCTGAGAC 1322
 1411 AACACCAAGCGCTCATGAGAGTGTGAGTGAAGCAGAGACAGAGCCCGGAGCTGAGAC 1470
 1323 GTCAATCAGAGAGCGCTGAGTGTGCTTGAATCTTCTTCAAGAACTGAGAGAGTCAAG 1382
 1471 GTCAATCAGAGAGCGCTGAGTGTGCTTGAATCTTCTTCAAGAACTGAGAGAGTCAAG 1530
 1383 CAAGGCTTGAAGAGATGAGAGCGGAGATATGAGCTGAGGCTGAGAGAACTTACTGAGCT 1442
 1531 CAAGGCTTGAAGAGATGAGAGCGGAGATATGAGCTGAGGCTGAGAGAACTTACTGAGCT 1590
 1443 ACGAACCAAGGCACTCAAACTCTGAGTACCATGAGAGAGCTGATCCGCGCGCAAGT 1502
 1591 ACGAACCAAGGCACTCAAACTCTGAGTACCATGAGAGAGCTGATCCGCGCGCAAGT 1650
 1503 TTTGCAAGAAATGAGCACTTTCCGCTGAGAACTGAGAGAGGATTAATTAAGCTGAGGCT 1562
 1651 TTTGCAAGAAATGAGCACTTTCCGCTGAGAACTGAGAGAGGATTAATTAAGCTGAGGCT 1710
 1563 GAGGCTTACCATGAGAGTGAAGTCTCTTCAATGAGCAGAGCGGAGCAAGTCAAC 1622
 1711 GAGGCTTACCATGAGAGTGAAGTCTCTTCAATGAGCAGAGCGGAGCAAGTCAAC 1770
 1623 ACCCTGAGCAGAGATCAATGATGCTTCAAGAGAACTGTGCGCACTTCAAGAGAGAGG 1682
 1771 ACCCTGAGCAGAGATCAATGATGCTTCAAGAGAACTGTGCGCACTTCAAGAGAGAGG 1830
 1683 TGTGATTAATGAGCGGCTGAGCACTTCAAGAGGCTGAGTCAAGCGGAGGAGCAT 1742

Db 1831 TGGTGTATACGCGCTGTGCCCCATCTCAACCGGGGTGTGTACCGCGGGGCCAT 1890
Qy 1743 TACCGAGCGCTACACGAGAGCTCTACTGGGCTGAGTCCGAGAGGCTTACTCA 1802
Db 1891 TACCGAGCGCTACACGAGAGCTCTACTGGGCTGAGTCCGAGAGGCTTACTCA 1950
Qy 1803 CTCAGAAAGTGTATGATGATCCGAAACCCCAACCTTCCACTAACCCAGCTCC 1862
Db 1951 CTCAGAAAGTGTATGATGATCCGAAACCCCAACCTTCCACTAACCCAGCTCC 2010
Qy 1863 CCTCGTACCTCTCGTGGCCATTTGCGAGAGCCCACTGTGTACGCTGGCGCAAGAC 1922
Db 2011 CCTCGTACCTCTCGTGGCCATTTGCGAGAGCCCACTGTGTACGCTGGCGCAAGAC 2070
Qy 1923 AAGAAACAACCTCTCAACGATTCTGAGGCTGGGAGACCGGATGCTGATTTCTGT 1982
Db 2071 AAGAAACAACCTCTCAACGATTCTGAGGCTGGGAGACCGGATGCTGATTTCTGT 2130
Qy 1983 TTTCGGAAGTCACTGAGGAGATGATGAACTGAATCGATACGGTGTCTTCTGCTCC 2042
Db 2131 TTTCGGAAGTCACTGAGGAGATGATGAACTGAATCGATACGGTGTCTTCTGCTCC 2190
Qy 2043 TACTTCTCTTCAACGAGACAGCCCTCATGTCTCCAGAGACAGAGACTACAGACA 2102
Db 2191 TACTTCTCTTCAACGAGACAGCCCTCATGTCTCCAGAGACAGAGACTACAGACA 2250
Qy 2103 CTCTTCTCTTAAATTAATTAAGTCTCTAATAAACA 2141
Db 2251 CTCTTCTCTTAAATTAATTAAGTCTCTAATAAACA 2289

RESULT 13
US-10-128-685A-267

/ Sequence 267, Application US/10128685A
/ Publication No. US20030203430A1
/ GENERAL INFORMATION:
/ APPLICANT: Baker, Kevin P.
/ APPLICANT: Beresini, Maureen
/ APPLICANT: DeForge, Laura
/ APPLICANT: Desnoyers, Luc
/ APPLICANT: Filvaroff, Ellen
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Gerritsen, Mary E.
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Sherwood, Steven
/ APPLICANT: Smith, Victoria
/ APPLICANT: Stewart, Timothy A.
/ APPLICANT: Tumas, Daniel
/ APPLICANT: Watanabe, Colin K
/ APPLICANT: Wood, William
/ APPLICANT: Zhang, Zemin
/ TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
/ FILE REFERENCE: P3330R1C116
/ CURRENT APPLICATION NUMBER: US/10/128,685A
/ PRIOR FILING DATE: 2002-04-23
/ PRIOR APPLICATION NUMBER: 60/049911
/ PRIOR FILING DATE: 1997-06-18
/ PRIOR APPLICATION NUMBER: 60/056974
/ PRIOR FILING DATE: 1997-08-26
/ PRIOR APPLICATION NUMBER: 60/059113
/ PRIOR FILING DATE: 1997-09-17
/ PRIOR APPLICATION NUMBER: 60/059115
/ PRIOR FILING DATE: 1997-09-17
/ PRIOR APPLICATION NUMBER: 60/059117
/ PRIOR FILING DATE: 1997-09-17
/ PRIOR APPLICATION NUMBER: 60/059122
/ PRIOR FILING DATE: 1997-09-17
/ PRIOR APPLICATION NUMBER: 60/059184
/ PRIOR FILING DATE: 1997-09-17
/ PRIOR APPLICATION NUMBER: 60/059263

/ PRIOR FILING DATE: 1997-09-18
/ PRIOR APPLICATION NUMBER: 60/059352
/ PRIOR FILING DATE: 1997-09-19
/ PRIOR APPLICATION NUMBER: 60/059588
/ PRIOR FILING DATE: 1997-09-19
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ SEQ ID NO: 267
/ LENGTH: 2290
/ TYPE: DNA
/ ORGANISM: Homo Sapien
US-10-128-685A-267

Query Match 98.1%; Score 2132.6; DB 13; Length 2290;
Best Local Similarity 99.8%; Pred. No. 0;
Matches 2135; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 3 AATGAGGCTGTGCGGAGCGCTGAGGATGAACCCCAAGCCCTGAGCTGCGGAGCTG 62
Db 151 AATGAGGCTGTGCGGAGCGCTGAGGATGAACCCCAAGCCCTGAGCTGCGGAGCTG 210
Qy 63 GCACGTGAGCAGCGGCTGACGCTACTGTGAGGAAAGAGTTGTAGCAGGCCCGCAGG 122
Db 211 GCACGTGAGCAGCGGCTGACGCTACTGTGAGGAAAGAGTTGTAGCAGGCCCGCAGG 270
Qy 123 ACCCTGCGCAGCCCTGCGCCCAAGCTCTGCGGAGCCCTGTGTGAGGCAAGCCAGT 182
Db 271 ACCCTGCGCAGCCCTGCGCCCAAGCTCTGCGGAGCCCTGTGTGAGGCAAGCCAGT 330
Qy 183 GAGCCAGTAGAGGAGGAGGCTGTGTGAGGCAACCGGCTGCAATCGAACCCTTCAG 242
Db 331 GAGCCAGTAGAGGAGGAGGCTGTGTGAGGCAACCGGCTGCAATCGAACCCTTCAG 390
Qy 243 AGGCGATGACAGGCTGCCCCGCTGACGCGCCAGGCTGAAGCATGTGAGAGCGGCCGG 302
Db 391 AGGCGATGACAGGCTGCCCCGCTGACGCGCCAGGCTGAAGCATGTGAGAGCGGCCGG 450
Qy 303 AGCCAGCAGAGGAGGAGGAGGCTTTCAATGATTTATTCACAAAGATAACCAATTT 362
Db 451 AGCCAGCAGAGGAGGAGGAGGCTTTCAATGATTTATTCACAAAGATAACCAATTT 510
Qy 363 GCAAAAGCAGTAGAGGAGGAGGCTGTGTGAGGCAATGTGTGCTGCTGCTGCTGCTG 422
Db 511 GCAAAAGCAGTAGAGGAGGAGGCTGTGTGAGGCAATGTGTGCTGCTGCTGCTGCTG 570
Qy 423 GAGCTGTGTGAGGAGGAGGAGGAGGCTGTGTGAGGCAATGTGTGCTGCTGCTGCTG 482
Db 571 GAGCTGTGTGAGGAGGAGGAGGAGGCTGTGTGAGGCAATGTGTGCTGCTGCTGCTG 630
Qy 483 TTCAATTACCTAAACAGGTACAGCGGCGGAGGAGGCTGCAAGAGTGCACCTACAC 542
Db 631 TTCAATTACCTAAACAGGTACAGCGGCGGAGGAGGCTGCAAGAGTGCACCTACAC 690
Qy 543 TTCAATTGTGCGCCAGCAGCGGCTGACGCGGCTGCTGCTGCTGCTGCTGCTGCTG 602
Db 691 TTCAATTGTGCGCCAGCAGCGGCTGACGCGGCTGCTGCTGCTGCTGCTGCTGCTG 750
Qy 603 GTGCTTGTGAGAGACGAGTGCATTAAGCAGAGCTGAGTGTGCTGCTGCTGCTGCTG 662
Db 751 GTGCTTGTGAGAGACGAGTGCATTAAGCAGAGCTGAGTGTGCTGCTGCTGCTGCTG 810
Qy 663 AAGCAGAGCGGAGATGAGAGCTGAGAGCTGCTGCTGCTGCTGCTGCTGCTGCTG 722
Db 811 AAGCAGAGCGGAGATGAGAGCTGAGAGCTGCTGCTGCTGCTGCTGCTGCTGCTG 870
Qy 723 AGGAGGTGAAGCTGCTGCGCAGAGGAGGCGGCAATGAATCTGCGGGTCAAGCAGCTC 782
Db 871 AGGAGGTGAAGCTGCTGCGCAGAGGAGGCGGCAATGAATCTGCGGGTCAAGCAGCTC 930
Qy 783 TACATGAGCTCTGACGAGATCATCCGACGCGGACAAACGCTTGAAGCTCTCCAG 842
Db 931 TACATGAGCTCTGACGAGATCATCCGACGCGGACAAACGCTTGAAGCTCTCCAG 990

Db	2071	AAAGACACTCCTCACCAATTCATCTGAGGGCTGGAGGACC GGGAATGCATGTCTGT	2130
Gy	1863	TTTCCGAAGTCACCGACGGAGTAGAAGAACTGAATGATAGCGTGTTTTCTGACCTCC	2042
Db	2131	TTTCCGAAGTCACCGACGGAGTAGAAGAACTGAATGATAGCGTGTTTTCTGACCTCC	2190
Gy	2043	TACTTTCTTCACACACGACAGCCCCCATGTCTCCAGGACAGAACGATACAGACAA	2102
Db	2191	TACTTTCTTCACACACGACAGCCCCCATGTCTCCAGGACAGGACAGGACTACAGACAA	2250
Gy	2103	CTCTTCTTTAAATAAATTAAAGTCTCTACAATAAAAAACA	2141
Db	2251	CTCTTCTTTAAATAAATTAAAGTCTCTACAATAAAAAAAA	2289

98.1%; Score 2132.6; DB 13; Length 2290;
99.8%; Pred. No. 0;

Matches 2135; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 3 AATATGAGGTGCTGCGGACGAGGCTTGAAGATGAACCCCAAGCCCTGGACCTGCGAGCTG 62
 Db 151 AATATGAGGTGCTGCGGACGAGGCTTGAAGATGAACCCCAAGCCCTGGACCTGCGAGCTG 210
 QY 63 GCACTAGGACGAGGCTGAGCGCTACTGTAGAGGAAAGAGTTGTAGAGAGCCCGCAGG 122
 Db 211 GCACTAGGACGAGGCTGAGCGCTACTGTAGAGGAAAGAGTTGTAGAGAGCCCGCAGG 270
 QY 123 ACCCTGCGCAGCCCTGCGCCCAAGCTTGTGCGGAGCCCTGTGTAGAGGACAGCCAGT 182
 Db 271 ACCCTGCGCAGCCCTGCGCCCAAGCTTGTGCGGAGCCCTGTGTAGAGGACAGCCAGT 330
 QY 183 GAGCCAGTGAAGGAGGAGGCTGTGTCAGGACCCGCGCTGCAACTCAGGAAACCCCTCAG 242
 Db 331 GAGCCAGTGAAGGAGGAGGCTGTGTCAGGACCCGCGCTGCAACTCAGGAAACCCCTCAG 390
 QY 243 AGGCGATGACAGGCTGCGCCGCTGACGCGCAGGCTGAGCATGTAGAGAGCGCGCCGG 302
 Db 391 AGGCGATGACAGGCTGCGCCGCTGACGCGCAGGCTGAGCATGTAGAGAGCGCGCCGG 450
 QY 303 AGCCAGACGAGAGGAGAGGCTTTGATGATTTCTATTCAAAAGATTAACCAATTT 362
 Db 451 AGCCAGACGAGAGGAGAGGCTTTGATGATTTCTATTCAAAAGATTAACCAATTT 510
 QY 363 GCAAAAGCATGAGGACCTGTGCTGACATGCTGTGCTGCGACTGCTGCTGCTGCAATG 422
 Db 511 GCAAAAGCATGAGGACCTGTGCTGACATGCTGTGCTGCGACTGCTGCTGCTGCAATG 570
 QY 423 GAGGCTGTGACGAGGACGAGGAGCGTTTGAAGGCACTGAGAGGAGCTGCGCAAGAG 482
 Db 571 GAGGCTGTGACGAGGACGAGGAGCGTTTGAAGGCACTGAGAGGAGCTGCGCAAGAG 630
 QY 483 TTCAATTACTTAAACAGGTACAAAGGAGGAGGAGGAGTCCAGAGCAAGTGCACTACAC 542
 Db 631 TTCAATTACTTAAACAGGTACAAAGGAGGAGGAGGAGTCCAGAGCAAGTGCACTACAC 690
 QY 631 TTCAATTACTTAAACAGGTACAAAGGAGGAGGAGGAGTCCAGAGCAAGTGCACTACAC 690
 Db 691 TTCAATTACTTAAACAGGTACAAAGGAGGAGGAGGAGTCCAGAGCAAGTGCACTACAC 750
 QY 543 TTCAATTACTTAAACAGGTACAAAGGAGGAGGAGGAGTCCAGAGCAAGTGCACTACAC 602
 Db 691 TTCAATTACTTAAACAGGTACAAAGGAGGAGGAGGAGTCCAGAGCAAGTGCACTACAC 750
 QY 603 GTGCTTTGAGAGAACCGAGTGCATAGCAGGAGCTAGAGCTGCTCAACATAGTGTCTC 662
 Db 751 GTGCTTTGAGAGAACCGAGTGCATAGCAGGAGCTAGAGCTGCTCAACATAGTGTCTC 810
 QY 663 AAGCAGAAAGCGGACAGTGCAGAGCGTGCAGAGCTGTGTAAGTGAAGCGCGCATTTGTG 722
 Db 811 AAGCAGAAAGCGGACAGTGCAGAGCGTGCAGAGCTGTGTAAGTGAAGCGCGCATTTGTG 870
 QY 723 AAGCAGAGTGAAGCTGTGCGCAAGGAGAGCCGCAACATGAACTCGCGGCTCACAGCTTC 782
 Db 871 AAGCAGAGTGAAGCTGTGCGCAAGGAGAGCCGCAACATGAACTCGCGGCTCACAGCTTC 930
 QY 871 AAGCAGAGTGAAGCTGTGCGCAAGGAGAGCCGCAACATGAACTCGCGGCTCACAGCTTC 930
 Db 931 AAGCAGAGTGAAGCTGTGCGCAAGGAGAGCCGCAACATGAACTCGCGGCTCACAGCTTC 990
 QY 843 CTGAGAAACAGAGATCCTGAACAGACAGCCGCAATGTCTGACGTGGCCAGCAAGTACAG 902
 Db 991 CTGAGAAACAGAGATCCTGAACAGACAGCCGCAATGTCTGACGTGGCCAGCAAGTACAG 1050
 QY 903 GACCTGAGGACAAAGTACAGACAGCTGCGCAACATGTGCGCCCAACCAATTCAGAGTATC 962
 Db 1051 GACCTGAGGACAAAGTACAGACAGCTGCGCAACATGTGCGCCCAACCAATTCAGAGTATC 1110
 QY 963 GCGCAGCTTGAAGAGACTGCCAGAGAGGAGGCTGCGCGCAGGCGCGTCCCGCAGCAGCC 1022
 Db 1111 GCGCAGCTTGAAGAGACTGCCAGAGAGGAGGCTGCGCGCAGGCGCGTCCCGCAGCAGCC 1170
 QY 1023 CCGCGTGGCCCGCCCGGGTTCACCAACACCACTTACAAACCGATATCAACAGATC 1082
 Db 1171 CCGCGTGGCCCGCCCGGGTTCACCAACACCACTTACAAACCGATATCAACAGATC 1230

QY 1083 TCTACCAACGAGATTCAGAGTGAACCAAGACCTGAAGTGTCTGCCACCCCTCTGCGCACT 1142
 Db 1231 TCTACCAACGAGATTCAGAGTGAACCAAGACCTGAAGTGTCTGCCACCCCTCTGCGCACT 1290
 QY 1143 ATGCCACTCTCACACGCTTCCATCTTCCACCGACAGCCGCTGAGGAGGAGAGC 1202
 Db 1291 ATGCCACTCTCACACGCTTCCATCTTCCACCGACAGCCGCTGAGGAGGAGAGC 1350
 QY 1203 TGCTGAGAGGCTGAGAGATGCGCACAGACCAAGCTTCATCTTCTGTGTAAGCCGAG 1262
 Db 1351 TGCTGAGAGGCTGAGAGATGCGCACAGACCAAGCTTCATCTTCTGTGTAAGCCGAG 1410
 QY 1263 AAGACCAACGCGCTTACAGAGTGTGTGAGACCAAGACAGCCCGGAGGCTGAGAC 1322
 Db 1411 AAGACCAACGCGCTTACAGAGTGTGTGAGACCAAGACAGCCCGGAGGCTGAGAC 1470
 QY 1323 GTCATCCAGAGACCGCTGATGCTCTGTTAATCTTTCAGAACTGTGAGAGCTACAG 1382
 Db 1471 GTCATCCAGAGAGCGCTGATGCTCTGTTAATCTTTCAGAACTGTGAGAGCTACAG 1530
 QY 1383 CAAGGTTTGGGAACTTGAACGCGGATTAATGCTGCGCTGAGAACTTTACTGCTG 1442
 Db 1531 CAAGGTTTGGGAACTTGAACGCGGATTAATGCTGCGCTGAGAACTTTACTGCTG 1590
 QY 1443 ACGAACCAAGCACTACAACTCTGCTGAGACATGAGAGGACTGCTCCGCGCGCAAGTC 1502
 Db 1591 ACGAACCAAGCACTACAACTCTGCTGAGACATGAGAGGACTGCTCCGCGCGCAAGTC 1560
 QY 1503 TTTGCAAGATACGCAAGTTTCCGCTGGAACCTGAGAGCGAGTATTAAGCTGCGCTG 1562
 Db 1651 TTTGCAAGATACGCAAGTTTCCGCTGGAACCTGAGAGCGAGTATTAAGCTGCGCTG 1710
 QY 1563 GGGCGCTACCATGAGCAATGCGGAGTACTGCTTTAATGAGGACAAAGGCAAGCTTACC 1622
 Db 1711 GGGCGCTACCATGAGCAATGCGGAGTACTGCTTTAATGAGGACAAAGGCAAGCTTACC 1770
 QY 1623 ACCCTGACAGAGATTCATGATGTCTACAGAGAACTGTGCCCATACAGAAAGGAGGC 1682
 Db 1771 ACCCTGACAGAGATTCATGATGTCTACAGAGAACTGTGCCCATACAGAAAGGAGGC 1830
 QY 1683 TGTGATATTAACGCTGTGCGCACTCCAACTCAACGCGGCTGTGTACCGCGGGGCGCAT 1742
 Db 1831 TGTGATATTAACGCTGTGCGCACTCCAACTCAACGCGGCTGTGTACCGCGGGGCGCAT 1890
 QY 1743 TACCGAGCGCTACACAGAGCGAGTCTAGGCTGAGTTCCAGAGGAGCTTTACTCA 1802
 Db 1891 TACCGAGCGCTACACAGAGCGAGTCTAGGCTGAGTTCCAGAGGAGCTTTACTCA 1950
 QY 1803 CTCAAGAAAGTGTGATGATGATTCGACCGAACCACCACTTTCACCTAAGCCAGCTCC 1862
 Db 1951 CTCAAGAAAGTGTGATGATGATTCGACCGAACCACCACTTTCACCTAAGCCAGCTCC 2010
 QY 1863 CCGCTCTGACCTCTGCGGACCTTGGCAGAGGACCACTCGTGTCAAGCGTCCAGCAGC 1922
 Db 2011 CCGCTCTGACCTCTGCGGACCTTGGCAGAGGACCACTCGTGTCAAGCGTCCAGCAGC 2070
 QY 1923 AAGACCAACTCTCTGACAGTTCATCTGAGGCTGTGAGAGACCGGAGTGTGATTTCTGT 1982
 Db 2071 AAGACCAACTCTCTGACAGTTCATCTGAGGCTGTGAGAGACCGGAGTGTGATTTCTGT 2130
 QY 1983 TTTTCCGAAGTCACTGACGCGGAGTGAATGGAATGAATGGAATGGAATGGAATGGAATG 2042
 Db 2131 TTTTCCGAAGTCACTGACGCGGAGTGAATGGAATGAATGGAATGGAATGGAATGGAATG 2190
 QY 2043 TACTTTCTTCAACACAGAGCCCTCATGTCTCCAGACAGACAGACAGACAGACAGACAG 2102
 Db 2191 TACTTTCTTCAACACAGAGCCCTCATGTCTCCAGACAGACAGACAGACAGACAGACAG 2250
 QY 2103 CTCCTTCTTAAATTAATTAAGTCTCTACAAATTAATAA 2141
 Db 2251 CTCCTTCTTAAATTAATTAAGTCTCTACAAATTAATAA 2289

RESULT 15
US-10-142-886-267
/ Sequence 267, Application US/10142886
/ Publication No. US20030203432A1
/ GENERAL INFORMATION:
/ APPLICANT: Baker, Kevin P.
/ APPLICANT: Beresini, Maureen
/ APPLICANT: DeForge, Laura
/ APPLICANT: Desnoyers, Ellen
/ APPLICANT: Filvaroff, Ellen
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Geritsen, Mary E.
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Sherwood, Steven
/ APPLICANT: Smith, Victoria
/ APPLICANT: Stewart, Timothy A.
/ APPLICANT: Tumas, Daniel
/ APPLICANT: Watanabe, Colin K.
/ APPLICANT: Wood, William
/ APPLICANT: Zhang, Zemin
/ TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
/ FILE REFERENCE: P330R1C236
/ CURRENT APPLICATION NUMBER: US/10/142,886
/ PRIORITY FILING DATE: 2002-05-10
/ NUMBER OF SEQ ID NOS: 550
/ SEQ ID NO 267
/ LENGTH: 2290
/ TYPE: DNA
/ ORGANISM: Homo Sapien
US-10-142-886-267
Query Match 98.1%; Score 2132.6; DB 13; Length 2290;
Best Local Similarity 99.8%; Pred. No. 0;
Matches 2135; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 3 AANTGAGGCTGCTGCGGAGCGGCTGAGATGAACCCCAAGCCTGAGCCTGCGAGCTG 62
DB 151 AANTGAGGCTGCTGCGGAGCGGCTGAGATGAACCCCAAGCCTGAGCCTGCGAGCTG 210
QY 63 GCACTGAGGCGAGGCGCTGACGCTACTGTGAGGAGAAAGGTTGTGAGAGCCCGCGAG 122
DB 211 GCACTGAGGCGAGGCGCTGACGCTACTGTGAGGAGAAAGGTTGTGAGAGCCCGCGAG 270
QY 123 ACCCTGCGCAGCCTGCGCCCGCAGCCTGCGGAGCCTCTGTGAGAGCGAGCCAGT 182
DB 271 ACCCTGCGCAGCCTGCGCCCGCAGCCTCTGTGAGAGCCTCTGTGAGAGCGAGCCAGT 330
QY 183 GAGCCAGTGAAGGAGGCTGCTGTGACAGCAACCGGCTGCAACTCAGGAAACCCCTCGAG 242
DB 331 GAGCCAGTGAAGGAGGCTGCTGTGACAGCAACCGGCTGCAACTCAGGAAACCCCTCGAG 390
QY 243 AGGCGATGAGCAGGCTGCGCCCGCTGACGCGCAGGAGTGAAGCATGTGAGAGAGCGCCCGG 302
DB 391 AGGCGATGAGCAGGCTGCGCCCGCTGACGCGCAGGAGTGAAGCATGTGAGAGAGCGCCCGG 450
QY 303 AGGCGAGGAGGAGGAGGCTTTCATAGATTCTATTCAAAAATAACCAACCATTTT 362
DB 451 AGGCGAGGAGGAGGAGGCTTTCATAGATTCTATTCAAAAATAACCAACCATTTT 510
QY 363 GCAAGACCATGAGGCGCACTGTGCTGATGATGCTGTGCTGCTGCTGCTGCTGCTGCTGCTG 422
DB 511 GCAAGACCATGAGGCGCACTGTGCTGATGATGCTGTGCTGCTGCTGCTGCTGCTGCTGCTG 570
QY 423 GAGGCTGTGAGAGGCGCAGGAGGAGCGTTTGTAGGGGCACTGAGAGAGGCTGCGCAAGAG 482
DB 571 GAGGCTGTGAGAGGCGCAGGAGGAGCGTTTGTAGGGGCACTGAGAGAGGCTGCGCAAGAG 630
QY 483 TTCATTACCTAAACAGGTACAAAGCGGCGGAGTCCAGAGCAAGTGCACTTACACC 542

DB 631 TTCATTACCTAAACAGGTACAAAGCGGCGGAGTCCAGAGCAAGTGCACTTACACC 690
QY 543 TTCATTGTGCCCCAGAGAGGCGGCTCAGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 602
DB 691 TTCATTGTGCCCCAGAGAGGCGGCTCAGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 750
QY 603 GTGCTTCTGAGAGACCGAGTGTGCTAAGCAGGCTGAGCTGCTCAACATGAGTGTCTC 662
DB 751 GTGCTTCTGAGAGACCGAGTGTGCTAAGCAGGCTGAGCTGAGCTGCTCAACATGAGTGTCTC 810
QY 663 AAGCAGAGGCGGAGATTCAGAGCGCTGACGAGCTGTGTAAGGTGAGCGGCGGCTGCTG 722
DB 811 AAGCAGAGGCGGAGATTCAGAGCGCTGACGAGCTGTGTAAGGTGAGCGGCGGCTGCTG 870
QY 723 AGGAGGTGAAGTGTGCGGAGAGAGAGCGGCAACATGATGATGCTGCGGCTGCTGAGCTC 782
DB 871 AGGAGGTGAAGTGTGCGGAGAGAGAGCGGCAACATGATGATGCTGCGGCTGCTGAGCTC 930
QY 783 TACATGAGCTCTGACAGATGATCCTGCAAGCGGAGCGGAGCAACGCTGAGCTCTCCAG 842
DB 931 TACATGAGCTCTGACAGATGATCCTGCAAGCGGAGCGGAGCAACGCTGAGCTCTCCAG 990
QY 843 CTGAGAGACAGATCTCTGAAACCGAGCGGAGCGGAGCAACGCTGAGCTCTCCAG 902
DB 991 CTGAGAGACAGATCTCTGAAACCGAGCGGAGCGGAGCAACGCTGAGCTCTCCAG 1050
QY 903 GACCTGAGCAGAGTACAGACAGCTGCGCAGCACTGCGCAGCAACCAATCAGATGATC 962
DB 1051 GACCTGAGCAGAGTACAGACAGCTGCGCAGCACTGCGCAGCAACCAATCAGATGATC 1110
QY 963 GCGCAGCTTGAAGAGACATGCGCAGAGGCTGCTGCGGCGGAGCGGCTGCGGAGCGGAG 1022
DB 1111 GCGCAGCTTGAAGAGACATGCGCAGAGGCTGCTGCGGCGGAGCGGCTGCGGAGCGGAG 1170
QY 1023 CCGGCTGCGGCGGCGGCTGCTGCAACCAACCGAGCGGAGCGGCTGCGGAGCGGAG 1082
DB 1171 CCGGCTGCGGCGGCGGCTGCTGCAACCAACCGAGCGGAGCGGCTGCGGAGCGGAG 1230
QY 1083 TCTACCAAGAGATCCAGAGTGAACCGAAGCTGAGAGCTGAGAGCTGAGAGCTGAGAG 1142
DB 1231 TCTACCAAGAGATCCAGAGTGAACCGAAGCTGAGAGCTGAGAGCTGAGAGCTGAGAG 1290
QY 1143 ATGCCCATCTGACAGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1202
DB 1291 ATGCCCATCTGACAGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1350
QY 1203 TGCTGAGGCGCTGAGAGTGGCAGACAGCAGCTGATCTTACTGCTGTAAGCTGAGAG 1262
DB 1351 TGCTGAGGCGCTGAGAGTGGCAGACAGCAGCTGATCTTACTGCTGTAAGCTGAGAG 1410
QY 1263 AACACCAACCGCTGATGAGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1322
DB 1411 AACACCAACCGCTGATGAGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1470
QY 1323 GTCATCAGAGAGCGCTGATGAGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1382
DB 1471 GTCATCAGAGAGCGCTGATGAGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1530
QY 1383 CAAGGCTTGGGAAACATTGACCGGCAATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1442
DB 1531 CAAGGCTTGGGAAACATTGACCGGCAATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1590
QY 1443 ACGAAGCAAGGCAATCAAACTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1502
DB 1591 ACGAAGCAAGGCAATCAAACTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1650
QY 1503 TTTGAGAAATAGCGCAGCTTCCGCTGGAACCTGGAAGGAGATTAATAAGCTGCGGCTG 1562
DB 1651 TTTGAGAAATAGCGCAGCTTCCGCTGGAACCTGGAAGGAGATTAATAAGCTGCGGCTG 1710
QY 1563 GGGGCTAACATGAGCAATGAGGCTGCTGCTTACATGAGCAACGAGCAAGCTTACAC 1622

Mon Aug 9 10:30:08 2004

us-10-018-386-1.rnpb

Page 21

Db 1711 GGGCGCTACCATGCGAATGCGGGTGATCTCTTACATGCGACAAAGCGCAGGATTACCC 1770
QY 1623 ACCCTGACAGAGATCATGATGTCTACACAGGAACTGTGCCCACTACACAGAGGAGGC 1682
Db 1771 ACCCTGACAGAGATCATGATGTCTACACAGGAACTGTGCCCACTACACAGAGGAGGC 1830
QY 1683 TGGTGGTAAACGCGCTGTGCCCACTCAACCTCAACGCGGCTGTGGTACCGCGGGGCCAT 1742
Db 1831 TGGTGGTAAACGCGCTGTGCCCACTCAACCTCAACGCGGCTGTGGTACCGCGGGGCCAT 1890
QY 1743 TACCGGAGCCGCTACACAGAGGAGTCTACTGGGCTGAGTTCCGAGAGGCTTTACTCA 1802
Db 1891 TACCGGAGCCGCTACACAGAGGAGTCTACTGGGCTGAGTTCCGAGAGGCTTTACTCA 1950
QY 1803 CTCAGAAAGTGGTATGATGATCCGACCGAACCACACCTTCACCTAAGCCAGCTCC 1862
Db 1951 CTCAGAAAGTGGTATGATGATCCGACCGAACCACACCTTCACCTAAGCCAGCTCC 2010
QY 1863 CCCTCTGACCTCTGTGGCCATTGCCAGAGGCCACCTGGTCAAGCTGGCCACAGCAC 1922
Db 2011 CCCTCTGACCTCTGTGGCCATTGCCAGAGGCCACCTGGTCAAGCTGGCCACAGCAC 2070
QY 1923 AAAGAACAACTCTCACCAGTTCACTGAGGCTGGAGGACCGGGATGCTGATTCGT 1982
Db 2071 AAAGAACAACTCTCACCAGTTCACTGAGGCTGGAGGACCGGGATGCTGATTCGT 2130
QY 1983 TTTCGAAAGTCACTGACGCGGATGATGGAATCGAATCGATACGGTGTTCGTCCCTCC 2042
Db 2131 TTTCGAAAGTCACTGACGCGGATGATGGAATCGAATCGATACGGTGTTCGTCCCTCC 2190
QY 2043 TACTTCTCTCAGACCAAGACGCCCTCATGTCTCCAGAGACAGACAGACTTACAGACA 2102
Db 2191 TACTTCTCTCAGACCAAGACGCCCTCATGTCTCCAGAGACAGACAGACTTACAGACA 2250
QY 2103 CTCTTCTTTAAATTAATTAAGTCTCTACAAATTAATAACA 2141
Db 2251 CTCTTCTTTAAATTAATTAAGTCTCTACAAATTAATAAAA 2289

Search completed: August 6, 2004, 20:44:37
Job time : 987 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 6, 2004, 13:47:28 ; Search time 5559 Seconds

(without alignments)
11673.056 Million cell updates/sec

Title: US-10-018-386-1

Perfect score: 2173

Sequence: 1 gaataatgagctcgtcgcga.....aaaaaaaaaaaaaaaa 2173

Scoring table: IDENTITY_NUC

Gapop 10.0, Gapext 1.0

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Database:

EST:*

1: em_estba:*

2: em_esthm:*

3: em_estin:*

4: em_estnu:*

5: em_estov:*

6: em_estpl:*

7: em_estro:*

8: em_hic:*

9: gb_est1:*

10: gb_est2:*

11: gb_hic:*

12: gb_est3:*

13: gb_est4:*

14: gb_est5:*

15: em_estum:*

16: em_estom:*

17: em_gss_hum:*

18: em_gss_inv:*

19: em_gss_pln:*

20: em_gss_vrt:*

21: em_gss_fun:*

22: em_gss_mam:*

23: em_gss_mus:*

24: em_gss_pro:*

25: em_gss_rtd:*

26: em_gss_pbg:*

27: em_gss_vrt:*

28: gb_gss1:*

29: gb_gss2:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match	Length	DB	ID	Description
1	1345.4	61.9	2062	11	AK037265	AK037265 Mus muscu
2	1039.4	47.8	1201	9	AL527015	AL527015 AL527015
3	989.6	45.5	1201	9	AL523842	AL523842 AL523842
4	939.8	43.2	1201	9	AL572386	AL572386 AL572386

Result 1	Score	Match	Length	DB	ID	Description
5	931.8	42.9	3560	11	AK041888	AK041888 Mus muscu
6	908.6	41.8	1201	9	AL547465	AL547465 AL547465
7	885.2	40.7	1201	9	AL546299	AL546299 AL546299
8	873.8	40.2	1201	9	AL54832	AL54832 AL54832
9	870.6	40.1	1111	12	BM906705	BM906705 AGENCOURT
10	865.4	39.8	929	13	BO711105	BO711105 AGENCOURT
11	865	39.8	881	13	BO879104	BO879104 AGENCOURT
12	826.8	38.0	1195	9	AL525269	AL525269 AL525269
13	825.2	38.0	1894	13	BO952353	BO952353 AGENCOURT
14	817.4	37.6	1201	9	AL527059	AL527059 AL527059
15	816.4	37.6	870	14	CD54561	CD54561 AGENCOURT
16	777.2	35.8	797	14	CF131488	CF131488 UI-HF-FOO
17	777	35.8	875	13	BO659478	BO659478 AGENCOURT
18	767.6	35.3	2306	11	AK011976	AK011976 Mus muscu
19	759.6	35.0	1201	9	AL523843	AL523843 AL523843
20	739.6	34.0	949	12	BI834238	BI834238 603084145
21	733.2	33.7	812	12	BI765043	BI765043 603051189
22	732.8	33.7	752	13	BO717905	BO717905 AGENCOURT
23	726.6	33.4	915	13	BO149131	BO149131 AGENCOURT
24	724.8	33.4	945	13	BO713459	BO713459 AGENCOURT
25	715.8	32.9	720	14	CF132047	CF132047 UI-HF-FOO
26	714.8	32.9	941	10	BF038654	BF038654 601460914
27	704.4	32.3	822	10	BF345980	BF345980 602018709
28	701	32.3	990	10	BE745986	BE745986 601573433
29	691.6	31.8	700	12	BE676460	BE676460 602622918
30	686.6	31.6	738	12	BI768582	BI768582 603056901
31	677	31.2	683	13	BX482997	BX482997 DKE2D686B
32	671.4	30.9	666	14	CA411602	CA411602 UI-HF-EUI-
33	659.6	30.4	666	12	CF131252	CF131252 UI-HF-FOO
34	659	30.3	880	12	BE818186	BE818186 602797974
35	657.4	30.3	673	13	BO574556	BO574556 UI-H-EZ1-
36	653.2	30.1	825	13	BU053122	BU053122 UI-M-FCO-
37	643.4	29.6	667	13	BU624314	BU624314 UI-H-FG1-
38	632.4	29.1	795	14	CF724071	CF724071 UI-M-GZO-
39	611	28.1	946	10	BF038016	BF038016 601461729
40	610.8	28.1	749	12	BM007984	BM007984 603617732
41	607.4	28.0	819	10	BF348335	BF348335 602022367
42	593	27.3	667	12	BE819300	BE819300 602781481
43	582.4	27.2	881	14	CB193085	CB193085 AGENCOURT
44	591.8	27.2	646	12	BM999031	BM999031 UI-H-DIO-
45	574.2	26.4	762	14	CK019588	CK019588 AGENCOURT

ALIGNMENTS

RESULT 1
LOCUS AK037265
DEFINITION Mus musculus 16 days neonate thymus cDNA, RIKEN full-length
enriched library, clone: A13002A02 product: ANGIOPOIETIN-RELATED
PROTEIN 2 PRECURSOR, full insert sequence.
ACCESSION AK037265
VERSION AK037265.1 GI:26323039
KEYWORDS
SOURCE HTG; CAP trapper.
MUS musculus (house mouse)
ORGANISM
REFERENCE
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1
Carninci, P. and Hayashizaki, Y.
High-efficiency full-length cDNA cloning
Meth. Enzymol. 303, 19-44 (1999)
MEDLINE 99279253
PUBMED 10349636-
2
Carninci, P., Shibata, Y., Hayatsu, N., Sugahara, Y., Shibata, K.,
Itoh, M., Kono, H., Okazaki, Y., Muramatsu, M. and Hayashizaki, Y.
Normalization and subtraction of cap-trapper-selected cDNAs to
prepare full-length cDNA libraries for rapid discovery of new genes
Genome Res. 10 (10), 1617-1630 (2000)
JOURNAL 20499374
MEDLINE
PUBMED 11042159


```

Db      876  ACATATGCGTGGAGCTCTCCAGCTGAGAGAACAGATCCTGAACCAAGACAGTGCATGC 935
Qy      880  TGCAGCTGGCCGAGAGTACAGAGACCTGGAGACAGAGACAGGACCTGGCCACATGG 939
Db      936  TGCAGCTGGCTTGCAGATGACAGAGAGCTGGAGACAGAGTTCAGACAGCTGGCTAGCTGG 995
Qy      940  CCCAGAACCAATCAGAGATCATGCGGAGCTTGAAGAGCATCTGCCAGAGAGGCTGCTGG 999
Db      996  CACACACCAACCAATCAGAGGCTCATTTGCTCAGCTCGAAGAGCATCTGCCAGAGAGCTGGAG 1055
Qy      1000  CCAGGCGGCTCCCGGAGAGACCCCGGCTGGCCCGCGCGGCTTACCAAGACAGGACCT 1059
Db      1056  CCAGGCGCTATGCCCCAGAGACCCCGGAGAGCTGCACCTCGGCTTACCAAGACAGGACCT 1115
Qy      1060  ACAACCGCATCATCAACAGATCTCTACCAAGAGATCCAGAGTACAGAGACCTGAAG 1119
Db      1116  ACACCGCATCATCAACAGATTTTCCACCAATGAGATCCAGAGTACAGAGATCTGAAG 1175
Qy      1120  TGTGCTGACCCCTCTGCTCCCATATGCGGCTCTACCAAGCTCCCTATTTCCACAGCA 1179
Db      1176  TGTGCTGCGCTCTCTGCTCCCATGCTGCGGCTTACAGATCTCCATCTTCCACTGATA 1235
Qy      1180  AGCGCTGCGGCGGAGAGAGAGCTGCTGAGGAGGCTGAGAGAGTGGCCAGACAGAGT 1239
Db      1236  AGCATCAGAGTCCATGAGAGAGAGCTGCTGAGAGGCTTGAAGAGTGTGACAGACAGCT 1295
Qy      1240  CCATCTACTGCTGAGAGCGGAGAACCAACCGGCTCATGAGAGTGTGTCAGACAGA 1299
Db      1296  CCATCTACTGCTGAGAGCGGAGAACCAACCGGCTCATGAGAGTGTGTCAGACAGA 1355
Qy      1300  GACACAGACCCCGGAGGCTGAGACCTGATCCAGAGAGCTGATGCTGCTTACTTCT 1359
Db      1356  GACATACACCTGAGAGTGTGAGCTGTATCATGAGAGAGCTGAGAGTGTGCTGCTTCT 1415
Qy      1360  TCAGAGTCTGGAGAGAGTACAGAGAGGTTTGGAGAACATTGACGCGAGATCTGCTGG 1419
Db      1416  TCAGAGTCTGGAGAGAGTATAGAGAGGTTTGGAGAACATTGAGTGTGAGTGTGCTGG 1475
Qy      1420  GCTGAGAGACATTACTGCTGAGAGACCAAGCACTTCAAACTCTGCTGAGACCATG 1479
Db      1476  GCTGAGAGACATTCTGCTGAGAGACCAAGCACTTCAAACTCTGCTGAGACCATG 1535
Qy      1480  AGGACTGCTGCGGCGGAGAGTCTTGGAGAGATCCGAGTTCGCTGAGACCTGAGA 1539
Db      1536  AGGACTGCTGCGGCGGAGAGTCTTGGAGAGATCCGAGTTCGCTGAGACCTGAGA 1595
Qy      1540  GCGAGTATTATTAAGCTGCGGCTGGGCGCTACCATGGAATGCGGCTGCTCTTACT 1599
Db      1596  GCGAGTATTATTAAGCTGCGGCTGGGCGCTACCATGGAATGCGGCTGCTCTTACT 1655
Qy      1600  GCGAGACCGGAGAGGTTTCAACACCTGAGAGAGATATGATGCTTCAAGAGAACT 1659
Db      1656  GCGAGACCGGAGAGGTTTCAACACCTGAGAGAGATATGATGCTTCAAGAGAACT 1715
Qy      1660  GTGCCACTATACAGAGAGAGGCTGTGATTAACGCTGTGCGCACTCCAACTTCAAG 1719
Db      1716  GTGCCACTATACAGAGAGAGGATGTGATTAACGCTGTGCGCACTCCAACTTCAAG 1775
Qy      1720  GGGTCTGTGTAAGCGCGGCGGCTATTAACGAGAGCGCTTACAGAGAGAGTCTTACTGG 1779
Db      1776  GGGTCTGTGTAAGCGTGGGCGGCTATTAACGAGAGCGGCTTACTGGGCTG 1835
Qy      1780  AGTTCGAGAGAGGCTTACTCACTCAGAGAAAGTGTGATGATCCGAGCGAGACCCCA 1839
Db      1836  AGTTCGAGAGAGGCTTACTCACTCAGAGAAAGTGTGATGATTCGAGCGAGACCCCA 1895
Qy      1840  ACACTTTCAGTAAGCCAGCTCCCGCT 1866
Db      1896  ACACTTTCAGTAAGCTCCCGCT 1922

```

RESULT 2
AL527015/c

```

LOCUS      AL527015      1201 bp      mRNA      linear      EST 23-MAY-2003
DEFINITION      AL527015 Homo sapiens NEUROBLASTOMA COT 25-NORMALIZED Homo sapiens
ACCESSION      AL527015
VERSION        AL527015.2
KEYWORDS       GI:31064871
SOURCE         Homo sapiens (human)
ORGANISM       Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE      1 (bases 1 to 1201)
AUTHORS        Li, M.B., Gruber, C., Jesse, J., and Polayes, D.
TITLE          Full-length cDNA libraries and normalization
JOURNAL        Unpublished (2001)
COMMENT         On Feb 13, 2001 this sequence version replaced gi:12790508.
Contact: Genoscope
Genoscope - Centre National de Sequencage
BP 191 91006 Evry cedex - France
Email: seqref@genoscope.cns.fr, Web: www.genoscope.cns.fr
Library was constructed by Life Technologies, a division of
Invitrogen. This sequence belongs to sequence cluster 4821.r For
more information about this cluster, see
http://www.genoscope.cns.fr/
cgi-bin/cluster.cgi?seq=CS0DC017CF02NP1&cluster=4821.r. Contact :
Feng Liang Email: fliang@lifetech.com URL :
http://fulllength.invitrogen.com/Invitrogen Corporation 1600
Faraday Avenue Genoscope sequence ID : CS0DC017CF02NP1.
FEATURES
source
1..1201
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CS0DC017YL03"
/tissue_type="NEUROBLASTOMA COT 25-NORMALIZED"
/clone_id="Homo sapiens NEUROBLASTOMA COT 25-NORMALIZED"
/note="1st strand cDNA was primed with a NotI-0.150 (dt)
primer. Five prime end enriched, double-strand cDNA was
digested with Not I and cloned into the Not I and EcoR V
sites of the pCMVSPORT 6 vector. Library was normalized."
ORIGIN
Query Match 47.8%; Score 1039.4; DB 9; Length 1201;
Best Local Similarity 94.3%; Pred. No. 4,76-128;
Matches 1096; Conservative 20; Mismatches 41; Indels 5; Gaps 4;
Qy      985  AGAGGCTGCTCGGCGGAGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCT 1044
Db      1162  RGAGATYKSCAGAGGCTYSGSAGCCCKCCCCAGACACCCGGTCCCGCCCGG--TT 1105
Qy      1045  ACCAACCCACCTACCAACCGCATTCACACAGATCTTACCAAGAGATCCAGAGTG 1104
Db      1104  TACWAMGACCCACCTTAMMCGGCMTCCTTACCAAGATTTTTC--ACGRKATCAGRTG 1046
Qy      1105  ACCAGAACCTTAAGTGTGCTCAACCCCTCTGCGCCACTATGCTCCAGCCCTCC 1164
Db      1045  ACCAGAACCTTAAGGCGGTGCGACCCCTCTGCAAACTATGCCCAATCTCACAGCTCC 986
Qy      1165  CATCTTCACGACAGAGCGCTGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCTGAGAGTG 1224
Db      985  CATTTTCCACGACAGAGCGGCTGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCTGAGAGTG 926
Qy      1225  GCGACGACACGCTTCATCTTACTGTTGAAGCGGAGAACACCAACCGGCTCATGCAAG 1284
Db      925  GCGACGACACGCTTCATCTTACTGTTGAAGCGGAGAACACCAACCGGCTCATGCAAG 866
Qy      1285  TGTGTGAGACAGAGACAGACACCCCGGCGGCGGCGGCGGCGGCGGCGGCGGCTGAGAGTG 1344
Db      865  TGTGTGAGACAGAGACAGACACCCCGGCGGCGGCGGCGGCGGCGGCGGCGGCTGAGAGTG 806
Qy      1345  GCTCTGTTAAGCTTCTTCAGAACTGGAGAGCTGACAGAGAGGTTTGGAGACATGACG 1404
Db      805  GCTCTGTTAAGCTTCTTCAGAACTGGAGAGCTGACAGAGAGGTTTGGAGACATGACG 746

```

QY 1405 GCGAATATCTGGCTGGGCTTGAGAACATTTTCTGCTGACGAAACCAAGCACTACAAAC 1464
 Db 745 GCGAATATCTGGCTGGGCTTGAGAACATTTTCTGCTGACGAAACCAAGCACTACAAAC 686
 QY 1465 TCCGTGTCACATGAGAGACTGGTCCGGCCGCAAGTCTTTGAGAAATACGACAGTTCC 1524
 Db 685 TCCGTGTCACATGAGAGACTGGTCCGGCCGCAAGTCTTTGAGAAATACGACAGTTCC 626
 QY 1525 GCGTGAACCTGAGAGAGAGATTTATTAAGCTGCGTGGGGCGCTTCCATGCAATGCGG 1584
 Db 625 GCGTGAACCTGAGAGAGAGATTTATTAAGCTGCGTGGGGCGCTTCCATGCAATGCGG 566
 QY 1585 GTGACTCTTATCATGAGCAACAGGAGAGATTCACACCTCGGACAGAGATTCATGATG 1644
 Db 565 GTGACTCTTATCATGAGCAACAGGAGAGATTCACACCTCGGACAGAGATTCATGATG 506
 QY 1645 TCTACACAGAAAATCTGTCCCACTACACAGAGAGAGTGTGTATTAAGCTGTGCC 1704
 Db 505 TCTACACAGAAAATCTGTCCCACTACACAGAGAGAGTGTGTATTAAGCTGTGCC 446
 QY 1705 ACTCCAACTCAACGGGGTCTGTGTACCGGGGGCCATTACCGGAGCGCTACCGAGAGC 1764
 Db 445 ACTCCAACTCAACGGGGTCTGTGTACCGGGGGCCATTACCGGAGCGCTACCGAGAGC 386
 QY 1765 GAGTCTACTGGGCTGAGTTCGAGAGAGCTCTTACTAC-TCAGAGAAAGTGTGATGATG 1823
 Db 385 GAGTCTACTGGGCTGAGTTCGAGAGAGCTCTTACTAC-TCAGAGAAAGTGTGATGATG 326
 QY 1824 ATCCGACCGAACCCCAACCTTCCACTAAGCAGTCCCTCTGACTCTGTGACC 1883
 Db 325 ATCCGACCGAACCCCAACCTTCCACTAAGCAGTCCCTCTGACTCTGTGACC 266
 QY 1884 ATTCGACGAGAGCCCACTGTGTACCGCTGGCCACAGCAACAAGAACTCTTACAGAGT 1943
 Db 265 ATTCGACGAGAGCCCACTGTGTACCGCTGGCCACAGCAACAAGAACTCTTACAGAGT 206
 QY 1944 TCACTCTGAGGCTGGAGAGACCGGATGCTGATTTCTTTCCGAAAGTCACTGAGCGG 2003
 Db 205 TCACTCTGAGGCTGGAGAGACCGGATGCTGATTTCTTTCCGAAAGTCACTGAGCGG 146
 QY 2004 ATGATGAACTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 2063
 Db 145 ATGATGAACTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 86
 QY 2064 GCGCCCTCATGTCTCCAGAGACAGAGACTACAGCACTCTTTC-TTTAAATTAATTA 2122
 Db 85 GCGCCCTCATGTCTCCAGAGACAGAGACTACAGCACTCTTTC-TTTAAATTAATTA 26
 QY 2123 AGCTCTACATTAATAACAA 2144
 Db 25 AGTATCTAAATTAATAANVAVM 4

RESULT 3
 AL523842/c
 LOCUS AL523842 Homo sapiens NEUROBLASTOMA COT 25-NORMALIZED Homo sapiens
 DEFINITION CDNA clone CS0DC003YP19 3-PRIME, mRNA sequence.
 ACCESSION AL523842
 VERSION AL523842.2 GI:31042103
 KEYWORDS EST.
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 REFERENCE 1 (bases 1 to 1201)
 AUTHORS Li, W.B., Gruber, C., Jessee, J. and Polayes, D.
 TITLE Full-length cDNA libraries and normalization
 JOURNAL Unpublished (2001)
 COMMENT On Feb 13, 2001 this sequence version replaced gi:12787335.
 Contact: Genoscope
 Genoscope - Centre National de Sequencage
 BP 191 91006 EVRY cedex - France

FEATURES
 source
 1..1201
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /clone="CS0DC003YP19"
 /tissue_type="NEUROBLASTOMA COT 25-NORMALIZED"
 /note="1st strand cDNA was primed with a NotI-oligo(dT) primer. Five prime end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library was normalized."
 ORIGIN
 Query Match 45.5%; Score 989.6; DB 9; Length 1201;
 Best local similarity 91.6%; Pred. No. 1,8e-121;
 Matches 1030; Conservative 37; Mismatches 53; Indels 4; Gaps 3;
 1012 CCCAGCCACCCCGCGCCGCCCGCGGCTACACACACCGACCTACACCGGATCA 1071
 Db 1120 CCCGCCACCGCCCGCGCGCGCGCGGCTTCCACACCGACCC-AAAAGSATCT 1063
 QY 1072 TCAACGATCTCTACCAAGATCCAGAGTACAGCAAGAACTGAGGTGCTCCACCC 1131
 Db 1062 TAAACGAG-TTTTACCAAGGATCCAGKXGACCAAGAACTGAGG-GCTCCACCC 1005
 QY 1132 CTCTGCCACTATGCCAGCTCTACACAGCTCCCATCTTCCACCGCAAGCGGTGGGCC 1191
 Db 1004 CTCTGCCACTATGCCAGCTCTACACAGCTCCCATCTTCCACCGCAAGCGGTGGGCC 945
 QY 1192 CATGAGAGAGCTCTGAGAGAGCTGAGAGAGTGGCCACAGCAACCTCATCTCACTG 1251
 Db 944 CATGAGAGAGCTCTGAGAGAGCTGAGAGAGTGGCCACAGCAACCTCATCTCACTG 885
 QY 1252 TGAAGCCGGAACACCAACCGCTCATGAGTGTGTGTGCGACAGACACAGCCCG 1311
 Db 884 TGAAGCCGGAACACCAACCGCTCATGAGTGTGTGTGCGACAGACACAGCCCG 825
 QY 1312 GGGGCTGAGACCTCATGAGAGAGCGCTGATGCTGTAACTTCTTACGAACTGGG 1371
 Db 824 GGGGCTGAGACCTCATGAGAGAGCGCTGATGCTGTAACTTCTTACGAACTGGG 765
 QY 1372 AGACGTACCAAGAGGTTTGGAGATTCAGCGGCAATAGTGGCTGGAGAGACA 1431
 Db 764 AGACGTACCAAGAGGTTTGGAGATTCAGCGGCAATAGTGGCTGGAGAGACA 705
 QY 1432 TTTACTGCTGAGAGAACCAAGGCACTACAAATCTCTGTGACCAAGAGAGTGGTCCG 1491
 Db 704 TTTACTGCTGAGAGAACCAAGGCACTACAAATCTCTGTGACCAAGAGAGTGGTCCG 645
 QY 1492 GCGCAAAAGTCTTGGAGATAAGCAGATTTCGCTGGAACCTGAGAGCGAGTATTATA 1551
 Db 644 GCGCAAAAGTCTTGGAGATAAGCAGATTTCGCTGGAACCTGAGAGCGAGTATTATA 585
 QY 1552 AGCTGGGCTGGGGCGCTACATGCAATGCGGGGTATCTTTTACATGGCACAAGGGA 1611
 Db 584 AGCTGGGCTGGGGCGCTACATGCAATGCGGGGTATCTTTTACATGGCACAAGGGA 525
 QY 1612 AGCAGTTACACACCTGAGACAGAGATCATGATGTCTACAGAGAACTGTGCCACTAC 1671
 Db 524 AGCAGTTACACACCTGAGACAGAGATCATGATGTCTACAGAGAACTGTGCCACTAC 465
 QY 1672 AGAAGGAGGCTGGGTATTAACGCTGTGCCCATCTCAACCTCAACGCGGTGTGTACC 1731

Db	Accession	Organism	Source	Reference	Authors	Title	Journal	Comment
Db	466	AAAAB68AAG6CTG6T8GTATTAAGCCTGTG6CCACTCCAACTCCAA686G6TCTGTATCC		1973				
QY	1732	GGCG9393CCATTACCGGAGCCGCTACAGAGACGAGTCTACTG6GCTGAGTTCCGAGAG		179				
Db	404	GGCG9393CCATTACCGGAGCCGCTACAGAGACGAGTCTACTG6GCTGAGTTCCGAGAG		345				
QY	1792	GCTCTTACTCACTCAAGAAGTGTATATATATCCGACCCGAACCTCCAACTCACTTTCAT		185				
Db	344	GCTCTGACTCACTCAAGAAGTGTATATATATCCGACCCGAACCTCCAACTCACTTTCAT		285				
QY	1852	AAGCCAGCTCCCCCTCTGACCTCTGTTGGCCATTGCCAGAGCCCACTCTGTCACGT		191				
Db	284	AAGCCCGCTCCCCCAAGCCCTCTGTGTGCTATGCCAGAGACCCACCCGGGTGAMGK		225				
QY	1912	GGCCACAGACAAAGAACAATCTCTACAGTTCACTCTGAGGCTGGAGAGACCGGAGATG		197				
Db	224	GGCAACAGACAAAGAACAATCTCTACAGTTCACTCTGAGGCTGGAGAGACCGGAGATG		165				
QY	1972	CTGATTCCTGTTTCCGAGTCACTGACGACCGGATATGGAACTGATCGATCGGAGTTT		203				
Db	164	CTGATTCCTGTTTCCGAGTCACTGACGACCGGATATGGAACTGATCGATCGGAGTTT		105				
QY	2032	TCTGTCCCTCTACTTTCCTTCACACACAGACCCCTCATGTCTCCAGACAGACAGG		2091				
Db	104	TCTGTCCCTCTACTTTCCTTCACACACAGACCCCTCATGTCTCCAGACAGACAGG		45				
QY	2092	ACTACAGACACTCTTTTCTTTAAATTAATTAAGTCTTCACATA		2135				
Db	44	ACTACAGACAGAGSKGCTTTTAAATTAATTCAGTGTGSKWMTM		1				

FEATURES
 Contact: Genoscope
 Genoscope - Centre National de Sequencage
 BP 191 91006 EVRY cedex - France
 Email: sgseq@genoscope.cns.fr, Web : www.genoscope.cns.fr
 Library was constructed by life Technologies, a division of
 Invitrogen This sequence belongs to sequence cluster 4821.r For
 more information about this cluster, see
<http://www.genoscope.cns.fr/cg3-bin/cluster.cgi?seq=CSOD1011DH07NP1&cluster=4821.r>. Contact :
 Feng Liang Email : liang@lifetech.com URL :
<http://f11length.invitrogen.com/> Invitrogen Corporation 1600
 Parady Avenue Genoscope sequence ID : CSOD1011DH07NP1.
 Location/Qualifiers

```

source
1. .1201
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CSDDI0111p14"
/tissue_type="PLACENTA COT 25-NORMALIZED"
/clone_id="Homo sapiens PLACENTA COT 25-NORMALIZED"
/note="1st strand cDNA was primed with a NotI-oligo(dT)
primer. Five prime end enriched, double-strand cDNA was
digested with NotI and cloned into the NotI and EcoRV
sites of the pCMVSPORT 6 vector. Library was normalized."

```

Query Match	3.2%	Score	99.8	DB	9	Length	1201
Best Local Similarity	89.0%	Pred.	6,7e-115				
Matches	1031	Conservative	37	Mismatches	82	Indels	9
				Gaps	6		
QY	986	GAGGTGCCCTTCGGCCAGGACCCCTGTCGCCAGCACCCCCGCTGCGCCCGCCGGGTCTA	1045				
Db	1152	GGGRASBSMRGGGCTCTGCGGAGCGCGCCCTGTCTCTCCCGCGKXCCCCCGGKTX	1093				
QY	1046	CCAACCAACCCACTCTCAACCCGATCATCAACAGATCTCTCAACAGAGATCAAGTGA	1105				
Db	1092	ACMACCCCCCKSCMAAACCSG----ATTCAACCADTCTTACCMASPAATTCAMRDTAA	1033				
QY	1106	CCAGAACTGAAGGTGCTGCCACCCCTCTGCCCCTATGCCCCACTCTACACGCTCC	1165				
Db	1036	CMA-AACCTGAAGGTG-TGCCACCTCTCTSCCACTAT-CTATATTTTCWCHABTACC	980				
QY	1166	ATCTTCCACCCGACAAGCGCTGGGGCCATGAGAGACTGCTGGAGGCGCTGGAGATG	1222				
Db	979	ATCTTCCACCCGACAAGCGCTGGGGCCATGAGAGACTGCTGGAGGCGCTGGAGATG	920				
QY	1226	CCAGACCAACGCTTCATCTAATTGTGAACCCGAGAACCAAC-C-GCCTCATGACG	1284				
Db	919	CCACACACACAGCTTCATCTTGTGAAACCGGAGAACCAACCTGCTTCATGACG	860				
QY	1285	TGTGGTGGACAACAAGACAGACCCCGGGGGCTGGACCGTATCCAGAGAGCGCTGATG	1344				
Db	859	TGTGGTGGACAACAAGACAGACCCCGGGGGCTGGACCGTATCCAGAGAGCGCTGATG	800				
QY	1345	GCTCTGTTAATCTTTCAGAACTGGAGACGTACAAGCAAGGTTGGAAATGAC	1404				
Db	799	GCTCTGTTAATCTTTCAGAACTGGAGACGTACAAGCAAGGTTGGAAATGAC	740				
QY	1405	GCGAATATGCTGGGCTGGAGAACTTATCTGGCTGACGACACCAAGGATTCAG	1464				
Db	793	GCGAATATGCTGGGCTGGAGAACTTATCTGGCTGACGACACCAAGGATTCAG	680				
QY	1465	TCTGTGTGACATGAGAGCTGTGTCCGCGCCAAAGTTTTCAGAAATACCCAGTTCC	1524				
Db	679	TCTGTGTGACATGAGAGCTGTGTCCGCGCCAAAGTTTTCAGAAATACCCAGTTCC	620				
QY	1525	GCGTGAACCTGAGAGCGAGTATATTAAGCTGGGGCTGGGGCGTACCATGSCAATGGG	1584				
Db	619	GCGTGAACCTGAGAGCGAGTATATTAAGCTGGGGCTGGGGCGTACCATGSCAATGGG	560				
QY	1585	GTCATCTCTTACATGGCACACGGCAACGATTCACCAACCTTGAACAGAGATCATGATG	1644				
Db	559	GTCATCTCTTACATGGCACACGGCAACGATTCACCAACCTTGAACAGAGATCATGATG	500				
QY	1645	TCTACACGAGAACTGTGCCCATCACTACAGAGAGGCTGGTGTATTAAGCGCTGTGCC	1704				
Db	499	TCTACACGAGAACTGTGCCCATCACTACAGAGAGGCTGGTGTATTAAGCGCTGTGCC	440				
QY	1705	ACTCCAACTTCAACGGGGTCTGTGATCCGGGGGCATTTACCGGAGCGCTTACCAAGACG	1764				
Db	439	ACTCCAACTTCAACGGGGTCTGTGATCCGGGGGCATTTACCGGAGCGCTTACCAAGACG	380				
QY	1765	GAGTCTACTGGGGCTGAGTTCGAGAGAGCTTCTACTACTCAAGAAAGTGGTATGATGA	1824				
Db	379	GAGTCTACTGGGGCTGAGTTCGAGAGAGCTTCTACTACTCAAGAAAGTGGTATGATGA	320				
QY	1825	TCCGACCGAACCCCAACAACCTTCCACTTAAGCAGCTCCCTCTGACCTTCTGTGGCCA	1884				
Db	319	CCCACCGAACCCCAACAACCTTCCACTTAAGCAGCTCCCTCTGACCTTCTGTGGCCA	260				
QY	1885	TTGCGAGAGCCACCTGTCGACGCTGGCCACAGCAACAAGAACACTCTCCACAGTT	1944				
Db	259	TTGCGAGAGCCACCTGTCGACGCTGGCCACAGCAACAAGAACACTCTCCACAGTT	200				
QY	1945	CATCTTAAGCTGGAGAGACCGGGATCTGATTTCTTTTTCCGAAGTCACTGACGCGGA	2004				
Db	199	CATCTTAAGCTGGAGAGACCGGGATCTGATTTCTTTTTCCGAAGTCACTGACGCGGA	140				

[illegible]

	TITLE	Sano, H., Saeki, D., Shibata, K., Shinagawa, A., Shiraki, T., Sogabe, Y., Tagami, M., Tagawa, A., Takahashi, F., Takaku-Akahira, S., Iakeda, Y., Tanaka, T., Tomaru, A., Toyota, T., Yasunishi, A., Muramatsu, M. and Hayashizaki, Y.
	JOURNAL	Direct Submission
	COMMENT	Submitted (16-JUL-2001) Yoshihide Hayashizaki, The Institute of Physical and Chemical Research (RIKEN), Laboratory for Genome Exploration Research Group, RIKEN Genomic Sciences Center (GSC), RIKEN Yokohama Institute; 1-7-22 Suehiro-cho, Tsurumi-Ku, Yokohama, Kanagawa 230-0045, Japan (E-mail:genome-re@gsc.riken.go.jp, URL:http://genome.gsc.riken.go.jp/, Tel:81-45-503-9222, Fax:81-45-503-9216)
	FEATURES	cDNA library was prepared and sequenced in Mouse Genome Encyclopedia Project of Genome Exploration Research Group in Riken Division of Experimental Animal Research in Riken contributed to prepare mouse tissues. Tissues were provided by Dr. John Todd (Dept. of Medical Genetics Wellcome Trust Centre for Molecular Mechanisms in Disease Wellcome Trust/MRC building Addenbrookes Hospital Cambridge) whose assistance we gratefully acknowledge. Please visit our web site for further details. URL:http://genome.gsc.riken.go.jp/ URL:http://fantom.gsc.riken.go.jp/. Location/Qualifiers 1..3560
	SOURCE	/organism="Mus musculus" /mol_type="mRNA" /serial="C57BL/6J" /db_xref="PANTOM DB:A630044F14" /db_xref="MGI:2406897" /db_xref="taxon:10090" /clone="A630044F14" /tissue type="thymus" /clone.lib="RIKEN full-length enriched mouse cDNA library" /dev stage="3 days neonate"
	misc_feature	1..3560 /note="ANGIOPOIETIN-RELATED PROTEIN 2 PRECURSOR (SWISSPROT Q9R045, evidence: PASTY, 99.6%id, 100%length, match=1479)"
	ORIGIN	
	Query Match	42.9%; Score 931.8; DB 11; Length 3560;
	Best Local Similarity	81.9%; Pred. No. 5,66-114;
	Matches 1149; Conservative	0; Mismatches 217; Indels 37; Gaps 5;
Dy	3	AATAGAGCTGTCTGGAGACCGGCTTGAGATGAACCCCAAGCCCTTGA----- 49
Dd	46	AATGAGGCTGTCTGTGGCCCTGGAGATGACCACCAAGCCCTGAGTGATTGTGGA 105
Oy	50	-----CTGCCGAGAGCTGACACTAGAGGAGGGGCTGACGTAAGTTGAGGAAAGA 101
Dd	106	CCACAGACTTCGAAGAACATGACTTAGAGCACTGCAGCACCACTGTAGGAGAGACA 165
Oy	102	GATTGTGAGACCCCGCAGAGACCCCTTGCCAGCCCTGGCCCCCAAGCTTGTCCCGAGCCC 161
Dd	166	GATTGGAGACGCCCCGGGTGACCAAGAGCAGGCTCATCCCTAGAGATTGAGAGACA 225
Oy	162	TCTGTGAGAGGAGACGACAGTGGAGCCAGTAGAGGAGGCGTGTGGAGACA---CGGGC 219
Dd	226	TAGACTG----CTGCCAGCTGAGGCCAGTAGAGAGGGCTGTGGCGGCACTGCACGC 280
Oy	220	CTGCAACTCAGAAACCCCTCCAGAGGCCATGACAGGCTGCCCGCTGACGAGGAGGTG 279
Dd	281	CTGAGACTCGGGAAGCTCTCTGAGAGGCCACGAGGCGAGGTGTGCTGATGAG-CACGCTG 339
Oy	280	AAGCATGTGAGAGACCGCCCGGAGGCCAAGAGAGAGGAAAGAGCTTTCATAGATTGAT 339
Dd	340	AGGATGTGAAAGCCCTGCTCCAGGGCCCAAGAGAGAAAGAGGCTTTC-----GT 391
Oy	340	TCACAAAGATAACACCACTTTTGCAAAGACATGAGGCGCACTGTGCTGACATGCTGT 399
Dd	392	TCTATTAAGACCAACAGCACTGAGAGAGCAATGAGGCCACTGTGTATGACTCTGTGT 451

QY 400 GGCTGGAGCTGCTGGCTGCGATGGAGCTGTTGACAGGCCAGAGCGGTTTGAAGGCA 459
 DB 452 GGCTTGGAGCTGCTGGCGACGGCTCGAGCTGCTACAGGCCAGGGCTGACGTTGAGGGCA 511
 QY 460 CTGAGAGGAGGCTGCGCAAGAGATTCTTACTTAAACAGGTACAGCGGGGGGGGAGT 519
 DB 512 CAGAGAGATGGTTACAGAGAGAGATTACTTACTTCAACAGGTACAGCGGGGGAGT 571
 QY 520 CCCAGAGACAGTGCACCTTACCTTATTTGTCGCCAGAGCGGGTACAGGGTGCATCT 579
 DB 572 CCCCCACAGAGTGCACCTTACCTTATTTGTCGCCAGAGCGGGTACAGGGTGCATCT 631
 QY 580 GGGTCACTCCAAAGAGGCTGAGGCTTCTGAGAGACCGAGTGCATTAAGCAGAGCTAG 639
 DB 632 GTGTCACTCCAAAGAGGCTGAGGCTGAGGCTGAGAGACCGGTGCAAGAGAGAGCTAG 691
 QY 640 AGCTGCTCAACATAGCTGCTCAAGCAGAGCGGAGATCGAGACGCTGACAGAGCTAG 699
 DB 692 AGCTGCTCAACATAGCTGCTTAAAGCAGAGCGGAGATCGAGAGCGCTGACAGAGCTAG 751
 QY 700 TGAAGTGAACGGCGGAGCTTGTGAGCGAGGTGAAGCTGCTGCAAGAGAGCGGCAACA 759
 DB 752 TGAAGTGAACGGAGGCTGAGCGAGGTGAAGCTGCTGCGCAAGAGAGCGGCAACA 811
 QY 760 TGAAGTGAACGGAGGCTGAGCGAGCTGATCATGAGAGTCCGTCAGAGAGCGG 819
 DB 812 TGAAGTGAACGGAGGCTGAGCGAGCTGATCATGAGAGTCCGTCAGAGAGCGG 871
 QY 820 ACAAAGCGTGGAGCTTCTCCAGCTGAGAGACAGGATCTGAAACAGACCGGCAATGC 879
 DB 872 ACAAAGCGTGGAGCTTCTCCAGCTGAGAGACAGGATCTGAAACAGACCGGCAATGC 931
 QY 880 TGCAGTGGCGCAGAGTCAAGAGACCTGAGAGACAGAGACAGAGCTGCGCAACTGCG 939
 DB 932 TGCAGTGGCGTCAAGAGTCAAGAGACCTGAGAGACAGAGTCCAGAGCTGCGTAACTGCG 991
 QY 940 CCCAGACCAATCAGAGATCATGCGCAAGCTTGAAGAGCAGTCCAGAGAGGCTGCGT 999
 DB 992 CACACACCAATCAGAGATCATGCGTCAAGCTTGAAGAGCAGTCCAGAGAGGCTGCGT 1051
 QY 1000 CAGAGCGGCTCCCCAGAGCTACCCCGCTGCGCCCGGCTTACCAACCCAGCT 1059
 DB 1052 CAGAGCGTATGCCCCAGAGCTACCCCGGCTGCGCCCGGCTTACCAACCCAGCT 1111
 QY 1060 ACAAAGCGATCATCAGAGATCTCTTAAACAGAGTCCAGAGTCCAGAGAGCTGAGG 1119
 DB 1112 ACAAAGCGATCATCAGAGATCTCTTAAACAGAGTCCAGAGTCCAGAGAGCTGAGG 1171
 QY 1120 TGTCTGCAACCCCTCTGCGCAATGAGCTTCTTCAACAGCGCTCCATTTCCACCGCA 1179
 DB 1172 TGTCTGCAACCCCTCTGCGCAATGAGCTTCTTCAACAGCGCTCCATTTCCACCGCA 1231
 QY 1180 AGCGCTCGAGGCGCATGAGAGAGCTGCTGAGAGCGGCTGAGAGAGGCGGCAACCGAGT 1239
 DB 1232 AGCGCTCGAGGCGCATGAGAGAGCTGCTGAGAGCGGCTGAGAGAGGCGGCAACCGAGT 1291
 QY 1240 CCATCTACCTGTTGAAGCGGAGAACACCAACCGGCTCATGAGGTGTGTGCGACCGA 1299
 DB 1292 CCATCTACCTGTTGAAGCGGAGAACACCAACCGGCTCATGAGGTGTGTGCGACCGA 1351
 QY 1300 GACAGAGACCGCGGGGCTGAGACCGGCTTACAGAGAGCGGCTGAGGTGTGTGCGACCGA 1359
 DB 1352 GACAGAGACCGCGGGGCTGAGACCGGCTTACAGAGAGCGGCTGAGGTGTGTGCGACCGA 1411
 QY 1360 TCAGAGACTGGAGAGCTAGAG 1382
 DB 1412 TCAGAGACTGGAGAGCTAGAG 1434

RESULT 6
 AL547465 1201 bp mRNA linear EST 31-MAY-2003
 LOCUS AL547465

DEFINITION AL547465 Homo sapiens PLACENTA COT 25-NORMALIZED Homo sapiens cDNA
 clone CSOD1011HP14 5-PRIME, mRNA sequence.
 ACCESSION AL547465
 VERSION AL547465.2 GI:11269296
 KEYWORDS EST
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
 REFERENCE Li, W.B., Gruber, C., Jessee, J., and Polayes, D.
 (bases 1 to 1201)
 TITLE Full-length cDNA libraries and normalization
 JOURNAL Unpublished (2001)
 COMMENT On Feb 15, 2001 this sequence version replaced gi:12881558.
 Contact: Genoscope
 Genoscope - Centre National de Sequencage
 BP 191 91006 Evry cedex - France
 Email: segre@genoscope.cns.fr Web: www.genoscope.cns.fr
 Library was constructed by Life Technologies, a division of
 Invitrogen. This sequence belongs to sequence cluster 4821.r For
 more information about this cluster, see
 http://www.genoscope.cns.fr/
 cgi-bin/cluster.cgi?seq=CSOD1011DH070P1&cluster=4821.r. Contact :
 Feng Liang Email: fliang@life.com URL :
 http://fulllength.invitrogen.com/Invitrogen Corporation 1600
 Faraday Avenue genoscope.sequence ID : CSOD1011DH070P1.
 Location/Qualifiers
 1..1201
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /clone="CSOD1011HP14"
 /issue_type="PLACENTA COT 25-NORMALIZED"
 /clone_id="Homo sapiens PLACENTA COT 25-NORMALIZED"
 /note="1st strand cDNA was primed with a NotI-oligo(dT)
 primer. Five prime end enriched, double-strand cDNA was
 digested with Not I and cloned into the Not I and EcoR V
 sites of the pCMVSPORT 6 vector. Library was normalized."
 ORIGIN
 Query Match 41.8%; Score 908.6; DB 9; Length 1201;
 Best Local Similarity 91.7%; Pred. No. 8,9e-111;
 Matches 981; Conservative 30; Mismatches 52; Indels 7; Gaps 5;
 QY 3 AAATGAGGCTGCTGGGAGCGGCTGAGAGTAAACCCCAAGCCCTGAGACCTGGGAGGCTG 62
 DB 69 AAATGAGGCTGCTGGGAGCGGCTGAGAGTAAACCCCAAGCCCTGAGACCTGGGAGGCTG 128
 QY 63 GCATGAGGAGCGGCTGAGCTACTGTGAGGAGAAAGAGTTGTGAGCAGGCCGAGG 122
 DB 129 GCATGAGGAGCGGCTGAGCTACTGTGAGGAGAAAGAGTTGTGAGCAGGCCGAGG 187
 QY 123 ACCGCTGGCGAGCGGCTGAGCGGCTGAGCGGAGCCCTCTGTGAGAGTGAAGCCAGTG 182
 DB 188 ACCGCTGGCGAGCGGCTGAGCGGCTGAGCGGAGCCCTCTGTGAGAGTGAAGCCAGTG 247
 QY 183 GAGCGCAGTGAAGGAGGCTGTTGGCAGCAGCGGCTGCACTCAGGAAACCCCTCCAG 242
 DB 248 GAGCGCAGTGAAGGAGGCTGTTGGCAGCAGCGGCTGCACTCAGGAAACCCCTCCAG 307
 QY 243 AGGCGATGAGCAGGCTGCGCCGCTGACGCGCAGGCTGGAAGCATGTGAGAGCCGCGG 302
 DB 308 AGGCGATGAGCAGGCTGCGCCGCTGACGCGCAGGCTGGAAGCATGTGAGAGCCGCGG 367
 QY 303 AGCCAGCAGAGAGGAGAGGCTTTATAGATTCTATTCAAAAGATAACCACTTTT 362
 DB 368 AGCCAGCAGAGAGGAGAGGCTTTATAGATTCTATTCAAAAGATAACCACTTTT 427
 QY 363 GCMAAGCATGAGGCGCACTGTGCGTGAATGTGTGTGCTGCGACTGCTGCTGCATG 422
 DB 428 GCMAAGCATGAGGCGCACTGTGCGTGAATGTGTGTGCTGCGACTGCTGCTGCATG 487
 QY 423 GAGCTGTTCAGAGCGCAGAGAGAGCGGTTTGAAGGCACTGAGAGGCGCTGCGCAAGAG 482

Db		488	GGAGCTGTGTCAGGCACAGAGGAACGGTTTTCAGGGCCACTGAGGAGGGCTCGCCCAAGAGAG	547
Oy		483	TTCAATTACCATAAACAGGTACAAGCAGGGCGAGTCCAGAGCAAATGTCACCTAACC	542
Db		548	TTCAATTAACTTAACAGGTACAAGCAGGGCGAGTCCAGAGCAAATGTCACCTAACC	607
Oy		543	TTCAATTGTGCCCCAGCAGCGGGGTACAGGGTCCCATCTGCGTCAATCCAAGAAGCTGAG	602
Db		608	TTCAATTGTGCCCCAGCAGCGGGGTACAGGGTCCCATCTGCGTCAATCCAAGAAGCTGAG	667
Oy		603	GTCGCTTCGAGAGAACCGAGTGSCATTAAGCAGAGGTAGAGCTGCTCAACATAGACTGCTC	662
Db		668	GTCGCTTCGAGAGAACCGAGTGSCATTAAGCAGAGGTAGAGCTGCTCAACATAGACTGCTC	727
Oy		663	AAGCAGAAAGCCGACAGATGAGAACGCTGCACAGCTGTGTAAGGTGAGACGGCGGCAATTGTC	722
Db		728	AAGCAGAAAGCCGACAGATGAGAACGCTGCACAGCTGTGTAAGGTGAGAGCGCGCAATTGTC	787
Oy		723	AGCAGAGGTGAAGCTGTGCTCGCAGAA--GGAAGCCGCGCAACATGAAGTCCAGCAGCT	781
Db		788	AGCAGAGGTGAAGCTGTGCTCGCAGAGGAGAGCCGCAACATGAAGTCCAGCAGCT	847
Oy		782	CTACATGACGAGTCTCTGTCACAGATCATTCGCAAGCGGACAAACGCGTTTGAGCTCTCCCA	841
Db		848	CTACATGACGAGTCTCTGTCACAGATCATTCGCAAGCGGACAAACGCGTTTGAGCTCTCCCA	907
Oy		842	GCTGAGAGAAACAGATCTCTGTAACAGAGCCGCAATGCTGACGTGCGCACAGTAGACAA	901
Db		908	GCTGAGAGAAACAGATCTCTGTAACAGAGCCGCAATGCTGACGTGCGCACAGTAGACAA	967
Oy		902	GGACCTGAGACCAAGTACAGACACTTGGCCCACTGGCCCCCAACCATAGAGATCAT	961
Db		968	GGACCTGAGACCAAGTACAGACACTTGGCCCACTGGCCCCCAACCATAGAGATCAT	1022
Oy		962	CCCGACAGTTGAGAGACACTGCGCAAGAGGGTGGCCCTCGGCGACGGCCGCCAGCCACCC	1021
Db		1023	ATGCGSCKTKAGAGGSMTGCMRPAAGGASCTCGCCAGCMCVNMAAMAMMCVVMKCC	1082
Oy		1022	CCCCGCTCCCGCCCGCGGATCTACCAACCAACCCACTCAACACCGCATCA	1071
Db		1083	CSCCCGKTTPACACCCCCTTYAMOSCITTTACGATTTTTTCMMCGGTTYH	1132
RESULT 7				
AL546299		1201 bp	mRNA	linear EST 31-MAY-2003
LOCUS		AL546299 Homo sapiens PLACENTA COR 25-NORMALIZED Homo sapiens cDNA		
DEFINITION		clone CS0D1031YF21 5-PRIME, mRNA sequence.		
ACCESSION		AL546299		
VERSION		AL546299.2 GI:31268133		
KEYWORDS		EST.		
SOURCE		Homo sapiens (human)		
ORGANISM		Homo sapiens		
REFERENCE		Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
AUTHORS		Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.		
TITLE		1 (bases 1 to 1201)		
JOURNAL		Li, W.B., Gruber, C., Jesses, J., and Polayes, D.		
COMMENT		Full-length cDNA libraries and normalization		
		Unpublished (2001)		
		On Feb 15, 2001 this sequence version replaced gi:12879279.		
		Contact: Genoscope		
		Genoscope - Centre National de Sequencage		
		BP 191 91006 EVRY cedex - France		
		Email: seq@genoscope.cns.fr Web : www.genoscope.cns.fr		
		Library was constructed by life technologies, a division of		
		Invitrogen. This sequence belongs to sequence cluster 4821.r For		
		more information about this cluster, see		
		http://www.genoscope.cns.fr/		
		cgi:bin/custer.cgi?seq=CS0D1031C11P1&custer=4821.r. Contact :		
		Peng Liang Email : fliang@life-tech.com URL :		
		http://fulllength.invitrogen.com/ invitrogen Corporation 1600		
		Fairday Avenue Genoscope sequence ID : CS0D1031C11P1.		

FEATURES		Location/Qualifiers
SOURCE		1..1201
/organism="Homo sapiens"		
/mol_type="mRNA"		
/db_xref="taxon:9606"		
/clone="CSOD1031P21"		
/tissue_type="PLACENTA COT 25-NORMALIZED"		
/clone_lib="Homo sapiens PLACENTA COT 25-NORMALIZED"		
/note="Test strand cDNA was primed with a NotI-oligo(dT) primer. Five prime end enriched, double-strand cDNA was digested with Not I and cloned into the NotI and EcoR V sites of the pCMVSPORT 6 vector. Library was normalized."		
ORIGIN		
Query Match	40.7%; Score 885.2; DB 9; Length 1201;	
Best Local Similarity	90.3%; Pred. No. 1.1e-107;	
Matches 912; Conservative 34; Mismatches 63; Indels 1; Gaps 1		
Db	3	AAATGAGCTGCTGGGAGGCGCTTGAAGATGAACCCCAACCCCTGGAGCTGGCGAGCGTG 62
Db	92	AAATGARGCTGCTGGCGAGCGGCTTGAAGATGAGCCCAAGCCCTGGAGCTGGCGAGCGTG 151
Qy	63	GCACTAGGAGAGCGGCTGACGCTTACTGTGAGGAGAAAGAGTTGTGAGCAAGCCCGCAGG 122
Db	152	GCACTAGGAGAGCGGCTGACGCTTACTGTGAGGAGAAAGAGTTGTAKKAGCCCGCAGG 211
Qy	123	ACCCCTGGCCAGCCCTGGCCCCAGCCTTCTGCCGAGCCCTTGTGAGAGCGAGCCAGTG 182
Db	212	ACCCCTGGCCAGCCCTGGCCCCAGCCTTGTGCCGAGCCCTTGTGAGAGCGAGCAATG 271
Qy	183	GAGCCAGTGAAGGAGGAGGCTGTCTTGAGCAAGCAAGCGGCTGCACTCAGAAACCCCTCGAG 242
Db	272	GAGCCAGTGAAGGAGGAGGCTGTCTTGAGCAAGCAAGCGGCTGCACTCAGAAACCCCTCGAK 331
Qy	243	AGGCCATGAGCAGGCTGCCCGCTGACGCGCCAGGTCAGATGTAGAGAGCCGCCCGG 302
Db	332	AGGCCATGAGCAGGCTGCCCGCTGACGCGCCAGGTCAGATGTTTGAAGAGCGCGCCCGG 391
Qy	303	AGCCAGCAGAGAGGAGAGGCTTCAATAGATTCATTAACAAGATTAACAACCATTTT 362
Db	392	AGCCAGCAGAGAGGAGAGGCTTCAATAGATTCATTTTAAAGATTAACAACCATTTT 451
Qy	363	GCAAAGCAGTGAAGGCGCACTGTGCGTGAATGTCTGGTGGCTGGACTGTGGCTGCATG 422
Db	452	GCAAAGCAGTGAAGGCGCACTTTCGTGCAATCTGTGTGGCTGGAGCTGGCTGCATG 511
Qy	423	GGAAGCTGTTCAGAGCCAGAGAGACGCTTTTGAAGGCGCTGAGAGAGGCTGCCAAGAG 482
Db	512	GGAAGCTGTTCAGAGCCAGAGAGACGCTTTTGAAGGCGCTGAGAGAGGCTGCCAAGAG 571
Qy	483	TTCAATTAAGCTAAACAGGTACAAGAGGAGGCGGCGAGTCCAGAGCAAGTGACCTACAC 542
Db	572	TTCAATTAAGCTAAACAGGTACAAGAGGAGGCGGCGAGTVCAGAGCAAGTGACCTACAC 631
Qy	543	TTCAATGTGCCAGAGCGGCTCAAGGCTGCAATCTGCTGCACTCCAGAGAGCCCTGAG 602
Db	632	TTCAATGTGCCAGAGCGGCTCAAGGCTGCAATCTGCTGCACTCCAGAGAGCCCTGAG 691
Qy	603	GTGCTTCTGGAGAACCGAGTGCATTAAGCAGAGAGCTAGAGCTCAACAATGAGCTGCTC 662
Db	692	GTGCTTCTGGAGAACCGAGTGCATTAAGCAGAGAGCTAGAGCTCAACAATGAGCTGCTC 751
Qy	663	AAGCAGAGGCGAGATTCAGAGCGCTGACGAGCTGTGAAGGTGAAGCGCGGCTATGTG 722
Db	752	AAGCAGAGGCGAGATTCAGAGCGCTGACGAGCTGTGTGAAGGTGAAGCGCGGCTATGTG 811
Qy	723	AGCAGAGTGAAGTGTCTGGCGCAAGAGAGCGCCCAATGAACTGCGGGGTCAACCACTC 782
Db	812	AGCAGAGTGAAGTGTCTGGCGCAAGAGAGCGCCCAATGAACTGCGGGGTCAACCACTC 871
Qy	783	TACATGAGCTCTCTGACAGAGATCAATCCGCAAGCGGAGCAAACGCGTTGAGCTTCCAG 842
Db	872	TACATGAGCTCTCTGACAGAGATCAATCCGCAAGCGGAGCAAACGCGTTGAGCTTCCAG 931

REFERENCE 1 (bases 1 to 1111).
 NIH-MGC <http://mgs.nci.nih.gov/>.
 AUTHORS National Institutes of Health, Mammalian Gene Collection (MGC)
 TITLE Unpublished (1999)
 JOURNAL Contact: Robert Strausberg, Ph.D.
 COMMENT Email: cgabbs-remail.nih.gov
 Tissue Procurement: Invitrogen
 cDNA Library Preparation: Life Technologies, Inc.
 DNA Library Arrayed by: The I.M.A.G.E. Consortium (LIML)
 DNA Sequencing by: Agencourt Bioscience Corporation
 Clone distribution: MGC clone distribution information can be
 found through the I.M.A.G.E. Consortium/LIML at:
<http://image.llnl.gov>
 Plate: LLM2714 row: 9 column: 03
 High quality sequence start: 3
 High quality sequence stop: 640.
 Location/Qualifiers

FEATURES

source

1..1111
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /clone="IMAGE:5724698"
 /lab_host="DH10B"
 /clone_1ib="NIH-MGC 125"
 /note="Organ: ovary (pool of 3); Vector: pCMV-Sport6;
 Site_1: EcoRV (destroyed); Site_2: NotI; RNA source pool
 of three ovaries, from females ranging in age from 38 to
 49 yo. Library is oligo-dT primed and directionally cloned
 (EcoRV site is destroyed upon cloning). Average insert
 size 2.1 kb, insert size range 1-3.5 kb. Library is
 normalized and enriched for full-length clones and was
 constructed by C. Gruber (Invitrogen). Research Genetics
 tracking code 036."

ORIGIN

Query Match 40.1%; Score 870.6; DB 12; Length 1111;
 Best Local Similarity 92.2%; Pred. No. 9.6e-106;
 Matches 987; Conservative 0; Mismatches 69; Indels 15; Gaps 6;

QY 3 AAATAGGCTGCTGCGGACGCGCTTGAAGTAAACCCCAAGCCTTGGACCTGCCAGCCTG 62
 DB 39 AAATAGGCTGCTGCGGACGCGCTTGAAGTAAACCCCAAGCCTTGGACCTGCCAGCCTG 98
 QY 63 GCACTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 122
 DB 99 GCACTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 158
 QY 123 ACCCTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 182
 DB 159 ACCCTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 218
 QY 183 GAGCCAGTGAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 242
 DB 219 GAGCCAGTGAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 278
 QY 243 AGGCCATGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 302
 DB 279 AGGCCATGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 338
 QY 303 AGCCAGCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 362
 DB 339 AGCCAGCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 398
 QY 363 GCAAAAGCATGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 422
 DB 399 GCAAAAGCATGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 458
 QY 423 GGAAGCTGTTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 482
 DB 459 GGAAGCTGTTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 518
 QY 483 TTCATTACTTAAACAGGTAAACAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 542

DB 519 TTCATTACTTAAACAGGTAAACAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 578
 QY 543 TTCATTGTCGCCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 602
 DB 579 TTCATTGTCGCCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 638
 QY 603 GTCTCTTGGAGAAACCGAGTGCATAGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 662
 DB 639 GTCTCTTGGAGAAACCGAGTGCATAGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 698
 QY 663 AAGCAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 722
 DB 699 AAGCAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 758
 QY 723 AGGAG 781
 DB 759 AGGAG 818
 QY 782 CTACATGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 840
 DB 819 CTACATGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 878
 QY 841 AGCTGAG 900
 DB 879 AGCTGAG 938
 QY 901 AGGA-CCTGAGAGCAAGTACCAAGCACTGGCCACACTGGCCACAA-CGAATCAGAGAT 958
 DB 939 AGGACCTGAGAGCAAGTACCAAGCACTGGCCACACTGGCCACAA-CGAATCAGAGAT 998
 QY 959 CATCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1007
 DB 999 CTTTCCCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1058
 QY 1008 GTCCCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1058
 DB 1059 CCAAGG 1109

RESULT 10
 BO711105 929 bp mRNA linear EST 16-JUL-2002
 LOCUS BO711105
 DEFINITION AGENCOURT_7976097 NIH-MGC_113 Homo sapiens cDNA clone IMAGE:6214550
 5' mRNA sequence.
 BO711105
 BO711105.1 GI:21850004
 EST.
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 929)
 NIH-MGC <http://mgs.nci.nih.gov/>.
 National Institutes of Health, Mammalian Gene Collection (MGC)
 JOURNAL Unpublished (1999)
 COMMENT Contact: Robert Strausberg, Ph.D.
 Email: cgabbs-remail.nih.gov
 Tissue Procurement: Dr. Mark Watson
 cDNA Library Preparation: Rubin Laboratory
 DNA Library Arrayed by: The I.M.A.G.E. Consortium (LIML)
 DNA Sequencing by: Agencourt Bioscience Corporation
 Clone distribution: MGC clone distribution information can be
 found through the I.M.A.G.E. Consortium/LIML at:
<http://image.llnl.gov>
 Plate: LLM2382 row: a column: 15
 High quality sequence stop: 542.
 Location/Qualifiers

FEATURES
 source
 1..929
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /clone="IMAGE:6214550"
 /lab_host="DH10B (phage-resistant)"

ORIGIN

/clone.lib="NIH_MGC_113"
 /note="Organ: spleen; Vector: pOTB7; Site_1: XhoI; Site_2:
 EcoRI; cDNA made by oligo-dt priming. Directionally cloned
 into EcoRI/XhoI sites using the following 5' adaptor:
 GGCACGAG(G). Library constructed by Ling Hong in the
 laboratory of Gerald M. Rubin (University of California,
 Berkeley) using ZAP-cDNA synthesis kit (Stratagene) and
 Superscript II RT (Life Technologies). Note: this is a
 NIH_MGC Library."

Query Match 39.8%; Score 865.4; DB 13; Length 929;
 Best Local Similarity 97.6%; Pred. No. 4,9e-105;
 Matches 908; Conservative 0; Mismatches 19; Indels 3; Gaps 3;

QY 460 CTGAGAGGGGCTGCCAAGAGAGTTCATTACCTAAACAGTACAGCGGGCGGCGAGT 519
 DB 1 CTGAGAGGGGCTGCCAAGAGAGTTCATTACCTAAACAGTACAGCGGGCGGCGAGT 60
 QY 520 CCCAGGACAGTGCACCTACCTTATGTCCTCCAGAGAGGGGTCACAGGGTGCATCT 579
 DB 61 CCCAGGACAGTGCACCTTACCTTATGTCCTCCAGAGAGGGGTCACAGGGTGCATCT 120
 QY 580 GGGTCACTCCAGAGAGCTGAGTGTCTTGAGAGAACGAGTGCATTAAGCAGAGCTAG 639
 DB 121 GGGTCACTCCAGAGAGCTGAGTGTCTTGAGAGAACGAGTGCATTAAGCAGAGCTAG 180
 QY 640 AGTGTCTCAACATAGTGTCTCAACAGAGAGGGGATTCAGAGCTGACAGCTGG 699
 DB 181 AGTGTCTCAACATAGTGTCTCAACAGAGAGGGGATTCAGAGCTGACAGCTGG 240
 QY 700 TGAAGTGAAGCGCGGCTTGTGAGGAGAGTGAAGTGTGCGCAAGAGAGAGCGGCA 759
 DB 241 TGAAGTGAAGCGCGGCTTGTGAGGAGAGTGAAGTGTGCGCAAGAGAGAGCGGCA 300
 QY 760 TGAAGTGAAGCGGCTTGTGAGGAGAGTGAAGTGTGCGCAAGAGAGAGCGGCA 819
 DB 301 TGAAGTGAAGCGGCTTGTGAGGAGAGTGAAGTGTGCGCAAGAGAGAGCGGCA 360
 QY 820 ACAAGCGGTGAGAGCTTCCAGCTGAGAGAGAGATCTCTGAACAGAGAGCGGCA 879
 DB 361 ACAAGCGGTGAGAGCTTCCAGCTGAGAGAGAGATCTCTGAACAGAGAGCGGCA 420
 QY 880 TCCAGCTGAGCAGAGTCAAGAGAGCTGAGAGAGAGTCAAGAGAGCTGAGCAGCTGG 939
 DB 421 TCCAGCTGAGCAGAGTCAAGAGAGCTGAGAGAGAGTCAAGAGAGCTGAGCAGCTGG 480
 QY 940 CCCACACCAATCAAGATATCGGCGAGCTTGAAGAGATCTGCCAGAGGGTGCCTTGG 999
 DB 481 CCCACACCAATCAAGATATCGGCGAGCTTGAAGAGATCTGCCAGAGGGTGCCTTGG 540
 QY 1000 CCAGGCGGCTCCCGCAGAGAGCGGCGGCTGCGCGCGGCTTACCAACAGAGAGCT 1059
 DB 541 CCAGGCGGCTCCCGCAGAGAGCGGCGGCTGCGCGCGGCTTACCAACAGAGAGCT 600
 QY 1060 ACAAACCGATCATCAACAGATCTTACCAAGAGATCCAGAGTCAAGAGAGCTGAAG 1119
 DB 601 ACAAACCGATCATCAACAGATCTTACCAAGAGATCCAGAGTCAAGAGAGCTGAAG 660
 QY 1120 TGGTGCACACCGCTTCCAGCTATGAGGAGTCTGACAGAGCTTCCAGTCTTCCAGGACA 1179
 DB 661 TGGTGCACACCGCTTCCAGCTATGAGGAGTCTGACAGAGCTTCCAGTCTTCCAGGACA 720
 QY 1180 AGCGGTGGGCGCATGAGAGAGTCTGAGAGAGCTTGAAGAGTGCACAGAGAGCT 1239
 DB 721 AGCGGTGGGCGCATGAGAGAGTCTGAGAGAGCTTGAAGAGTGCACAGAGAGCT 780
 QY 1240 CCATCTACTGAGTGAAGCGGAGAGACCAACCGGCTCATGAGAGTGTGTGCGAGCAGA 1299
 DB 781 CCATCTACTGAGTGAAGCGGAGAGACCAACCGGCTCATGAGAGTGTGTGCGAGCAGA 838
 QY 1300 GACAGAGAGCGGCGGCTGAGAGAGTCTGAGAGAGTCTGAGAGAGTCTGAGAGAGTCT 1358

DB 839 GACAGAGAGCGGCGGCTGAGAGAGTCTGAGAGAGTCTGAGAGAGTCTGAGAGAGTCT 898
 QY 1359 TTCAGAGAGTGGAGAGCTGACAGAGAGAGG 1388
 DB 899 TTCAGAGAGTGGAGAGCTGACAGAGAGAGG 928

RESULT 11

BQ879104

LOCUS

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

COMMENT

BQ879104 881 bp mRNA linear EST 16-AUG-2002
 AGENCOURT 8118172 Lupski dorsal root ganglion Homo sapiens cDNA
 clone IMAGE:6181203 5', mRNA sequence.
 BQ879104
 BQ879104.1 GI:22271112
 EST.
 Homo sapiens (human)
 Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniala; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 1 (bases 1 to 881)
 NIH-MGC http://mgi.nci.nih.gov/
 National Institutes of Health, Mammalian Gene Collection (MGC)
 Unpublished (1999)
 Contact: Robert Strausberg, Ph.D.
 Email: sgabbs@mail.nih.gov
 Tissue Procurement: Dr. James R. Lupski
 cDNA Library Preparation: Life Technologies, Inc.
 cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNL)
 DNA Sequencing by: Agencourt Bioscience Corporation
 Clone distribution: MGC clone distribution information can be
 found through the I.M.A.G.E. Consortium/LNL at:
 http://image.lnl.gov
 Plate: LLM3565 row: d column: 04
 High quality sequence stop: 671.
 Location/Qualifiers
 1..881
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /clone="IMAGE:6181203"
 /sex="male"
 /tissue_type="dorsal root ganglia"
 /dev_stage="adult, 36 yr"
 /lab_host="DH108"
 /clone.lib="Lupski dorsal root ganglion"
 /note="Vector: pCMV-Sport6 (Life Technologies); Site_1:
 NotI; Site_2: SalI; cDNA made by oligo-dt priming.
 Directionally cloned using the following adaptors:
 5'-TCGACCCAGCGGTCG-3' and
 5'-GACTAGTCTAGATCGGAGCGGCGGCTT(15)-3'. Size selected >
 1 kb for average insert length 1.7 kb. This is a primary
 library, non-amplified. Library constructed by Life
 Technologies and donated by J. Lupski, M.D./Ph.D. (Baylor
 College of Medicine) and is available through Life
 Technologies."

FEATURES

source

ORIGIN

Query Match 39.8%; Score 865; DB 13; Length 881;
 Best Local Similarity 98.9%; Pred. No. 5,6e-105;
 Matches 871; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

QY 30 GATGACCCCAAGGCTGAGCTTCCGAGCGTGCCTGAGGAGCGGCTGACGTA 89
 DB 1 GATGACCCCAAGGCTTCCGAGCGTGCCTGAGGAGCGGCTGACGTA 60
 QY 90 TGAAGGAAAGAGTGTGAGAGAGCGGCGAGAGCGGCGGCGGCGGCGGCGGCGGCGG 149
 DB 61 TGAAGGAAAGAGTGTGAGAGAGCGGCGAGAGCGGCGGCGGCGGCGGCGGCGGCGG 120
 QY 150 CTGCGGAGGCGCTTGTGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 209
 DB 121 CTGCGGAGGCGCTTGTGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 180

Db	278	GGCCATTGCCAGSAGACCACCTGGTCAAGCTGCGCACAAGCAAAGAACAATCCTCAC	219
Qy	1340	CAGTTTCATCTGAGSGCTGGAGAGACCGGAATGCTGGATTTGTTTCCGAAGTCACTGCA	1999
Db	218	CAGTTTCATCTCGAGGCTGGAGAGACCGGAATGCTGGATTTGTTTCCGAAGTCACTGCA	159
Qy	2000	GCGATGATGGAACACTGCATACGATGTTTTCTGTCCCTCTACTTTCCTT--CACACC	2058
Db	158	GCGATGATGGAACCTGATTCATAAGTGTTTTCTGTCCCTCTCAACTTTCCTTAACACC	99
Qy	2059	AGACAGCCCCCTCATGTCTTCACGAGACGAGACAGGACTCAAGACAACCTTTTCTTTAAATPA	2118
Db	98	AGACAGCCCCCTCATCTTCMCAGRAPACAGPAMGRAPACAGAMAATCACTMATCTTTAAAAA	39
Qy	2119	ATTAAGTCTCTACANTAAAACACACAGCCGAAAGTNA	2155
Db	38	AAAAAAAAAAAAAAAAAAAAVAVVAALMAAATAAVA	2

RESULT 13				
B0958353				
LOCUS	B0958353	884 bp	mRNA	linear
DEFINITION	AGENCOURT 8963557 lmpsk1-sciatic.nerve Homo sapiens			EST 21-AUG-2002
	IMAGE:6200431 5', mRNA sequence.			CDNA clone

ACCESSION	BQ952353
VERSION	BQ952353.1
DATE	GI:22367831

KEYWORDS	EST.
SOURCE	Homo sapiens (human)
ORGANISM	Homo sapiens

REFERENCE
1 (bases 1 to 884)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.

REFERENCE 1 (bases 1 to 884)
AUTHORS NIH-MGC <http://mgc.ncl.nih.gov/>.
TITLE National Institutes of Health, Mammalian Gene Collection (MGC).
JOURNAL Unpublished (1999)
COMMENT Contact: Robert Strausberg, Ph.D.

Email: CSapbs-@email.nih.gov
Tissue Procurement: Dr. James R. Lupski
cDNA Library Preparation: Life Technologies, Inc.
cDNA Library Arrayed by: The I.M.A.G.E Consortium (LNL)
DNA Sequencing by: Agencourt Bioscience Corporation
Clone distribution: WGC clone distribution information can be
found through the I.M.A.G.E. Consortium/LNL at:

<http://image.liml.gov>
 Plate: L1AM13615 row: e column: 08
 High quality sequence stop: 624.

FEATURES

source

```

/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:6200431"
/sex="male"
/tissue_type="sciatic nerve"
/dev_stage="adult, 70 yr"
/lab_host="DH10B"
/clone_id="Lupsk1_sciatic nerve"
/note="vector: pCMV-SPORT6 (Life Technologies); Site_1:
Not1; Site_2: SalI; cDNA made by oligo-dT priming.
Directionally cloned using the following adaptors:
5'-TCGACCGACGCGCGG-3' and
5'-GACGTGTTCTAGATCGCAGCGGCGCCCTT(15)-3'. Size selected >
1 kb for average insert length 1.67 kb. This is a primary
library, non-amplified. Library constructed by Life
Technologies and donated by J. Lupski, M.D./Ph.D. (Baylor
College of Medicine) and is available through Life
Technologies."

```

QY	667	AGAAAGCCGACAGATCGAAGCCGCTGGACAGAGCTGTGTGAAGGTGAGAGCGGCGGCAATTGTGAGCG	726
Db	1	AGAAAGCCGACAGATCGAAGCCGCTGGACAGAGCTGTGTGAAGGTGAGAGCGGCGGCAATTGTGAGCG	60
QY	727	AGGTGAAGCTGTCTGGCGAAGAGAGCCGCAACATGAACCTCGCGGGTGCACGACGCTTACA	786
Db	61	AGGTGAAGCTGTCTGGCGAAGAGAGCCGCAACATGAACCTCGCGGGTGCACGACGCTTACA	120
QY	787	TGCAAGCTCTTGCAAGATCATCTCGCAAGGGGGAACAACGGCTTGAAGCTCTCCAGCTGG	846
Db	121	TGCAAGCTCTTGCAAGATCATCTCGCAAGGGGGAACAACGGCTTGAAGCTCTCCAGCTGG	180
QY	847	AGAAACAGGATCTTAAACCAAGACCAAGCCGACATGTCTGACCTTGGCCAGACAGATACAAAGACCC	906
Db	181	AGAAACAGGATCTTAAACCAAGACCAAGCCGACATGTCTGACCTTGGCCAGACAGATACAAAGACCC	240
QY	907	TGAGAGCAAGATCCAGACCTTGGCCACCTGTGGCCACACCTGACCAATTCAGATCATCGGCG	966
Db	241	TGAGAGCAAGATCCAGACCTTGGCCACACCTGTGGCCACACCAATTCAGATCATCGGCG	300
QY	967	AGCTTTAGAGAGCATCTGCCAAGAGGGTGGCCCTGCGACAGGCCGTCCCCAGACCAACCCCGC	1028
Db	301	AGCTTTAGAGAGCATCTGCCAAGAGGGTGGCCCTTGGCGAAGGCCGTCCCCAGACCAACCCCGC	360
QY	1027	CTGCCCCGCCCCGGGCTTACCAACCAACCCATCTACAAACCGCATATCAACCAATCTTTA	1088
Db	361	CTGCCCCGCCCCGGGCTTACCAACCAACCCATCTACAAACCGCATATCAACCAAGATCTTTA	420
QY	1087	CCAAACGAGATCCAGAGTGAACCAAGAACTGAAAGTGTGGCCACCCGCCCTGTGCCCACTATGC	1148
Db	421	CCAAACGAGATCCAGAGTGAACCAAGAACTGAAAGTGTGTGCCACCCGCCCTGTGCCCACTATGC	480
QY	1147	CCACTCTCACACGCTCCCATCTTCCACCCGACAGCCGTGGGGCCCATGAGAGACTGGC	1208
Db	481	CCACTCTCACACGCTCCCATCTTCCACCCGACAGCCGTGGGGCCCATGAGAGACTGGC	540
QY	1207	TGCAAGCCCTTGAGAGATGGCCACGACACACAGCTCATCTTACCTGTGTAAGCCGAGAAACA	1268
Db	541	TGCAAGCCCTTGAGAGATGGCCACGACACACAGCTCATCTTACCTGTGTAAGCCGAGAAACA	600
QY	1267	CCAAACCGCTCATGACAGGTGTGTGCCAACAGACACGACCCCGGGGGCTGACCCGTCA	1328
Db	601	CCAAACCGCTCATGACAGGTGTGTGCCAACAGACACGACCCCGGGGGCTGACCCGTCA	660
QY	1327	TCCAGAGACCCCTGGATGGCTGTCTTAACTTTCACAGAACTGGGAGACCTACACAGCAAG	1388
Db	661	TCCAGAGACCCCTGGATGGCTGTCTTAACTTTCACAGAACTGGGAGACCTACACAGCAAG	720
QY	1387	GG-TTTGGGAACATTGACAGGGAATATCTGGCTGGGGCTGCGAACAATTACTGTGCTGACG	1448
Db	721	GGTTTGGGAACATTGATGGGAATATCTGGCTGGGGCTGCGAACAATTACTGTGCTGACG	780
QY	1446	AACCAAGGCAACTACAAACTCTCTGTGTGACCATGGAGACTGTGTCGGCCGCAAACTCTTT	1508
Db	781	AACCAAGGCAACTACAAAACTCTCTGTGTGTGACCATGGAGACTGTGTCGGCCGCAAACTCTTT	839
QY	1506	GCAAAATATGCGCAG-TTTCCGCTCGAAACCTGAGAGCGATATT	1548
Db	840	GCAAAATATGCGCAGATTTTCCGCTCGGAAACTGAAAGCGAGATTT	883

RESULT 14

AL527059				
LOCUS	AL527059	1201 bp	mRNA	linear EST 23-MAY-2003
DEFINITION	AL527059 Homo sapiens NEUROBLASTOMA COT 25-NORMALIZED Homo sapiens			

cdna clone	CS0DC017YL03
ACCESSION	AL527059
VERSION	AL527059.2
	GI:31064913

KEYWORDS	EST.
SOURCE	Homo sapiens (human)
ORGANISM	Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

Mon Aug 9 10:30:09 2004

us-10-018-386-1.rst

Page 15

```
"/lab.host="DH10B-Ton A ( T1 and T5 phage resistances)"  
/clone.lib="NIH_MGC_181"  
/note="Vector: PCMV-SPORT6.1; Site 1: NotI; Site 2: EcoRV  
(destroyed); Library is oligo-dT primed and directionally  
cloned (EcoRV site is destroyed upon cloning). Average  
insert size 1.42 kb. Library was constructed by  
(Invitrogen). Note: this is a NIH_MGC Library."
```

ORIGIN

```
Query Match      37.6%; Score 816.4; DB 14; Length 870;  
Best Local Similarity 98.9%; Pred. No. 1.5e-98;  
Matches 843; Conservative 0; Mismatches 6; Indels 3; Gaps 2;
```

```
QY 16 GCGAGCGGCTTAGAGATGAACCCCAAGCCCTTGACCTGCGAGCGTGGCACTGAGGAGC 75  
Db 1 GCGGACGGCTGAGGATGAGCCCAAGCCCTTGAGCTGCGAGCGTGGCACTGAGGAGC 60  
QY 76 GGGTGAAGCTACTGTGAGGAGAAAGAGGTTGTGAGCAGCCCGCAGAGACCCCTGGCCAGC 135  
Db 61 GGGTGAAGCTACTGTGAGGAGAAAGAGGTTGTGAGCAGCCCGCAGAGACCCCTGGCCAGC 120  
QY 136 CCGGACCCCGAGCCTTGGCCGAGCCCTCTGTGAGAGCAGAGCCAGTGGAGCCAGTGAAG 195  
Db 121 CCGGACCCCGAGCCTTGGCCGAGCCCTCTGTGAGAGCAGAGCCAGTGGAGCCAGTGAAG 180  
QY 196 CAGGGCTGTGGGAGCCAGCCGCTGCACTCAGAGAAACCCCTCCAGAGCCATGAGCAG 255  
Db 181 CAGGGCTGTGGGAGCCAGCCGCTGCACTCAGAGAAACCCCTCCAGAGCCATGAGCAG 240  
QY 256 GCTGCCCGCTGACCGGAGGAGTGAAGCATGAGAGAGCCCGCCGAGCCAGCAGAGAG 315  
Db 241 GCTGCCCGCTGACCGGAGGAGTGAAGCATGAGAGAGCCCGCCGAGCCAGCAGAGAG 300  
QY 316 GGAAGAGGCTTCAATAGATTCTATTCAACAAAGATTAACACCATTTGCAAAAGCATGA 375  
Db 301 GGAAGAGGCTTCAATAGATTCTATTCAACAAAGATTAACACCATTTGCAAGAGCATGA 360  
QY 376 GGGCACTGTGGGTGATGATGTGGTGGCTCGGAGTGGTGGCATGGGAGCTGTGGAG 435  
Db 361 GGGCACTGTGGGTGATGATGTGGTGGCTCGGAGTGGTGGCATGGGAGCTGTGGAG 420  
QY 436 GCCAGAGAGCGTTTGTAGGCGACTGAGAGAGGCTCGCCAGAGAGTTCAATTACCTAA 495  
Db 421 GCCAGAGAGCGTTTGTAGGCGACTGAGAGAGGCTCGCCAGAGAGTTCAATTACCTAA 480  
QY 496 ACAAGTAAAGCGGGCGGGCGAGTCCAGAGCAAGTGAACCTTCACTTGTGCCCC 555  
Db 481 ACAAGTAAAGCGGGCGGGCGAGTCCAGAGCAAGTGAACCTTCACTTGTGCCCC 540  
QY 556 AGCAGCGGGTCAAGGGTGTCCATCTGCTCAACTCCAAAGAGCTGAGGTCTTCTGAGA 615  
Db 541 AGCAGCGGGTCAAGGGTGTCCATCTGCTCAACTCCAAAGAGCTGAGGTCTTCTGAGA 600  
QY 616 ACCGAGTGCATAGCAGAGAGCTAGAGCTGCTCAATGAGTGTCTCAAGCAGAAAGCGGC 675  
Db 601 ACCGAGTGCATAGCAGAGAGCTAGAGCTGCTCAATGAGTGTCTCAAGCAGAAAGCGGC 660  
QY 676 AGATGAGAGCGGTGAGAGCTGAGTGAAGTGAAGCGGCGCATTTGTGAGCGAGGTGAAGC 735  
Db 661 AGATGAGAGCGGTGAGAGCTGAGTGAAGTGAAGCGGCGCATTTGTGAGCGAGGTGAAGC 720  
QY 736 TGCTGCGCAAGAGAGCGCGCAACATGAATCTCGGGGTACGAGCTTACATGACGCTCC 795  
Db 721 TGCTGCGCAAGAGAGCGCGCAACATGAATCTCGGGGTACGAGCTTACATGACGCTCC 780  
QY 796 TGCAGAGATCATCCGCAAGCGGAGCAAC--GGTTGAGAGCTTCCCAAGCTGG--AGAACA 852  
Db 781 TGCAGAGATCATCCGCAAGCGGAGCAAC--GGTTGAGAGCTTCCCAAGCTGGAGAAACA 840  
QY 853 GGATCCTGAACC 864  
Db 841 GGATCCTGAACC 852
```

Search completed: August 6, 2004, 18:16:03
Job time : 5573 secs

